AMERICAN SOCIETY OF HEMATOLOGY

67th ASH Annual Meeting and Exposition

 

December 6-9, 2025 Orlando
Close
N. Poster
Poster title
Applicant name
Status
  1099-SAT Pure red cell aplasia associated with thymic follicular lymphoid hyperplasia: Complete remission after thymectomy without immunosuppression Chanakarn Kanitthamniyom Received Received
  1100-SAT Real world use of sutimlimab in patients with cold agglutinin disease: An international study Bruno Fattizzo Received Received
  1101-SAT Comparative efficacy of complement inhibitors in complement Inhibitor–Naïve PNH: A network meta-analysis of randomized trials Rehan Ishaque Received Received
  1102-SAT First report of novel biallelic KLF1 variants causing prenatal onset severe transfusion-dependent non-spherocytic hemolytic anemia in North America Laila Alkhouli Received Received
  1103-SAT Efficacy and safety analysis of iptacopan in paroxysmal nocturnal hemoglobinuria: A real world retrospective study of China Yanli Feng Sr Received Received
  1104-SAT Efficacy and safety of bruton tyrosine kinase (BTK) inhibitor zanubrutinib in relapsed/refractory warm autoimmune hemolytic anemia (wAIHA) after multiple lines of therapy: A prospective phase 2 single-arm study Miao Chen Received Received
  1105-SAT Fatigue, hemoglobin, and inflammatory markers in warm autoimmune hemolytic anemia: Analysis from a phase 2b trial of rilzabrutinib (LUMINA2) David Kuter Received Received
  1106-SAT Downregulation of TANK gene affects erythroid differentiation in PNH patients. Liyan Li Received Received
  1107-SAT Assessment of the angiogenic proteins placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1) in patients with hereditary spherocytosis Antonis Kattamis Received Received
  1108-SAT Pseudo-thrombotic microangiopathy secondary to severe vitamin B12 deficiency: A case series Ashley Rose Received Received
  1109-SAT PRC2-regulated glycolysis-to-oxphos metabolic switch coordinates the onset of terminal erythropoiesis Zhiling Shi IV Received Received
  1110-SAT The N6-methyladenosine methyltransferase wtap maintains erythropoiesis by stabilizing STAT5a mRNA Xia Wu Received Received
  1111-SAT The use of anticoagulation on paroxysmal nocturnal hemoglobinuria. Louise Marianne Arnold Received Received
  1112-SAT The role of neutrophil extracellular traps in thrombosis of paroxysmal nocturnal hemoglobinuria Rong Fu Received Received
  1113-SAT Consistent benefits of pegcetacoplan treatment in PNH patients with and without a history of aplastic anemia in real world: Analysis of the ongoing COMPLETE Phase IV observational study Regis Peffault De Latour Received Received
  1114-SAT Switching between complement inhibitors in patients with PNH: A real-world analysis of strategy, efficacy, and safety. Morag Griffin Received Received
  1115-SAT The phosphorylation by aurkb regulates transcriptional functions of KLF1 during erythropoiesis Rachael White Received Received
  1116-SAT Early efficacy and safety of luspatercept in myelofibrosis-associated anemia: A clinical study with biomarker exploration Yunfan Yang Received Received
  1117-SAT a-synuclein aggregates inhibit reticulocyte maturation Yijin Chen Received Received
  1118-SAT KP104, a bifunctional C5 mAb–Factor h fusion protein, demonstrates sustained long-term efficacy and safety in complement inhibitor–naïve PNH patients: 2-year results from A phase 2 study with 8-week post-treatment safety follow-up. Li Zhang Received Received
  1119-SAT Thrombopoietin receptor agonists combined with intensive immunosuppressive therapy improve outcomes in elderly patients with severe aplastic anemia: A single-center retrospective study Jinsong JIA Received Received
  1120-SAT Inflammatory signaling selectively disrupts GATA factor-regulated networks governing erythroid differentiation and hemoglobin synthesis Ruiqi Liao Received Received
  1121-SAT Activation of pyruvate kinase by mitapivat potentially rescues ineffective erythropoiesis in models of diamond blackfan anemia. Jonathan Roelof Adriaan de Wilde Received Received
  1122-SAT Characterization of bone marrow B-cells in patients with warm autoimmune hemolytic anemia by single-cell analysis Bruno Fattizzo Received Received
  1123-SAT Phase 3 Study to evaluate the efficacy and safety of rilzabrutinib in primary warm autoimmune hemolytic anemia (wAIHA): LUMINA 3 Study design David Kuter Received Received
  1124-SAT Pregnancy outcomes in hereditary and transfusion-associated hemochromatosis: A focused, propensity-matched cohort study using a nationwide inpatient sample Mariana Marrero Castillo Received Received
  1125-SAT Prediction and prevalence of non-anemic iron deficiency (NAID) in early pregnancy Sarah Detlefs Received Received
  1126-SAT Pharmacokinetics of ferric maltol oral suspension in children and adolescents (1 month to 17 years); A study of iron and maltol metabolism following single and multiple dosing Andrew Freiberg Received Received
  1127-SAT Targeting NLRP3 with ofirnoflast, alone or in combination with semaglutide, ameliorates inflammatory anemia associated with obesity-induced inflammation in rodent models Margit Janat-Amsbury Received Received
  1128-SAT The dilemma of glycemic control: Hemoglobin A1c or fructosamine as a measurement related to serum iron Taha Farrukh Hassan Received Received
  1129-SAT Intravenous iron administration during sepsis: Outcomes, safety, and hemoglobin response Lindsay Wilson Received Received
  1130-SAT Diagnostic test accuracy of serum ferritin and prevalence of iron deficiency in pregnant and menstruating individuals: A systematic review and meta analysis Ali Choaib Received Received
  1131-SAT HIF-1 and HIF-2 pathways in regulation of hepcidin Josef Prchal Received Received
  1132-SAT Evaluation of new deferasirox-derived compounds for the treatment of iron overload Marina Dorigatti Borges Received Received
  1133-SAT Delivery of HFE mRNA by lipid nanoparticles corrects iron parameters and BMP responsiveness in murine hereditary hemochromatosis Nermi Parrow Received Received
  1134-SAT Decoding the gene regulatory response to iron through multiomics Kwame Forbes Received Received
  1135-SAT Safety data from the non-transfusion-dependent dose-confirmation cohort: A phase 2a study of luspatercept in pediatric patients with ß-thalassemia Vip Viprakasit Received Received
  1136-SAT A genome-wide CRISPR activation screen identifies novel ?-globin regulators Carea Mullin Received Received
  1137-SAT Chromameter-measured skin lightness: A novel noninvasive marker for liver iron in thalassemia patients Phimpraphan Khumngeon Received Received
  1138-SAT Morbidities in ß-thalassemia intermedia across the spectrum of disease severity: A nationwide study in Tuerkiye Yesim Aydinok Received Received
  1139-SAT Revisiting erythroid response in the phase 3 BELIEVE trial of luspatercept in patients with transfusion-dependent ß-thalassemia using real-world criteria Khaled Musallam Received Received
  1140-SAT Pharmacogenetic variants in UGT1A1/UGT1A3 and ABCC2 associate with deferasirox efficacy in transfusion-dependent thalassemia. Chandni Patel Received Received
  1141-SAT High morbidity in adults with non-transfusion-dependent thalassemia referred to u.S. specialty centers Aaron N. Cheng Received Received
  1142-SAT A clinical study on the Efficacy and safety of luspatercept in Chinese patients with non-transfusion-dependent ß-thalassemia Chuan He Sr Received Received
  1143-SAT Thrombophilia testing and thrombotic risk evaluation in beta-thalassemia: A cohort analysis from a hub regional center Mariasanta Napolitano Received Received
  1144-SAT Oral glucose tolerance test remains the gold standard for diagnosis of glucose metabolism disturbances in thalassemia patients Antonis Kattamis Received Received
  1145-SAT Luspatercept in ß-thalassemia: Meta-analysis of efficacy and safety across transfusion-dependent and non-transfusion-dependent populations Amruth Akhil Alluri Received Received
  1146-SAT Mitapivat improves red blood cell integrity by reducing membrane ubiquitination accumulation Kang Le Received Received
  1147-SAT Targeting hemolysis and raas: Osivelotor and losartan ameliorate sickle cell renal pathology Najmeh Eskandari Received Received
  1148-SAT Resolvins modulate haematopoietic stem and progenitor cell dysfunction and neutrophil activation in sickle cell disease Vishaka Gorur Received Received
  1149-SAT Single-cell analysis reveals distinct ?-globin expression profiles in sickle cell disease with pancellular fetal hemoglobin Phillip Doerfler Received Received
  1150-SAT Optimization of stem cell fitness and mobilization using moderate transfusion and an oral anti-sickling agent in the sickle mouse model. Justin Yoo Received Received
  1151-SAT Ofirnoflast suppresses heme-induced inflammation, representing a novel therapeutic strategy for hemolytic anemias David Bearss Received Received
  1152-SAT Red cell rheology predicts acute chest syndrome and vaso-occlusive events in sickle cell disease Ashwin Prahladbhai Patel Received Received
  1153-SAT The role of hepatocyte nuclear factors in the externalization of phosphatidylserine in sickle erythrocytes Paritosh Mondal Received Received
  1154-SAT Pharmacological mechanism of action and therapeutic potential of a quantitative and qualitative RBC- and hemoglobin-elevating agent AND017 in the Townes SCD model Jie Bai Received Received
  1155-SAT Innate immune dysregulation in monocytes in sickle cell disease Sarah Hinderstein Received Received
  1156-SAT Biophysical characterization of red blood cells in sickle cell trait reveals heterogeneous and intermediate pathophysiological profiles Zoe Sekyonda Received Received
  1157-SAT Pociredir, a novel oral once-daily fetal hemoglobin inducer: Results from the Phase 1b pioneer study in adult participants with severe sickle cell disease and hydroxyurea intolerance or unresponsiveness Sheinei Alan Received Received
  1158-SAT Smartphone app for noninvasive, at-home pediatric hemoglobin monitoring in sickle cell disease. Rob Mannino Received Received
  1159-SAT Follicular disorganization of the spleen in sickle cell disease identified by a convolutional neural network model Venee N. Tubman Received Received
  1160-SAT Assessment of red blood cell functional biomarkers following hematopoietic cell transplantation in sickle cell disease patients Patrick Hines Received Received
  1161-SAT Examining the utility of RBC transfusions in uncomplicated vaso-occlusive episodes Matthew Nguyen Received Received
  1162-SAT A retrospective cross-sectional study to investigate femoral head avascular necrosis in sickle cell disease in Tuerkiye Selma Unal Received Received
  1163-SAT Early life anthropometrics predict anthropometrics later in children with sickle cell disease and are different from the general population Chinenye Rebecca Dike Received Received
  1164-SAT Effects of vaso-occlusive episodes, acute kidney injury, and APOL1 status on urine albumin concentration in patients with sickle cell disease Chang Xu Received Received
  1165-SAT Lower neutrophil counts after hematopoietic stem cell transplant for sickle cell disease patients using donors with duffy-null phenotype Megan Civitello Received Received
  1166-SAT Sickle cell disease trials redefined: Toward unified clinical endpoints through international consensus Biree Andemariam Received Received
  1167-SAT Complement dysregulation during vaso-occlusive episodes can predict development of acute chest syndrome in pediatric patients with sickle cell disease Akshaya Arjunan Received Received
  1168-SAT Measles vaccine-induced sero-protection among children with sickle cell anemia Alexandra Power-Hays Received Received
  1169-SAT Prediction model for pediatric return visits for sickle cell disease post-emergency department discharge for acute pain Keli D. Coleman Received Received
  1170-SAT Paradoxical urban mortality penalty in sickle cell disease: A 20-year national analysis revealing age-dependent disparities Abdul Rahman Al Armarshi Received Received
  1171-SAT Antibody- and equipment-free, ultralow-cost point-of-care sickle cell disease diagnostic: An equitably accessible powerful assay Sevde Nur Karatas Received Received
  1172-SAT Maternal outcomes in sickle cell trait patients hospitalized with preeclampsia and eclampsia Abdulsabur Sanni Received Received
  1173-SAT Uric acid - a potent antioxidant with protective and toxic affects on renal function Robert Ward Hagar Received Received
  1174-SAT The national burden of opoid use disorder on hospital outcomes in sickle cell disease: A database review and analysis Kaung Htet Hla Win Received Received
  1175-SAT Clinical and laboratory findings in adults with sickle cell disease which increase risk for severe acute chest syndrome Jason Lofters Received Received
  1176-SAT Ascertaining sickle cell disease: Comparing electronic health record and genomic data in the all of us research program Elizabeth A Linton Received Received
  1177-SAT Sight: Sickle cell identification from general hematological testing, a machine learning approach for rapid screening in emergency medicine Jedrzej Michal Konarkowski Received Received
  1178-SAT Is hydroxyurea treatment associated with an increased risk of malignancy in sickle cell disease? a propensity-matched analysis of 27,854 patients in the real world Syeda Ashna Fatima Kamal Received Received
  1179-SAT Splenic dysfunction in young children with sickle cell disease Gaby Stegemann Received Received
  1180-SAT Mean corpuscular hemoglobin modulates HbF distribution and sub-phenotypes of sickle cell disease Jason Lofters Received Received
  1181-SAT Keeping it renal: Results of applying guideline-based management in sickle cell nephropathy Elena Wernecke Received Received
  1182-SAT The impact of duffy-null phenotype on neutrophil counts in patients with HbSC/ HbSß+-thalassemia treated with hydroxyurea Yan Zheng Received Received
  1183-SAT Electrocardiographic abnormalities and QTc prolongation in sickle cell disease: Insights from the CSSCD cardiac ancillary Study Mohammad Medical Salameh Received Received
  1184-SAT Associations between chronic kidney disease, proteinuria, and thrombotic risk in SCD Mary Elizabeth Sehl Received Received
  1185-SAT Mapping activated microglial density in individuals with sickle cell disease utilizing time-dependent diffusion-weighted MRI and correlation with cognitive performance Kristine Anne Karkoska Received Received
  1186-SAT Psychometric evaluation of the self-management skills checklist across Brazil and the United States: Toward global measurement of transition readiness in sickle cell disease Kelly Pimenta Received Received
  1187-SAT Demographic, neurocognitive, disease impact, and social characteristics of patients served by embedded neuropsychological services in an adult sickle cell clinic Kyle J Jennette Received Received
  1188-SAT Imaging flow cytometry for detection of red blood cell inclusions: A quantitative approach to assess splenic filtration function in sickle cell disease Charles T Quinn Received Received
  1189-SAT Using a magnetic column separator to determine the magnetophoretic behavior and adhesion characteristics of oxygenated sickle and healthy red blood cells Poornima Ramesh Iyer Received Received
  1190-SAT Seasonal variation in chronic and acute pain in patients with sickle cell disease Galia Pollock Received Received
  1191-SAT Pilot study on thrombosis risk factors in sickle cell anemia Nicoy Downie Received Received
  1192-SAT Cerebral hemodynamic changes during vaso-occlusive episodes in pediatric sickle cell disease Tisha Sumara Boodooram Received Received
  1193-SAT Sex-related differences in silent cerebral infarction burden among adults with sickle cell disease Sally Momoh Received Received
  1194-SAT Novel use of a privacy-preserving hashed identifier to match individuals in different sickle cell disease registries and assess acute care utilization Julie Kanter Received Received
  1195-SAT Interim analysis of a placebo controlled study of dronabinol for adults with sickle cell disease and chronic pain Susanna Curtis Received Received
  1196-SAT The impact of viral pneumonia on hospital outcomes in sickle cell disease: A database review and analysis Kaung Htet Hla Win Received Received
  1197-SAT Utilization and outcomes of erythropoietin stimulating agents in sickle cell disease patient: A real world data analysis Devashish Desai Received Received
  1198-SAT A phase III, multicenter, randomized, placebo controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult sickle cell disease patient Andrew Campbell Received Received
  1199-SAT An evaluation of the relationship between abnormal myocardial perfusion and diastolic dysfunction in sickle cell disease using PET rest-stress myocardial perfusion imaging: Mypers Parul Rai Received Received
  1200-SAT Influenza as a less commonly recognized cause of hemophagocytic lymphohistiocytosis: A systematic review of case reports and case series Kavya Balusu Received Received
  1201-SAT Delta opioid receptor (DOR): A novel target for reprogramming tumor-associated macrophage (TAM) immunosuppressive phenotype to overcome acquired resistance and enhance the effectiveness of cancer immunotherapies KRIT Ritthipichai Received Received
  1202-SAT Characteristics and prognostic factors in adult hemophagocytic lymphohistiocytosis: A large single-institution analysis Guneet Singh Janda Received Received
  1203-SAT Late onset and long lasting neutropenia & primary immune-dysregulation : Early signals & genetic connections Maria Carla Giarratana Received Received
  1204-SAT A novel spontaneous HLH mouse model by engrafting human HSCs into b-ndg MGMT3 mice Qiurong Wang Received Received
  1205-SAT Pathogenesis on dysregulated blood glucose homeostasis in severe hand-foot-mouth disease mouse model Hong Cao Received Received
  1206-SAT Oral mucosal complications in chronic granulomatous disease - a role of Nox2 oxidase in regulating oral neutrophil responses Juhi Bagaitkar Received Received
  1207-SAT Home monitoring of neutrophil counts by patients with cyclic and congenital neutropenia David C. Dale Received Received
  1208-SAT Single-cell transcriptomics reveals monocytic glycolytic reprogramming in lymphoma-associated hemophagocytic lymphohistiocytosis Xuelian Hu Received Received
  1209-SAT Ruxolitinib concentrations in cerebrospinal fluid in patients with hemophagocytic lymphohistiocytosis and potential significance of central nervous system involvement Wu Shishuang Received Received
  1210-SAT Emergency myelopoiesis and monocyte reprogramming underlie immune dysregulation in lymphoma-associated secondary hemophagocytic lymphohistiocytosis Jeong-Eun Kwak Received Received
  1211-SAT Proteomic landscape of histiocytic neoplasms: Advancing precision biomarkers, molecular mechanism, and targeted therapies Oshrat Hershkovitz-Rokah Received Received
  1212-SAT Mapping proteomic signatures in iPSC-derived neutrophils: Modeling neutropenia Daniel Petersheim Received Received
  1213-SAT Successful bone marrow transplantation in 20 patients with severe congenital neutropenia using an immunosuppressive conditioning regimen: Results of a single institute Risa Matsumura Received Received
  1214-SAT Survival outcomes in tickborne infection-associated hemophagocytic lymphohistiocytosis treated with antibiotics alone versus antibiotics and HLH-directed therapy: A multicenter real-world study Grace Gorecki Received Received
  1215-SAT Effects of golidocitinib and gecacitinib in mouse models of primary and secondary hemophagocytic lymphohistiocytosis Yijun Wu Received Received
  1216-SAT 25-year trends in autoimmune neutropenia-related mortality in the United States: A national CDC wonder analysis (1999-2023) Swapna Gangasani Received Received
  1217-SAT Neutrophil subpopulation-specific ratio and neutrophil extracellular traps are dynamic and sensitive biomarkers of thrombo-inflammation in patients with acute coronary syndrome – a prospective study Ofir Wolach Received Received
  1218-SAT MSC regulates the function of neutrophils through mitochondrial transmission to treat early pulmonary fibrosis Rongjia Zhu Received Received
  1219-SAT Clinical and genetic features of primary hemophagocytic lymphohistiocytosis: A single-center analysis Yu Li Received Received
  1220-SAT Why are mice lymphocytic and primates granulocytic? an evo-devo approach to granulopoiesis Eliezer Yampel Received Received
  1221-SAT Hepatic intravital imaging reveals the contribution of peptidylarginine deiminase 4 (PAD4) to the spatiotemporal dynamics of neutrophil recruitment and NET release during bacterial infection Weronika Ortmann Received Received
  1222-SAT Testing for hereditary a-tryptasemia (HaT) / TPSAB1 copy number analysis by droplet digital PCR: Genotypes and phenotypes one year after TPSAB1 assay go-live Malia Deshotel Received Received
  1223-SAT The surpass trial: a phase 2/3 registrational trial of ELA026 in subjects with treatment-Naïve secondary hemophagocytic lymphohistiocytosis Swami P. Iyer Received Received
  1224-SAT Memory NKG2C+ NK cells develop from NKG2C+ transitional precursors and persist within secondary lymphoid organs Mohamed Khalil Received Received
  1225-SAT Senescence-prone immune cell subsets expand in the aged environment Yuki T. Okamura Received Received
  1226-SAT Humanized anti-CD25 monoclonal antibody for previously treated hemophagocytic lymphohistiocytosis in adults: A prospective, open-label clinical trial Tingting Liu Received Received
  1227-SAT Decoding neurotoxicity: A multi-disease single-cell atlas of cerebrospinal fluid reveals conserved and context-specific pathogenic hallmarks Xia Li Received Received
  1228-SAT Idiopathic multicentric castleman disease unresponsive to one IL-6 inhibitor may respond to another IL-6 inhibitor Kayla McHugh Received Received
  1229-SAT Prognostic significance of pulmonary involvement in idiopathic multicentric castleman disease Yu-han Gao Received Received
  1230-SAT Idiopathic multicentric castleman disease - tafro: A potentially curable disease? Lu Zhang Received Received
  1231-SAT Evolutionarily divergent notch regulation underpins the initiation of human T-cell development Vinothkumar Rajan Received Received
  1232-SAT Extrafollicular B cell expansion in COVID-19 patients with prothrombotic antibodies linked to inflammatory and Th1 signatures Mei Yu Received Received
  1233-SAT Castleman disease as a spectrum: Characterization of novel subtypes using data from the spanish GELTAMO registry Gianfranco Lapietra Received Received
  1234-SAT Xgboost profiling of quantitative lymph-node and symptom signatures distinguishes idiopathic multicentric castleman disease and its clinical subtypes Michael Vincent Gonzalez Received Received
  1235-SAT Rituximab for KSHV-associated multicentric castleman disease: A phase II safety/efficacy trial Amon Chirwa Received Received
  1236-SAT T follicular helper cells are mis-localized in idiopathic multicentric castleman disease Katherine Shona Forsyth Received Received
  1237-SAT Structural insights of stomatin from native human platelets by cryo-EM coupled with "Build and Retrieve" (BaR) data processing. Xu Han Received Received
  1238-SAT Distinct sialylation profiles of neonatal and adult platelets revealed by lectin flow cytometry Muataz Ali Hamad Received Received
  1239-SAT Transcriptomic characterization of platelets in immune thrombocytopenia indicates sustained activation and mitochondrial dysfunction Julia-Annabell Georgi Received Received
  1240-SAT Favorable safety and therapeutic efficacy of a novel humanized anti-ADAMTS13 antibody in acquired von willebrand syndrome: A preclinical study Kenki Saito Received Received
  1241-SAT High concentrations of 17ß-estradiol suppress CORO7 and impair megakaryocyte proplatelet formation in individuals with immune thrombocytopenia during pregnancy Jian-Ying Zhou Received Received
  1242-SAT Impact of treatment with fostamatinib on coagulation profile of patients with immune thrombocytopenia Ana Mendoza Martínez Jr Received Received
  1243-SAT All-trans retinoic acid mitigates IL-1ß-driven NEU1-mediated megakaryocyte desialylation and dysfunction in immune thrombocytopenia Jing-Li Han Received Received
  1244-SAT Lysophosphatidylcholine-induced macrophage polarization imbalance and functional dysregulation in immune thrombocytopenia Shuwen Wang Received Received
  1245-SAT De novo glycosylation of MHC class I in platelets Li Guo Received Received
  1246-SAT Probiotics supplementation ameliorates bone marrow mesenchymal stem cells injury via IFN-I/STAT1 signaling pathway in immune thrombocytopenia during pregnancy Qi Chen Received Received
  1247-SAT Defective mitophagy of CD4+T cells in ITP via NAD+/SIRT1 reduction Yu-Xiu Chen Received Received
  1248-SAT Non-response to rituximab during immune thrombocytopenia is associated with more differentiated circulating B cells and CD8 T cells Sylvain Audia Received Received
  1249-SAT Enhanced procoagulant activity of phosphatidylserine-positive platelets in antiphospholipid syndrome Charles Sukin Received Received
  1250-SAT Tumor necrosis factor-alpha (TNFa) drives pathologic platelet hyperreactivity through signaling on hematopoietic stem/progenitor cells and expansion of canonical megakaryocytic progenitors. Joshua Siner Received Received
  1251-SAT Comparative risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag versus romiplostim: A target trial emulation in the french adult immune thrombocytopenia (FAITH) cohort Jérémy Zordan Jr Received Received
  1252-SAT Clinical and demographic characteristics of MYH9-related disorders patients: A comprehensive analysis of 16 cases from a single center Maha Aljasser Received Received
  1253-SAT Switching ITP patients to avatrombopag from other TPO-ras: A real-world experience of the spanish ITP group (GEPTI). Maria Cristina Pascual Izquierdo IV Received Received
  1254-SAT Improved health-related quality of life (HRQoL) and bleeding scores with oral bruton tyrosine kinase (BTK) inhibitor rilzabrutinib in the open-label (OL) period of the multicenter Phase 3 LUNA3 study in adults with immune thrombocytopenia (ITP) Nicola Cooper Received Received
  1255-SAT Real-world safety and efficacy of avatrombopag in adults with immune thrombocytopenia: A systematic review and meta-analysis. Maria Lozano Received Received
  1256-SAT Hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in advanced solid tumors: A multicenter, randomized, double-blind, placebo-controlled phase III trial ShuKui Qin Received Received
  1257-SAT Immature platelet fraction as a marker for romiplostim discontinuation in immune thrombocytopenia: Experience from cuenca, Ecuador Héctor Chiang Wong Sr Received Received
  1258-SAT Comparative efficacy and safety of FcRn inhibitors versus placebo in adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials Akhil Deepak Vatvani Received Received
  1259-SAT Thrombotic risk with thrombopoietin receptor agonists in immune thrombocytopenia: Real-world evidence from a multicenter Japanese study. Masahiro Yoshida Received Received
  1260-SAT Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent/chronic immune thrombocytopenia in the long-term extension period of the Phase 3 LUNA3 study David Kuter Received Received
  1261-SAT Outcomes of immune thrombocytopenia hospitalizations in patients with diabetes mellitus Amro Awad Received Received
  1262-SAT Outcomes of septic shock in immune thrombocytopenia Abdulmalek Aljafari Received Received
  1263-SAT Clinical characteristics, treatment strategies, and response patterns in evans syndrome: Initial analysis from the spanish resti cohort Maria Eva Mingot Sr Received Received
  1264-SAT Clinical profiling and outcomes of ischemic stroke patients with immune thrombocytopenia: A multicenter real-world study Liqin Cao Received Received
  1265-SAT All-trans retinoic acid for refractory cancer therapy-induced thrombocytopenia: A new option beyond TPO-ras? Linya Wang Received Received
  1266-SAT Characterization of platelet autoantibody prevalence, serology, and predictive value for progression to immune thrombocytopenia in patients with persistent isolated mild thrombocytopenia (PIMT) Ellen Zhang Received Received
  1267-SAT BCMA-targeted CAR T cells for multi-refractory primary immune thrombocytopenia: A pilot study Heng Mei Received Received
  1268-SAT Complement activation profile in primary immune thrombocytopenia: Its association with PA-IgM, increased platelet turnover and clinical outcomes Keiichi Nakata Received Received
  1269-SAT Use of thrombopoietin receptor agonists for thrombocytopenia in pediatric malignancies: A retrospective cohort study Anna Jane Elias Received Received
  1270-SAT Hospitalization and thromboembolic outcomes in patients with immune thrombocytopenic purpura and celiac disease: A retrospective cohort study Manas Pustake Received Received
  1271-SAT Teriflunomide, an oral dihydroorotate dehydrogenase inhibitor, in immune thrombocytopenia Li-Ping Yang Received Received
  1272-SAT Early loss of platelet response and rehospitalization following high-dose dexamethasone in patients with newly diagnosed ITP Galia Spectre Received Received
  1273-SAT Efficacy and safety of Bruton´s tyrosine kinase inhibitors in adults with immune thrombocytopenic purpura: A systematic review and meta-analysis Tooba Fida Received Received
  1274-SAT A Phase 1b/ 2a study of budoprutug in patients with immune thrombocytopenia (ITP) Jay Mitchell Received Received
  1275-SAT Effects and interferences of NXT007, a novel bispecific antibody, on coagulation assays Anna Kiialainen Received Received
  1276-SAT A partial neutralizing antibody to Protein C: Hemophilic bleeding preventive effects and thrombotic risks in nonhuman primates Takehisa Kitazawa Received Received
  1277-SAT VGA039 as a protein S-targeted hemostatic promoting monoclonal antibody, promotes in-vitro thrombin generation in plasma samples from subjects across a broad range of bleeding disorders, including von Willebrand disease, hemophilia A, hemophilia B and hem Chris Del Nagro Received Received
  1278-SAT Use of population-scale multiomics to define the prothrombotic phenotype of Protein C deficiency Alfonso Rodriguez Espada Received Received
  1279-SAT Enhancing joint and bone health outcome in Hemophilia A by protein S inhibition Raja Prince-Eladnani Jr Received Received
  1280-SAT Fibroblast-activating protein as a biomarker for blood-induced joint inflammation in hemophilia Jan Pilch Received Received
  1281-SAT Factor XI haploinsufficiency is protective against venous thromboembolism and myocardial infarction in population-scale multidimensional datasets Alfonso Rodriguez Espada Received Received
  1282-SAT Novel protective role of factor XII in kidney ischemia/reperfusion injury in a rat model Bal Krishan Sharma Received Received
  1283-SAT Factor v inhibits factor x activation by the tissue factor-factor VIIa complex Keith Neeves Received Received
  1284-SAT Unconventional mechanism of estrogen-induced thrombosis: The role of tissue factor and non-canonical pathways Murat Yaman Received Received
  1285-SAT Evolution of joint health and physical activity in people with hemophilia A without factor VIII inhibitors switching to emicizumab prophylaxis: A second interim analysis of the BEYOND ABR study Rebecca Kruse-Jarres Received Received
  1286-SAT Real-world experience of efanesoctocog alfa in Hemophilia A patients in the US: A retrospective analysis Sibgha Zaheer Received Received
  1287-SAT Long-term outcomes with emicizumab prophylaxis in patients with hemophilia a in China Yuan Xu Received Received
  1288-SAT Concizumab efficacy in patients with Hemophilia A/B without inhibitors from the Phase 3 explorer8 study: A post-hoc sensitivity analysis for the intra-patient comparison of concizumab with previous prophylaxis Anthony KC Chan Received Received
  1289-SAT Cost comparison of prophylactic vs. on-demand use of a 1:1 ratio pdVWF/FVIII concentrate in type 3 von willebrand disease with severe bleeding phenotype in the United States: A payer and societal perspective Robert F. Sidonio, Jr. Received Received
  1290-SAT Patient characteristics, treatment patterns, and bleeding in people with Hemophilia A without inhibitors initiating efanesoctocog alfa in the US: An administrative claims analysis Jennifer Dumont Received Received
  1291-SAT Human hepatocyte engraftment in F8KO TK-NOG mice: Creating a novel Hemophilia A mouse model with functional human coagulation cascade Naoki Matsumoto Received Received
  1292-SAT A low-cost Clinical Prediction model for identifying female hemophilia carriers and women and girls with hemophilia (WGH) in central China Li Zhou Received Received
  1293-SAT Prophylaxis CTLA4-ig reduces anti-AAV neutralizing antibodies in AAV gene therapy for hemophilia Dandan Yu Received Received
  1294-SAT HLA alleles associated with inhibitor development in severe hemophilia A: Analysis of the "My life, our Future" hemophilia A cohort Kathleen P Pratt Received Received
  1295-SAT In vitro comparison of eptacog beta and eptacog alfa with antithrombin lowering (simulated fitusiran) using thrombin generation assay Sibgha Zaheer Received Received
  1296-SAT Comparative analysis between inhibitor screen and mini bethesda assay to diagnose low titre inhibitors in hemophilia patients - an experience from a hemophilia comprehensive care center in India Madhura Sagar Deshpande Received Received
  1297-SAT First report of high-titer FVIII inhibitor development following AAV-mediated gene therapy in Hemophilia A Davide Matino Received Received
  1298-SAT High treatment compliance and tolerability with fitusiran antithrombin-based dose regimen in people with hemophilia A or B, with or without inhibitors: ATLAS-OLE study Mindy Simpson Received Received
  1299-SAT Major bleeding and stroke in patients with hemophilia and atrial fibrillation Walker Michael Schmidt Received Received
  1300-SAT Blood group o and a lower endogenous thrombin potential are associated with increased risk for future bleeding after hemostatic challenges in bleeding disorder of unknown cause Tim Dreier Received Received
  1301-SAT A retrospective analysis of the safety and effectiveness of recombinant von willebrand factor in children with von willebrand disease undergoing surgery Tammuella Chrisentery-Singleton Received Received
  1302-SAT Tissue factor bearing microparticles drive thromboinflammation and predict DIC and mortality in sepsis: Results from the roadmap-sepsis study Patrick Van Dreden Received Received
  1303-SAT EASIX-guided risk stratification of severe coagulopathy and early mortality among newly diagnosed acute myeloid leukaemia with APL-like phenotype Mingkai Shu Received Received
  1304-SAT Recombinant von willebrand factor for perioperative management of bleeding in pediatric patients with severe von willebrand disease: Interim results from a phase 3 multicenter study and a phase 3b continuation study Eric Mullins Received Received
  1305-SAT Monoclonal gammopathy-related coagulopathies: A systematic analysis Tessa Lavorgna Received Received
  1306-SAT Direct thrombin inhibition by paraprotein in multiple myeloma: A rare mechanism of paraprotein-mediated coagulopathy, corrected with myeloma therapy Tessa Lavorgna Received Received
  1307-SAT Congenital factor II deficiency presenting with recurrent thrombosis Selin Sevkiye Aytaç Eyüpoglu Received Received
  1308-SAT Prevalence and management of iron deficiency in patients with bleeding disorders: A single-center, retrospective cohort study Troy Holden Received Received
  1309-SAT HMG-CoA reductase inhibitors and the attenuation of risk for disseminated intravascular coagulation in patients with sepsis: Secondary analysis finds no change in the index outcome based on reason for statin prescription William Ciurylo Received Received
  1310-SAT Treatment of type 1 plasminogen deficiency in women and girls with reproductive tract lesions: Pharmacokinetics and clinical outcomes with plasminogen therapy Karen Thibaudeau Received Received
  1311-SAT Aquired hemophilla a after covid-19 infection in an 5-week old infant Anyka A Clouden-James Received Received
  1312-SAT Emicizumab levels in patients with acquired and congenital Hemophilia A Christiane Dobbelstein Received Received
  1313-SAT Bleed-versus-clot paradox under immune-checkpoint inhibition: A decade-long US faers analysis reveals divergent class-specific hemostatic phenotypes Manzer Ali Received Received
  1314-SAT Efficacy and safety of RCD pulse regimen for acquired Hemophilia A Xianghua Wang Received Received
  1315-SAT Emicizumab for severe von willebrand disease (VWD): The (EmiVWD) study enrollment 2025 Jonathan C. Roberts Received Received
  1316-SAT Fibrin clot shields drive clonal selection of cancer cells: Procoagulant properties and proliferative survival of clot embedded cancer cells. a novel model of tumor microenvironment remodeling Patrick Van Dreden Received Received
  1317-SAT The formation of cryptococcus neoformans biofilms contributes to the pyroptosis of cerebral microvascular endothelial cells Hong Cao Received Received
  1318-SAT Why is diagnosing antiphospholipid syndrome so complex? characterization of cardiolipin chemical features required for antigenicity James Lee Received Received
  1319-SAT Enhanced clot formation and altered platelet subpopulations in mesothelioma characterized by a high-dimensional analytical platform Deepa Gautam Received Received
  1320-SAT P-selectin blockade effectively prevents trauma-induced microvascular obstruction Reheman Adili Received Received
  1321-SAT Anti-platelet factor 4 antibodies in MGUS-related thrombosis Adam Kanack Received Received
  1322-SAT Platelet factor 4 (PF4) modulates endothelial cell antimicrobial activity to enhance bacterial clearance and improve sepsis outcomes Anh T. P. Ngo Received Received
  1323-SAT Results from the first 200 ordered clinical modified ham (mHam) functional complement tests Bradley Lewis Received Received
  1324-SAT Deciphering the origin and plasticity of circulating endothelial cells reveals a systemic angiogenic program in breast cancer Orly Efros Received Received
  1325-SAT Association between sars-cov-2 infection, COVID-19 vaccines and immune thrombocytopenia in adults. a nationwide population-based study in France. Margaux Lafaurie Received Received
  1326-SAT Caplacizumab for pediatric immune thrombotic thrombocytopenic purpura: A scoping review of current evidence Sarah Elkourashy Received Received
  1327-SAT Preliminary analysis of the role of magnesium in transplant-associated thrombotic microangiopathy via complement activation pathways Chunxiao He Received Received
  1328-SAT Splenectomy as a treatment for relapsed or refractory immune thrombotic thrombocytopenic purpura: A systematic review Zahrah Talawala Received Received
  1329-SAT Characterization and risk factors of anticoagulation-related bleeding in patients with thrombotic antiphospholipid syndrome: An analysis using a synthetic real-world data platform Amir Mahmoud Received Received
  1330-SAT Complement inhibition in pediatrics: Comprehensive infection analysis from a large pediatric single center Sara Hawley Graciaa Received Received
  1331-SAT Patterns of antiphospholipid antibody positivity in a real-world laboratory over two decades Maria J Lizarazo Jimenez Received Received
  1332-SAT Thrombotic thrombocytopenic purpura-related mortality trends among the United States population: A retrospective study using the CDC wonder database Aqsa Zoey Sorathia Received Received
  1333-SAT Preemptive Rituximab in patients with ADAMTS13 relapse in thrombotic thrombocytopenic purpura: A systematic review Moazzam Shahzad Received Received
  1334-SAT Assessing the association between antiphospholipid syndrome and non-melanoma skin cancers: A case-control study on the role of a chronic inflammatory condition Ruhi Kanwar Received Received
  1335-SAT Cva with undetectable ADAMTS13 without hemolysis: An atypical presentation of thrombotic thrombocytopenic purpura (TTP) Osama Mohiuddin Received Received
  1336-SAT Management of heparin-induced thrombocytopenia in impella-supported cardiac surgery: A comprehensive four-patient case series with novel anticoagulation strategies Jugraj Singh Received Received
  1337-SAT Therapeutic plasma exchange and intravenous immunoglobulin facilitate safe heparin re-exposure in acute heparin-induced thrombocytopenia: A five-patient case series Jugraj Singh Received Received
  1338-SAT Fixed-duration preemptive rituximab maintenance over two years in recurrent thrombotic thrombocytopenic purpura with low ADAMTS13: A single-center case series Mohamad Khawandanah Received Received
  1339-SAT Injectable pentosan polysulfate: A novel cause of heparin-induced thrombocytopenia and stroke Alexandra Rusz Received Received
  1340-SAT Impact of race on the incidence, diagnosis and outcomes of pregnancy-associated venous thromboembolism: A nested case-control study Yan Xu Received Received
  1341-SAT Enhancing specificity in factor v leiden screening: Performance of the hemoclot quanti v-l assay Joshua Thomas Wischmeyer Received Received
  1342-SAT Current practices of anticoagulant utilization in pediatric patients with acute myeloid leukemia (AML) Abbey Elsbernd Received Received
  1343-SAT Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism, including by cancer site: Post-hoc analysis of the API-CAT randomised trial Isabelle Mahe Received Received
  1344-SAT VTE risk in transgender women on estrogen therapy: A review of formulation-specific risks, management strategies, and evidence gaps Sai Sushrutha Mudupula Vemula Sr Received Received
  1345-SAT Undiagnosed patent foramen ovale with bi-atrial thrombus in transit: A case of pulmonary embolism and refractory hypoxia Pedrom Farid Received Received
  1346-SAT Safety of prothrombin complex concentrate for emergency surgery according to the oral factor xa inhibitor level Ali Eshaghpour Received Received
  1347-SAT Impact of thrombocytopenia on hemorrhage and recurrent thrombosis in patients with cancer associated thrombosis, a time varying analysis Vasiliki Xirou Received Received
  1348-SAT The score settles it? maybe not: Navigating postpartum VTE prophylaxis Jennifer McIntosh Received Received
  1349-SAT In-hospital outcomes of patients admitted due to first-time acute chest syndrome with preexisting pulmonary embolism: A nationwide analysis 2016-2022 Ben Lerman Received Received
  1350-SAT VTE management in primary central nervous system neoplasms : A retrospective cohort study in a Canadian tertiary center between 2013 and 2023 Bobby Gouin Received Received
  1351-SAT Epidemiology of cancer-associated venous thromboembolism in a nationwide electronic healthrecord database Ang Li Received Received
  1352-SAT Temporal trends in cancer-associated venous thromboembolism mortality: A nationwide analysis (1999–2020) Dosbai Saparov Received Received
  1353-SAT Catheter-related risk factors for neonatal venous thrombo-embolism: A systematic review of the literature Rukhmi Bhat Received Received
  1354-SAT Dysregulation of fibrinolysis and its relationship with blood cellular indices in acute pulmonary embolism Mira Nigudkar Received Received
  1355-SAT Real-world practices in the management of pediatric iliofemoral deep vein thrombosis, results of the elite-kids survey from the CHAT consortium Maha Al-Ghafry Received Received
  1356-SAT Comparative performance of khorana, padua, and improve-VTE risk assessment models for venous thromboembolism risk stratification in hospitalized oncology patients Michael Streiff Received Received
  1357-SAT Transferrin and protection from thrombosis in sickle cell disease Lewis L. Hsu Received Received
  1358-SAT Increased FXII activation in endovascular treated stroke patients on periprocedural antithrombotic treatment Magdolna Nagy Received Received
  1359-SAT Defining resistance: Clinical outcomes based on varying definitions of heparin resistance Simon Bechara Received Received
  1360-SAT Disease-specific safety and efficacy of doacs vs. LMWH for venous thromboembolism in patients with brain metastases: A real-world trinetx analysis Ali Mushtaq Received Received
  1361-SAT More than a bulk: Higher incidence of venous thromboembolism (VTE) in patients with primary mediastinal B-cell lymphoma compared to patients with bulky mediastinal Hodgkin lymphoma Wysterlanyo Kayo Barros Received Received
  1362-SAT Distribution and risk for bleeding in patients with cancer by anticoagulant therapy exposure Kristen Marie Sanfilippo Received Received
  1363-SAT Efficacy and safety of adjunctive eptifibatide or argatroban versus control for acute ischemic stroke: A systematic review and network meta-analysis of randomized control trials Teja Sureddi Received Received
  1364-SAT Red blood cell transfusion thresholds in acute leukemia: Current practice and physician perspectives from a national survey Dimpy Modi Received Received
  1365-SAT Association of red blood cell transfusion and clinical outcomes in chimeric antigen receptor T-cell therapy: Insights from a six-year nationwide analysis Adamsegd Isac Gebremedhen Received Received
  1366-SAT Transfusion dosing targets; Concentration vs potency (a case for oxygen delivery-based metrics) Stephen C. Rogers Received Received
  1367-SAT Production of lab-grown red blood cells in hollow fiber bioreactors Eric Bouhassira Received Received
  1368-SAT GMP compliant CRISPR/Cas9 gene editing of B2 microglobulin in cord blood derived megakaryocytes and platelets for patients with refractory thrombocytopenia Hila Shaim Received Received
  1369-SAT Evaluating leukemogenic transmission via blood transfusion from genetically modified leukemic mice to healthy recipients Majed Refaai Received Received
  1370-SAT Efficacy of acute normovolemic hemodilution in adult cardiac surgery in reducing the need for allogenic red cell transfusion: A systematic review and updated meta-analysis of randomized controlled trials. Hrithik Dakssesh Putta Nagarajan Received Received
  1371-SAT Prophylactic transfusion in pregnant in women with sickle cell disease (ProTIP) Abraham Attah Received Received
  1372-SAT Abnormal adhesion of particular hematopoietic stem and progenitor cell subpopulations in the bone marrow, driven by aberrant interaction between VCAM-1 and VLA-4, ultimately contributes to leukemogenesis Tsila Zuckerman I Received Received
  1373-SAT Asynchronous acquisition of hematopoietic stem cell (HSC) quiescence, regenerative potential, and immune competence during neonatal maturation Chia-Jo Chen Received Received
  1374-SAT GPRASP2 maintains hematopoietic stem cell quiescence and self-renewal by receptor-mediated endocytosis Alanna Van Huizen Received Received
  1375-SAT The role of xdh and hprt1 on purine metabolism in hematopoiesis and leukemia Zhu Qianzhe Received Received
  1376-SAT Piezo1 is essential for endothelial-to-hematopoietic transition and hematopoietic stem/progenitor cell generation during embryonic development Shuwen Wang Received Received
  1377-SAT Single-cell multiomic dissection of human hematopoietic stem cells reveals novel transcriptional fingerprints and regulatory programs in bone marrow and mobilized peripheral blood Juan Roberto Rodriguez-Madoz Received Received
  1378-SAT Chronic alcohol consumption epigenetically reactivates transposable elements in aged hematopoietic stem cells Ridzky Anis Advent Yuda Received Received
  1379-SAT Expansion of human hematopoietic stem cells by inhibiting translation Chenchen Li Received Received
  1380-SAT RNA editing of H19 shapes hematopoietic stem cell function and differentiation via cell cycle regulation Shuangshuang Pu Received Received
  1381-SAT A branched chain amino acid rheostat controls hematopoietic stem cell replicative lifespan Sydney Treichel Received Received
  1382-SAT Cellpolaris: A novel tool to quantify cell polarity reliably at scale in fixed and living cells Dirk Loeffler Received Received
  1383-SAT Space associated stem cell hallmarks of aging (SASHA) in astronauts Jessica Pham Received Received
  1384-SAT Loss of ADAR1-mediated RNA editing disrupts lineage fidelity in human T cell development by inducing interferon response genes Maria Rivera Received Received
  1385-SAT GLP-1 receptor agonists and clonal hematopoiesis: Early human signals of anti-inflammatory clone mitigation and lower MDS-to-AML progression Mark Orland Received Received
  1386-SAT A pre-NGS screening strategy to identify populations with high-risk clonal hematopoiesis Riya Nandi Received Received
  1387-SAT Prevalence and significance of cytoses in clonal hematpoiesis Virginia O Volpe Received Received
  1388-SAT Srsf2P95H and Nf1 deficiency synergistically activate JAK-STAT signaling and exacerbate age-related clonal hematopoiesis in mice Wangqing Dun Received Received
  1389-SAT Asxl1 mutant cells suppress Dnmt3a mutant clonal expansion. Apoorva Thatavarty Received Received
  1390-SAT The role of sole loss of chromosome y in myeloid neoplasms Sandra Huber Received Received
  1391-SAT Concurrent clonality of multiple hematopoietic lineages: Implications for pathogenesis and management of cytopenia Carlos Bravo-Perez Received Received
  1392-SAT Loss of endothelial mir-126 drives age-related reduction of hematopoietic activity Bin Zhang Received Received
  1393-SAT Distinct patterns of clonal hematopoiesis exist in a longevity enriched cohort Salman Sadullah Usmani Received Received
  1394-SAT Longterm outcome of patients with clonal cytopenia of undetermined significance: 10 year follow-up of a large unselected cohort Catherine Cargo I Received Received
  1395-SAT U2AF1S34F mutant HSPCs have a fitness advantage in aged and inflamed bone marrow Bridget Kathleen Hoag Received Received
  1396-SAT Clonal hematopoiesis drives T cell dysregulation and immune remodeling revealed by GWAS-based mendelian randomization and single-cell transcriptomics Janghee Woo Received Received
  1397-SAT Beyond clonal hematopoiesis of indeterminate potential: Understanding how the trisomy 21 context promotes TET2 mutations Edward James Evans Jr Received Received
  1398-SAT The bromodomain and extra-terminal domain protein BRD4 promotes both self renewal and inflammation in TET2 mutated clonal hematopoiesis Nicole Renee Grieselhuber Received Received
  1399-SAT Characterization of antecedent clonal hematopoiesis (CH) mutations in lymphoid and plasma cell neoplasms Pinkal Desai Received Received
  1400-SAT Impact of innate immune memory on MDS progression by TET2-driven inflammation Alyssa Nicole Louise Jarabek Received Received
  1401-SAT The CD33 SNP rs3865444 modulates the association of clonal hematopoiesis with Alzheimer´s disease Christopher Maximilian Arends Received Received
  1402-SAT Macrophage subsets provide distinct niches for normal and clonal hematopoiesis Yirong Zhang Received Received
  1403-SAT Generating ectopic subcutaneous bone marrow by reconstitution of endochondral ossification Hinako Notoh Received Received
  1404-SAT miRNA-mRNA analysis of mesenchymal stem cell derived extracellular vesicle mediated ex vivo expansion of hematopoietic stem cells Kunye Kwak Received Received
  1405-SAT Bone marrow microenvironment retinoic acid receptor signaling represses multipotential progenitor dependent B cell lymphopoiesis through secretion of resistin Parash Prasad Received Received
  1406-SAT Lysyl oxidases directly control cell surface abundance of platelet-derived growth factor receptors and signaling in osteoblasts Wolfgang Gunter Jarolimek Received Received
  1407-SAT Soluble factors in the AML secretome drive macrophage polarization toward an M2-like state promoting an immunosuppressive microenvironment Giorgia Longo Received Received
  1408-SAT IDH2 mutant hematopoietic stem and progenitor cells promote endothelial niche remodeling Edgardo Ismael Franco Jr Received Received
  1409-SAT Single-cell transcriptomic analysis reveals impaired immune profiles in elderly AML patients Yebo Peng Jr Received Received
  1410-SAT A novel dll4 enhancer regulates sinusoidal niche-mediated HSC proliferation and maintenance Wantong Li Received Received
  1411-SAT Peripheral blood and bone marrow immune profiles are strongly correlated in patients with plasma cell disorders Jens Hillengass Received Received
  1412-SAT Leveraging an integrated single cell atlas to understand perinatal bone marrow development Brian M. Dulmovits Received Received
  1413-SAT Beyond the unknown: Leveraging machine learning to predict adverse outcomes in pregnant women with aplastic anemia from a representative nationwide cohort Qiuyu Guo Received Received
  1414-SAT Hematological and inflammatory response trajectories in vexas syndrome patients treated with hypomethylating agents Fieke Hoff Received Received
  1415-SAT Real-world application of AI in expediting paroxysmal nocturnal hemoglobinuria diagnosis Robert Dewor Jr Received Received
  1416-SAT Efficacy and safety of romiplostim N01 for refractory aplastic anemia: A retrospective single-center study Zhuang Qilin I Received Received
  1417-SAT DNA methylation variability in pediatric aplastic anemia contributes to T cell differentiation Xinan Wang Received Received
  1418-SAT Development and validation of the predictive aplastic score system (PASS): A simplified tool to diagnose acquired aplastic anemia in adults Gabriel Francisco Pereira Aleixo Received Received
  1419-SAT Iron overload and iron chelation therapy in PNH patients on complement inhibitors: A single centre experience. Miguel Gómez Álvarez Sr Received Received
  1420-SAT Efficacy and safety of pozelimab plus cemdisiran versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria who received prior C5 therapy Jun Ho Jang Received Received
  1421-SAT Rare germline complement gene variants in severe aplastic anemia Luca Arcuri Received Received
  1422-SAT Aplastic anemia in pregnancy: A case series review of hematologic parameters, treatment, and maternal-fetal outcomes Selma S EL Jabbouri Received Received
  1423-SAT Evaluation of current diagnostic workup for pediatric severe aplastic anemia: Low incidence of cryptic inherited bone marrow failure syndromes Helen Reed Received Received
  1424-SAT Eltrombopag promotes hematopoietic engraftment and improves the survival of bone marrow failure disease following hematopoietic stem cell transplantation Meng Zhou Received Received
  1425-SAT Ruxolitinib may treat aplastic anaemia by reducing levels of macrophage pyroptosis Xintong Xu I Received Received
  1426-SAT First-line romiplostim combined with immunosuppressive therapy for severe aplastic anemia: A prospective, single-arm, Phase II study Lele Zhang Received Received
  1427-SAT Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria Matthew Holt Received Received
  1428-SAT Unique NK-like T cell population identified in UBA1mt cells in vexas associated with IL-8 mediated activity and cytotoxic response pathways Terra Lasho Received Received
  1429-SAT Real-world treatment patterns and clinical outcomes among patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan in the United States David Dingli Received Received
  1430-SAT Management of a real-world cohort of patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan: A multi-institutional analysis Mark Orland Received Received
  1431-SAT Prevalence and impact of somatic mutations in patients with aplastic anemia (AA) undergoing allogeneic hematopoietic cell transplantation (HCT): A single center retrospective analysis Salman Otoukesh Received Received
  1432-SAT Epidemiologic clues, current management and diagnostic trends in idiopathic budd-chiari syndrome: Implications of PNH and diagnostic testing Aashray Mandala Received Received
  1433-SAT Navigating the complement cascade: A multicenter journey from pegcetacoplan to iptacopan in paroxysmal nocturnal hemoglobinuria Praveena Thiagarajan Received Received
  1434-SAT Multiple HLA-loss clones are required for hematologic regeneration in immune aplastic anemia Miku Kobayashi Received Received
  1435-SAT A pilot study of low-dose sirolimus to increase hematopoietic function in patients with RUNX1 familial platelet disorder Leticia Campoverde Received Received
  1436-SAT Liver disease in shwachman-diamond syndrome: A report from the shwachman-diamond syndrome registry Jane Koo Received Received
  1437-SAT Hematologic malignancies in pediatric patients with RUNX1-familial platelet disorder with associated myeloid malignancy Amra Kajdic Received Received
  1438-SAT A zebrafish model of parn deficiency identifies altered lipid metabolism as a novel therapeutic target for restoring hematopoiesis in dyskeratosis congenita Sarada Ketharnathan Received Received
  1439-SAT Granulocyte maturation and splicing defects in DDX41-mutated leukemia Ira Lignugaris Kraft Received Received
  1440-SAT ANKRD26-related thrombocytopenia: Hematologic malignancy characteristics, clinical outcomes, and precursor states Lauren G. Banaszak Received Received
  1441-SAT First-in-class small molecule calmodulin pathway modulators attenuate excess p53 activity and correct erythropoietic defects in models of diamond-blackfan anemia (DBA) Avik Choudhuri Received Received
  1442-SAT Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients Talha Badar Received Received
  1443-SAT Unsupervised clustering of DDX41 mutants informs on the somatic landscape of single germline hits Arda Durmaz Received Received
  1444-SAT Modeling germline DDX41 and/or CHEK2 mutations using patient-derived bone marrow Organoids Inci Aydemir Received Received
  1445-SAT Exploring the spectrum of non-malignant complications in germline DDX41-associated hematologic disorders Valeria Visconte Received Received
  1446-SAT The role of G0S2 in FLT3+ AML bone marrow microenvironment and metabolism Mayra Alejandra Henry Received Received
  1447-SAT Pan-leukemia 3D genomic profile reveals extreme long polycomb loop in subset of CEBPA mutated AMLs sensitive to EZH2 inhibition Xiaotian Zhang Received Received
  1448-SAT Beyond the genome: An integrated multi-omics approach to uncover histone ptm-driven metabolic and proteomic regulation in AML Tim Lammens Received Received
  1449-SAT Loss of the Y chromosome drives context-dependent transcriptional reprogramming in myeloid progenitors and AML1-ETO acute myeloid leukemia (AML) Hayden Luke Bell Received Received
  1450-SAT Repertoire of driver events in coding and non-coding regions identified by whole-genome sequencing of myeloid neoplasms Koji Okazaki Received Received
  1451-SAT Hypermethylation of the ribosomal DNA coding sequence and disordered transcription factor binding as hallmarks of acute myeloid leukemia James Wengler Received Received
  1452-SAT Ribosome biogenesis and its regulation by the exportin, CSE1L, are targetable vulnerabilities in childhood and young adult Acute Myeloid Leukemia Grace Egan Received Received
  1453-SAT The PDI-ATF6-axis as a novel treatment target in CSF3R driven chronic neutrophilic leukemia (CNL) Alessandra Hartke Received Received
  1454-SAT Inhibition of prolyl-tRNA synthetase sensitizes acute myeloid leukemia to venetoclax through bmf-mediated apoptosis Yuri Okazoe-Hirakawa Received Received
  1455-SAT Allergin-1 marks leukemic stem cells and enables immune evasion in AML: A target for therapeutic antibody development Yi Pan Received Received
  1456-SAT Deciphering the bone marrow inflammatory cytokine network in AML prognosis and immune evasion: A focus on the IL-1A-CCL3/4 axis as a novel therapeutic target Wang Shuqing Received Received
  1457-SAT Somatic ASXL1 mutations in chronic myelomonocytic leukemia result in loss of imprinting control and overexpression of DLK1 through deregulation of DNA methylation Pankaj Pradeep Received Received
  1458-SAT Clonal heterogeneity of acute myeloid leukemia under nutrient and chemotherapy stress Christina Mayerhofer Received Received
  1459-SAT ST2 promotes leukemia transformation by reshaping the immune landscape in Acute Myeloid Leukemia Yu-Hsuan Fu Received Received
  1460-SAT PTP4A3: A potential therapeutic target in Acute Myeloid Leukemia Changqing Jiao Received Received
  1461-SAT Acute depletion of HOXA9 reveals its direct role in cis-elements regulation and 3D genome organization during Acute Myeloid Leukemia Qili Shi Received Received
  1462-SAT Synergistic effects of ASXL1 and BCOR on hematopoiesis and MDS/AML progression Rongtao Xue Received Received
  1463-SAT Targeting BRD9 in KMT2A-rearranged Acute Myeloid Leukemia to circumvent MEN1 inhibitor resistance Ning Qing Liu Received Received
  1464-SAT Azin1/tecr reprograms fatty acid metabolism to drive Acute Myeloid Leukemia progression Meng Yang Received Received
  1465-SAT The chromatin remodeling protein ARID1A is required for MLL-AF9 leukemogenesis Kira Cozzolino Received Received
  1466-SAT Missense mutations in the PWWP domain of DNMT3A can cause cytoplasmic mislocalization of DNMT3A in AML cells Alice Y. Lo Received Received
  1467-SAT Enhanced FLI1 accessibility mediates STAG2-mutant leukemogenesis Jane J Xu Received Received
  1468-SAT Machine learning approach identifies targeting strategy for selective AML dependency Enea Provenzano Received Received
  1469-SAT Cd39 overexpression in AML blasts elicits an immune suppressive bone barrow microenvironment via G3/G4 neutrophils and Th1 cells Hanheng Mai Received Received
  1470-SAT NEAT1-triggered collateral activity of CRISPR/Cas13 exhibits antileukemic activity Ruka Shimura Received Received
  1471-SAT ENO1 promotes Acute Myeloid Leukemia progression through SCD1-mediated lipid metabolism reprogramming Yijun Wu Received Received
  1472-SAT Single-cell tracing of myeloid leukemia evolution in down syndrome reveals a latent progenitor bridging disease onset, progression and relapse Stephanie Frenz-Wiessner Received Received
  1473-SAT CBFA2T3::GLIS2 directly represses differentiation and is required for AMKL disease maintenance Rachel Brooke Mersfelder Received Received
  1474-SAT Novel therapeutics for SF3B1 mutant cancers which exploit the missplicing of DCAF16 Sydney Xin-Li Lu Received Received
  1475-SAT MYC-dependent permissiveness of PI3K hyperactivation renders metabolic vulnerability in R/R b-ALL Junzhe Song Received Received
  1476-SAT Targeting hells-mediated chromatin accessibility to sensitize ALK-negative anaplastic large cell lymphoma to JAK/STAT and DNA-PK inhibition Valentina Fragliasso Received Received
  1477-SAT The chromatin remodeler hells regulates transcription-replication conflicts and genome integrity in ALK-negative anaplastic large cell lymphoma Selene Mallia Received Received
  1478-SAT Murine modeling of cluster 1 diffuse large B-cell lymphoma reveals transformation from marginal zone lymphoma Tianfang Ma Received Received
  1479-SAT EZH2 oncogenic mutation disrupts germinal center B cell dynamics and promotes early lymphomagenic behaviors Kibaek Choe Received Received
  1480-SAT Neomorphic chromatin engagement and epigenetic reprogramming by the IKZF1 N159Y tandem duplication mutant in b-acute lymphoblastic leukemia Ruth W. Wang´ondu Received Received
  1481-SAT Targeting VDAC1 to induce mitochondrial DNA–STING signaling and lysosomal cell death in T-cell lymphoma Po Hu Received Received
  1482-SAT A mouse model of aggressive ATL associated with oncogenic mutations and an HBZ-expressing hematopoietic environment Takuro Kameda Received Received
  1483-SAT SLC7A11 suppresses ferroptosis via arginine metabolism and promotes tumor immune escape in acute lymphoblastic leukemia Jianda Hu Received Received
  1484-SAT Autonomous BCR signaling and the CARD11 L251P mutation as alternative oncogenic drivers induce identical gene expression profiles in genetically engineered ABC-DLBCL models Hendrik Veelken Received Received
  1485-SAT Alternating cycles of quiescent and proliferative cell states determine stemness and leukemia-initiation capacity in acute lymphoblastic leukemia Zhangliang Cheng Received Received
  1486-SAT SMARCD1 subunit of SWI/SNF chromatin remodeling complexes collaborates with p53 to exert an oncogenic role in B-ALL by maintaining high metabolic activity Laurence Côté Received Received
  1487-SAT Ferroptosis escape in AML stem cells uncovered by single-cell profiling and reversed by STAT3/NRF2 inhibition Ritu Gupta Received Received
  1488-SAT Combined FLT3 and EZH1/2 inhibition reduces LSCs and promotes myeloid differentiation in PDX models of AML Pamela J. Sung Received Received
  1489-SAT Amx-883, a potent and selective degrader of BRD9 drives differentiation in acute myeloid leukaemia and shows synergistic efficacy in combination with venetoclax In Vivo and prevents the emergence of resistance to venetoclax in vitro. Martin Pass Received Received
  1490-SAT Pharmacological targeting of CTPS1 elicits macrophage-mediated anti-leukemia immunity Meng Liu Received Received
  1491-SAT TP53 activation by the natural quassinoid brusatol enhances venetoclax efficacy and overcomes resistance in myeloid leukemias Shin-ichiro Kawaguchi Received Received
  1492-SAT Targeting ribonucleotide reductase to overcome FLT3 Inhibitor Resistance in acute myeloid leukemia Jian Huang Received Received
  1493-SAT Liposomal melatonin targets mutant hematopoiesis and bone marrow remodeling in MPN Siddharth Rakesh Gupta Received Received
  1494-SAT Chidamide reprograms AML-associated macrophages via HDAC3 inhibition to boost CD8+ T cell immunity Zhili Tan I Received Received
  1495-SAT Clonal persistence of BRAFV600E under MEK inhibition in histiocytosis Julien Haroche Received Received
  1496-SAT Ferroptosis activates NK and CAR T cell-mediated anti-tumor immunity in Acute Myeloid Leukemia Saurabh Kumar Kumar Gupta Received Received
  1497-SAT Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models Warren Fiskus Received Received
  1498-SAT Targeting DNA repair vulnerabilities to eradicate TP53 mutated AML. Rifat Ara Najnin Received Received
  1499-SAT Single-cell insights into acute myeloid leukemia treated with venetoclax-based therapy Prajwal Dhakal Received Received
  1500-SAT Identifying novel ´druggable´ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML Christopher P Mill Received Received
  1501-SAT Novel BCR::ABL1 fusion alongside T315I reveals mechanism for dual ponatinib/asciminib resistance and proves sensitive to addition of axitinib Mohammad Azam Received Received
  1502-SAT The fanconi anemia pathway restrains MLL-rearranged leukemogenesis through suppressing NHEJ-mediated genomic instability Jian Xu Received Received
  1503-SAT Nonclinical evaluation of APL-4098, a novel GCN2 kinase inhibitor, reveals potent anti-leukemic effects through mitochondrial stress induction and synergy with venetoclax, targeting AML blasts and LSCs Nadine Clemo Received Received
  1504-SAT Investigating KAT2A protac therapy for targeting leukemic blast differentiation in acute myeloid leukaemia. Agisilaos Zerdelis Received Received
  1505-SAT Targeting nucleotide metabolism to enhance ara-c sensitivity in myeloid leukemia associated with down syndrome Jenna Thibodeau Received Received
  1506-SAT Pharmacokinetics and cardiac impact of arsenic trioxide (ATO) oral solution (SDK001) under fasting, fed, and calcium carbonate co-administration conditions compared with intravenous ATO in patients with acute promyelocytic leukemia Harinder Gill Received Received
  1507-SAT PPM1D mutations confer resistance to venetoclax in pre-leukemic and AML populations Jules Higue Received Received
  1508-SAT Disrupting monocytic AML and monocytic leukemia stem cells with a novel cladribine regimen: From bench to bedside Jie Sun Received Received
  1509-SAT C?TA-mediated up-regulation of MHC reverses immune evasion of leukemia stem cells in refractory/relapsed AML Li Hou Received Received
  1510-SAT Protein degradation of MYC/GSPT1 combined with menin inhibition overcomes resistance to menin inhibition in KMT2A-rearranged Acute Myeloid Leukemia Yuki Nishida Received Received
  1511-SAT A novel role for SIX1 and EYA2 and a novel EYA2 inhibitor in myeloid leukemogenesis Waitman Aumann Received Received
  1512-SAT Mechanism of acquired resistance to histone deacetylase inhibitor, romidepsin, in myeloid leukemia associated with down syndrome Kader Cicek Received Received
  1513-SAT Mechanistic approach exploring combination agents to potentiate anti-leukemia activity of Hu8F4, a clinical stage T cell receptor mimic antibody Anna Sergeeva Received Received
  1514-SAT Negative feedback regulation of nfkb, MAPK, and JAK-STAT drives adaptive resistance to gilteritinib in AML Meenu Kesarwani Received Received
  1515-SAT Optimizing establishment of high need pediatric Acute Myeloid Leukemia (AML) patient derived xenograft (PDX) models Shivani Gollapudi Received Received
  1516-SAT Numerous clinically-detected asciminib-resistant BCR::ABL1 mutations disrupt allostery and confer cross-resistance to the novel clinically-active allosteric TKI tgrx-678 Ariel Leyte-Vidal Received Received
  1517-SAT Targeting the compass complex to overcome resistance in KMT2A-rearranged Acute Myeloid Leukemia Sandhya Dhiman Received Received
  1518-SAT Azacitidine-panobinostat activates NF-kb signaling in the bone marrow microenvironment to chemosensitize KMT2A rearranged pediatric AML Kara Lehner Received Received
  1519-SAT Next-generation tumor-specific anti-CD30 ADC as a new therapy in hemato-oncology Johanna Marines Received Received
  1520-SAT ARV-393, a PROTAC BCL6 degrader, combined with the CD20×CD3 bispecific glofitamab in a preclinical model of high-grade B-cell lymphoma (HGBCL) Anna Van Acker Received Received
  1521-SAT IRF4 maintenance in multiple myeloma is conserved in de novo-derived inobrodib resistance, conferring cross resistance to immunomodulatory drugs Jason Taslim Received Received
  1522-SAT Tyrosine phosphorylation and allosteric regulation of IMPDH2 reveals a novel therapeutic vulnerability in hematologic malignancies Johnvesly Basappa Received Received
  1523-SAT Dioscin suppresses the progression of diffuse large B-cell lymphoma by modulating acaca-dependent histone H3K27 acetylation and inducing mitophagy Qianqian Guo Received Received
  1524-SAT Repurposing of disulfiram as a novel therapeutic agent to treat crebbp-mutant diffuse large B-cell lymphoma (DLBCL) James Boncan Received Received
  1525-SAT CD47-blockade induces programmed necroptosis and complements the effects of BCL-2 inhibition in lymphoid malignancies Stephen Jun Fei Chong Received Received
  1526-SAT Selenocysteine dependency renders central nervous system leukaemia therapeutically sensitive to ferroptosis Nikolai Gajic Received Received
  1527-SAT A combination strategy of inotuzumab ozogamicin (InO) and BCL-2 family inhibitors prevents the emergence of PGP+ ino-resistant MRD in B-cell acute lymphoblastic leukemia Anna Akaogi Received Received
  1528-SAT Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM) Yan Yin Received Received
  1529-SAT PRMT5 is a therapeutic vulnerability in cutaneous T-cell lymphoma Nicole Peterman Received Received
  1530-SAT The efficacy of Obinutuzumab , zanubrutinib combined with pomalidomide and Venetoclax for the treatment of high-risk mutated Mantle Cell Lymphoma (MCL): A prospective, open-label, single-arm study Ping Yang I Received Received
  1531-SAT Biphasic effects of cyclophosphamide on l-asparaginase hypersensitivity and resistance in mice Ai Nogami-Hara I Received Received
  1532-SAT Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib Britten Kalib Gordon Received Received
  1533-SAT Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma Omar Nadeem Received Received
  1534-SAT Vitamin K3 metabolic fate determines pro-survival or ferroptotic outcomes in multiple myeloma via UBIAD1 and reductase axis Yonggang Zhang Received Received
  1535-SAT Immunotherapy resistant ALL cells exhibit selective dependence on glutamine and specific transporters for growth and survival Jessica Briggs Received Received
  1536-SAT ATR inhibition with nucleoside analog therapy synergistically overcomes chemoresistance and reprograms dark zone lymphomas toward immune-accessible phenotypes Anand Devaprasath Jeyasekharan Received Received
  1537-SAT A laser-based nanoparticle platform to enhance T cell–Mediated immunity without direct tumor access John Weber Received Received
  1538-SAT CRISPR-Cas9 screen-driven identification of metabolic vulnerabilities reveals synthetic lethality via synergistic targeting of mitochondrial energy pathways and lactate export in oxphos-dependent T-ALL Natalia Baran Received Received
  1539-SAT Protein degradation of MYC/GSPT1 is a novel treatment modality for aggressive T-cell acute lymphoblastic leukemias Mikaela Garza Received Received
  1540-SAT Effectiveness and prognostic impact of BMI, MRD and CNS involvement in AYA patients with Philadelphia-negative ALL treated using the AYA-15 protocol: Real-world from a tertiary center in the middle east Ahmed Abdrabou Sr Received Received
  1541-SAT Real-world survival outcomes of Japanese adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with ponatinib Naoto Takahashi Received Received
  1542-SAT Obesity is associated with poor prognosis in ph-like acute lymphoblastic leukemia Maiah Zarrabi Received Received
  1543-SAT Predicting mortality in ICU patients with acute leukemias: A new risk score Jose Manuel Sánchez Albarran Received Received
  1544-SAT Impact of uncontrolled hyperglycemia during induction chemotherapy on response and survival outcomes in patients with adult B-cell acute lymphoblastic leukemia (B-ALL) on HCVAD-based regimens Grace Park Received Received
  1545-SAT Induction mortality in acute leukemia: The hidden burden of infections in a middle-income country Analy Mora Received Received
  1546-SAT Beyond MRD: The importance of weight recovery in adults with ALL Frida Valeria Rodriguez Contreras Received Received
  1547-SAT Targeting the sanctuary sites: Allogeneic CD19 CAR-T therapy for extramedullary relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation Rui multiple Liu Received Received
  1548-SAT Revisiting the role of second allogeneic HCT for post-transplant relapse in acute lymphoblastic leukemia: Comparative outcomes in the era of targeted therapies Jaehyun Ahn Received Received
  1549-SAT Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab Bhavana Bhatnagar Received Received
  1550-SAT Robust assessment of early MRD levels could further improve treatment outcomes in low-risk patients of pediatric acute lymphoblastic leukemia: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL Study Hsi-Che Liu Received Received
  1551-SAT Patient-reported quality of life in Chinese children with B-cell acute lymphoblastic leukemia receiving first-line treatment with blinatumomab Jia Fan Received Received
  1552-SAT Venetoclax in combination with hypomethylating agents are effective salvage therapy in relapse/refractory ETP-ALL and near-ETP-ALL Carol Yuk-Man Cheung Received Received
  1553-SAT Temporal trends in treatment outcomes of acute lymphoblastic leukemia in Japan: Progress and unmet needs Ryo Koizumi Received Received
  1554-SAT Fixed-dose inotuzumab ozogamicin combined with vincristine and prednisone regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia Lei Ju Received Received
  1555-SAT Use and outcomes following blinatumomab rechallenge in adolescents and young adults (AYA) and adults with B-cell acute lymphoblastic leukemia (B-ALL) Mark Blaine Geyer Received Received
  1556-SAT Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia Hannah Goulart Received Received
  1557-SAT Disease characteristics and outcomes of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) involvement Michal Bar-Natan Received Received
  1558-SAT Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of Trevor Jamison Received Received
  1559-SAT Safety of lumbar puncture in adult patients with acute lymphoblastic leukemia and thrombocytopenia: A retrospective study Andres Yesid Yesid Bonilla Salcedo I Received Received
  1560-SAT Survival outcomes in therapy-related acute lymphoblastic leukemia: A population-based analysis from SEER (2000–2022) Anish Shah Received Received
  1561-SAT Front-line consolidation with CAR-t therapy in newly diagnosed adult ph-negative b-acute lymphoblastic leukemia: Results from a prospective, phase 2 study Shaowei Qiu Received Received
  1562-SAT Efficacy of short-course versus standard-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia Qingsong Yin Received Received
  1563-SAT Kte-X19 in relapsed or refractory adult B-cell acute lymphoblastic leukemia in the Chinese population: 6-month analysis of a phase II multicenter trial Meng Lv Received Received
  1564-SAT Excellent prognosis for adult patients with Philadelphia chromosome-negative ALL with standard genetic risk and EARLY clearance of MRD. sub-analysis of pethema LAL19 trial Anna Torrent Received Received
  1565-SAT An updated UK real-world analysis of factors affecting outcome following brexucabtagene autoleucel for relapsed or refractory adult acute lymphoblastic leukemia Anna Castleton Received Received
  1566-SAT Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis Hannah Goulart Received Received
  1567-SAT The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study Hannah Goulart Received Received
  1568-SAT Daratumumab and venetoclax-based combined regimen for relapsed/refractory T-lymphoblastic leukemia/lymphoma Shan Shao Jr Received Received
  1569-SAT Efficacy and safety of inotuzumab ozogamicin combined with venetoclax and dexamethasone in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) Zhuo Wan I Received Received
  1570-SAT A real-world multi-institution experience of standard vs alternative dosing of inotuzumab ozogamicin for Relapsed/Refractory pediatric B-cell acute lymphoblastic leukemia Morgan Drucker Received Received
  1571-SAT Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: Long-term follow-up from a phase 2 Study Hannah Goulart Received Received
  1572-SAT Asciminib for relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and lymphoid blast crisis of chronic myeloid leukemia (LBC-CML) in Italy: A Campus ALL real life study Matteo Dragani Received Received
  1573-SAT Brexucabtagene autoleucel (Brexucel) as a consolidation therapy in B-cell acute lymphoblastic leukemia (B-ALL) post HCVAD/minihcvd-inotuzumab-blinatumomab regimens: Initial Results of a prospective Phase 2 trial. Jayastu Senapati Received Received
  1574-SAT Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) Suning Chen Received Received
  1575-SAT Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher Caitlin Rausch Received Received
  1576-SAT Blinatumomab versus high-dose chemotherapy in the first-line therapy of high-risk childhood B-cell acute lymphoblastic leukemia: The results of a Phase 3 trial of the cALL-pol consortium in Poland Wojciech Michal Michal Mlynarski Received Received
  1577-SAT Phase II Results of ECOG-ACRIN EA9152: A multicenter study of liposomal vincristine (L-VCR) or vincristine sulfate (VCR) and venetoclax (VEN) in relapsed or refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) Neil D Palmisiano Received Received
  1578-SAT Blinatumomab and ponatinib vs. hyper-CVAD and ponatinib in patients with Philadelphia-chromosome positive acute lymphoblastic leukemia: A propensity score analysis Koji Sasaki Received Received
  1579-SAT Study on the efficacy and safety of HDAC inhibitor combined with venetoclax and azacitidine in the treatment of adult T-ALL Li Hui Received Received
  1580-SAT Cytopenias and infectious complications following CD19-directed CAR-T cell therapy in patients with B-ALL: A single-center retrospective analysis Kriti Gera Received Received
  1581-SAT Trial in progress: nutrition and exercise to optimize muscle and adiposity in adolescents and young adults with B-cell acute lymphocytic leukemia: The neoma ALL trial Samuel Yates Received Received
  1582-SAT HEM-ismart: An international proof-of-concept therapeutic stratification trial of molecular anomalies in relapsed or refractory hematological malignancies in children Andrej Lissat Sr Received Received
  1583-SAT Low-intensity cytoreduction with low-dose cytarabine prior to blinatumomab for pediatric and AYA R/R ALL integrated with multi-omics analysis to discover predictive biomarkers: Initial results from JPLSG-ALL-R19-blin Itaru Kato Received Received
  1584-SAT EZH2 inactivation cooperates with HOXA9 to induce leukemic transformation of human t-cell progenitors and sustain high-risk subsets of early t-cell precursor acute lymphoblastic leukemia (ETP-ALL) Mattia Colucci Received Received
  1585-SAT Long-read profiling of structural variants reveals mechanisms of chemo-resistance and prognostic heterogeneity in acute lymphoblastic leukemia Xiaofang Ma Received Received
  1586-SAT PROK1 locus variant identified as a genetic determinant of anthracycline-related cardiomyopathy in long-term childhood acute leukemia survivors Mathilde Veneziano Broccia Received Received
  1587-SAT Clinical value of advanced genomic testing in adult Philadelphia-negative B-ALL: Results from the CZ national leukemia study group (CELL) Zuzana Vrzalova Received Received
  1588-SAT Endogenous regulation of inflammatory response as a determinant of durable remission without stem cell transplant following brexucabtagene autoleucel (Brexu-cel) therapy in ALL Jae Park Received Received
  1589-SAT Effects of ZMIZ1 mutations in newly defined early T-cell precursor leukemia Jannaldo Nieves-Salva Received Received
  1590-SAT Increased yield of recurrent structural variants (SVs) in Ph-like B-cell acute lymphoblastic leukemia (B-ALL) using a streamlined clinical whole-genome sequencing (WGS) assay David H Spencer Received Received
  1591-SAT Utility of peripheral blood cell-free DNA in detecting minimal residual disease in patients receiving CAR T-cell therapy for B-acute lymphoblastic leukemia (B-ALL) Yannan J Wang Received Received
  1592-SAT Siglec-15 dependent alteration of the leukemia immune microenvironment Dailia B. Francis Received Received
  1593-SAT Protein expression signatures reveal age-specific risk patterns in B-ALL Samanta Catueno Received Received
  1594-SAT Characterization of cerebrospinal fluid pleocytosis and cell subsets during blinatumomab therapy for pediatric B-ALL: A real-life study from China Ying Wu Received Received
  1595-SAT Single cell transcriptomics of matched cerebrospinal fluid and bone marrow patient samples highlights the role for CXCR4 in acute lymphoblastic leukemia CNS disease Signe Modvig Received Received
  1596-SAT Hemodilution assessment for high-sensitivity flow cytometric measurable residual disease evaluation in pediatric B-cell acute lymphoblastic leukemia Prashant Tembhare Received Received
  1597-SAT Exploring the immunodynamic landscape of blinatumomab therapy in pediatric BCP-ALL through full-spectrum flow cytometry Mingying Zhang Received Received
  1598-SAT Dynamic changes in myeloid derived suppressor cells subsets in pediatric B cell acute lymphoblastic leukemia : Correlation with measurable residual disease status. Prisla Maria Dalton III Received Received
  1599-SAT Risk factors for disseminated intravascular coagulation in pediatric acute promyelocytic leukemia: Insights from the cclg-APL 2016 study Qingyuan Xu Received Received
  1600-SAT The 10-minute targeted geriatric assessment (10-TaGA), a 10-domain-to-one-score tool, predicts early death in intensively treated older AML patients: First results from a multicenter study Frederico Lisboa Lisboa Nogueira Received Received
  1601-SAT Neutropenia, infections, and mortality across Acute Myeloid Leukemia induction strategies: A single center retrospective study Rohan Singh Received Received
  1602-SAT CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients Saubia Fathima Received Received
  1603-SAT Real-world outcomes and a novel prognostic assessment model for high-risk acute promyelocytic leukemia receiving all-trans retinoid acid and arsenic trioxide dual induction based on lasso-cox regression Kai Shen Received Received
  1604-SAT Outcomes and cause-specific mortality of AML in adults from Chile Macarena Salinas Roa Received Received
  1605-SAT The need for re-induction based on D14-residual acute myeloid leukemia in patients achieving complete remission predicts higher relapse rate and inferior post-remission survival Abiola Bolarinwa Received Received
  1606-SAT Central nervous system relapse in acute promyelocytic leukemia in the arsenic era: A case series and review of emerging evidence Amjad Hmaid Received Received
  1607-SAT Shifting treatment paradigms lead to improved overall survival in Acute Myeloid Leukemia: Real-world data from an integrated health system. Sabiha Tamima Received Received
  1608-SAT Clinical, cytogenetic and molecular characteriszation of Mecom- rearranged pediatric de novo Acute Myeloid Leukemia (AML): A retrospective cohort study of the international-berlin-frankfurt-Muenster (I-BFM) AML-study group Anna Cvrtak Jr Received Received
  1609-SAT Real-world insights into ATRA-based maintenance therapy and prognostic markers of relapse in acute promyelocytic leukemia Kunye Kwak Received Received
  1610-SAT The infection spectrum in newly diagnosed Acute Myeloid Leukemia patients treated with venetoclax-based or conventional chemotherapy: A real-world retrospective study Guilin Ren Jr Received Received
  1611-SAT Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia Wenbing Duan Received Received
  1612-SAT Optimizing ELN 2022: Developing and validating a dynamic prognostic model for AML using platelet change rates and MRD kinetics Ning Liu Received Received
  1613-SAT Allogeneic hematopoietic stem cell transplantation in CR1 and continuous Chemotherapy plus FLT3-targeting inhibitor had comparable outcomes in FLT3-ITD mutated Acute Myeloid Leukemia with negative measurable residual disease Sen Yang Received Received
  1614-SAT Real-world practice patterns of IDH inhibitors and outcomes of on-label IDH inhibitor use for Acute Myeloid Leukemia in the United States Chenyu Lin Received Received
  1615-SAT Impact of obesity on survival outcomes in Acute Myeloid Leukemia patients treated with hypomethylating agents: A retrospective multicenter cohort study using real-world data Teja Sureddi Received Received
  1616-SAT Characteristics and outcomes in Acute Myeloid Leukemia with Mecom rearrangement treated with hypomethylating agent plus venetoclax Leora Boussi Received Received
  1617-SAT 7-day venetoclax combined with intensive chemotherapy as induction treatment in high-risk newly diagnosed Acute Myeloid Leukemia Xiaohan Zhang Received Received
  1618-SAT 7-day venetoclax combined with intensive chemotherapy as induction treatment in newly diagnosed Acute Myeloid Leukemia with splicing factor gene mutations Congcong Zhang Received Received
  1619-SAT Real-world outcomes of FLAG-ida salvage therapy in relapsed/refractory AML and validation of the salflage score: A pethema registry study Gaspar Aspas Requena Sr Received Received
  1620-SAT Clinical characteristics, demographics, and survival outcomes in newly diagnosed CUX1-mutated Acute Myeloid Leukemia Michelle Nwachukwu Received Received
  1621-SAT Behind the blood-brain barrier: Contemporary screening practice patterns and trends of central nervous system involvement in acute myeloid leukemia treated with intensive regimens and hypomethylating agent/venetoclax Jamila Mammadova Received Received
  1622-SAT Dose-adjusted treatment with venetoclax for 7 days and 5-azacitidine or decitabine in patients with Acute Myeloid Leukemia or higher risk myelodysplastic neoplasms Laurenz Steiner Received Received
  1623-SAT Prognostic relevance of mutational profile in secondary Acute Myeloid Leukemia patients treated with CPX-351. Carola Riva Received Received
  1624-SAT Real-world validation of ELN2024 and BEAT-AML2024 risk-stratification in patients with Acute Myeloid Leukemia unfit for intensive chemotherapy in a multicenter italian cohort. Giovanni Fornari Received Received
  1625-SAT The presence of secondary type or DNMT3A mutations does not affect prognosis in NPM1 mutated AML treated with intensified fludarabine-high dose cytarabine and idarubicine (FLAI) induction regimen. Paola Minetto Received Received
  1626-SAT Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium Onyee Chan Received Received
  1627-SAT Acute Myeloid Leukemia and sepsis-related mortality in the United States (U.S.) older adults: Nationwide trends and disparities over 25 years (1999 – 2023) Muhammad Zahid Anwar Received Received
  1628-SAT The Impact of the number of cytogenetic abnormalities on clinical outcomes in Acute Myeloid Leukemia with complex karyotype Moath Albliwi Received Received
  1629-SAT CPX-351 is effective in secondary Acute Myeloid Leukemia, regardless if defined according to 2016 or 2022 edition of who classification. Fabio Guolo Received Received
  1630-SAT Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation Roberta S. Azevedo Received Received
  1631-SAT Evolving use of blast percentage thresholds and classification systems in AML clinical trials (2022–2025): A data-driven trend analysis Tiantian Zhang Received Received
  1632-SAT Predictors of early mortality in Acute Myeloid Leukemia: A population based analysis using SEER data. Ahmad Iftikhar Received Received
  1633-SAT Acute Myeloid Leukemia mortality in u.S. older adults: A 45-year nationwide analysis with forecasting through 2050 Saif Ali Khan Received Received
  1634-SAT Fusion transcript dynamics as predictor of optimal molecular response in core-binding factor Acute Myeloid Leukemia Roberta S. Azevedo Received Received
  1635-SAT Comparative epidemiological analysis of hematological malignancies in adolescents and young adults (AYA) in the United States of America (USA), 1990–2021, with projections to 2040 Rupayan Kundu Received Received
  1636-SAT Clinical significance of apoe genotypes in older adults with Acute Myeloid Leukemia: Insights from a consecutively treated cohort Daehun Kwag Received Received
  1637-SAT Single-cell sequencing reveals the impact of low-dose vs standard-dose chemotherapy and infection on lymphocytes in pediatric AML Qingwei Wang Received Received
  1638-SAT Impact of initial FLT3-ITD mutated clone numbers on clinical outcomes in Acute Myeloid Leukemia Daehun Kwag Received Received
  1639-SAT Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia Jia Wei Received Received
  1640-SAT Umbilical cord blood CD34+ hematopoietic stem cell-derived natural killer cells in Acute Myeloid Leukemia – a phase I clinical study Michael Heuser Received Received
  1641-SAT Results of the APG2575AU101 Study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignancies Tapan Kadia Received Received
  1642-SAT BMS-986397, a first-in-class casein kinase 1a (CK1a) degrader in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): A phase 1 dose escalation study Courtney DiNardo Received Received
  1643-SAT CD123-directed chimeric antigen receptor T-cell (CART123) therapy for relapsed/refractory pediatric acute myeloid leukemia Lucy E. Cain Received Received
  1644-SAT Post-transplant maintenance with sorafenib is safe and effective in pediatric patients with har FLT3/ITD AML: A report from the Children´s oncology group protocol AAML1031 Caitlin W. Elgarten Received Received
  1645-SAT Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy Gabriel Mannis Received Received
  1646-SAT A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms Tapan Kadia Received Received
  1647-SAT Post-remission immunotherapy with vididencel for a measurable residual disease defined high-risk sub-group of adult patients with Acute Myeloid Leukemia in first complete hematological remission: Updated results of the european advance II study demonstrat Arjan Van de Loosdrecht Received Received
  1648-SAT A phase I dose escalation and expansion trial of lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) alone and in combination with venetoclax/HMA in Relapsed/Refractory AML/MDS Amir T. Fathi Received Received
  1649-SAT Preliminary safety and efficacy results of A phase ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML Curtis Lachowiez Received Received
  1650-SAT Results of the Phase 1B study of pegargiminase (ADI-PEG 20) in combination with AZA-VEN in newly diagnosed high-risk AML patients not candidates for intensive chemotherapy Justin Watts Received Received
  1651-SAT Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia Brian A Jonas Received Received
  1652-SAT A phase 1/2 study of GB3226, a novel dual inhibitor of ENL-yeats and FLT3, in patients with relapsed/refractory Acute Myeloid Leukemia Abhishek Maiti Received Received
  1653-SAT Phase 1b study of HC-7366 alone and in combination with venetoclax and azacitidine in relapsed/refractory Acute Myeloid Leukemia Abhishek Maiti Received Received
  1654-SAT Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A Marc Raaijmakers Received Received
  1655-SAT A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS Eytan Stein Received Received
  1656-SAT ITCC-101/APAL2020D: A randomized Phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamycin with or without venetoclax in children with relapsed Acute Myeloid Leukemia Sae Ishimaru Received Received
  1657-SAT A Phase 1/2 study of the menin inhibitor revumenib with the celmod mezigdomide in relapsed/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias Kuo-Kai Chin Received Received
  1658-SAT Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo Pierre Peterlin Received Received
  1659-SAT Clinical characteristics and response in olutasidenib-treated Relapsed/Refractory mIDH1 Acute Myeloid Leukemia (AML) patients with stable disease following two treatment cycles Justin Watts Received Received
  1660-SAT Real-world survival outcomes with first-line venetoclax therapy in AML Nia M. Mitchell Received Received
  1661-SAT Low-dose chemotherapy for induction in pediatric AML: Retrospective outcome analysis across expanded cohorts Li Gao Jr Received Received
  1662-SAT Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients Matteo Molica Received Received
  1663-SAT A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms Anna Halpern Received Received
  1664-SAT Transfusion burden among older US patients with relapsed FLT3-mutated Acute Myeloid Leukemia treated with gilteritinib: A Medicare claims-based cohort study Thomas W LeBlanc Received Received
  1665-SAT Efficacy and safety of azacitidine, venetoclax combined with gha priming regimen in the treatment of adult refractory and relapsed acute myeloid leukemia: A prospective single-arm multicenter study Shan Meng Received Received
  1666-SAT High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: "Less is More" on days of venetoclax in the intensive regimen Kateryna Fedorov Received Received
  1667-SAT Real-world analysis of time spent at home for patients with secondary acute myeloid leukemia treated with CPX-351 or venetoclax plus azacitidine in England Tomas Skacel Received Received
  1668-SAT Real-world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia Benjamin Joseph McCormick Received Received
  1669-SAT A retrospective survival outcomes analysis of acute erythroid leukemia patients treated with upfront 7+3 induction chemotherapy versus hypomethylating agents with venetoclax utilizing real-world data Mohamed Zakee Mohamed Jiffry Received Received
  1670-SAT Efficacy and safety of sorafenib combined with Standard Chemotherapy in adult patients with Myeloid sarcoma: A multi-center, cohort study Qiuxiao Li Received Received
  1671-SAT Oral etoposide vs intravenous daunorubicin plus ATRA-RIF as induction therapy for low-risk acute promyelocytic leukemia: A phase II randomized controlled Trial Xiaolu Zhu Received Received
  1672-SAT FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML Akhil Rajendra Received Received
  1673-SAT Selinexor-based non-intensive chemotherapy regimens adjusted according to early responses achieve high early remission in newly diagnosed AML or MDS Shiyuan Zhang Received Received
  1674-SAT Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFß::MYH11(+) acute myeloid leukemia Ying Wang Received Received
  1675-SAT Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia:updated results of a phase II trial ZePing Zhou Received Received
  1676-SAT 10-day decitabine versus conventional chemotherapy ("3+7") followed by allografting in AML patients = 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group Michael Lübbert Received Received
  1677-SAT Concurrent use of nucleoside reverse transcriptase inhibitors and purine analogs is associated with worse survival for patients with myeloid neoplasms: A single-center retrospective analysis Jason Sean Gilbert Received Received
  1678-SAT Cladribine, idarubicin, and AraC (CLIA) combined with a FLT3 inhibitor in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia: A pooled analysis of prospective trials Hannah Goulart Received Received
  1679-SAT Hypomethylating agents or chemotherapy in combination with venetoclax and gilteritinib for FLT3-mutated Acute Myeloid Leukemia Andrius Zucenka Received Received
  1680-SAT Safety and efficacy of venetoclax plus CAG (cytarabine, aclarubicin, G-CSF) regimen in patients with relapsed or refractory Acute Myeloid Leukemia: A prospective single-arm phase II study Wen-Jing Yu Received Received
  1681-SAT Extended aprepitant in control of delayed emesis during induction chemotherapy for acute myeloid leukaemia – an multicentric, investigator-initiated, open label randomized controlled trial Sameer Bakhshi Received Received
  1682-SAT Impact of midostaurin in younger AML patients intensively treated with high-dose anthracycline Pierre-Yves Dumas Received Received
  1683-SAT The efficacy and safety of venetoclax-based and anthracycline-free induction therapy followed by allogeneic hematopoietic stem cell transplantation in the treatment of transplant-eligible Acute Myeloid Leukemia patients Tran-Der Tan Received Received
  1684-SAT The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML) Jose Tinajero Received Received
  1685-SAT Selinexor in combination with venetoclax and azacitidine for newly diagnosed (ND) unfit Acute Myeloid Leukemia (AML): A multicenter, open-label prospective study Ligen Liu Received Received
  1686-SAT Results of part 1 of a two-part study evaluating the combination of tazemetostat and CPX-351 (part 1) and palbociclib with CPX-351 (part 2) for the treatment of relapsed or refractory Acute Myeloid Leukemia Gina Keiffer Received Received
  1687-SAT Comparison of consecutive versus alternate day schedules of high-dose cytarabine consolidation chemotherapy in Acute Myeloid Leukemia: Single-center randomized controlled trial from India Kavya Ronanki Sr Received Received
  1688-SAT Combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory (R/R) Acute Myeloid Leukemia and post-hypomethylating agent (HMA) failure high-risk myelodysplastic syndrome (HR-MDS) Farah Al Haj Received Received
  1689-SAT Intermediate-dose cytarabine is noninferior to high-dose cytarabine for AML consolidation: A systematic review and meta-analysis Flávia Dias Xavier Received Received
  1690-SAT A phase II study of IDH1 inhibition with ivosidenib as maintenance therapy after ivosidenib, azacitidine, and venetoclax for Acute Myeloid Leukemia: Trial in progress Kuo-Kai Chin Received Received
  1691-SAT ICAM-2 mediates adhesion of acute myeloid leukemia cells to bone marrow microenvironment and promotes chemoresistance Fuling Zhou Jr Received Received
  1692-SAT Acute myeloid leukemia with 4q12 rearrangements does not involve pdgfra Long Chen Received Received
  1693-SAT Multi-omics unveils ER stress-driven pDC-like leukemia stem cells in pDC-AML Xingcheng Yang Received Received
  1694-SAT Prognosis of FLT3 ligand level in newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial Pau Montesinos Received Received
  1695-SAT New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein Dijiong Wu Received Received
  1696-SAT Longitudinal single-cell spatial proteomics reveals predictive immune and stem cell signatures in Relapsed/Refractory AML Varun Saichandan Sudunagunta Received Received
  1697-SAT Distinct transcriptomic signatures in non-hispanic black AML patients with NPM1 mutations reveal potential drivers of poor prognosis Sarvath Aafreen Sanaullah Received Received
  1698-SAT Adult Acute Myeloid Leukemia with fus::ERG fusion: A national, retrospective, multi-center study Yunxiang Zhang Received Received
  1699-SAT The synonymous IDH1 p.Gly105Gly (rs11554137) variant associates with AML post-transplant relapse via aberrant signal transduction pathways Olisaemeka Ogbue Received Received
  1700-SAT High levels of PTPN11 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia Eduardo de Camargo Magalhaes Received Received
  1701-SAT Novel epitranscriptomic biomarker discovery through ensemble analysis and multi-omics integration in AML Dona Hasini Vathsalya Gammune Received Received
  1702-SAT NUP98::NSD1 fusion is associated with poor outcomes in Acute Myeloid Leukemia regardless of co-occurring mutations and treatment regimen Katherine Tarlock Received Received
  1703-SAT FLT3-ITD mutation promotes leukemic differentiation toward an immature cytotoxic stage Allana Guimarães de Carvalho Received Received
  1704-SAT Anti-TIM3 with hypomethylating agent revives NK and cytotoxic CD4+ T cell activity in patients with AML or MDS Sofia Forstén Received Received
  1705-SAT TP53-mutated AML and treatment outcomes in the era of hypomethylating agent/venetoclax therapy David M. Mueller Received Received
  1706-SAT Fus::ERG fusion represents adverse-plus risk group in AML patients: Evidence from a registry-based matched cohort Study Yi-Han Yang Received Received
  1707-SAT A perturb-seq map of a differentiation hub reveals synergistic vulnerabilities in KMT2A-rearranged AML Sajesan Aryal Received Received
  1708-SAT Genetic risk model to predict outcomes for AML treated with HMA and venetoclax Rafeh Safdar Received Received
  1709-SAT Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group Julia Stomper Received Received
  1710-SAT DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors Shirley S. Mo Received Received
  1711-SAT Molecular gene panel analysis in aplastic anaemia: Diagnostic utility and clinical implications Francesco Versino Jr Received Received
  1712-SAT Prognostic relevance of epigenetic regulation of drug pharmacology and myeloid genes in pediatric AML Naifah Alshameri Received Received
  1713-SAT TGF-ß regulates CD123 and chemotherapy resistance in Acute Myeloid Leukemia stem cells Daniel Thomas I Received Received
  1714-SAT Secondary Acute Myeloid Leukemia transformed from chronic myelomonocytic leukemia is strongly resistant to venetoclax but demonstrates sensitivity to anti-GM-CSF lenzilumab immunotherapy Daniel Thomas I Received Received
  1715-SAT Multi-omics integration reveals therapeutic vulnerabilities and immune microenvironment subtypes in Acute Myeloid Leukemia Elina Alaterre Received Received
  1716-SAT Functional drug response profiling predicts clinical outcomes and shows utility for treatment stratification in AML Nikolaus Krall Received Received
  1717-SAT Apcin-derived CDC20 inhibitors synergize with microtubule disruptors to induce mitotic catastrophe in acute leukemias Giorgia Simonetti Received Received
  1718-SAT Clinical characteristics and comutational landscape of CSF3R mutations in acute myeloid leukemia Lara Wiechers Received Received
  1719-SAT Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial Pau Montesinos Received Received
  1720-SAT Mitochondrial DNA heteroplasmy and haplogroup variation in pediatric Acute Myeloid Leukemia Audrey Zhu Received Received
  1721-SAT Clonal evolution of pediatric Acute Myeloid Leukemia Masayuki Umeda Received Received
  1722-SAT DNMT3A and NPM1 co-mutations in Acute Myeloid Leukemia (AML): A genomic landscape study Osama Batayneh Received Received
  1723-SAT Loss of the Y chromosome defines a biologically distinct subtype of Acute Myeloid Leukemia (AML), associated with decreased inflammatory response patterns, and favorable outcomes in young male patients (pts) Maria Velegraki Received Received
  1724-SAT Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial Jayastu Senapati Received Received
  1725-SAT Pediatric Acute Myeloid Leukemia associated S100A9 promotes T cell dysfunction Grace A Ward Received Received
  1726-SAT Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML) Roberta S. Azevedo Received Received
  1727-SAT Radiotherapy of extramedullary acute myeloid leukemias overcomes resistance to checkpoint blockade that is enhanced by natural killer cell depletion Michael Spiotto Received Received
  1728-SAT Construction and evaluation of a prognostic model for patients with Acute Myeloid Leukemia Feng Zhu Received Received
  1729-SAT Prognostic impact of co-occurring mutations in NPM1-mutated Acute Myeloid Leukemia Cole Blanford Received Received
  1730-SAT Impact of cancer and therapy on the epigenetic landscapes of normal cells: Describing a novel biomarker in survivorship Sushil Selvarajan Received Received
  1731-SAT AI-derived prediction of response and relapse to venetoclax plus hypomethylating agent based therapy in Acute Myeloid Leukemia Sarvarinder Kaur Gill Received Received
  1732-SAT Natural killer cell heterogeneity reflects AML cell-states and predicts clinical outcome at diagnosis Paran Goel Received Received
  1733-SAT Integrative clinical and molecular analysis of outcome in elderly African ancestry Acute Myeloid Leukemia Jonathan Andreadakis Received Received
  1734-SAT Inflammatory and metabolic gene signatures predict overall survival and response to venetoclax-based therapy in TP53 mutant AML Sarah Skuli Received Received
  1735-SAT The cachexia hematologic severity score (CHeSS): Use of a laboratory-based tool to predict survival and mutation-associated wasting in Acute Myeloid Leukemia and myelodysplastic syndrome Sikander Chohan Received Received
  1736-SAT CD39 defines an exhausted effector memory T cell subset associated with poor outcome in Acute Myeloid Leukemia: Immunophenotypic and transcriptomic analysis Yoon Seok Choi Received Received
  1737-SAT A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study Agnieszka Wierzbowska Received Received
  1738-SAT Outcomes following MRD relapse in AML patients monitored by droplet digital PCR Bo Wan Received Received
  1739-SAT Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries Leticia Marani Received Received
  1740-SAT Residual mutations in epigenetic modifiers are associated with poor prognosis and high relapse rate in Acute Myeloid Leukemia Zheng Ge Received Received
  1741-SAT CD48 as an additional marker for measurable residual disease assessment in pediatric Acute Myeloid Leukemia. Michael N. Dworzak Received Received
  1742-SAT Prognostic impact of MRD negativity in AML patients treated with venetoclax-based therapy: A systematic review and meta-analysis Shivam Chetankumar Patel Received Received
  1743-SAT A plasma-based test for the measurable residual disease informs the response to treatment in AML patients Jiajun Xie Received Received
  1744-SAT Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study. Francois Vergez Sr Received Received
  1745-SAT Dynamic monitoring of circulating tumor DNA for real-time risk assessment in early-stage natural killer/t-cell lymphoma Tongyu Lin Received Received
  1746-SAT Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma Ling-Shuang Sheng Received Received
  1747-SAT Identifying biological differences between two clinical risk groups of cutaneous CD30+ T cell lymphoproliferative disorders Jie Wang Received Received
  1748-SAT Non-invasive detection and classification of lymphoma via cell-free DNA methylation profiling Victoria Buse Shelton Received Received
  1749-SAT The rearrangement partner and the presence of MYC mutations determines outcome of patients with MYC and BCL6 rearrangements Anna Stengel Received Received
  1750-SAT Impact of PRF 1 A91V germline carrier status in patients with aggressive b-NHL treated with rituximab Onur Cetin Received Received
  1751-SAT Multi-dimensional transcriptomic profiling reveals novel tumor microenvironment landscape and subtype-specific therapeutic Vulnerabilities of MALT lymphomas Yijun Wu Received Received
  1752-SAT Assessment of EBV DNA methlyation to guide antiviral use in EBV-associated lymphoma Cara M Noel Received Received
  1753-SAT Multiparametric integration improves diagnostic categorisation of mature, non-CLL B-cell leukemias including atypical CLL - results from the prospective enable-NGS study Li Yuan Chan Received Received
  1754-SAT B- and T-cell clonality using peripheral blood cell-free RNA (cfRNA) in liquid biopsy Adam Albitar Received Received
  1755-SAT Somatic mutations and clinical outcomes in primary central nervous system lymphoma among hispanic and non-hispanic patients: A study from the University of California hematologic malignancies consortium (UCHMC) Haifaa Abdulhaq Received Received
  1756-SAT Mechanistic role and prognostic value of CD20-positive microvesicles in rituximab-treated diffuse large B-cell lymphoma Bon Park Received Received
  1757-SAT Generation of faithful autochthonous mouse models of Mantle Cell Lymphoma Ron Jachimowicz Received Received
  1758-SAT Integrated multi-omic profiling identifies molecular subtypes and predicts outcomes in newly diagnosed peripheral T-cell lymphomas Cristiana Carniti Received Received
  1759-SAT Prognostic impact of cytogenetic abnormalities in aggressive T-cell lymphomas: Defining high-risk subgroups through conventional karyotyping. Ahmad Kiwan Received Received
  1760-SAT Clinical characteristics and whole-exome sequencing-based genomic profiling of post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation Tatsuro Hirao Received Received
  1761-SAT Genomic and transcriptomic landscape of extranodal marginal zone lymphoma Izidore S. S. Lossos Received Received
  1762-SAT Single-cell and spatial transcriptomics analyses decipher malignant B cell heterogeneity and immunosuppressive microenvironment in primary central nervous system lymphoma Cong Wang Received Received
  1763-SAT Pre-treatment circulating tumor DNA predicts survival of diffuse large B-cell lymphoma patients and allows genetic and biological evaluation Ondrej Havranek Received Received
  1764-SAT Artificial intelligence predicts genetic network disruptions to overcome CAR-T resistance in Mantle Cell Lymphoma Fangfang Yan Received Received
  1765-SAT Dissecting pirtobrutinib resistance in Mantle Cell Lymphoma through single-cell multi-omics Fangfang Yan Received Received
  1766-SAT MSK-impact heme accurately reproduces diffuse large B-cell (DLBCL) dlbclass cluster classification across clinical scenarios, including diagnosis, relapse, and histological transformation Aaron Gillmor Received Received
  1767-SAT Enrichment of rare pathogenic variants in common cancer predisposition genes in lymphatic malignancy: A comprehensive analysis of 2,138 cases Lea Dewi Schlieben Received Received
  1768-SAT Genetic analysis and clinical correlations in marginal zone lymphoma Wei Wang Received Received
  1769-SAT B-like natural killer cells related to the epstein-barr virus infection present an adaptive immune phenotype and stronger killing activity in lymphomas Chenfei Liu Received Received
  1770-SAT The molecular landscape of Waldenstroem macroglobulinemia identified using whole genome sequencing Sanghoon Lee Received Received
  1771-SAT NOTCH pathway activation is mediated by DTX1 loss of function mutations in DLBCL Abigail Rose Dropik Received Received
  1772-SAT Pharmacologic overactivation of ALK activity by PTPN2/PTPN1 inhibition induces a combination of tumor-intrinsic oncogenic stress and immune responses to promote tumor eradication in ALK-positive lymphoma Marta Rubin Jr Received Received
  1773-SAT Dual HDAC and EZH2 inhibition modulates RFX5 activity to increase the immunogenicity of germinal center-derived B-cell lymphoma Ted Piorczynski Received Received
  1774-SAT Cell differentiation stage drives mechanisms of apoptosis evasion in Waldenstroem macroglobulinemia Isacco Ferrarini Received Received
  1775-SAT INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile Manali Kamdar Received Received
  1776-SAT A genetic comparison of epstein-barr virus-associated polymorphic lymphoproliferative disorder and diffuse large B cell lymphoma Jennifer Chapman Received Received
  1777-SAT Inflammatory Waldenstroem macroglobulinemia is associated with monocyte dysregulation and IL-1ß production Pierre-Edouard Debureaux Received Received
  1778-SAT Combination of golidocitinib with chidamide for peripheral T-cell lymphoma: Possible mechanisms and therapeutic potential in inhibiting tumor proliferation and modulating the immune microenvironment Li Li Received Received
  1779-SAT Higher helios? treg levels pre- and post-CAR T infusion are associated with inferior outcomes in patients with LBCL Hilde T Van Der Galien Received Received
  1780-SAT Idiotype mRNA therapeutic vaccination in a mouse model of B cell lymphoma Debra Katherine Czerwinski Received Received
  1781-SAT Multi-omic spatial profiling of EBV+ hodgkinoid lymphoproliferation reveals divergent biological features and novel diagnostic biomarkers. Matthew Richard Pugh Received Received
  1782-SAT SAMHD1 dependence of cgas-sting-associated anti-tumor immune responses in classical Hodgkin lymphoma Ioanna Xagoraris Received Received
  1783-SAT Multimodal discovery of distinct tumor ecosystems for classic Hodgkin lymphoma Shengqin Su Received Received
  1784-SAT Deep learning-based histopathological subtyping of peripheral T-cell lymphoma (PTCL) on H&E-stained whole slide images Thomas Weber Received Received
  1785-SAT Enhancing the expansion of Naïve, potent T-cells via BTK inhibition reinvigorates CD19-CAR T-cell immunity and boosts antitumor efficacy in relapsed Mantle Cell Lymphoma Yixin Yao Received Received
  1786-SAT The effects of bruton tyrosine kinase inhibitors on the waldenstrom macroglobulinemia microenvironment Stephen D Blackmore Received Received
  1787-SAT Single-nucleus dissection of peripheral T-cell lymphomas reveals distinct microenvironmental ecosystems and therapeutic vulnerabilities Wen-Hsuan Wendy Lin Received Received
  1788-SAT Longitudinal single-cell profiling in canine DLBCL reveals regulatory networks driving chemotherapy resistance. Steven Tur Received Received
  1789-SAT Non-invasive Mantle Cell Lymphoma risk stratification by inference of tumor proliferation from cfDNA Amirsaman Ashtari Received Received
  1790-SAT Immune cell dynamics following rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma Ioulia Vogiatzi Received Received
  1791-SAT Immune exhaustion limits CD19 CAR-T efficacy in Richter´s transformation M Bakri Hammami Received Received
  1792-SAT Single-cell transcriptomic profiling reveals tumor-intrinsic heterogeneity and immune-microenvironment dynamics in the order trial for mantle-cell lymphoma Lu Jiang Received Received
  1793-SAT Low-intensity focused ultrasound with microbubbles enhances CD20 monoclonal antibody delivery across the blood-brain barrier in primary central nervous system lymphoma Jiawen Huang Jr Received Received
  1794-SAT Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenstroem macroglobulinemia Jorge J Castillo Received Received
  1795-SAT Real-world treatment and safety outcomes of patients with Mantle Cell Lymphoma in the United States Yangyang Liu Received Received
  1796-SAT Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial Zhengming Jin Received Received
  1797-SAT Valemetostat monotherapy in patients with relapsed or refractory B-cell lymphoma: Final results of the Phase 2 valym study from the lysa Emmanuel Bachy Received Received
  1798-SAT Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions Ajay Major Received Received
  1799-SAT Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy Tom Van Meerten Received Received
  1800-SAT Promising response rates and manageable safety with mosunetuzumab plus lenalidomide (Mosun-Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): US extension cohort from the Phase III CELESTIMO study Dahlia Sano Received Received
  1801-SAT Phase 2 bellwave-003 cohort f: Updated clinical outcomes of nemtabrutinib in participants with relapsed or refractory marginal zone lymphoma Muhit Ozcan Received Received
  1802-SAT Hairy cell leukemia treatment strategies: A real-world multicenter experience James Fradin Received Received
  1803-SAT Novel triplet combination of orelabrutinib, lenalidomide, and rituximab as frontlinetherapy for mantle cell lymphoma: Final results of polaris multicenter phase II study Xiaohui Wang I Received Received
  1804-SAT Conventional quality-of-life data analyses underestimate gains in Mantle Cell Lymphoma clinical trials: A re-examination of enrich study data Jeremy Hobart Received Received
  1805-SAT Long-term outcomes of patients with hairy cell leukemia treated with first-line cladribine in British Columbia Jonathan Isenberg Sr Received Received
  1806-SAT Mosunetuzumab and lenalidomide combination therapy augments CD8+ T cells with enhanced T cell-dependent cytotoxicity against follicular lymphoma cells Hayato Mizuta Received Received
  1807-SAT Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma Jose Villasboas Bisneto Received Received
  1808-SAT A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL) Shuhua Yi Received Received
  1809-SAT Trium study: Exploring MRD-guided triplet therapy with sonrotoclax, zanubrutinib, and CD20mab in Untreated Mantle Cell Lymphoma: A prospective, multicenter, Phase II Study Peiqi Zhao Received Received
  1810-SAT Utility of 18F-FDG PET/CT for response assessment in marginal zone lymphomas: Preliminary results of the IELSG44 international study Emanuele Zucca Received Received
  1811-SAT Insights in the management of older adults with mantle cell lymphoma amidst a changing therapeutic landscape: Lessons from a 25-year institutional experience Pallawi Torka Received Received
  1812-SAT Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximab Hari S. Raman Received Received
  1813-SAT Real-world treatment patterns and survival in splenic marginal zone lymphoma: A national analysis in the rituximab era Olisaemeka Ogbue Received Received
  1814-SAT Efficacy and tolerability of bendamustine, rituximab and acalabutinib in elderly treatment naïve Waldenstroem´s macroglobulinemia Neil Berinstein Received Received
  1815-SAT Association between progression-free survival and overall survival in mantle cell lymphoma: A trial-level surrogate endpoint analysis Alexander Gorzewski Received Received
  1816-SAT Is ´severe´ imcd-IPL really severe? Siyuan Li Received Received
  1817-SAT Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma Yunhong Huang Received Received
  1818-SAT Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma Zhijuan Lin Received Received
  1819-SAT Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of patients receiving second-line treatment Ajay Gopal Received Received
  1820-SAT Optimal dose regimen of epcoritamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma - analyses of pharmacokinetics and exposure-response relationships of epcore FL-1 Phase 3 study Behnam Noorani Received Received
  1821-SAT Prognostic and therapeutic implications of the immune landscape in Mantle Cell Lymphoma Changjian Yan Received Received
  1822-SAT Indirect comparison of bendamustine-rituximab and R-CHOP with rituximab maintenance in first-line treatment of elderly Mantle Cell Lymphoma: Data from the enrich trial David Lewis Received Received
  1823-SAT Efficacy and safety of zanubrutinib-containing regimens in patients with newly diagnosed Mantle Cell Lymphoma: Interim results from a Phase II investigator-initiated study Qing Zhang Received Received
  1824-SAT Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma Jean Fan Received Received
  1825-SAT Real-world outcomes of Y90-ibritumomab tiuxetan (Zevalin) in low-grade B-cell non-Hodgkin lymphoma: A single-institution experience Abida Babu Received Received
  1826-SAT FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis Prokop Vodicka Received Received
  1827-SAT TP53 aberrant Mantle Cell Lymphoma treated with first-line systemic therapy: A real-world analysis of outcomes in 120 patients treated in the United Kingdom Rory McCulloch Received Received
  1828-SAT Rituximab plus lenalidomide (R²) versus standard therapies in follicular lymphoma: A systematic review and meta-analysis of randomized controlled trials Abat Khan Received Received
  1829-SAT Prognostic impact of CXCR4 mutation type on clinical features and outcomes of patients with Waldenstroem macroglobulinemia Anath Christopher Lionel Received Received
  1830-SAT Biallelic TP53 alterations predict poorer survival in Mantle Cell Lymphoma: Insights from a national real-world cohort high-touch project Mayur Narkhede Received Received
  1831-SAT Efficacy of acalabrutinib in treatment-naive Mantle Cell Lymphoma: A systematic review and meta-analysis Megha Sasidhar Handral Received Received
  1832-SAT Assessment of minimal residual disease with droplet digital polymerase chain reaction for BRAF V600E mutation in patients with hairy cell leukemia treated with purine analogs Gianmarco Favrin Received Received
  1833-SAT Btkis and DRC show a reduction of infections and need of hospitalization towards BR and other chemo-immunotherapies in waldenstrom macroglobulinemia. Francesco Autore Received Received
  1834-SAT Validation of novel prognostic models in symptomatic Waldenstroem´s macroglobulinemia based on real-world data Michal Kascak Jr Received Received
  1835-SAT Divergent trends in high BMI-associated NHL mortality: An analysis of the globalburden of disease database 1990-2021 Amar Lal Received Received
  1836-SAT Funcional cure in advanced follicular lymphoma: Real word experience from two academic centers from Argentina Sofía Rivarola Received Received
  1837-SAT Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium Chijioke Nze Received Received
  1838-SAT A phase II study of acalabrutinib in combination with R-CHOP for previously untreated transplant-ineligible mantle cell lymphoma patients in Spain (the SOUND-MCL Study) Ana Marin Niebla Received Received
  1839-SAT CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies Chan Cheah Received Received
  1840-SAT S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) VS. venetoclax and rituximab (VR) in previously untreated waldenstrom´s macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL). Sikander Ailawadhi Received Received
  1841-SAT A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study Allison Marie Bock Received Received
  1842-SAT Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP Maria Carmen Martinez Munoz Received Received
  1843-SAT Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates Zhao Peiqi Received Received
  1844-SAT Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the chariot trial Sairah Ahmed Received Received
  1845-SAT External validation of the early-stage classic Hodgkin lymphoma (cHL) international prognostication index (E-HIPI) in the german Hodgkin study group (GHSG) unfavorable clinical trials Angie Mae Rodday Received Received
  1846-SAT Safety and efficacy of MT-601 in relapsed or refractory (r/r) Hodgkin lymphoma Haitham Abdelhakim Received Received
  1847-SAT Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT Induces Durable Remissions in PD-(L)1 inhibitor-resistant Refractory/relapsed classical Hodgkin lymphoma: A single-center, long-term study Xingchen Liu Received Received
  1848-SAT Burden of Hodgkin lymphoma from 1990 to 2021 and modelled projection to 2050 shensui li Received Received
  1849-SAT Age-related differences in presentation among pediatric, adolescent, and young adults with mixed cellularity vs. nodular sclerosis histology Hodgkin lymphoma on Children´s oncology group treatment and registry trials Mallorie B Heneghan Received Received
  1850-SAT Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial Kishan Patel Received Received
  1851-SAT Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study Nancy L Bartlett Received Received
  1852-SAT Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma Karan L. Chohan Received Received
  1853-SAT Treatment options, responses and outcome of 1220 classic Hodgkin lymphoma patients included in realysa, a prospective multicentric lysa cohort Herve Ghesquieres Received Received
  1854-SAT Dose Escalation shows no benefit compared to continuing ABVD in Hodgkin´s lymphoma patients with an interim PET deauville score of 4 Andre Meireles Received Received
  1855-SAT Low-dose nivolumab combined with AVD chemotherapy (Nivo40-AVD) for advanced stage classic Hodgkin lymphoma Mobil Akhmedov Received Received
  1856-SAT Outcomes in octo- and nonagenarians treated with mogamulizumab-based regimens for cutaneous T-cell lymphoma Omar Elghawy Received Received
  1857-SAT Determinants of survival in t-cell large granular lymphocytic leukemia (T-LGL): Analysis of a real-world pooled database Philip A Haddad Received Received
  1858-SAT Determinants of survival in primary cutaneous CD4+ small-to-medium-sized pleomorphic t-cell lymphoproliferative disorder (PC4SMPTCL): Analysis of a real-world pooled database Philip A Haddad Received Received
  1859-SAT Azacytidine combined with CHOP regimen for the treatment of newly diagnosed angioimmunoblastic T-cell lymphoma Chunmei Yang Received Received
  1860-SAT Favorable safety and efficacy in a phase II trial using duvelisib maintenance after autologous stem cell transplant in T-cell and B-cell non-Hodgkin lymphomas Hunter Cassidy Cochran Received Received
  1861-SAT Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas Christina Poh Received Received
  1862-SAT Comparative outcomes of adult T-cell leukemia/lymphoma in academic and community cancer programs Erin Kaser Received Received
  1863-SAT The charlson comorbidity index as a predictor of survival in peripheral T-cell lymphoma: A multicenter analysis from the gifu hematology study group Naoki Hayase Received Received
  1864-SAT Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-naïve TFH-derived peripheral T-cell lymphoma Huimin Liu Received Received
  1865-SAT Outcomes of relapsed or refractory mature T/NK-cell lymphomas in the era of novel agents: A nationwide observational Study in Japan Hideki Uryu Received Received
  1866-SAT Health-related quality of life (HRQoL) in real-world patients with cutaneous T cell lymphoma (CTCL): Evaluation of patient reported outcomes using the Skindex-16 in a multidisciplinary CTCL clinic Elisa Hofmeister Received Received
  1867-SAT Integrated analysis of mogamulizumab trials for mature T-cell lymphomas, investigating differences in longitudinal effects between responders and non-responders Nobuaki Nakano Received Received
  1868-SAT Adding selinexor to ifosfamide, etoposide and desametasone does not improve the outcome in relapsed and refractory peripheral T-cell lymphomas: First report of phase II S-ide study. Annalisa Chiappella Received Received
  1869-SAT Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis Chitra Hosing Received Received
  1870-SAT Diagnostic and therapeutic patterns in cutaneous T-cell lymphomas (CTCL): Real-world data from the lymphoma epidemiology outcome-molecular epidemiology resource (LEO-MER) prospective cohort study. Muhammad Saad Hamid Received Received
  1871-SAT Contemporary survival trends in patients with adult T-cell leukemia/lymphoma (ATLL) in the United States: Insights from the national cancer database Nadia Toumeh Received Received
  1872-SAT Cytotoxic lymphoma assessment response (CLyAR): A harmonized, compartment-based consensus response assessment framework for cytotoxic T-cell lymphomas Swami P. Iyer Received Received
  1873-SAT Prognostic significance of post-treatment EBV clearance and relapse patterns in localized extranodal NK/T-cell lymphoma treated with low-dose radiotherapy: A single-center analysis of 155 patients Yoon Sang Eun Received Received
  1874-SAT Upregulation of extracellular matrix remodeling gene set drives progression and poor prognosis in angioimmunoblastic T-cell lymphoma. Jieyu Xu Received Received
  1875-SAT A Phase 2, multicenter, open-label, single-arm study assessing a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sezary syndrome (MOGA-2MG-Q4W) Julia Scarisbrick Received Received
  1876-SAT Evaluation of treatment responses to methotrexate and cyclophosphamide among T-LGL patients with and without Y640F and D661Y STAT3 mutations – a retrospective observational study Emma Gray Received Received
  1877-SAT GATA-3 identifies a distinct subset of T-cell prolymphocytic leukemia (T-PLL) and is associated with CCR4 expression Marc Gabriel Gutierrez Received Received
  1878-SAT Efficacy and safety of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma: A multicenter, non-interventional, ambispective cohort real-world study Donglu Zhao Received Received
  1879-SAT Efficacy and safety of duvelisib combined with chidamide as first-line treatment for angioimmunoblastic T-cell lymphoma (AITL) Liling Zhang Received Received
  1880-SAT Detection of intratumoral microorganisms in CTCL and patients symptoms and outcomes. Paola Ghione Received Received
  1881-SAT Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL) Yumeng Zhang Received Received
  1882-SAT Treatment related outcomes of very old (85 years) diffuse large b-cell lymphoma patients. Sushmita Khadka Received Received
  1883-SAT Age at diagnosis drives molecular pathology and prognosis in diffuse large B-cell lymphoma Rabsa Rahman Sikder Received Received
  1884-SAT Facility-level differences in treatment and outcomes for intravascular large B-cell lymphoma: A national cancer database analysis Eleftheria Atalla Received Received
  1885-SAT Estimating the United States cure-adjusted prevalence of diffuse large B-cell lymphoma (DLBCL): An epidemiological model Mahmoud Hashim Received Received
  1886-SAT IVIG prevents infections without affecting mortality in DLBCL patients treated with CAR T-cell or bispecific antibody therapy: A real-world propensity-matched study Nehemias Guevara Received Received
  1887-SAT CD5 positivity and aberrant P53 expression predict primary refractoriness to first-line pola-R-CHP in patients with diffuse large B-cell lymphoma Xia Zhao Sr Received Received
  1888-SAT Is autologous hematopoietic stem cell transplantation as consolidation therapy superior to chemotherapy alone in newly diagnosed intermediate-high risk DLBCL patients? Shuozi Liu Received Received
  1889-SAT Molecular insights from ctdna dynamics: Monitoring MRD and tracking divergent progression modes and clonal evolution patterns Jinhua Liang Received Received
  1890-SAT Post-transplant lymphoproliferative disorders in adult transplant recipients: Preliminary results of the multicenter italian FIL_PTLD study Chiara Consoli Received Received
  1891-SAT Survival outcomes for newly diagnosed non-germinal center large B cell lymphoma patients treated with R-CHOP based on double expressor status and genomic features Alyssa M Klein Received Received
  1892-SAT Real-world evaluation of cardiac outcomes after CAR-T in patients with hematologic malignancies Maryam Naser Received Received
  1893-SAT Clinical characteristics and outcome of diffuse large B-cell lymphoma: Real world data from Saudi Arabia Mohsen Alzahrani Sr Received Received
  1894-SAT Diffuse large B cell lymphoma in Brazil: Understanding the patient journey to improve healthcare assistance. Thais Fischer Received Received
  1895-SAT Academic vs. community care in HHV8+ DLBCL: Dissecting disparities in the HIV-positive population Esteban Toro Velez Received Received
  1896-SAT Impact of radiation in limited stage diffuse large B-cell lymphoma in the modern era Juan Carlos Ramirez Received Received
  1897-SAT HIV infection and survival of diffuse large B-cell lymphoma in the era of combined antiretroviral therapy: Comparative and trend analysis Youjin Oh Received Received
  1898-SAT Real-world outcomes, access, and role of autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma among AYAs and non-AYAs: A multicenter study from Peru Thanya Runciman Received Received
  1899-SAT Disparities in palliative care consultation among hospitalized patients with diffuse large B-cell lymphoma in the United States: A national analysis from 2016–2022 Alexandra Sueldo Received Received
  1900-SAT No increase in incidence of central nervous system (CNS) relapse after removal of cns prophylaxis in large B cell lymphoma: A real-world retrospective study. Hannah R Bailey Received Received
  1901-SAT Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis Hanzala Jehangir Received Received
  1902-SAT Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations Fei Li Received Received
  1903-SAT The influence of racial, socioeconomic, and geographic disparities in the survival of patients with plasmablastic lymphoma: A population-based analysis from the surveillance, epidemiology, and end Results (SEER) database (2000–2022). Imran Khan Received Received
  1904-SAT First results of the methoglu Trial, a phase 1 Trial from the LOC network evaluating the reduction of the time interval between methotrexate perfusions combined with glucarpidase in relapsed primary CNS lymphomas Caroline Houillier Received Received
  1905-SAT Efficacy of brentuximab vedotin combination treatment in patients with relapsed or refractory diffuse large B-cell lymphoma with CD30 Grzegorz Nowakowski Received Received
  1906-SAT Preliminary results of first-line selinexor plus R-CHOP in TP53-mutated diffuse large B-cell lymphoma (Smart trial): A single-arm, phase II trial Qingqing Cai Received Received
  1907-SAT Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL). Chunmei Yang Received Received
  1908-SAT Lessons from the IELSG45 trial: The impact of patient fitness on dropout rate in primary central nervous system lymphoma (PCNSL) studies Andrés José María Ferreri Received Received
  1909-SAT Tislelizumab combined with zanubrutinib and high-dose methotrexate in newly diagnosed primary central nervous system DLBCL: A phase 2 study Xia Zhao Sr Received Received
  1910-SAT Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma Fei Li Received Received
  1911-SAT Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma Chunmei Yang Received Received
  1912-SAT Pomalidomide, rituximab, and orelabrutinib in combination with polatuzumab vedotin for newly diagnosed diffuse large B-cell lymphoma in elderly, unfit, or frail patients:a prospective phase II study Changju Qu Received Received
  1913-SAT Pola-R-CHP in previously untreated diffuse large B-cell lymphoma: Real-world data in Russia Gayane Tumyan Received Received
  1914-SAT The preliminary results of MRG001-C002: A phase II Study of MRG001 combined with Orelabrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) Keshu Zhou Received Received
  1915-SAT Phase II study of lenalidomide in combination with rituximab, cyclophosphadmie, doxorubicin, vincristine, and prenisone (R-CHOP) for central nervous system prophylaxis in high-risk diffuse large B cell lymphoma Dok Hyun Yoon Received Received
  1916-SAT Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization Jingrui Sui Received Received
  1917-SAT Phase 2 Study of polatuzumab vedotin, zanubrutinib and rituximab (Pola-ZR) in untreated elderly and frail DLBCL patients: Molecular features and follow-up updates Yuhong Ren Received Received
  1918-SAT Phase 2 trial of polatuzumab vedotin, rituximab and dose attenuated CHP in patients 75 years and older with large B-cell lymphoma Patrick M Reagan Received Received
  1919-SAT Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without anti-CD20 antibody (GVM±CD20) in patients with relapsed or refractory aggressive non-Hodgkin´s lymphoma: A prospective, multicenter, Phase ? study Wei LIU Received Received
  1920-SAT R-cmop and pola-R-CMP regimens as first-line treatment for diffuse large B-cell lymphoma with cardiac comorbidity: A prospective, single-arm, multicenter study Xu Wei Received Received
  1921-SAT Efficacy and safety of R-CDOP in treatment-Naïve non-Hodgkin lymphoma with high tumor burden: A multicenter, prospective study Wei Guo Received Received
  1922-SAT First-line selinexor plus R-CHOP for high-risk GCB-subtype diffuse large B-cell lymphoma: A multi-center, single-arm, Phase II trial Zhiming Li Received Received
  1923-SAT Polatuzumab vedotin retains potent activity against CD79B mutations: Preclinical and clinical efficacy in diffuse large B-cell lymphoma Zigang Dai Sr Received Received
  1924-SAT Mitoxantrone hydrochloride liposome-based CMOP±R regimen achieves superior response in treatment-Naïve non-Hodgkin lymphoma: A phase III clinical trial with matching-adjusted indirect comparison Tao You Received Received
  1925-SAT Safety characteristics of brentuximab vedotin among patient subgroups: Insightsfrom pooled clinical trial database Heather Ward Received Received
  1926-SAT Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study Ross Salvaris Received Received
  1927-SAT Daratumumab for relapsed/refractory primary effusion lymphoma, plasmablastic lymphoma and multicentric castleman disease. Jose Mercado-Matos Received Received
  1928-SAT Absolute lymphocyte count is predictive of response to salvage therapies for post-CAR T failure Hazim Ababneh Received Received
  1929-SAT Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma Lixia Sheng Received Received
  1930-SAT Correlation of T cell fitness of apheresis products with response to CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma: A prospective observational study at a single center Yuya Nagai Received Received
  1931-SAT Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy Anath Christopher Lionel Received Received
  1932-SAT Clinical characteristics and prognosis analysis of autologous hematopoietic stem cell transplantation in 33 patients with HIV-associated lymphoma: A multicenter real-world retrospective study from China (CALL-005 Study) Jun Liu Received Received
  1933-SAT Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma Jiaqi Li Received Received
  1934-SAT Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease Sarah Nikiforow Received Received
  1935-SAT Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin´s lymphoma and concurrent autoimmune disease Zachary Braunstein Received Received
  1936-SAT Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement Catelyn Cashion Received Received
  1937-SAT Impact of prior B-cell-directed immunotherapy on the outcome of CD19 CAR T-cell therapy in aggressive B-cell lymphoma - an analysis of the EBMT and the GoCART coalition Jan Christian Schroeder Received Received
  1938-SAT Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy Hesong Zou Received Received
  1939-SAT CRE intestinal colonization correlates with increased progression risk following CAR T cell therapy in relapsed/refractory lymphoma Qing Yin Received Received
  1940-SAT Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma Mingming Zhang Received Received
  1941-SAT Efficacy and safety analysis of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment Liang Wang Sr Received Received
  1942-SAT A simple, 3-factor pre-treatment score (Toranomon Prognostic Score) robustly stratifies progression risk in patients with relapsed/refractory large B-cell lymphoma receiving commercial CAR T-cell therapy: A real-world analysis Rikako Tabata Received Received
  1943-SAT Icans mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol – a pilot study Gil Fridberg Received Received
  1944-SAT Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma Gloria Iacoboni Received Received
  1945-SAT Pre-manufacturing CD8+ central-memory type 2 T cells predict axicabtagene ciloleucel failure in large B-cell lymphoma J. Joseph Joseph Melenhorst Received Received
  1946-SAT Updated clinical outcomes of a Phase I/II trial of bispecific CD19/CD20-targeted CAR-T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma Chuling Fang Received Received
  1947-SAT Distinct inflammatory and immune recovery patterns after CD19-directed CAR T-cell therapy in SLE and B-cell lymphoma Nora Rebecca Schwingen Received Received
  1948-SAT Characterizing differences in CAR-T cell therapy outcomes based on sex in patients with large B-cell lymphoma John Behman Received Received
  1949-SAT Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter Julia Katharina Scholz Received Received
  1950-SAT Bendamustine combined with fludarabine/cyclophosphamide as a enhanced lymphodepletion regimen demonstrates favorable efficacy and safety in CAR-T therapy for extranodal/bulky R/R B-cell lymphoma Cong Lu Received Received
  1951-SAT Risk of second primary hematological malignancy post chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: Propensity-matched analysis using trinetx database Juhi Chovatiya Received Received
  1952-SAT Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas Elise A. Chong Received Received
  1953-SAT A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation Aseel Alsouqi Received Received
  1954-SAT Phase 1 assessment of novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) Paolo Fabrizio Caimi Received Received
  1955-SAT Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial Lorenzo Falchi Received Received
  1956-SAT Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States Yun Kyoung Tiger Received Received
  1957-SAT JS203, a CD20×CD3 bispecific antibody, demonstrated promising anti-cancer activity in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): Updated results from a phase I study Yan Xie Received Received
  1958-SAT Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthet Pierre Sesques Received Received
  1959-SAT Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity Adelba Torres Received Received
  1960-SAT Epcoritamab (epcor) monotherapy offers long-term disease control in large B-cell lymphoma (LBCL): NHL-1 subgroup analysis in patients with prior chimeric antigen receptor T-cell (CAR T) therapy from the 3-year follow-up Catherine Thieblemont Received Received
  1961-SAT Real-world outcomes of glofitamab therapy in CAR-T naive patients with relapsed/refractory B-cell lymphoma Liudmila Fedorova Received Received
  1962-SAT Impact of extranodal involvement on bispecific antibody (BsAb) outcomes in patients with large B-cell lymphoma (LBCL) Jonay Méndez Received Received
  1963-SAT A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study Nikita K Dave Received Received
  1964-SAT Split dose R-CHOP mitigates toxicity while preserving dose intensity and response in frail elderly patients with diffuse large B cell lymphoma (DLBCL) - a Wisconsin oncology network (WON) study Christopher David Fletcher Received Received
  1965-SAT Combination anti-PD1 antibody and rituximab followed by R-CHOP for newly diagnosed DLBCL in elderly patients: Updated results of the phase II TREND trial Huiqiang Huang Received Received
  1966-SAT Efficacy and safety of loncastuximab tesirine and rituximab (Lonca-R) followed by dose-adjusted rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine and prednisone (DA-R-EPOCH) in previously untreated high-risk diffuse large B-cell lymphom Jacqueline Hsieh-Wong Received Received
  1967-SAT Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium Study Kunhwa Kim Received Received
  1968-SAT Improving outcomes with nivolumab consolidation among older patients (=65) with previously untreated primary CNS lymphoma Steven I Park Received Received
  1969-SAT Interim analysis of a Phase I/II study of tafasitamab with lenalidomide in patients with relapsed central nervous system lymphoma James Louis Rubenstein Received Received
  1970-SAT Daratumumab with dose-adjusted EPOCH feasibility and early efficacy in newly diagnosed plasmablastic lymphoma: AIDS malignancy consortium 105 Ariela Noy Received Received
  1971-SAT Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial Pallawi Torka Received Received
  1972-SAT Trials in progress - a Phase Ib trial of epcoritamab in combination with ibrutinib in relapsed or refractory central nervous system lymphoma (EIFEL) Narendranath Epperla Received Received
  1973-SAT A proteomics-driven machine learning tool for distinguishing ET from pre-PMF Qing Wen Received Received
  1974-SAT Differential impacts of Lama4 deficient microenvironment on fitness of BCR::ABL1-expressing cells during chronic myeloid leukemia initiation and progression Alma Mansson Received Received
  1975-SAT Immunophenotypic and cytokine profiling reveal robust immunomodulation after dasatinib treatment and identify a subgroup with rapid and deep molecular response in CML patients: A multi-center prospective study Shih-Feng Cho Received Received
  1976-SAT Extracellular matrix-targeting oligonucleotide reverses marrow fibrosis Alessandro Malara Received Received
  1977-SAT Discovery of JAK2V617F mutant specific allosteric inhibitors for the treatment of myeloproliferative neoplasms Anil K Padyana Received Received
  1978-SAT Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort Julia-Annabell Georgi Received Received
  1979-SAT Preclinical and clinical Study of olverembatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement Wenzhi CAI Received Received
  1980-SAT Advanced myelofibrosis is marked by loss of NKG2D and DNAM-1 NK activating signaling and increased TIM-3 T CD8 exhaustion Camila Garcia Sr Received Received
  1981-SAT Myelofibrosis stem cell fitness requires microenvironmental cell interactions Min Lu Received Received
  1982-SAT Immune Dysregulation and State-Transition Transcriptomic Signatures Underlying Pediatric Chronic Myeloid Leukemia Pathogenesis Tiffany Kanesa Ybarra Received Received
  1983-SAT AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs) Andrew Dunbar Received Received
  1984-SAT A collective non-mutational transition governs the development of chronic myeloid leukemia Richard A Van Etten Received Received
  1985-SAT T cell-derived TNF-a mediates myelofibrosis via JAK2/STAT3-ADAM17 axis in JAK2V617F? myeloproliferative neoplasms Zhuming Yang Received Received
  1986-SAT Proteomic analysis identifying biomarkers in the progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: A retrospective cohort study Mingyu Jin Received Received
  1987-SAT Thrombopoietin inhibition abrogates JAK2V617F clonal expansion in a murine model of myeloproliferative neoplasm Karnsasin Seanoon Received Received
  1988-SAT ZE74-0282 is a novel JH2 domain JAK2 inhibitor with promising pre-clinical activity in JAK2 V617F mutant diseases Shailaja Hegde Received Received
  1989-SAT Peripheral blood dendritic cell subtype alterations in polycythemia vera: Clinical correlations with disease risk and inflammatory profile Tayfur Toptas Received Received
  1990-SAT Disrupting a new NFkB-IL-6-JAK2-STAT cascade with novel NFkB inhibitors reduces primary myelofibrosis growth Huiqin Bian Received Received
  1991-SAT Immune deconvolution from whole transcriptomic data suggests expansion of exhausted T-cells and natural killer cells following tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients Yael Morgenstern Received Received
  1992-SAT Identification of predictive protein signatures of treatment-free remission in patients with chronic myeloid leukaemia Isla Nosratzadeh Received Received
  1993-SAT ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibit Massimo Breccia Received Received
  1994-SAT Risk of secondary chronic myeloid leukemia in cancer survivors: A nationwide population-based study in Taiwan Chia-Jen Liu Received Received
  1995-SAT Nanopore sequencing to detect BCR::ABL1 and associated genomic rearrangements in CML Nicholas Cross Received Received
  1996-SAT Real-world cardiovascular risk of ponatinib in chronic Phase CML: Insights from a nationwide Korean claims-based cohort study Jeong-Ok Lee Received Received
  1997-SAT Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis Jorge Cortes Received Received
  1998-SAT Chronic myelogenous leukemia: A real-world experience from a Los Angeles county safety net hospital Dominick Zheng Received Received
  1999-SAT Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice report Xiaoyu Zhang Received Received
  2000-SAT Somatic mutations in cancer-related genes in chronic myeloid leukemia patients receiving asciminib Elena Kuzmina Received Received
  2001-SAT What is the optimal threshold for aberrant lymphoblasts at diagnosis to predict lymphoid transformation in chronic myeloid leukemia? Zhenzhen Jiang Received Received
  2002-SAT Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response Sewon Lee Received Received
  2003-SAT Prognostic utility of the ELTS score in pediatric chronic myeloid leukemia: Is it a valid clinical tool? Shivani Sai Ranga Jr Received Received
  2004-SAT Comparative impact of tyrosine kinase inhibitor dose-reduction on ability to achieve treatment-free remission among TKI-intolerant patients with chronic myeloid leukemia Melanie Rebechi Received Received
  2005-SAT Long-term imatinib therapy leads to significant reduction in GFR Kundan Mishra Received Received
  2006-SAT Is initial treatment with dasatinib for newly diagnosed chronic Phase chronic myeloid leukemia, followed by switching to imatinib for those that achieve MR3.0 at 12 months, an effective strategy? Results of the Phase 2 kinase inhibition with sprycel start Peter J. Browett Received Received
  2007-SAT Sequential monitoring using NGS allows detection of ABL1 KD mutations in patients with chronic Phase CML: Results from the prospective calls trial Ipek Baymul Received Received
  2008-SAT Frontline tyrosine kinase inhibitor selection influences eventual treatment-free remission eligibility and sustained treatment-free remission: A registry analysis of patients treated at CML referral sites in Australia Naranie Shanmuganathan Received Received
  2009-SAT Impact-CML: Indian multicentric data supporting safe pregnancy and molecular control in women with chronic myeloid leukemia Pankaj Malhotra Received Received
  2010-SAT Phase II study of clia (cladribine, idarubicin, cytarabine) plus tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia in myeloid blast Phase Mina Abdelmalek Received Received
  2011-SAT Standard tyrosine kinase inhibitor dose versus dose de-escalation prior to treatment-free remission attempt in chronic myeloid leukemia: A single-center 25-year retrospective study Mark Pusung Received Received
  2012-SAT Longitudinal analysis of first and subsequent-line tyrosine kinase inhibitor use in chronic myeloid leukemia: A 16-year single-center experience Moaath Mustafa Ali Received Received
  2013-SAT CSF3R-mutated chronic neutrophilic leukemia: A two-center study of 44 consecutive patients Abiola Bolarinwa Received Received
  2015-SAT Real-world risk of vascular events in patients with myeloproliferative neoplasms compared to the danish general population Dustin Andersen Patel I Received Received
  2016-SAT Diagnostic relevance of SH2B3 mutations in suspected myeloid malignancies: Insights from a large-scale NGS-based screening study Leïla BEN DHIA Received Received
  2017-SAT MAPS-R: International consensus classification-guided revision of the mayo alliance prognostic system for systemic mastocytosis Ayalew Tefferi Received Received
  2018-SAT Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study Lindsay Rein Received Received
  2019-SAT Pacritinib in patients with high-risk myelofibrosis: Outcomes from post-hoc analyses of two Phase 3 studies Pankit Vachhani Received Received
  2020-SAT Decreased serum total cholesterol is associated with worse outcomes among patients with myeloproliferative neoplasms Orly Leiva Jr Received Received
  2021-SAT Identification of red cell distribution width as a key predictor of leukemic transformation in polycythemia vera and essential thrombocythemia: A machine learning approach involving 10,560 cases Lior Rokach Received Received
  2022-SAT Clinical spectrum of noonan syndrome–associated myeloproliferative disorder Shinsuke Hirabayashi Received Received
  2023-SAT Dual transfusion independence and spleen volume reduction is associated with overall survival in patients with myelofibrosis treated with momelotinib: Post hoc analyses of SIMPLIFY-1 and MOMENTUM Stephen Oh Received Received
  2024-SAT Avapritinib achieves deep and durable symptom control with a well-tolerated safety profile in ism: Long-term outcomes from pioneer Tsewang Tashi Received Received
  2025-SAT Transfusion independence with momelotinib regardless of baseline erythropoietin levels in the Phase 3 SIMPLIFY-1 trial Stephen Oh Received Received
  2026-SAT Clinical outcomes in patients with accelerated or blast-Phase MPN treated with triplet regimen of hypomethylating agent, JAK inhibitor, and venetoclax (HMA/JAKi/Ven): A multicenter case series Ettaib El Marabti Received Received
  2027-SAT A phase 1/2a trial of amsulostat, a novel pan-lysyl oxidase inhibitor, in patients with advanced myelofibrosis as an add-on to ruxolitinib treatment for up to 52 weeks Ross Baker Received Received
  2028-SAT Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients Yi Zhang Received Received
  2029-SAT Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib Yi Zhang Received Received
  2030-SAT Effect of avapritinib on skin lesions in patients with advanced systemic mastocytosis using a novel, artificial intelligence-based technology Deepti H. Radia Received Received
  2031-SAT Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis Andrew T Kuykendall Received Received
  2032-SAT Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera Veronika Buxhofer-Ausch Received Received
  2033-SAT Shorespan-017: Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study Monia Marchetti Received Received
  2034-SAT BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study Jian Huang Received Received
  2035-SAT Detection of mutation in cell-free DNA predicts poor outcomes in adult patients with langerhans cell histiocytosis Long Chang Received Received
  2036-SAT Distinctive features of patients with MPN during pregnancy: Thrombotic risk, molecular drivers, and differential outcomes by subtype Anait Melikyan Received Received
  2037-SAT Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders Hannah Goulart Received Received
  2038-SAT Circulating cell-free BRAFV600E as a biomarker in patients with erdheim-chester disease Long Chang Received Received
  2039-SAT Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera Shanshan Suo Received Received
  2040-SAT Transcriptomic signatures associated with deep molecular response to ropeginterferon alfa-2b in polycythemia vera Seug Yun Yoon Received Received
  2041-SAT Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry Vivian Li Received Received
  2042-SAT RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia Naseema Gangat Received Received
  2043-SAT Interferon alfa treatment of early primary myelofibrosis is associated with improved overall survival Katie Erdos Received Received
  2044-SAT Ruxolitinib mitigates interferon-induced autoimmune toxicity: Clinical insights from a 465-patient MPN Cohort Retrospective study Guangshuai Teng Received Received
  2045-SAT An open-label, Phase I/II clinical trial of romaciclib (RVU120) as monotherapy and in combination with ruxolitinib in patients with intermediate or high-risk, primary or secondary myelofibrosis (POTAMI-61) Tomasz Sacha Received Received
  2046-SAT Clonal persistence and early cooperative mutations shape transformation in myelofibrosis Noushin Farnoud Received Received
  2047-SAT Impact of early dose escalation and treatment duration on hematologic response in ropeginterferon alfa-2b treatment for polycythemia vera Novella Pugliese Received Received
  2048-SAT Epidemiology and outcomes of patients with myeloproliferative neoplasms in the United States: A SEER database analysis, years 2000-2021 Sachi Singhal Received Received
  2049-SAT Disparities related to myelofibrosis: A retrospective analysis of US mortality data Aqsa Zoey Sorathia Received Received
  2050-SAT Real-world evidence demonstrates superior overall survival and favorable safety of avapritinib over midostaurin in newly diagnosed advanced systemic mastocytosis Mostafa Eysha Received Received
  2051-SAT A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia Jason Gotlib Received Received
  2052-SAT Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis John O. Mascarenhas Received Received
  2053-SAT A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV) Marcus Carden Received Received
  2054-SAT 5-azacytidine treatment reshapes clonal structure and alters mutation-dependent splicing in MDS patients Xuan Zhang Received Received
  2055-SAT Characterizing the In Vivo impact of inflammation on Samd9l hematopoietic phenotypes. Melvin Thomas III Received Received
  2056-SAT Single-cell transcriptomics reveal long non-coding RNA dysregulation in PPP1R15B-EIF2A axis impairing erythroid maturation in myelodysplastic syndromes Francisco Beas Jr Received Received
  2057-SAT Neutrophil extracellular traps drive myeloproliferation and immune dysfunction in chronic myelomonocytic leukemia Saveg Yadav Received Received
  2058-SAT Intermediate and high-risk clonal hematopoiesis in germline predisposition families Sandra Novoa Jáuregui I Received Received
  2059-SAT The USP22-NAP1L1 deubiquitination axis in the pathogenesis of myelodysplastic syndromes Lijuan Li Received Received
  2060-SAT Machine learning uncovers invariant evolutionary molecular trajectories in MDS. Matteo D´Addona Jr Received Received
  2061-SAT Single-cell transcriptomic insights into venetoclax response and resistance in secondary AML evolving from MDS Silvia Park I Received Received
  2062-SAT Lymphotoxin alpha (LTA) secretion correlates with gene expression and myeloid malignancy disease state Daniel Zaldumbide Received Received
  2063-SAT The variable splicing factor RBM17 regulates MDS cell proliferation through H3K27la Zhihong Wang Received Received
  2064-SAT C-CBL mutations affecting residue 371 confer dismal prognosis in MDS and CMML Luca Guarnera Received Received
  2065-SAT High dose ascorbate downregulates innate immune cytokines in the bone marrow of TET2 mutant chronic myelomonocytic leukemia Daniel Thomas I Received Received
  2066-SAT Deciphering clonal progression in MDS via longitudinal sequencing Asmita Shukla Received Received
  2067-SAT Myeloproliferative neoplasm driver mutations (JAK2/CALR/MPL) in chronic myelomonocytic leukemia are associated with an increased risk of blast transformation Muhammad Yousuf Received Received
  2068-SAT Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes Maria Julia Montoro Montoro Received Received
  2069-SAT Additional myelodysplasia-related genes mutations affected the clinical presentations and prognosis of patients with SRSF2/TET2 co-mutations Michael Sean Martin Received Received
  2070-SAT The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms Maria Julia Montoro Montoro Received Received
  2071-SAT MDS without clonal marker: When depth outperforms breadth Sandra Huber Received Received
  2072-SAT The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes Rami Komrokji Received Received
  2073-SAT Chronic myelomonocytic leukemia: Clinical outcomes from clinical trials submitted to the FDA over the past 25 years dianne pulte Received Received
  2074-SAT Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS) Valeria Santini Received Received
  2075-SAT Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes Kelly Sharon Chien Received Received
  2076-SAT Occurrence of immune-mediated inflammatory disorders (IMIDs) during the course of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) negatively impacts overall survival (OS): A cohort-based study Jose Torregrosa Received Received
  2077-SAT Validation of blast and blast-mol risk models in chronic myelomonocytic leukemia: Mayo-humanitas collaborative project involving 1,101 patients Saubia Fathima Received Received
  2078-SAT Molecular and cytogenetic landscape of black patients with myelodysplastic syndrome in the veterans health affairs Veronica Analia Guerra Received Received
  2079-SAT LS1781 (Arm E): Phase II clinical trial to assess the safety and efficacy of high dose IV ascorbic acid with decitabine in newly diagnosed TET2 mutant chronic myelomonocytic leukemia (CMML) Mrinal M. Patnaik Received Received
  2080-SAT Thrombocytopenia at diagnosis adversely affects overall and leukemia-free survival in lower-risk MDS patients: A retrospective study from the FISiM registry Anna Calvisi Sr Received Received
  2081-SAT Clinical and biological correlates of blast-transformed chronic myelomonocytic leukemia (CMML): A multicenter study of 493 paired cases at chronic phase and at blast transformation Clifford Csizmar Received Received
  2082-SAT High efficacy of azacitidine combined with lenalidomide in TP53 mutation-positive and other high-risk myelodysplastic neoplasms Zheng Ge Received Received
  2083-SAT Better discriminative capacity of blast and blast-mol scores in chronic myelomonocytic leukemia (CMML) Ana Mellado Jr Received Received
  2084-SAT EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group Anna Martín Carrizosa Jr Received Received
  2085-SAT Prognostic and therapeutic impact of FLT3 mutations and allelic burden in myelodysplastic syndromes and chronic myelomonocytic leukemia: Results from a multicenter cohort study Juan Jose Rodriguez-Sevilla Received Received
  2086-SAT A mutational grouping involving SRSF2, TET2, ASXL1, RUNX1, and STAG2 identifies patients with lower-risk myelodysplastic syndrome who benefit from higher-risk treatment strategies Brandon James Aubrey Received Received
  2087-SAT Integrated prognostic model for TP53-mutated myeloid neoplasms across all myeloid neoplasm subtypes Devendra Hiwase I Received Received
  2088-SAT Clinical characteristics and prognosis of 197 pediatric patients with refractory cytopenia: A single-center retrospective analysis Zixi Yin Received Received
  2089-SAT Optimizing elritercept benefit-risk profile by response-based adaptive dosing in patients with low-risk Myelodysplastic Syndromes (LR-MDS) Christine Neumar Received Received
  2090-SAT Beyond TP53: Molecular IPSS-genes multihit status revisited Marina Serra Carrera Received Received
  2091-SAT The prognostic impact of MTHFR gene polymorphisms and p15 gene methylation in Myelodysplastic Syndromes Marta Isabel Pereira Received Received
  2092-SAT The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) suppresses IL-8 and other pro-inflammatory cytokines in patients with low-risk myelodysplastic syndrome and symptomatic anemia Devan Bursey Received Received
  2093-SAT The novel allosteric NEK7 inhibit ofirnoflast (HT-6184) reduces oxidized mitochondrial DNA in patients with low-risk myelodysplastic syndrome Devan Bursey Received Received
  2094-SAT Trends in overall survival in MDS from 2000–2022: Have therapeutic advances made a difference? Sai Abhishek Narra Received Received
  2095-SAT Maintaining higher hemoglobin levels is associated with improved overall survival in Myelodysplastic Syndromes (MDS): A real-world retrospective analysis of electronic health records from a US community setting over the past 20 years Ira Zackon Received Received
  2096-SAT A phase II study of eltrombopag in patients with low-risk MDS and CMML harboring TET2 mutations Abhay Singh Received Received
  2097-SAT A prospective, single site, single-arm pilot study of CPX-351 (Vyxeos) in individuals Alyssa L. Kennedy Received Received
  2098-SAT SAT1, a novel target of SF3B1 K700E mutant in chronic lymphocytic leukemia, facilitates disease development via regulating T-cell function Hao Guo Received Received
  2099-SAT Genetic analysis of B and T cell subsets from CLL patients prior to and at Richter´s transformation Sutapa Sinha Received Received
  2100-SAT CD49d expression is epigenetically regulated in chronic lymphocytic leukemia: Insights from CD49d bimodal cases Erika Tissino Received Received
  2101-SAT Ibrutinib enhances 41BB-costimulated CART19 function and persistence through immune reprogramming: Insights from the phase 3 ECOG-ACRIN E1912 clinical Trial Truc Ngoc Huynh Received Received
  2102-SAT Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation Quinlan Sievers Received Received
  2103-SAT Integrated single-cell RNA sequencing and TCR profiling identifies immune drivers of severe early toxicity in CLL patients treated with idelalisib Saurabh Yadav Received Received
  2104-SAT PD-1 expression on richter syndrome tumor cells does not provide a growth advantage in murine or patient-derived xenograft models In Vivo Ivan Negara Received Received
  2105-SAT Single cell multiomics dissection of In Vivo immune modulation and reconstitution induced by bruton´s kinase inhibitors in CLL patients Anna Gurevich Shapiro Received Received
  2106-SAT JAK1/2 inhibition with ruxolitinb potentiates ex vivo activity of epcoritamab in primary CLL cells Xiao Lyu Received Received
  2107-SAT Redefining early vs late progressive disease (PD) in chronic lymphocytic leukemia: A pooled analysis of fixed-duration therapies Florian Simon Received Received
  2108-SAT Venetoclax retreatment of real-world patients with chronic lymphocytic leukemia previously treated with venetoclax-based regimens Mazyar Shadman Received Received
  2109-SAT Impact of FMC7 expression on baseline characteristics and outcomes in CLL patients treated with upfront BTKi monotherapy. Nikita Malakhov Received Received
  2110-SAT Outcomes of patients with Richter transformation (RT) treated with frontline chemoimmunotherapy (CIT) and BTK inhibitor (BTKi) Sirui Ma Received Received
  2111-SAT Real-world (RW) treatment (Tx) patterns, factors associated with discontinuation and toxicity across covalent BTK inhibitors (cBTKis) in first-line (1L) tx of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) Ira Zackon Received Received
  2112-SAT Long-term event-free survival in patients with IGHV-mutated high-count monoclonal B-cell lymphocytosis and atypical, non-CLL-like phenotypes Jan-Paul Bohn Jr Received Received
  2113-SAT Molecular determinants of outcome in CLL patients treated on zanubrutinib registration trials Inhye E Ahn Received Received
  2114-SAT CLL with t(11;14)(q13;q32) or t(14:18)(q32:q21) –­­ is this CLL or lymphoma? Alessandro Baldi Received Received
  2115-SAT Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up William G. Wierda Received Received
  2116-SAT Retrospective evaluation of the G8 score in CLL patients treated with targeted therapies: A single-center experience Alessandro Sanna Received Received
  2117-SAT Venetoclax plus obinutuzumab improves quality of life in treatment-naive CLL: Prospective real-world insights from the verve study Ingo Schwaner Received Received
  2118-SAT A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial John F. Seymour Received Received
  2119-SAT Nemtabrutinib plus venetoclax in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the dose escalation and confirmation segment of the Phase 3 bellwave-010 study Paolo Ghia Received Received
  2120-SAT Dissecting the heterogeneity of IGHV-mutated CLL: An eric study. Thomas Chatzikonstantinou Received Received
  2121-SAT Comparative analysis of characteristics and outcomes in CD5+/FMC7+ lymphoproliferative disorders and classic CLL immunophenotype patients. Allison Kagerer Received Received
  2122-SAT Genetic and clinical profiles of chronic lymphocytic leukemia in Thailand: Nationwide insights from the thai lymphoma study group Ornnicha Sathitakorn Received Received
  2123-SAT Long-term results of patients receiving zanubrutinib in the phase 3 ALPINE study confirm sustained benefit of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL): Up to 6 years of foll Constantine S. Tam Received Received
  2124-SAT A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial) Shuhua Yi Received Received
  2125-SAT Encouraging long-term efficacy and safety from first-in-human phase 1 study of time-limited NVG-111 in relapsed/refractory CLL and MCL Parag Jasani Received Received
  2126-SAT Impact of autoimmune hemolytic anemia on prognosis in chronic lymphocytic leukemia patients: A comprehensive retrospective analysis Liang Wang Sr Received Received
  2127-SAT Orelabrutinib combined with short-course bendamustine-rituximab (BR) for first-line treatment of chronic lymphocytic leukemia: A prospective multicenter study Linlin Cao Received Received
  2128-SAT Ibrutinib plus rituximab leads to superior progression-free and overall survival to FCR in previously untreated CLL: Results of the Phase III NCRI FLAIR trial Talha Munir Received Received
  2129-SAT Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year Constantine S. Tam Received Received
  2130-SAT Continuous venetoclax for relapsed chronic lymphocytic leukemia (CLL) – characteristics and outcomes of long-term responders Sean McKeague Received Received
  2131-SAT Initial treatment of chronic lymphocytic leukemia with low-dose high-frequency rituximab followed by addition of acalabrutinib Charles C. Chu Received Received
  2132-SAT New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival Yang Liang Received Received
  2133-SAT Concurrent loss of TP53 and CDKN2A with tetraploidy predicts richter transformation and poor prognosis in chronic lymphocytic leukemia Jennifer A. Woyach Received Received
  2134-SAT A phase 2 study with tafasitamab and zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – taza CLL Georgios Pongas Received Received
  2135-SAT Impact of prior venetoclax use on mortality in CLL patients treated with pirtobrutinib: A propensity-matched cohort study Kanishka Uttam Chandani Received Received
  2136-SAT Sonic: Escalated inpatient ramp-up of sonrotoclax in CLL/SLL and MCL Jennifer J. Huang Received Received
  2137-SAT A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL- Othman Al-Sawaf Received Received
  2138-SAT Preclinical evaluation of SWI/SNF targeting agents in multiple myeloma including t(4;14) subtypes Yusuke Yamashita Received Received
  2139-SAT Targeting lysosomes to overcome albumin-mediated proteasome inhibitor resistance in multiple myeloma Sinto Sebastian Chirackal Received Received
  2140-SAT Integrated multidisciplinary approaches to improve prognosis prediction in multiple myeloma Claudio Cerchione Received Received
  2141-SAT Long-read RNA sequencing of first multiple myeloma patient cohort reveals landscape of variant expression in newly diagnosed patients from the UKMRA RADAR trial Bethan Hudson-Lund Received Received
  2142-SAT The TEMPI syndrome: Unique patient specific monoclonal antibodies as tools for target antigen discovery David Sykes Received Received
  2143-SAT LDHAL6B promotes lactate-mediated histone H4K8 lactylation and enhances malignant cellular behaviors in multiple myeloma Liping Zuo Received Received
  2144-SAT Single-cell analysis identifies a KLF5–Neutrophil–Plasma cell axis driving immune suppression in POEMS syndrome Ting Zhang Received Received
  2145-SAT The c-terminal to lish (CTLH) E3 ligase complex modulates myeloma glucocorticoid sensitivity by regulating nfkb signaling Amin Sobh Received Received
  2146-SAT CRISPR-ko screen identifies RARa inhibition as a strategy to increase CD38 expression in multiple myeloma and potentiate anti-CD38 therapy. Laura Alibert Received Received
  2147-SAT Downregulation of midnolin mediating non-ubiquitin protein degradation and its role in myelomagenesis. Anna Besschetnova Received Received
  2148-SAT The unique role of PSMD2/Rpn1 among ubiquitin receptors in multiple myeloma highlights its potential as a therapeutic target to overcome proteasome inhibitor resistance Ting Du Received Received
  2149-SAT Altered bone marrow (BM) plasma amino acid (AA) composition reflects microenvironmental remodeling in patients with multiple myeloma (MM) compared to monoclonal gammopathy of unknown significance (MGUS) Michael Joseph Egan Received Received
  2150-SAT Deciphering the IKZF1 and MAP4K2 protein interactome in RASMut multiple myeloma reveals a novel regulatory pathway of IKZF1 Josefine Krüger Received Received
  2151-SAT Selective germline testing in multiple myeloma patients yields a six-fold increase in actionable cancer predisposition findings: Time for screening guidelines? Maria Victoria del Rosal Received Received
  2152-SAT Modeling of a hyper-inflammatory hematopoietic niche ex vivo reveals a multi-step process driving CAR T- cell associated myeloid leukemia in multiple myeloma Max Köppel Received Received
  2153-SAT Immunomodulatory drugs rewire mTORC1-dependent pathways in multiple myeloma to trigger cytotoxicity and immunogenic cell death Jiye Liu Received Received
  2154-SAT Plasma proteomic analysis as a tool for monitoring the development of ibrutinib resistance in Waldenstroem macroglobulinemia. Tina Bagratuni Received Received
  2155-SAT Proof of concept and mechanistic evaluation of lbl-034, a potent GPRC5D-targeting T cell engager with affinity-optimized, sterically engineered anti-CD3 arm, in a multiple myeloma xenograft mouse model Bin Fan Received Received
  2156-SAT Super-enhancer-mediated regulation of CD38 inducibility in multiple myeloma via the MAF/TRIM47/RARa axis Qiqi Shen Received Received
  2157-SAT Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma Ava Lilly Amidei Received Received
  2158-SAT Single–cell analysis of BCR and transcriptome uncovers plasma cell clonal dynamics and immune exhaustion linked to daratumumab response in primary light–chain amyloidosis Xuezhu Wang Received Received
  2159-SAT Cell-free CAR therapy: BCMA-CAR-T cell-derived exosomes exhibit potent anti-myeloma activity Bin Sun Received Received
  2160-SAT Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma Patrizia Porazzi Received Received
  2161-SAT Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma Amanda Duplan Received Received
  2162-SAT Integrative omics analysis of TP53 in multiple myeloma patients Cristina De Ramón Sánchez Received Received
  2163-SAT Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells Noemie Leblay Received Received
  2164-SAT PHF19 inhibition increases IMiDs sensitivity by epigenetically regulating IRF4 and MYC in multiple myeloma Xiyue Sun Received Received
  2165-SAT Triptonide and bortezomib synergistically inhibit multiple myeloma by enhancing DNA damage through blocking TRIP13-mediated DNA repair Fen He Received Received
  2166-SAT Plasma cell senescence in relapsed multiple myeloma revealed by integrated single-cell RNA-seq analysis Gabriel Alvares Borges Received Received
  2167-SAT The core role of exosomal mir-21-5p/TGF-ß1-CXCL12/RANKL axis in bone marrow microenvironment remodeling in multiple myeloma and targeted intervention strategies Li Wang Received Received
  2168-SAT Characterization of the plasma proteome of multiple myeloma and its precursor conditions and identification of a prognostic high-risk signature of progression Elizabeth D Lightbody Received Received
  2169-SAT SKP2/CKS1B as a rational drug target in 1q21 amplified multiple myeloma. Fei Liu Received Received
  2170-SAT Deciphering the cellular hierarchy of multiple myeloma uncovers a therapeutically exploitable EP300/TBX2 axis in LILRB4+ myeloma-initiating cells Qiqi Shen Received Received
  2171-SAT Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas. Shirong Liu Received Received
  2172-SAT Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum David E Mery Received Received
  2173-SAT Identification of novel "driver" genes of multiple myeloma through genome-scale CRISPR activation studies Huihui Tang Received Received
  2174-SAT Impact of bortezomib on T-cell subsets and immune checkpoints under bispecific antibody therapy in multiple myeloma Xiang Zhou Received Received
  2175-SAT Genomic and transcriptomic signatures of extramedullary multiple myeloma reveal possible drivers of therapeutic resistance Catherine Elizabeth Duane Received Received
  2176-SAT Synthetic lethal targeting of PSMC2-dependent p97-adapted proteasome complexes that confer chemoresistance in multiple myeloma James Driscoll II Received Received
  2177-SAT Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming Shannon Matulis Received Received
  2178-SAT Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma Cecilia Bonolo De Campos Received Received
  2179-SAT Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes William Cain Pilcher Jr Received Received
  2180-SAT Myscape: Myeloma single cell atlas for precision exploration reveals stage-specific T cell dysregulation associated with progression and therapy Siddhartha Mantrala Received Received
  2181-SAT The real-world safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy in systemic AL amyloidosis Matthew James Rees Received Received
  2182-SAT The real-world safety and efficacy of bispecific t-cell engager therapy in systemic AL amyloidosis Matthew James Rees Received Received
  2183-SAT Diagnostic and prognostic value of 18f-florbetapir PET/CT in systemic light-chain amyloidosis. Shanhu Qian Sr Received Received
  2184-SAT Management and long-term hematologic and neurologic outcomes of IgM-related neuropathy: A single center experience Maria Gavriatopoulou Received Received
  2185-SAT Monoclonal light chain glycosylation is associated with evolution of incidental MGUS Karthik Ramasamy Received Received
  2186-SAT Longitudinal biomarker dynamics for accurate risk prediction in 464 patients with asymptomatic IgM gammopathy: A spanish multicenter study Elena Medina Jr Received Received
  2187-SAT Light-chain MGUS defined as per the revised definition of the istopmm study: Experience from the university of calgary MGUS clinic Victor Jimenez-Zepeda Received Received
  2188-SAT Daratumumab-pomalidomide-dexamethasone (DPd) in newly diagnosed AL amyloidosis: High rates of hematologic and organ responses with manageable safety Yongyong Ma Received Received
  2189-SAT Proteomic profiling of amyloid deposits in advanced systemic light-chain (AL) amyloidosis: Insights into clonal light chains, chaperone proteins, and cardiac involvement Piaorong Zeng I Received Received
  2190-SAT Prognostic analysis of newly diagnosed systemic light-chain amyloidosis patients treated with daratumumab Yi Xu Jr Received Received
  2191-SAT Characteristics and clinical course of younger Patients with early lesions in a contemporary cohort of 1240 patients: Low risk features and low risk of complications Eirini Solia Received Received
  2192-SAT Von willebrand factor levels show independent prognostic significance in patients with AL amyloidosis treated with daratumumab-based therapies Foteini Theodorakakou Received Received
  2193-SAT National trends and disparities in AL amyloidosis-related mortality among multiple myeloma patients in the United States: A population-based study (1999–2023) Haseeb Tareen Received Received
  2194-SAT Better renal response with daratumumab in patients with monoclonal immunoglobulin deposition disease Divaya Bhutani Received Received
  2195-SAT External validation of the istopmm prediction model in a US population Marisa Ann Sobczak Received Received
  2196-SAT Association between soluble immune biomarkers and monoclonal gammopathy of undetermined significance (MGUS) in three large cancer epidemiology cohorts with participants from underrepresented groups. Wendy Cozen Received Received
  2197-SAT Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis Rajshekhar Chakraborty Received Received
  2198-SAT Prognostic independence of double-hit multiple myeloma based on mayo definition, and nomogram was established Fuling Zhou Jr Received Received
  2199-SAT Exploring the interplay of myeloma and acute decompensated heart failure: Mortality and comorbidity insights Brett Cohen Received Received
  2200-SAT Dermatologic adverse effects with elranatamab mimicking talquetamab M Bakri Hammami Received Received
  2201-SAT Real world test characteristics of mass spectrometry monoclonal protein monitoring in multiple myeloma Kevin Guanwen Shim Received Received
  2202-SAT Impact of low disease burden on the safety and efficacy of BCMA CAR-T in patients with Relapsed/Refractory multiple myeloma Kevin Robert Reyes Received Received
  2203-SAT Improved survival in patients with multiple myeloma over time: A retrospective single-center study focusing on patients aged 80 years and above Masaki Iino Received Received
  2204-SAT Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses Aarif Ahsan Received Received
  2205-SAT Multiple myeloma with =1% circulating plasma cells in peripheral blood has a poor prognosis Kosuke Miki Received Received
  2206-SAT Comparative effectiveness of CAR-T cell therapy vs. teclistamab in relapsed/refractory multiple myeloma: A real-world propensity-matched analysis revealing survival advantages and treatment disparities Nehemias Guevara Received Received
  2207-SAT Dexamethasone dose intensity does not improve 6-month responses in newly diagnosed multiple myeloma and may contribute to hyperglycemia Gui Zhen Chen Received Received
  2208-SAT Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma Jan Vorwerk Received Received
  2209-SAT Real-world study on discontinuation strategies after MRD negativity in multiple myeloma patients Xiaozhe Li Received Received
  2210-SAT Low dose tocilizumab for mitigation of cytokine release syndrome with bispecific antibodies in relapsed/refractory multiple myeloma Issam S Hamadeh Received Received
  2211-SAT Comparative real-world outcomes of bispecific antibodies versus pomalidomide-based regimens in relapsed/refractory multiple myeloma: A propensity-matched cohort analysis Renu Bhargavi Boyapati Received Received
  2212-SAT Comparative outcomes of CAR-T therapy in elderly (=70 Years) versus younger ( Renu Bhargavi Boyapati Received Received
  2213-SAT Second primary malignancies in multiple myeloma: Incidence, survival and prognostic factors from a large single-center observational study Noriko Nishimura Received Received
  2214-SAT Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma Doris K. Hansen Received Received
  2215-SAT Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma Binod Dhakal Received Received
  2216-SAT Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival Panagiotis Malandrakis Received Received
  2217-SAT Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells Yulia Shifrin Received Received
  2218-SAT Feasibility of risk classification with newly proposed international myeloma working group (IMWG) high-risk definition: A single-center analysis using natural language processing Michael Slade Received Received
  2219-SAT Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma Yamuna Kondapally Received Received
  2220-SAT Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study Noa Biran Received Received
  2221-SAT Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups. Ghassan Zammar Received Received
  2222-SAT Beyond FISH: CMA detects 8p-, xq+, and y- as markers of early post-transplant progression in myeloma Yuliya Shestovska Received Received
  2223-SAT Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM) Jesús Berdeja Received Received
  2224-SAT Artificial intelligence accelerates the identification of measurable residual multiple myeloma by flow cytometry Clarissa E Jordan Received Received
  2225-SAT Clinical course, predictors of development, and therapeutic response in multiple myeloma with central nervous system involvement Alexander Xiao Received Received
  2226-SAT A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma Nicholas Semenkovich Received Received
  2227-SAT Burden and characteristics of infections in patients treated with bispecific antibodies and the impact of immunoglobulin replacement Efstathios Kastritis Received Received
  2228-SAT Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimens Efstathios Kastritis Received Received
  2229-SAT Pomalidomide salvage in T-cell engager monotherapy failures: Real-world experience with talquetamab or elranatamab with pomalidomide combinations in heavily pretreated multiple myeloma James C Di Palma-Grisi Received Received
  2230-SAT The clinical utility of MALDI-TOF MS in multiple myeloma Wenming Chen Received Received
  2231-SAT Pre-diagnostic biomarkers show disease susceptibility continuum and enable early prediction of multiple myeloma Jiadai Xu Received Received
  2232-SAT Tracking MRD in multiple myeloma: Soluble BCMA reflects flow cytometry changes Masanori Toho Received Received
  2233-SAT Lenalidomide-related diarrhea is associated with gut microbiota dysbiosis and disruption of the bile acid pool Kevin Charles Miller Received Received
  2234-SAT Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center Alberto Blanco Received Received
  2235-SAT BCMA+ extracellular vesicles predict response and toxicity in patients with multiple myeloma treated with anti-BCMA bispecific antibodies Carmine Liberatore Received Received
  2236-SAT Quantification of circulating plasma cells at diagnosis can identify functional high risk multiple myeloma patients ALESSANDRA ROMANO Received Received
  2237-SAT Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis Hamza Hashmi Received Received
  2238-SAT Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial Noemi Puig Received Received
  2239-SAT Predictors of renal recovery in newly diagnosed multiple myeloma with light chain cast nephropathy Jeet Patel Received Received
  2240-SAT Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights Binod Dhakal Received Received
  2241-SAT Dynamic evolution of minimal residual disease and normal plasma cells following autologous stem cell transplantation in multiple myeloma Qirui Bai Received Received
  2242-SAT Prognostic significance of 1q21 gain/amplification and co-existing cytogenetic abnormalities in Chinese patients with newly diagnosed multiple myeloma Xinyuan Dai Received Received
  2243-SAT Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T. Joshua Gustine Received Received
  2244-SAT Computational immunophenotypic profiling of multiple myeloma by flow cytometry and bioinformatics integration Aldair Paiva Received Received
  2245-SAT Evaluation of serum TIE-2 levels in newly diagnosed and untreated multiple myeloma patients Zeynep Tugba Karabulut Received Received
  2246-SAT Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China Gang An Received Received
  2247-SAT Therapy-related malignancies in myeloma: SEER comparison of IMiD vs anti-CD38 eras Kalan Patel Received Received
  2248-SAT Patients with multiple myeloma and CKD: Should we really hold off on bispecific therapy in this subgroup? Kirti Arora Received Received
  2249-SAT Thromboembolic and cardiovascular events after CAR-T cell therapy in multiple myeloma: A propensity-matched real-world analysis Moath Albliwi Received Received
  2250-SAT Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM) Rintu Sharma VI Received Received
  2251-SAT Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries Kiran Lakhani Received Received
  2252-SAT Racial and socioeconomic disparities in smoldering multiple myeloma: Insights from the surveillance, epidemiology, and end Results (SEER) database. Imran Khan Received Received
  2253-SAT A clinical overview of infection in patients receiving elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) for newly diagnosed multiple myeloma in the MagnetisMM-6 trial Ja Min Byun Received Received
  2254-SAT Safety and efficacy of linvoseltamab (LINVO) combined with anti-CD38 monoclonal antibodies (mAbs) daratumumab (DARA) or isatuximab (ISA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the multicohort, Phase 1b LIN Meletios Athanasios Dimopoulos Received Received
  2255-SAT Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial Danny Jeyaraju Received Received
  2256-SAT Carfilzomib Augmented with high-dose melphalan conditioning regimen Enhances Response in patients with multiple myeloma eligible for ASCT:an investigator-initiated, prospective, multicenter study Xiaotao Wang III Received Received
  2257-SAT Efficacy of maintenance therapy after auto-HSCT in patients with multiple myeloma (MM) in sustained minimal residual disease (MRD) negativity remission Maksim V Solovev Received Received
  2258-SAT Randomized comparison between isatuximab-rd versus rd induction, followed by isa-R versus R maintenance in very elderly patients with NDMM: Efficacy data on MRD after induction (AGMT-MM04 Trial) Heinz Ludwig Received Received
  2259-SAT T-cell engager activity of etentamig (BCMA x CD3) is potentiated by daratumumab in preclinical models of multiple myeloma Aarif Ahsan Received Received
  2260-SAT Impact of belantamab mafodotin–containing regimens on renal function in patients with Relapsed/Refractory multiple myeloma (RRMM) and mild/moderate renal impairment in the dreamm-7 and dreamm-8 trials Marcelo Pitombeira de Lacerda Received Received
  2261-SAT Maintenance therapy discontinuation for patients diagnosed with multiple myeloma without high-risk features in minimal residual disease (MRD) negative remission: An interim analysis Sam Holt Received Received
  2262-SAT Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma Vania Hungria Received Received
  2263-SAT Health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation and treated with isatuximab, lenalidomide, bortezomib, and dexamethasone (Isa-RVd) versus rvd alone: Results from part 1 of the GM Elias K. K. Mai Received Received
  2264-SAT Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study Suzanne Trudel Received Received
  2265-SAT Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial María-Victoria Mateos Received Received
  2266-SAT Restarting etentamig therapy after dosing delays or interruptions: Population pharmacokinetics (PopPK) and PK/PD simulations and supporting clinical data Sneha Rathi Received Received
  2267-SAT Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients Enrique Ocio Sr Received Received
  2268-SAT Clonotypic peptide mass spectrometry to monitor m-protein reduction in patients with relapsed/refractory multiple myeloma from ikema Study Vincent Bonifay Received Received
  2269-SAT Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3 Alexander M. Lesokhin Received Received
  2270-SAT Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma Huanxin Zhang Received Received
  2271-SAT Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study Huixing huixing Zhou I Received Received
  2272-SAT Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing María-Jesús Blanchard Received Received
  2273-SAT Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial Urvi Shah Received Received
  2274-SAT MBS314, a GPRC5DxBCMAxCD3 trispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results from a Phase 1 dose escalation study Gang An Received Received
  2275-SAT Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05) Arthur Bobin Received Received
  2276-SAT Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study Jing Chen Received Received
  2277-SAT Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: A network meta-analysis and reconstructed individual patient data meta-analysis Joao Tadeu Damian Souto Filho Received Received
  2278-SAT GT919, a novel IKZF3/1 molecular glue degrader: Phase 1 safety and preliminary efficacy in relapsed or refractory multiple myeloma (R/R MM) Chengcheng Fu Received Received
  2279-SAT Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study Peng Liu Received Received
  2280-SAT Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease Aijun Liu Received Received
  2281-SAT The SCOPE trial: A phase 2 Study of selinexor in combination with pomalidomide and dexamethasone for patients with relapsed and/or refractory multiple myeloma Prashant Kapoor Received Received
  2282-SAT Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study Hang Quach Received Received
  2283-SAT Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial Cyrille Touzeau Sr Received Received
  2284-SAT An exploratory analysis of health-related quality of life measures with belantamab mafodotin in combination with pomalidomide and dexamethasone (BPd) in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in dreamm-8 Paul G. Richardson Received Received
  2285-SAT Daratumumab, bortezomib, thalidomide and dexamethasone improves renal outcomes in multiple myeloma transplant eligible patients presenting with renal failure: A real life experience from northeastern Italy Valeria Ruocco Received Received
  2286-SAT Real-world comparison of CAR-T therapy versus bispecific antibodies in Relapsed/Refractory multiple myeloma Henna Qadri Received Received
  2287-SAT Real-world sequencing of anti-BCMA CAR T-cells and bispecific T-cell engagers in Relapsed/Refractory multiple myeloma: A multi-country analysis Nicolas Blin Received Received
  2288-SAT A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma Anders Svensson Received Received
  2289-SAT Trial in progress: CAR-T (idecabtagene vicleucel) in advanced myeloma plus iberdomide or usual monitoring (The Alliance A062102 CADMIUM Study) Sascha Tuchman Received Received
  2290-SAT Prolonged cytopenias after BCMA CAR-T are associated with impaired endogenous T cell recovery characterized by decreased CD8+ T cell diversity Abigail Chutnik Received Received
  2291-SAT Functionally high-risk disease is associated with inferior outcomes after chimeric antigen receptor T-cell therapy for relapsed refractory multiple myeloma Tara Sebastian Received Received
  2292-SAT Optimal trispecific CAR construct simultaneously targets BCMA, GPRC5D, and CD38 to treat antigen-heterogeneous multiple myeloma Xiaowen He Received Received
  2293-SAT BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001) Wenqiang Yan Received Received
  2294-SAT Multi-omic analysis reveals metabolic fitness of the ARI0002h BCMA CAR T-cell infusion product as a key predictor of clinical outcomes in multiple myeloma Joan Mañé Pujol Received Received
  2295-SAT Phase I study of NPB5005-V283 in patients with relapsed/refractory multiple myeloma Wanyan Ouyang Jr Received Received
  2296-SAT A first-in-human study of CT0596, an allogeneic CAR T-cell therapy targeting BCMA, in patients with relapsed/refractory multiple myeloma Juan Du Received Received
  2297-SAT KarMMa-3 subgroup analysis in older patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel Sikander Ailawadhi Received Received
  2298-SAT Safety and efficacy of autologous hematopoietic stem cell transplantation followed by CAR-T therapy in patients with high-risk or advanced plasma cell neoplasms Yanli Feng Sr Received Received
  2299-SAT Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center Ruike Yan Received Received
  2300-SAT Prospective study of fluoroquinolone resistance colonization in patients undergoing autologous hematopoietic stem cell transplantation in the treatment of multiple myeloma. Chintan Patel Received Received
  2301-SAT Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM) Nisha Joseph Received Received
  2302-SAT Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide Eyal Lebel Received Received
  2303-SAT Post-transplant cyclophosphamide facilitates preservation of intestinal innate lymphoid cells and intestinal stem cells. Guillermo Orti Received Received
  2304-SAT Murine regulatory NK cells restrict allogeneic CD4? T cell-driven gvhd without compromising cytotoxic function Madeline Patricia Lauener Received Received
  2305-SAT Novel CD117 T-cell engagers for targeted bone marrow HSPC depletion Mukul Girotra Received Received
  2306-SAT LRP-1 regulates T cell proliferation and activation through global lipid network and loss of LRP-1 eliminates GVHD In Vivo Qing Ma Received Received
  2307-SAT Histone acetyltransferase p300/CBP as a therapeutic target to ameliorate gvhd-induced inflammatory memory Toru Miyajima Received Received
  2308-SAT Sorafenib enhances anti-leukemia effect via promoting macrophage-NK cell immune crosstalk in FLT3-ITD+ AML patients receiving allo-HSCT Ruoyang Shao Received Received
  2309-SAT Development of CD371 shielded hematopoietic stem cell grafts for protection against AML-directed immunotherapies Satoshi Kaito Received Received
  2310-SAT Inhibition of DRP1–FIS1–Mediated mitochondrial fission as a novel strategy to prevent gvhd Hao Yan Received Received
  2311-SAT Multiplex detection of gastrointestinal microbiota using short probes in graft vs. host disease Albert C Yeh Received Received
  2312-SAT Tracking clonal dynamics, tolerance, and adverse events after CD45-ADC–Conditioned autologous HSPC transplantation in rhesus macaques Taha Bartu Hayal Received Received
  2313-SAT Physiologic oxygen expansion of murine lineage negative bone marrow cells enhances lymphocyte recovery following transplantation Sarah Gutch Received Received
  2314-SAT New evidence indicates that the NLRP3 inflammasome in hematopoietic stem and progenitor cells (HSPCs) maintains proper mitochondrial electron transport chain function and affects both cellular trafficking and metabolism through a gasdermin pore-mediated, Magdalena Kucia Received Received
  2315-SAT CCR2 chemokine receptor promotes hematopoietic stem and progenitor cell mobilization Farnaz Razmkhah Received Received
  2316-SAT T cell resistance to glucocorticoids in graft-versus-host disease Andrew Clark McIntyre Received Received
  2317-SAT Timed inhibition of the sting pathway improves tissue regeneration and prevents GVHD following allo-HSCT Sascha Göttert Received Received
  2318-SAT Hematopoietic cell-derived mitochondria transfer reduces morbidity and mortality in a mouse model of leigh syndrome Ritsuko Nakai Received Received
  2319-SAT Overcoming CAR T cell resistance in NPM1c and KMT2Ar AML through menin pathway inhibition Sara Piccinelli Received Received
  2320-SAT Metabolism-focused CRISPR screen in B cell tumor identifies sphingolipid metabolism promotes resistance to CAR-T cell therapy Qiqi Zhang Received Received
  2321-SAT Tumor-derived microRNA-125a impairs CART cell function and predicts treatment failure in B cell malignancies Olivia Lynn Sirpilla Received Received
  2322-SAT Venetoclax enhances T cell fitness and CAR T-cell manufacturing potential in chronic lymphocytic leukemia (CLL) Arun Kumar Arunachalam Received Received
  2323-SAT In Vivo CAR-t generation using an engineered lentiviral vector platform targeting BCMA, CD19 and CD20. yongke zhang Received Received
  2324-SAT Impact of CAR-T cells expansion and tumor burden on the outcome after inotuzumab ozogamicin as bridging therapy in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia. Patricia Alcalde-Mellado Received Received
  2325-SAT Enhanced efficacy and safety of optimized tandem CD19/CD20 CAR T-cell Therapy in refractory/relapsed B-cell lymphoma Jia Wei Received Received
  2326-SAT Dasatinib enhances potency of a novel CD123 CAR against AML by improving cell fitness Genqing Liang Received Received
  2327-SAT iPSC-derived, multiplex-engineered CD8aßT cells deliver antigen-specific, potent, and durable tumor cytotoxicity without CD4aßT support – powering scalable, off-the-shelf allogeneic aßT cell therapy in hematological malignancies Chih-Lung Chen Sr Received Received
  2328-SAT New evidence that complement activation and NLRP3 inflammasome signaling work together to cause cytokine release syndrome after CAR-T cell therapy Magdalena Kucia Received Received
  2329-SAT A first-in-primate In Vivo CRISPR/Cas9 screen in a rhesus macaque model identifies drivers of CAR-T expansion, tissue tropism and persistence Francesca Alvarez Calderon Received Received
  2330-SAT Enhancing CD33.CAR NK cell therapy for acute myeloid leukemia through TGFß imprinting and NKTR-255 Yanling Liao Yanling Liao Received Received
  2331-SAT Ponatinib alleviates CAR-T cell exhaustion and remodels the immune microenvironment: A promising combination strategy for relapsed/refractory b-ALL Yi Zhou Received Received
  2332-SAT Development of novel MZB1-directed HLA-dependent CAR T cell and CAR enhancer therapy in MM and other B-cell malignancies Elena Maroto Martin Received Received
  2333-SAT Circadian rhythm disruption impairs CAR-T cell efficacy by promoting an immunosuppressive tumor microenvironment through enhancing monocyte-MDSC infiltration Wanying Zhang Received Received
  2334-SAT Afatinib boosts CAR-T cell antitumor therapeutic efficacy via metabolism and fate reprogramming Yueyu Dai Received Received
  2335-SAT Immune recovery and immunologic remodeling after CD19-directed chimeric antigen receptor T cell therapy in autoimmune diseases Andreas Riedel Received Received
  2336-SAT Mechanistic basis of the acute safety profile of rese-cel, an autologous CD19-CAR T, in patients with autoimmune disease treated in four ongoing phase 1/2 clinical trials Samik Basu Received Received
  2337-SAT A novel CD94-targeting CAR T cell therapy for cytotoxic subtypes of T/NK-cell malignancies Cuong Cao Le Received Received
  2338-SAT IL-4 epigenetically reprograms CART19-28? cells to drive dysfunction Carli Mae Stewart Received Received
  2339-SAT Pre-infusion ADAMTS13 and VWF levels are associated with clinical outcomes of patients receiving CAR-T cell therapy Abdalla Mohamed Shoaib I Received Received
  2340-SAT Microrna-142 improves IL1RAP CAR-T cell activity in Acute Myeloid Leukemia Kaito Harada Received Received
  2341-SAT Precision targeting of immune-mediated thrombotic thrombocytopenic purpura (iTTP) with chimeric auto-antigen receptor (CAAR) T cells Roman H Khadka Received Received
  2342-SAT Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy Selma Sorri Received Received
  2343-SAT Multi-faceted influence of immunomodulatory metabolites on CAR-T cell therapy Dhyani Shah Received Received
  2344-SAT A novel immune signature characterized by activation of the IFN?-IL18 axis identifies immune effector cell-associated HLH-like syndrome after CD22 chimeric antigen receptor T-cell therapy Joseph Rocco Received Received
  2345-SAT Non-hematotoxic Tim-3/CD70 dual-targeting CAR T cells promote potent anti-leukemia activity against acute myeloid leukemia Sophia Chen Received Received
  2346-SAT CAR-T with ICOS costimulation lacks therapeutic efficacy in patient due to strong trogocytosis and failure of expansion Yongxia Wu Received Received
  2347-SAT SPPL3-glycosylation axis governs CD22 CAR T-cell susceptibility in B-ALL independent of antigen recognition Jaehyun Suh Received Received
  2348-SAT Precision targeting of the malignant clone in B-cell malignancies using chimeric antigen receptor T cells against the clonotypic IGHV3-23 B cell receptor Jean Lemoine Received Received
  2349-SAT Targeting TP53 promotes anti-leukemia immunity and enhances CD70 CAR-T efficacy in AML by transcriptionally upregulating CD70 Chuqi Wang Received Received
  2350-SAT Targeting of tumor antigen CD38 and stress antigens MICA/B by CAR T cells provides a unique approach for the comprehensive treatment of multiple myeloma Soheila Shirinbak Received Received
  2351-SAT Glucose transporter 5 enhances CAR-T cell metabolic function and serial killing Roddy O´Connor Received Received
  2352-SAT Development of a novel multiomic sequencing approach to characterize infused donor memory-like NK cells in an immune compatible environment Roman Shapiro Received Received
  2353-SAT A novel CD20-conjugated ?d T cell therapy via unnatural sugar-mediated chemical modification for the treatment of EBV-PTLD Xuying Pei Received Received
  2354-SAT Ex vivo expanded adaptive NK cells in combination with a bispecific NK cell engager targeting BCMA for synergistic control of multiple myeloma Thorstein Boxaspen Received Received
  2355-SAT CD84-CD3 bispecific antibody achieves potent anti-leukemic activity with favorable safety profile in Acute Myeloid Leukemia Nanfang Zhuo Received Received
  2356-SAT Overcoming maturation deficits in iPSC-NK cells through programmable T-bet induction Claire Marsal Received Received
  2357-SAT PARP1 inhibition sensitizes AML to CD123 CAR-NK cells via immunophenotypic remodeling Lea Kramer Received Received
  2358-SAT Pretargeted glycoengineered NK cell (PG-NK) therapy: A universal off-the-shelf platform redefining targeted cell therapy strategies in lymphoma Supriya Chakraborty Received Received
  2359-SAT Dual targeting of ROR1 and ROR2 with glycoengineered antibodies elicits potent and selective immunotherapy in hairy cell leukemia Md Kamrul Hasan Received Received
  2360-SAT Phenotyping of ex vivo expanded NK cells reveals unique transcriptomic and epigenetic signatures Megan Megan Zinsky Received Received
  2361-SAT Acute Myeloid Leukemia eradication targeting cathepsin g with a dual HLA-restricted TCR Francesca Marzuttini Received Received
  2362-SAT TCR-T cells expressing a TCR recognizing the MPO propeptide-derived MPO132-140:HLA-a*02:01 specifically kill AML and spare healthy myeloid cells Yibin Chen Received Received
  2363-SAT TCR-T cells targeting a public neoantigen produced by the SF3B1 K700E mutation kill SF3B1-mutant AML/MDS Noah Tubo Received Received
  2364-SAT Renal and urinary adverse events following CAR-t therapy: A faers-based pharmacovigilance analysis Kevin Zhu Received Received
  2365-SAT ST2 as a biomarker of cytokine release syndrome following CD19-targeted chimeric antigen receptor T-cell therapy Guillermo Orti Received Received
  2366-SAT Pre-existing clonal hematopoiesis in CAR-T recipients is not associated with increased immunotoxicity and inflammatory serum signatures Giulia Petra Rappa Received Received
  2367-SAT Evaluation of commercially available chimeric antigen receptor (CAR) detection reagents for monitoring of CAR T-cell (CAR T) expansion and persistence in patients (pts) treated with obecabtagene autoleucel (obe-cel) William Day Received Received
  2368-SAT CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study Rui Liu Jr Received Received
  2369-SAT INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US Anna Castleton Received Received
  2370-SAT Safety and preliminary efficacy of a novel loop-optimized, BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune diseases patients SiYu Liu Received Received
  2371-SAT Safety and preliminary efficacy of combined lenalidomide and CD19 CAR T-cell therapy in relapsed/refractory CLL: A phase I study Mikalai Katsin IV Received Received
  2372-SAT CLL-1 chimeric antigen receptor T-cells for the treatment of Acute Myeloid Leukemia: A phase 1 clinical trial Erin Eileen Doherty Received Received
  2373-SAT Pre-CAR-T pulmonary function test and respiratory comorbidities have limited predictive value for survival, toxicities, and respiratory complications Yuanli Lei Received Received
  2374-SAT Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results Kara L. Davis Received Received
  2375-SAT Optimizing fludarabine exposure using pharmacokinetic modeling in pediatric patients receiving tisagenlecleucel: A step toward personalized lymphodepletion Alex Hoover Received Received
  2376-SAT Long-term follow up of nivolumab/ipilimumab-primed immunotransplant in patients with Relapsed/Refractory DLBCL Graham Wehmeyer Received Received
  2377-SAT The ratio of post-infusion circulating PD-1+ CAR-T subsets to product PD-1+ CAR-T cells serves as a predictive biomarker for long-term disease control in CAR T-cell therapy for R/R B-cell lymphoma Rui Liu Jr Received Received
  2378-SAT BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial Shlomo Elias Received Received
  2379-SAT Summary analysis of the phase 1a/b study with HBI0101, an academic anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed/refractory multiple myeloma Eyal Lebel Received Received
  2380-SAT Safety and preliminary efficacy of anti-CD19 CAR T cells zorpocabtagene-autoleucel in systemic autoimmune diseases: Final analysis of the castle trial Fabian Hospital Müller Received Received
  2381-SAT Immune remodeling enables sustained EBV clearance in B-cell and plasma cell malignancies after anti-CD19/BCMA CAR-T therapy: A post-hoc analysis Shuyang Wang Received Received
  2382-SAT Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients Xiyang Liu Received Received
  2383-SAT Predictive model based on post CAR-T cell therapy cytokine signature can help predict cytopenia Noam Benyamini Received Received
  2384-SAT One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus Jingjing Feng Received Received
  2385-SAT Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results Nathan Denlinger Received Received
  2386-SAT Direct IL-6 sequestration with siltuximab rescues CAR T-cell proliferation from inflammatory suppression: A longitudinal multi-omic analysis supporting a paradigm shift in CRS management Yajing Zhang Received Received
  2387-SAT OL-101, a BCMA/GPRC5D dual-targeting autologous CAR-T for relapsed/ refractory multiple myeloma (R/R MM): Results from a Phase I study Yongxian Hu Received Received
  2388-SAT Safety, tolerability and early efficacy of mdc-CAR-BCMA001 – a high affinity BCMA targeting CAR T-cell therapy in patients with multiple myeloma and diffuse large B-cell lymphoma Martin Wermke Received Received
  2389-SAT Parkinsonism and other non-immune effector cell-associated neurotoxicities related to BCMA-directed chimeric antigen receptor T-cell therapy Paul Worsley Received Received
  2390-SAT Fraternal but not identical twins: HLH and ICANS look a lot alike Heather Gustafson Received Received
  2391-SAT TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial Monzr M. M Al Malki Received Received
  2392-SAT Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma Viktoria Blumenberg Received Received
  2393-SAT Clinical burden and predictors of cytokine release syndrome in CAR-T cell therapy for hematologic malignancies: Insights from a national cohort Anand Shah Received Received
  2394-SAT IL18-armored CAR T cells in patients with CLL/SLL and Richter´s transformation after prior BTK inhibitor and venetoclax failure Jakub Svoboda Received Received
  2395-SAT Ultra-low-dose IL-10-expressing CAR-T cells achieve high efficacy in R/R DLBCL: An update analysis Yongxian Hu Received Received
  2396-SAT CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel Ross McCauley Received Received
  2397-SAT Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies Agrima Mian Received Received
  2398-SAT Inotuzumab ozogamicin vs blinatumomab bridging optimization and second CD19 CAR-T efficacy in Relapsed/Refractory B-ALL Lin Liu Received Received
  2399-SAT Trial in progress: A Phase 2a Study of GI-102 (CD80/IL2v3) as a consolidation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma following anti-CD19 chimeric antigen receptor T-cell therapy (CARNATION trial) Dok Hyun Yoon Received Received
  2400-SAT Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS Monzr M. M Al Malki Received Received
  2401-SAT Optimizing the manufacturing and delivery of LV20.19 CAR T cells for relapsed, refractory DLBCL and FL Nirav N. Shah Received Received
  2402-SAT Expansion, differentiation, and culture of hematopoietic stem & progenitor cells using an ancillary GMP-compliant medium Tim Le Fevre Received Received
  2403-SAT Development of a high-yield cGMP lentiviral vector manufacturing process using suspension culture, a syenex lvv enhancer, and a closed aseptic system. Xiulian Sun Received Received
  2404-SAT Engineering Quiescent Viral Entry Pathways for in Vivo CAR-T Generation via Binder-Fusogen Combinatorics Luhan Yang Received Received
  2405-SAT Results of the first Latin American point of care manufactured, Phase I anti- CD19 CAR-T study (CARTHIAE) for Relapsed/Refractory B-cell neoplasms Lucila Nassif Kerbauy Received Received
  2406-SAT Disrupting the global CAR T paradigm from the Middle East: Ultra-fast swift CAR T and scalable point-of-care manufacturing of autologous CAR T cells for hematologic malignancies Farhatullah Syed Received Received
  2407-SAT Next-day manufactured CD19 CAR-T cells exhibit superior persistence compared to conventional CAR-T therapy in R/R B-ALL Meng Lv Received Received
  2408-SAT Clinical study on the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor injection (PEG-rhG-CSF) in autologous hematopoietic stem cell mobilization for lymphoma - Results of interim analysis Wei Guo Received Received
  2409-SAT Varnimcabtagene autoleucel in relapsed / refractory B-cell malignancies: Manufacturing experience from India Anil Kamat Received Received
  2410-SAT Development of multi-targeting CAR-double-negative T cells for allogeneic immunotherapy in B-cell leukemia Jessica López Espinosa Received Received
  2411-SAT Ciltacabtagene autoleucel out-of-specification manufacturing outcomes improve with earlier lines of therapy Robert Bowden Received Received
  2412-SAT Improved graft-versus-host-disease/relapse free survival due to reduced relapse rate and acute gvhd with pharmacokinetics-guided busulfan conditioning regimen for allogeneic stem cell transplantation in adult patients with myeloid hematologic malignancies Jacopo Mariotti Received Received
  2413-SAT Impact of oral eicosapentaenoic acid on veno-occlusive disease/sinusoidal obstruction syndrome onset prevention: Single-center retrospective analysis Yuya Masuda I Received Received
  2414-SAT GVHD-free/relapse-free survival in severe aplastic anemia: Outcomes following allogeneic hematopoietic cell transplantation: King hussein cancer center experience Mayada Abu Shanap Sr Received Received
  2415-SAT Conditioning with alkylating agents, cytarabine, cladribine, hypomethylating agents, and venetoclax (ARCHIVE) for upfront allogeneic stem cell transplantation in patients with active Acute Myeloid Leukemia or myelodysplastic syndrome with increased blasts Andrius Zucenka Received Received
  2416-SAT QTc prolongation in allogeneic bone marrow transplantation: Assessing cardiac complications and survival outcomes in the modern era Mark Francis deBettencourt Received Received
  2417-SAT Comparative analysis of efficacy and safety between high-dose TMLI and TBI combined with myeloablative chemotherapy in allogeneic hematopoietic stem cell transplantation for acute leukemia with extramedullary lesions Zilong Yang Received Received
  2418-SAT Restoring hematopoiesis after low dose decitabine of poor graft function post allogenic hematopoietic stem cell transplantation Tang Yaqiong Received Received
  2419-SAT Role of fludarabine exposure on post-transplant outcomes in high-risk ß-thalassemia patients undergoing allogeneic HCT with thiotepa/ fludarabine/ treosulfan conditioning Rachel Mariam Renji Received Received
  2420-SAT Mini-ATG/TBI conditioning regimen facilitates cure of acquired aplastic anemia in children via unrelated umbilical cord blood transplantation Xiaofan Zhu Received Received
  2421-SAT BuCy combined with cladribine and medium-dose cytarabine as an intensified conditioning regimen for allogeneic hematopoietic stem cell transplantation in T-ALL/lbl patients Fangping Chen Received Received
  2422-SAT Clinical outcomes following single unrelated cord blood transplantation with ATG conditioning regimen for the treatment of mucopolysaccharidosis Feng Shunqiao Received Received
  2423-SAT Mitoxantrone hydrochloride liposome injection combined with thiotepa-busulfan-fludarabine (MTBF) as conditioning regimen in patients undergoing allogeneic hematopoietic stem cell transplantation for central nervous system leukemia:a single-center retrospe Xiaoning Wang Received Received
  2424-SAT Adaptation, refinement and clinical correlation of a pharmacokinetics model for patients receiving anti-T-lymphocyte globulin as part of their conditioning regimen: Advances towards individualized dosing. Amin T. Turki Received Received
  2425-SAT Comparative outcomes of fludarabine-melphalan versus fludarabine-busulfan reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta-analysis Chalothorn Wannaphut Received Received
  2426-SAT Luspatercept in patients with hematological diseases who have delayed erythroid recovery after allogeneic hematopoietic stem cell transplantation. Bingqian Jiang Received Received
  2427-SAT Enhanced engraftment and immune recovery in thalassemia via optimized conditioning for TCRaß?-depleted haploidentical transplants Jianyun Liao Received Received
  2428-SAT Salvage allogeneic hematopoietic stem cell transplantation conditioning regimens for relapsed/refractory acute leukemia: Efficacy of radiotherapy combined with CLAG vs FLAG Xiaoyong Man Received Received
  2429-SAT Pre-HCT creatinine defines sex-specific risk for severe TMA after allogeneic transplantation: A report from the MIDAS consortium. Theresa Hahn Received Received
  2430-SAT Comorbid but transplantable: Favorable outcomes with RIC and ptcy in patients with an HCT-CI score of 3 or higher in the modern era Alberto Mussetti Received Received
  2431-SAT Oral iptacopan demonstrates efficacy as salvage therapy for high-risk transplant-associated thrombotic microangiopathy: First real-world experience Fei Gao Received Received
  2432-SAT Hematopoietic stem cell transplantation using briquilimab (Anti-CD117 Antibody-Conditioning), immunosuppression and TCRaß+ T-cell/CD19+ B-cell depleted haploidentical grafts in patients with fanconi anemia: An approach without irradiation, busulfan and ca Rajni Agarwal Received Received
  2433-SAT Pentostatin/TBI conditioning for allogeneic transplantation in T-cell lymphomas Cristian Camilo Taborda Received Received
  2434-SAT Impact of HLA alloimmunization on availability of HLA well matched and mismatched unrelated allogeneic hematopoietic cell donors for transplantation Brian C Shaffer Received Received
  2435-SAT HLA and non-HLA factors in haploidentical donor selection: Insights from a brazilian single-center study Newton de Freitas Centurião Received Received
  2436-SAT Avoidance of ATG improves outcomes in double-cord blood transplantation for hematological malignancies Filippo Milano Received Received
  2437-SAT A pilot study of nicotinamide riboside supplementation in allogeneic bone marrow transplantation Ronald Sobecks Received Received
  2438-SAT Efficacy and safety of luspatercept in the treatment of anemia in allo-HSCT for patients with hematological diseases Shi-wei Jin Received Received
  2439-SAT Total marrow irradiation-based, intensified reduced-intensity conditioning regimen for hematopoietic cell transplantation in patients aged 60 years or older: A prospective study Leonardo Javier Arcuri Sr Received Received
  2440-SAT Efficacy and safety analysis of letermovir for the prevention of CMV infection after haploidentical hematopoietic stem cell transplantation in children with acute leukemia Huili Zhu Received Received
  2441-SAT Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality Anthony Stein Received Received
  2442-SAT TBI based VS chemotherapy based myeloablative conditioning in T cell replete haploidentical transplant Yanal Alnimer Received Received
  2443-SAT Ibrutinib in the treatment of allogeneic stem cell transplant-related pure red cell aplasia: A single center experience Roberta C. G. Azbell Received Received
  2444-SAT Total marrow irradiation based conditioning for allogeneic hematopoietic stem cell transplantation in elderly or frail patients with hematological malignancies: A single center analysis Jieling Jiang Received Received
  2445-SAT Risk factors for transplant-associated thrombotic microangiopathy in pediatric patients undergoing haploidentical hematopoietic stem cell transplantation Dao Wang Received Received
  2446-SAT Clinical and disease characteristics of initial participants at time of enrollment in THRIVE, a prospective, observational cohort study of patients at risk for chronic graft-versus-host disease Catherine Lee Received Received
  2447-SAT Pharmacokinetics-guided ATG targeted dosing strategy in unmanipulated haploidentical haematopoietic stem cell transplantation: A randomized, multicenter, phase 3 clinical trial Daihong Liu Received Received
  2448-SAT IL-17 as a targetable pathway to reverse early NK cell dysregulation in high-risk MDS with late relapse Weiping Yuan Received Received
  2449-SAT Ectopic EBV infection in T cells following allogeneic hematopoietic stem cell transplantation: Clinical outcomes and immunological characterization Zhifan Zhao Received Received
  2450-SAT Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysp Tereza Coman Received Received
  2451-SAT Vorinostat for GVHD prophylaxis in children, adolescents, and young adults (AYA) shows low incidence of acute GVHD and relapse with encouraging overall survival after allogeneic hematopoietic cell transplantation (HCT): A multisite, nonrandomized clinical Nicolas Parnell Received Received
  2452-SAT Impact of ruxolitinib on corticosteroid treatment patterns in 1147 patients with chronic graft-versus-host disease in real-world practice in the United States: A long-term follow-up analysis Jingbo Yu Received Received
  2453-SAT Human intestinal acute graft-versus-host disease is governed by a subset of transition-like tissue-resident memory CD8+ T cells Yiming Sun Received Received
  2454-SAT Pre-transplant aTREC diversity reflects thymic function and independently predicts mortality following allogeneic hematopoietic cell transplantation Itauá Leston Araujo Sr Received Received
  2455-SAT Itacitinib in combination with post-transplant cyclophosphamide and tacrolimus (ICT) as GVHD prophylaxis for reduced intensity matched donor peripheral blood stem cell hematopoietic cell transplantation: Interim analysis Monzr M. M Al Malki Received Received
  2456-SAT Longitudinal multiproteomic analysis reveals persistent underlying inflammation in acute graft-versus-host disease patients responding to corticosteroid treatment Audrey Le Floch-Ramondou Received Received
  2457-SAT Disruption of intestinal homeostasis reflected by DAO and microbiota alterations in gvhd post-HSCT. Saori Shimoyama-Ibuki Received Received
  2458-SAT Pharmacodynamic analysis of AGAVE-201 indicates changes in CSF-1R–expressing cells and associated biomarkers potentially contributing to chronic graft-versus-host disease resolution Michael A. Pratta Received Received
  2459-SAT An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplant Ramzi Abboud Received Received
  2460-SAT Outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis using post-transplant cyclophosphamide-based gvhd prophylaxis Moazzam Shahzad Received Received
  2461-SAT Grade I acute graft-vs-host disease: Treat or not? Yu Akahoshi Received Received
  2462-SAT Anti-inflammatory drug pegtarazimod (RLS-0071) demonstrates clinical improvement in lower gastrointestinal acute graft-versus-host disease (aGvHD) and target engagement of key inflammatory marker myeloperoxidase (MPO) Robert Zeiser Received Received
  2463-SAT Stage 0+ lower gastrointestinal (LGI) acute graft-versus-host disease (aGVHD) is associated with high response to non-systemic treatment, low incidence of moderate to severe chronic graft-versus-host disease (cGVHD) and low non-relapse mortality (NRM) Natalia Tijaro Ovalle Received Received
  2464-SAT Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients Sunmin Park Received Received
  2465-SAT Persistent microbiome dysbiosis following hematopoietic cell transplantation: Gut GvHD as the most severe manifestation of microbial disruption Hasan Hashem Received Received
  2466-SAT CDCP1+ mesenchymal stem cells preferentially inhibit acute graft-versus-host disease(aGVHD) Lun Yan I Received Received
  2467-SAT Belumosudil for chronic graft-versus-host disease in children under 12: A retrospective analysis of effectiveness and safety Jingtao Chen Received Received
  2468-SAT Comparison of different dose of anti-T lymphocyte globulin (ATLG) in haploidentical HSCT for gvhd prophylaxis Yigeng Cao II Received Received
  2469-SAT ABC: Highly active and entirely calcineurin and m-TOR inhibitor-free gvhd prevention regimen A Samer Al-Homsi Received Received
  2470-SAT Clinically meaningful improvement of the modified lee symptom score in patients treated with belumosudil for steroid-refractory chronic GVHD: Evidence from Canadian real-world outcomes Sergio Rodriguez-Rodriguez Received Received
  2471-SAT The dimorphism at the HLA-B leader and molecular HLA compatibility impact on haplo-HSCT: Experience of a single-center based on ptcy strategies Rodrigo Gil-Manso Jr Received Received
  2472-SAT Predicting donor engraftment success in adults post haploidentical bone marrow transplant for sickle cell disease: BMT CTN 1507 Joshree Shrestha Received Received
  2473-SAT Orca-T demonstrates favorable quality of life and healthcare resource use compared to standard allohsct plus tac/MTX for GVHD prevention in a randomized Phase 3 clinical trial (Precision-T) Arpita Gandhi Received Received
  2474-SAT Synergistic effect of HLA evolutionary divergence and post-transplant biomarkers on non-relapse mortality prediction in adult haploidentical hematopoietic stem cell transplantation Liping Dou Received Received
  2475-SAT Enhancing graft-versus-host disease prophylaxis with modern strategies in matched-sibling or unrelated donor hematopoietic cell transplantation does not lead to higher relapse rates: A systematic review and meta-analysis of 15 randomized trials Leonardo Javier Arcuri Sr Received Received
  2476-SAT Hallmarks of allogeneic hematopoietic cell transplant success: A study on immune signatures and predictive features of graft versus host disease-free remission states from the SFGM-TC registry and cryostem biobank Adrien Lapoutge Received Received
  2477-SAT Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial Everett Meyer Received Received
  2478-SAT Topical cyclosporine vs tacrolimus for ocular GVHD prophylaxis after outpatient allogeneic hematopoietic stem cell transplantation: A Phase I–II trial Michelle Morcos Received Received
  2479-SAT Phase I trial of ruxolitinib plus fostamatinib for the treatment of steroid refractory chronic graft versus host disease Chenyu Lin Received Received
  2480-SAT Cost and quality of life analysis associated with allogeneic hematopoietic progenitor transplantation Sara Fernandez-Luis Received Received
  2481-SAT Association of CD34+ cell dose on outcome after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation (PBSCT) for adults with Acute Myeloid Leukemia (AML) in measurable residual disease (MRD)-negative remission Margery Gang Received Received
  2482-SAT Long-term outcomes of allo-HSCT in SET::CAN-positive Hematological Malignancies: A 12-year single-center Study of 36 patients Xiaomei Liu Received Received
  2483-SAT Mechanisms of immune escape and altered tissue homing in leukemia cutis Livius Penter Received Received
  2484-SAT Graft-versus-HIV-reservoir reactivity: Long term HIV remission after allogeneic stem cell transplantation from a donor with active CCR5 Olaf Penack Received Received
  2485-SAT The fertility outcome in a cohort of SCD patients undergoing haploidentical allogeneic stem cell transplant using NMA regimen. Mazin Mohamed Abdulsalam Received Received
  2486-SAT Droplet digital PCR outperforms conventional methods for early relapse prediction in AML/MDS patients post-transplant Xiao Zhou Received Received
  2487-SAT Haploidentical hematopoietic stem cell transplantation in adults with severe sickle cell disease: Long-term outcomes using a modified conditioning regimen with peripheral blood stem cells. Ana Maria Avila Rodriguez Received Received
  2488-SAT Cardiovascular disease risk scores as predictors of cardiovascular disease and heart failure in allogeneic hematopoietic cell transplant survivors Victoria Stepanyants Received Received
  2489-SAT A novel, structured peer support intervention (STEPP) for patients undergoing hematopoietic stem cell transplantation: A pilot randomized clinical trial Hermioni Amonoo Received Received
  2490-SAT Allogeneic hematopoietic cell transplantation in dyskeratosis congenita: Short and long- term outcome of 183 consecutive patients transplanted at EBMT centers Fabiana Cacace Received Received
  2491-SAT Blinatumomab improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation Haonan Yang Received Received
  2492-SAT Clinical and microbiological insights into invasive fusariosis following allogeneic hematopoietic stem cell transplantation: A 15-year single-center analysis Jotaro Yamamoto Received Received
  2493-SAT Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes Yanli Zhao Received Received
  2494-SAT Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation Alfonso Molina Jr Received Received
  2495-SAT No reduction in gvhd risk for aplastic anemia patients to combined third-party unrelated cord blood in haploidentical hematopoietic stem cells transplantation Wei Zhao I Received Received
  2496-SAT Impact of HLA-b leader matching status on prognosis and underlying mechanism in patients with hematological malignancies following haploidentical hematopoietic stem cell transplantation Minghao Lin Received Received
  2497-SAT Psychosocial well-being in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their caregivers: A prospective study Elsa Cavagna Received Received
  2498-SAT The impact of HLA loss of heterozygosity on outcome after haploidentical hematopoietic stem cell transplantation in hematological malignancies Xingyu Cao Received Received
  2499-SAT Azacitidine monotherapy versus combination regimens as post-allogeneic transplantation maintenance in high-risk myeloid malignancies: A retrospective cohort Study Ying Shen Received Received
  2500-SAT Optimizing letermovir timing: Day +5 to +8 post haplo-HSCT minimizes EBV dnaemia without compromising CMV prophylaxis Xingyu Cao Received Received
  2501-SAT Vancomycin-resistant enterococci (VRE) colonization is associated with worse outcomes post allogenic hemopoietic stem cell transplantation Haitham Abdelhakim Received Received
  2502-SAT Allogeneic hematopoietic stem cell transplantation in sil::TAL1-positive T-ALL: Prognostic impact of pre-transplant remission and molecular status Xiao-hong Liu Received Received
  2503-SAT Impact of angiotensin-converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) on kidney functions in allogeneic stem cell transplant patients receiving tacrolimus Saad Javaid Received Received
  2504-SAT Efficacy of low-dose rituximab as preemptive treatment of EBV-DNA-emia after allogeneic hematopoietic stem cell transplantation Yaoyao Shen Received Received
  2505-SAT Upfront vs posttherapy allogeneic stem cell transplantation for high-risk myelodysplastic syndrome – a real-world analysis in the era of molecular risk stratification Tim Richardson Received Received
  2506-SAT Limitations of the IWG-MRT/ELN response criteria in defining post-transplant remission and clinical success in patients with myelofibrosis: A retrospective study Charlotte FM Hughes Received Received
  2507-SAT The single-center retrospective analysis of steroid-free rmap regimen (ruxolitinib, montelukast, azithromycin, and pirfenidone) treating moderate-to-severe bronchiolitis obliterans syndrome (BOS). Xi Yang III Received Received
  2508-SAT Three decades of allogeneic transplantation showing improved survival, persistent relapse and post-relapse outcomes of donor lymphocyte infusion versus second transplant Smita Hiwase Received Received
  2509-SAT Signal-rich and signal-poor: Divergent detection of early bacterial sepsis and latent viral complications after hematopoietic stem cell transplantation in the FDA adverse event reporting system Manzer Ali Received Received
  2510-SAT A Phase 1B/2A study of weekly decitabine and venetoclax treatment as maintenance therapy in high-risk myeloid malignancy patients post allogeneic stem cell transplantation Sophia Rebecca Balderman Received Received
  2511-SAT Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation Betul Oran Received Received
  2512-SAT Superior outcome from frontline cord blood transfusion combined HLA-full-matched unrelated donor hematopoietic stem cell transplantation for aplastic anemia Dijiong Wu Received Received
  2513-SAT Serum albumin, but not gnri, is an independent prognostic factor for survival after first allogeneic SCT: A large-scale multicenter analysis Yasutaka Sadaga Received Received
  2514-SAT Sustained donor engraftment and clinical remission after hematopoietic cell transplantation for vexas syndrome, but with observed toxicities: Results from a prospective phase II clinical Trial Bhavisha Patel Received Received
  2515-SAT Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for acute lymphoblastic leukemia following allogeneic stem cell transplantation Betul Oran Received Received
  2516-SAT Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis Salman Otoukesh Received Received
  2517-SAT Autologous stem cell transplantation versus consolidation chemotherapy as post-remission treatment in newly diagnosed favorable and intermediate risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials Dimitrios Kotsos Received Received
  2518-SAT Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes Lusine Harutyunyan Received Received
  2519-SAT Efficacy of the triplet therapy with venetoclax, azacitidine and gilteritinib for the treatment of FLT3-ITD mutated AML patients with refractory/relapsed disease or persistent minimal residual disease bridging to allogeneic hematopoietic stem cell transpl Chen Liang Received Received
  2520-SAT Blinatumomab before and after allogeneic hematopoietic stem cell transplantation in adult patients with B-cell acute lymphoblastic leukemia Piyatida Chumnumsiriwath Received Received
  2521-SAT Allogeneic hematopoietic stem cell transplantation for transfusion-dependent pyruvate kinase deficiency in Chinese children: A multicenter retrospective study Xia Qin Received Received
  2522-SAT TP53, EZH2, or RUNX1 mutations predict poor outcomes in ELN 2022 adverse risk group of adult AML patients undergoing allo-HSCT Kairi Kojo Received Received
  2523-SAT Allogeneic hematopoietic cell transplantation in TP53-mutated Acute Myeloid Leukemia patients with active disease: A study from the global committee and the acute leukemia working party of the EBMT Lin Li Received Received
  2524-SAT Impact of TBI, donor age, and transplant era on outcomes of allogeneic transplantation in acute lymphoblastic leukemia: Evidence from 748 patients in Latin America Wellington Silva Jr Received Received
  2525-SAT Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT Nikeshan Jeyakumar Received Received
  2526-SAT Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT Jia Chen Received Received
  2527-SAT Enhanced chimerism detection with multiple single Nucleotide Polymorphism Sequencing: Improving risk stratification post-allogeneic hematopoietic stem cell transplantation Shichun Tu Received Received
  2528-SAT Matched sibling donors still provide superior survival outcomes in older patients with AML in second complete remission. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation Depei Wu Sr Received Received
  2529-SAT Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy for pediatirc relapsed and Refractory Acute lymphoblastic leukemia followed by TCRaß-depleted haplo-HSCT Huaying Liu Received Received
  2530-SAT Mismatched unrelated and haploidentical transplant with post-transplant cyclophosphamide-based graft versus host disease prophylaxis are effective for myelofibrosis Richard Stephen Sheppard I Received Received
  2531-SAT Multiplex base editing enhances fetal hemoglobin production in sickle cell disease erythroid cells Kyle Cromer Received Received
  2532-SAT Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study Ashish Gupta Received Received
  2533-SAT Long-term follow-up of the first in human post-transcriptional genetic silencing of BCL11A in sickle cell disease in a phase 1 pilot and feasibility trial Erica Esrick Received Received
  2534-SAT Engineered extracellular vesicles for In Vivo gene therapy in sickle cell disease Michaela Eleanor Bhoorasingh Received Received
  2535-SAT Prime Editing–Mediated BCL-2 hematopoietic stem cell shielding as a strategy for leukemia therapy Jessica Zuin Received Received
  2536-SAT In Vivo correction of the sickle cell disease mutation in hematopoietic stem cells using RNA gene writers Yaser Heshmati Received Received
  2537-SAT Long-term follow-up demonstrates durable clinical benefits of exagamglogene autotemcel for sickle cell disease with recurrent vaso-occlusive crises: Final results of climb SCD-121 Stephan A Grupp Received Received
  2538-SAT MiR-146b restoration in T-large granular lymphocyte leukemia: Molecular insights for a new therapeutic strategy Antonella Teramo Received Received
  2539-SAT Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia Lili Ren Received Received
  2540-SAT CD7 CAR-T cell therapy based on "Natural Selection" for the treatment of Relapsed or Refractory CD7-positive Hematologic Malignancies: A large cohort study Na Kuang Received Received
  2541-SAT CD19 antigen: From tumor target to safety switch able to improve the safety profile of CAR T cell therapy Simona Manni Received Received
  2542-SAT Improved hematopoietic stem cell mobilization for gene therapy using single agent motixafortide in sickle cell disease John P Manis Received Received
  2543-SAT CD90-targeted multiplex virus-like particles (MVPs) for concomitant In Vivo gene editing, transduction, and transcription factor delivery into HSCs Justin Thomas Received Received
  2544-SAT Enhanced tyrosine kinase inhibitor response on chronic myeloid leukemia cells upon MS4A3 mRNA delivery Cansu Umran Tunc Received Received
  2545-SAT FerroEVs drive serial propagation of pharmacologically induced ferroptosis in acute leukemia cells Hiroki Doi I Received Received
  2546-SAT Simultaneous PD-1 and VIP receptor blockade optimizes tumor immunotherapy in P815 Acute Myeloid Leukemia model Stella Lee Received Received
  2547-SAT Global proteomic profiling of tgrx-3247,a heterobifunctional degrader for the treatment of BCR::ABL1-driven chronic myeloid leukemia Yihan Wang Received Received
  2548-SAT Efficacy of the JAK2/FLT3 inhibitor pacritinib in NPM1 mutated Acute Myeloid Leukemia Eva Daniela Mendoza Ortiz Received Received
  2549-SAT Novel small molecule inhibitors of mitochondrial permeability transition pore (mPTP) block platelet procoagulant activity Yiheng Zhang Received Received
  2550-SAT Targeting B-cell lymphoma surface protein with a novel peptide: Therapeutic potential and clinical implications Haiwen Huang Sr Received Received
  2551-SAT Development of a NO probe cell imaging method based on CD58 expression in diffuse large B-cell lymphoma and as a tool to predict CAR-T efficacy Xiyue Xu Received Received
  2552-SAT Translational investigation of tolinapant (ASTX660) in Acute Myeloid Leukemia using integrated clinical, bioinformatic, and pharmacological approaches Keli Lima Received Received
  2553-SAT A VPAC1/2-targeted antagonist, preferentially binds to activated T cells and enhances T cell activation Sonia Mecorapaj Received Received
  2554-SAT Development and characterization of a potent and selective BLIMP1 protac as a novel, first-in-class therapy for multiple myeloma Minhui Shen Received Received
  2555-SAT Large language models mediated extraction of clinical information from bone marrow biopsy pathology reports Luca Lanino Received Received
  2556-SAT Generative AI–Powered clinical decision support in germline predisposition to myeloid neoplasms Carmelo Gurnari Received Received
  2557-SAT Refining diffuse large B-cell lymphoma subtyping using lymphly, an evidence-based classifier Pavel Zemskiy Received Received
  2558-SAT Deep learning predicts IDH1 mutation status in Acute Myeloid Leukemia from bone marrow smear images Andrew Srisuwananukorn Received Received
  2559-SAT CRS-RS.5p predictive model informs risk stratification and cytokine release syndrome management following glofitamab treatment in patients with relapsed or refractory diffuse large B-cell lymphoma Haifaa Abdulhaq Received Received
  2560-SAT Magnetic resonance imaging maps spatiotemporal changes in bone marrow composition of murine JAKV617F models of myelofibrosis during progression and therapy Brian D. Ross Received Received
  2561-SAT Feasibility and utility of unmatched whole-genome sequencing (uWGS) for pediatric acute leukemias: An analysis of leukemia precision-based therapy (LEAP) study samples Jesús Gutiérrez-Abril Received Received
  2562-SAT Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients Juan Manuel Rosa-Rosa Received Received
  2563-SAT Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy Jonas Paludo Received Received
  2564-SAT AI-based diagnosis of cutaneous lymphoma and lymphoproliferative disorders via H&E morphology and LLM-assisted cohort curation Ali Kamali Received Received
  2565-SAT Using large language models to identify frailty among older adults with blood cancer Gregory A. Abel Received Received
  2566-SAT Transcriptomic profiling of T cell immune states before and after donor lymphocyte infusion in a patient with acute myeloid leukemia Tania Konry Received Received
  2567-SAT Polygenic scores as a clinical diagnosis tool for abnormal hematological values Thomas Pincez Received Received
  2568-SAT Development of a machine learning model to predict overall survival in patients with peripheral T-cell lymphoma in a minority enriched population Kimberly H Seymour Received Received
  2569-SAT Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence Cristiana Carniti Received Received
  2570-SAT Diagnosing mycosis fungoides using AI powered histologic analysis Mohamed Salah Mohamed Sharaf Received Received
  2571-SAT Detection of NPM1 mutation in Acute Myeloid Leukemia by multiple droplet digital PCR and its clinical application value keyi chen II Received Received
  2572-SAT Spatial single-cell multiomics of the bone marrow microenvironment in NPM1-mutant Acute Myeloid Leukemia Jan Christian Schroeder Received Received
  2573-SAT Field-level visual explanations for leukocyte classification using AI model: Enhancing interpretability in peripheral smear diagnostics Manpreet Saini I Received Received
  2574-SAT Unlocking new frontiers in leukemia diagnostics through large language Model–Driven report generation Vivian Wuerf Received Received
  2575-SAT Visualizing systemic light chain amyloidosis with 18f-flutemetamol PET/CT: Correlation with biomarkers and clinical outcome Sung-Soo Park Received Received
  2576-SAT Automated multi-source data consensus classification of low-frequency variants in hematologic malignancies using transparent artificial intelligence Niroshan Nadarajah Received Received
  2577-SAT Supporting routine diagnostics: AI for interpretation of interphase FISH images Dennis Bode Received Received
  2578-SAT Artificial intelligence system for delivering interactive and verifiable guideline-based clinical decision support in hematology Jiasheng Wang Received Received
  2579-SAT Mapping skeletal muscle mitochondrial oxidative phosphorylation (OXPHOS) in childhood acute lymphoblastic leukemia survivors using a novel technique oxcest MRI Puneet Bagga Received Received
  2580-SAT Machine learning framework for molecular classification of hematologic malignancies using transcriptome data Karolis Sablauskas Received Received
  2581-SAT In silico structural biology studies inform the identification of "druggable" pockets in previously understudied dependencies with tumor type/lineage-selective roles. Evangelos Papadopoulos Received Received
  2582-SAT Automatic identification of blast leukemic cells types using deep learning with vision transformers. Adriana Bornacelly Received Received
  2583-SAT Machine learning-derived, comprehensive "Geno-Immunome" of bone marrow failure syndromes reveals complex immunogenetic interactions with clinical implications Aashray Mandala Received Received
  2584-SAT Accounting for long-term survivors and population-expected survival improves survival outcomes estimation and prediction in older patients with core-binding factor (CBF) Acute Myeloid Leukemia (AML) Justice Ameyi Received Received
  2585-SAT Deep learning-based image analysis of pretreatment FDG-PET/CT predicts CAR-T cell treatment outcome at month-12 for patients with Relapsed/Refractory large B-cell lymphomas Stephen J Schuster Received Received
  2586-SAT Comprehensive characterization of multiple myeloma genomes from bone marrow or peripheral blood with a novel clinical assay enables identification of resistance mechanisms Bruno Paiva Received Received
  2587-SAT Accurate quantification of lowly expressed SBDS by integrating pacbio iso-seq long-read and illumina short-read sequencing Zhongshan cheng Cheng Received Received
  2588-SAT Dismantling systemic barriers in sickle cell disease care: Design and rationale of a municipal public health initiative in New York City Kenneth Rivlin Received Received
  2589-SAT Tailoring pediatric to adult care transition from high to low-resource settings: A user-centered design approach Tarun Aurora Received Received
  2590-SAT Cost-effectiveness of hydroxyurea for children with sickle cell disease in sub-saharan Africa: A discrete event simulation model to inform policy and government planning Patrick T. McGann Received Received
  2591-SAT Empowering families through conversational design: A chatbot for sickle cell care Tarun Aurora Received Received
  2592-SAT Pediatric sickle cell outpatient pain management: A quality improvement initiative Sasidhar Goteti Received Received
  2593-SAT Consolidation of adult inpatient sickle cell care to improve patients´ and learners´ experiences: A qualitative exploration of various stakeholders´ perspectives Max Jordan Nguemeni Tiako Received Received
  2594-SAT Face validity of progressive rank criteria to identify high-utilizer sickle cell patients in an adult sickle cell disease medical home Wally Smith Received Received
  2595-SAT Reproductive health care in a post-dobbs landscape for people with sickle cell disease: Clinical practices and challenges from hematologist perspectives Preetha Nandi Received Received
  2596-SAT Addressing functional asplenia in sickle cell disease: A quality improvement approach to improve vaccination rates Evan Keiser Received Received
  2597-SAT Increasing the proportion, accessibility, and quality of individualized pain plans for adults with sickle cell disease Rania Mohamed Received Received
  2598-SAT Transportation barriers and Medicaid´s transportation service use in sickle cell disease: A mixed methods study in Wisconsin Ashima Singh Received Received
  2599-SAT Analysis of healthcare utilization costs prior to and after non-myeloablative haploidentical allogeneic stem cell transplantation in adults with sickle cell disease Ijele Adimora Received Received
  2600-SAT Feasibility of wearable technology for remote monitoring in high-risk adults with sickle cell disease: Baseline data from the SCD-carre trial Charles Jonassaint Received Received
  2601-SAT Sickle cell disease in the global south: Mapping the unmet burden using global burden of disease DALY estimates and its relevance to United States hematologists Sravani Bhavanam Received Received
  2602-SAT Weekend admission and in-hospital outcomes in cancer-related pulmonary embolism (CAP): A 2016–2022 national inpatient sample study Xiaoyi Zhang Received Received
  2603-SAT AI-enhanced image analysis of point of care tests for sickle cell disease screening in Uganda – a pilot cluster randomized trial Anne Akullo Received Received
  2604-SAT 30 years of classical hematology drugs in the US: Approvals, costs, and sales Lewis Go Received Received
  2605-SAT A triple threat to diagnostic safety in CTPA: Diagnostic uncertainty, sspe, and reporting discrepancies Abdulrahman Al Raizah Received Received
  2606-SAT Retrospective real-world data analysis of morbidity burden and healthcare costs in idiopathic multicentric castleman disease compared with matched controls (BURDEN-iMCD) Sudipto Mukherjee Received Received
  2607-SAT A quality improvement project to improve the recognition and management of iron delivery in the postpartum patient Ishan Tatake Received Received
  2608-SAT Expert consensus on the clinical management of congenital thrombotic thrombocytopenic purpura in Asia-Pacific: A modified Delphi panel Spero Cataland Received Received
  2609-SAT Ferritin reference ranges and improving diagnosis of iron deficiency without anemia Camille Morgan Received Received
  2610-SAT Economic and clinical impact of emicizumab in people with moderate and severe Hemophilia A in the US Janet S Lee Received Received
  2611-SAT The first characterization of disease burden and healthcare resource utilization for the recent definition of severe von Willebrand disease using a large United States real-world dataset Angela Weyand Received Received
  2612-SAT Assessing bone marrow biopsy utility in patients with unexplained cytopenias Mariam Mostafa Received Received
  2613-SAT Overcoming surveillance gaps: Deep learning for accurate detection and chronicity classification of hospital-acquired pulmonary embolism Abdulrahman Al Raizah Received Received
  2614-SAT Optimizing emergency department care for people with bleeding disorders: A scoping review of barriers and interventions for improvement Linda Guo Received Received
  2615-SAT Healthcare resource utilization in people with hemophilia treated within vs. outside u.S. hemophilia treatment center network clinics: An interim analysis of the CHESS US study Randall Curtis Received Received
  2616-SAT Evaluating the management of severe anemia in the emergency department: A single-center analysis Kabeer Ali Received Received
  2617-SAT A quality improvement project to optimize VTE prophylaxis in surgical patients Aimn W Abdujawad Received Received
  2618-SAT Innovating rare disease care: A digital health network for the remote management of acquired Hemophilia A Mariasanta Napolitano Received Received
  2619-SAT A retrospective quality improvement review of cryoprecipitate overuse in a community hospital Sooraj Srirangadhamu Gopu Received Received
  2620-SAT Standardizing VTE prophylaxis in the inpatient setting: A quality improvement project Sharanya Tripathi Received Received
  2621-SAT Red cell indices in adolescents with iron deficiency and heavy menstrual bleeding Lam Duc Received Received
  2622-SAT Inequity in travel burden among patients receiving bispecific antibodies (BsAbs) for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): A real-world study of Medicare beneficiaries in the United States (US) Zachary A.K Frosch Received Received
  2623-SAT Palliative care consultation reduces hospital costs and length of stay among decedents with hematologic malignancies: A propensity score matched analysis from the national inpatient sample, 2016-2022 Mariana Marrero Castillo Received Received
  2624-SAT Optimizing adherence to oral CLL therapies in community oncology centers: Key findings from a quality improvement initiative Javier Pinilla-Ibarz Received Received
  2625-SAT Advancing adoption of evidence-based quadruplet treatment regimens for newly diagnosed multiple myeloma in community practice: Insights from a quality improvement initiative Nisha Joseph Received Received
  2626-SAT Trends in triplet and quadruplet regimen utilization among patients with newly diagnosed multiple myeloma during 2017-2024 Hamlet Gasoyan Received Received
  2627-SAT Budget impact of fixed duration acalabrutinib in combination with venetoclax in previously untreated chronic lymphocytic leukemia patients in the United States Farrukh Awan Received Received
  2628-SAT A national lens on follicular lymphoma: Academic care linked to improved survival in 158,000 patients Daniel Rosas Received Received
  2629-SAT Invisible wounds: Suicide in military service members with lymphoma Hannah Lee Received Received
  2630-SAT Differences in insurer payments for hematology part B drugs between traditional Medicare and Medicare advantage Brendon Lee Received Received
  2631-SAT Factors influencing patient treatment selection among bispecific antibodies for relapsed/refractory multiple myeloma (RRMM): A mixed methods study Thomas W LeBlanc Received Received
  2632-SAT Factors associated with remote healthcare utilization in MM patients undergoing autologous stem cell transplantation Molly Benson Received Received
  2633-SAT A population-based gap analysis of bispecific antibody trial access: Racial, geographic, and Medicaid-linked disparities in lymphoma and myeloma Bella Gnakou Received Received
  2634-SAT Cost-conscious CAR T delivery: Outpatient (OP) cilta-cel administration reduces health care resource utilization (HCRU) and the associated post-infusion cost Christopher J. Ferreri Received Received
  2635-SAT Treatment setting matters: Academic cancer centers deliver superior survival in MALT lymphoma – an NCDB analysis of 77,000 patients Esteban Toro Velez Received Received
  2636-SAT Economic burden of relapse in patients with acute lymphoblastic leukemia: A retrospective claims-based analysis Diana Boyko Received Received
  2637-SAT Optimizing multiple myeloma assessment for newly diagnosed patients across a large, 33 hospital healthcare system: A mixed methods analysis Bradley Hunter Received Received
  2638-SAT Policy and systems solutions to expand timely access to CAR T-cell therapy: Findings from a national survey of oncology professionals Caroline Offit Received Received
  2639-SAT Evaluating the implementation of an electronic patient-reported outcome system supporting self-management of treatment-related impairments among patients with lymphoma Vishal Kukreti Received Received
  2640-SAT Evaluating the impact of language on health care utilization outcomes in paitents with diffuse large B-cell lymphoma at a large safety-net hospital Sarika D Gurnani Received Received
  2641-SAT CAR-seet 01: A pilot study for diagnosing CRS and icans using wearable consumer devices Nazila Shafagati Received Received
  2642-SAT Accelerating practical solutions for bispecific antibody consideration for multiple myeloma in the community setting: Findings from an implementation science initiative Tariqa Ackbarali Received Received
  2643-SAT Building a kenyan framework for advanced multiple myeloma care: Outcomes from the 2024 national workshop Attaya Suvannasankha Received Received
  2644-SAT Creating a tool for measuring preferences for treating blood cancers in older adults using implementation science Daniel R Richardson Received Received
  2645-SAT Impact of protein-energy malnutrition on in-hospital outcomes in patients undergoing bone marrow transplantation: Insights from a national inpatient sample Srinishant Rajarajan Received Received
  2646-SAT Oncodif: An auditable AI framework for automated genomic curation and natural-language clinical querying in hematologic malignancies Mujahid Ali Quidwai Received Received
  2647-SAT Healthcare resource utilization with prophylactic intravenous anakinra following anti-CD19 CAR-T therapy in B-cell lymphoma: A Canadian single-center quality improvement experience. Alex Chi Fung Kwan Received Received
  2648-SAT Inclusive practices for safe and equitable donor assessment Warren Benjamin Fingrut Received Received
  2649-SAT Evaluating bone marrow sample quality derived using a non-redirection versus a traditional bone marrow aspiration and biopsy technique Isabella Gau Received Received
  2650-SAT Healthcare resource utilization in patients receiving quizartinib or placebo in combination with chemotherapy for newly diagnosed, FLT3-ITD+ acute myeloid leukemia: An analysis from the QuANTUM-first trial Harry Erba Received Received
  2651-SAT Real-world rates of tyrosine kinase inhibitor prescription approval, fill, and adherence and associated factors in a national sample of patients with chronic myeloid leukemia Pengxiang Li Received Received
  2652-SAT Frailty assessed by HCT-FS predicts survival and non-relapse mortality across hematologic disorders undergoing allo-HCT: A multicenter Study of 992 patients Tommy Alfaro Moya Received Received
  2653-SAT Patient and clinician perspectives on the diagnosis and management of polycythemia vera: Results from concurrent surveys Makaela Premont Received Received
  2654-SAT Disparities in diagnosis and management of myelodysplastic syndromes in a brazilian cancer center: A comparison between public and private healthcare systems. Arthur Gomes Oliveira Braga Sr Received Received
  2655-SAT Trends and disparities in myelodysplastic Syndrome–Associated mortality in the u.S. from 1999 to 2020: A population-based study using the CDC wonder database Ilias Oulidi Jerrar Received Received
  2656-SAT Socioeconomic disparities in the receipt of allogeneic stem cell transplantation among patients with relapsed Acute Myeloid Leukemia: A national inpatient sample analysis, 2016–2020 Lemchukwu Chukwunonye Amaeshi Received Received
  2657-SAT Aromatherapy oil during bone marrow biopsy procedure and association with anxiety and pain: An interim analysis Krisstina Gowin Received Received
  2658-SAT Longitudinal trends (1999–2023) and forecasted mortality (2024–2030) in sepsis-associated mortality among patients with Myelodysplastic Syndromes in the United States. Maha Veer Received Received
  2659-SAT Impact of hospital admissions through the emergency department versus direct admissions for patients with hematologic malignancies: A single site analysis Benyamin Yaniv Received Received
  2660-SAT External validation of an online predictive model for myelodysplastic syndrome Nina Castrogiovanni Received Received
  2661-SAT Risk of death and comorbidities in ß-thalassemia carriers identified by consecutive genotyping: A prospective cohort study of 467,242 general population individuals Lilla Gaál Received Received
  2662-SAT Support isn´t always supportive: Relational and cultural misalignment in black sickle cell disease adult caregiving norms Persis Ayeh Received Received
  2663-SAT Association of obstructive sleep apnea with readmission and healthcare utilization in adults with sickle cell disease: A propensity-matched analysis of national readmission data Mariana Marrero Castillo Received Received
  2664-SAT Increased risk of venous thromboembolism and hypertensive disorders during pregnancy in sickle cell disease patients: A meta-analysis focused on actionable outcomes Onajite Onome Ifie Received Received
  2665-SAT Real-world effectiveness of l-glutamine in Texas Medicaid patients with sickle cell disease Hyeun Ah Kang Received Received
  2666-SAT Implementing patient-centered PROMs in sickle cell disease care: A european consensus approach Anna Collado Gimbert Sr Received Received
  2667-SAT Iron overload is prevalent, likely underdiagnosed and undertreated in sickle cell disease: A real-world report from the ASH research collaborative Samuel Robert Wilson Received Received
  2668-SAT Health status of Ugandan children born with sickle cell anemia and congenital HIV identified through newborn screening Teresa Smith Latham Received Received
  2669-SAT Trust and relationships between people with sickle cell disease and healthcare professionals: Regional comparisons from the listen survey Biree Andemariam Received Received
  2670-SAT Disease stigma and salivary stress biomarkers among adolescents and young adults with sickle cell disease Kemar V. Prussien Received Received
  2671-SAT Clinical impact of individualized care plans on management of acute pain in the emergency department for children and adults with sickle cell disease Madhav Vissa Received Received
  2672-SAT Household material hardship as a barrier to accessing sickle cell disease curative therapy Colleen A. Kelly Received Received
  2673-SAT Chronic opioid medication use is associated with healthcare utilization and fatigue in adults with sickle cell disease Eli Salzberg Received Received
  2674-SAT We know what we need: Exploring the communicative and structural gaps in support for caregivers of adults with sickle cell disease (CASPS) Persis Ayeh Received Received
  2675-SAT Real world outcomes analysing the use of glucocorticoids in patients with acute chest syndrome: A propensity score matched analysis from global federated health research network Yajur Arya Received Received
  2676-SAT Understanding chronic pain in pediatric sickle cell disease: Insights from a retrospective chart review Elizabeth Alden Anderson Received Received
  2677-SAT Evaluation for non-accidental trauma (NAT) and bleeding disorders in infants referred to pediatric hematology Abbey Elsbernd Received Received
  2678-SAT Chinese pediatric cGvHD patients and caregivers perspectives: Patient journey and trial participation Maoquan Qin Received Received
  2679-SAT Understanding unmet needs for people with haemophilia a receiving factor and non-factor treatments Nana Kragh Received Received
  2680-SAT Relationship of sociodemographic factors to presentation and natural history of provoked venous thromboembolism in u.s. children: A secondary analysis of the multinational kids-DOTT trial Hope P. Wilson Received Received
  2681-SAT Overall survival (OS) in patients with metastatic colorectal cancer (mCRC) following persistent chemotherapy-induced thrombocytopenia (pCIT) Ju-Hyeun Kim Received Received
  2682-SAT Thrombotic and hemorrhagic events and their impact on mortality among adults with newly diagnosed acute myeloid leukemia Diego Adrianzen Herrera Received Received
  2683-SAT Real-world treatment patterns & outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the real-AVA 3.5 study Caroline Piatek Received Received
  2684-SAT External validation of the intermountain risk scores for post-discharge (PD) thrombosis and bleeding in an independent population Mansour Gergi Received Received
  2685-SAT Health-related quality of life and symptom burden of patients with vexas: Real-world data from a multicenter observational study Fabio Efficace Received Received
  2686-SAT Social determinants of health and outcomes of bone marrow transplantation in patients with aplastic anemia: A 23-year retrospective cohort study Phuong Vo Received Received
  2687-SAT Venous thromboembolism in multiple myeloma patients treated with BCMA-directed CAR T-cell therapy: A systematic review and meta-analysis Pedro Henrique Las Casas Received Received
  2688-SAT Evaluation of a newly formulated intranasal desmopressin versus intranasal and subcutaneous desmopressin in individuals with type 1 von Willebrand disease and mild Hemophilia A Sanjay Ahuja Received Received
  2689-SAT Atypical hemolytic uremic Syndrome Triggered by malignancy and drug exposure: A systematic review and meta-analysis Moazzam Shahzad Received Received
  2690-SAT Impact of cytoreduction on thrombotic and bleeding outcomes in patients with myeloproliferative neoplasms and atrial fibrillation Carlos Patino Received Received
  2691-SAT Adolescent cardiovascular-kidney-metabolic health and estrogen exposure: A cross-sex, gender-inclusive cohort analysis Izola M M Ramalho Received Received
  2692-SAT It´s that time of the month: Menstrual suppression among adolescents and young adults with cancer and quality of life Rebekah Proctor Received Received
  2693-SAT Autoimmune hemolytic anemia: An underrecognized contributor to anemia and hemolysis in babesiosis infection Valentina Restrepo Received Received
  2694-SAT Mortality associated with warm autoimmune hemolytic anemia among Medicare beneficiaries Louis Jackson Received Received
  2695-SAT Real-world outcomes of extended reduced-dose apixaban versus full-dose apixaban in cancer-associated venous thromboembolism Jia Yi Tan Received Received
  2696-SAT Double jeopardy: Heart failure and thrombotic thrombocytopenic purpura in the inpatient setting Abdulmalek Aljafari Received Received
  2697-SAT The global PNH patient registry: real-world data on PNH symptom burden and quality of life David Araten Received Received
  2698-SAT Complement inhibitor use is not a significant predictor of cancer incidence: A real-world study of patients requiring chronic complement blockade. Bailey Brooks Received Received
  2699-SAT Comparative efficacy and safety of FDA-approved prophylactic treatments for hereditary angioedema, including garadacimab, haegarda, lanadelumab, and berotralstat: A network meta-analysis Abhishek Mehan Received Received
  2700-SAT Correlates of breakthrough bleeding and emicizumab plasma levels in patients with hemophilia A Chiamaka Nwachukwu Received Received
  2701-SAT The impact of day of admission on morbidity and mortality outcomes on patients with febrile neutropenia in the United States: A nationwide analysis Aseel El-Jabali Received Received
  2702-SAT An interim assessment of bleeding events in a prospective natural history study of hereditary hemorrhagic telangiectasia patients using a validated bleeding scale and a novel daily reporting instrument John Lee I Received Received
  2703-SAT High dose iron infusions in pregnant women are effective, safe, and well-tolerated Steven Fein Received Received
  2704-SAT Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma (MCL) after receiving covalent bruton tyrosine kinase inhibitors (cBTKi) in China Yuqin Song Received Received
  2705-SAT Clinical and economic burden of cytokine release syndrome in a nationally representative cohort of patients receiving CAR-t therapy Mariana Marrero Castillo Received Received
  2706-SAT Social support and barriers to medication adherence among adolescents and young adults with leukemia and lymphoma Katia M Crisler Received Received
  2707-SAT Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium Alexandra Ewa Rojek Received Received
  2708-SAT Six versus eight doses of rituximab in combination with six cycles of CHOP chemotherapy in patients with previously untreated diffuse large b-cell lymphoma Yoshimasa Kamoda Received Received
  2709-SAT Infections in patients with aggressive B-cell lymphomas treated with CD3xCD20 bispecific antibodies Daniel Klein Reef Received Received
  2710-SAT Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study Zachary Epstein-Peterson Received Received
  2711-SAT Clinical characteristics and treatment patterns of elderly patients living with Mantle Cell Lymphoma Sachi Singhal Received Received
  2712-SAT Interim analysis of a non-interventional prospective descriptive study to assess the impact on Patient´s well-being of fixed-time duration (FTD) and continuous oral regimens for newly diagnosed and relapsed/refractory (R/R) chronic lymphocytic leukemia (C Raul Cordoba Received Received
  2713-SAT Safety and efficacy of implanted port use for CAR T-cells infusion in large B-cell lymphoma Zachary Hunzeker Received Received
  2714-SAT Socio-economic deprivation in paediatric patients with B cell -acute lymphoblastic leukaemia : A possible modifiable risk factor based on the real world data from a retrospective survival analysis from the national registry in England Sandheeah Sandheeah Ramdeny Received Received
  2715-SAT Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis Yannis Valtis Received Received
  2716-SAT Mortality outcomes compared to the general population among long-term Hodgkin lymphoma survivors: A population-based analysis Bryan Valcarcel Received Received
  2717-SAT Impact of statin use on outcomes in chronic lymphocytic leukemia patients receiving ibrutinib therapy: A real-world study Lay She Ng Received Received
  2718-SAT Multiple medication use is associated with increased lymphoma risk in autoimmune diseases: Analysis from the life study Ami Inokuchi Received Received
  2719-SAT Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes Rahul Shah Received Received
  2720-SAT Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study Jacqueline Barrientos Received Received
  2721-SAT Barriers to receiving CAR T-cell treatment among patients with non-Hodgkin lymphoma who were deemed eligible for CAR T-cell therapy Andrew Park Received Received
  2722-SAT Racial and socioeconomic disparities in adult acute lymphoblastic leukemia: A multicenter cohort study Erin Kaser Received Received
  2723-SAT Real-world treatment patterns and biomarker utilization among patients aged =65 years with CLL/SLL from 2020 to 2024 Paul J. Hampel Received Received
  2724-SAT Real-world incidence of bleeding events in patients with chronic lymphocytic leukemia treated with acalabrutinib +/- obinutuzumab and requiring direct oral anticoagulation Klaus Fenchel Received Received
  2725-SAT Real-world treatment patterns, patient characteristics, and outcomes of cbtki-based therapies amongst a contemporary cohort of patients with R/R MCL in the United States Kami Maddocks Received Received
  2726-SAT Influence of HIV status, age and ethnicity on survival in patients with burkitt lymphoma (BL) and diffuse large B cell lymphoma (DLBCL): A real-world nationwide database study Himil Mahadevia Received Received
  2727-SAT Optimizing the treatment of secondary central nervous system lymphoma (SCNSL) with intensive systemic and cns-targeted chemoimmunotherapy followed by autologous stem cell transplant (ASCT): A retrospective, single-center analysis of a modified ferreri pro Fnu Amritpal Singh Received Received
  2728-SAT First worldwide real-life data on fixed-duration ibrutinib+venetoclax treatment for previously untreated CLL/SLL patients: Updated interim analysis of Spain´s LI+VE observational study Jose Angel Hernandez Rivas Received Received
  2729-SAT Effect of immunoglobulin-replacement therapy on the incidence of severe infections in patients with chronic lymphocytic leukemia Jiani Zhou Received Received
  2730-SAT Patient journey with axicabtagene ciloleucel for relapsed or refractory large B cell lymphoma in Canada: Manufacturing experience and impact of patient location to treatment centre Natasha Kekre Received Received
  2731-SAT Pediatric-inspired regimens for ALL are not associated with improved overall survival in US hispanic adult patients Alexander Krule Received Received
  2732-SAT Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma Mariana Bastos-Oreiro Received Received
  2733-SAT Academic cancer programs deliver improved long-term survival in nodular lymphocyte predominant Hodgkin lymphoma: Insights from 7,000+ United States patients Nikki Verma Received Received
  2734-SAT Evolving patient-reported value of treatment attributes in follicular lymphoma: Insights from the lymphoma coalition 2024 global patient survey on lymphomas and CLL Natacha Bolanos Received Received
  2735-SAT Therapeutic ANC attainment during maintenance chemotherapy for pediatric acute lymphoblastic leukemia Julia Santarosa Received Received
  2736-SAT Association of race and ethnicity and incidence and severity of hyperglycemia and clinically-treated hypertension during induction therapy for pediatric acute lymphoblastic leukemia Jason Stevenson Received Received
  2737-SAT Prognostic factors and survival outcomes of urgent inpatient chemotherapy for relapsed/refractory lymphoma in the modern era Abhishek Kataria Received Received
  2738-SAT The influence of age on patient-reported outcomes (PROs) endpoints on the S1826 cross-network Phase III trial of advanced-stage, classic Hodgkin lymphoma (cHL) Kelly Davison Received Received
  2739-SAT Incidence of bleeding and hypertension in patients with hematologic malignancies treated with next-generation Bruton tyrosine kinase (BTK) inhibitors: A meta-analysis of randomized controlled trials Jason Ta Received Received
  2740-SAT Efficacy of CAR-T cell therapy in chronic lymphocytic leukemia: A meta-analysis Jaison Lawrence Alexander Santhi Received Received
  2741-SAT Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma Prokop Vodicka Received Received
  2742-SAT Feasibility of collecting social determinants of health data in the frontline pediatric acute lymphoblastic leukemia (ALL) trial AALL1731: A report from the Children´s oncology group Haley Newman Received Received
  2743-SAT The time toxicity of CAR-T cell therapy for non-Hodgkin´s lymphoma Daniel Clancy Trotier Received Received
  2744-SAT CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party Remy Dulery Received Received
  2745-SAT Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry Remy Dulery Received Received
  2746-SAT Addressing psychological burden in patients newly diagnosed with lymphoma or myeloma: Patient perspectives on potential interventions Andrew M. Ferrar Received Received
  2747-SAT Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China Wei Li Received Received
  2748-SAT Real world population-based outcome analysis of small lymphocytic lymphoma (SLL) in British Columbia (BC) Solomon Abate Received Received
  2749-SAT Beyond remission: Sexual health and quality of life in survivors of acute leukemia Lyam Carlo Chacon Rangel Received Received
  2750-SAT Pulmonary function tests performed prior to CAR-T cell administration could be instrumental in predicting post-treatment pulmonary toxicity: A single-arm prospective study Ofrat Beyar-Katz Received Received
  2751-SAT Effectiveness of remote patient monitoring in enabling outpatient step-up dosing for bispecifics at a large academic cancer center in the USA Sridevi Rajeeve Received Received
  2752-SAT The whole brain radiotherapy is a safe and effective backbone in primary central nervous system lymphoma: A 23-year real-world experience Cong Li Received Received
  2753-SAT Association between COMT activity and development of infections during therapy for pediatric acute lymphoblastic leukemia Tamara P. Miller Received Received
  2754-SAT Incidence and risk factors of chronic kidney disease (CKD) in lymphoma survivors Nidhi Umesh Desai Received Received
  2755-SAT Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells Federico Stella Received Received
  2756-SAT Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need Mika Geva Received Received
  2757-SAT Survival outcomes of adult patients diagnosed with acute lymphoblastic leukemia in the US between 2000-2020 are associated with their sociodemographic characteristics Rachelle Monteau Received Received
  2758-SAT Real-world comparative outcomes of CAR-T cell therapy versus bispecific T-cell engagers in patients with relapsed acute lymphoblastic leukemia Danielle C Thor Received Received
  2759-SAT Real-world comparative outcomes of pola-R-CHP versus R-CHOP in patients with diffuse large B-cell lymphoma Danielle C Thor Received Received
  2760-SAT Analysis of lymphoma subtypes, involved sites, and treatment outcomes in primary gastrointestinal B-cell lymphomas: A subset analysis within the PELÉ study of brazilian centers. Guilherme Duffles Sr Received Received
  2761-SAT Outcomes of autologous stem cell transplantation using busulfan-melphalan conditioning with pharmacokinetic monitoring for relapsed diffuse large B-cell lymphoma Colin Stewart Received Received
  2762-SAT Chemo ± immunotherapy remains utilized for chronic lymphocytic lymphoma in the real-world practice: Unmet needs, treatment patterns, and age disparities in the United States Javier Pinilla-Ibarz Received Received
  2763-SAT Improved survival outcomes in angioimmunoblastic T-cell lymphoma linked to care at academic cancer centers: A national cancer database study. Vanessa Velazquez Received Received
  2764-SAT Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries Gabriel Brisou Received Received
  2765-SAT Variances in patient reported experiences with shared decision-making by biological sex in patients with diffuse large B-cell lymphoma (DLBCL) – an analysis from the lymphoma coalition 2024 global patient survey on lymphomas and CLL Lorna Warwick Received Received
  2766-SAT Outcome disparities among survivors of hematologic malignancies diagnosed in childhood Camila Pabon Received Received
  2767-SAT Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations Daniel DeAvila Jr Received Received
  2768-SAT Outcomes during BTKi treatment for chronic lymphocytic leukemia: Insights from remote therapeutic monitoring Gurjyot Doshi Received Received
  2769-SAT Limited-stage Mantle Cell Lymphoma: Real-world outcomes according to nodal vs. extranodal presentation Sun-Hye Ko Received Received
  2770-SAT Preliminary data on epcoritamab and glofitamab as bridging therapy prior to CAR T-cell treatment in Relapsed/Refractory large B cell lymphoma Pauline PIAZZOLA Received Received
  2771-SAT From response to rupture: Evaluating GI perforation after CD19 CAR-T in LBCL Arash Velayati Received Received
  2772-SAT Reassessing bone marrow staging practices in limited-stage follicular lymphoma in the PET era Marissa Solow Received Received
  2773-SAT Impact of age on outcomes of CAR-T cell therapy in multiple myeloma, DLBCL, and follicular lymphoma: A real-world multi-center propensity-matched analysis Mohammed Aloqaily Received Received
  2774-SAT Cardiovascular outcomes in CLL patients receiving GLP-1 agonists and BTK inhibitors: A global propensity-matched study Angimar Uriepero Received Received
  2775-SAT Frontline therapy patterns and outcomes in chronic lymphocytic leukemia: A real-world, multicenter analysis from Latin America. Celso Arrais-Rodrigues Sr Received Received
  2776-SAT Post-traumatic stress disorder in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) Yagnapriya Ammakola Received Received
  2777-SAT Comparable outcomes after autologous hematopoietic cell transplantation in T-cell lymphoma regardless of pre-transplant response: A key finding in resource-limited countries. Byron Figueroa I Received Received
  2778-SAT Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study Dok Hyun Yoon Received Received
  2779-SAT Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia. Jian Li Received Received
  2780-SAT Social determinants of health and long-term survival in chronic lymphocytic leukemia/small lymphocytic lymphoma: A population-based analysis of 118,667 patients Xiaoyi Zhang Received Received
  2781-SAT Fungal infections following chimeric antigen receptor T-cell (CAR-T) cell therapy: A retrospective case-control study in the south-central US Bibi Maryam Received Received
  2782-SAT Racial disparities in health outcomes of patients with diffuse large B-cell lymphoma using real-world data Nneoma Ubah Received Received
  2783-SAT Cause of non-cancer related death among patients diagnosed with lymphoid neoplasm: A SEER-based study Nikita Tripathi Received Received
  2784-SAT First-line treatment in patients with transplant-ineligible, newly diagnosed multiple myeloma by age, frailty, and comorbidity Dongyu Zhang Received Received
  2785-SAT Steroid-toxicity in newly diagnosed patients with multiple myeloma treated with a limited dexamethasone regimen; Results from the nmsg rest study Frida Bugge Askeland Received Received
  2786-SAT Association between extreme heat exposures and survival in patients with multiple myeloma Thomas Kuczmarski Received Received
  2787-SAT Chimeric antigen receptor T cells in real-world care of multiple myeloma: Patient characteristics and healthcare resource utilization Natalie Boytsov Received Received
  2788-SAT Limited diagnostic utility of abdominal fat pad biopsy for systemic amyloidosis: A single institution´s experience Mark David Oliver Received Received
  2789-SAT What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma Ahmed Sawas Received Received
  2790-SAT Bispecific antibodies in real-world care of multiple myeloma: Patient characteristics and healthcare resource utilization Natalie Boytsov Received Received
  2791-SAT Characteristics and outcomes of non-transplanted newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, lenalidomide, dexamethasone (DVRd) with once-weekly bortezomib dosing Laahn Foster Received Received
  2792-SAT The impact of frailty on real world outcomes for multiple myeloma patients in England – a cohort study from the uncover study group and ukmra frailty group. Thea Chandler Received Received
  2793-SAT Rising mortality trends in elderly multiple myeloma patients with hypertension: A CDC wonder database analysis (1999–2023) Abdul basit Khan Received Received
  2794-SAT Utilization and outcome disparities in autologous hematopoietic stem celltransplantation among patients with multiple myeloma in the United States Emeka Agudile Received Received
  2795-SAT Real-world outcomes for anti-CD38 monoclonal antibody-naive and exposed patients receiving treatment for multiple myeloma Benjamin A Derman Received Received
  2796-SAT Integrating the cardiovascular-renal-metabolic syndrome(ckm): Construction and validation of a comprehensive model for early identification of high-risk multiple myeloma Xiaoman Sun Received Received
  2797-SAT A prospective pilot study integrating health care coaching into VA hematologic cancer care: A VA-leukemia & lymphoma society (LLS) collaborative initiative Mark Alexander Rudolph Received Received
  2798-SAT Real-world experience with first-line regimens in transplant-ineligible patients with multiple myeloma Danyal Ladha Received Received
  2799-SAT Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma Jia Yi Tan Received Received
  2800-SAT Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses Abhishek Janardan Received Received
  2801-SAT Real-world treatment patterns of elranatamab in patients with multiple myeloma in Japan: Findings from the EVEREST study Satoshi Yoshihara Received Received
  2802-SAT Systematic review of non-icans neurological toxicities associated with BCMA and GPRC5D-directed CAR-T cell therapy in plasma cell dyscrasia Manpreet Saini I Received Received
  2803-SAT Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network Javier de la Rubia Received Received
  2804-SAT Years of life lost to multiple myeloma remains high: A targeted literature review Alex Bates Received Received
  2805-SAT Impact of maintenance strategies post-autologous stem cell transplant in patients with newly diagnosed multiple myeloma and high-risk cytogenetic abnormalities Arvind Suresh Received Received
  2806-SAT Subcutaneous daratumumab at home is a safe and effective procedure allowing active treatment of frail patients with multiple myeloma Roberto Latagliata Sr Received Received
  2807-SAT Quality of life in multiple myeloma: A scoping review Chunyan Sun Received Received
  2808-SAT Chronological age predicts suboptimal multiple myeloma treatment independent of frailty and socioenvironmental factors: A retrospective multi-center cohort study Maya Abdallah Received Received
  2809-SAT Unstructured serum electrophoresis data limits real world AI models in multiple myeloma: Evaluation of 384 institutions across United States Ehsan Malek Received Received
  2810-SAT Race agnostic models maintain accuracy in predicting m-protein levels in multiple myeloma Ehsan Malek Received Received
  2811-SAT Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma Nisha Joseph Received Received
  2812-SAT Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance Om Raval Received Received
  2813-SAT Impact of race and socioeconomics on access to T-cell engaging therapy in US patients with relapsed/refractory multiple myeloma (RRMM) Yvonne Efebera Received Received
  2814-SAT Infection risk factors and burden in patients treated with T-cell engaging bispecific antibodies for relapsed B-cell lymphoma and multiple myeloma Rafaella Ferreira De Araujo Litvin Received Received
  2815-SAT Who participates in myeloma trials? clinical and geographic predictors of access and outcomes in British Columbia, Canada. Hong Li Received Received
  2816-SAT No CARs for miles: Geographic disparities in access to multiple myeloma CAR-T therapy Olga M Lytvynova Received Received
  2817-SAT High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies Stephanie Yohay Received Received
  2818-SAT Real-world patient characteristics, treatment patterns, and outcomes among relapsed/refractory multiple myeloma patients receiving talquetamab-tgvs Darren Pan Received Received
  2819-SAT Unpredictability of caregiver gaps in multiple myeloma: Results from a survey of 1000 patients Rahul Banerjee Received Received
  2820-SAT Real-world outcomes of standard and modified daratumumab-based therapy in AL amyloidosis: A cohort study from a multidisciplinary program in south India Neeraj Sidharthan Received Received
  2821-SAT Outcomes for black persons with multiple myeloma: A national retrospective trend analysis from 2015 to 2022 Vineet Polineni Received Received
  2822-SAT Assessing patient-reported outcomes in Phase 3 multiple myeloma trials between 2020-2024 – a systematic review. Nawaraj Adhikari Received Received
  2823-SAT Equalizing access to chimeric antigen receptor (CAR) T-cell therapies for myeloma patients Ajay K Nooka Received Received
  2824-SAT Epidemiological trends in leukemia and heart failure-associated mortality: A CDC wonder database analysis Hafiz Muhammad Hannan Javed Received Received
  2825-SAT A retrospective study to assess real-world treatment patterns and outcomes in luspatercept-treated patients with myelofibrosis-associated anemia who required red blood cell transfusion in the United States Gabriela Soriano Hobbs Received Received
  2826-SAT Ruxolitinib duration of treatment and effect on phlebotomy use among 2369 patients with polycythemia vera: A real-world analysis of the Medicare fee-for-service claims database Naveen Pemmaraju Received Received
  2827-SAT Quality of life and organization of care in patients with chronic myeloid leukemia (CML) within the lombardy hematologic network (REL): The CML-OPERAP study Giacomo Mossini Received Received
  2828-SAT Global gender and geographic disparities in leukemia clinical trials authorship Kellen Cristine Tjioe Received Received
  2829-SAT Less-intensive therapy in newly diagnosed acute myeloid leuekmia (AML) in India: Real-world adoption and prognostic utility of ELN-LI and ELN-2022 classification Chepsy C Philip Received Received
  2830-SAT Palliative care for AML patients on venetoclax-based therapy: A single-center real-world study Cheryl H. Chang Received Received
  2831-SAT Optimal dose and duration of venetoclax for induction therapy in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis Moazzam Shahzad Received Received
  2832-SAT Outcomes of adolescent and young adult patients with AML treated on adult versus pediatric protocols Ira Lignugaris Kraft Received Received
  2833-SAT Impact of treatments with food restrictions on adherence and quality of life aspects among CML patients Dan Douer Received Received
  2834-SAT Determinants of early mortality following induction chemotherapy in Acute Myeloid Leukemia: Experience from a comprehensive cancer center in Latin America Melanie Wendy Castro Mollo Jr Received Received
  2835-SAT Treatment cost per AE symptom-free day of asciminib and second-generation tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia Jennifer Vaughn Received Received
  2836-SAT The association of a novel psychosocial and mobility assessment with outcomes of veterans with acute myeloid leukemia (AML) Michelle Hyunju Lee Received Received
  2837-SAT Real-world treatment patterns and clinical outcomes in patients with essential thrombocythemia treated with cytoreductive therapy: A retrospective analysis of electronic health records data Evan Chen Received Received
  2838-SAT The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis Andrew Palmer Received Received
  2839-SAT Pre-emptive multidisciplinary approach to overcome the negative impact of high psychosocial risk factor on outcomes after allogeneic hematopoietic cell transplantation Dawn Speckhart Received Received
  2840-SAT Patterns of management and healthcare utilization in older adult patients with TP53-mutated AML and MDS: A retrospective analysis Tina Zhang Received Received
  2841-SAT Impact of recipient sociodemographic factors on allogeneic transplant conditioning intensity and survival outcomes in myeloid malignancies: A secondary analysis of CIBMTR data Allison O. Taylor Received Received
  2842-SAT Voriconazole (VCZ) therapeutic drug monitoring (TDM) for prophylaxis and treatment of invasive fungal diseases in hematology patients – daily clinical practice and evidence from clinical trials Meinolf Karthaus Received Received
  2843-SAT Age-ing study: A prospective evaluation of geriatric, patient-reported and frailty assessments to predict outcomes in older adults with acute myeloid leukemia Catherine Lai Received Received
  2844-SAT Real world outcomes of patients with CML-CP treated with tyrosine kinase inhibitors from the h. jean khoury cure CML consortium (HJKC3) Ehab Atallah Received Received
  2845-SAT Management of chronic myeloid leukaemia (CML) during pregnancy: A systematic review of maternal and foetal outcomes Nicholas Hsien Han Pua Received Received
  2846-SAT Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome Krischan Braitsch Received Received
  2847-SAT Area deprivation index as a predictor of survival and treatment disparities in older adults with Acute Myeloid Leukemia: A population-based Study Valerie Tran Received Received
  2848-SAT Influence of air quality on clinical acuity at presentation in pediatric patients with newly diagnosed Acute Myeloid Leukemia Alexis Chen Boulter Received Received
  2849-SAT Hematologic predictors of serious infection and impact of serious infection on long-term mortality in AML patients: Insights from propensity-matched real-world cohorts Dikshya Shrestha Received Received
  2850-SAT Dosing patterns of ponatinib in patients with chronic-Phase chronic myeloid leukemia and effect on treatment: Analysis of specialty pharmacy data in the United States Jorge Cortes Received Received
  2851-SAT Impact of pre-transplant anxiety and depression on outcomes of AML patients after allogeneic transplantation Neda Amirmokhtari Received Received
  2852-SAT Disparities and trends in hospice facility deaths among leukemia patients Alaa Mahmoud Received Received
  2853-SAT County-level analysis reveals two high-incidence regions and potential environmental contributors to myeloid malignancies in Colorado Jason Sean Gilbert Received Received
  2854-SAT Burden of illness and hematocrit control among patients with high- and low-risk polycythemia vera receiving current standard of care treatment in the United States Aaron T. Gerds Received Received
  2855-SAT Treatment-associated healthcare utilization in older adults with AML: A retrospective single-center study Joshua Lyons Received Received
  2856-SAT Outcomes of Acute Myeloid Leukemia patients undergoing hematopoietic stem cell transplantation with and without pre-existing heart failure: A national inpatient analysis Abdulmalek Aljafari Received Received
  2857-SAT A real-world analysis on the impact of GLP-1 receptor agonist use on all-cause mortality and hematological outcomes in AML/CML patients with obesity Muluken Megiso Received Received
  2858-SAT Risk of thrombotic and bleeding events in patients with MPNs - does SSRI use have an impact? Kirti Arora Received Received
  2859-SAT A retrospective analysis of outcomes of high-risk myelodysplastic syndrome patients treated with upfront decitabine/cedazuridine versus hypomethylating agents with venetoclax utilizing real-world data Mohamed Zakee Mohamed Jiffry Received Received
  2860-SAT Trends and disparities in hematologic malignancy and sepsis-related mortality in adults aged = 65 years in the United States from 1999 to2023: A CDC wonder database analysis Ahmed Raza Received Received
  2861-SAT Marrow-ly we learn along: A needs assessment of the educational needs of pediatric and young adult patients with bone marrow failure Sara Bowman Received Received
  2862-SAT Partnering with patients to guide the development of impactful educational resources for warm autoimmune hemolytic anemia (wAIHA) Azreen Iqbal Received Received
  2863-SAT An analysis of sickle cell disease content on tiktok Lucie Pham Received Received
  2864-SAT Clinics and clicks: Understanding hematology healthcare delivery utilization and preferences in the digital era Rosalyn Marar Received Received
  2865-SAT Fertility preservation in AYA oncology: Provider knowledge gaps, counseling practices, and barriers to care Anjani Kapadia Received Received
  2866-SAT Classical hematology education in pediatric hematology/oncology fellowship: A national needs assessment Jillian Simoneau Received Received
  2867-SAT A Canadian national needs assessment for an immunology curriculum for hematology residents Jennifer Teichman Received Received
  2868-SAT Artificial intelligence–supported insight generation to inform medical education priorities in multiple myeloma Carley E Yawn Received Received
  2869-SAT Demystifying changes with upfront therapy in Mantle Cell Lymphoma: Global clinician preparedness in the aftermath of educational interventions Carmine Deluca Received Received
  2870-SAT A fellow-led communication skills training (CST) curriculum for hematology/oncology (HO) trainees Ahmad Nassar Received Received
  2871-SAT Leveraging real-world workshop insights for improving education design: Patient-centered care of myelofibrosis with JAK inhibitors Kristen M Rosenthal Received Received
  2872-SAT We´re not talking about sex: Hematopoietic stem cell transplant provider practices and barriers to sexual health discussions with adolescents and young adults Brittany C Kimball Received Received
  2873-SAT A mixed methods evaluation of American society of Hematology´s (ASH) clinical guidelines Deirdra Terrell Received Received
  2874-SAT Navigating hematology and medical oncology fellowship websites: A comprehensive review and implications for applicants Rafi Aibani Received Received
  2875-SAT Barriers to optimal care and educational opportunities for european physicians treating patients with relapsed/refractory (R/R) CLL Ryan Topping Received Received
  2876-SUN Exacerbation of anemia from hereditary spherocytosis during pregnancy: Characterization of severity and use of medical interventions Arielle Langer Received Received
  2877-SUN Next-generation sequencing panel for hereditary erythrocytosis identifies genomic variants in over half of adults with otherwise unexplained erythrocytosis Mahsa Rezasoltani Received Received
  2878-SUN Real-world evidence from China: Clinical characteristics, treatment landscape and long-term outcomes in 566 autoimmune hemolytic anemia patients Junan Zhang Received Received
  2879-SUN AI-based characterization of terminal erythroid differentiation as a prognostic biomarker in myelodysplastic syndromes David Bermejo-Peláez Received Received
  2880-SUN Severe hemolysis flare of refractory warm hemolytic anemia with positive complement component C3d responsive to iptacopan with cyclophosphamide and prednisone Yawen Zhang Received Received
  2881-SUN Impact of rilzabrutinib on gene-expression of inflammatory factors in patients with warm autoimmune hemolytic anemia who participated in the Phase 2B lumina 2 study Alessandro Lucchesi Received Received
  2882-SUN Mapping genomic responses to kit receptor tyrosine kinase signaling in erythroid progenitors Venkatasai Rahul Dogiparthi Received Received
  2883-SUN Arsenite and its primary metabolite monomethylarsonous acid impair early human red blood cell development Lauren Heine Received Received
  2884-SUN ASF1B promotes erythropoiesis by regulating the establishment and dynamics of H3.3 nucleosomes Xiang Guo Jr Received Received
  2885-SUN Lamin B1 mediates dynamic changes in heterochromatin and regulates erythropoiesis Dawei Huo Jr Received Received
  2886-SUN Effect of baseline hemoglobin on survival in renal cell cancer patients on tyrosine kinase inhibitors Abbas Gain Received Received
  2887-SUN Recreational use of nitrous oxide resulting in severe B12 deficiency, pancytopenia and hemolytic anemia Yahye Mohamed Farajuun Received Received
  2888-SUN Efficacy and safety observation of luspatercept for refractory anemia associated with hematologic malignanciesluspatercept??????????????????????????luspatercept ??????????????????????????:???? Ping Zhang Received Received
  2889-SUN Decoding the ektacytometric landscape of hereditary spherocytosis: Insights from 204 cases Paola Bianchi Sr Received Received
  2890-SUN Impact of iptacopan, a complement inhibitor, on Chinese patients with paroxysmal nocturnal hemoglobinuria: A multicenter retrospective cohort study Shuqian Xu Received Received
  2892-SUN The improvement of renal function by complement inhibitors in patients with paroxysmal nocturnal hemoglobinuria Guangsheng He Received Received
  2893-SUN Efficacy and safety of iptacopan in Chinese patients with paroxysmal nocturnal hemoglobinuria: A multicenter retrospective study Xiaoqing Li Received Received
  2894-SUN Clinical efficacy and diagnostic value of metagenomic next-generation sequencing for pathogen detection in severe aplastic anemia patients with suspected infectious diseases Jinsong JIA Received Received
  2895-SUN NLRP3 inflammasome inhibition fails to prevent red blood cell lysis in PNH Nikhil Ranjan Received Received
  2896-SUN Pyruvate kinase deficiency is associated with mitochondrial retention, decreased antioxidant and HIFs activity correlating with hemolysis Jihyun Song Received Received
  2897-SUN Novel single red blood cell lifespan measurement assay through glycated hemoglobin assessment by flow cytometry Nicolas Hebert Received Received
  2898-SUN Who needs second-line therapy? predictors of sustained response in autoimmune hemolytic anemia Alfredo Pinedo Rodríguez Received Received
  2899-SUN Efficacy of daratumumab in treatment of relapsed and/or refractory warm autoimmune hemolytic anemia in children Faryal Munir Received Received
  2900-SUN Trial in progress: A phase 1b, open-label, multiple ascending dose study of OM336, a novel BCMAxCD3 T cell engager, in patients with relapsed/refractory autoimmune cytopenias (NCT07083960) Charlie Zhou Received Received
  2901-SUN Age-related differences in outcomes and treatment patterns of iron deficiency anemia in patient´s with crohn´s disease Angimar Uriepero Received Received
  2902-SUN Genome-wide association of pica within a cohort of volunteer blood donors implicates the gene encoding neuropeptide VF Hefei Liu Received Received
  2903-SUN Morbidity and mortality in 128 otherwise healthy Canadian children with severe iron deficiency anemia in the setting of ongoing bottle use and excessive cow´s milk intake: A massive preventable problem demanding action Rachelle Zipper Received Received
  2904-SUN Dxo-1801, a liver-targeted siRNA, attenuates inflammation-driven iron restriction and enhances erythropoiesis in non-human primates Keren Moss Received Received
  2905-SUN Prevalence and timing of iron deficiency among youth with sickle cell disease receiving chronic transfusions Abbigail Bernice Di-Nardo Received Received
  2906-SUN Safety and efficacy analysis of IV iron formulations in children: Results from a large pediatric cohort Reeja Raj Received Received
  2907-SUN Finding ferritin footprints in 5-fluorouracil-induced cardiotoxicity Grace M Ferri Received Received
  2908-SUN Ferroportin Q248H mutation is associated with the less weight loss in persons with HIV-1 Sergei Nekhai Received Received
  2909-SUN Iron-regulatory gene variants and their association with clinical phenotypes in Nigerian patients with sickle cell disease Abiola Bolarinwa Received Received
  2910-SUN Iron deficiency at neonatal intensive care unit discharge in very preterm infants Victoria Hamilton Received Received
  2911-SUN Intracellular iron levels alter the protein interactome of PCBP1 Michael E. Sullivan Received Received
  2912-SUN Molecular spectrum of alpha thalassemia: An unrecognised blood disorder in Nepal Suravi Pandey Sr Received Received
  2913-SUN High complicated incidence of Gilbert´s syndrome in patients with thalassemia: Deserve earlier identification and less oversight Dijiong Wu Received Received
  2914-SUN Evaluating the efficacy and safety of gene therapy in transfusion-dependent ß-thalassemia: A focus on hemolysis improvement and clonal hematopoiesis monitoring Gonzalo De Luna Received Received
  2915-SUN Patients with thalassemia have weaker bones relative to body size compared with healthy controls Ellen B Fung Received Received
  2916-SUN Ex vivo treatment by mitapivat, an allosteric pyruvate kinase activator, reduced oxidative stress to support terminal erythropoiesis of non-transfusion dependent thalassemia patients due to ß-thalassemia/hb e disease Thidarat Suksangpleng Received Received
  2917-SUN Multimodal evaluation of brain injury and cerebral iron deposition in thalassemia patients: A combined human-imaging and murine model study Jingxuan Shao Received Received
  2918-SUN The central role of liver stifness measurement in adults with transfusion dependent thalassemia (TDT) beyond what could be informed by liver iron concentration Gian Luca Forni Received Received
  2919-SUN Hydroxyurea sequesters the histone methyltransferase G9a at stressed replication forks to reactivate fetal hemoglobin Brian Tshao Do Received Received
  2920-SUN Founder effects and consanguinity shape beta-thalassemia genetics: A five-year hospital-based cohort study from Pakistan Ayaz Khan Jr Received Received
  2921-SUN Transfusion independence in thalassemia patients after failure of gene therapy or with hemoglobin h constant spring and hb e using luspatercept: A case series Sherif Badawy Received Received
  2922-SUN Cryo-electron tomography of sickled red blood cells towards a high-resolution in situ structure of HbS polymers and red cell cytoskeleton Yuan Yee Lee Received Received
  2923-SUN Secretory phospholipase A2 (sPLA2) during vaso-occlusive pain episodes (VOE) and acute chest syndrome (ACS) in sickle cell disease (SCD): Results from a prospective multi-center randomized controlled trial (RCT) Rawan Korman Received Received
  2924-SUN Metabolomic and epigenetic signatures of hemin-induced stress in sickle cell erythroblasts Xingguo Zhu Received Received
  2925-SUN Platelet proteomic signatures reveal neurodegenerative and mitochondrial pathways associated with pain phenotypes in sickle cell disease Keesha Powell-Roach Received Received
  2926-SUN Selective PAR1 activation mitigates pain and neuroinflammatory markers in a murine model of sickle cell disease Nirupama Ramadas Received Received
  2927-SUN In vitro and In Vivo FOXO3 dependent induction of fetal hemoglobin Anupama Priyadarshini Received Received
  2928-SUN Phosphorylation-induced structural remodeling of band 3 as a driver of metabolic dysfunction in sickle cell disease Amy Argabright Received Received
  2929-SUN Characterization of sickle cell disease-associated organ dysfunction in aged Townes HbSS mice and effect of IMA001 Matthias Canault Received Received
  2930-SUN Cell-free DNA (cfDNA) and plasma proteomics reveal inflammatory heterogeneity in vaso-occlusive crises in sickle cell disease (SCD). Magdalene Ruth Ford Received Received
  2931-SUN Unlocking the genetics of sickle cell disease Mina Cintho Ozahata Received Received
  2932-SUN Direct hemoglobin S polymerization inhibitor MCP435 completely halts ongoing disease pathophysiology in transgenic sickle cell disease mice Osheiza Abdulmalik Received Received
  2933-SUN Multidimensional profiling of dendritic cell and monocyte subsets in sickle cell anemia: Correlation with clinical and inflammatory parameters Renata Sesti-Costa Received Received
  2934-SUN Novel trajectory-informed mendelian randomization demonstrates consistent causal protective effect of fetal hemoglobin on clinical outcomes in children with sickle cell disease Chengzhou Wu Received Received
  2935-SUN Pharmacological CD206 blocking attenuates cell-free hemoglobin-induced liver damage in sickle cell disease Tomasz W Kaminski Received Received
  2936-SUN Advancing sickle cell disease diagnosis in low-resource settings using Gazelle™, a paper-based microchip electrophoresis platform Arwa Fraiwan Received Received
  2937-SUN Cerebral and peripheral microvascular function in sickle cell disease: Blood flow and oxygen extraction via diffuse correlation and Near-Infrared spectroscopy Dheemant Jallepalli Received Received
  2938-SUN Double-blind randomized study to evaluate the effect of hydroxycarbamide on albuminuria in adults with sickle cell disease: Sikamic (SIklos on Kidney Function and AlbuMInuria Clinical Trial) Pablo Bartolucci Received Received
  2939-SUN Impact of the duffy-null phenotype on hydroxyurea dosing and clinical outcomes in children with sickle cell disease Megan Civitello Received Received
  2940-SUN Does stroke or silent infarct affect quality of life in adults with sickle cell disease?: A multi-centre study Amy Cooper Received Received
  2941-SUN Improvement in kidney function after 12 months of voxelotor in sickle cell disease patients Gonzalo De Luna Received Received
  2942-SUN Development of the sickle cell outcome grading system (SCOGS), a novel classification system for sickle cell disease severity Tarun Aurora Received Received
  2943-SUN Predictive value of lung function results for sleep-disordered breathing in children with sickle cell disease: A multicenter cross-sectional study Ammar Saadoon Alishlash Received Received
  2944-SUN Maternal and fetal risks in patients with sickle cell disease: Results of the retrospective drepamom study Christophe FERREIRA Received Received
  2945-SUN Cardiopulmonary complications during pregnancy as a risk factor for cesarean delivery in a two center, sickle cell disease pregnancy cohort Ria Arora Received Received
  2946-SUN Revisiting acute chest syndrome (ACS) associated with sickle cell disease (SCD) vaso-occlusive pain episodes (VOE): Insight from a prospective, multicenter Phase-3 randomized controlled trial Dunia Hatabah Received Received
  2947-SUN Venous thromboembolism and bleeding rates in pregnant and postpartum patients with sickle cell disease Alexandra Galls Received Received
  2948-SUN Real-world experience of voxelotor treatment in patients with sickle cell disease Caroline Horne Received Received
  2949-SUN Understanding the impact of chronic red blood cell transfusion on day-to-day functioning in sickle cell disease (SCD): A mixed methods study of pediatric and adult experience Chinonso Onuoha Received Received
  2950-SUN Shear wave elastography as a screening modality for hepatic fibrosis in a comprehensive sickle cell disease clinic Marissa Solow Received Received
  2951-SUN Applying the bedside SaO2/FiO2 ratio to adolescents with acute chest syndrome to triage ICU transfer Manuel Ivan Patiño Received Received
  2952-SUN Bridging the gap: Global caregiver perspectives on awareness, motivators, and barriers to clinical trial participation in sickle cell disease John James Received Received
  2953-SUN Subtotal versus total splenectomy in children with sickle cell disease: Clinical outcomes and splenic function assessed by pocked red blood cell count Slimane Allali Received Received
  2954-SUN Lived experience of pregnant patients with sickle cell disease: A qualitative study Lindsey Ze Jing Zhang Received Received
  2955-SUN Combined nutrition education and vocational training for caregivers of children with sickle cell anemia and severe malnutrition: A feasibility study Eliza Brown Received Received
  2956-SUN Subclinical neurovascular injury and cognitive outcomes in adults with sickle cell disease: Prevalence and imaging correlates Jonathan St-Onge Received Received
  2957-SUN Impact of disease genotype and severity of anemia on myocardial extracellular volume fraction in sickle cell disease (SCD) and non-SCD hemolytic anemias Omar Niss Received Received
  2958-SUN First miniaturized electrophoresis diagnostic platform in USA for hemoglobinopathies : From diagnosis to therapeutic monitoring in real time. Akshat Jain Received Received
  2959-SUN Pharmacokinetic (PK)-guided vs weight-based dosing of hydroxyurea for tanzanian children with sickle cell anemia Luke R. Smart Received Received
  2960-SUN Pulmonary hypertension as an independent predictor of mortality in hospitalized sickle cell disease patients: A national analysis of comorbidities and outcomes Brett Cohen Received Received
  2961-SUN Systematic intensification of red cell exchange with hydroxyurea decreased the transfusion burden in patients with sickle cell disease: A single-center retrospective cohort study Maria Alexandra Nica Received Received
  2962-SUN Correlation between outpatient opioid dosage and hospital visits in sickle cell disease patients Elizabeth Minten Received Received
  2963-SUN VTE outcomes in hemoglobinopathy patients: A propensity-matched analysis. insights from the riete registry. Gabriela Nathaly Bastidas Mora Received Received
  2964-SUN Raising hemoglobin level with erythropoietin improves cerebral but not muscle tissue oxygenation in patients with sickle cell disease Nelly Kageha Kiriza Received Received
  2965-SUN Meteorological impact on ventricular arrhythmias in sickle cell disease Thomas d´Humieres Received Received
  2966-SUN Availability of blood products and transfusion practices in sub-saharan Africa for the management of patients with sickle cell disease: A survey in 16 countries. Geoffrey Cheminet Received Received
  2967-SUN Explainable AI-based prediction of chronic kidney disease as a long-term outcome of sickle cell disease in a large, multi-site observational data cohort Biree Andemariam Received Received
  2968-SUN Multimodal neuroimaging and neurocognitive assessment in adolescents with and without sickle cell disease David Keith Wilson Received Received
  2969-SUN Application and challenges of the sickle cell outcome grading system (SCOGS) for classifying acute chest syndrome severity Joseph R Wardell Received Received
  2970-SUN Targeting inflammation in sickle cell disease: Association of GLP-1 agonist use with improved survival and reduced sickle cell crisis and cardiopulmonary complications Asfand Yar Cheema Received Received
  2971-SUN Splenomegaly patterns and clinical impact in African children with sickle cell anemia on hydroxyurea treatment Leon Tshilolo Received Received
  2972-SUN Impact of episodes of acute chest syndrom on the cardiac remodeling in children and young adults with sicle cell disease. Luu-Ly Pham Received Received
  2973-SUN Mortality in sickle cell disease: A report from the grndad registry Joshua Rivenbark Received Received
  2974-SUN Disparities in venous thromboembolism management in patients with sickle cell disease: A nationwide inpatient sample study Sukhmani Sidhu Received Received
  2975-SUN A randomized, double-blind, placebo-controlled trial of a novel BTK inhibitor (rilzabrutinib) in patients with sickle cell disease (SCD) aged 10–65 years: LIBRA Study Kenneth I Ataga Received Received
  2976-SUN Hibiscus 2 (Trial-in-Progress): A global, Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease Guanglin Wu Received Received
  2977-SUN Granulocyte transfusion improves survival and clinical recovery in pediatric febrile neutropenia: A 15-year real-world cohort study from Thailand Witsanu Phetsai Received Received
  2978-SUN Rethinking neutropenia thresholds: Ethnicity-specific distributions and mortality associations in the United States adult population using national health and nutrition examination survey 2017–2018 Tiantian Zhang Received Received
  2979-SUN Use of emapalumab is associated with rapid and sustained benefits in primary HLH subgroups, including CNS involvement and previously untreated patients: Pooled analysis of prospective trials NI-0501-04, NI-0501-05 and NI-0501-09 Franco Locatelli Received Received
  2980-SUN Hodgkin lymphoma-driven hemophagocytic lymphohistiocytosis (HLH) in a predominantly hispanic cohort: A multicenter analysis of clinical features and treatment outcomes Mitchell Boshkos Received Received
  2981-SUN Targeting mitochondrial metabolism to suppress neutrophil overactivation in sepsis: Therapeutic potential of the mitochondrial uncoupler BAM15 Kritsanawan Sae-khow Received Received
  2982-SUN CXCR4 antagonism reduces pneumonia severity in a pharmacological mouse model of CXCR2 loss-of-function-mediated neutropenia. Daniel Zaldumbide Received Received
  2983-SUN Mitochondria contribute to naip/NLRC4 inflammasome assembly and activation in macrophage Ling Yang Received Received
  2984-SUN Clinical and biological characteristics of autoimmune neutropenia in adults according to the presence of anti-granulocyte antibodies: A multicenter retrospective Study of 79 cases Dorann Bartebin Received Received
  2985-SUN Redefining hematology referral thresholds for eosinophilia: A 10-year experience at an academic medical center Payal Bharatkumar Patel Received Received
  2986-SUN Integrated genomic and immunophenotypic profiling of histiocytic disorders reveals therapeutic implications of differential BCL2 expression Yasir M. Alsubhi Received Received
  2987-SUN Bromodomain and extra-terminal domain (BET) as a therapeutic target in a mouse model of secondary hemophagocytic lymphohistiocytosis (HLH) Paola Marra Received Received
  2988-SUN Beyond complement: Patient and in vitro evidence for alternative mechanisms of Monocyte–Platelet aggregation in PNH Nora Sophia Rogmann Received Received
  2989-SUN Blood cell counts and the duffy null phenotype: Beyond neutropenia Elvira Velloso Sr Received Received
  2990-SUN Evolving insights and changes in survival of erdheim-chester disease over time Mia Poleksic Received Received
  2991-SUN Erythrocyte membrane-camouflaged JAK1 inhibitor for the treatment of hemophagocytic lymphohistiocytosis Mengran Chen I Received Received
  2992-SUN Outcomes of plasmapheresis in patients with HLH: A nationwide analysis from 2016–2022 Adnan Humam Hajjar Received Received
  2993-SUN Targeted base editing enables safe and efficient knockout of ELANE for the treatment of ELANE-associated severe congenital neutropenia Lokesh Panigrahi Received Received
  2994-SUN Bifidobacterium BX520 supplementation prevents neuroinflammation in necrotizing enterocolitis by inhibiting IDO1 through the gut-brain axis Qiongxi Lin Received Received
  2995-SUN Idiopathic neutropenia after clonal and antigenic exclusion: A progesterone-dependent subtype Mark Orland Received Received
  2996-SUN CXCL9 is a predictive biomarker of survival with IFN?-targeted therapy in adult HLH patients William T. Johnson Received Received
  2997-SUN Sars-cov-2 NSP10 protein activates the p38 MAPK signaling pathway by downregulating DUSP2 to trigger cytokine storm Lixia Gao Received Received
  2998-SUN Dual pathways of antibody-dependent phagocytosis: Distinct kinetics, finite capacities, and therapeutic implications Michael R. Elliott Received Received
  2999-SUN Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study Carla Isabel Borre Received Received
  3000-SUN The dysregulated lipid metabolism is associated with CD8+ T cell senescence in HIV-associated diffuse large B cell lymphoma Qing Xiao Received Received
  3001-SUN Comprehensive analysis of subtype-specific outcomes and management in castleman disease: A 20-year cohort Study Yoshito Nishimura Received Received
  3002-SUN Automated grading of castleman disease histopathology using an attention-based multiple-instance learning model Muir Morrison Received Received
  3003-SUN Knockdown of the long isoform of the prolactin receptor selectively targets pathogenic immune cells and averts lupus nephritis Kory Hamane Received Received
  3004-SUN Lipid metabolism disorders and immune metabolic programming in patients with idiopathic multicentric Castleman disease Liangshun You Received Received
  3005-SUN Tfeb regulates CD8+ T-cell proliferation In Vivo Marisa J L Aitken Received Received
  3006-SUN Epidemiology and clinical characteristics of idiopathic multicentric castleman disease in Spain (ARCANA study): Prevalence cohort Jose Tomas Navarro Received Received
  3007-SUN MEFV E148Q-P369S-R408Q germ line variant identified from the adolescent imcd-tafro family conferred severe disease manifestations in a cohort of 37 patients with castleman disease Kezhi Huang Received Received
  3008-SUN Real-world safety profile of PD-1 inhibitors in Epstein–Barr Virus–Associated lymphoproliferative disorders: A retrospective analysis from west China hospital Manikanta Boda Received Received
  3009-SUN Pediatric idiopathic multicentric castleman disease is often severe and responds to siltuximab Bridget Austin Received Received
  3010-SUN Aberrant thymic architecture and enhanced interferon signaling in down syndrome Trent Hall Received Received
  3011-SUN A chronotherapeutic approach to VIP receptor antagonist (ANT308) in anti-tumor activity Isabella Lin Received Received
  3012-SUN ROCK2 inhibition attenuates CTL-mediated platelet destruction by suppressing IL-6/STAT3-driven glycolysis in primary immune thrombocytopenia Juanjuan Song Jr Received Received
  3013-SUN The ribosome biogenesis inhibitor CX-5461 increases platelet count in humans and enhances murine megakaryopoiesis Elizabeth E. Gardiner Received Received
  3014-SUN Metabolic reprogramming of megakaryocyte subpopulations in ITP: Implications for TSPO in predicting response to TPO-RA Yu Hou Received Received
  3015-SUN Murine reticulated platelets generated during recovery from antibody-induced thrombocytopenia are functionally impaired and transcriptionally rewired Muataz Ali Hamad Received Received
  3016-SUN A murine monoclonal antibody to integrin aIIbß3 that inhibits protein disulfide isomerase binding to platelets and platelet aggregation LU WANG Received Received
  3017-SUN Single cell transcriptional profiling reveals distinct subsets of human megakaryocytes in myelofibrosis MD Babu Mia Received Received
  3018-SUN Differential expression of coagulation and inflammation genes in ITP patients before and after treatment with thrombopoietin receptor agonists Lamya Garabet Received Received
  3019-SUN Patient-derived monoclonal anti-HPA-1a can induce platetet activation through fcyriia Rick Kapur Received Received
  3020-SUN Inhibition of platelet kinase signaling and scaffolding activities with small molecule proteolysis-targeting chimeras (PROTACs) Eliana Grace Choi Received Received
  3021-SUN Paquinimod regulate megakaryocyte function by restoring mitochondrial oxidative phosphorylation in acute myeloid leukemia Meng-Yu Xiao Received Received
  3022-SUN The long non-coding RNA SMART regulates human megakaryopoiesis by modulating rRNA processing in the nucleolus Huang Wu Received Received
  3023-SUN Exploration of the role of macrophage mitochondrial damage-mediated excessive pyroptosis in ITP Guoyang Zhang Received Received
  3024-SUN Single-cell dissection of pathogenic T-cell response to tacrolimus in immune thrombocytopenia Li-Ping Yang Received Received
  3025-SUN Enhancing hemostasis in glanzmann thrombasthenia via protein S inhibition Rim Diab Jr Received Received
  3026-SUN Platelet mTOR is a regulator of sterile immunothrombosis Irina Portier Received Received
  3027-SUN Reproductive health in patients with primary immune thrombocytopenia (ITP) receiving rilzabrutinib: A subgroup analysis from the Phase 3 LUNA3 multicenter study Michele Lambert Received Received
  3028-SUN Post-operative thrombocytopenia in on- versus off-pump coronary artery bypass grafting Thomas Francis Fusillo Received Received
  3029-SUN Assessment of thrombotic risk and pathophysiological mechanisms of splenectomy-associated hypercoagulability in patients with immune thrombocytopenia Artur Saldanha Received Received
  3030-SUN Double or triple therapy in newly diagnosed immune thrombocytopenia: Improving outcomes from the west-central Mexican experience. Gregorio Campos-Cabrera I Received Received
  3031-SUN Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B) Ying Wang Received Received
  3032-SUN Long-term remissions in refractory ITP patients by daratumumab Julian List Received Received
  3033-SUN Outcome and recovery trajectories for intracerebral hemorrhage in adults with primary immune thrombocytopenia Peng Zhao Received Received
  3034-SUN Real-world safety and effectiveness of hetrombopag in patients with primary immune thrombocytopenia Heng Mei Received Received
  3035-SUN A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of CID-103 in adults with persistent or chronic immune thrombocytopenia Chen Yunfei Received Received
  3036-SUN Clonal T-large granular lymphocytes (LGL) in chronic relapsing-remitting and refractory immune thrombocytopenia Sana Ali Received Received
  3037-SUN The platelet variability index tool to determine the likelihood of immune thrombocytopenia (ITP): User testing and tool refinement Syed Mahamad Received Received
  3038-SUN Measuring success by different rulers: Heterogeneity in definition of outcomes in immune thrombocytopenia trials Sofia Isabel Isabel Quezada Ramirez Received Received
  3039-SUN Interim report of a phase 1/2 study of ESG206 in patients with refractory or relapsed primary immune thrombocytopenia Yu Hou Received Received
  3040-SUN Efficacy and safety of romiplostim N01 for second-line treatment of pediatric immune thrombocytopenia: A multicenter prospective observational study Aijun Zhang Received Received
  3041-SUN Shared decision making for immune thrombocytopenia (ITP) treatment: Data from the ITP natural history study registry Taylor Bowles Received Received
  3042-SUN Dose dense rituximab for high-risk children and adolescents with newly diagnosed acute immune thrombocytopenic purpura (ITP) (NCT04323748) Edo Schaefer Received Received
  3043-SUN A prospecitive, multicenter study of chidamide in adult patients with refractory primary immune thrombocytopenia Ming Hou Received Received
  3044-SUN Iguratimod plus low-dose rituximab as second-line treatment in adults with primary immune thrombocytopenia: A multicenter, open-label, randomized, controlled, Phase 2 trial Qiu-Sha Huang Received Received
  3045-SUN Impact of obesity on response to first line treatment in primary immune thrombocytopenia - data from Latin America population Joao Conrado dos-Santos Received Received
  3046-SUN Treatment strategies and outcomes in pediatric patients with immune thrombocytopenia (ITP) undergoing surgical procedures: A multicenter study Matthew Ross Received Received
  3047-SUN Efficacy and safety of hetrombopag in the treatment of Pediatric immune thrombocytopenia: A Real-World Observational Study Sun Ting Received Received
  3048-SUN Real-world study on thrombopoietin receptor agonists combined with rituximab in the treatment of Relapsed/Refractory primary immune thrombocytopenia Hong Tian Received Received
  3049-SUN Trial in progress: Study design of a randomized, phase 3 trial evaluating the efficacy and safety of mezagitamab (TAK-079) compared with placebo in adults with chronic primary immune thrombocytopenia David Kuter Received Received
  3050-SUN Tissue factor pathway inhibitor-reduced and antithrombin-reduced hemophilia state exhibit different coagulation responses to bypassing agents Shigeharu Oh Received Received
  3051-SUN A protein S-targeting monoclonal antibody, VGA039, improves both primary and secondary hemostatic activity of von Willebrand disease patient blood in an ex vivo vascularized hemostasis-on-a-chip Yumiko Sakurai Received Received
  3052-SUN Identification of novel variants in congenital fibrinogen deficiency by next-generation sequencing Long Chen Received Received
  3053-SUN Novel mechanisms of cell-based blood coagulation: Roles of integrin ß3 psi domain and its L33P polymorphism Sladjana Slavkovic Received Received
  3054-SUN Engineered platelets as immune modulators: A novel strategy to prevent FVIII inhibitor formation in hemophilia A Yingyu Chen Received Received
  3055-SUN Targeting hyperfibrinolysis: A novel prevention and reversal strategy. Abd Alroof Higazi Sr Received Received
  3056-SUN RBCs promote VWF tension-dependent activation and hemostatic clot formation under hemodilution: A combined in silico and ex vivo study Leo Liu Received Received
  3057-SUN Association of factor VIII inhibitors with genetic variants implicated in immune dysregulation Silvia Juarez Rojas Received Received
  3058-SUN Hepatic plasminogen lowering with a galnac-conjugated siRNA reduces plasmin generation and fibrinolysis but has no effect on thrombin generation in rats and mice Martina Helena Lundberg Slingsby Received Received
  3059-SUN Intravital imaging of the spatiotemporal dynamics of fibrinolysis in a murine model of vascular injury Tomasz Brzoska Received Received
  3060-SUN Platelets enhance factor VIII activity through protection from activated Protein C Valerie Novakovic Received Received
  3061-SUN Ex vivo evaluation of the procoagulant effect of NXT007 prophylaxis in people with Hemophilia A without factor VIII inhibitors: Phase I/II study (NXTAGE) Keiji Nogami Received Received
  3062-SUN RESHAPE: A non-interventional study of real-world treatment patterns and outcomes across age groups in people with severe hemophilia A in Latin America, Eastern Europe, Africa, Asia, and the Middle East Guillermo Tobaruela Received Received
  3063-SUN Real-world factor VIII trough levels of severe-type people with Hemophilia A (PwHA) on efanesoctocog alfa prophylaxis: Interpersonal variation, clinical correlates and predictors Tefu Weng Received Received
  3064-SUN Outcomes of arthroplasty in persons with hemophilia: A survey of Medicare data Mohamad Ali Tfaily Received Received
  3065-SUN A FXIa-modified clot waveform analysis for estimation of factor VIII level and emicizumab concentration in hemophilia A Oliver Königsbrügge Received Received
  3066-SUN Management of breakthrough bleeds in participants with hemophilia ? or ? without inhibitors receiving marstacimab prophylaxis in the phase 3 BASIS study Travis Gould Received Received
  3067-SUN A risk-based scoring approach to individualize prophylaxis in patients with Hemophilia A: Results from the predict study Fernando Corrales-Medina Received Received
  3068-SUN Real-world experience with anti-TFPI agent (Marstacimab) in severe and non-severe hemophilia: First reported successful use in a female with non-severe hemophilia b Akshat Jain Received Received
  3069-SUN Perioperative use of efanesoctocog alfa in Hemophilia A: A dual-center real-world study Kadhim Al-Banaa Received Received
  3070-SUN Concizumab plasma concentration measurements for personalized dose adjustment in patients with Hemophilia A/B with and without inhibitors: Data from the Phase 3 explorer7 and explorer8 studies Hermann Eichler Received Received
  3071-SUN Updated meta-analysis of inhibitor development in previously untreated patients with severe Hemophilia A: Plasma-derived versus recombinant FVIII products Anthony Maurice Navarrete Rios Received Received
  3072-SUN Genetic landscape of Hemophilia A in Korea: Insights from precision diagnosis in Hemophilia A Jeong A Park Received Received
  3073-SUN Pregnancy and delivery outcomes in women with Hemophilia A and B: A multicenter cohort study from the Italian association of haemophilia centers Mariasanta Napolitano Received Received
  3074-SUN Efficacy and safety of fitusiran prophylaxis in people with haemophilia a or haemophilia B: A systematic review and meta-analysis Dua Azim Received Received
  3075-SUN Modeling disability reduction through low-dose prophylaxis versus on-demand therapy in hemophilia A: A meta-analysis and gbd-inspired yld framework for resource-limited settings Muhammad Ahtizaz Ahmed I Received Received
  3076-SUN Evaluating the safety and tolerability of switching from emicizumab to fitusiran prophylaxis in adult males with severe hemophilia A, with or without inhibitors: SWITCH study, a trial in progress Guy Young Received Received
  3077-SUN Implementation of 2020 international guidelines in acquired hemophilia: Insights from a decade of national registry data in Spain Maria Eva Mingot Sr Received Received
  3078-SUN Acquired hemophilia a results from a provincial registry highlight the need for improvement of clinical outcomes and bypassing agent use Nicholas Chornenki Received Received
  3079-SUN Peripartum FXI replacement supports safe neuraxial anesthesia in FXI-deficient parturients Tabea Sutter Received Received
  3080-SUN Unusual laboratory manifestations of fibrinogen ? chain p.Ala108Gly genetic variant: A case report Joseph Mah Received Received
  3081-SUN Pharmacokinetic-pharmacodynamic modelling of von willebrand factor/factor VIII prophylaxis in von willebrand disease Jelien den Hollander Received Received
  3082-SUN Efficacy and safety of tranexamic acid in non-haemophilia bleeding disorders: A systematic review of randomized controlled trials Kirti Arora Received Received
  3083-SUN Impact of VEGF inhibition on the development of erythrocytosis in hereditary hemorrhagic telangiectasia Zureyat Tammy Sola-Odeseye Received Received
  3084-SUN Real-world treatment characteristics and outcomes in patients with von Willebrand disease treated prophylactically with plasma-derived or recombinant von Willebrand factor in europe: A multi-center, retrospective study Andreas Tiede Received Received
  3085-SUN Post partum haemorrhage (PPH): Differences in coagulation patterns between vaginal deliveries and c-section - and why prophylactic txa is unlikely to be of advantage Wolfgang Korte Received Received
  3086-SUN A 10-year retrospective review of the effectiveness and safety of tranexamic acid in women with inherited bleeding disorders in the peripartum setting Tharani Anpalagan Received Received
  3087-SUN Trends in coagulation defects related mortality in adults in the United States - a retrospective analysis from 1999-2023. Aditi Parulkar Received Received
  3088-SUN Acquired Hemophilia A (AHA) associated with monoclonal gammopathy: A single institution case series Saumya Easaw Received Received
  3089-SUN Preliminary immunophenotyping in acquired Hemophilia A reveals an imbalanced immune activation landscape Ye Jieyu Received Received
  3090-SUN Acquired factor v inhibitor and granulomatosis with polyangiitis: Diagnostic challenges and therapeutic implications Ankushi Sanghvi Received Received
  3091-SUN National trends in mortality due to disseminated intravascular coagulation and sepsis: A 21-year analysis of hematologic emergencies in the United States Sidra Naz Received Received
  3092-SUN ReInspire: A phase 2 study of mutant-selective PI3Ka inhibitor, RLY-2608, in adults and children with PIK3CA-related overgrowth spectrum and malformations driven by PIK3CA mutation Shelley Crary Received Received
  3093-SUN Hepatic stellate cell activation leads to impaired ADAMTS13 secretion and VWF/ADAMTS13 imbalance in liver cirrhosis Ryan Hunt Received Received
  3094-SUN Tissue factor and extracellular vesicles from PASC patients exert procoagulant effects and mediates venous thrombosis in a murine model Gokul Deoram Patil Received Received
  3095-SUN Inflammatory biomarkers in immune thrombotic thrombocytopenic purpura (iTTP): Focus on citrullinated H3 histone, tumor necrosis factor-alpha, and interleukin-6. Anna Falanga Received Received
  3096-SUN The title of the abstract is : COVID-19 IgG antibodies drive endothelial cell activation and dysfunction Bhagwati Joshi Received Received
  3097-SUN Novel PF4/heparin complexes drive platelet activation in heparin-induced thrombocytopenia Daniel Villalobos Received Received
  3098-SUN Role of ADAMTS13 and von Willebrand factor in pathogenesis of experimental preeclampsia in rats Zhirong Chai Received Received
  3099-SUN HIT immune complexes activate the inflammasome pathway in a complement-dependent manner James Michael Received Received
  3100-SUN HIT antibodies activate platelets by interacting with a negatively charged epitope on human PF4 Guoping Fu Received Received
  3101-SUN Myeloid-derived suppressor cells are expanded in the antiphospholipid antibody syndrome Anne Hubben Received Received
  3102-SUN An updated systematic review and meta-analysis of caplacizumab for immune thromboticthrombocytopenic purpura: Insights into efficacy and safety Mohamed Yassin Received Received
  3103-SUN Retrospective analysis of mortality and morbidity among thrombotic thrombocytopenia purpura presenting to Georgia cancer center Jacob Boccucci Received Received
  3104-SUN Early vs late plasmapheresis in TTP: A u.s. national study on in-hospital mortality Barath Prashanth Sivasubramanian Received Received
  3105-SUN Mortality in immune TTP remains unpredictable: Shortcomings of prediction models despite machine learning advances Mouhamed Yazan Abou-Ismail Received Received
  3106-SUN Real world outcomes in patients with acquired thrombotic thrombocytopenic purpura (TTP) treated with caplacizumab Jawria Tufail Received Received
  3107-SUN Comparison of outcomes in antiphospholipid syndrome diagnosed by ISTH versus EULAR criteria Shreya Srivastava Received Received
  3108-SUN Embolic stroke of undetermined source with low ADAMTS13 level without evidence of microangiopathic hemolytic anemia- case series from single center experience Zhengrui Xiao Received Received
  3109-SUN Aspirin use among patients with thrombotic antiphospholipid antibody syndrome Steven King Received Received
  3110-SUN JMJD1C-mediated epigenetic control of HIT antibody production Yuhong Chen Received Received
  3111-SUN Thrombotic microangiopathy among hospitalized patients: Demographic characteristics, diagnostic trends, and resource use from a national database study Christopher Poletes Received Received
  3112-SUN A case series of pediatric patients with congenital thrombotic thrombocytopenia purpura (cTTP) treated with recombinant ADAMTS13 Erin Christensen Received Received
  3113-SUN Clinical parameters and outcomes associated with genetic alterations in patients diagnosed with complement-mediated hemolytic uremic syndrome (CM-HUS): A single center experience Hafez Ammar Abdullah Received Received
  3114-SUN HIT or miss?: Long-term outcomes of direct thrombin inhibitors vs fondaparinux use in heparin-induced thrombocytopenia Juhi Chovatiya Received Received
  3115-SUN Association of delayed platelet recovery and lower nadir counts with adverse outcomes in heparin-induced thrombocytopenia Hannah Mahjoub Received Received
  3116-SUN Caplacizumab as a single agent without plasma exchange in relapsed and refractory thrombotic thrombocytopenic purpura: A systematic review. Bibi Maryam Received Received
  3117-SUN Analysis of no bolus versus bolus unfractionated heparin nomograms in the management of pulmonary embolism: Insights from a real-world cohort Jia Qi Xiong Received Received
  3118-SUN Antithrombin deficiency, venous thromboembolism risk, and peripartum antithrombin supplementation: A real-world analysis of delivery encounters from 2015–2024 Michael Calloway Received Received
  3119-SUN Management and outcomes in patients with cryptogenic stroke and weakly positive antiphospholipid antibodies Macy Gatti Received Received
  3120-SUN Long-term risk of thromboembolic events in patients with post-acute sequelae of COVID-19: A retrospective propensity-matched cohort study Jowan Al-Nusair Received Received
  3121-SUN Comparison of outcomes with different approaches to antithrombotic therapy after venous stenting Luise Froessl Received Received
  3122-SUN Evaluating the effect of morbid obesity on DVT in patients already on doac therapy: A retrospective analysis Husham Hashim Received Received
  3123-SUN Safety and effectiveness of standard versus extended duration of anticoagulation in children with acute lymphoblastic leukemia and venous thrombo-embolism Marie-Claude Pelland-Marcotte Received Received
  3124-SUN Real-world analysis of thromboprophylaxis use during autologous hematopoietic stem cell transplantation for lymphoma and multiple myeloma Hannah Lee I Received Received
  3125-SUN Biomarkers for venous thromboembolism in children with central venous catheters Neha Bhasin Received Received
  3126-SUN Clinical characteristics and outcomes of cerebral venous sinus thrombosis in hematologic malignancy patients pre- and post-hematopoietic stem cell transplantation: A single-center retrospective study in China Juanjuan Li Received Received
  3127-SUN Plasma protein biomarkers associated with venous thromboembolism (VTE) and mortality in patients with cancer: A substudy of the avert trial Mehrie Harshad Patel Received Received
  3128-SUN Comparing the safety of direct oral anticoagulants vs. low-molecular-weight heparin in patients with thrombocytopenia and venous thromboembolism Nithin Thomas Received Received
  3129-SUN Antiplatelet therapy in anticoagulated cirrhotic patients with chronic portal vein thrombosis: A retrospective multicenter study Gary Batra Received Received
  3130-SUN Risk of thrombosis in multiple myeloma patients treated with carfilzomib-based regimens: A systematic review and meta-analysis of clinical trials Prateek Pophali Received Received
  3131-SUN Thrombosis and outcomes in hematologic neoplasia: Experience from a specialized cancer center in a developing country Jhoan Sebastian Gonzalez Diaz Received Received
  3132-SUN Real-world thrombotic and survival outcomes with erythropoiesis-stimulating agents in cancer-related anemia: A propensity-matched cohort Study Rafi Aibani Received Received
  3133-SUN Venous thromboembolism in hospitalized tuberculosis patients: Incidence, racial disparities, and factors associated with in-hospital mortality: An observational study Manas Pustake Received Received
  3134-SUN Use of apixaban for the prevention of thrombosis in children with coronary artery aneurysms secondary to kawasaki disease Matthew Willis Received Received
  3135-SUN Risk factors and mortality associated with venous thromboembolism in elderly patients with non-Hodgkin lymphoma Ambarina S. Faiz Received Received
  3136-SUN Risk of serious bleeding with concomitant use of apixaban or rivaroxaban with amiodarone compared to flecainide or sotalol in patients with atrial fibrillation Ghadeer K. Dawwas Received Received
  3137-SUN Role in of primary VTE prophylaxis in pediatric patients in hospitalized and critically ill settings: A systematic review and meta-analysis Ali Choaib Received Received
  3138-SUN Incidence of arterial thromboembolism in patients with myeloproliferative neoplasms treated with anticoagulation for venous thromboembolism Antonia Chan Received Received
  3139-SUN Title: Role of primary VTE prophylaxis in pediatric leukemia, lymphoma, and solid tumors: A systematic review and meta-analysis. Qais Hamarsha Received Received
  3140-SUN Utilization and outcomes of inferior vena cava (IVC) filters in patients with cancer-associated acute venous thromboembolism hospitalizations: Insights from the u.S. national inpatient sample 2018–2022 Raj Shah Received Received
  3141-SUN Prevalence and factors associated with acute transfusion reactions among patients receiving blood transfusions in regional referral hospitals in dar es salaam, Tanzania Tarun Aurora Received Received
  3142-SUN Scalable production of stem cell–derived artificial platelets: A safe alternative in the era of blood shortage Chihwa Kim Received Received
  3143-SUN Short-term erythrocytapheresis is associated with resolution of vertebral osteonecrosis in children with sickle cell disease Bindu Kanathezhath Sathi Received Received
  3144-SUN In severely injured civilian trauma patients, preemptive transfusion of low-titer group o+ non-leukoreduced whole blood promotes significantly improved 30-day survival Eldad Dann Received Received
  3145-SUN Impact of whole blood amustaline pathogen inactivation on plasma coagulation factor activity; Mechanism of action Stijn Agten Received Received
  3146-SUN Unraveling the mysteries of platelet fatigue in cold storage: Calcium release dynamics and energy metabolism as therapeutic targets. Daniel Zaldumbide Received Received
  3147-SUN Distinct hematologic profiles in mesoamerican versus classical chronic kidney disease: A focus on anemia, platelets, and transfusion burden Luis Luis Espinoza Received Received
  3148-SUN Aldehyde dehydrogenase 2 plays a dispensable role in hematopoiesis in response to DNA damage Xingmin Feng Received Received
  3149-SUN JAK2 signalling to HNRNPA1 represses retrotransposon activity in haematopoietic stem cells. Jeremy Werner Deuel Received Received
  3150-SUN Distinct roles of fetal hematopoietic stem and progenitor cells in building the immune system Ramy Elsaid Received Received
  3151-SUN Spatial transcriptomics identified dynamic and spatial-resolved niche cell and signal architecture for hematopoietic stem cell specification Xinjian Mao Received Received
  3152-SUN Cdc42 controls spatial organization of autophagy in hematopoietic stem cells Cuiqing Fan Received Received
  3153-SUN Optimizing Bcl11b timing enhances natural killer cell differentiation and cytotoxicity from human pluripotent stem cells for effective immunotherapy Akhilesh Kumar Received Received
  3154-SUN Restoration of inflammatory and transcriptional axes via temporal TNFa and CDK8/19 modulation enhances hemogenic specification from human iPSCs Rong Qiu Received Received
  3155-SUN Novel evidence shows that intracellular complement (complosome) expressed in hematopoietic stem cell progenitor cells regulates hematopoiesis at both the mitochondrial and cellular metabolism levels. Magdalena Kucia Received Received
  3156-SUN Using iPSC-derived hematopoietic stem cells with long-term engraftment capability to model fetal blood disorders Giulia Pavani Received Received
  3157-SUN Son haploinsufficiency in hematopoietic cells disrupts the crosstalk between splicing fidelity and chromatin accessibility, impairing lymphoid lineage commitment Saeed ZakaKhosravi Received Received
  3158-SUN Real-time tracking of RNA splicing in aged bone marrow hematopoietic stem and progenitor cells Emma Klacking Received Received
  3159-SUN Transcriptomic identification of functionally potent human hematopoietic stem and progenitor cells James Ropa Received Received
  3160-SUN A multi-site break through cancer pilot study testing the feasibility and safety of therapeutic intervention for patients with high-risk clonal cytopenia of undetermined significance (CCUS) Danielle Hammond Received Received
  3161-SUN Single-cell multi-omics uncovers transposable element regulation in hematopoietic stem and progenitor cells during aging Logan Rivera Received Received
  3162-SUN Inflammatory remodeling and CD4+ T cell expansion in TET2-mutated myeloid disorders Kehan Ren Received Received
  3163-SUN Aberrant autophagy in TET2-deficient macrophages exacerbates foam cell formation Camille Brzechffa Received Received
  3164-SUN Single-cell multiomic profiling of gene mutation, chromatin accessibility, and gene expression in TET2-mutant clonal hematopoiesis Masanori Motomura Received Received
  3165-SUN Characteristics and prognostic significance of myelodysplastic syndrome (MDS)-related features in vexas syndrome Lin-Pierre Zhao Received Received
  3166-SUN Leveraging clonal competition between chip and malignant clones as a novel therapeutic strategy in hematologic malignancy Kiana Kalei Kaumaka Guillermo Received Received
  3167-SUN Real world experience of patient outcomes in a dedicated clonal hematopoiesis hematology clinic Jayanshu Jain Received Received
  3168-SUN Thrombosis, bleeding, and progression in JAK2 V617F clonal hematopoiesis Rathnam Kumar Venkat Received Received
  3169-SUN IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease Griffen R Mustion Received Received
  3170-SUN DNMT3A-driven clonal hematopoiesis permits colitis-associated tumorigenesis by promoting innate immune tolerance Qingchen Yuan Received Received
  3171-SUN Chronic stress promotes myeloid bias in hematopoiesis via the lactobacillus-ila-FoxO1 signaling axis Hexiao Jia Received Received
  3172-SUN Lower risk of incident dementia in males but not females with TET2 clonal hematopoiesis - a secondary analysis of the aspriin in reducing events in the elderly (ASPREE) trial Jasmine Singh Received Received
  3173-SUN Butyrate ameliorates Tet2-deficient clonal hematopoiesis phenotypes driven by high B12-induced gut dysbiosis. John P Brabson Received Received
  3174-SUN Serum erythropoietin level as a selective pressure in clonal hematopoiesis: Insights into the mutational landscape of myeloid neoplasias Zachary Brady Received Received
  3175-SUN Chronic pulmonary LPS exposure in cystic fibrosis drives maladaptive pro-inflammatory hematopoietic stem and progenitor cells Rubia Isler Mancuso Received Received
  3176-SUN Clonal hematopoiesis does not predict solid tumor malignancy in people living with HIV Manasa Bhatta Received Received
  3177-SUN HMGA1 chromatin regulator induces inflammatory signals and promotes atherogenesis in Tet2 mutant clonal hematopoiesis Zanshe Thompson Received Received
  3178-SUN Characterising the leukaemic microenvironment in a mouse model of infant AML with prenatal KMT2A-MLLT3 expression Christopher Gerard Mullen Received Received
  3179-SUN CLL bone marrow infiltration is associated with osteocyte loss and adipose tissue fragmentation: A high-resolution imaging study In Kyu Lee Received Received
  3180-SUN Osteoblasts differentiated from FVIII-deficient mice exhibit impaired mineralization capacity and promote excessive in vitro osteoclastogenesis Chiara Borsotti Received Received
  3181-SUN Single cell spatial transcriptomics reveals age-dependent cellular organization of mouse bone marrow Christian Reardon-Lochbaum Received Received
  3182-SUN Netrin-1 regulates hematopoietic stem cell function via UNC5A Bianca Elizabeth Bean Received Received
  3183-SUN Bone marrow immune and stromal niche remodeling in myelodysplastic neoplasm patients under erythropoietic therapies by 29-color full-spectrum flow cytometry Claudia Pellin Jou Received Received
  3184-SUN Targeting BRD4 to reshape the inflammatory microenvironment of senescent bone marrow mesenchymal stem cells for improved hematopoietic stem cell transplantation reconstitution Cong Wang Received Received
  3185-SUN FGF11–HIF-1a glycolytic epigenetic axis drives AML progression and chemoresistance via metabolic reprogramming Yifen Shi Received Received
  3186-SUN Apolipoproteins from the microenvironment promote aggressive myeloid leukemia progression Christina Marie Kaszuba Received Received
  3187-SUN Pre-malignant extracellular matrix drives leukemia transformation through reprogramming of pre-leukemic stem cells Alvaro Cuesta-Dominguez Received Received
  3188-SUN Treatment-requiring paroxysmal nocturnal hemoglobinuria in association with myeloproliferative neoplasms (MPNs): Clinical correlations and outcomes Priyansh Faldu Received Received
  3189-SUN Early results from the ongoing pegcetacoplan silo of the international paroxysmal nocturnal hemoglobinuria interest group registry Carlos de Castro Received Received
  3190-SUN Comprehensive multiproteomic analysis reveals an inflammatory phenotype in immune aplastic anemia characterized by broad activation of antigen presenting cells and t helper/cytotoxic 1.17 immune responses Audrey Le Floch-Ramondou Received Received
  3191-SUN Interplay between mutant DNMT3A and UBA1 worsens survival through altered inflammatory and metabolic pathways Jerome Hadjadj Received Received
  3192-SUN Thymoglobuline and grafalon show comparable transplant outcomes in patients with aplastic anemia undergoing allogeneic stem cell transplantation: A multicenter EBMT saawp study of 1603 patients Fabian Fabian Beier Received Received
  3193-SUN The effect of breakthrough hemolysis on complement factor h and factor I levels in paroxysmal nocturnal hemoglobinuria Matthew Holt Received Received
  3194-SUN 6pLOH as a marker of immune-mediated bone marrow failure: Insights from a large single center experience Francesco Versino Jr Received Received
  3195-SUN Efficacy and safety of romiplostim N01 combined with cyclosporine in refractory aplastic anemia patients:a multicenter phase II study Ting Wang Received Received
  3196-SUN The basis for the differential impact of BCOR and BCORL1 in aplastic anemia/paroxysmal nocturnal hemoglobinuria and myeloid neoplasia Atsushi Marumo Received Received
  3197-SUN Long-term follow-up of patients with aplastic anemia enrolled in two phase 2/3 trials of immunosuppressive therapy plus romiplostim as a first-line treatment: Final report for up to 5 years Jong Wook Lee Received Received
  3198-SUN Long-term safety and efficacy of iptacopan in patients with paroxysmal nocturnal hemoglobinuria: 4- and 5-year follow-up of patients from Phase 2 studies who entered the roll-over extension program Antonio M. Risitano Received Received
  3199-SUN Maternal and fetal pharmacokinetics (PK) of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH): A case report of use in pregnancy Benjamin Chin-Yee Received Received
  3200-SUN Sodium-glucose cotransporter-2 inhibitors may modulate complement pathway activation in paroxysmal nocturnal hemoglobinuria Asfand Yar Cheema Received Received
  3201-SUN Outcomes of eltrombopag combined with immunosuppressive therapy in adults with severe aplastic anemia: A large, propensity-matched retrospective analysis Mostafa Eysha Received Received
  3202-SUN Iptacopan monotherapy demonstrated improved clinical outcomes in a real-world cohort with paroxysmal nocturnal hemoglobinuria: Evidence from a managed access program Silvia Sanz Received Received
  3203-SUN Pregnancy outcomes after crovalimab exposure: Analysis of animal model and clinical trial data suggest no adverse effects in paroxysmal nocturnal hemoglobinuria Erfan Nur Received Received
  3204-SUN Disrupted DNA repair and oxidative stress responses underlie hematopoietic stem cell failure after spinal cord injury Kyleigh Rodgers Received Received
  3205-SUN Real-world breakthrough hemolysis patterns across 1,723 patient-years of complement inhibition in paroxysmal nocturnal hemoglobinuria Mark Orland Received Received
  3206-SUN Clinical outcomes of frontline ATG-based immunosuppressive therapy in older patients with aplastic anemia Eitan Kugler Received Received
  3207-SUN Global immunopeptidome remodeling favors piga mutant clones in bone marrow failure Kartik Lakhotiya Received Received
  3208-SUN Clonal hematopoiesis and immune dysregulation in classic PNH Jinhui Ye Received Received
  3209-SUN Complete donor chimerism following deceased-donor liver transplant in an adolescent with hepatitis-associated severe aplastic anemia Alison A. Bertuch Received Received
  3210-SUN A Phase I, open-label study of CTD402, a universal CD7-targeting CAR T-cell therapy, in patients with relapsed/refractory severe aplastic anemia Lele Zhang Received Received
  3211-SUN Rapid hematologic germline testing using hair follicle-derived DNA for germline predisposition and inherited marrow failure states Emma St. Martin Received Received
  3212-SUN Mitochondrial dysfunction as a key factor in the predisposition to 14q32-related myeloid hematological malignancies Isabelle Plo Received Received
  3213-SUN Germline predisposition in pediatric malignancies: Insights from a retrospective study at Dana-Farber Cancer Institute Sabrina Testa Received Received
  3214-SUN Increased prevalence and severity of cardiac iron overload in transfusion dependent diamond-blackfan anemia syndrome caused by small versus large ribosomal subunit mutations Catherine Sheehy Received Received
  3215-SUN Genoprime-Perturb-seq: Functional dissection of GATA2 variants via simultaneous Genotyping-coupled Prime-editing Perturb-seq Shigeki Hirabayashi Received Received
  3216-SUN Small molecule OTS167 increases erythropoiesis and improves anemia in diamond blackfan anemia models in vitro and In Vivo Aya Shibuya Received Received
  3217-SUN A subset of myeloid progenitors drives leukemogenesis in familial CEBPA-mutated acute myeloid leukaemia Alexandra Lubin Received Received
  3218-SUN Luspatercept rescues the disease phenotype of a congenital dyserythropoietic anemia type II patient and an in vitro patient-derived iPSC erythroid differentiation model Yuan Xue Received Received
  3219-SUN Transcriptomic analysis identifies lipid metabolism signature of defective erythropoiesis in diamond blackfan anemia syndrome Sharon Singh Received Received
  3220-SUN Spectrum, molecular features, and clinical outcomes of hematologic malignancies and clonal hematopoiesis in li fraumeni syndrome Elise Fiala Received Received
  3221-SUN The somatic hotspot mutation of DDX41 (p.R525H) elicits dominant-negative effects upon non-truncating germline variants, explaining similar disease risk as truncating variants. Julianna Fisher Received Received
  3222-SUN Germline variant database and visualization platform for BMF and hematologic malignancy predisposition syndromes: BMFgenes1.0 Lili Kotmayer Received Received
  3223-SUN Targeting bcaa metabolism induces synthetic lethality in DNMT3A-mutated acute myeloid leukemia Chengyang Xu Received Received
  3224-SUN Inhibition of CPT1A reverses AML1-ETO-induced differentiation blockage by activating BCL-2/MYC signaling and metabolic reprogramming Fan Ding Received Received
  3225-SUN Tissue specific requirement for the inv(16) oncogene CBFB::MYH11 implies unique leukemia survival mechanisms in the bone marrow microenvironment Sipra Panda Received Received
  3226-SUN Cooperative activation of NF-?B by inv(3)/t(3;3) and NRAS mutations drives myeloid leukemogenesis Takayuki Sakuma Received Received
  3227-SUN Transgenic expression of enhanced AsCas12a in mice enables In Vivo multiplex genetic editing and development of diverse novel models of myeloid neoplasms (Justin) Ching Ting Loke Received Received
  3228-SUN ZBTB7A loss promotes RUNX1::RUNX1T19a-driven leukemia by enhancing the block of erythroid differentiation Vanessa Cristina Arfelli Received Received
  3229-SUN RAS G12 and Q61 codon mutations confer distinct disease characteristics in Acute Myeloid Leukemia and exhibit differential response to RAS(ON) inhibitor RMC-7977. Annabelle Jacinta Anandappa Received Received
  3230-SUN Ectopic BCL11B disrupts the activity of early hematopoietic transcription factors to skew lineage commitment Lindsey Elizabeth Montefiori Received Received
  3231-SUN Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements Mahmoud Adel Bassal Received Received
  3232-SUN PSF3 recruits DNA polymerase theta (Pol?) to stalled replication forks to promote DNA repair and survival of myeloid malignant cells. Umeshkumar Vekariya Received Received
  3233-SUN Next generation sting agonist in combination with DNA methyltransferase inhibitors induce an apoptotic cell death mechanism driven by apoptosis in TP53-mutated Acute Myeloid Leukemia Lora Stojanovic Received Received
  3234-SUN PTPN11 copy number gain drives leukemogenesis via mutant SHP2 in juvenile myelomonocytic leukemia Zhizhuang Zhao Received Received
  3235-SUN Interleukin-8 inhibition by reparixin protects megakaryocytes and alleviates thrombocytopenia in Acute Myeloid Leukemia Jing-Li Han Received Received
  3236-SUN Oncofetal RNA-binding proteins IGF2BP suppress innate immunity signaling pathways in leukemia stem cells Garrett Knox Received Received
  3237-SUN Chromodomain helicase DNA binding protein CHD2 interacts with TET2 and regulates lineage defining transcription in hematopoietic stem and progenitor cells Songa Bae Received Received
  3238-SUN Deciphering the mechanistic role of mixed lineage leukemia partial tandem duplications (MLLPTD) in MDS and AML Roberta Dollinger Received Received
  3239-SUN DNA-proximal MYB phosphorylation is required for oncogenic transcription in acute myeloid leukemia Shuyuan Cheng Received Received
  3240-SUN PKM2 modulation regulates leukemia cell survival. Nikolina Vrdoljak Received Received
  3241-SUN The recurrent AML-associated CBFBD87GDSY mutation has hypomorphic function and is mechanistically distinct from CBFB:MYH11 Ryan B. Day Received Received
  3242-SUN STAG2 mutation preserves a stem cell phenotype in FLT3-ITD-mediated MDS to leukemia transformation Jane J Xu Received Received
  3243-SUN HDAC inhibitors potentiate the efficacy of antineoplastic agents in acute megakaryoblastic leukemia via dual activation of apoptosis and pyroptosis Hu Liu Received Received
  3244-SUN Therapy-induced senescence reprograms non-M3 AML into a drug-exploitable APL-like state Martin Schönlein Received Received
  3245-SUN Peripheral blood plasma proteomics reveals dysregulated cholesterol transport and complement pathways in myeloproliferative neoplasms Max Petersen Received Received
  3246-SUN Increased prevalence of alternative splicing in core-cohesin subunit mutated AML as compared to STAG2 mutated AML Josiah Murray Received Received
  3247-SUN Epigenetic basis of MDS/MPN overlap syndrome with compound loss of Kmt2c and Dnmt3a Prabhjot Kaur Received Received
  3248-SUN Redefining eIF4E´s function in Acute Myeloid Leukemia: Implications for engraftment and survival Leandro Marcelo Martinez Sr Received Received
  3249-SUN Cytokine-medated expansion of clonal hematopoiesis after CART therapy Daniel Brown Received Received
  3250-SUN Vitamin B12 drives epigenetic reprogramming and leukemia progression through metabolic rewiring in AML Peter Lyon Received Received
  3251-SUN LDB1-dependent enhancer networks drive high-risk transcriptional programs in T-cell acute lymphoblastic leukemia Rahul S Bhansali Received Received
  3252-SUN Dissecting mechanisms at an IKZF1 cis-regulatory element harboring ancestry-specific and cross-ancestry B-cell acute lymphoblastic leukemia risk variation Luana Miria Messa Received Received
  3253-SUN The CML and the ALL inducing isoforms of BCR::ABL1 differ for the induction of genomic instablity Martin Ruthardt Received Received
  3254-SUN PIM2-dependent modulation of mitochondrial mass and function in multiple myeloma Daniela Petrusca Received Received
  3255-SUN Virma epitranscriptomically regulates cell proliferation, apoptosis, and mitochondrial function via m6A in multiple myeloma Estibaliz Urizar Compains Received Received
  3256-SUN Potential biomarkers and mechanisms in central nervous system involvement of KMT2A rearranged b-ALL: Insights from Patient-derived xenograft models Der-Shiun Wang Received Received
  3257-SUN PIM1 mutation drives ANXA2 membrane relocalization and promotes lymphomagenesis through PI3K/AKT/mTOR pathway in DLBCL Ning Zhang Received Received
  3258-SUN Revealing oncogenic enhancer regulation by epigenomic profiling of multiple myeloma and plasma cell leukemia patient samples Nick T Crump Received Received
  3259-SUN Cell cycle dependent and independent regulation of AKT activity in germinal center B-cell-like diffuse large B-cell lymphoma – a dual role of cyclin dependent kinase 2 Ondrej Havranek Received Received
  3260-SUN Fusion-specific regulation of polyamine synthesis sensitizes to BCL-XL inhibition in TCF3::PBX1+ B-ALL James Kim Received Received
  3261-SUN EZH2 gain-of-function events distinctly impact germinal center B cells depending on timing in the B lineage Sofia Rose Smith Received Received
  3262-SUN Gut microbiota-mediated tryptophan metabolism plays dual-effects in diffuse large B-cell lymphoma via regulating 3-IAA/5-HTP balance and antitumor immunity Na He Received Received
  3263-SUN FBXO7 ???? TMED10 ???????????? wnt ??????? T-ALL ?????? zefan du Received Received
  3264-SUN Disruption of NAD? and gsh/GPX4 axis via NAMPT inhibition by elaiophylin sensitizes AML to ferroptosis Fuling Zhou Jr Received Received
  3265-SUN Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia Rahul Vedula Received Received
  3266-SUN Cardio-safe degrader CT-03p degrades MCL-1 and overcomes venetoclax resistance in AML. Bing Z Carter Received Received
  3267-SUN Targeting SP1 condensates suppresses HNRNPUL1 via super-enhancers to attenuate Acute Myeloid Leukemia progression Yuchen Wen I Received Received
  3268-SUN PTEN loss reprograms lipid metabolism to modulate venetoclax resistance in acute myeloid leukemia Mutian Cao Received Received
  3269-SUN Identifying epigenetic vulnerabilities for treatment of HMA refractory myeloid leukemia Alan Shih Received Received
  3270-SUN Cytoplasmic localization of qki mediates therapeutic resistance and immune evasion Sadik Karma Received Received
  3271-SUN Overcoming midostaurin resistance via dual MYC and GSPT1 degradation by the protac GT19715 in FLT3-amplified AML cells Xuan Zhang Received Received
  3272-SUN Identification of therapeutic vulnerabilities in FLT3-mutated AML through customized CRISPR screens Phani Krishna Parcha Received Received
  3273-SUN The efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitor AND017 in NUP98-HOXD13transgenic mouse Bing Li Received Received
  3274-SUN ZBTB7A modulates response to BCL-2 inhibition by venetoclax in acute myeloid leukemia (AML) Fu Jun Li Received Received
  3275-SUN INCB160058 selectively targets JAK2V617F-driven hematopoiesis in diverse and drug-resistant models of myeloproliferative neoplasms Hamza Celik Received Received
  3276-SUN CSF1R-CSF1 axis blockade with axatilimab effectively targets leukemia stem cells and monocytes in AML resistant to BH3 mimetics Bing Z Carter Received Received
  3277-SUN Synergistic efficacy of EZH2 inhibitor combined with new flavonoid derivatives in AML patient-derived xenograft mouse models Chunhua Song Received Received
  3278-SUN Mecom gene network drives chemotherapy resistance in high-risk acute myeloid leukemia Sanjana B. Shah Received Received
  3279-SUN Extracellular arginine deprivation enhances venetoclax sensitivity in acute myeloidleukemia via mitochondrial fission impairment and apoptotic priming Yoko Tabe Received Received
  3280-SUN Unleashing intrinsic inflammation in AML using therapeutic cytokines overcomes pro-survival pathways and induces deep and durable remission In Vivo. Sayantanee Dutta Received Received
  3281-SUN PARP inhibition by talazoparib results in leukemia cell death via induction of myeloid differentiation Leslie Martinez-Gutierrez Received Received
  3282-SUN Inhibition of nicotinamide metabolism by the novel NAMPT inhibitor OT-82 potentiates venetoclax in paediatric and adult acute myeloid leukaemia models Donia Moujalled* Received Received
  3283-SUN Targeting metabolic vulnerabilities in Acute Myeloid Leukemia: Therapeutic potential of l-asparaginase and synergy with venetoclax Junji Ikeda Received Received
  3284-SUN Ponatinib-based combination therapies including asciminib and venetoclax were effective on patient-derived xenograft models of chronic myeloid leukemia in blast Phase Adam Laznicka Received Received
  3285-SUN Butyrate up-regulates the expression of CDKN1A to block the cell cycle and inhibits the PI3K-AKT signaling pathway to promote apoptosis to play an anti-Acute Myeloid Leukemia role Shujuan An Received Received
  3286-SUN BT1: A CD84-targeting T-cell engager for selective eradication of leukemic stem cells in Acute Myeloid Leukemia Ottavio Napolitano Received Received
  3287-SUN Mechanisms of chemotherapy resistance driven by Mecom overexpression Michael D. Bern Received Received
  3288-SUN Sphingosine-1-phosphate receptor modulators overcome FLT3 inhibitor resistance in Acute Myeloid Leukemia with FLT3-ITD and NRAS mutations through sphingosine kinase 1/AKT pathway downregulation. Aditi Chatterjee Received Received
  3289-SUN Aberrant activation of clpp exerts multifaceted anti-AML activity beyond tumor cells Xinrong Xiang Received Received
  3290-SUN Selinexor enhances the effect of venetoclax on Acute Myeloid Leukemia stem and progenitor cells by disrupting lysosomal function Ran Zhao Received Received
  3291-SUN MRC2: A tumor-restricted surface antigen for immunotherapy in Acute Myeloid Leukemia Ruotong Chen Received Received
  3292-SUN Synergistic targeting of KMT2A-rearranged AML with combined LSD1 and menin inhibitors Mina M. Tayari Received Received
  3293-SUN LSD1 inhibition enhances venetoclax efficacy in Acute Myeloid Leukemia via metabolic rewiring Kanwaldeep Singh Received Received
  3294-SUN Allosteric inhibition of RAN decreases mir-126 biogenesis in endothelial cells and controls Acute Myeloid Leukemia growth Melissa Valerio Received Received
  3295-SUN Therapeutic effect of menin inhibitors is reversible in AML treatment and could be enhanced by the targeting of differentiation associated chromatin complex Zhong Fan Received Received
  3296-SUN AZD4512: A novel CD22-directed antibody-drug conjugate for the treatment of b-cell malignancies Huiying Han Received Received
  3297-SUN A cyno cross reactive CD3 VHH antibody enables engineering of a potent CD20-targeted t cell engager with enhanced safety Suraj Kachgal Received Received
  3298-SUN Arginine deprivation activates immunogenic cell death and enhances anti-tumor immunity in diffuse large B-cell lymphoma Guangcai Zhong Jr Received Received
  3299-SUN First-in-human phase I study of HCB101, a 3.5th-generation CD47-SIRPa fc fusion protein: Cytopenia-sparing safety, broad pharmacologic window, and low-dose clinical activity in relapsed/refractory non-Hodgkin lymphoma Alvin Luk Received Received
  3300-SUN Overcoming resistance to bispecific antibodies through epigenetic priming in B-cell lymphoma Ted Piorczynski Received Received
  3301-SUN Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia Jacqueline Barrientos Received Received
  3302-SUN Lbl-076, a first-in-class GPRC5DxCD38xCD3 trispecific T cell engager (TCE) for the treatment of relapsed/refractory multiple myeloma Xiao Huang Received Received
  3303-SUN Identification of ferroptosis-sensitizers for DLBCL treatment Rica Hagenbrock Received Received
  3304-SUN BCL-2 inhibition in North American adult T-cell leukemia/lymphoma: Preclinical insights and early clinical outcomes Ankit Tanwar Received Received
  3305-SUN Targeting the casein kinase II /ikaros axis sensitizes TKI activity by suppression of GLUT1 expression and glycolysis in ph+ ALL Chunhua Song Received Received
  3306-SUN Expression of the cancer testis antigen PRAME is associated with response to immune checkpoint inhibitor and rituximab priming in treatment-naïve diffuse large B-cell lymphoma Melinda Burgess Received Received
  3307-SUN Polatuzumab vedotin induced activation of B-cell receptor signaling creates a synthetic lethality with BTK and AKT inhibition in Mantle Cell Lymphoma Ondrej Havranek Received Received
  3308-SUN An orally bioavailable and dual-targeting GSPT1 and CK1a molecular glue degrader targets double-hit lymphoma cells Shi Feng Received Received
  3309-SUN ST6GALNAC4 promotes DLBCL progression by regulating ldha sialylation to enhance glycolysis and lactate production Anqi Zhou Received Received
  3310-SUN Epigenetic targeting of SETD8 in multiple myeloma Rudra Prasad Dutta Received Received
  3311-SUN MDX2003, a novel tetraspecific T cell engager-expander targeting CD19xCD20xCD3xCD28, demonstrates potent preclinical activity against B cell malignancies Ronnie Wei Received Received
  3312-SUN Pre-clinical evaluation of surovatamig (AZD0486) in comparison to CD20xCD3 bispecific antibodies Corinne Cayatte Received Received
  3313-SUN Harnessing BCL2 inhibition with BTK inhibition in follicular lymphoma: A translational trial with mechanistic insights from single cell analysis Y. Lynn Wang Received Received
  3314-SUN MYC/GSPT1 protein degradation in refractory/relapsed T-cell prolymphocytic leukemias Yuki Nishida Received Received
  3315-SUN Identification of XPO1 interactors and modulation by selinexor in diffuse large B cell lymphoma Kyla Trkulja Received Received
  3316-SUN Autophagy/lysosome disruption via pikfyve inhibition in multiple myeloma Cecilia Bonolo De Campos Received Received
  3317-SUN Serum neurofilament light chain (NfL) as a biomarker for chemotherapy-induced peripheral neuropathy (CIPN) in pediatric acute lymphoblastic leukemia (ALL) Giacomo Gotti Received Received
  3318-SUN Unwelcome guests: Risk factors for multidrug-resistant bacterial infections in adults with acute lymphoblastic leukemia Mario Alberto Ochoa Rodriguez Received Received
  3319-SUN Prospective analysis and clinical implications of therapy-related clonal hematopoiesis in adolescent and young adult survivors of acute lymphoblastic leukemia Habib El-Khoury Received Received
  3320-SUN Clinical and molecular characteristics of Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia with central nervous system relapse versus systemic relapse: Results from consortium on myeloid malignancies and neoplastic diseases ( Rafael Madero-Marroquin Received Received
  3321-SUN Disease status at initiation of blinatumomab and depth of response after cycle 1 are associated with survival in Philadelphia chromosome positive B cell acute lymphoblastic leukemia patients treated with blinatumomab and tyrosine kinase inhibitors Ori Grossberger Received Received
  3322-SUN Osteonecrosis risk in adult ALL: Insights from real-world clinical laboratory data in eighty-seven patients treated with peg-asparaginase Felix Klingler Received Received
  3323-SUN Cell cycle-related genetic variants are frequently acquired at relapse of acute lymphoblastic leukemia and predict worse post-relapse prognosis Jinho Lee Received Received
  3324-SUN Prevalence of TPMT and NUDT15 diplotypes in Mexican children with B-cell acute lymphoblastic leukemia Carmen Alaez-Verson I Received Received
  3325-SUN Longitudinal immune reconstitution dynamics in refractory T-ALL treated with CD7 CAR-T cells bridging to allogeneic stem cell transplantation Guo-Ling Wang Received Received
  3326-SUN Safety and efficacy of carniospinal irradiation (CSI) before CAR T cell therapy in patients with acute lymphoblastic leukemia (ALL) with central nervous system (CNS) disease: A potential role for CSI beyond cell killing and into immune priming Bouthaina S. Dabaja Received Received
  3327-SUN MRD-guided outcome analysis of ponatinib plus hyper-CVAD versus historical imatinib in ph-positive ALL: Impact of early response and dose-adjusted ponatinib Kyoung Il Min Received Received
  3328-SUN Lack of efficacy of levocarnitine for the treatment of pegylated asparaginase-related hepatotoxicity during induction or salvage chemotherapy in adults with acute lymphoblastic leukemia: A comparative, retrospective, University of California hematologic m Logan Deyo Received Received
  3329-SUN Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (=10-4) pre-blinatumomab Benjamin Frost Received Received
  3330-SUN Mixed phenotype acute leukemia: Clinical characteristics and real-world outcomes Ana Flavia Patiño IV Received Received
  3331-SUN Risk of therapy-related acute lymphoblastic leukemia (t-ALL) in cancer patients secondary to either chemotherapy, radiation, or both: A retrospective cohort study from 1975-2021 using SEER registry Krishna Desai Received Received
  3332-SUN Severe toxicities in survivors of pediatric and adolescent acute lymphoblastic lymphoma: A population-based study in Ontario, Canada Karen Arane Received Received
  3333-SUN Long-term follow-up for newly diagnosed BCR::ABL1 negative B cell acute lymphoblastic leukemia from China: 10-year outcome of RJ-ALL 2014 protocol Jiayi Ren Received Received
  3334-SUN Metabolic and genetic determinants of severe asparaginase toxicities in adolescent and young adult acute lymphoblastic leukemia. Manuel Alejandro Alejandro Cruz Martínez Received Received
  3335-SUN The effect of steroid-induced hyperglycemia in early mortality during induction treatment of Philadelphia-negative acute lymphoblastic leukemia in Latino young adults Daniel Enriquez-Vera Jr Received Received
  3336-SUN Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia Yile Zhou Received Received
  3337-SUN Treatment of pediatric patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with obecabtagene autoleucel (obe-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy: Preliminary findings from the Phase Ib/I Sara Ghorashian Received Received
  3338-SUN Comparison of simulated exposure of inotuzumab ozogamicin with and without dose capping in overweight and obese patients with relapsed/refractory acute lymphoblastic leukemia Nathan Braniff Received Received
  3339-SUN Optimal therapy for pediatric B-ALL in first relapse: Comparative effectiveness of blinatumomab to hematopoietic cell transplantation versus CD19 CAR T cell therapy Regina M. Myers Received Received
  3340-SUN Outcome after relapse in older patients with Philadelphia Chromosome–Negative B-cell ALL treated with inotuzumab ozogamicin and low-dose chemotherapy in first-line therapy: A graall study Perrine Moyer Received Received
  3341-SUN Immunological responses to blinatumomab treatment in B-acute lymphoblastic leukaemia (B-ALL) patients - australasian leukemia and lymphoma group ALL08 blam study David Ritchie Received Received
  3342-SUN First promising results in younger adult patients ( Fabian Lang Received Received
  3343-SUN SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes Anjali Sunder Advani Received Received
  3344-SUN Toxicity of reduced dose versus standard dose pegaspargase in adolescents and young adults with acute lymphoblastic leukemia Megan Fleming Received Received
  3345-SUN Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study Ibrahim Aldoss Received Received
  3346-SUN Treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia using hypercvad with ponatinib is associated with excellent survival with selective use of blinatumomab and allogeneic hematopoietic cell transplantation Jiyong Ahn Received Received
  3347-SUN Efficacy and safety of melphalan/TBI-based conditioning regimens (MCAC/TCAC) for autologous HSCT in adult acute lymphoblastic leukemia: A multicenter, prospective cohort study Xinhui Zheng Received Received
  3348-SUN Inotuzumab ozogamicin leads to high rates of measurable residual disease negativity for patients with B-cell acute lymphoblastic leukemia in morphologic remission Hannah Goulart Received Received
  3349-SUN Auto-HSCT combined with blinatumomab as an allo-HSCT-sparing strategy in newly diagnosed B-ALL: Phase II trial results Zihao Wang Received Received
  3350-SUN Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab Hannah Goulart Received Received
  3351-SUN Inotuzumab ozogamacin in refractory or 1st or greater relapse of pediatric B-ALL as bridge to cure: A single center experience Waitman Aumann Received Received
  3352-SUN High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study Karamjeet Sandhu Received Received
  3353-SUN Deeper remission achievement and longer leukemia-free survival with inati-cel as consolidation therapy in allogeneic transplant-ineligible adolescent and adult patients with B-ALL Yuhua Li Received Received
  3354-SUN Venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab for the upfront treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), Results from a Phase 1B study Jessica Leonard Received Received
  3355-SUN Two decades of risk directed therapy for childhood acute lymphoblastic leukemia in a resource limited setting: Lessons from a modified st. jude total XV protocol Mayada Abu Shanap Sr Received Received
  3356-SUN Ibrutinib plus blinatumomab in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Results of A phase 2 study Brian A Jonas Received Received
  3357-SUN Real world outcomes of asciminib in relapsed/refractory Philadelphia chromosome positive B-ALL and blast Phase CML Kriti Gera Received Received
  3358-SUN Safety and efficacy of low-intensity chemotherapy combined with sequential blinatumomab and inotuzumab ozogamicin immunotherapy in newly diagnosed B-ALL patients unfit/fit-declined for intensive chemotherapy: A prospective, open-label, single-arm Phase II Shenhao Liu Received Received
  3359-SUN Phase 2 study of brexu-cel in minimal residual disease positive B-cell acute lymphoblastic leukemia Bijal Shah Received Received
  3360-SUN Single-cell RNA-sequencing of cerebrospinal fluid reveals transcriptional divergence of leukemia cells from bone marrow in pediatric B-ALL Samuel Wong Received Received
  3361-SUN Mitochondrial hyperactivity predicts chemotherapy relapse and venetoclax resistance in pediatric B-cell acute lymphoblastic leukemia Jingliao Zhang Received Received
  3362-SUN Simvastatin targets the cholesterol–bile acid axis to improve ALL survival by remodeling the metabolic microenvironment Junyu Wang Received Received
  3363-SUN Evaluating flow cytometry (FC) and next generation sequencing (NGS) for assessing minimal residual disease (MRD) and B-cell aplasia (BCA) in children, adolescents and young adults (CAYA) with B-cell acute lymphoblastic leukemia (B-ALL) Chelsea O´Koren Received Received
  3364-SUN AP-3 targets the mrgbp/Tip60/MYC axis to exert potent anti T-ALL effects in a Notch1 independent manner Fenglin Li Received Received
  3365-SUN KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel) Jessica Leonard Received Received
  3366-SUN Synergistic integration of CAR-T cell pharmacokinetics and NGS-MRD evolution enables precision risk stratification in relapsed/refractory B-cell acute lymphoblastic leukemia Runxia Gu Received Received
  3367-SUN Adverse genetic alterations and their prognostic impact in Chinese b-ALL patients with DUX4 rearrangement Xiayu Xia Received Received
  3368-SUN Backtracking the cellular origins of ETV6::RUNX1 childhood acute lymphoblastic leukemia in cord blood (ReCord study) Adam J de Smith Received Received
  3369-SUN Immunophenotypic identification of ETP-like T-ALL using CD1a, CD165 and CD184. Monica Singh Received Received
  3370-SUN Next-generation sequencing as a powerful tool for measurable residual disease assessment in pediatrics: Identifying time points of true remission David McCall Received Received
  3371-SUN Targeting ß-catenin nuclear export and protein degradation in high-risk acute lymphoblastic leukemia Jodi Forward Received Received
  3372-SUN The impact of first line tyrosine kinase inhibitors (TKI) on the development of resistance mutations in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) Virginia Tan Received Received
  3373-SUN Impact of IKZFplus status and ABL1 kinase domain mutations in patients with newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia receiving imatinib and chemotherapy followed by allogeneic SCT within GMALL07/03 Heike Pfeifer Received Received
  3374-SUN IDH1/2 mutations predict a distinct high-risk subset in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia Lijuan Hu Received Received
  3375-SUN Specific environmental factors are associated with increased rates of invasive mucormycosis infections in patients with acute leukemia and myelodysplastic syndrome Thomas Kuczmarski Received Received
  3376-SUN Molecular mutations may influence cytokine expression and critical illness subphenotyping in septic patients with Acute Myeloid Leukemia Lukas Ronner Received Received
  3377-SUN Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML Daniel T Peters Received Received
  3378-SUN Fractionated gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) based induction chemotherapy is safe and highly effective for newly diagnosed favorable risk AML. Brenda Sofia Castillo Received Received
  3379-SUN Impact of social determinants of health on access to molecular targeted therapy in AML and MDS: A real-world analysis Pierantonio Russo Received Received
  3380-SUN Beyond age: Genomic features and treatment outcomes in older versus younger adults with Acute Myeloid Leukemia Hardik Dand Received Received
  3381-SUN Pulmonary complications in acute myelogenous leukemia in post allogenic hematopoietic stem cell transplant period and yield of bronchoalveolar lavage and biopsy- single center experience Aneela Majeed Received Received
  3382-SUN Only young age and genetics retain prognostic value for 2-year relapse-free survival in AML Wissam Mahrez Received Received
  3383-SUN Treatment initiation pattern, ramp-up measures and management of AML patients treated in real life in Italy with venetoclax+azacitidine - first interim analysis of the prospective vero study Marta Ubezio Received Received
  3384-SUN Interim analysis after 3 months of AML patients treated with venetoclax + azacitidine – first effectiveness and safety data from the prospective real world vero study Elisabetta Todisco Received Received
  3385-SUN Real-world treatment patterns and outcomes among patients with newly diagnosed NPM1-mutated acute myeloid leukemia in the United States Kuo-Kai Chin Received Received
  3386-SUN Differences in outcomes with intensive chemotherapy in AML patients according to mutational status – recent real-world results Joseph Brandwein Received Received
  3387-SUN Central nervous system involvement in acute myeloid leukemia: A national analysis of inpatient outcomes using the 2022 national inpatient sample Inae Park Received Received
  3388-SUN Extramedullary disease in AML: A high-risk feature beyond ELN 2022 classification Yael Morgenstern Received Received
  3389-SUN Real-world survival of IDH-mutant patients in China before IDH-inhibitor era: A multicenter retrospective study from anhui cooperative hematology group(ACHG) Enbo Chen Received Received
  3390-SUN Comparable remission rates in therapy-related and myelodysplasia-related Acute Myeloid Leukemia (AML) versus de novo AML treated with azacitidine and venetoclax: A contemporary real-world study. Zahra AlHaj Issa Sr Received Received
  3391-SUN Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation Hongming Zhu Received Received
  3392-SUN Unmasking myeloid sarcoma: A SEER database study of an underrecognized malignancy Berkha Rani Received Received
  3393-SUN Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors Omar Alzarkali Received Received
  3394-SUN Impact of induction response and co-mutations on transplant outcomes in AML with myelodysplasia-related gene mutations: A multicenter retrospective study Yang Cao Received Received
  3395-SUN Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion Fang Zheng Received Received
  3396-SUN Spliceosome mutations in AML: Prevalence, clinical features, and treatment outcomes in a contemporary cohort Yomna Abu-Farsakh Received Received
  3397-SUN Treatment intensity may alter the prognostic impact of baseline co-mutations in newly diagnosed FLT3-ITD AML treated with FLT3 inhibitor-based therapy Sankalp Arora Received Received
  3398-SUN Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study Gaspar Aspas Requena Sr Received Received
  3399-SUN ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT) Jennifer Marvin-Peek Received Received
  3400-SUN Co-mutation of BCOR and BCORL1 was associated with favorable outcome in the adverse risk patients with Acute Myeloid Leukemia Shunjie Yu Received Received
  3401-SUN Real-world overall survival in patients with Acute Myeloid Leukemia treated with ivosidenib plus azacitidine in the USA: Trinetx-based analysis Joshua Zeidner Received Received
  3402-SUN Molecular profile linked to resistance to hypomethilating agents plus venetoclax does not predict outcome in secondary Acute Myeloid Leukemia patients receiving CPX-351 induction. Carola Riva Received Received
  3403-SUN Central nervous system involvement in pediatric Acute Myeloid Leukemia: A comprehensive report from the AML-BFM group Katje Helene Kleyer Received Received
  3404-SUN Genetic risk stratification in adults with AML receiving venetoclax-based intensive therapy: A real-world study Yanmin Zhao Received Received
  3405-SUN Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia Vanthana Bharathi Received Received
  3406-SUN Single-center experience with mitoxantrone hydrochloride liposome-based therapy for patients with myeloid sarcoma Wenjuan He Received Received
  3407-SUN FLAG/VEN as a frontline induction therapy for AML: A multi-centre experience of Anthracycline free approach from India Mohd Rizwan Shaikh Received Received
  3408-SUN Evaluation of cytarabine consolidation dosing in older adult patients with Acute Myeloid Leukemia Pooja S. Kumar Received Received
  3409-SUN Treatment of Acute Myeloid Leukemia patients over the age of 80 with venetoclax and azacitidine Yakir Moshe Received Received
  3410-SUN Safety and outcomes of venetoclax initiation in patients with AML and hyperleukocytosis Hiba Khan Received Received
  3411-SUN Intensive chemotherapy bridging to allogeneic hematopoietic cell transplant in relapsed or refractory Acute Myeloid Leukemia Jose Tinajero Received Received
  3412-SUN Cardiopulmonary complications of DIC in AML: A nationwide inpatient study Ridda Khattak Received Received
  3413-SUN Real-world validation of the molecular prognostic risk signature in acute myeloid leukemia treated with hypomethylating agents plus BCL-2 inhibitor. Jonathan Andreadakis Received Received
  3414-SUN Evaluating optimal HCT bridging strategies in TP53-mutated myeloid neoplasms Akhil Rajendra Received Received
  3414-SUN Use of G-CSF in AML patients with febrile neutropenia: Friend or foe? Zaid Zahid Received Received
  3415-SUN A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701) Geoffrey L. Uy Received Received
  3416-SUN Venetoclax-azacitidine in combination with chidamide and CAG versus daunorubicin and cytarabine in newly diagnosed AML Lei Lv I Received Received
  3417-SUN Safety, tolerability and efficacy of mesutoclax to treat patients with myeloid malignancies Qian Jiang Jr Received Received
  3418-SUN Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study Martha L. Arellano Received Received
  3419-SUN Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication Pierre Bories Received Received
  3420-SUN Final results of a phase I/II trial of palbociclib and CPX-351 in patients with Acute Myeloid Leukemia Chana Peysin Received Received
  3421-SUN Odyssey: A first-in-human study of the aldehyde dehydrogenase (ALDH) inhibitor abd-3001 in patients with refractory/relapsed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) Mael Heiblig Received Received
  3422-SUN Pivekimab sunirinine (PVEK) combined with FLAG-IDA for medically fit adults with untreated adverse-risk Acute Myeloid Leukemia (AML) or other high-grade myeloid neoplasms (NCT06034470) Jacob Appelbaum Received Received
  3423-SUN Phase 2 study of SLS009 in combination with azacitidine and venetoclax for relapsed/refractory AML with MDS-related changes (AML-MR) after prior venetoclax treatment Joshua Zeidner Received Received
  3424-SUN Preliminary results from RIVER-81, a phase 2 study of romaciclib (RVU120) + venetoclax in patients with acute myeloid leukemia failing first-line venetoclax + hypomethylating agent (HMA) Pau Montesinos Received Received
  3425-SUN Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708 Ibrahim Aldoss Received Received
  3426-SUN Allogeneic CAR-T therapy AVC-201 in AML positive for CD123 Martin Wermke Received Received
  3427-SUN Preliminary Results of A phase 1 study of the safety and tolerability of the combination of revumenib (REV) with gilteritinib (GILT) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Uma Borate Received Received
  3428-SUN Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML Ghayas C. Issa Received Received
  3429-SUN Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are inel Elias Jabbour Received Received
  3430-SUN A first-in-human phase 1 Study of cbx-250, a TCR-mimetic bispecific T cell engager targeting CG1/ HLA-a*02:01 in patients with relapsed or refractory AML, HR-MDS, or CMML (CROSSCHECK-001) (Trial in Progress) Shaliny Kushwaha Received Received
  3431-SUN Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML) Evan C. Chen Received Received
  3432-SUN Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged = 60 years old Emily Curran Received Received
  3433-SUN Phase I/II clinical trial of bortezomib in combination with CPX-351 for the treatment of newly-diagnosed TP53-mutated Acute Myeloid Leukemia (NCT07008638) Joseph Norton Received Received
  3434-SUN Prognostic impact of cognitive and other impairments in older adults with acute myeloid leukemia (AML) participating in a geriatric assessment-guided treatment selection trial Vijaya Raj Bhatt Received Received
  3435-SUN Outcomes of mecom rearranged AML undergoing intensive chemotherapy in the NCRI AML17 and AML19 trials. Mike Dennis Received Received
  3436-SUN Molecular subtype combined with peripheral blast clearance rate to optimize the treatment of newly diagnosed Acute Myeloid Leukemia: Interim analysis of the multicenter, Phase II study (IA+X 2024) Yunxiang Zhang Received Received
  3437-SUN Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study Laura Cicconi Received Received
  3438-SUN Elderly Acute Myeloid Leukemia (AML) with NPM1 or FLT3-ITD mutated: Is venetoclax the game changer also in fit patients? a real-life retrospective analysis by the rete ematologica lombarda Erika Borlenghi Received Received
  3439-SUN Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib Eunice Sue Wang Received Received
  3440-SUN CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study Andre C. Schuh Sr Received Received
  3441-SUN Oral azacitidine maintenance improved survival for t-AML or AML-MR patients in first remission after CPX-351 and not eligible to HSCT Caroline Fileni Received Received
  3442-SUN Clinical outcome of patients with TP53 AML treated with non-intensive vidaza-venetoclax chemotherapy : Venaura retrospective regional multicenter study. Emmanuelle Tavernier Received Received
  3443-SUN ALIDHE: An ongoing open-label phase 3b study investigating ivosidenib with azacitidine in clinical practice in adult patients with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) ineligible for intensive induction ch Paresh Vyas Received Received
  3444-SUN Palbociclib combined with venetoclax and azacitidine in NUP98-rearranged pediatric AML: A multicenter phase II trial demonstrating durable remission and survival benefit Huan Xu Received Received
  3445-SUN Impact of G-CSF in AML patients treated with venetoclax and azacitidine: A dataml registry study Leopoldine Lapierre Received Received
  3446-SUN Epigenetic priming improves survival for pediatric Acute Myeloid Leukemia: Results from the multicenter randomized AML16 trial Tanja Gruber Received Received
  3447-SUN Mitoxantrone liposome, subcutaneous cytarabine and G-CSF (CMG) combined with venetoclax as first-line treatment in secondary Acute Myeloid Leukemia (sAML) or elderly AML patients: A multicenter, prospective, single-arm clinical trial with concurrent contr Xiaoqian Xu Received Received
  3448-SUN Early real-world experience with revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability Umar Iqbal Received Received
  3449-SUN Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS Weiyan Zheng Received Received
  3450-SUN Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia:a phase III, prospective, multicenter, randomized controlled trial ZePing Zhou Received Received
  3451-SUN Venetoclax combined with three-day multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction treatment for patients with de novo acute leukaemias of ambiguous lineage Xingli Zhao Received Received
  3452-SUN Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study Xin Chen Received Received
  3453-SUN A study on the efficacy, safety and mechanism of venetoclax combined with CAR-T targeting CLL1 in the treatment of Acute Myeloid Leukemia Bing Wang Received Received
  3454-SUN Efficacy and safety of clia plus venetoclax as salvage therapy for relapsed or refractory Acute Myeloid Leukemia Sarah Sertich Received Received
  3455-SUN Ivosidenib in refractory or relapsed IDH1-mutated Acute Myeloid Leukemia patients in real life settings: The ivoobs observational study from the french AML intergroup ALFA/filo Mael Heiblig Received Received
  3456-SUN Venetoclax plus mitoxantrone hydrochloride liposome and Azacitidine As first-line treatment for adults with Acute Myeloid Leukemia Weiwei Qi Received Received
  3457-SUN Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment Caitlin Rausch Received Received
  3458-SUN A prospective clinical study of venetoclax plus azacitidine for the maintenance treatment of post-remission Acute Myeloid Leukemia Jinqiang Guo Received Received
  3459-SUN Outcomes in patients with newly diagnosed Acute Myeloid Leukemia with KMT2A rearrangement treated with cladribine, idarubicin, cytarabine (CLIA) with or without venetoclax Niranjan Khaire Received Received
  3460-SUN Outcomes with ATO/ATRA based regimen in apml - steroid induced toxicities are a concern in LMICs Hasmukh Jain Received Received
  3461-SUN Post-transplant maintenance with revumenib in children with HOX-driven AML Branko Cuglievan Received Received
  3462-SUN Thioguanine and decitabine can overcome hypomethylating agent resistance in patients with advanced myeloid malignancies Sunil Iyer Received Received
  3463-SUN Efficacy and prognosis of venetoclax combined with the 3+7 regimen in fit AML: A propensity score-matched cohort study Li Hui Received Received
  3464-SUN A novel strategy to circumvent venetoclax resistance in relapsed/refractory Acute Myeloid Leukemia Huafeng Wang Received Received
  3465-SUN Identifying patients at risk of prolonged neutropenia and enhanced risk of complications during AZA-VEN induction for AML Jules Higue Received Received
  3466-SUN A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03) Eric Huselton Received Received
  3467-SUN AML maturation stages associate with disease-permissive and immunosuppressive effects in newly diagnosed AML patients: An analysis at the single-cell level Jana Ihlow Received Received
  3468-SUN Abnormal metabolic activation of CD8+ t cells correlates with poor prognosis in acute myeloid leukemia Jianing Tang Received Received
  3469-SUN Molecular and clinical characteristics of NUP98 rearrangements and their therapeutic responses in 6,000 patients with hematologic malignancies Bingqing Huang Received Received
  3470-SUN TP53 inactivation confers resistance to the menin inhibitor revumenib in Acute Myeloid Leukemia Jeevitha D´Souza Received Received
  3471-SUN Developing artificial intelligence-based transcriptomic signature for selecting patients with HOXA-MEIS1 pathway abnormalities for the treatment with menin inhibitors Maher Albitar Received Received
  3472-SUN NRAS mutation drives excessive netosis and differentiation syndrome in acute promyelocytic leukemia Xiaojing Lin Sr Received Received
  3473-SUN Improving karyotype success for myelomatch: Evidence-based culturing optimization for rapid AML screening - an NCI myelomatch and SWOG report Xiaoyu QU Received Received
  3474-SUN DNA methylation profiling identifies two epigenetic subgroups with prognostic implications in pediatric acute promyelocytic leukemia: The JCCG study, JPLSG AML-P05 Etsuko Murayama Received Received
  3475-SUN Transcriptomic subclasses of KMT2A and NUP98 gene fusions in adolescent and adult Acute Myeloid Leukemia Jianfeng Li Received Received
  3476-SUN ESAM is functionally involved in the activity of cancer stem-like cells in human acute myeloid leukemia Henyun Shi Received Received
  3477-SUN SNAI2 orchestrates a hypo-oxidative mitochondrial phenotype with elevated FAO dependence in acute myeloid leukemia Xuntao Lai Received Received
  3478-SUN The impact of monocytic phenotype and NPM1-mutation status in Acute Myeloid Leukemia when treated with traditional induction chemotherapy compared to azacitidine and venetoclax Michael K Jones Received Received
  3479-SUN Integrating EVI1 expression into prognostic models for MDS: Insights from IPSS-R and IPSS-m subgroup analyses Xiaohang Ma Received Received
  3480-SUN Computational profiling of predicted neoantigen landscape reveals differential immunogenicity at AML diagnosis and relapse Othmane Jadi Received Received
  3481-SUN CD132 expression promotes AML aggressiveness via the JAK-STAT signaling pathway Yiyang Ding Received Received
  3482-SUN A baseline transcriptomic signature predictive of clinical response to menin inhibitors in AML : The PRE-men retrosprospective Study Vincent Alcazer Received Received
  3483-SUN Real-life CD34+CD38- leukemic stem cell (LSC) flow quantification in adult AML at diagnosis independently predicts survival of intensively but not AZA-VEN treated patients: A study of prospective observational ALFA-PPP acute leukemia french association Adriana Plesa Sr Received Received
  3484-SUN EV-mirnas predict outcomes in pediatric AML: A pilot study Abdullah Alhumaid Received Received
  3485-SUN Which molecular patterns of high-risk myeloid malignancies are concordantly identified using two machine learning algorithms? Tariq Kewan Received Received
  3486-SUN Integrative analysis of the interplay between peripheral immune landscape and leukemic blast adaptation in Acute Myeloid Leukemia Ela Cerovska Received Received
  3487-SUN Identifying treatment response in AML through a multi-omics classifier of malignant cell states Yang Song Received Received
  3488-SUN A defined culture model for ex vivo expansion of primary AML cells preserves leukemic stem cells and clonal architecture for functional and therapeutic studies Charyguly Annageldiyev Received Received
  3489-SUN Eccdna-encoded LIPIN1 drives DGAT1-dependent lipid droplet biogenesis to promote Acute Myeloid Leukemia progression and chemoresistance Wancheng Liu Received Received
  3490-SUN Dynamics of leukemic blast and immune cell populations in Acute Myeloid Leukemia Sadiksha Adhikari Received Received
  3491-SUN The laminin receptor integrin a7ß1 marks a highly migratory cell population and correlates with poor prognosis in Acute Myeloid Leukemia. Saskia Simone Rudat Received Received
  3492-SUN Changing dogma regarding mutation primacy in acute myelogenous leukemia : Protein expression supersedes mutation status Steven Kornblau Received Received
  3493-SUN Prospective clinical validation of MAC-scoring as an affordable, real-time biomarker for HMA/venetoclax response in AML Simon Renders Received Received
  3494-SUN Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia Eduardo de Camargo Magalhaes Received Received
  3495-SUN VIP, a novel phagocytosis checkpoint in TP53-mutated Acute Myeloid Leukemia Zihan Chen Received Received
  3496-SUN Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia Jeff Justin Aguilar Received Received
  3497-SUN Novel AML specific splice junction evaluation identifies ubc and DMBT1 as top proteins of clinical and therapeutic relevance in pediatric Acute Myeloid Leukemia Ryanne June Mulligan Received Received
  3498-SUN Machine learning-powered integration of global proteomics and ex vivo sensitivity unveils a protein signature predictive of treatment success to AML therapy: Validation in patients treated with FHD-286, a SMARCA2/4 dual inhibitor James Sorrentino Received Received
  3499-SUN 1,200+ U2AF1 mutations reveal distinct clinicobiological features of the S34/Q157 co-mutation subgroup Yujiao Jia Received Received
  3500-SUN Dogs with acute leukemia have shared and unique genetic mutations compared to human acute leukemia Robert Adam Harris Received Received
  3501-SUN Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratefication - an NCI myelomatch and SWOG report Min Fang Received Received
  3502-SUN Functional plasma cell signatures mark AML chemotherapy responders: Evidence from immune niche profiling Makayla Pardo Received Received
  3503-SUN A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia Sara Nofal Received Received
  3504-SUN A patient-derived CRISPR platform reveals selective dependencies in Acute Myeloid Leukemia Aneesha Nath Received Received
  3505-SUN Cholesterol biosynthesis-related genes reveal new opportunities for risk stratification and treatment in Acute Myeloid Leukemia Maria Luiza Salustiano-Bandeira Received Received
  3506-SUN 17p cytogenetic changes in TP53-mutated AML David M. Mueller Received Received
  3507-SUN Determining sensitivity to FLT3 inhibitors prior to therapy in FLT3 mutant acute myelogenous leukemia Salvador Martinez-Bartolome Received Received
  3508-SUN Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax Aarya Murali Sr Received Received
  3509-SUN Multimodal epigenetic microarray classifies AML, MDS and controls using peripheral blood Miriam Neaman Received Received
  3510-SUN Clinical and molecular characterization of pure erythroid leukemias and sarcomas driven by nfia::CBFA2T3 Benjamin J. Huang Received Received
  3511-SUN Targeting CCL3+mono like LSC overcomes chemotherapy resistance in NPM1 mutant AML Zhao Yin Received Received
  3512-SUN Comparable efficacy of CR, CRh, and CRi in pediatric acute myeloid leukemia: A report from the Japan Children´s Cancer Group Shota Kato Received Received
  3513-SUN A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia Annalisa Condorelli Received Received
  3514-SUN A novel intercontinental external quality assessment program for flow cytometric measurable residual disease assessment in pediatric AML Michael N. Dworzak Received Received
  3515-SUN Monitoring of CNS involvement in AML using ultrahigh-sensitivity next-generation sequencing of cell-free DNA Henri C. Hupe Received Received
  3516-SUN A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial Chiara Sartor Received Received
  3517-SUN Comprehensive profiling of the bone marrow microenvironment reveals an exhausted immune signature associated with tumor burden in Acute Myeloid Leukemia Nicole Fincato Jr Received Received
  3518-SUN Droplet digital PCR improves measurable residual disease detection and predicts relapse in KMT2A-rearranged leukemia after allogeneic hematopoietic stem cell transplantation: A prospective study Ya Luo Received Received
  3519-SUN Type and degree/number of immunophenotypic abnormalities refine multiparameter flow cytometry (MFC)-based measurable residual disease (MRD) testing in adults allografted for Acute Myeloid Leukemia (AML) in morphologic remission Calvin M. Le Received Received
  3520-SUN The role of MYD88L265P in extranodal manifestations of B-cell non-Hodgkin lymphomas Alisa Maier Received Received
  3521-SUN Clonal hematopoiesis in t-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution Chong Wei Received Received
  3522-SUN A single-cell co-expression score of MYC and BCL2 identifies high-risk BCR-addicted DLBCL benefiting from polatuzumab vedotin in the POLARIX trial Anand Devaprasath Jeyasekharan Received Received
  3523-SUN Tracing the evolution of clonal T cell responses in LGL leukemia with single-cell whole genome sequencing Aino Elina Häkkinen Received Received
  3524-SUN Molecular distinctiveness of duodenal-type follicular lymphoma revealed by integrated multi-omic analysis Hisashi Hashimoto Received Received
  3525-SUN Developing artificial intelligence-based transcriptomic signature for the diagnosis of dark zone lymphoma in patients without MYC gene rearrangement Andrew Ip Received Received
  3526-SUN Impact of ALK fusion variants and genetic profiles on prognosis in Chinese pediatric patients with ALK-positive anaplastic large cell lymphoma Yang Li Received Received
  3527-SUN Single-cell profiling of natural killer T-cell lymphoma reveals stratified immune features and therapeutic strategies Yi Cao Received Received
  3528-SUN IRF2BP2 mutations activate IL-1ß-mediated NF-?B signaling and confer actionable anti-IL-1ß sensitivity in DLBCL Areya William Tabatabai Received Received
  3529-SUN Hi-c FFPE sequencing analysis is highly concordant with FISH and detects additional variants informing diagnosis and treatment in diffuse large B-cell lymphoma Ken H. H. Young Jr Received Received
  3530-SUN IFN-?-induced CD4+ CADM1+ T cells emerged as malignancy-progressive biomarkers in EBV NK/T lymphoproliferative disorders and potential drivers of malignant expansion in AITL Qinhuan Luo Received Received
  3531-SUN Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies Fnu Amisha Received Received
  3532-SUN MAP2K1 and MAP2K2 genes alterations in hairy cell leukemia and hairy cell leukemia variant. Evgeny Arons Received Received
  3533-SUN Multi-omics profiling of the gut Microbiota–Metabolism–Immunity axis reveals predictive biomarkers of treatment response and survival in diffuse large B-cell lymphoma Lixia Sheng Received Received
  3534-SUN RAG1/2 expression in follicular lymphoma marks candidate precursor cells of high-grade B cell lymphoma with MYC and BCL2 rearrangements Stefano Casola Received Received
  3535-SUN Combining next-generation sequencing and optical genome mapping techniques to analyze genomic abnormalities in marginal zone lymphoma Xi Zhang Received Received
  3536-SUN Germline osmr mutation drives familial unicentric castleman disease with osteosclerosis Miaoyan Zhang Received Received
  3537-SUN Dissecting clonal hematopoiesis in diffuse large B-cell lymphoma through multi-compartment genomic profiling Nawar Maher Received Received
  3538-SUN Transcriptome sequencing of Hodgkin lymphoma Hodgkin and reed-stenberg cells reveals escape from NK cell recognition and an unfolded protein response Isabella Y Kong Received Received
  3539-SUN Integrated single-cell and spatial analysis identifies T cell exhaustion and adhesion signatures in early follicular lymphoma transformation Sofia Huerga Received Received
  3540-SUN Genetic evolution of Waldenstroem macroglobulinemia across disease stages Saurabh Zanwar Received Received
  3541-SUN Prognostic value of minimal residual disease detection by circulating tumor DNA in Hodgkin lymphoma. Cristina Teresa Fuentes-Morales Sr Received Received
  3542-SUN Genomic and immune determinants of response to CD3 x CD20 bispecific antibodies in aggressive B-cell lymphoma XI Yang Received Received
  3543-SUN Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom´s macroglobulinemia. Zachary R Hunter Received Received
  3544-SUN Discovery of an undocumented pattern of intron retention that is abundant in healthy B-cells and circumvented in Waldenstrom´s macroglobulinemia impacting genes driving cellular growth and survival Zachary R Hunter Received Received
  3545-SUN The predictive value of mosaic chromosomal alterations for lymphoid malignancies varies by monoclonal B-cell lymphocytosis status Rosalie Griffin Received Received
  3546-SUN Characterizing the biological function FOXO3 and its role as a predictive biomarker in HTLV-1 related adult T-cell leukemia-lymphoma Georgios Pongas Received Received
  3547-SUN Evaluating targeted long-read sequencing as a diagnostic tool for burkitt lymphoma Giuliano Aldo Banco Received Received
  3548-SUN Circulating tumor DNA-based minimal residual disease assessment predicts progression-free survival in diffuse large B-cell lymphoma: A systematic review and meta-analysis Faiza Khan Received Received
  3549-SUN Lisocabtagene maraleucel (liso-cel) demonstrates superior efficacy across inflammatory risk subgroups in second-line (2L) large B-cell lymphoma (LBCL): A retrospective analysis of the TRANSFORM study Abood Okal Received Received
  3550-SUN From mechanistic synergy to clinical breakthrough: Updated results from a phase II Trial of HD-MTX, selinexor, and zanubrutinib in CNS lymphoma Li Li Received Received
  3551-SUN Baseline intratumoral CD4? T-cell abundance and frequency correlates with durable clinical response to acalabrutinib, venetoclax, and obinutuzumab (AVO) treatment in Mantle Cell Lymphoma Mingzeng Zhang Received Received
  3552-SUN Multimodal single-cell and spatial analyses reveal a distinct immune ecosystem in pediatric classic Hodgkin lymphoma Shinichiro Oshima Received Received
  3553-SUN Trends in muscle and fat metrics and their association with outcomes following CAR T-cell therapy in older adults with non Hodgkin lymphoma. Gabriel Francisco Pereira Aleixo Received Received
  3554-SUN Thyroid hormones enhance the responsiveness of T-cell lymphomas to romidepsin María Mercedes Debernardi Received Received
  3555-SUN A unified spatial & molecular atlas of anatomically restricted large B-cell lymphomas defines stereotyped cell ecosytems Troy Noordenbos Received Received
  3556-SUN Single-cell atlas of circulating immunity identifies shared specific DLBCL signatures predicting response to R-CHOP and CD19 CAR-t therapies Sicong Zhang Received Received
  3557-SUN The first integrated proteomic and lipidomic profiling reveals immune, metabolic, and membrane remodeling signatures in patients experiencing cytokine release storm (CRS) undergoing CAR-T cell therapy and serves as a new predictive and prognostic factor. Magdalena Kucia Received Received
  3558-SUN Ruxolitinib increases immunogenicity and primes the tumor microenvironment for immune checkpoint blockade in 9p24.1 amplified lymphomas Seda S. Tolu Received Received
  3559-SUN Spatial profiling of the bone marrow microenvironment in patients with IgM gammopathies reveals a T cell–Enriched tumor niche associated with asymptomatic waldenstrom macroglobulinemia progression Kane Foster Received Received
  3560-SUN Clinical impact of untargeted baseline plasma metabolomics in newly diagnosed diffuse large B-cell lymphoma Riccardo Dondolin Received Received
  3561-SUN Integrated clinical and radiomic PET-FLIPI score for risk stratification in newly diagnosed follicular lymphoma Stefano Luminari Sr Received Received
  3562-SUN Lactate promotes DLBCL progression via NAT10/ldha axis and immune suppression Xiaodong Guo Received Received
  3563-SUN Integrative analysis of the tumour immune microenvironment of breast implant-associated anaplastic large cell lymphoma using multi-omics Criselle Dsouza Received Received
  3564-SUN Machine learning models improve survival prediction in DLBCL: Analysis from the goya trial Shuna Yao Received Received
  3565-SUN Phenotype and functional state of endogenous T-cells support T-cell engager therapy in the post-CAR T therapy setting Valerie Robinson Received Received
  3566-SUN Exposure to epcoritamab is associated with improved T-cell functionality and dynamic changes in CD8+ T-cells in diffuse large B-cell lymphoma: Insights from epcore NHL-6 Gregory P. Takacs Received Received
  3567-SUN Single-cell metabolic profiling of T cells identifies a fitness signature associated with early CAR T failure in large B cell lymphoma Inna Y Gong Received Received
  3568-SUN Comparative immune profiling reveals T-cell exhaustion in EBV+ monomorphic PTLD vs. immunocompetent DLBCL Aleksandr Lazaryan Received Received
  3569-SUN Post-treatment outcomes of TP53-mutant Mantle Cell Lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): Durable responses in patients who achieve complete remissions with undetectable MRD Sean Edward Healton Received Received
  3570-SUN Nemtabrutinib in participants with relapsed or refractory follicular lymphoma: Updated efficacy and safety from cohort g of the phase 2 bellwave-003 study Wojciech Jurczak Received Received
  3571-SUN A phase II investigator-initiated frontline trial of evorpacept (ALX148), lenalidomide and rituximab for high tumor burden indolent b-cell non-Hodgkin lymphoma Paolo Strati Received Received
  3572-SUN Impact of treatment facility type on survival outcomes in mantle cell lymphoma: A 20-year NCDB analysis Eleftheria Atalla Received Received
  3573-SUN Transformed Waldenstroem macroglobulinemia is associated with poor outcomes and chemorefractory disease Jennifer Kimberly Lue Received Received
  3574-SUN Phase II study of bendamustine, rituximab, and venetoclax (BR-VEN) for the front-line treatment of Mantle Cell Lymphoma (MCL) in patients =60 years old; Updated survival and minimal residual disease (MRD) analysis of precog PrE0405 Craig A Portell Received Received
  3575-SUN Outcomes from the Multicenter ACCRU-LY-1804/CARiBOU (Cytarabine, Acalabrutinib and Rituximab integrated with Bortezomib-based Outpatient therapy) Trial in 1st line Mantle Cell Lymphoma Stephen Douglas Smith Received Received
  3576-SUN Plasma protein ADAMTS8 as a minimally invasive favorable prognostic biomarker in mantle cell lymphoma Ingrid Glimelius Received Received
  3577-SUN Venetoclax or pirtobrutinib in relapsed/refractory Waldenstroem macroglobulinemia: Clinical and molecular predictors and sequencing implications Alberto Guijosa Received Received
  3578-SUN Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the phase 3 ECHO trial Chan Cheah Received Received
  3579-SUN Socio-clinical determinants and demographic disparities of survival in splenic marginal zone lymphoma: A retrospective cohort study Manas Pustake Received Received
  3580-SUN Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial Bing Xu Received Received
  3581-SUN Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide Christine Ryan Received Received
  3582-SUN Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes by age Christina Poh Received Received
  3583-SUN Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenstroem macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study Constantine S. Tam Received Received
  3584-SUN Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study Romain Guieze Received Received
  3585-SUN Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group Mariana Bastos-Oreiro Received Received
  3586-SUN Real-world treatment and outcomes of Mantle Cell Lymphoma in Latin America: A multinational cohort analysis Adriana Bornacelly Received Received
  3587-SUN Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton´s tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study Yuqin Song Received Received
  3588-SUN Efficacy and safety of long-term odronextamab treatment in patients with relapsed/refractory follicular lymphoma: 3-year follow-up from the Phase 2 ELM-2 study Jose Villasboas Bisneto Received Received
  3589-SUN Heterogeneous TP53 mutation subtypes define prognostic classification in Mantle Cell Lymphoma Shuozi Liu Received Received
  3590-SUN Genomic characterization uncovers molecular subtypes in Mantle Cell Lymphoma Changjian Yan Received Received
  3591-SUN Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis Ryan C Lynch Received Received
  3592-SUN Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study Ana Marin Niebla Received Received
  3593-SUN Prognostic significance of clinical risk models and genomic alterations in Waldenstroem macroglobulinemia before or after BTK inhibitor era Weihao Chen Received Received
  3594-SUN EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171) Jan Fagerberg Received Received
  3595-SUN Clinical activity and immune correlates of glofitamab combined with tislelizumab in relapsed/refractory follicular lymphoma: A translational study Zhao Peiqi Received Received
  3596-SUN Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study Xuewu Zhang Received Received
  3597-SUN Efficacy and safety of first-line orelabrutinib combined with obinutuzumab (With or Without Bendamustine) in high-risk marginal zone lymphoma: Results from the orchid study Hu Mao Gui Received Received
  3598-SUN Anti-CD19 CAR-T cells for Mantle Cell Lymphoma with central nervous system involvement: A study of the french descart registry. Stephanie Guidez Received Received
  3599-SUN Orelabrutinib plus bendamustine-rituximab (OBR) Versus Bendamustine-rituximab (BR) in transplant-ineligible, intermediate- to high-risk Mantle Cell Lymphoma (MCL) Li Wang III Received Received
  3600-SUN Odronextamab plus chemotherapy in patients with previously untreated follicular lymphoma: First results from part 1 of the Phase 3 Olympia-2 study Kitsada Wudhikarn Received Received
  3601-SUN Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation Prokop Vodicka Received Received
  3602-SUN Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial Reid W Merryman Received Received
  3603-SUN SGR-1505, a potent and selective MALT1 inhibitor with preliminary efficacy in BTKi exposed Waldenstroem macroglobulinemia (WM) and "double-exposed" CLL/SLL Frank Gerard Basile Received Received
  3604-SUN Impact of baseline suvmax in untreated high-tumor-burden follicular lymphoma Ikram Bouguern I Received Received
  3605-SUN Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study Efrat Luttwak Received Received
  3606-SUN Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel) Amer Beitinjaneh Received Received
  3607-SUN Quantitative 18F-FDG-PET/CT analysis of splenic suvmax enhances diagnostic accuracy in primary splenic non-Hodgkin lymphoma Mengqi Xiong Received Received
  3608-SUN Characteristics, treatment outcomes, and prognostic analysis of 118 cases of lymphoplasmacytic lymphoma/Waldenstroem macroglobulinemia wei Guo Received Received
  3609-SUN Phase 2 trial of cladribine plus immediate rituximab for 1st-line treatment of hairy cell leukemia – long term follow-up of original and additional patient cohorts Robert J Kreitman Received Received
  3610-SUN Increasing incidences in primary lung marginal zone lymphoma: A SEER database analysis. Kevin Cheng Liang Wu Received Received
  3611-SUN CD20 (MS4A1) mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenstroem macroglobulinemia and have predicted functional consequences for the development of CD20-directed cellular therapies. Alberto Guijosa Received Received
  3612-SUN A retrospective population-based study of long-term treatments and outcomes inwaldenstrom macroglobulinemia in Ontario, Canada Arjun Pandey Received Received
  3613-SUN Elevated risk of non-neoplastic mortality among adolescent and young adult patients with low-grade B-cell lymphoma Rahul Mishra Received Received
  3614-SUN SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma Chan Cheah Received Received
  3615-SUN Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator´s choice in patients with Relapsed/Refractory follicular lymphoma who have received =1 line of systemic therapy Charalambos Andreadis Received Received
  3616-SUN Trials in progress - a Phase II study of pirtobrutinib in combination with rituximab in untreated marginal zone lymphoma (PIONEER-MZL) Narendranath Epperla Received Received
  3617-SUN A multicenter real-world analysis of combined chemotherapy followed by consolidative radiation versus chemotherapy alone in the management of early-stage Hodgkin lymphoma – the HODGKIN25 study Nikita K Dave Received Received
  3618-SUN Real world experience with brecadd protocol as frontline therapy for patients with advanced stage classical Hodgkin lymphoma: A multicenter retrospective study Tzvika Porges Received Received
  3619-SUN Inflammatory and oxidative stress biomarkers associated with cognitive function in patients with Hodgkin lymphoma treated with chemotherapy Tianming Zhao Received Received
  3620-SUN Outcomes of autologous hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP Maria Carmen Martinez Munoz Received Received
  3621-SUN Real-world outcomes and prognostic factors in older adults with early-stage classic Hodgkin lymphoma: A study from the spanish relinf-geltamo registry Maria Carmen Martinez Munoz Received Received
  3622-SUN Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world? Pallawi Torka Received Received
  3623-SUN Relapsed/Refractory Hodgkin lymphoma after first-line escalated beacopdac: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis Lisa Jeffers Received Received
  3624-SUN Smart start with tislelizumab as frontline treatment in advanced-stage classical Hodgkin lymphoma:a PET-adapted, chemotherapy-sparing phase 2 study Zhiming Li Received Received
  3625-SUN Rural-urban disparities in survival rates in adult Hodgkin lymphoma: A population-based study Khaled Elhusseiny Received Received
  3626-SUN Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study Hishan Tharmaseelan Received Received
  3627-SUN Immune checkpoint Inhibitors´ impact on outcomes of relapsed and refractory Hodgkin lymphoma: A real-world study Moath Albliwi Received Received
  3628-SUN Fertility outcomes following beacopp and ebeacopp chemotherapy in Hodgkin´s lymphoma: A systematic review Hafiz Muhammad Hannan Javed Received Received
  3629-SUN National trends and demographic disparities in Hodgkin disease mortality across the United States, 1999–2024 Alaa Mahmoud Received Received
  3630-SUN Pembrolizumab + GVD with ctdna-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: A multicenter phase 2 Study of the University of California hematologic malignancies consortium Michael Paul Randall Received Received
  3631-SUN Chidamide-BEAM conditioning plus autologous stem cell transplantation forperipheral t-cell lymphoma: A single-arm, single-center, phase 2 trial Meng-Meng Ji Received Received
  3632-SUN Prognostic value of interim PET in patients with extranodal natural killer/T-cell lymphoma treated with non-anthracycline containing l-asparaginase based regimen Sojin Kim Received Received
  3633-SUN BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter, showing promising efficacy in T cell lymphoma patients Stefan K Barta Received Received
  3634-SUN Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final results from the phase 2 PRIMO trial - impact of prior therapy and expanded safety analysis Pier Luigi Zinzani Received Received
  3635-SUN Patterns of care in second line management of nodal peripheral T-cell lymphoma from the lymphoma epidemiology of outcomes (LEO) and molecular epidemiology resource (MER) prospective cohort Study N. Nora Bennani Received Received
  3636-SUN Clinical features and outcomes of adult T-cell leukemia/lymphoma across world regions: An international retrospective cohort study Bryan Valcarcel Received Received
  3637-SUN CHOP combined with linperlisib or chidamide may decrease the risk of mortality of monomorphic epitheliotropic intestinal T-cell lymphoma: A single-center cohort study Ning Su Received Received
  3638-SUN Facility-level variation in hepatosplenic T-cell lymphoma care: Comparative outcomes from academic and community cancer centers Daniel Rosas Received Received
  3639-SUN Combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: Updated results of the phase II study Zhiming Li Received Received
  3640-SUN Autologous stem cell transplantation and real-world outcomes in angioimmunoblastic T-cell lymphoma: A national cohort study Yu Tao Received Received
  3641-SUN Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis Asaad Trabolsi Received Received
  3642-SUN A national analysis on ALK+ anaplastic large cell lymphomas: Community-based care linked to similar survival outcomes compared to academic centers. Victor Ramon Mendiola Received Received
  3643-SUN Treatment patterns and survival outcomes after immunotherapy failure in patients with NK/T cell lymphoma: A multicenter retrospective study Yuchen Zhang Received Received
  3644-SUN Heterogeneity of circulating CD57+ cytotoxic cell subsets across disease stage and aggressiveness in cutaneous T cell lymphoma Sara Niyazi Received Received
  3645-SUN Elevated interleukin-10 at diagnosis and during treatment independently predicts adverse outcomes in angioimmunoblastic T-cell lymphoma Yi Zhong Received Received
  3646-SUN Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas Steven Horwitz Received Received
  3647-SUN First evaluation of novel cmoep (Liposomal Mitoxantrone-Based Chemotherapy) in front-line peripheral T-cell lymphoma: The compass Phase II study Jingwei Yu Received Received
  3648-SUN Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia Ying Yu Received Received
  3649-SUN Golidocitinib combined with CHOP in treatment-Naïve monomorphic epitheliotropic intestinal T-cell lymphoma: Preliminary results from A phase 2 multicenter, single-arm goal study Yu-Ran Qiu Received Received
  3650-SUN Condensed total skin electron beam therapy prior to allogeneic stem cell transplantation in patients with cutaneous T-cell lymphoma/sezary syndrome Jillian R. Gunther Received Received
  3651-SUN Performance of radiomics features in patients with peripheral T-cell lymphoma: Data from international prospective T-cell project 2.0 Tetiana Skrypets Received Received
  3652-SUN Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with azacitidine and Chidamide can be an effective chemotherapy regimen for patients with angioimmunoblastic T-cell lymphoma (AITL) Liping Su Received Received
  3653-SUN Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia Roberta S. Azevedo Received Received
  3654-SUN Clinical significance of blood EBV-DNA in peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and EBV-positive nodal T-cell lymphoma Dok Hyun Yoon Received Received
  3655-SUN Enhanced clinical and systemic response with combination radiation therapy and topical imiquimod in mycosis fungoides: A pilot study Katherine De Jong Received Received
  3656-SUN Can the development of drug-induced rash after mogamulizumab administration predict survival in mycosis fungoides/sezary syndrome? a trinetx-based analysis Toshali Pandey Received Received
  3657-SUN Plat?form: A multicenter, multi-arm, academic platform trial evaluating novel agents and combinations in relapsed or refractory peripheral T-cell lymphomas David Sibon Sr Received Received
  3658-SUN Craniofacial involvement is associated with poor prognosis in extranodal DLBCL patients Jian-guo Fang I Received Received
  3659-SUN High levels of soluble TREM2 predict poor survival outcomes and facilitate the expansion of immunosuppressive monocytic-lineage cells in patients with DLBCL. Hao-Yuan Wang Received Received
  3660-SUN Prognostic value of baseline FDG PET/CT total metabolic tumor volume and MYC/BCL2 double expression status in patients with diffuse large B-cell lymphoma Shodai Takahashi Received Received
  3661-SUN Aggressive lymphomas that are treated early have worse outcomes: Counterintuitive results from a national database study. Anand Shah Received Received
  3662-SUN Real-world outcomes in T-cell/histiocyte-rich large B-cell lymphoma: Insights from the largest u.S. cohort to date Laura Reyes-Uribe Received Received
  3663-SUN Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study David Qualls Received Received
  3664-SUN Improved survival with third-line CAR-T therapy vs alternative treatment in DLBCL: A propensity score–matching analysis Prokop Vodicka Received Received
  3665-SUN Prognosis prediction beyond MTV using easy to calculate parameters derived from FDG-PET/CT, a pilot Study Zsombor Ritter Received Received
  3666-SUN Age at diagnosis shapes stage and survival in diffuse large B-cell lymphoma: A 22-year, population-based study of 94,598 SEER patients Aftab Ahmed Received Received
  3667-SUN A predictive model based on NCCN-IPI and 2 pirnas for prognostic risk stratification of diffuse large B-cell lymphoma (DLBCL) Min Zhang Received Received
  3668-SUN Concurrent viral infection as an adverse prognostic factor in diffuse large B-cell lymphoma, not otherwise specified Ou Bai Received Received
  3669-SUN Sex-and-ethnicity-related differences in primary central nervous system lymphoma based on the SEER database Sajed Salem Received Received
  3670-SUN Integrating genomic features for prognosis in Chinese patients with B-cell lymphoma following R-CHOP therapy Shi Han Received Received
  3671-SUN Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients Yun Kyoung Tiger Received Received
  3672-SUN Tumor-specific risk of acute kidney injury: A multi-cancer comparison across matched real-world cohorts Syed Emir Pasha Received Received
  3673-SUN Impact of high-dose methotrexate in both central nervous system relapse and systemic progression in high-risk DLBCL: A retrospective analysis of a brazilian cohort Paloma Resende Received Received
  3674-SUN Epigenetically driven upregulation of immunoproteasome component PSMB8 characterizes diffuse large B-cell lymphoma (DLBCL) with inflammatory microenvironment in African ancestry patients María Victoria Revuelta Received Received
  3675-SUN Anatomical localization-based analysis of de novo secondary cns lymphoma Izel Okcu Received Received
  3676-SUN Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort Michal Masar Received Received
  3677-SUN First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO) Ana Jiménez Ubieto Received Received
  3678-SUN Baseline CD4 count is associated with early mortality in HIV-associated lymphoma: A retrospective cohort study Emily Nicole Davidson Received Received
  3679-SUN Salvage whole brain radiotherapy after methotrexate failure in primary cns lymphoma Gustav Cederquist Received Received
  3680-SUN Diffuse large B cell lymphoma: A study of second primary malignancies among adults in the United States Oboseh Ogedegbe Received Received
  3681-SUN Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH). John N Allan Received Received
  3682-SUN Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability Xue Yang Received Received
  3683-SUN Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study Wei LIU Received Received
  3684-SUN BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Li Wang III Received Received
  3685-SUN Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola R+CHP) results in similar clinical outcomes than rituximab and dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R+DA- Rahul Thakur Received Received
  3686-SUN Effectiveness and toxicity of cyclophosphamide, etoposide, and prednisone as an outpatient oral chemotherapy regimen in elderly and frail patients with non-Hodgkin lymphoma Marina Herrero López Received Received
  3687-SUN primary efficacy and safety of first-line R-MTO regimen (rituximab, methotrexate, thiotepa, and orelabrutinib) followed by autologous hematopoietic stem cell transplantation in PCNSL Haichen Wei Received Received
  3688-SUN Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma Rebecca Wurm-Kuczera Received Received
  3689-SUN Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China Pengpeng Xu Sr Received Received
  3690-SUN Preliminary result of first-line orelabrutinib plus R-CHOP in CD5-positive diffuse large B-cell lymphoma (Rocket trial): A single-arm, phase II trial Qingqing Cai Received Received
  3691-SUN Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma Eduardo Edelman Saul Received Received
  3692-SUN Poseltinib combined with rituximab and lenalidomide is a promising chemotherapy-free therapy in relapsed or refractory primary central nervous system lymphoma Dong Hyun Kim Received Received
  3693-SUN Exploration of optimal high-dose methotrexate-based therapy for patients with primary CNS lymphoma: A real-world study in China Huiying Zhu Received Received
  3694-SUN Combination therapy with methotrexate, ifosfamide, cytarabine, dexamethasone and rituximab (R-MIAD) improves clinical outcomes in primary central nervous system lymphoma: A monocentric retrospective observational study Qu Cui Received Received
  3695-SUN Prophylaxis with thiotepa and high-dose methotrexate showed lower central nervous system relapse rate in high-risk diffuse large B-cell lymphoma Ruolan Zeng Received Received
  3696-SUN A prospective, multicenter, randomized, controlled clinical trial comparing polatuzumab vedotin, zanubrutinib, lenalidomide, and rituximab (Pola-ZR2) versus zanubrutinib, lenalidomide, and rituximab (ZR2) in the treatment of previously untreated, elderly Fan Zhang I Received Received
  3697-SUN Rituximab, cyclophosphamide, mitoxantrone hydrochloride liposome, vincristine, and prednisone (R-CMOP) in elderly patients with newly diagnosed diffuse large B-cell lymphoma: A multicenter, prospective study Liping Su Received Received
  3698-SUN Polatuzumab vedotin plus R-CHP demonstrates high efficacy with manageable toxicity in treatment-Naïve dual-expressor DLBCL (DEL): Real-world analysis with focus on elderly high-risk patients Kexing Ren Jr Received Received
  3699-SUN Real-world study of rituximab, methotrexate, and zanubrutinib (R-MZ) in the treatment of newly diagnosed primary central nervous system lymphoma Xiaojing Yan Received Received
  3700-SUN Efficacy and safety of chidamide and Bruton tyrosine kinase inhibitors combination therapy in relapsed/refractory diffuse large B-cell lymphoma Lili Zhou Received Received
  3701-SUN ICE therapy for primary and secondary central nervous system involvement of lymphomas Ofir Wolach Received Received
  3702-SUN Phase I/II study of zanubrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (ZR-ICE) in Relapsed/Refractory diffuse large B-cell lymphoma: Results of the Phase I portion Dok Hyun Yoon Received Received
  3703-SUN Trial in progress: A phase 3, multi-regional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide in participants with Relapsed/Refractory primary central nervous system lymphoma Christian Grommes Received Received
  3704-SUN Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma Jason Westin Received Received
  3705-SUN The first program for local CD19-CAR-T production and treatment of lymphoma in the UAE update median 1 year follow up and CART cell persistence Mohamed Abu Haleeqa Received Received
  3706-SUN Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma Rui Liu Jr Received Received
  3707-SUN FOXO1?themis? memory t cells underpin long-term remission after cytokine-armored CD19 CAR-t therapy in refractory lymphoma Aiqi Zhao Received Received
  3708-SUN CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier Kai Hu Sr Received Received
  3709-SUN Targeting B- and T-cell lymphomas with anti-CXCR5 CAR T cell therapy Jinsheng Weng Received Received
  3710-SUN Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM Manali Kamdar Received Received
  3711-SUN First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy Silvia Escribano Serrat Received Received
  3712-SUN Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma Juan Peng Received Received
  3713-SUN Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma Xiyang Liu Received Received
  3714-SUN Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE Roch Houot Received Received
  3715-SUN Efficacy and safety of selinexor in combination with CD19/CD22 bispecific chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory diffuse large B-cell lymphoma: A single-center, retrospective, real-world study Jia Cong Received Received
  3716-SUN Feasibility, outcomes and challenges of CAR-T cell therapy as advanced or earlier line of treatment for B-cell non-Hodgkin lymphomas: A multicenter national study Eleni Gavriilaki Received Received
  3717-SUN Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma Sattva S Neelapu Sr Received Received
  3718-SUN Autologous, allogeneic haemopoietic stem cell transplantation and CART cell therapy for tranformed Waldenstroem´s macroglobulinemia to high grade non-Hodgkin lymphoma. real world outcomes report from the lymphoma working party of the european society for Charalampia Kyriakou Received Received
  3719-SUN Modified beac as bridging/lymphodepletion therapy followed by CAR-T and autologous stem cell support in relapsed or refractory DLBCL patients: Insights from safety and efficacy outcomes in 12 patients Haiwen Huang Sr Received Received
  3720-SUN Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience Wei LIU Received Received
  3721-SUN Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study Martina Pennisi Received Received
  3722-SUN Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study Nicola Polverelli Received Received
  3723-SUN Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study Elan Baskir Received Received
  3724-SUN Nanobody-based CD19/CD20 bispecific CAR-T achieves durable remissions in r/r NHL patients Na Kuang Received Received
  3725-SUN Propensity score-matched analysis supports the survival benefits of combination chimeric antigen receptor T-cell therapy with autologous transplantation in relapsed or refractory B-cell non-Hodgkin lymphoma: Insights from a real-world study in China Haiwen Huang Sr Received Received
  3726-SUN Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models Sanjog Bastola Received Received
  3727-SUN Assessing the utility of the charlson comorbidity index in predicting outcomes of CAR-T therapy in patients with diffuse large B-cell lymphoma Abdulmalek Aljafari Received Received
  3728-SUN Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival Emeline R Chong Received Received
  3729-SUN Risk of venous and arterial thromboembolic events following CAR-T therapy in relapsed or refractory non-Hodgkin lymphoma: A propensity-matched multicenter analysis. Faris Wael Musa Naffa Received Received
  3730-SUN First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open-label Phase 2 ALPHA3 study John M. M. Burke Received Received
  3731-SUN Trial in progress: Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) nathali-01 Vivian Dai Received Received
  3732-SUN Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma Meng-Meng Ji Received Received
  3733-SUN Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis Jean Galtier Received Received
  3734-SUN Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab Ruth Fluemann Received Received
  3735-SUN Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study Manali Kamdar Received Received
  3736-SUN Epcoritamab + GemOx achieves durable 2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population Joshua Brody Received Received
  3737-SUN Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience Angel Serna Received Received
  3738-SUN A chemo-free tumor microenvironment (TME) reshaping regimen combining glofitamab induces a high CR rate in relapsed/refractory diffuse large B cell lymphoma (DLBCL) Zhijuan Lin Received Received
  3739-SUN Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab Allison Marie Bock Received Received
  3740-SUN Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory diffuse large B-cell lymphoma Yuqin Song Received Received
  3741-SUN Efficacy and safety of CAR-T cell therapy versus bispecific antibodies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: A single-arm meta-analysis Jie Wang Received Received
  3742-SUN Efficacy and safety of the polatuzumab, acalabrutinib, rituximab, and lenalidomide (Pola-AR2) regimen as first-line therapy in unfit or frail patients with diffuse large B-cell lymphoma Haiwen Huang Sr Received Received
  3743-SUN Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups Haifaa Abdulhaq Received Received
  3744-SUN Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma Rong Shen Received Received
  3745-SUN Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003 Philippe Armand Received Received
  3746-SUN Real-world outcomes with bispecific antibody therapies for aggressive B-cell lymphomas in octogenarians Lindsey Fitzgerald Received Received
  3747-SUN SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma Chan Cheah Received Received
  3748-SUN Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress Sandeep Sunder Raj Received Received
  3749-SUN Longitudinal genomic shifts associated with disease transformation in patients with polycythemia vera (PV) enrolled in REVEAL Stephen Oh Received Received
  3750-SUN Unravelling molecular determinants of ruxolitinib treatment response in myelofibrosis using single cell multiomics Sebastiano Rontauroli Received Received
  3751-SUN Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine Paola Guglielmelli Received Received
  3752-SUN Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor Mark J Chicarelli Received Received
  3753-SUN Clonal architecture inferred from routine NGS data predicts outcome and response to JAK-inhibitors in myelofibrosis Valentina Boldrini Received Received
  3754-SUN FBXO3-mediated DUSP9 ubiquitination reprograms MAPK signaling to eradicate tyrosine kinase inhibitor-resistant CML stem cells Xudong Li Received Received
  3755-SUN Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey. Fabio Stagno Received Received
  3756-SUN Allele-dependent activity of promoters of genes SLC22A4 and SLC22A5 encoding imatinib transporters in chronic myeloid leukemia Pavel Burda Received Received
  3757-SUN Therapeutic targeting of focal adhesion kinase (FAK) modulates oncogenic and immune pathways in myeloid progenitor cells expressing oncogenic Janus kinase 2-V617F. Subbaiah Chary Nimmagadda Received Received
  3758-SUN Integrative proteomics and machine learning identify subtype- and symptom-associated signatures in systemic mastocytosis Wei Xiao Received Received
  3759-SUN EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF) Linda Fabris Received Received
  3760-SUN Mutational architecture and clonal heterogeneity in myelofibrosis: Prognostic role of variant type and acquisition sequence Fiorenza Vanderwert Received Received
  3761-SUN Spatial transcriptomic dissection of the myeloproliferative neoplasm niche uncovers mutant clone interactions and microenvironmental rewiring Honghao Bi Received Received
  3762-SUN Evaluating reverse transcriptase efficiency in CML: Consequences for deep molecular response classification and treatment-free remission decisions Katerina Machova Polakova Received Received
  3763-SUN Investigating the clonal and biological underpinnings of systemic mastocytosis with an associated hematological neoplasm Nana Adjoa Ben-Crentsil Received Received
  3764-SUN Single-cell transcriptomic studies reveal altered heterogeneity in CD41 enriched megakaryocytes after targeted therapy in myeloproliferative neoplasm Man Mohan Received Received
  3765-SUN Distinct and non-overlapping epigenetic signatures differentiate MPN subtypes and reveal hydroxyurea-induced remodeling Maya Koren-Michowitz Received Received
  3766-SUN Functional annotation of MPN clones reveals mutation-specific fitness and fate bias Franco Castillo Tokumori Received Received
  3767-SUN Emergence of new somatic mutations in CML patients optimally responding to tyrosine kinase inhibitor therapy: Proposal of long-term genomic monitoring Yael Morgenstern Received Received
  3768-SUN Mutant megakaryocytes orchestrate marrow immune remodeling via inflammatory and LINE-1–Driven mechanisms in MPNs Xiaoxi Yang Received Received
  3769-SUN Integrated machine learning, cosmic signatures, and AI-driven genomic profiling of highly heterogeneous blast crisis CML at single patient level resolution: Implication as a versatile risk stratification and precision oncology approach for refractory and Dr Zafar Iqbal Received Received
  3770-SUN Whole genome sequencing reveals that the Philadelphia chromosome (Ph) can evolve and gain complex chromoplectic sequence rearrangements associated with tyrosine kinase inhibitor (TKI) resistance Susan Branford Received Received
  3771-SUN Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with CML driven by atypical fusion transcripts Andreas Hochhaus Received Received
  3772-SUN Survival and risk of second primary malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: A retrospective US population-level analysis Debolina Pramanik Received Received
  3773-SUN Additional genetic abnormalities (AGA) and microhomology end-joining DNA repair (MMEJ) signatures influence the outcome of newly diagnosed chronic phase (CP) CML: Ancillary study of the Trial of imatinib after ponatinib induction (TIPI) Franck Emmanuel Nicolini Received Received
  3774-SUN Frontline nilotinib vs dasatinib in newly diagnosed chronic phase chronic myeloid leukemia: A propensity score analysis based on AIFA monitoring registries Massimo Breccia Received Received
  3775-SUN Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts) Moshe Levy Received Received
  3776-SUN Flumatinib versus nilotinib as first-line therapy for chronic myeloid leukemia in chronic Phase: A propensity score-matched cohort study Na Xu Received Received
  3777-SUN Exploring co-mutations in CML and ph(+) b-ALL with ABL1 variants: Correlations with survival and treatment response. Kaitlyn Cecilia Dykes Received Received
  3778-SUN Ponatinib as a consolidation strategy for a second attempt at TKI discontinuation in chronic myeloid leukemia: Interim results from the restop Trial Almudena Zaratiegui Vergara Received Received
  3779-SUN The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, controll trial Bingbing Wen Received Received
  3780-SUN A randomized study of ropeginterferon in combination with bosutinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic Phase. the bosupeg trial from the Nordic CML study group Henrik Hjorth-Hansen Received Received
  3781-SUN Identification of factors associated with a high success rate of treatment-free remission in chronic myeloid leukemia: A multicenter study in Taiwan Ning-Chun Chen Received Received
  3782-SUN Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients (pts) with chronic Phase-chronic myeloid leukemia (CP-CML) Li Weiming Received Received
  3783-SUN Early reduction of BCR-ABL at 3 months predicts deeper molecular remission in pediatric CML Xingchen Wang Received Received
  3784-SUN Changes in disease responses after discontinution of tyrosine kinase inhibitors (TKI) for pregnancy in established chronic myeloid leukaemia (CML): Evidence for the basis of advice for women of child-bearing age Jenny Chan Received Received
  3785-SUN Integrating cytokine profiles with clinical and molecular biomarkers to predict molecular relapse after TKI discontinuation in CML patients Carolina Pavlovsky Received Received
  3786-SUN Treatment-free remission outcomes in pediatric chronic myeloid leukemia: Second-generation TKIs vs. Imatinib–a real-world multicenter study from China Li xin Liang Received Received
  3787-SUN Hematopoietic architecture drives biological and metabolic heterogeneity and predicts treatment-free remission outcomes in chronic myeloid leukemia Francois Vergez Sr Received Received
  3788-SUN Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial: Up to 4-year fol Qian Jiang Jr Received Received
  3789-SUN Two decades of pregnancy outcomes in women with CML: Insights from a real-world single-center cohort Sadashivudu Gundeti Sr Received Received
  3790-SUN Risk of second primary malignancies and leukemic transformation in patients with Philadelphia chromosome-negative myeloproliferative neoplasms: A population-level US retrospective cohort study Debolina Pramanik Received Received
  3791-SUN Post-FDA approval experience with momelotinib in JAK inhibitor-naïve myelofibrosis: Focus on anemia response and treatment-emergent nephropathy and peripheral neuropathy Ayalew Tefferi Received Received
  3792-SUN XPO1 inhibitor WJ01024 monotherapy or in combination with ruxolitinib in myelofibrosis Hu Zhou Received Received
  3793-SUN The transition from CHIP to overt myeloproliferative neoplasms: A 13-year longitudinal study of JAK2 positive citizens Lea Löffler Received Received
  3794-SUN Interim analysis of promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib Adam Mead Received Received
  3795-SUN The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results Prithviraj Bose Received Received
  3796-SUN Ruxolitinib and cardiovascular outcomes among patients with myelofibrosis Orly Leiva Jr Received Received
  3797-SUN Trial in progress: A study of roginolisib in combination with ruxolitinib in patients with myelofibrosis who are unresponsive to JAK inhibitors (HEMA-MED) Chiara Paoli Received Received
  3798-SUN Clinical NGS detection of TP53 mutations in chronic phase primary myelofibrosis: Comparative analyses of genotype and prognosis Yassin Bashir Received Received
  3799-SUN Disease stage-specific mutational landscape in essential thrombocythemia and prognostic correlates: A Mayo Clinic study of 500 NGS-informative cases Merry Nakhleh Received Received
  3800-SUN Multiple ASXL1 mutations and G646fs alterations confer increased risk of leukemic Transformation in patients with myelofibrosis Jian Huang Received Received
  3801-SUN Celfib-AI: A machine learning model to predict bone marrow fibrosis and cellularity from complete blood count – a multicenter model development and validation study in France Vincent Alcazer Received Received
  3802-SUN Clinical and molecular predictors of interferon-a response in erdheim-chester disease and myeloproliferative neoplasm. Julien Haroche Received Received
  3803-SUN Preliminary experience from the ODYSSEY trial: Efficacy and safety of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis Prithviraj Bose Received Received
  3804-SUN Fedratinib in combination with CC-486, an oral hypomethylating agent, in patients with accelerated phase myelofibrosis: Results from the phase I/II famy trial Haifa Kathrin Al-Ali Received Received
  3805-SUN A practical tool for predicting outcomes in essential thrombocythemia: Triple (or quadruple) a risk model Ahmet Emre Eskazan Received Received
  3806-SUN Prognostic impact of persistent and treatment-emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib: The "RUX-MF" study Francesca Palandri Received Received
  3807-SUN Refining thrombotic risk stratification in essential thrombocythemia: Impact of european leukemia net clinical signs and symptoms in patients treated with hydroxyurea Francesca Palandri Received Received
  3808-SUN Molecular predictors of anemia response to momelotinib in patients with myelofibrosis: Real-world outcomes from the momgemfin study. Adrian Segura Diaz Received Received
  3809-SUN Impact of new or worsening anemia and thrombocytopenia on clinical outcomes in JAK inhibitor–naive myelofibrosis patients treated with ruxolitinib Vikas Gupta Sr Received Received
  3810-SUN Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study Naveen Pemmaraju Received Received
  3811-SUN Real-world characteristics and treatment patterns in patients with essential thrombocythemia by thrombosis risk levels Helmneh Sineshaw Received Received
  3812-SUN Mapping out the impact of MAP kinase in primary myelofibrosis Samuel Benjamin Reynolds Received Received
  3813-SUN Clinical, molecular, and demographic features of systemic mastocytosis: Analysis of a large cohort Annie Hoai Hoai Nguyen Received Received
  3814-SUN The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study Jan Philipp Bewersdorf Received Received
  3815-SUN Not so exclusive: Co-mutations in JAK2, MPL and CALR define distinct hematologic and clonal signatures Ekrem Turk Received Received
  3816-SUN Targeting HMGA1-driven leukemic transformation in myeloproliferative neoplasms with pacritinib Can Yang II Received Received
  3817-SUN Establishment of differential diagnostic model for ET and pre-PMF based on circulating CD34+ cells and its clinical significance Shixuan Wang Received Received
  3818-SUN Evaluation of low-intensity treatment strategies and outcomes in patients with accelerated Phase and blast Phase myeloproliferative neoplasms: A hero consortium study Jenna Ciervo Received Received
  3819-SUN Rapid JAK2 V617F decline predicts response durability: Kinetics of JAK2 V617F in ropeginterferon alfa-2b treated polycythemia vera Sung-Eun Lee Received Received
  3820-SUN It´s not yet time to abandon ruxolitinib in anemic myelofibrosis: Predictive factors of erythroid response to standard anemia-directed therapies combined with ruxolitinib Massimiliano Bonifacio Received Received
  3821-SUN Myeloproliferative neoplasm thrombosis risk characterized by MerTK biomarker Nithita Nanthatanti Received Received
  3822-SUN The prognostic value of JAK2V617F burden for discontinuation of interferon-a2 in patients with myeloproliferative neoplasms Lea Löffler Received Received
  3823-SUN Predictors of symptom improvement in myeloproliferative neoplasms: A real-world retrospective cohort study Muhammad Ali Khan Received Received
  3824-SUN Ruxolitinib and interferon alfa induce superior rates of complete peripheral blood count remission compared to anagrelide in hydroxyurea-exposed essential thrombocythemia Tripura Vithala Received Received
  3825-SUN Trends in second primary malignancies in myelofibrosis pre- and post-JAK inhibitor era: A surveillance, epidemiology and end-Results database study Bana Antonios Received Received
  3826-SUN Comparative risk of major adverse cardiovascular events in polycythemia vera patients treated with ruxolitinib, hydroxyurea, or interferon: A real-world, propensity-matched cohort study Ali Mushtaq Received Received
  3827-SUN Trial in progress - a randomized study of ASTX727 with or without Iadademstat in accelerated/blast-phase myeloproliferative neoplasms Anand Ashwin Patel Received Received
  3828-SUN Trial in progress: Efficacy and safety of givinostat versus hydroxyurea in patients with polycythemia vera (GIV-IN-PV) Alessandro Rambaldi Received Received
  3829-SUN Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial Marina Kremyanskaya Received Received
  3830-SUN Single-cell multi-omics profiling reveals distinct patterns of clonal expansion and microenvironmental shifts associated with disease evolution in patients with Myelodysplastic Syndromes Matteo Zampini Received Received
  3831-SUN Spatial multiomics reveal a critical role for TIM4-expressing macrophages in blast transformation of chronic myelomonocytic leukemia Abhishek Avinash Mangaonkar Received Received
  3832-SUN Short-term and long-term sting activation elicit divergent cellular responses in distinct hematopoietic populations in chronic myelomonocytic leukemia Guillermo Montalban-Bravo Received Received
  3833-SUN Immunosuppressive T-cell landscape in myelodysplastic Neoplasms with TP53 mutations Lingxu Jiang Received Received
  3834-SUN Integrated analysis of autoantibody profiles and clonal distribution of RAS mutations in juvenile myelomonocytic leukemia Manabu Wakamatsu Received Received
  3835-SUN Functional classification of monoallelic TP53 mutations refines prognostic stratification in myelodysplastic neoplasms Alexander Streuer Received Received
  3836-SUN Treatment with luspatersept exerts a pleiotropic effect on the molecular signatures of bone marrow cell subsets Ioannis Kotsianidis Received Received
  3837-SUN Examining the role of U2AF1 and TET2 mutations in a myeloid malignancy mouse model Matthew Cheng Received Received
  3838-SUN Novel approaches to identify cellular vulnerabilities in TET2-dependent MDS Valeria Visconte Received Received
  3839-SUN Synergistic apoptotic effect by the combination of clk inhibitor CTX-712 and BCL-2 inhibitor ABT-199 with or without azacytidine in AML and MDS Hui Yang Received Received
  3840-SUN Interim Results of the CMML scrna-seq atlas: GMP skewing is independently associated with overall survival in CMML. Amy McLemore Received Received
  3841-SUN Delta opiod receptor signaling modulates myeloid suppression in Myelodysplastic Syndromes Erika Adriana Eksioglu Received Received
  3842-SUN Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM) Luca Lanino Received Received
  3843-SUN Differential trends in survival after allogeneic transplantation for MDS and MDS/MPN in a real-world experience Hidehiro Itonaga Received Received
  3844-SUN CMML2AML: Machine-learning discovery of co-mutations predictive of blast transformation in chronic myelomonocytic leukemia Saubia Fathima Received Received
  3845-SUN Clinical, genetic, and pathologic differences across race, ethnicity, and sex in patients with MDS and precursor conditions from the national MDS natural history study Nancy Gillis Received Received
  3846-SUN Evaluation of levofloxacine as antibiotic prophylaxis in MDS and AML patients treated with azacitidine: Results from the randomized open-label phase III azabac study Juliette Pénichoux Jr Received Received
  3847-SUN Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach Ivan Civettini Received Received
  3848-SUN Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition Guillermo Montalban-Bravo Received Received
  3849-SUN Consideration of genomic determinants improves the diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia Guillermo Montalban-Bravo Received Received
  3850-SUN Non-infectious fever predicts poor survival in azacitidine-treated high-risk, but not low-risk, myelodysplastic syndromes:a multicenter real-world cohort study (KOTOSG) Takahisa Nakamura Received Received
  3851-SUN IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies Rami Komrokji Received Received
  3852-SUN Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts Ted M Getz Received Received
  3853-SUN Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis Abigail Huetteman Received Received
  3854-SUN TCL1A polymorphism predicts AML progression in myeloid neoplasms Alfonso Molina Jr Received Received
  3855-SUN Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement Daniel Thomas I Received Received
  3856-SUN Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes Zena Komrokji Received Received
  3857-SUN RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation Roberta S. Azevedo Received Received
  3858-SUN 17p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease Gunin Singhal Received Received
  3859-SUN Multivariable-adjusted validation of IWG23-defined peripheral blood complete remission (PB-CR) and IWG23 response criteria in 2,042 patients with MDS, CMML or AML treated with diverse first-line therapies: Insights from the AML-001 trial (NCT01074047) and Lisa Pleyer Received Received
  3860-SUN Comparative evaluation of ipss-m and cpss-mol in CMML: Impact of molecular markers on prognosis Alexander Streuer Received Received
  3861-SUN Cardiovascular disease in myelodysplastic syndromes and related disorders: Frequency, risk factors, and outcomes Nantawan Numkaitsakul Received Received
  3862-SUN A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study James Thomas England Received Received
  3863-SUN Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international co Tariq Kewan Received Received
  3864-SUN ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features Steven Tessier Received Received
  3865-SUN The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome Benjamin Rolles Received Received
  3866-SUN From chaos to clarity? decoding the inflammatory profiles in lower-risk MDS Sven De Pourcq Received Received
  3867-SUN Outcomes of clinical trial screening in patients with Myelodysplastic Syndromes and chronic myelomonocytic leukemia Kelly Sharon Chien Received Received
  3868-SUN Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD) Ana Alfonso-Pierola Received Received
  3869-SUN Molecular subclusters across the continuum of myelodysplastic neoplasms and acute myeloid leukaemia define distinct clinical entities Catherine Cargo I Received Received
  3870-SUN Short-term outcomes of rituximab versus thrombopoietin receptor agonists in Myelodysplastic Syndromes: A 90-day propensity-matched analysis using real-world data Jamil Nazzal Received Received
  3871-SUN Enhanced IPSS-m: A comorbidity-integrated model for improved clinical risk stratification in myelodysplastic neoplasms Vikramjit Dhillon Received Received
  3872-SUN Prognostic impact of pre-transplant IPSS-m risk downstaging in Myelodysplastic Syndromes Asmita Shukla Received Received
  3873-SUN Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML) Zhuoer Xie Received Received
  3874-SUN A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML) Guillermo Montalban-Bravo Received Received
  3875-SUN MCL1 copy number gain is a recurrent mark of venetoclax resistance in patients with chronic lymphocytic leukemia Carolyne Croizier Received Received
  3876-SUN Acquisition of CLL-like epigenetic and transcriptomic states in low-count MBL Livius Penter Received Received
  3877-SUN Machine learning-based classification of chronic lymphocytic leukemia signalotypes to allows biological and clinical insights into novel CLL subgroups Alexander Egle Received Received
  3878-SUN Pirtobrutinib, a non-covalent BTK inhibitor, enhances T-cell anti-tumor immunity in chronic lymphocytic leukemia (CLL) Sonia Rodriguez-Rodriguez Received Received
  3879-SUN Loss of cell cycle regulators RB1 and CDKN2A/2B induces CLL with distinct disease kinetics in murine models and shows distinct outcomes in CLL patients Ivan Negara Received Received
  3880-SUN Spatial transcriptomic analysis of chronic lymphocytic leukemia lymph nodes reveals tumor microenvironment evolution during disease progression Carla Minoia Sr Received Received
  3881-SUN Systematic molecular profiling to identify determinants of response to ibrutinib Negin Karisani Received Received
  3882-SUN Foreign antigen delivered to CLL B cells via membrane IgD leads to a distinct antigen processing pathway that allows antigen-specific T cell activation that is superior to membrane IgM delivery Martina Cardillo Received Received
  3883-SUN A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial Anne-Sophie Michallet Received Received
  3884-SUN Comparison of infections in patients with chronic lymphocytic leukemia (CLL) treated with BTKi versus venetoclax obinutuzumab in first line therapy Jawria Tufail Received Received
  3885-SUN Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience Beenish S. Manzoor Received Received
  3886-SUN Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG). John N Allan Received Received
  3887-SUN Upfront continuous BTK inhibitor (BTKi) versus time-limited venetoclax-BTKi combinations in CLL across IGHV subgroups: Results of an indirect analysis Stefano Molica Received Received
  3888-SUN Correlation between real-world (RW) progression-free survival (rwPFS) and overall survival (OS) among patients (Pts) with first-line (1L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) receiving covalent bruton tyrosine kinase inhibitor Ira Zackon Received Received
  3889-SUN Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report Keshu Zhou Received Received
  3890-SUN Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101 Jacob Soumerai Received Received
  3891-SUN Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-1 Constantine S. Tam Received Received
  3892-SUN Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study Nitin Jain Received Received
  3893-SUN Real-world efficacy and safety of venetoclax-based therapy in israeli patients with CLL/SLL: Results from the reveal study Yair Herishanu Received Received
  3894-SUN Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia Brian Koffman Received Received
  3895-SUN Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study Meghan C. Thompson Received Received
  3896-SUN Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Yuqin Song Received Received
  3897-SUN Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions Mark-David Levin Received Received
  3898-SUN Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY Paolo Ghia Received Received
  3899-SUN Characterization of IGHV subgroups and their prognostic relevance in CLL Daniel Sungchul Choi Received Received
  3900-SUN Development and multicenter evaluation of a novel 12-color flow cytometric antibody panel and dedicated analysis algorithm for fully standardized automated measurable residual disease (MRD) detection in chronic lymphocytic leukemia (CLL) at a sensitivity Sebastian Böttcher Received Received
  3901-SUN Multilayer profiling of MRD in patients with relapsed/refractory CLL treated with venetoclax-based regimens in a real-world setting Ilaria Romano Received Received
  3902-SUN Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia Meghan C. Thompson Received Received
  3903-SUN Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective co Catherine Thieblemont Received Received
  3904-SUN Elevated circulating activated FOXP3+ regulatory T cell subset in patients with advanced chronic lymphocytic leukemia as a marker for severe infections during 1000 days of follow-up Mojca Dreisinger I Received Received
  3905-SUN Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population Lauren Danielle Pomerantz Received Received
  3906-SUN SF3B1 mutations are associated with shorter time to first treatment in chronic lymphocytic leukemia Fernanda Santos Azevedo Received Received
  3907-SUN Long-term outcomes in high-risk patients with chronic lymphocytic leukemia treated with targeted therapies in the real-world Anna Petrackova Received Received
  3908-SUN Baseline clinical characteristics of patients with chronic lymphocytic leukemia (CLL) from 11 Latin American countries: A real-world registry analysis Ana Oliver Received Received
  3909-SUN Concomitant use of venetoclax 100 mg and ketoconazole, a strong CYP3A4 inhibitor, is clinically equivalent to venetoclax 400 mg for treating relapsed or refractory chronic lymphocytic leukemia (CLL): A real-world analysis from the brazilian CLL registry." Pedro dos Santos Perez Received Received
  3910-SUN Normal B Cells in MBL follow divergent maturation pathways that correlate with the IGHV mutation status of the pre-leukemic clone Gonzalo Blanco Received Received
  3911-SUN A decade of progress: A comparative analysis of real-world survival in chronic lymphocytic leukemia across therapeutic eras Mostafa Eysha Received Received
  3912-SUN Mutation-guided finite-duration acalabrutinib plus venetoclax for relapse after first-line finite-duration COVALENT Bruton tyrosine kinase inhibitor plus venetoclax?based combination therapy in patients with chronic lymphocytic leukemia/small lymphocytic Matthew S Davids Received Received
  3913-SUN Roginolisib (IOA-244), an orally bioavailable, selective PI3Kd inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) Jennifer R. Brown Received Received
  3914-SUN Phenotypic evolution of circulating tumor plasma cells across MGUS, SMM and multiple myeloma Martin Pietzsch Received Received
  3915-SUN Long-read direct RNA-seq reveals dynamic MM transcriptome made of novel isoforms and post-transcriptional modifications Christopher Schorr Received Received
  3916-SUN Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy Kevin Robert Reyes Received Received
  3917-SUN Improve therapeutic response through inhibition of endosome machinery in multiple myeloma Yutong Wang Received Received
  3918-SUN Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma Ilaria Vigliotta Received Received
  3919-SUN Harnessing phagocytes for amyloid clearance: Development of a novel bispecific phagocyte engager (LC Fibril x CD64) for AL amyloidosis Jing Fu Received Received
  3920-SUN Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma Benjamin Diamond Received Received
  3921-SUN Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy David Cordas Dos Santos Received Received
  3922-SUN Determinants of response of the BCMA/GPRC5D-dual-targeting T-cell redirecting trispecific antibody JNJ-5322 in multiple myeloma Chloe O Neill Received Received
  3923-SUN Single-cell transcriptomics of AL amyloidosis reveals pathogenic mechanisms, immune interactions and altered clonal and polyclonal plasma cell phenotypes Jackson Smith Received Received
  3924-SUN Enhancing immunotherapy efficacy in myeloma with a novel dual-action mitochondrial toxic peptide that overcomes resistance and induces immunogenic cell death. Smriti Gurung Received Received
  3925-SUN Semaphorin 4D and interleukin 1beta-complement cascade axis are key drivers of disease progression in multiple myeloma Ioannis Ntanasis-Stathopoulos Received Received
  3926-SUN PSMD3 orchestrates metabolic reprogramming and immunogenic cell death in multiple myeloma Teng Fang Received Received
  3927-SUN Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden Daniel Bilek Received Received
  3928-SUN Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes Nathan J Becker Received Received
  3929-SUN Single-cell transcriptomics reveals pathogenic interactions between clonal plasma cells and monocytes in POEMS syndrome Xinli Han Received Received
  3930-SUN Identification of persister cells and evolution of tumor clones during immunotherapy and at minimal residual disease timepoints decoded by single-cell whole-genome sequencing in multiple myeloma Rosa Toenges Received Received
  3931-SUN Integrated transcriptomic and proteomic analysis of clonal plasma cells from patients with AL amyloidosis Ourania Theologi Received Received
  3932-SUN Single-cell immune landscape associated with isatuximab, carfilzomib, lenalidomide, and dexamethasone induction efficacy in newly diagnosed myeloma Ludovic Martinet Sr Received Received
  3933-SUN Indole-related metabolites suppress the anti-tumor function of CD8+ T cells in the bone marrow microenvironment of multiple myeloma Shengdian Wang Received Received
  3934-SUN Discovery of JNJ-87562761, a novel anti-GPRC5D enhanced effector function (eEF) antibody with multiple mechanisms of action for the treatment of multiple myeloma Bradley Heidrich Received Received
  3935-SUN Accelerated immune aging after induction therapy in multiple myeloma revealed by donor-referenced immune age modeling Ehsan Malek Received Received
  3936-SUN IFN-a potentiates daratumumab response in multiple myeloma: A commpass study Colton Henry Dysart Received Received
  3937-SUN Development of novel small-molecule DDX5 inhibitors for treating relapsed and/or refractory multiple myeloma Teigen Nelson Received Received
  3938-SUN An acquired immune-metabolic shift to common chemotherapy confers resistance to immunotherapies in relapsed, high-risk multiple myeloma Mara John Received Received
  3939-SUN Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma Huihuang Yan Received Received
  3940-SUN Single-cell transcriptomics reveals proliferative, immune-evasive, and bone marrow–independent transcriptional programs in extramedullary multiple myeloma. Saurabh Zanwar Received Received
  3941-SUN Modeling del(17p) in multiple myeloma for molecular and functional characterization Yuanyuan Jin Received Received
  3942-SUN Recurrent loss of chromosome y in multiple myeloma is linked to disease progression and altered tumor immune microenvironment Luis Antonio Corchete Sanchez Received Received
  3943-SUN A human IL-6–Expressing PDX model of multiple myeloma recapitulates clinical features and supports patient-derived tumor engraftment Bonell Patino-Escobar Received Received
  3944-SUN DDX3X facilitates adaption to proteotoxic stress by regulating the translation of MAPKAPK2 and the stability of TMCO1 via stress granules in multiple myeloma Fengjuan Fan Received Received
  3945-SUN Disruption of NEAT1-transcriptional network identifies targetable non-genetic dependencies in multiple myeloma Noemi Puccio Jr Received Received
  3946-SUN Genomic alterations in TET2 and EZH2 serve as critical drivers of clonal malignant evolution in anti-BCMA CAR-T therapy for multiple myeloma. Adolfo Aleman Received Received
  3947-SUN RXR agonist IRX4204 enhances BCMA CAR-T-cell efficacy by suppressing ferroptosis via CHAC1 downregulation Jian Wu Received Received
  3948-SUN Diagnosis and prediction of precursor states in multiple myeloma using cell-free chromatin Noa Omer Vilk Received Received
  3949-SUN Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy Junia Vieira Received Received
  3950-SUN RXR agonist IRX4204 induces ferroptosis in multiple myeloma via HMOX1/GPX4 axis and enhances lenalidomide efficacy Jian Wu Received Received
  3951-SUN Reprogrammed regulatory T cells as cytotoxic effectors drive anti-tumor immunity under bispecific T cell engager therapy Julius Michel Received Received
  3952-SUN Immune aging and macrophage inhibitory factor (MIF) – mediated stromal rewiring drives pre-malignant evolution in smoldering multiple myeloma Rajib Shome Received Received
  3953-SUN Impact of the stromal microenvironment on the extrinsic apoptotic pathway in multiple myeloma James Ackley Received Received
  3954-SUN Pharmacologic activators of immunoproteasomes unmask actionable public and private neoantigens in multiple myeloma patients James Driscoll II Received Received
  3955-SUN Daratumumab-based quadruplet therapy in functional high-risk relapse/refractory multiple myeloma patients induces changes associated with CD8 T cell signaling, activation and expansion Chaitanya Acharya Received Received
  3956-SUN NSD2 inhibition suppresses t(4;14) gene expression and oncogenic signaling to impair proliferation in multiple myeloma Robert M Chavez Received Received
  3957-SUN In Vivo postnatal loss of mature osteoblasts creates an immunosuppressive bone marrow microenvironment to permit the engraftment and proliferation of myeloma cells Cristina Panaroni Received Received
  3958-SUN Distinct predictors of mortality and conduction disease in AL cardiac amyloidosis Ali Mushtaq Received Received
  3959-SUN Calcineurin inhibitors reduce risk of MGUS progression to multiple myeloma in immunosuppressant users: A retrospective multi-institution cohort study Li-Yang Shiau Received Received
  3960-SUN Cardiac complete response in AL amyloidosis: Phenotypic characteristics, functional recovery, and survival outcomes of 63 patients Eli Muchtar Received Received
  3961-SUN Real-world safety and efficacy of BCMA bispecific antibodies in relapsed light chain amyloidosis Vasil Mico Received Received
  3962-SUN Clinical, anatomic, and histologic determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis: A cohort study of 560 patients Max Johannes Steinhardt Received Received
  3963-SUN MGUS like phenotype in patients with AL amyloidosis: Impact on clinical outcomes for patients treated with bortezomib-containing regimens (BCR). Victor Jimenez-Zepeda Received Received
  3964-SUN Renal amyloidosis-related mortality trends and disparities: A retrospective nationwide analysis using the CDC wonder database Aqsa Zoey Sorathia Received Received
  3965-SUN Long-term follow-up of a prospective phase 2 Study of daratumumab plus bortezomib and dexamethasone in newly diagnosed mayo 2004 stage IIIA and IIIb light-chain amyloidosis Xuemin Gao Received Received
  3966-SUN Association between monoclonal gammopathy of undetermined significance and cardiovascular disease risk among individuals with type 2 diabetes: A Taiwan nationwide Study Su-Hsin Chang Received Received
  3967-SUN Bayesian machine learning, medical history, and predictive models for early diagnosis of systemic light chain amyloidosis Anita D´Souza Received Received
  3968-SUN Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD Dominique Mosley Received Received
  3969-SUN Fat pad biopsy versus target organ biopsy in systemic AL amyloidosis detection Kristina Nasr Received Received
  3970-SUN Unwinding the genomic threads of monoclonal gammopathy of renal significance through ultra-low pass whole genome sequencing Louis Samuel Williams Received Received
  3971-SUN Single-cell landscape of clonal plasma cells in t(11;14) primary light-chain amyloidosis reveals molecular insights into venetoclax response Xinyi Xiong Received Received
  3972-SUN Impact of slim-CRAB criteria on diagnostic practices among patients with MGUS in the veteran health administration Mahta Salehi Received Received
  3973-SUN Determinants of renal survival in patients treated for monoclonal gammopathy of renal significance Samuel Rubinstein Received Received
  3974-SUN TeclistAMY (EMN40): A Phase 2 trial of teclistamab in patients with previously treated light-chain (AL) amyloidosis Murielle Roussel Received Received
  3975-SUN Health care resource utilization in patients with multiple myeloma receiving bispecific antibody therapy with teclistamab: A Medicare claims database analysis in the US Sikander Ailawadhi Received Received
  3976-SUN Impact of 1q gain/amplification in multiple myeloma patients treated with daratumumab-based regimens: A retrospective single-center study Emiliano Barbieri Received Received
  3977-SUN The treatment of transplant eligible primary plasmacell leukemia patients: An italian real-life Study Gregorio Barila Received Received
  3978-SUN First report of AI derived metrics from whole-body MRI in patients with multiple myeloma reveals unique insights into body composition and changes on therapy Nicolas Basty I Received Received
  3979-SUN Real-world outcomes of newly diagnosed multiple myeloma patients in the veterans affairs healthcare system Alexander Lazzaro Received Received
  3980-SUN Evolution of myeloma bone disease over time: Comparison of selected biomarkers in MGUS, SMM and active MM Jiri Minarik Received Received
  3981-SUN Multiple myeloma with concomitant chronic lymphocytic leukemia: Common or distinct clonal origin? Jana Wobst Received Received
  3982-SUN Interim results from a multicenter trial assessing the clinical relevance of copy number aberrations detected by a shallow whole-genome sequencing analysis (LeukoPrint) in multiple myeloma. Shichun Tu Received Received
  3983-SUN Isotype-specific heavy/light chain quantification identifies prognostic biomarkers after ARI0002h BCMA-directed CAR-T cell therapy in multiple myeloma Anna de Daniel Received Received
  3984-SUN Dynamic monitoring of circulating plasma cells in multiple myeloma: A Prospective multicenter study in China Qun Li Received Received
  3985-SUN Efficacy and safety of recombinant adjuvanted zoster vaccine in patients with monoclonal gammopathies: A prospective study Vasiliki Spiliopoulou Received Received
  3986-SUN The novel ims / IMWG high-risk multiple myeloma criteria may omit individuals with renal impairment and adverse disease prognosis Ioannis Ntanasis-Stathopoulos Received Received
  3987-SUN Simplified frailty score for patients with multiple myeloma undergoing autologous stem cell transplant Oren Pasvolsky Received Received
  3988-SUN Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study Rushir Choksi Received Received
  3989-SUN Systematic analysis of gene mutations in Chinese multiple myeloma patients. Wang Jinhua Received Received
  3990-SUN Incidence and characteristics of myeloid neoplasms in patients with multiple myeloma treated with novel myeloma-directed therapies Benedetto Bruno Received Received
  3991-SUN Significance of CD229 expression assessment for detection of minimal residual disease in patients with multiple myeloma. Darya Kisilichina Received Received
  3992-SUN Population differences and comparative efficacy between ciltacabtagene autoleucel (cilta-cel) from the cartitude-1 study and anitocabtagene autoleucel (anito-cel) from the iMMagine-1 study in patients with relapsed / refractory multiple myeloma (RRMM) Luciano Jose Costa Received Received
  3993-SUN Infections following combined therapy with a GPRC5DxCD3 bispecific antibody, talquetamab, and an interleukin-6 receptor inhibitor, tocilizumab, in multiple myeloma patients Bojana Mandic Received Received
  3994-SUN Serum BCMA (sBCMA) levels in plasma cell dyscrasias: Insights from a south Indian prospective study Neeraj Sidharthan Received Received
  3995-SUN Rebuilding immunity: Kinetics and clinical impact of immune reconstitution after CAR T-cell therapy in multiple myeloma Heta Patel Received Received
  3996-SUN Development of predictive relapse indicators for myeloma T cell engagers (PRIME) model for myeloma patients receiving BCMA- and GPRC5D-targeting T cell engagers Tarek Mouhieddine Received Received
  3997-SUN Advantages of less frequent doing of BCMA-directed bispecific antibodies Michael Schuster Received Received
  3998-SUN Tracking peripheral residual disease in myeloma: Clonotypic sequencing and mass spectrometry in the teclistamab era Anna Sabouret Received Received
  3999-SUN Impact of immunoglobulin supplementation on infection rates in myeloma patients receiving novel immunotherapies Efstathios Kastritis Received Received
  4000-SUN Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM) Danai Dima Received Received
  4001-SUN Association of the easix score with survival and adverse outcomes in a large elderly hispanic cohort of patients with multiple myeloma. Marco Ruiz Received Received
  4002-SUN Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025: A real life multicentre analysis in Italy Sonia More´ Received Received
  4003-SUN Machine-learning-augmented prediction of tumor metabolic burden and survival in multiple myeloma using clinical indicators Fuling Zhou Jr Received Received
  4004-SUN Patient-reported outcomes and actigraphy following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in newly diagnosed multiple myeloma (NDMM): Subgroup analysis of US MM-6 by race/ethnicity, renal function, and area income Leon Bernal-Mizrachi Received Received
  4005-SUN Tradeoff between vaccine-induced immunity and depth of response following autologous stem cell transplantation in multiple myeloma David M Foureau Received Received
  4006-SUN Anti-CD38 immunotherapy assay and monitoring in patients with multiple myeloma: A monocentric pilot study Emilie Chalayer Received Received
  4007-SUN Characterization of a population with newly diagnosed standard risk multiple myeloma by the 2025 ims/IMWG definition with exceptional long-term outcomes after fixed duration therapy Bhagirathbhai Dholaria Received Received
  4008-SUN Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants Arjun Raj Rajanna Received Received
  4009-SUN Liquid biopsy by analysis of circulating tumor cells, hormonal and inflammatory biomarkers in plasma cell neoplasms, at Fundacion Santa Fe de Bogota hospital Martha Romero Prieto Received Received
  4010-SUN Selinexor, mezigdomide, and dexamethasone in patients with Relapsed/Refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results Clifton C. Mo Received Received
  4011-SUN Daratumumab provides equivalent survival benefits in first-line and second-line treatment of transplant-ineligible multiple myeloma: A computational analysis of Phase 3 trials in first-line and second-line settings. Noah Schlachter Received Received
  4012-SUN Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM) Binod Dhakal Received Received
  4013-SUN Examining TP53-mutated plasma cell disorders across the disease spectrum using broad next generation sequencing Kristin Ezell Received Received
  4014-SUN Defining functional high-risk multiple myeloma in the era of modern induction therapy Barry Paul Received Received
  4015-SUN Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity Chun Gan Received Received
  4016-SUN Feasibility of anti-BCMA CAR-T therapy in a middle-income country Humberto Villefort Received Received
  4017-SUN Incidence, outcomes and economic burden of cytokine release syndrome and immune effector cell associated neurotoxicity syndrome in patients undergoing CAR-T cell therapy for multiple myeloma Evani Jain Received Received
  4018-SUN Baseline [18F] FDG PET biomarkers of host and tumor predict efficacy and CRS in multiple myeloma patients treated with CAR-T cell therapy Jing Chen Received Received
  4019-SUN Determinants of renal recovery and survival in patients with myeloma presenting with high circulating free light chains and renal impairement Suvir Singh Received Received
  4020-SUN Comparative analysis of next generation flow (NGF) and next generation sequencing based clonoseq for MRD detection in multiple myeloma using paired bone marrow samples J Wiedmeier-Nutor Received Received
  4021-SUN Cytokine release syndrome prophylaxis strategy with dipyrone in patients receiving bispecific Antibodies—Elranatamab, teclistamab, talquetamab and Epcoritamab—at a private hospital in southern Brazil: Preliminary Results Erica Lammerhirt Ottoni Received Received
  4022-SUN Impact of pre-existing cardiovascular disease on inpatient arrhythmias following autologous stem cell transplantation in multiple myeloma: A national inpatient sample database analysis Hector Jose Garcia Pleitez Received Received
  4023-SUN Survival outcomes and treatment patterns in primary and secondary plasma cell leukemia: A multicenter retrospective cohort study Chenyun Wang Received Received
  4024-SUN Mapping the immune checkpoint receptor-ligand landscape in newly diagnosed multiple myeloma may help prioritize patients for immune checkpoint inhibitor therapy Steven Mason Foltz Received Received
  4025-SUN Underexplored mutations in plasma cell myeloma Yasar Shad Received Received
  4026-SUN Targeted deep sequencing of myeloma in a multi-institutional clinical workflow Parth Shah Received Received
  4027-SUN The association between sglt-2 inhibitor use and progression from monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans Byron Seiya Sigel Received Received
  4028-SUN Real-world pharmacovigilance of BCMA-targeted CAR-T therapy in refractory multiplemyeloma: A comparative analysis of idecabtagene vicleucel and ciltacabtagene autoleucel Ahmed Mustafa Received Received
  4029-SUN Health-related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM): An exploratory analysis of overall quality of life in dreamm-7 Sagar Lonial Received Received
  4030-SUN Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farbe Peter J. O´Gorman Received Received
  4031-SUN Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population Janusz Krawczyk Received Received
  4032-SUN Optimizing lenalidomide therapy in renal impairment: Analysis of renal response in the prospective remnant study in transplant-eligible newly diagnosed multiple myeloma Frida Bugge Askeland Received Received
  4033-SUN Melphalan weight-based dosing in overweight and obese patients undergoing autologous transplant for multiple myeloma Anmol Goyal Received Received
  4034-SUN Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe), report of primary endpoint, nordic myeloma study group 29/21 Ida Bruun Bruun Kristensen Received Received
  4035-SUN Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM) Nisha Joseph Received Received
  4036-SUN Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study gro Evangelos Terpos Sr Received Received
  4037-SUN Response-adapted randomization to Q2W vs Q4W isatuximab beyond cycle 6 in relapsed multiple myeloma: Results from a phase 2 Study of isa-pd in lenalidomide- and PI-exposed patients Evangelos Terpos Sr Received Received
  4038-SUN Hematologist based management of ocular adverse events using the VRA tool in newly-diagnosed myeloma patients, ineligible for ASCT who received belantamab mafodotin plus lenalidomide/dexamethasone: Updated results from the randomized part 2 of bela-rd Stu Evangelos Terpos Sr Received Received
  4039-SUN Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND) Matthew James Rees Received Received
  4040-SUN Reassessing ASCT in patients aged 65–75 with multiple myeloma in the era of anti-CD38 therapies Angelo Belotti Received Received
  4041-SUN Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received =1 prior line of therapy Attaya Suvannasankha Received Received
  4042-SUN Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma Amrita Krishnan Received Received
  4043-SUN Integrated modeling analyses for belantamab mafodotin in combination with standard of care in patients with Relapsed/Refractory multiple myeloma (RRMM) from dreamm-6, dreamm-7, and dreamm-8 Fernando Carreño Received Received
  4044-SUN Home administration of isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study María-Victoria Mateos Received Received
  4045-SUN Elranatamab for relapsed/refractory multiple myeloma – multi-centre real-world outcomes from the United Kingdom Oliver Tomkins Received Received
  4046-SUN Comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus belantamab mafodotin (belamaf), bortezomib, and dexamethasone and versus belamaf, pomalidomide, and dexamethasone in patients with relapsed / refractory multiple myeloma (RRMM) previousl Christopher Strouse Received Received
  4047-SUN Low-dose teclistamab in newly diagnosed multiple myeloma patients Michelle Morcos Received Received
  4048-SUN Phase II trial of maintenance therapy with iberdomide after autologous hematopoietic cell transplant for patients with multiple myeloma previously treated with lenalidomide Natalia Tijaro Ovalle Received Received
  4049-SUN Updated results of a first-in-human, Phase ?a/?b study of QLS32015 (GPRC5D×CD3) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) Gang An Received Received
  4050-SUN Feasibility and efficacy of daratumumab-vcd in transplant-ineligible elderly patients with newly diagnosed multiple myeloma: First results from the multicenter GMMG-dada study Christof Scheid Received Received
  4051-SUN Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma Karun Neupane Received Received
  4052-SUN A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study) Ola Landgren Received Received
  4053-SUN A randomized phase II study of daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible or deferred patients with newly diagnosed multiple myeloma: Alliance Foundation Trial 41 (AFT-41) Andrew J. Yee Received Received
  4054-SUN Clinical pharmacology strategies to support dose optimization of the recommended Phase 2 dose regimen of JNJ-5322, a BCMA×GPRC5D×CD3 trispecific antibody, in Relapsed/Refractory multiple myeloma Ashley Nguyen Received Received
  4055-SUN Belantamab mafodotin (belamaf) ocular events are manageable and reversible with dose modifications guided by standard assessments Sagar Lonial Received Received
  4056-SUN Quantitative clinical pharmacology analysis to support the dose escalation of elranatamab + nirogacestat in the MagnetisMM-4 study Sibo Jiang Received Received
  4057-SUN Hyperfractionated cyclophosphamide, bortezomib and dexamethasone for initial treatment of newly diagnosed multiple myeloma with renal dysfunction Guneet Kaleka Received Received
  4058-SUN Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study Ola Landgren Received Received
  4059-SUN Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study Qiuqing Xiang Received Received
  4060-SUN Belantamab mafodotin, nirogacestat, and pomalidomide in patients with relapsed/refractory multiple myeloma Malin Hultcrantz Received Received
  4061-SUN Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg/m2 VS. 200 mg/m2 as a conditioning regimen prior to autologous stem cell transplantation. Beatriz Chiclana-Rodríguez Received Received
  4062-SUN Effect of isatuximab use in combination with autologous stem cell transplant on mobilized stem cell product and post-transplant immune recovery - Results of a randomized prospective Phase 2 trial Divaya Bhutani Received Received
  4063-SUN Teclisito: Low-intensity teclistamab in the outpatient setting for Relapsed/Refractory multiple myeloma Ana Laura Varela Constantino I Received Received
  4064-SUN Fixed-duration teclistamab and talquetamab for frail patients with newly diagnosed multiple myeloma: The EMN37 fitfix study Sonja Zweegman Received Received
  4065-SUN Can a patient questionnaire (VRAT) reduce the need for ocular examinations with less frequent belantamab mafodotin combined with bortezomib and dexamethasone? the ukmra prommise d trial Rakesh Popat Received Received
  4066-SUN Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium. Dae Hyun Lee Received Received
  4067-SUN CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia Jingyu Xu Received Received
  4068-SUN CAC-MM-001: Anti-BCMA CAR-T therapy followed by autologous stem cell transplantation and second CAR-T (CART-ASCT-CART2) in newly diagnosed multiple myeloma patients with P53 gene abnormalities. Yuntong Liu Received Received
  4069-SUN Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations Saurabh Zanwar Received Received
  4070-SUN Pharmacokinetics, pharmacodynamics, and biomarkers of lbl-034, a GPRC5D-targeted T cell engager, in a first-in-human phase ?/? study in relapsed/refractory multiple myeloma Bin Fan Received Received
  4071-SUN Impact of antibiotic exposure on CAR-T cell therapy outcomes: Analysis in multiple Myeloma and lymphoma Feng Zhu Received Received
  4072-SUN Innovative sdab-based CAR-T cells targeting BCMA outperform current CAR-T therapies for multiple myeloma Juan Roberto Rodriguez-Madoz Received Received
  4073-SUN The allogeneic fully human anti-CD38-CAR-?d T cells enable off-the-shelf CAR-T cell therapy for myeloma Yuji Hattori Received Received
  4074-SUN Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center Ruike Yan Received Received
  4075-SUN Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant Ehsan Malek Received Received
  4076-SUN Favorable impact of patient´s selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the des Bertrand Arnulf Sr Received Received
  4077-SUN TPO-ras for persistent thrombocytopenia following CAR-T therapy in multiple myeloma: A multicenter clinical experience Yinqiang Zhang Received Received
  4078-SUN CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel) Shree Allada Received Received
  4079-SUN Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM) Ciara Louise L Freeman Received Received
  4080-SUN CD8+hla-DR+CD27+ t cells define a population of naturally occurring regulatory precursors in humans Huidong Guo Received Received
  4081-SUN Enteral supplementation with a TGF-ß-enriched polymeric diet mitigates gastrointestinal acute gvhd Sangya Chatterjee Received Received
  4082-SUN High fructose diet exacerbates acute GVHD through microbiota dysbiosis and HIF-1a–mediated macrophage activation Kunpeng Wu Received Received
  4083-SUN Galectin-3 in host murine models lessens the severity of graft-versus-host disease by preserving intestinal stem cells irrespective of gut microbiota composition Nour Nassour Received Received
  4084-SUN Gastrin for the treatment of acute graft-versus-host disease of the stomach Jana Gawron Received Received
  4085-SUN TIM3-Galectin9 axis drives CSF-1R–independent senescent macrophage and TSCM crosstalk in chronic graft-versus-host disease Xiaodong Xie Jr Received Received
  4086-SUN Enhancing donor cell engraftment in prenatal hematopoietic stem cell transplantation with novel antibody-drug conjugates Oluwaseun Babatunde Received Received
  4087-SUN Phytosphingosine alleviates acute gvhd by inducing th cell differentiation to Tr1 through GPR120/IL-10 axis Rui Wang Received Received
  4088-SUN Microbiota metabolite phenlyacetylglycine alleviates acute graft-versus-host diseases Yuqing Wang Received Received
  4089-SUN Specific targeting of HLA genes generates hypoimmunogenic hematopoietic stem cells for allogeneic transplantation Yiwen Han Received Received
  4090-SUN NLRP6 regulates ZAP-70-erk signaling in both murine and human T cells and influences acute graft-versus-host disease(GVHD) Tomomi Toubai Received Received
  4091-SUN Integrated multi-omics study identifies ursolic acid as a novel therapeutic agent targeting the TNF-a/TAK1/IKKß/NF-?B axis in hepatic sinusoidal obstruction syndrome Jie Wei Received Received
  4092-SUN Haploidentical and neonatal combined transplant generates GVL effect in a murine model of haplo-cord transplant. Eric Irons Received Received
  4093-SUN Dysfunction of the neurovascular unit (NVU) presents a novel indicator for CNS injury after allogeneic hematopoietic stem cell transplantation Vasantharaja Raguraman Received Received
  4094-SUN Quizartinib enhances conditioning for hematopoietic stem cell transplantation via transcriptional suppression of DNA repair pathways Samuel John Taylor Received Received
  4095-SUN Ex vivo-generated T cell precursors enhance thymic regeneration and T cell immunity after allogeneic hematopoietic cell transplantation Jennifer J. Tsai Received Received
  4096-SUN Modal CAR T cells: A synthetic cytokine circuit to overcome TGFß-mediated immunosuppression in AML Fuguo Liu Received Received
  4097-SUN SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence against cancer Melody Tan Received Received
  4098-SUN CD83 CAR T overcome CD19 antigen loss in B cell malignancies after CD19-directed therapy Marco Davila Received Received
  4099-SUN Comparative high-dimensional profiling reveals distinct immune reconstitution dynamics between CD19 and CD7 CAR-T therapies in acute leukemia Zhipeng Zhou Received Received
  4100-SUN Single-cell dissection of CAR-T and blinatumomab-elicited T cell states uncovers therapy-specific functional decay patterns Kexin Wang Received Received
  4101-SUN From bench to IND: Validation of TSLPR CAR T-cells reveal discrepancies in detection modalities and inform dose selection for a Phase 1 clinical trial in relapsed/refractory CRLF2-rearranged B-ALL patients. Christopher Daniel Chien Received Received
  4102-SUN High-affinity PD-1-CD28 switch receptor enhances sustained antitumor activity of CAR-T cells in both lymphoma and ewing sarcoma. Hanzhi Du, MD I Received Received
  4103-SUN Synkir-310 split-signaling based KIR-CAR T cell therapy achieves faster and deeper anti-B cell tumor efficacy with reduced cytokine levels Megan C Blair Received Received
  4104-SUN Cytokine receptor armored CAR-T cells enable robust T cell expansion and function in the absence of lymphodepletion Luhan Yang Received Received
  4105-SUN Live imaging of human xenogeneic CART cells in a clinical trial of companion dogs with lymphoma Elizabeth Louise Siegler Received Received
  4106-SUN In Vivo generation of anti-CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases Eli Pasackow Received Received
  4107-SUN Temporal control of CAR expression enables thymic generation of autoreactive T cells targeting tumor-associated antigens Manpreet Bariana Received Received
  4108-SUN PI3 kinase inhibition reduces CAR T cell trogocytosis mediated fratricide Tarang Sharma Received Received
  4109-SUN Genome-wide CRISPR screening identifies CRL1 as a therapeutic target for restoring CD19 expression and improving immunotherapy efficacy in B-cell malignancies Narendra Varma Gottumukkala Received Received
  4110-SUN Novel CTLA-4 costimulatory domain mitigates cytokine-related toxicity, improving the anti-cancer therapeutic index of CS1-CAR T cells for multiple myeloma Xiuli Wang Received Received
  4111-SUN This is a title in sentence case:synnotch CD123 and CLL1 CAR-T can specifically target AML to avoid the off-target effects Rui Zhang Received Received
  4112-SUN Development of a novel CAR-T cell therapy using a multimodal approach to target T cell lymphoma Criselle Dsouza Received Received
  4113-SUN Impact of antibiotic timing on survival outcomes in CD19 and BCMA CAR-T cell therapy Serena Tharakan Received Received
  4114-SUN Mitochondrial mass in pre-lymphodepletion T cells predicts early response to CAR-T therapy in relapsed/refractory non-Hodgkin lymphoma Yun Kang Received Received
  4115-SUN Survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T therapy: An AI-optimized cox regression model based on CCL5, scgf-ß, and TRAIL Hu Qian Jr Received Received
  4116-SUN Allogeneic CD19-directed CAR T-cell therapy derived from umbilical cord blood for relapsed acute lymphoblastic leukemia Xiao Wang Received Received
  4117-SUN In Vivo pan CAR therapy utilizing circular RNA for treatment of multiple myeloma Rebecca Silver Received Received
  4118-SUN B-lineage acute lymphoblastic leukaemia disrupts a LepR+ bone marrow stromal niche which is critical for CAR-T cell persistence Aideen Therese O´Neill Received Received
  4119-SUN Identifying splice variants of cell surface proteins for chimeric antigen receptor T cell therapy of Acute Myeloid Leukemia Fabiana Perna Received Received
  4120-SUN Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4-34 B cell receptor Audrey C Bochi-Layec Received Received
  4121-SUN Development of next generation multi-antigen targeting off-the-shelf CAR T cells for conditioning-free treatment of B-cell lymphoma Shilpi Chandra Received Received
  4122-SUN Target enrichment long-range sequencing (TLES) reveals structural variations missed by PEM-seq Jiangtao Ren Received Received
  4123-SUN CLEC2A, a validated cancer-specific antigen, is an ideal candidate for immunotherapeutic targeting in KMT2A-rearranged AML Danielle Kirkey Received Received
  4124-SUN Dual-armoring of CLL-1 CAR-T cells with IL-18 and an RQR8 suicide switch enhances efficacy and safety in Acute Myeloid Leukemia Wenyi Lu Received Received
  4125-SUN Intein-based modular assembly of multi-receptor CAR T cells Bintao Wang Received Received
  4126-SUN TCF-1 overexpression enhances CD19.CAR-T cell potency by attenuating activation-induced cell death Qian Chen Received Received
  4127-SUN Metabolic conditioning for enhanced CAR T cell function Roddy O´Connor Received Received
  4128-SUN Elimination of alloantibody responses using chimeric HLA-II antibody receptor T cells Georgia F. Papadaki Received Received
  4129-SUN Reprogramming CAR-NK cells with IL-7/IL-7Ra to amplify STAT1 signaling and activate bystander T cells for enhanced immunotherapy Andreia Maia Received Received
  4130-SUN A long-term antigen-spreading by novel cancer vaccine with hyaluronic acid nanogel accelerate the anti-neoplastic efficacy of cytotoxicity of infused TCR-T cells and altered neplastic microenvironment Keiki Nagaharu Received Received
  4131-SUN Novel In Vivo CAR platform for autoimmune disease therapy Asen Bagashev Received Received
  4132-SUN T cell receptors targeting mutant NPM1 for adoptive cell therapy in acute myeloid leukemia Aidan J. Pursley Received Received
  4133-SUN PU.1: C/EBPa ratio-directed reprogramming converts B-ALL cells into stable M1 macrophages for scalable cancer immunotherapy Mengjie Li Received Received
  4134-SUN Metabolic reprogramming via targeting the medium-chain fatty acid receptor enhances the anti-tumor activity of lymphocytes in cancer immunotherapy Anamaria Morales-Alvarez Received Received
  4135-SUN Therapeutic targeting of the recurrent mutant TP53R248Q neoantigen by T cell receptor-engineered T cells in human cancers lianghua shen Received Received
  4136-SUN Differentiation of human induced pluripotent stem cells expressing chimeric antigen receptors into distinct immune cells as an off-the-shelf strategy for tumor treatments Paula do Amaral Costa Ribeiro Received Received
  4137-SUN Engineered IL7/IL15 secreting iPSC-derived mesenchymal stromal cells reprogram the immunosuppressive tumor microenvironment and potentiate antitumor immunity Sandeep Singh Received Received
  4138-SUN Small molecule-regulated BCMA-CAR expression switch enables precise control of trispecific BCMA/CD20/CD79b targeting PSC-NK cell function against B cell-related disorders Tiantian Ji Received Received
  4139-SUN Novel ?d T cell engager platform for cancer immunotherapy promoted T cell expansion with a persistence-indicating phenotype Lawrence Lamb Jr Received Received
  4140-SUN The CHD1L protein regulates cell activation by controlling lipid-related metabolism in B cells JUN Zeng Received Received
  4141-SUN In-depth, quantitative characterization of important regulators and predictive biomarkers for CAR T-cell therapy induced toxicities in a clinical cohort Marco Davila Received Received
  4142-SUN CD19/CD22 CAR-T cells in adult patients with relapsed/refractory B-cell malignancies Laurent Phely Received Received
  4143-SUN First-in-human study of CTX130, a CD70-directed allogeneic CAR T therapy, in adult T-cell leukemia/lymphoma: Clinical and genomics findings from a long-term follow-up of subgroup analysis from the cobalt-LYM Phase 1 trial Emma Cordover Received Received
  4144-SUN Parkinsonism after treatment with anti-CD19 CAR-T: Case report, institutional data review, and pharmacovigilance analysis of the FDA adverse event reporting system database Kevin Zhu Received Received
  4145-SUN Tri-specific autologous CD19.20.22 chimeric antigen receptor (CAR) T-cells for patients with Relapsed/Refractory B-cell lymphomas. Samuel Weeks Received Received
  4146-SUN SL0439: A structure-tuned bispecific nanobody CAR-T cells targeting BCMA/GPRC5D for relapsed/refractory multiple myeloma with extramedullary disease Su Li Received Received
  4147-SUN Independent assessment of ALC thresholds currently in use to predict motor/neurocognitive toxicities (MNTs) after treatment with ciltacabtagene autoleucel Yein Jeon Received Received
  4148-SUN Intratumoral cellular immunotherapy with autologous hyperactivated M1 SIRPa-low macrophages in non-Hodgkin lymphoma: Clinical results from a first-in-human Phase 1 study Paolo Strati Received Received
  4149-SUN Immune reconstitution and infectious complications following CAR-T cell therapy Pedro Rodrigues Santos Received Received
  4150-SUN Five year follow-up of donor-derived CD7 CAR T-cell therapy for r/r T-cell acute lymphoblastic leukemia Jing PAN Received Received
  4151-SUN Atypical neurotoxicity in CAR-T cell therapy: A retrospective analysis of unusual icans presentations and their clinical implications Melissa Nicholas Received Received
  4152-SUN A novel loop-structured CD19/CD22 dual-targeting CAR-T therapy for patients with refractory/relapsed B-cell non-Hodgkin lymphoma Wei Zhang Received Received
  4153-SUN A multicentre Phase I clinical trial demonstrates manufacturing feasibility, safety and activity of novel humanized BCMA-directed CAR-T cell therapy. Rahul Purwar Received Received
  4154-SUN Allogenic donor-derived cytokine-induced killer (CIK) cells as a safe post-transplant treatment for disease recurrence in the setting of HLA-mismatched donors Benedetta Rambaldi Received Received
  4155-SUN Prospective predictors of toxicity of BCMA-directed CART therapy in multiple myeloma Eyal Lebel Received Received
  4156-SUN Anti-CD7 CAR T-cell therapy for ultra-high-risk relapsed/refractory T-ALL/lbl: Insights into lineage switch and consolidation strategies Jiahua Niu Received Received
  4157-SUN Assessment of prolonged thrombocytopenia after CD19 CAR-T therapy: Evidence for reduced production Toral Manesh Shastri Received Received
  4158-SUN The impact of clonal hematopoiesis on CAR-T cell therapy outcomes: A single-center analysis Grace Mercadante Received Received
  4159-SUN CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity Hrishikesh Srinagesh Received Received
  4160-SUN Non-relapse mortality in patients who received CAR T-cell therapy at an urban hospital Saumya Latha Karne Received Received
  4161-SUN Anti-CD7 CAR-T cells in patients with relapsed or refractory CD7+ Acute Myeloid Leukemia: First-in-human phase I study Lianxuan Liu Received Received
  4162-SUN A subset of patients achieve prolonged remission beyond 3–5 years with FHVH33-CD8BBZ BCMA CAR T-cells for RRMM Lekha Mikkilineni Received Received
  4163-SUN WU-CART-007, a CD7-directed allogeneic CAR-T cell therapy for R/R T-cell acute lymphoblastic leukemia/lymphoma: Phase 1/2 correlative data and long-term follow-up update Alexander S. Hamil Received Received
  4164-SUN LV20.19 CAR T cells for methotrexate relapsed/refractory primary or secondary CNS lymphoma with parenchymal involvement Ashley Carol Dunton Received Received
  4165-SUN UCD19 CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia in first complete remission with MRD positivity: Preliminary Results of A phase I/ib clincal trial Marc Schwartz Received Received
  4166-SUN Optimizing immunity to pneumococcus by vaccination with pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T cell immunotherapy M Bakri Hammami Received Received
  4167-SUN An IL-10-incorporated predictive model for late immune effector cell-associated hematotoxicity following CAR-T therapy in B-cell malignancies Shujia Zhang Received Received
  4168-SUN Lymphodepletion-free jl-lightning CAR-T targeting CD19/CD22/BCMA achieved 100% CR in 3 Relapsed/Refractory B-NHL patients: A lymphodepletion regimen comparison study Yi Liu Received Received
  4169-SUN Prolonged thrombocytopenia following diverse CAR-T cell therapies: High incidence, inflammatory risk factors, and a comparative efficacy analysis of TPO-receptor agonist strategies in a real-world cohort Yajing Zhang Received Received
  4170-SUN Race matters: Cytopenia trajectories after chimeric antigen receptor T- cell therapy in a single-center study Sushmitha Nanja Reddy Received Received
  4171-SUN Late re-expansion and high-level persistence of CAR T-cells can be driven by single CAR+ T-cell clones without clinically evident CAR+ T-cell lymphoma Simon Voelkl Received Received
  4172-SUN Neuroinflammation detected by TSPO-PET precedes dopaminergic neuronal loss in mnt following BCMA-directed CAR-T therapy: Longitudinal multimodal neuroimaging and biomarker insights Veit Buecklein Received Received
  4173-SUN CAR-T cells co-targeting BCMA and CD19 in RRMM: Results from the UKMRA Phase 1 MCARTY trial in relapsed refractory multiple myeloma Lydia Sarah Hui Lee Received Received
  4174-SUN Title first-in-human Phase 1 dose-finding study (VIPER 101) of dual-population autologous CD5-deleted anti-CD5 CAR-T (Senza5 CART5) cells in Relapsed/Refractory T-cell lymphomas Stefan K Barta Received Received
  4175-SUN Autologous CD19-directed CAR-T exhibit promising safety and efficacy in refractory primary immune thrombocytopenia Shiqi Li Received Received
  4176-SUN Phase I study of FH FOLR1 CAR T for pediatric patients with FOLR1+/CBFA2T3::GLIS2+ relapsed or refractory Acute Myeloid Leukemia Katherine Tarlock Received Received
  4177-SUN Safety and efficacy of transposon, BAFF-ligand directed chimeric antigen receptor T cells (LMY-920) with pre-apheresis obinutuzumab for patients with Relapsed/Refractory chronic lymphocytic leukemia and small lymphocytic lymphoma Paolo Fabrizio Caimi Received Received
  4178-SUN A novel IL-11/G-CSF mobilization regimen improves delayed platelet engraftment via targeted megakaryocyte progenitor expansion Jiexian Ma Received Received
  4179-SUN A prospective, multicenter study on stem cell mobilization using EAP regimen as first-line mobilization in patients with multiple myeloma and lymphoma Peipei Ye Sr Received Received
  4180-SUN CTD402: Allogeneic CAR-t manufacturing that overcomes donor- & process-derived variation with robust clinical activity Jiangtao Ren Received Received
  4181-SUN Enhanced vsvg variants for binder-dependent and high-specificity transduction of primary T cells Luhan Yang Received Received
  4182-SUN Etoposide-cytarabine-pegfilgrastim (EAP) and disease-specific chemotherapy regimens for hematopoietic stem cell mobilization in lymphoma: A randomized phase III trial Peipei Ye Sr Received Received
  4183-SUN Detection of CPC in peripheral blood after G-CSF mobilization reduces the contamination rate of autologous transplantation stem cell collections for multiple myeloma and explore strategies for graft purification treatment Xi Zhang Received Received
  4184-SUN Generation of iNKT cells with hematopoiesis-promoting properties from human iPSCs Saritha D´Souza Received Received
  4185-SUN Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers Sara Close Received Received
  4186-SUN A mammalian coacervate-based platform for high-efficiency gene editing in hematopoietic stem cells Renxia Zhang Received Received
  4187-SUN Single-day non-activated IL-18-armed CAR T cells with enhanced persistence and durable efficacy Saba Ghassemi Received Received
  4188-SUN Shift toward more naïve phenotype of the T cell compartment in patients with aggressive B cell non-Hodgkin lymphoma undergoing high-dose methotrexate therapy Vanessa Ridder Received Received
  4189-SUN Umbilical cord blood microtransplantation as consolidation therapy for elderly patients with newly diagnosed Acute Myeloid Leukemia: A single-center randomized controlled trial Fuling Zhou Jr Received Received
  4190-SUN TBI-ATG based conditioning regimen is a promising approach for adult patients with refractory and relapsed peripheral T cell lymphoma undergoing allogeneic peripheral blood stem cell transplantation Chuxian Zhao Jr Received Received
  4191-SUN Rapid genomic analysis for the early identification of complement abnormalities in adults with transplant associated thrombotic microangiopathy Jacopo Mariotti Received Received
  4192-SUN Efficacy of thiotepa-containing conditioning regimens and mucositis burden in allogeneic HSCT for relapsed/refractory acute leukemia with extramedullary disease Minglu Li Received Received
  4193-SUN Young (35 years) matched sibling donors for allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT Arnon Nagler Received Received
  4194-SUN Melphalan versus cyclophosphamide combined with fludarabine and low dose total body irradiation (TBI) prior to ptcy-based allogeneic transplantation Scott R Solomon Received Received
  4195-SUN Clinical characteristics of human herpesvirus 7 (HHV-7) reactivation following umbilical cord blood transplantation: A retrospective study Kai Ishimaru Jr Received Received
  4196-SUN Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse. Yasser K Khaled Received Received
  4197-SUN Characteristics and outcomes of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy: A retrospective single-center analysis Taylor Luckie Received Received
  4198-SUN Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study. Kayleigh Ingersoll Omdahl Received Received
  4199-SUN Establishing the impact of effective donor-specific antibody (DSA) desensitisation in haploidentical and mismatched donor haematopoietic stem cell transplants: An Australian experience Louis Do Received Received
  4200-SUN Impact of early bacteremia on clinical outcomes following allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based gvhd prophylaxis Moazzam Shahzad Received Received
  4201-SUN Fludarabine, cyclophosphamide, and melphalan (FCM) preconditioning in haploidentical hematopoietic stem cell transplantation for severe aplastic anemia: Update of a prospective, multicenter, single-arm clinical study Xiaoping Li II Received Received
  4202-SUN Macrophage CD38 overexpression drives primary platelet engraftment failure via paracrine suppression following allogeneic hematopoietic stem cell transplantation Peng Wang Received Received
  4203-SUN Diagnostic value of pathogen metagenomic next-generation sequencing (mNGS) for early bloodstream infections in pediatric allogeneic hematopoietic stem cell transplantation recipients yang wan Received Received
  4204-SUN Blood microbial DNA as a non-invasive diagnostic surrogate for pneumonia pathogens in immunocompromised patients: A real-world outcomes analysis Kun Zhou Received Received
  4205-SUN Prognostic impact of transplant conditioning intensity (TCI) score and minimal identifiable disease (MID) in MDS: A multicenter trophy group study Ruoxuan Zhang Jr Received Received
  4206-SUN Ven+FluBu2 with ptcy/tac/MMF RIC transplant followed by venetoclax/azacitidine maintenance for high-risk MDS/AML H. Moses Murdock Received Received
  4207-SUN Comparison of alemtuzumab and ATG-based conditioning in adult recipients of allogeneic hematopoietic cell transplantation (HCT) for severe aplastic anemia: A retrospective study Murad Almowarey Received Received
  4208-SUN Real-world outcomes of total body irradiation-based conditioning in allogeneic hematopoietic stem cell transplantation: A single-center retrospective study Mirko Farina Received Received
  4209-SUN Germline genetic variants and post-HCT cytokine/chemokine milieu may identify those at higher risk of primary graft failure after allogeneic hematopoietic cell transplantation, a blood and marrow transplant clinical trials network (BMT CTN) study Kirsten M Williams Received Received
  4210-SUN Usefulness of C5b9 deposition analysis for the diagnosis, treatment, and monitoring of patients with transplant-associated thrombotic microangiopathy Julia Martinez-Sanchez Received Received
  4211-SUN Higher busulfan cumulative exposure predicts better thalassemia-free survival in patients with beta thalassemia undergoing HCT with busulfan-cyclophosphamide containing conditioning regimen Poonkuzhali Balasubramanian Received Received
  4212-SUN The impact of cytokine release syndrome on survival following allogeneic stem cell transplantation with post transplantation cyclophosphamide: Insights from real-world data Carolina Velez-Mejia Received Received
  4213-SUN Comparative efficacy of TBI-based vs. non-TBI reduced toxicity conditioning regimens in adult ALL undergoing allogeneic HCT in CR1: Improved outcomes with TBI-based RTC and ATG/ptcy combination Kyung won Park Received Received
  4214-SUN Real world data on the use of thrombopoietin receptor agonists in patients after allogeneic hematopoietic stem cell transplantation Julia Cserna Jr Received Received
  4215-SUN Single center evaluation of TCRaß+ T cell depletion using CliniMACS® plus platform: Optimizing cell selection for hematopoietic stem cell transplantation Rilan Ou Received Received
  4216-SUN Immune tolerance induction after haploidentical stem cell transplant following organ transplantation in sickle cell disease Ali D Alahmari Received Received
  4217-SUN Tocilizumab for cytokine release syndrome after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide Tuan Le Phan Received Received
  4218-SUN Abatacept in combination with post-transplant cyclophosphamide and tacrolimus may improve survival and non-relapse mortality without increasing relapse risk after allogeneic stem cell transplantation Yasser K Khaled Received Received
  4219-SUN Coronary artery calcification and its effect on cardiac events in patients undergoing allogeneic stem cell transplantation using nonmyeloablative conditioning Christopher D Graham Received Received
  4220-SUN Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for gr Christopher D Graham Received Received
  4221-SUN Hematopoietic stem cell transplantation with reduced toxicity myeloablative conditioning regimen for children and adults with sickle cell disease: A brazilian single center experience. Thalita Cristina de Mello Costa Received Received
  4222-SUN Development and evaluation of a protein language model-based prediction model for acute graft-versus-host disease in HLA-mismatched hematopoietic stem cell transplantation Makoto Moriguchi Received Received
  4223-SUN Evaluating gvhd outcomes after chemotherapy-only conditioning in nicotinamide-expanded umbilical cord blood (omidubicel) transplantation: A retrospective cohort study Alexander O´Hara Received Received
  4224-SUN Low incidence of agvhd with ptcy, tacrolimus and post-engraftment low dose ATG-based GvHD prophylaxis in haplo-identical donor transplantation and establish of new predict score for grade II-iv agvhd Lining Wang Received Received
  4225-SUN Longitudinal and integrated analysis of oral and stool microbiome in allogeneic hematopoietic cell transplantation recipients. Ronald Francis Siebenaler Received Received
  4226-SUN Gut microbiota recovery via butyrate supplementation prevents acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Seug Yun Yoon Received Received
  4227-SUN Impact of graft versus host disease prophylaxis with post transplant cyclophosphamide on the prognostic value of HCT-CI Ansh Mehta Received Received
  4228-SUN Vedolizumab for treating steroid-refractory lower gastrointestinal acute graft-versus-host disease: a single-center real-world study Jieya Luo Received Received
  4229-SUN TDI01 in the treatment of moderate to severe chronic graft-versus-host disease: Updated results from a multicenter, OPEN-label phase IB/II study (An Update) Daniel Zaldumbide Received Received
  4230-SUN Donor and recipient age-related differences in immunological reconstitution affect development of chronic graft-versus-host disease Fumihito Tajima Received Received
  4231-SUN A multi-timepoint immune profiling model for differentiating gvhd- and infection-associated diarrhea following allo-HSCT Hui Wang IV Received Received
  4232-SUN Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study Steven Michael Devine Received Received
  4233-SUN Real world experience of alpha-1 antitrypsin in steroid-refractory acute graft versus host disease: Higher durable response rate compared to ruxolitinib Henry Castellani Received Received
  4234-SUN Control of gvhd by probiotics with a single strain of muribaculaceae bacterium through secretory proteins Qiao Cheng Received Received
  4235-SUN Identification of CD4+ T cells targeting DM-sensitive antigens presented on mismatched HLA-DP alleles, as mediators of a selective graft-versus-leukemia effect. Katharina Korn Received Received
  4236-SUN The role of microbial metabolites in fecal microbiota transplantation in patients with acute gvhd of the gut Alix Schwarz Received Received
  4237-SUN Mesenchymal stem cells for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: A multicenter, single-arm, pivotal clinical Trial Yawei Zheng Received Received
  4238-SUN Peri-transplant ruxolitinib therapy significantly improves GVHD-free, relapse-free survival rates in transplantation for myelofibrosis Jack Illingworth Received Received
  4239-SUN Multicenter real-world experience of belumosudil treatment in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: Clinical outcomes and risk factor analysis for failure-free survival. Sergio Rodriguez-Rodriguez Received Received
  4240-SUN Thymic dysfunction promotes the emergence of pathogenic peripheral CD4?CD8? T cells and induces tissue injury in acute gvhd Hengwei Wu Received Received
  4241-SUN CXCR5?PD-1? circulating T follicular helper cells identify vaccine readiness in pediatric allogeneic hematopoietic cell transplantation Leena Babiker Received Received
  4242-SUN Graft vs host disease outcomes in early tacrolimus withdrawal following allogeneic hematopoietic stem cell transplant Chase Junge Received Received
  4243-SUN GVHD intel 1.0: A scalable, HLA-enhanced machine learning model for predicting acute and chronic GVHD Naveed Syed Received Received
  4244-SUN Fludarabine and total body irradiation 800 cgy or 1125 cgy for allogeneic stem cell transplant using graft versus host disease prophylaxis with post-transplant cyclophosphamide and tacrolimus, without mycophenolate mofetil (OmitMMF trial) Ronald Paquette I Received Received
  4245-SUN Peripheral plasmablast expansion as a predictor and therapeutic target in chronic GVHD Katharina Marie Habenicht Received Received
  4246-SUN An optimized MSC product promotes GvHD prophylaxis through exosome-mediated regulatory T cell induction Brian H. Johnstone Received Received
  4247-SUN In Vivo evaluation of autologous serum eye drops obtained via a closed-circuit collection device: Preliminary analysis of a Phase 2 pilot trial Giancarlo Fatobene Received Received
  4248-SUN T-cell tolerant fraction as a predictor of graft-versus-host disease in murine and human allogeneic hematopoietic cell transplantation Jared Ostmeyer Received Received
  4249-SUN HLA mismatch-derived epitopes predict acute graft-versus-host disease risk after unrelated donor transplantation Nicoletta Cieri Received Received
  4250-SUN Poor nutritional intake prior to allogeneic hematopoietic cell transplantation is associated with higher incidence of lower-gastrointestinal graft-versus-host disease Natalie Grier Smith Received Received
  4251-SUN Improvement of signs and symptoms of vulvovaginal chronic graft-versus-host disease with non-ablative radiofrequency therapy Giancarlo Fatobene Received Received
  4252-SUN Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more Howard Chang Received Received
  4253-SUN Antibiotic risk score for acute graft-versus-host disease Armin Rashidi Received Received
  4254-SUN Factors associated with acute and chronic graft-versus-host disease after unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis Moazzam Shahzad Received Received
  4255-SUN Computational dissection of immune reconstitution across diverse conditioning regimens in adults with sickle cell disease undergoing allogeneic stem cell transplantation Abdul-Hamid Bazarbachi Received Received
  4256-SUN Trial in progress: A phase 3, randomized, double-blind, placebo-controlled study of axatilimab and corticosteroids as initial treatment for moderate to severe chronic graft-versus-host disease Zachariah Defilipp Received Received
  4257-SUN Long-term outcomes of allogeneic stem cell transplantation in ß-thalassemia major: A single centre experience from Algeria Mounira Baazizi III Received Received
  4258-SUN Improved Survival outcomes with allo-HSCT in NUP214::ABL1-Positive Acute leukemia: A pooled analysis and single-center experience Jiu-jiang He Received Received
  4259-SUN Outcomes of second hematopoietic stem cell transplantation for relapsed myelodysplastic syndrome: An updated analysis of Japanese nationwide transplant registry Kamma Shiraishi Received Received
  4260-SUN Effect of graft cellular content on outcomes in HLA mismatched hematopoietic cell transplantation using post-transplant cyclophosphamide Remy Dulery Received Received
  4261-SUN Improved outcomes with low-dose hypomethylating agent plus venetoclax as post-transplant maintenance in patients undergoing reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for myeloid malignancies Kendall Diebold Received Received
  4262-SUN Enhanced long-term outcomes with third-party unrelated cord blood co-infusion in a 122-patients cohort undergoing second allo-HSCT for AML in remission Wei Zhao I Received Received
  4263-SUN Acute myocardial infarction following allogeneic hematopoietic stem cell transplantation: Lessons learned from a national representative study Peng Zhao Received Received
  4264-SUN Maribavir for cytomegalovirus infections after hematopoietic stem cell transplantation: A real world comparative cohort study jiaxin cao Received Received
  4265-SUN Hematopoietic cell transplantation in acute lymphoplastic leukemia: The Mexican experience Gerardo Garcia-Salas Received Received
  4266-SUN Organ dysfunction in pediatric patients with HSCT-TMA treated with ravulizumab Sonali Chaudhury Received Received
  4267-SUN Insights from a multicenter study on the outcomes of liver abscess after allogeneic hematopoietic stem cell transplantation Fanhao Nie Received Received
  4268-SUN Divergence in post-traumatic stress disorder status between children receiving hematopoietic stem cell transplantation and their primary caregivers Jiali Ma Received Received
  4269-SUN A novel predictive model for posttransplant lymphoproliferative disorder in the letermovir prophylaxis era Chen-Cong Wang Received Received
  4270-SUN Allo-HCT outcomes for AML patients with NUP98 rearrangements: A study on behalf of the global committee, the ALWP and the PDWP of the EBMT Yishan Ye Received Received
  4271-SUN Low CMV and EBV infections in the era of letermovir with post-transplantation cyclophosphamide combined with tacrolimus and low-dose post engraftment ATG as gvhd prophylaxis. Wenhui Gao Received Received
  4272-SUN Peripheral blood CD34 donor chimerism and flow cytometry for measurable residual disease are complementary assays for predicting relapse of AML after allogeneic transplantation in AML Michael Ashby Received Received
  4273-SUN Relapse with post-transplant tyrosine kinase inhibitor (TKI) maintenance therapy in phliladelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) after allogeneic hematopoietic stem cell transplantation: Incidence and risk factor analysis Eshrak Al-Shaibani Received Received
  4274-SUN Clinical outcome of hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia: A Single center in China Sa Zong Received Received
  4275-SUN Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers Maria Gabarros-Subira Received Received
  4276-SUN Development and prospective validation of a prognostic model for diffuse alveolar hemorrhage after allogeneic hematopoietic stem cell transplantation Qiu-Sha Huang Received Received
  4277-SUN Letermovir cytomegalovirus prophylaxis in hematopoietic-cell transplantation; Real world evidence from high endemic regions. Rahaf Salem Received Received
  4278-SUN Children and adolescents with sickle cell disease demonstrate improved health-related quality of life and low decisional regret after hematopoietic cell transplantation: A sickle cell transplant advocacy and research alliance (STAR) study Gregory Michael Taylor Guilcher Received Received
  4279-SUN Real world outcomes of FLT3 inhibitors and hypomethylating agents as post transplant prophylaxis in Acute Myeloid Leukemia patients transplanted in first complete remission: From the EBMT acute leukemia working party Nour Moukalled Received Received
  4280-SUN Incidence and risk factors of Epstein–Barr virus reactivation and post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: A 985-patient retrospective cohort analysis Fei Gao Received Received
  4281-SUN Superior disease-free survival of allogeneic hematopoietic stem cell transplantation in elderly patients with hematological malignancies in complete remission by reduced-intensity or myeloablative conditioning Yongqiang Zhao Received Received
  4282-SUN Allogeneic hematopoietic stem cell transplantation for acute leukemias of mixed or ambiguous lineage Sunmin Park Received Received
  4283-SUN Incidence and risk factors for new overweight or obesity following hematopoietic cell transplantation for sickle cell disease Grace Kalmus Received Received
  4284-SUN Risk factor analysis of relapse risk during FLT3-inhibitor post-transplant maintenance therapy following allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia with FLT3-ITD Yomna Eissa Received Received
  4285-SUN Pre-transplant nutritional status and hospitalization risk in outpatient hematopoietic stem cell transplantation: A prospective study using the patient-generated subjective global assessment Alexia E. Gonzalez-Lozano Received Received
  4286-SUN Comprehensive analysis of long-term outcomes in adult patients with acute lymphoblastic leukemia who received allogeneic stem cell transplantation: Real-world data of the Korean society of blood and marrow transplantation registry Dong Won Baek Sr Received Received
  4287-SUN Trial in progress: Pilot trial of olutasidenib maintenance post allogeneic hematopoietic cell transplantation in patients carrying IDH1 mutation with AML, MDS, or CMML Abhay Singh Received Received
  4288-SUN Early TCR diversity and recipient stem-cell persistence predict relapse and reveal therapeutic targets after allogeneic transplantation Nurefsan Sariipek Received Received
  4289-SUN Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapsed/refractory FLT3-mutated acute myeloid leukemia: A Japanese nationwide registry study Yasuyuki Arai Received Received
  4290-SUN Clinical impact of predicted indirectly recognizable HLA epitopes (PIRCHE) in single unit cord blood transplantation using tacrolimus and methotrexate for graft-versus-host disease prophylaxis Tomoki Naito Received Received
  4291-SUN Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy David Sallman Received Received
  4292-SUN Impact of pre-transplant chemotherapy cycles on allogeneic hematopoietic cell transplant outcomes in pediatric acute myeloid leukemia Alex Hoover Received Received
  4293-SUN Dynamic ?EASIX score is a robust predictor of survival and relapse after allogeneic hematopoietic cell transplantation in acute leukemia Esra Gulderen Received Received
  4294-SUN Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center Alexandre Bazinet Received Received
  4295-SUN Post-transplant monitoring of multiparameter flow-cytometry (MFC)-based measurable residual disease (MRD) assessment combined with T-cell chimerism following allogeneic stem cell transplantation (HCT) in Acute Myeloid Leukemia (AML) and myelodysplastic sy Reem Alasbali Received Received
  4296-SUN The evaluation of the HLA-KIR interaction models may predict the NK alloreactivity in haplo-HSCT based on ptcy: Experience of a single spanish center Rodrigo Gil-Manso Jr Received Received
  4297-SUN Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom Mauricette Michallet Received Received
  4298-SUN Selecting the optimal bridging therapy for B-ALL: A multicenter comparison of blinatumomab, inotuzumab ozogamicin, and CAR-T prior to allo-HSCT Ao-Ran Zhang Received Received
  4299-SUN Predicting algorithm for GRFS after allogeneic hematopoietic stem cell transplantation: A study by the SFGM-TC Estelle Hamon Received Received
  4300-SUN Outcomes of elderly (= 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT) Onyee Chan Received Received
  4301-SUN Acrobat interim results: Alloheme surveillance enables early detection of relapse in post-HCT AML and MDS patients Monzr M. M Al Malki Received Received
  4302-SUN Multicenter Phase II trial of enasidenib as maintenance treatment following allogeneic stem cell transplantation in IDH2-mutated myeloid neoplasms – the IDH2-post-allo-trial (NCT04522895) Thomas Schroeder Received Received
  4303-SUN Fapi PET/CT as an innovative imaging tool for monitoring bone marrow fibrosis and treatment response in myelofibrosis patients undergoing allogeneic stem cell transplantation Victoria Panagiota Received Received
  4304-SUN Impact of pre-transplant bone marrow cellularity and fibrosis on post-transplant outcomes in sickle cell disease Umar Qadri Received Received
  4305-SUN Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival Claire Carlson Received Received
  4306-SUN Allogeneic hematopoietic cell transplantation risk stratification and eligibility using race-neutral versus race-specific pulmonary equations Felipe Soto Received Received
  4307-SUN Monte Carlo simulation of HLA-DQ heterodimers and their interactions to predict relapse and GVHD risk in cord blood transplantation Julio Cesar Alvarenga Thiebaud Received Received
  4308-SUN All 19 subjects with transfusion-dependent ß-thalassemia achieved transfusion independence after treatment with RM-001 (autologous HBG1/2 promoter-modified CD34+ hematopoietic stem and progenitor cells) Hui Xu Received Received
  4309-SUN Decoding the role of inflammatory signaling in shaping HSC heterogeneity and engraftment in gene therapy-treated ß-thalassemia pediatric patients Maria Rosa Lidonnici Received Received
  4310-SUN Decoding Transgene Silencing from Stably Maintained AAV Genomes in Human Liver: Epigenetic Insights to Guide Next-Generation Vector Design Giulia Simini Received Received
  4311-SUN Activated factor IX ?adua delivered via adeno-associated virus enhances therapeutic efficacy in hemophilia B Li Liu Received Received
  4312-SUN Lentiviral hematopoietic stem and progenitor cell gene therapy for Wiskott-Aldrich Syndrome: Early access experience in Italian patients based on 648/1996 law Sabina Cenciarelli Received Received
  4313-SUN Arvenacogene sanparvovec: A novel gene therapy for hemophilia B – results from A phase I–II first-in-human trial Vadim Ptushkin Received Received
  4314-SUN CRISPR-Cas12a gene editing of the HBG1/2 promoters leads to sustained normalization of total hemoglobin and increased fetal hemoglobin in patients with severe sickle cell disease: Updated Results from the RUBY trial Rabi Hanna Received Received
  4315-SUN Adeno-associated viral integration profiles in human liver biopsies following Hemophilia A gene therapy Paul Batty Received Received
  4316-SUN Transduction efficiency and vector biodistribution following prenatal vs neonatal AAV5 gene therapy for Hemophilia A in a sheep model Martin Rodriguez Received Received
  4317-SUN Low dose AAV8-FVIII gene therapy on Chinese severe Hemophilia A patients with sustainable efficacy and safety Xinyue Dai Received Received
  4318-SUN In Vivo RNA delivery by targeted lipid nanoparticles enable gene editing in hematopoietic stem cells and T cells Rahul Palchaudhuri Received Received
  4319-SUN First in human prime edited autologous hematopoietic stem cell therapy for the treatment of p47phox CGD: Initial results of PRIME-0101 Elie Haddad Received Received
  4320-SUN Transient ATM inhibition enhances knock-in efficiency and long-term engraftment of genome-edited hematopoietic stem cells Fumio Nakahara Received Received
  4321-SUN Synthetic oligonucleotides contain synthesis errors that are propagated into the genome by editing through homology-directed repair Mark C Walters Received Received
  4322-SUN Silver nanoparticles trigger proteotoxicity in multiple myeloma cells via a mechanism distinct from bortezomib and remain efective in BTZ-resistant myeloma Khushbu Patel Received Received
  4323-SUN EMU-116: An oral CXCR4 antagonist as mobilizer of stem and immune cells in normal, neutropenic and sickle cell mice. Lawrence Joseph Wilson I Received Received
  4324-SUN Disrupting the PA2G4-NPM1 axis induces nucleolar stress in NPM1c AML Elisa Simoncini Received Received
  4325-SUN Vaccination targeting azacytidine-induced neoantigens in the C1498 murine AML model Othmane Jadi Received Received
  4326-SUN Identification of novel, potent, and selective JAK2V617F inhibitors Kimberly Ornell Received Received
  4327-SUN The asns inhibitor asx-173 potentiates l-asparaginase anticancer activity Philip Lorenzi Received Received
  4328-SUN The transition from myelodysplastic neoplasm to secondary acute myeloid leukemia is revealed by molecular analysis, while functional drug screening demonstrates novel sensitivity patterns with clinical implication Jieya Wu Received Received
  4329-SUN Momelotinib inhibition of JAK/STAT in a mouse JAKV617F myelofibrosis model showed concurrent activation of p-ERK and p-AKT which was reversed by combination therapy using LP-182, a novel MEK/PI3K/mTOR inhibitor Brian D. Ross Received Received
  4330-SUN Gold salt phospholipid inhibits glutathione peroxidase 4 (GPx4) and causes cell death in Mantle Cell Lymphoma: Demonstration of single agent activity and synergy with ibrutinib Jonathan Scott Rink Received Received
  4331-SUN Code red (Codigo Rojo): Multimodal generative AI for specialized hematology education Adrian Mosquera Received Received
  4332-SUN Developing a simplified ex vivo culturing protocol for personalized myeloma treatment in rural areas Zhi Wen Received Received
  4333-SUN Detection of minimal residual disease in t-cell acute lymphoblastic leukemia by 16-color full-spectrum flow cytometry Hui Wang IV Received Received
  4334-SUN DNA sequencing outperforms RNA sequencing for comprehensive fusion detection in lymphoma diagnostics Bingzong Li Received Received
  4335-SUN Toward precision pathology: Deep learning supported fibrosis grading augments performance of international hematopathologists in a large real-world cohort Timothy Ebsworth Received Received
  4336-SUN A novel method for molecular subtyping diffuse-large B-cell lymphoma using whole-exome sequencing Daniel A. Kerr Received Received
  4337-SUN Comprehensive and rapid detection of genomic alterations in pediatric leukemias using whole-genome sequencing with adaptive sampling Nicholas Geoffrion Received Received
  4338-SUN Uncovering bispecific antibody mechanisms via 3D superresolution imaging of T cell-tumor cell membrane contacts Neal Ramseier Received Received
  4339-SUN The clinical utility of COMET™ sequential immunofluorescence in lymphoma tissue diagnostics: Next generation diagnosis. Matthew Richard Pugh Received Received
  4340-SUN Using a medically trained LLM-based end-to-end system in automating patient eligibility screening across a health system for A phase 3 study evaluating the safety of givinostat in patients with polycythemia vera. Aaron T. Gerds Received Received
  4341-SUN Early identification of patients likely to benefit from paroxysmal nocturnal hemoglobinuria workup using machine learning on large-scale real-world data. Sandeep Jain Received Received
  4342-SUN Distinct morphological features of malignant cells in large B-cell lymphoma identified by soft-segmentation in imaging-based spatial proteomics Junming Shi Received Received
  4343-SUN Lattice light-sheet microscopy reveals patient specific responses to CD20-directed antibodies in B cell malignancies Julia Weingart Received Received
  4344-SUN Interpretable deep learning predicts polycythemia vera and identifies novel genomic associations Tejas Rao Received Received
  4345-SUN A predictive framework leveraging integration site profiling to stratify CAR-T response in Relapsed/Refractory multiple myeloma Heng Mei Received Received
  4346-SUN Delta oscillation enhancement and alpha oscillation attenuation as electroencephalogram biomarkers of CNS demyelination in patients with hematologic malignancies Jiajing Wang Received Received
  4347-SUN Redefining the myeloid disease continuum: Machine learning–based development and validation of an integrated multimodal classification of myeloid neoplasms Yu-Hung Wang Received Received
  4348-SUN Xgboost model using diagnostic CBC to predict early mortality in newly diagnosed AML patients Pedro dos Santos Perez Received Received
  4349-SUN Evaluating large language models in real-world hematologic clinical decision-making: Performance, limitations, and clinical implications David M Swoboda Received Received
  4350-SUN Development and validation of synthetic data generation over a federated learning computing framework to accelerate innovation and boost personalized medicine in hematological diseases Gianluca Asti Received Received
  4351-SUN AI-based, secure and privacy-preserving synthetic data generation platform in transfusion-dependent ß-thalassemia applied to the Webthal® dataset Mattia Delleani Received Received
  4352-SUN Locally deployed large language models for automated data curation in allogeneic hematopoietic stem cell transplantation Jiasheng Wang Received Received
  4353-SUN Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL) Basem William Received Received
  4354-SUN Image-based classification of lymphocyte subsets from routine blood smears reveals distinct immune dynamics after CAR-T infusion Sean Paulsen Received Received
  4355-SUN Application of hi-c sequencing to detect cryptic and novel structural aberrations in lymphoid neoplasms Krasimira Rozenova Received Received
  4356-SUN Alphagenome-enabled analysis of non-coding regulatory variants underlying rhd expression Na Yu Received Received
  4357-SUN Machine learning using bayesian networks to predict response in patients with newly diagnosed Acute Myeloid Leukemia Onyee Chan Received Received
  4358-SUN AI-based classification and outcome prediction in BCR::ABL1-like B-cell precursor acute lymphoblastic leukemia patients using targeted RNA-seq Juan Manuel Rosa-Rosa Received Received
  4359-SUN Performance of different large language models (LLMs) as decision support tools across various hematologic malignancies Chadi Nabhan Received Received
  4360-SUN TP53 mutational spectrum and fitness landscape in myeloid neoplasia ERSAN ALP UNLU Received Received
  4361-SUN Translational potential in research focused on hematological neoplastic diseases – results of automated large-scale analysis of pubmed and icite databases Nikola Cihoric Received Received
  4362-SUN Validation of the artificial intelligence prediction of acute leukemia tool in a Latin American retrospective cohort Jade Zezzi Martins do Nascimento Received Received
  4363-SUN A multi-institutional machine-learning score that predicts bacteremia and gram class at blood-culture initiation Jamin Koo Received Received
  4364-SUN Behavioral health and biophysical complexity as predictors of healthcare utilization in adults with sickle cell disease Daniel M Sop Received Received
  4365-SUN Evaluating reproductive health service delivery at nascc recognized comprehensive sickle cell centers Preetha Nandi Received Received
  4366-SUN A pilot study evaluating the feasibility and usability of an mHealth application: SCD warrior Nancy Asomaning Received Received
  4367-SUN Contact modality and contact intensity over time among community health workers in adult sickle cell disease Andrea Burton Received Received
  4368-SUN Community health worker contacts for high utilizer vs. other sickle cell patients in an adult sickle cell disease medical home Andrea Burton Received Received
  4369-SUN Budget impact analysis for sickle cell disease point-of-care testing in Mozambique La´Ron Browne Received Received
  4370-SUN Community health worker training for sickle cell disease education in the consortium for newborn screening in Africa Bernard Awuonda Received Received
  4371-SUN Burden of comorbid conditions and hospital outcomes in sickle cell trait patients with atrial fibrillation: A retrospective nationwide analysis Sangam Sangam Received Received
  4372-SUN Temporal external validation of an individuals machine learning clinical decision support prediction tool for hematopoietic cell transplantation for sickle cell disease Rajagopal Subramaniam Chandrashekhar Received Received
  4373-SUN How should fever be managed in adults with sickle cell disease? a quality metrics study and mapping of essential elements to improve care delivery Qianqian Zhou Received Received
  4374-SUN An experiential learning intervention with community advisory boards to enhance clinical trial literacy in sickle cell disease: A baseline analysis Tilicia Mayo-Gamble Received Received
  4375-SUN Feasibility and acceptability of point of care lung ultrasound for identification of acute chest syndrome in an inpatient pediatric hematology unit Thomas Carroll Fisher-Heath Received Received
  4376-SUN Healthcare utilization in patients with sickle cell disease on buprenorphine for chronic pain Ronay Thomas Received Received
  4377-SUN Clinician documentation and practices after declined medications for patients with sickle cell disease Austin Wesevich Received Received
  4378-SUN Provider practices and preparedness for gene therapy in pediatric sickle cell disease: A national survey of pediatric hematologists Cecile Karsenty Received Received
  4379-SUN Barriers to continuity of care and adult practice retention among adolescents and young adults with sickle cell disease Yogindra Persaud Received Received
  4380-SUN Cost effectiveness of in-house HIT screening testing in community based hospital Jankikeerthika Muthukaruppan Dharmarpandi Received Received
  4381-SUN Optimizing anticoagulation for hospitalized children: A single-institution pediatric anticoagulation stewardship experience Rachel Kronenfeld Received Received
  4382-SUN Developing expert consensus for specialist e-consult response: A delphi study to inform graduate medical education Kylee L. Martens Received Received
  4383-SUN Clinical management of congenital thrombotic thrombocytopenic purpura in Latin America: Expert consensus from a modified Delphi panel Spero Cataland Received Received
  4384-SUN Patterns and clinical impacts of hematology electronic consults: A retrospective, single-center analysis Shrinkhala Khanna Received Received
  4385-SUN A quality improvement project to improve the delivery rate of IV iron to patients admitted with severe gastrointestinal hemorrhage Ishan Tatake Received Received
  4386-SUN Beliefs about medicines and self-reported medication adherence in patients with primary immune thrombocytopenia: A cross-sectional Study in Greece Charalampos G Pontikoglou Received Received
  4387-SUN Access to innovative treatment for paroxysmal nocturnal hemoglobinuria in low- and middle-income countries Andrielle Yost Received Received
  4388-SUN Sustainability and cost-avoidance of reduced inappropriate red cell transfusion at community hospitals in niagara region: A follow-up analysis on a quality improvement initiative. Mohammad Refaei Received Received
  4389-SUN Peripheral cytopenias and bone marrow findings in patients with liver failure: A ten-year retrospective analysis at a high-volume transplant center Ricardo Vallejo Calzada Received Received
  4390-SUN Bridging the gap between protocol and practice: A quality improvement initiative to optimize platelet use in a community healthcare setting Amanda Lussier Received Received
  4391-SUN Assessing clinical practice variation and provider comfort in the management of pediatric iron deficiency anemia in the acute care setting Madhav Vissa Received Received
  4392-SUN Optimizing essential, complex hematologic care for patients living with disabilities Caitlin Sarubbi Received Received
  4393-SUN Rethinking ferritin reference ranges for diagnosing iron deficiency at Denver health Megan Connor Received Received
  4394-SUN Transition of care of youth with bone marrow failure conditions: Current practices, barriers, and burden- a survey of hematology-oncology providers in the US. Swapna Thota Received Received
  4395-SUN Nationwide and regional trends, outcomes, and cost of systemic thrombolysis,standard catheter-directed thrombolysis, and ultrasound-assisted thrombolysisfor pulmonary embolism Emeka Agudile Received Received
  4396-SUN Transition readiness assessment in patients with bleeding disorders at Arkansas center for bleeding disorders Divyaswathi Citla Sridhar Received Received
  4397-SUN Miscalibration of venous thromboembolic risk assessment models across race and ethnicity in medical patients: A cross-model analysis, correction strategy and potential mediators Ryan Sun Received Received
  4398-SUN Trends in cardiovascular eligibility criteria in clinical trials of hematologic malignancies: a 20-year analysis Daniel Zaldumbide Received Received
  4399-SUN Understanding the burden and predictors of 90-day all-cause readmissions following hospitalization for diffuse large B-cell lymphoma: An analysis of the nationwide readmissions database Jasneet Randhawa Received Received
  4400-SUN Estimated total cost of care and patient out-of-pocket cost savings with first-line fixed duration venetoclax + obinutuzumab compared with treat-to-progression BTKi regimens among Medicare-eligible patients with chronic lymphocytic leukemia in the United Sophia S. Li Received Received
  4401-SUN Early methotrexate level thresholds predictive of acute kidney injury in patients with b cell lymphomas receiving high-dose methotrexate Shazia Nakhoda Received Received
  4402-SUN Real-world utilization patterns of bone-modifying agents for multiple myeloma in the era of novel therapies Hamlet Gasoyan Received Received
  4403-SUN A tale of two settings: Survival disparities in CLL/SLL between academic and community cancer programs in the u.S. national cancer database William Ciurylo Received Received
  4404-SUN Identifying barriers to clinical trial enrollment for children with relapsed or refractory hematologic malignancies Kristen J Kurtz Received Received
  4405-SUN Perceived treatment and clinical trial access barriers in relapsed/refractory (R/R) follicular lymphoma: Findings from a national survey Caroline Offit Received Received
  4406-SUN Patient preferences and factors affecting patient treatment decisions for chronic lymphocytic leukemia (CLL) in Japan Sikander Ailawadhi Received Received
  4407-SUN Racial disparities in inpatient outcomes and resource utilization in multiple myeloma: An NIS-based analysis (2016–2022) Ameerdad Khan Received Received
  4408-SUN Quality and timing of patient-reported outcome reports in randomized controlled trials (RCTs) of patients with lymphoid malignancies: Analysis of 83 RCTs published between 2015 and 2025 Fabio Efficace Received Received
  4409-SUN Cost savings across bone marrow testing strategies in persons with suspected monoclonal gammopathy of undetermined significance Manraj Sra Received Received
  4410-SUN Representation of older adults in registrational trials associated with therapeutic approvals in follicular lymphoma Ronit Juthani Received Received
  4411-SUN Real-world healthcare resource utilization (HCRU) following CAR T-cell therapy in US patients treated in newly authorized treatment centers Olalekan Oluwole Received Received
  4412-SUN Parental perspectives on financial distress during treatment for childhood acute lymphoblastic leukemia: A qualitative report from Children´s oncology group (COG) study ACCL20N1CD Joanna Maria Robles Received Received
  4413-SUN Experiences of patients with multiple myeloma enrolled in high-deductible health plans: A mixed-methods study Matthew Kaczynski Received Received
  4414-SUN Cumulative cardiac risk strongly predicts in-hospital mortality and cost burden in patients hospitalized with chronic lymphocytic leukemia: A national inpatient analysis, 2020–2022 Canan Dilay Dirican Received Received
  4415-SUN Willingness to pay for DLBCL treatment characteristics in Japan Yasuyuki Arai Received Received
  4416-SUN A discrete choice experiment (DCE) to determine preferences for relapsed-refractory follicular lymphoma (R-R FL) treatment attributes among patients and physicians in the USA Swetha Thiruvengadam Received Received
  4417-SUN Geriatric hematologic care in Latin America: Results from a regional survey of hematology centers Héctor Alejandro Vaquera Alfaro Received Received
  4418-SUN Patterns of patient referral for CAR-T cell therapy: Increasing access and changing utilization trends at a german tertiary care hospital from 2018 to 2024 Christian Rausch Received Received
  4419-SUN Consensus on cytokine release syndrome (CRS) monitoring practices: A Delphi approach Elisabeth Piault-Louis Received Received
  4420-SUN Measuring patient preference information for blood cancer treatments and outcomes: A systematic review and meta-analysis Daniel R Richardson Received Received
  4421-SUN Beyond approval: Lymphoma drugs and real-world representation (2015–2025) Maya Nicole Birhiray Received Received
  4422-SUN Characteristics, epidemiology and outcomes of post-transplant lymphoproliferative disorders associated hospitalizations: A 2016-2022 national inpatient sample analysis Deepika Dilip Received Received
  4423-SUN Cost-effectiveness of CAR-T cell therapy compared to bispecific T-cell engagers in Relapsed/Refractory multiple myeloma: A retrospective study using a markov model Harry Balanta Murcia Received Received
  4424-SUN Evaluating a doctor-in-the-loop AI-agent for multiple myeloma chart reviews Juan Pablo Capdevila Received Received
  4425-SUN A multinational study to explore patient preferences for chronic myeloid leukaemia treatments Jan Geissler Received Received
  4426-SUN Clinical impact of delays in insurance authorization for newly diagnosed Acute Myeloid Leukemia considered for intensive induction chemotherapy Daniel Olivieri Received Received
  4427-SUN A review and analysis of reported global blood and marrow transplantation costs in comparison to macroeconomic factors including gross national income per capita and out-of-pocket health expenditures Syed Shahrukh Rizvi Received Received
  4428-SUN Virtual reality and hypnosis to alleviate anxiety and pain in patients undergoing bone marrow aspiration and biopsy: A randomized controlled trial Tamar Tadmor Received Received
  4429-SUN Low dose weekly HMA-venetoclax dosing is associated with greater cost-effective efficacy than standard dosing in AML/MDS: Real-world evidence Wing Fai Li Received Received
  4430-SUN Evaluating artificial intelligence (AI) as a clinical decision support tool for AML patients Ankushi Sanghvi Received Received
  4431-SUN Access to acute promyelocytic leukemia treatment in New York City James Yoon Received Received
  4432-SUN The utility of CT sinus screening in the pre-bone marrow transplant evaluation Medha Guduru Received Received
  4433-SUN Two-decade trends and future projections of heart failure mortality in Myelodysplastic Syndromes: A nationwide population-based study (1999–2030) Safi Ur Rehman Daim Received Received
  4434-SUN Animated Patient´s guide to Acute Myeloid Leukemia: Assessing patient understanding, shared decision-making, and health outcomes. Ashley Moncrief Received Received
  4435-SUN Incidence burden of AML across the US and Puerto Rico: A two-decade analysis of trends and disparities (1999-2021) Ummul Asfeen Received Received
  4436-SUN Cost-effectiveness of post-transplant gilteritinib maintenance in MRD-positive FLT3-ITD Acute Myeloid Leukemia: A microsimulation model based on the morpho trial Tina Q Huang Received Received
  4437-SUN Impact of a near-peer group mentorship program on improving transition skills for adolescents and young adults living with sickle cell disease Midori Hosoda Received Received
  4438-SUN Association of social determinants of health (SDoH) with clinic visit adherence, healthcare utilization and hydroxyurea (HU) acceptance and adherence in children with sickle cell disease (SCD) Melinda D. Chance Received Received
  4439-SUN Causes of death in young children with sickle cell disease and sickle trait in young children investigated by the child health and mortality prevention surveillance (CHAMPS) network Chris A. Rees Received Received
  4440-SUN No overall increased risk of death or cardiovascular disease in individuals with sickle cell trait: A prospective study of 467,957 general population adults Andreas Glenthoej Received Received
  4441-SUN Patient-driven insights in sickle cell disease: Results from a global survey informing public health strategies Mariangela Pellegrini Received Received
  4442-SUN Rapid immune reconstitution in patients with transfusion-dependent thalassemia following betibeglogene autotemcel: A real-world experience Benjamin I. Philipson Received Received
  4443-SUN Data validation and quality framework for building a european multimodal real-world dataset for clinical outcome research in sickle cell disease Sara Reidel Received Received
  4444-SUN Impact of preexisting chronic obstructive pulmonary disease on in-hospital outcomes in first-time acute chest syndrome: A nationwide analysis, 2016–2022 Vera Jokic Received Received
  4445-SUN Menstruation-induced vaso-occlusive crisis in women with sickle cell disease Sherraine Della-Moretta Received Received
  4446-SUN Type 2 diabetes screening and management in individuals with sickle cell disease is compromised by the predominant reliance on glycosylated haemoglobin (HbA1c) Arne de Kreuk Received Received
  4447-SUN Psychiatric comorbidities and the mortality paradox in sickle cell disease: A national inpatient analysis Canan Dilay Dirican Received Received
  4448-SUN Understanding the menopause transition in sickle cell disease: An analysis of the implementation of the adapted menopause quick 6 Marwah Farooqui Received Received
  4449-SUN Chorionic villus sampling acceptability and therapeutic abortion compliance in beta-thalassemia minor parents: A study in low-middle income country Laila Bahadur Received Received
  4450-SUN Social isolation and patient-reported and healthcare utilization in adults with sickle cell disease Richard Newcomb Received Received
  4451-SUN Characterizing return-to-school after pain-related hospitalizations and hospital re-admission risk in pediatric sickle cell disease Megan Connolly Received Received
  4452-SUN Thrombotic outcomes in sickle cell disease patients treated with crizanlizumab with or without hydroxyurea: A real-world retrospective cohort analysis using the trinetx database Reyad Al Jabiri Received Received
  4453-SUN Characteristics of women who have beta thalassemia discovered during pregnancy Steven Fein Received Received
  4454-SUN Disease monitoring and management among pediatric patients with pyruvate kinase deficiency: Real-world practices from pyruvate kinase deficiency registries prior to 2024 international expert guidelines Sule Unal Received Received
  4455-SUN Prognostic consequences of delayed treatment in severe aplastic anemia: A challenge in resource-constrained healthcare systems Irune Marti Larrucea Received Received
  4456-SUN A comparison of intravenous iron formulations for treating iron deficiency anemia after bariatric surgery Sufyan Baig Received Received
  4457-SUN Reducing premedication use with intravenous iron in the outpatient setting: A quality improvement project Tara Rakiewicz Received Received
  4458-SUN Safety of ravulizumab use in pregnancy: Insights from a global pharmacovigilance analysis Cory Williams Received Received
  4459-SUN Treatment patterns and outcomes among warm autoimmune hemolytic anemia patients receiving rituximab in the United States: A retrospective database study Louis Jackson Received Received
  4460-SUN Increased age-adjusted mortality rates from hemophagocytic lymphohistiocytosis (HLH), 2010-2023 James C Di Palma-Grisi Received Received
  4461-SUN Real-world treatment patterns for Hemophilia A since the launch of emicizumab in the US Janet S Lee Received Received
  4462-SUN Outcomes of splenectomy in benign and malignant hematologic conditions in the immunotherapy era Mahija M Cheekati Received Received
  4463-SUN Investigating patients´ experiences with dyspnea associated with warm antibody hemolytic anemia (wAIHA) and cognitive debriefing of the FACIT-dyspnea 10 item short form: A qualitative patient interview study Ahmed Daak Received Received
  4464-SUN Evaluation of medical provider practice patterns in the assessment and management in heavy menstrual bleeding for patients on anticoagulation Michael Pfeffer Received Received
  4465-SUN Patient perspectives on the burden of hypereosinophilic syndrome: Results from the Phase 3 natron interview sub-study Amy D. Klion Received Received
  4466-SUN Clinical and economic burden of steroids in primary immune thrombocytopenia: A real-world italian analysis Tommaso Salvini Received Received
  4467-SUN Rapid decrease in age-adjusted mortality rates associated with ITP following eltrombopag aand romiplostin approvals, but not in TMA following eculizumab approval, 1999-2023 James C Di Palma-Grisi Received Received
  4468-SUN Fostamatinib significantly increases risk of hypertension in hematologic patients: A meta-analysis of randomized trials Alexander Rabadi Received Received
  4469-SUN Social vulnerability predicts higher county-level pulmonary embolism mortality in the United States : A 2016-2020 nationwide analysis Ayushi Garg Received Received
  4470-SUN Systematic review and meta-analysis of randomized controlled trials on outpatient thromboprophylaxis (OTP) in patients with cancers with khorana score (KS) = 2 receiving chemotherapy Yin Mon Myat Received Received
  4471-SUN Real-world burden and risk analysis of hematologic iraes in patients treated with immune checkpoint inhibitors: 5-year cohort study Ali Awada Received Received
  4472-SUN Real-world use of prophylaxis in people with non-severe hemophilia in the United States: Insights from the athn transcends Study - hemophilia natural history arm Fernando Corrales-Medina Received Received
  4473-SUN In-hospital stroke, myocardial infarction, and venous thrombosis in immune thrombocytopenia: Incidence, risk factors, and outcomes from a national cohort Manas Pustake Received Received
  4474-SUN Hematologic toxicities associated with PARP inhibitors: Real world pharmacovigilance updated study using faers database with era-trend evaluation and serious outcome modeling Rushi Shah Received Received
  4475-SUN National trends and demographic disparities in perinatal non-traumatic intracranial hemorrhage mortality in the United States, 1999–2024 Ibrahim Hassan Received Received
  4476-SUN A propensity-matched analysis of real-world outcomes comparing direct oral anticoagulants and warfarin in patients diagnosed with portal vein thrombosis Muhammad Mujtaba Bhinder Received Received
  4477-SUN Iron infusions in pregnant women are associated with comparable efficacy and safety compared to non-pregnant women Steven Fein Received Received
  4478-SUN Iron deficiency anemia and health equity: Persistent gaps among reproductive-age women in the United States Pranav Singh Received Received
  4479-SUN Hematological symptom burden and treatment patterns in patients with IgG4-related disease: A real-world, multicenter retrospective analysis Nikhil Vojjala Received Received
  4480-SUN Site-specific and latency - associated second primary malignancy in follicular lymphoma survivors : A SEER MP-SIR study (2000-2022) Priyanka Nagdev Received Received
  4481-SUN Underreporting of prognostic factors in real-world studies for bispecifics in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) Marin Xavier Received Received
  4482-SUN Real-world treatment patterns and clinical outcomes in high-risk Mantle Cell Lymphoma: A retrospective analysis Preetesh Jain Received Received
  4483-SUN Real-world survival, cognitive and health-related quality of life outcomes of methotrexate/ifosfamide plus whole brain radiotherapy for newly diagnosed primary central nervous system lymphoma Chantiya Chanswangphuwana Received Received
  4484-SUN Real-world measurable residual disease (MRD) testing patterns and associated outcomes in patients with Philadelphia-negative B-cell acute lymphoblastic leukemia Anthony Proli Received Received
  4485-SUN A standardized rapid dose escalation of epcoritamab for patients with lymphoid malignancies Kelsey Baron Received Received
  4486-SUN Real-world effectiveness of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among elderly Medicare beneficiaries with diff Matthew Matasar Received Received
  4487-SUN Real-world insights into diffuse large B-cell lymphoma from EHR-derived data in Germany and the United Kingdom Christoph Buhl Received Received
  4488-SUN Risk of mental health outcomes and peak risk periods post-hematologic cancer diagnosis in the United States Tara Beaulieu Received Received
  4489-SUN Treatment inequities in newly diagnosed diffuse large B-cell lymphoma (DLBCL): Comparing polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) vs rituximab in combination with cyclophosphamide, doxoru Scott Huntington Received Received
  4490-SUN Cyclophosphamide versus methotrexate for treating large granular lymphocyte leukemia: Real-world data insights Vladimir Otasevic Received Received
  4491-SUN Real-world barriers to treatment access in T-cell lymphoma Christina Poh Received Received
  4492-SUN BTKi in the peri-infusion period in lymphoma patients receiving CD19 CAR T cell therapy Alexander P. Boardman Received Received
  4493-SUN Unequal outcomes: The role of institutional setting in the management of primary CNS lymphoma Ysaith Orellana Ascencio Received Received
  4494-SUN Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database Ayo Samuel Falade Received Received
  4495-SUN Center effect on large B-cell lymphoma outcome in frontline prospective Phase II and III trials : A lysa study Tristan Robert-Van Houtteghem Received Received
  4496-SUN Incidence of thrombosis and bleeding in patients receiving CAR-T cell therapy: A multicentric retrospective analysis of the Canadian experience Luciana Melo Garcia Received Received
  4497-SUN Risk of cardiovascular disease-related mortality in hematologic malignancy patients: A population-level US retrospective cohort study, 1975-2022 Husayn Mohamed Ladha Received Received
  4498-SUN Respiratory viral infections are a significant cause of morbidity during long-term follow-up after CAR T cell therapy: Analysis of 445 episodes Sigrun Einarsdottir Received Received
  4499-SUN Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospectiv Taylor Brooks Received Received
  4500-SUN Clinical characteristics, treatment patterns, clinical outcomes and resource utilization in patients with chronic lymphocytic leukaemia (CLL): CREEK-Latin America subgroup analysis Miguel A. Pavlovsky Received Received
  4501-SUN Overlap of post-CAR T HLH toxicity definitions and their prognostic significance in children and young adults with B-acute lymphoblastic leukemia Kevin Owen McNerney Received Received
  4502-SUN Bispecific antibody vs non-bispecific antibody systemic therapy as immediate next line treatment after chimeric antigen receptor T-cell (CART) failure in large B-cell lymphoma Kyle S.Y. Miyazaki Received Received
  4503-SUN Real-world treatment patterns and survival outcomes in second and third line settings in large B-cell lymphoma (LBCL) Joseph P McGuirk Received Received
  4504-SUN Real-world safety and mortality outcomes of CAR-T cell therapies versus bispecific antibodies in DLBCL: Insights from the faers database Fatma Temiz II Received Received
  4505-SUN Real-world comparison of treatment outcomes between BCL2i and 2nd generation BTKi therapy in first-line CLL patients Rushir Choksi Received Received
  4506-SUN Real-world incidence of treatment-emergent cardiovascular events among chronic lymphocytic leukemia/small lymphocytic lymphoma patients receiving acalabrutinib or zanubrutinib monotherapy Jing-Zhou Hou Received Received
  4507-SUN The impact of marginalization on outcomes in patients with Hodgkin lymphoma Daniel Teitelbaum Received Received
  4508-SUN Effectiveness of comprehensive geriatric assessment (CGA) in older patients with diffuse large B-cell lymphoma (DLBCL) and the impact of frailty in treatment tolerability and survival in a prospective, multicenter study. Raul Cordoba Received Received
  4509-SUN Clinician-assessed eastern cooperative oncology group performance status vs. patient-reported health-related quality of life: Insights from malignant lymphoma Fangping Chen Received Received
  4510-SUN Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the United States (US) Frederick Locke Received Received
  4511-SUN Analysis of real-world overall survival (rwOS) among patients with third-line or later (3L+) diffuse large B-cell lymphoma (DLBCL) with multiple qualifying index dates treated in the United States Michael Wallington Received Received
  4512-SUN Race/ethnicity reporting and representation in clinical trials presented at plenary and late-breaking abstract sessions at the American society of hematology (ASH) from 2014 to 2024 Bingtao Xiang Received Received
  4513-SUN Real-world selection of fixed-duration versus continuous therapies for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma Rebecca Tidswell Received Received
  4514-SUN Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers Alex Niu Received Received
  4515-SUN Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas Andrew P. Jallouk Received Received
  4516-SUN Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma Prokop Vodicka Received Received
  4517-SUN The impact of distance to CAR-T centre on CAR-T delivery and CAR-T outcomes: A single centre retrospective cohort study Bradley Rutherford Received Received
  4518-SUN Impact of preexisting mental health disorders and psychiatric pharmacotherapy on hospital length of stay in immune effector cell therapy recipients Chad Markey Received Received
  4519-SUN Lymphoma are the most frequent secondary hematologic malignancies following solid tumors: A large cohort study from the german cancer registry nrw Amin T. Turki Received Received
  4520-SUN Causes of death in chronic lymphocytic leukemia/small lymphocytic lymphoma during the novel agent era: A population-based analysis Mengyang Di Received Received
  4521-SUN Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party Ali Bazarbachi Received Received
  4522-SUN Real-world monotherapy and combination usage of mogamulizumab among patients with mycosis fungoides or Sezary syndrome in the United States Bradley Haverkos Received Received
  4523-SUN Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study Alexander D. Sanjurjo Received Received
  4524-SUN Rehabilitation needs and clinical associations post CAR T-cell therapy: A retrospective analysis Kristen Harkins Received Received
  4525-SUN Disparate post-relapse survival outcomes by race/ethnicity for children with B-cell acute lymphoblastic leukemia: An analysis from the recall-1 study Abigale M. Berry Received Received
  4526-SUN Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis Alyssa Kassouf Received Received
  4527-SUN Impact of angiotensin converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARB) on tumor lysis syndrome, acute kidney injury, and rasburicase use in patients undergoing chemotherapy for hematologic malignancies Haris Sohail Received Received
  4528-SUN Treatment patterns and outcomes among patients treated with second-generation BTK inhibitors in CLL Aryan Ayati Received Received
  4529-SUN Other cancers in patients with chronic lymphocytic leukemia/SMALL lymphocytic lymphoma Helen Ma Received Received
  4530-SUN Longitudinal assessments of simple frailty tools can help predict outcomes of patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy: A prospective pilot study at Princess Margaret Cancer Centre Anca Prica Received Received
  4531-SUN Optimizing high-dose methotrexate treatment regimens to improve exposure and mitigate toxicity in infant patients with acute lymphoblastic leukemia Tamara P. Miller Received Received
  4532-SUN Real-world comparative outcomes of CAR-T cell therapy versus bispecific antibodies in patients with diffuse large B-cell lymphoma Danielle C Thor Received Received
  4533-SUN Evaluation of outcomes by line of therapy in marginal zone lymphoma: Real-world evidence from 10 US academic centers Narendranath Epperla Received Received
  4534-SUN Evaluation of real-world outcomes with zanubrutinib in patients with marginal zone lymphoma: Results from multicenter cohort study Narendranath Epperla Received Received
  4535-SUN Nationwide impact of CAR-T approval on acute lymphoblastic leukemia mortality in the United States, 1999-2023: Difference-in-differences and synthetic control analyses Woo Joo Lee Received Received
  4536-SUN Suboptimal cancer-screening adherence in CLL/SLL patients Carolina Velez-Mejia Received Received
  4537-SUN Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study Fatima Tuz Zahra Received Received
  4538-SUN Adherence to the 2018 world cancer research fund/American institute for cancer research cancer prevention recommendations and mortality among blood cancer survivors LaShae D. Rolle Received Received
  4539-SUN Long-term outcomes of dexamethasone prophylaxis after axicabtagene ciloleucel for non-Hodgkin lymphoma: A single-center retrospective study Christina Darwish Received Received
  4540-SUN Clinical outcomes of first-line venetoclax-based regimens vs second-generation BTK inhibitors in CLL/SLL: A retrospective cohort study Angimar Uriepero Received Received
  4541-SUN Real-world data of lisocabtagene maraleucel as second line therapy for patients with large B-cell lymphoma: Updated Results of the french descar-T registry by lysa Gabriel Brisou Received Received
  4542-SUN Cardiotoxicity profile of novel bispecific T-cell engager therapies Malak Munir Received Received
  4543-SUN Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease Luca Paruzzo Received Received
  4544-SUN The relationship of social support and psychosocial complexity with chimeric antigen receptor T-cell therapy outcomes Jessica Nino De Rivera Received Received
  4545-SUN Bispecific antibodies serve as a safe and effective bridging therapy prior to CD19 CAR T-cell therapy/combinational therapy of CD19 CAR-T cell and HDT/ASCT in patients with R/R DLBCL Yi Wang Received Received
  4546-SUN Patient-reported outcomes and quality of life over time in relapsed/refractory diffuse B-cell lymphoma (DLBCL) patients treated with CAR T-cells therapy in clinical practice Catherine Rioufol Received Received
  4547-SUN Feasibility and preliminary efficacy of a Mediterranean diet and home-based exercise intervention during chemotherapy for lymphoma survivors: The life-l study Melissa Lopez-Pentecost Received Received
  4548-SUN Anti-CD3/CD20 bispecific antibodies as salvage therapy after CAR-T failure in Relapsed/Refractory large B-cell lymphoma: A systematic review and meta-analysis Peng SUN Received Received
  4549-SUN Early PET response for relapse prediction in 2nd or higher line lisocabtagen maraleucel in large B-cell lymphoma Marcel Teichert Received Received
  4550-SUN Outcomes and treatment strategies following CD20/CD3 bispecific antibody failure in non-Hodgkin´s lymphoma: A retrospective single-center study Sun-Hye Ko Received Received
  4551-SUN Outcomes of patients with Relapsed/Refractory aggressive B-cell lymphoma receiving bispecific antibody therapy as monotherapy or in combination with targeted therapy Timothy S Oh Received Received
  4552-SUN Incidence of second primary malignancies in patients with hematologic malignancies treated with next-generation bruton tyrosine kinase (BTK) inhibitors: A meta-analysis of randomized controlled trials Rishi Kumar Nanda Received Received
  4553-SUN Number needed to treat to avoid progression or death: Zanubrutinib vs other COVALENT bruton tyrosine kinase inhibitors in Relapsed/Refractory chronic lymphocytic leukemia Mazyar Shadman Received Received
  4554-SUN Incidence of cardiac toxicities in patients with hematologic malignancies treated with zanubrutinib compared to control, including BTK inhibitor (Ibrutinib): A meta-analysis of randomized controlled trials Abbas Hussain Received Received
  4555-SUN Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas Fatima Tuz Zahra Received Received
  4556-SUN Long-term risk and racial disparities in second primary malignancies among diffuse large B-cell lymphoma survivors: A SEER-based analysis MP-SIR analysis (2000–2022) Priyanka Nagdev Received Received
  4557-SUN Reduction of infections with intravenous immunoglobulin in chronic lymphocytic leukemia: A single-center retrospective analysis Nirja Shah Received Received
  4558-SUN Acalabrutinib monotherapy versus acalabrutinib plus obinutuzumab combination therapy in treatment-naïve chronic lymphocytic leukemia: A ´real-world´ study of efficacy and safety at a tertiary academic medical center Ken Zou Received Received
  4559-SUN Automated classification of acute lymphoblastic leukemia in peripheral blood smears using a convoluted neural network, ResNet18 model Harshitha Jagarlamudi Received Received
  4560-SUN Effect of prior CD19-directed monoclonal antibody exposure on outcomes in patients subsequently treated with CD19 targeting CAR-T therapy: A multicenter propensity score matched retrospective cohort study Shanawar Ali Waris Received Received
  4561-SUN Non-cancer related mortality in hematological cancers: A nation-wide population based study Nikita Tripathi Received Received
  4562-SUN Real-world outcomes in relapsed/refractory multiple myeloma: Retreatment versus no retreatment with an anti-CD38 monoclonal antibody in the 2L and 3L in patients from the Flatiron Health database Maria Nieto Received Received
  4563-SUN Real-world comparison of progression-free and overall survival between idecabtagene vicleucel (ide-cel) and teclistamab in triple-class exposed relapsed/refractory multiple myeloma Luciano Jose Costa Received Received
  4564-SUN Shifting symptom profiles and accelerated diagnosis in AL amyloidosis: Findings from ARC community surveys 2022–2024 Sabrina Rebello Received Received
  4565-SUN Treatment patterns and real-world effectiveness in patients with Relapsed/Refractory multiple myeloma (RRMM) and lenalidomide-exposure who received 1 to 3 prior lines of therapy Peter M. Voorhees Received Received
  4566-SUN Prevalence, incidence, and outcomes of multiple myeloma patients using electronic health records and natural language processing Joaquin Martinez Lopez Received Received
  4567-SUN Optimizing skeletal health: An analysis of bone-modifying agent prescription patterns and incidence of skeletal-related events in multiple myeloma Amy H. Huang Received Received
  4568-SUN Lenalidomide (LEN) and anti-CD38 monoclonal antibodies (mAbs) utilization in patients with newly diagnosed and relapsed/refractory multiple myeloma (MM) in Germany: Real-world insights on epidemiology and clinical outcomes Amol D. Dhamane Received Received
  4569-SUN Reveal-MM: Retrospective evaluation of variables in early assessment and landmark trends in multiple myeloma – a US claims-based case-control study Faith Davies Received Received
  4570-SUN Understanding access and treatment challenges in multiple myeloma care Caidon Iwuagwu Received Received
  4571-SUN Impact of vitamin d deficiency on quality of life and clinical outcomes in patients with multiple myeloma Kawita Kitichotkul Received Received
  4572-SUN Impact of minimal residual disease outcomes with ciltacabtagene autoleucel in cartitude-4: Oncologist treatment preferences in lenalidomide-refractory multiple myeloma Puja Aggarwal Received Received
  4573-SUN Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials Rakesh Popat Received Received
  4574-SUN Survival differences in transplant ineligible multiple myeloma patients in Japan and Taiwan: Exploring the potential influence of timely and unrestricted access to novel therapies Hsin-An Hou Received Received
  4575-SUN Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma Christen M Dillard Received Received
  4576-SUN Incidence of severe infections in patients with multiple myeloma treated with immunoglobulin-replacement therapy Jiani Zhou Received Received
  4577-SUN Bi-specific T-cell engagers as a bridge to ciltacabtagene autoleucel in Relapsed/Refractory multiple myeloma: Real-world outcomes in an underserved urban population Santiago Beltran Received Received
  4578-SUN Risk factors and prevalence of monoclonal gammopathy of undetermined significance (MGUS) by duffy genotype Lauren E Merz Received Received
  4579-SUN Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies Victoria Nachar Received Received
  4580-SUN B cell kinetics on next generation sequencing after CAR T-cell therapy in multiple myeloma Abigail P Sneider Received Received
  4581-SUN Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network Roman Hajek Received Received
  4582-SUN Real-world disease burden and treatment patterns among triple-class–exposed patients with relapsed/refractory multiple myeloma and extramedullary disease in the US: A retrospective analysis using Flatiron Health electronic medical records Noa Biran Received Received
  4583-SUN Outcomes of multiple myeloma (MM) patients with del 17p as a sole high risk cytogenetic abnormality who underwent either single or tandem upfront autologous stem cell transplant approaches in EBMT centres between 2016 and 2022 Conal Houstoun V Received Received
  4584-SUN Comparative analysis of ide-cel and cilta-cel in patients with Relapsed/Refractory multiple myeloma: A nationwide, retrospective, real-world analysis across Austria Irene Strassl Received Received
  4585-SUN Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd) Ricardo Daniel Parrondo Received Received
  4586-SUN Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM) Masooma Shifa Rana Received Received
  4587-SUN National cross-sectional Study to explore current state of patient awareness of multiple myeloma (MM) disease basics and its management: Identifying gaps and associations Kenyot´a Russell Received Received
  4588-SUN Real world efficacy and safety of elranatamab, a BCMA bispecific antibody for patients with relapsed and refractory multiple myeloma: An international myeloma working group immunotherapy database analysis Rakesh Popat Received Received
  4589-SUN Artificial intelligence/machine learning-based risk prediction model guiding individualized interventions to improve outcomes for patients with multiple myeloma Stuart Sommers Received Received
  4590-SUN CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison Maximilian Merz Sr Received Received
  4591-SUN Outcomes of CAR-T therapy in HIV-positive multiple myeloma patients: A retrospective database analysis Esteban Toro Velez Received Received
  4592-SUN Real-world comparative effectiveness of quadruplet vs triplet induction in multiple myeloma Anuja Abhyankar Received Received
  4593-SUN Real-world outcomes with CAR-T therapy in relapsed/refractory multiple myeloma and severe renal failure: A propensity matched multi-center retrospective Study using trinetx database Deevyashali Parekh Received Received
  4594-SUN Trends and disparities in multiple myeloma mortality in the United States: A 25-year analysis from 1999 to 2023 Muhammad Zahid Anwar Received Received
  4595-SUN Real-world analysis of infections after bispecific antibodies targeting anti-B-cell maturation antigen (BCMA) and protective impact of intravenous immunoglobulin (IVIG) in patients with multiple myeloma Amandeep Godara Received Received
  4596-SUN Real-world incidence and management of non-icans neurologic events following ciltacabtagene autoleucel in multiple myeloma Doris K. Hansen Received Received
  4597-SUN Bridging the rural gap: Real-world teclistamab outcomes from the u.S. midwest myeloma network Adam Stepanovic Received Received
  4598-SUN Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis Murali Janakiram Received Received
  4599-SUN Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors Samer Al Hadidi Received Received
  4600-SUN Racial disparities in clinical outcomes among patients with newly diagnosed and relapsed multiple myeloma in the United States: A 21-year comparative analysis Tarfa Verinumbe Received Received
  4601-SUN Outcomes of urgent inpatient chemotherapy for relapsed/refractory multiple myeloma in the modern era Abhishek Kataria Received Received
  4602-SUN Acute myeloid leukemia during the venetoclax era: Trends in survival across demographic and socioeconomic groups. Lisa Liu Received Received
  4603-SUN Mortality trends of sepsis in patients with leukemia in the United States (1999–2020): A CDC wonder database analysis Hafiz Muhammad Hannan Javed Received Received
  4604-SUN Outcomes with a combination of treosulfan and fludarabine in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis Hafiz Muhammad Hannan Javed Received Received
  4605-SUN Real-world study of treatment landscape and safety outcomes of US patients with blastic plasmacytoid dendritic cell neoplasm Naveen Pemmaraju Received Received
  4606-SUN Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation Diego Adrianzen Herrera Received Received
  4607-SUN Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib (PAC): Results from the my-PAC study Douglas Tremblay Received Received
  4608-SUN CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective Elisabetta Todisco Received Received
  4609-SUN Impact of chemotherapy on survival in patients aged 75 years and older with Acute Myeloid Leukemia: A contemporary population-based analysis (2000–2022) from a national database Noor Khalid Received Received
  4610-SUN Global, regional, and national burden of myelodysplastic, myeloproliferative, and other hematopoietic neoplasms from 1990 to 2021, and projections to 2050: A systematic analysis for the global burden of disease study 2021 Jieya Luo Received Received
  4611-SUN Indirect treatment comparison (ITC) of asciminib and dasatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) Onyee Chan Received Received
  4612-SUN Longer survival with tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a real-world analysis Anthony Stein Received Received
  4613-SUN Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center Mahesh Swaminathan Received Received
  4614-SUN High-dose ponatinib in Korean CML and Ph+ ALL: real-world outcomes in early and heavily pretreated settings Dong-Wook Kim Received Received
  4615-SUN The burden of hematological malignancies in Latin America and the Caribbean: A 30-year global burden of disease analysis Héctor Alejandro Vaquera Alfaro Received Received
  4616-SUN Assessment of real-world treatment patterns and outcomes of olutasidenib in patients with mutated isocitrate dehydrogenase 1 Acute Myeloid Leukemia previously treated with venetoclax using electronic health record data Jorge Cortes Received Received
  4617-SUN Can we perform allogeneic hematopoietic cell transplantation (HCT) safely in patients with limited social supports and substantial psychosocial complexity? Nicolas Trad Received Received
  4618-SUN Integrating palliative care for adolescents and young adults with hematologic malignancies: Insights from a dedicated french unit. Florian Chevillon Received Received
  4619-SUN Comparative trends in mortality from acute lymphoblastic and Acute Myeloid Leukemia in the United States: A CDC wonder analysis (1999–2020) Rehan Ishaque Received Received
  4620-SUN Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US Idoroenyi Amanam Received Received
  4621-SUN Social vulnerability and mortality trends in Acute Myeloid Leukemia in the United States adults (2010 to 2020): The paradoxical role of minority-language communities Ayushi Garg Received Received
  4622-SUN Characterizing palliative care utilization among patients with Acute Myeloid Leukemia (AML): Insights from analysis of AML hospitalizations in the United States. Oluwafemifola Oyedeji Received Received
  4623-SUN Trends and race-sex disparities in in-hospital mortality of chemotherapy-induced cardiomyopathy in hematologic malignancies Anushree Venkatesh-Murthy Received Received
  4624-SUN Disaggregated outcomes of Asian Americans, Native Hawaiian and Pacific Islander populations with Acute Myeloid Leukemia Erin Garbes Feliciano Received Received
  4625-SUN Determining barriers to access first-line treatment in high volume facilities in adolescents and young adults (AYA) with acute leukemias Laneisha Maldonado Jaime Received Received
  4626-SUN Impact of cohesin complex gene mutations on clinical outcomes in Acute Myeloid Leukemia Jessica El-Asmar Received Received
  4627-SUN Major adverse cardiovascular events (MACE) in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A target trial emulation study Omer Ashruf Received Received
  4628-SUN The effect of Medicaid expansion on survival outcomes among individuals with chronic myeloid leukemia Oladayo A Oyebanji Received Received
  4629-SUN Outcomes of low-intensity AML therapy based on treatment facility Aditya Ravindra Received Received
  4630-SUN Racial disparities in genomic alterations and survival outcomes in Acute Myeloid Leukemia (AML) Utsav Joshi Sr Received Received
  4631-SUN Patient reported outcome design, conduct and reporting in australasian leukaemia & lymphoma group (ALLG) cooperative group trials Arina Martynchyk Received Received
  4632-SUN Comorbidities and outcomes in patients with Acute Myeloid Leukemia with and without type II diabetes mellitus admitted for chemotherapy: A national inpatient sample analysis Harshank Vishnubhai Patel Received Received
  4633-SUN The effect of chronic kidney disease on outcomes in patients admitted with acute promyelocytic leukemia not in remission: A nationwide analysis from 2016–2022 Adnan Humam Hajjar Received Received
  4634-SUN Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center Mahesh Swaminathan Received Received
  4635-SUN Real world outcomes comparing the use of GLP-1 receptor agonists in patients with CML and comorbid obesity: A propensity score matched analysis from global federated health research network Arshi Syal Received Received
  4636-SUN Association of socioeconomic indicators with survival in chronic myeloid leukemia: A retrospective analysis Hadil Zureigat Received Received
  4637-SUN Proportion of second hematologic malignancies linked to radiotherapy treatment in adults: A cohort study in the US SEER cancer registries 2001-2022 Rupayan Kundu Received Received
  4638-SUN The impact of patient personality traits on adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia Mahtab Jafari Received Received
  4639-SUN Revolutionizing hematology/oncology education through visual storytelling and gamification for internal medicine residents Cameron Laverne Smith Received Received
  4640-SUN Targeted online education in obstetric hematology significantly improves resident knowledge and addresses a critical training gap Tabea Sutter Received Received
  4641-SUN Using electronic consultations to identify hematology education needs in primary care Saumya Bansal Received Received
  4642-SUN #asheducation: Data and insights on social media´s unique power for hematology education Aakanksha Angra Received Received
  4643-SUN Embedding narrative medicine into subspecialty training: A novel clinical rotation to foster humanism, empathy, and systems awareness Andrew Freiberg Received Received
  4644-SUN The phases of hematology-oncology fellowship: A single site qualitative Study Lisa Pei Chu I Received Received
  4645-SUN Longitudinal quality improvement curriculum for hematology/oncology fellows in an academic training program Michael Keng Received Received
  4646-SUN Impact of short-form, case-based continuing medical education on community clinicians´ knowledge and competence in optimizing bispecific antibody therapy for Relapsed/Refractory multiple myeloma Meghan Coulehan Received Received
  4647-SUN Training program for DATA managers in hematopoietic cell transplantation and advanced cell therapy: A nine-year overview from Brazil Fernando Duarte Barroso Duarte Received Received
  4648-SUN Real-world implementation of bispecific antibody delivery in community oncology: Overcoming operational barriers through partnerships & interprofessional education Carmine Deluca Received Received
  4649-SUN Assessing the impact of an OSCE-style workshop on internal medicine residents´ ability to manage hematologic emergencies: An iterative pilot study Danyal Ladha Received Received
  4650-SUN Evolution of expert and healthcare professional treatment recommendations in the management of Mantle Cell Lymphoma Amber Luna Williams Received Received
  4651-SUN Enhancing hematology education through structured case-based learning and formal assessment: An approach to address learning gaps in clinical training Kevin Chandler Graf Received Received
  4652-SUN Interest, barriers, and motivators for pursuing hematology electives among fourth-year Caribbean medical students: A cross-sectional survey Amruth Akhil Alluri Received Received
  4653-SUN Adapting the American society of hematology crti-la model to build clinical research capacity in Mexico: Results from the ameh-I3 course Andres Gomez-De Leon Jr Received Received
  4654-MON Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebo-controlled ACTIVATE-Kids trial Satheesh Chonat Received Received
  4655-MON Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up Bruno Fattizzo Received Received
  4656-MON Treatment response, relapse and survival of hospitalized adult primary warm autoimmune hemolytic anemia: A multicenter retrospective cohort study Meng Shu Received Received
  4657-MON Long-term outcome and risk factors for relapse in pediatric warm autoimmune hemolytic anemia. Diane Roze Jr Received Received
  4658-MON Pharmacological inhibition of polrmt mimicking polrmt rare variants associated with sideroblastic anemia, strongly inhibits proliferation and differentiation of human erythroblasts Ophélie Evrard Received Received
  4659-MON High mortality rate of warm autoimmune haemolytic anaemia: Real-world incidence and outcomes from a comprehensive regional audit Jun Yen Ng Received Received
  4660-MON Characteristics at diagnosis of autoimmune hemolytic anemias in adults: First results from a prospective, multicenter cohort of 413 patients included in the carmen-France registry Yoann Zadro Received Received
  4661-MON Erythropoietin stimulates rapid egress of erythroid and lymphoid cells via the CXCR4–CXCL12 axis Anton Gorodov Received Received
  4662-MON Paroxysmal nocturnal hemoglobinuria in pediatric patients: A UK experience Morag Griffin Received Received
  4663-MON PORT-77 is a potent inhibitor of ABCG2 that reduces efflux of protoporphyrin IX from erythrocytes of patients with protoporphyria and reduces plasma protoporphyrin IX levels in healthy human subjects Bhavik Shah Received Received
  4664-MON Role of NK cells in immune escape in patients with classical paroxysmal nocturnal hemoglobinuria Rong Fu Received Received
  4665-MON Early access program for danicopan (ALXN2040) as add-on treatment to eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH): Preliminary data from the Italian real-world survey. Bruno Fattizzo Received Received
  4666-MON Treatment with sirolimus for refractory/relapsed primary or secondary warm autoimmune hemolytic anemia/evans syndrome: A single centre prospective study Qi Wang Received Received
  4667-MON Hereditary spherocytic pyropoikilocytosis: Expanding the clinical and genetic spectrum of red blood cell membrane disorders Athina Ntoumaziou Received Received
  4668-MON Circulating glycornas: A novel class of glycoconjugates in blood and implications for erythrocyte biology Leon Zheng Received Received
  4669-MON Prednisolone and mycophenolate mofetil as first-line therapy in warm autoimmune hemolytic anemia: A prospective pilot study Aditya Jandial Received Received
  4670-MON AI-assisted diagnosis of paroxysmal nocturnal hemoglobinuria Adam M Bowen Received Received
  4671-MON Vitamin B6 deficiency: A cause of unexplained anemia in hospitalized patients in a tertiary care center Kabeer Ali Received Received
  4672-MON Epidemiological and molecular analysis of thalassemia (Beta Globin Gene) in the heterogeneous population of gwadar, Pakistan Shali Anwar Received Received
  4673-MON DNA methylation episignature as a novel diagnostic tool for diamond-blackfan anemia Paola Quarello Received Received
  4674-MON Stepwise genetic testing refines the diagnosis of suspected congenital dyserythropoietic anemias: A cohort study of 76 Indian families Manu Jamwal Received Received
  4675-MON Clinical characterization of the rare G6PD pawnee variant: A five-patient case series Nishi Arun Harwani Received Received
  4676-MON Adherence to oral iron in adolescent females with iron deficiency secondary to heavy menstrual bleeding Kennedy Sheedy Received Received
  4677-MON Real world outcomes of patients with cold agglutinin disease Jahanzaib Khwaja Received Received
  4678-MON Functional inactivation of duodenal ferroportin by hepcidin drives iron-dependent degradation of DMT1 in lysosomes Kostas Pantopoulos Received Received
  4679-MON Transferrin receptor 2 (Tfr2) is necessary for hepcidin induction in mice with hepatocyte-specific transferrin receptor 1 (Tfr1) deficiency Kostas Pantopoulos Received Received
  4680-MON Liver knock-out of nuclear inhibitor of protein phosphatase-1 in mice decreases hepatic iron Asrar Ahmad Received Received
  4681-MON Diffuse fractures in a neonate with homozygous UROS C73R congenital erythropoietic porphyria: An unreported phenotype Ahsan Wahab Received Received
  4682-MON Single-dose IV ferric derisomaltose improves hematologic and patient-reported outcomes in pregnant individuals with iron deficiency anemia Thalia Padilla Kelley Received Received
  4683-MON Iron overload disrupts alveolar-capillary tight junctions via oxidative stress in a murine model Xiao Liang Received Received
  4684-MON Biomarkers of ineffective erythropoiesis in patients with transfusion- dependent thalassemia Lubna Hamdan Received Received
  4685-MON Congenital dyserythropoietic anemia type I: Updated report from the congenital dyserythropoietic anemia registry of North America Lubna Hamdan Received Received
  4686-MON Biomarkers of ineffective erythropoiesis in patients with sickle cell anemia, at baseline and while treated with hydroxyurea, in comparison to patients with other iron-loading red cell disorders Yasmin Elgammal Received Received
  4687-MON Reduction of iron overload in hereditary hemochromatosis model mice by presence of iron metabolism mutant Staton McBroom Received Received
  4688-MON Total effect of gestational hypertension on neonatal iron deficiency in very-preterm infants. Hudson Barr Received Received
  4689-MON A phase 2 study of luspatercept in adults and adolescents with a-thalassemia: Findings from the dose-confirmation cohort in adolescents Pablo Gurman Received Received
  4690-MON Revisiting morbidities and predictors in transfusion-dependent thalassemia: A cohort study over 10 years from the national registry of hemoglobinopathies in Tuerkiye Yesim Aydinok Received Received
  4691-MON Pregnancy outcomes in alpha thalassemia major: A population-based analysis using the national inpatient sample 2017-2022 Mariana Marrero Castillo Received Received
  4692-MON Beta thalassemia major and pregnancy outcomes: Evidence of severe transfusion burden and iron overload complications in a national cohort Mariana Marrero Castillo Received Received
  4693-MON Challenges in hemoglobinopathy control programs: Insights from Tuerkiye Yesim Aydinok Received Received
  4694-MON Developing ß-thalassemia mouse model by deleting hbb genes for therapeutic evaluation Qiurong Wang Received Received
  4695-MON Impact of long-term luspatercept treatment on iron parameters in patients with transfusion-dependent and non-transfusion-dependent ß-thalassemia: Results from the phase 3b long-term follow-up study Ali Taher Received Received
  4696-MON Thalassemia in europe: A cross-border real-world data analysis from the radeep registry Anna Collado Gimbert Sr Received Received
  4697-MON Long-term transfusion-free duration and impact on transfusion-related burdens: Results from the ongoing ENERGIZE-T open-label extension study of mitapivat in transfusion-dependent alpha- or beta-thalassemia Sujit Sheth Received Received
  4698-MON Snh-119014, a novel pyruvate kinase activator, enhances ATP production and reduces oxidative stress in erythroid cells from patients with ß-thalassemia major Huang Qiulin Received Received
  4699-MON Efficacy of mitapivat in patients with transfusion-dependent alpha-thalassemia: Subgroup analysis from the ENERGIZE-T trial Ashutosh Lal Received Received
  4700-MON Defining therapeutic chimerism thresholds for comprehensive sickle cell disease correction in the townes mouse model Nicole Mende Received Received
  4701-MON Caspase-4/11 alters circulating immune cells and mediates organ damage in Townes SCD mice Suruchi Salgar Received Received
  4702-MON Impact of G6PD ?- mutation on hemoglobin function and RBC rheology in sickle cell disease Temiloluwa Okusolubo Received Received
  4703-MON Machine Learning–Guided identification of survival-associated genetic variants in sickle cell disease Shijinqiu Gao Received Received
  4704-MON Mechanisms of acute pain involve spinal IL17-TNF-a/IL-6–p38 MAPK activation in sickle cell disease Yugal Goel Received Received
  4705-MON R-propranolol Promotes lipid synthesis via a novel, non-adrenergic pathway to treat sickle cell cardiomyopathy Yangfan Jia Received Received
  4706-MON Validation of a sickle cell disease-specific iPSC platform as a preclinical screening tool Kim Vanuytsel Received Received
  4707-MON Dual complement and P-selectin inhibitor, IHP-102, prevents lung vaso-occlusion in P-selectin-deficient townes SS mice John Paderi Received Received
  4708-MON IHP-102 compound decreases the adhesion of sickle cell disease RBCs to acutely activated endothelial cells in biochip labs endothelial-on-a-chip assay Chiara Federici Received Received
  4709-MON Interleukin-27 ameliorates inflammation-induced chronic pain in sickle cell disease Adekunle Emmanuel Alagbe Received Received
  4710-MON IHP-102 reduces pain and modulates complement activation in a sickle cell mouse model Kennedy Nichelle Goldsborough Received Received
  4711-MON In vitro microfluidics model revealed red blood cell derived extracellular vesicles cause second hit to heme-primed endothelial cells Qingrong He Received Received
  4712-MON Sickling kinetics drive genotype-specific impairment of RBC deformability in sickle cell disease Yuxuan Du Received Received
  4713-MON Circulating endothelial extracellular vesicles from sickle cell patients promote susceptibility of pulmonary endothelium to thrombotic injury Amit K Srivastava Received Received
  4714-MON Hemoglobin uptake by liver endothelium prevents von Willebrand factor clearance in sickle cell disease Marta Wolosowicz Received Received
  4715-MON Targeting the SDF-1/CXCR4 axis to attenuate pain in sickle cell disease: A preclinical evaluation of AMD3100 as a non-opioid therapeutic strategy Ammar Saadoon Alishlash Received Received
  4716-MON Description of neurocognition in adult sickle cell disease patients using the NIH toolbox Olivia Perez De Acha Received Received
  4717-MON Early weight gain predicts nutritional recovery in children with sickle cell anemia and severe acute malnutrition in Nigeria Lauren Jane Klein Received Received
  4718-MON Baseline data from the prioritizing utilization and safety of hydroxyurea using precision in Africa (PUSHUP) trial Christine Briscoe Received Received
  4719-MON Rheological effects of voxelotor in SCD: A double-edged sword? Gonzalo De Luna Received Received
  4720-MON Impact of pain sensitization phenotypes on quality of life among adults with sickle cell disease Rachael O. Ajiboye Received Received
  4721-MON Association of low annexin A2 levels with venous thromboembolism in sickle cell anemia: A potential biomarker Ugochi O Ogu Received Received
  4722-MON The psychometric properties of the stoplight pain scale in children with sickle cell disease Keli D. Coleman Received Received
  4723-MON Registration and characterization of patients with Glucose-6-Phosphate Dehydrogenase Deficiency in Spain: A real-world study of the Spanish Erythropathology Group (GEE) María Menor Gómez Received Received
  4724-MON Racial and socioeconomic disparities in transfusion utilization among hospitalized sickle cell disease patients: An analysis of the 2022 national inpatient sample Inae Park Received Received
  4725-MON Bone mineral density findings in patients with sickle cell disease Madeline Evans Received Received
  4726-MON Describing the feasibility and acceptability of an electronic adherence monitor to measure hydroxyurea adherence among youth with sickle cell disease Anyssa Nicole Young Received Received
  4727-MON Impact of obesity on inpatient outcomes in patients hospitalized with acute chest syndrome Abdulmalek Aljafari Received Received
  4728-MON Efficacy and safety of osivelotor in participants with sickle cell disease in a 12-week phase 2, multicenter, open-label, dose-finding trial and extension study Santosh L Saraf Received Received
  4729-MON Correlation of antral follicle count and antimullerian hormone in women with sickle cell disease Lydia Pecker Received Received
  4730-MON Chronic kidney disease risk stratification in compound sickle cell disease variants: A single center review Abraham Attah Received Received
  4731-MON Exercise capacity and oxygen saturation on six-minute walk testing relate to markers of organ dysfunction in adults with sickle cell disease Michelle L Gillespie Received Received
  4732-MON Diagnostic accuracy and challenges of AI/ML models for sickle cell disease detection in blood smears: A meta-analysis and systematic review Nimra Shafi Received Received
  4733-MON Machine learning replicates and extends clinician-informed disease severity grading classification for acute pain and CKD in sickle cell disease Minzhang Zheng Received Received
  4734-MON Standard transcranial doppler as a resource-efficient first step to screen for MRA-defined cerebral vasculopathy in adults with sickle cell disease Olivier Pouliot Received Received
  4735-MON Genetic variants and hemoglobinopathies among Indian sickle cell disease patients: A systematic review Nagateja Yedida Received Received
  4736-MON Avascular necrosis of the femoral head in children and adolescents with sickle cell disease presenting with HIP PAIN Khalid Elsir Elbashir Received Received
  4737-MON Modified-release formulation of decitabine and tetrahydrouridine combination not only increases exposure to decitabine but reduces exposure to unfavorable decitabine metabolites in healthy volunteers Marie Aavang Geist Received Received
  4738-MON Raising pre-transfusion HbS levels from 30% to 50% does not increase ischemic stroke recurrence in sickle cell disease: Results from a long-term single-center study Karina Tozatto-Maio Received Received
  4739-MON Feasibility, reliability, and accuracy of point-of-care measurements of fetal hemoglobin Charles T Quinn Received Received
  4740-MON Healthcare transition readiness for sickle cell disease: A high- and low- income comparative analysis Kelly Pimenta Received Received
  4741-MON Cancer specific risk and mortality due to autoimmune hemolytic anemia (AIHA) associated with immune checkpoint inhibitors (ICI) Haris Sohail Received Received
  4742-MON Exploring experiences and perceptions of fertility and reproductive technology among people with sickle cell disease Kayla Dyson Received Received
  4743-MON High-accuracy, transfusion-aware machine learning pipeline for hemoglobin genotype classification with shap-based interpretability Jonathan Winslow Wade Received Received
  4744-MON Pregnancy related complications and placenta pathology in pregnant women with sickle cell disease Nneka Nwachukwu Received Received
  4745-MON Influenza vaccine coverage, effectiveness, and disease burden among pediatric sickle cell patients in Connecticut from 2021-2024: A test-negative case-control study Inci Yildirim Received Received
  4746-MON Investigation of predictive markers of disease complications in children with sickle cell disease: Preliminary findings from a multicenter prospective inception cohort study Marisol Betensky Received Received
  4747-MON The contemporary adolescent and young adult sickle cell population in Malawi Luke Eastburg Received Received
  4748-MON Elevated d-dimer predicts worse outcomes in hospitalized adults with sickle cell crisis: A real-world multicenter study Divya Samat Received Received
  4749-MON Assessing replicability in chronic kidney disease severity scoring classifications using the sickle cell outcome grading system India Sisler Received Received
  4750-MON Assessing the prevalence of sickle cell retinopathy in clinical practice Elexis Price Received Received
  4751-MON Venous thromboembolism in adults with sickle cell disease: A national inpatient sample analysis (2016–2020) Mohammed Saleh Received Received
  4752-MON Pilot of standardized cognitive behavioral therapy for young adults with sickle cell disease Alexander Boucher Received Received
  4753-MON Randomized controlled trial-in-progress of an interdisciplinary treatment program for youth with chronic SCD pain: Integrative strong body and mind training for sickle cell disease (I-STRONG) Soumitri Sil Received Received
  4754-MON A phase 2 open-label study of epeleuton in patients with sickle cell disease Biree Andemariam Received Received
  4755-MON Evaluation of clinical significance of circulating growth differentiation factor-15 levels in patients with gaucher disease Ioannis Papassotiriou Received Received
  4756-MON Bystander activation drives CD8+ t cells response in lymphoma-associated hemophagocytic lymphohistiocytosis Jing Quan Lim Received Received
  4757-MON Rising burden of hemophagocytic lymphohistiocytosis in the United States: A nationwide analysis of mortality, disparities, and underdiagnosis Aqsa Zoey Sorathia Received Received
  4758-MON Emapalumab induces rapid, durable responses and reliable bridging to curative HSCT in patients with primary HLH: Pooled analysis of prospective trials NI-0501-04, NI-0501-05 and NI-0501-09 Franco Locatelli Received Received
  4759-MON Hemophagocytic lymphohistiocytosis in the community: Real-world evidence and insights from a rare illness in the tertiary university system. Sumrah Khan Received Received
  4760-MON Excessive neutrophil extracellular traps formation in sepsis induced acute respiratory distress syndrome: Role of citrullinated histone H3 as a surrogate biomarker and clinical implication Awirut Charoensappakit Received Received
  4761-MON Identification of stage-specific regulators for neutrophil granule biogenesis Wimeth Dissanayake Received Received
  4762-MON Malignancy as a secondary cause of hemophagocytic lymphohistiocytosis: Outcomes and complications, a national inpatient sample analysis from 2016 to 2020 Santiago Imhoff Received Received
  4763-MON Incidence and risk factors of hemophagocytic lymphohistiocytosis after bispecific antibody therapy in hematologic malignancies: Insights from a global real-world cohort Kausik Maiti MD Received Received
  4764-MON Increased serum h-ferritin and its imbalance with l-ferritin distinguish hemophagocytic lymphohistiocytosis among critically ill patients with hyperferritinemia. France Debaugnies Received Received
  4765-MON Single-cell immunophenotyping reveals mutation-specific immune alterations in severe congenital neutropenia Aleksandra Maria Oszer Received Received
  4766-MON Spermine alleviates EV71-induced inflammation by inhibiting GBP5 and NLRP3 activation in macrophages Hong Cao Received Received
  4767-MON Evaluating the clinical utility of soluble interleukin-2 receptor testing in diagnosing adult HLH: A single-center retrospective study McKailey Salard Received Received
  4768-MON Hereditary alpha-tryptasemia (HaT) extends the symptom spectrum to cardiovascular, pain and neuropsychiatric symptoms in patients with mast cell-related conditions Daniel Koch Received Received
  4769-MON The predictive value of the interleukin 2 receptor (IL2)/ferritin ratio in the diagnosis of lymphoma associated hemophagocytic lymphohistiocytosis (LAHS): A United States, multi center experience Dariusz Uczkowski Received Received
  4770-MON Impact of additional genetic variants in the course of erdheim-chester disease and their evolution on treatment: A multicentric longitudinal Study of 445 french patients Félicien Triboulet Received Received
  4771-MON Role of genetic testing in diagnosing patients with severe congenital neutropenia: Results from PATH4WARD genetic testing program Jolan Walter Received Received
  4772-MON Real-world analysis of ICI-associated HLH reveals early mortality despite standard interventions Grace Gorecki Received Received
  4773-MON Temporal trends of mortality, associated conditions, hospitalizations, and costsrelated to hemophagocytic lymphohistiocytosis in the US. Emeka Agudile Received Received
  4774-MON Interpreting tryptase levels and avoiding common pitfalls in screening for clonal mast cell disease Mariana Castells Received Received
  4775-MON Imatinib in mast cell activation syndrome: A retrospective pilot study Abhay Aradhya Received Received
  4776-MON Prognostic impact of molecular genetic and cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with azacitidine and venetoclax: A real-world cohort study Cristiano Machado De Freitas Sr Received Received
  4777-MON Divergent exhaustion networks define memory CD8+ T cell subset fate under chronic stimulation and reveal targets for epigenetic reprogramming Leonel Torres Received Received
  4778-MON Early recognition and optimized management of tafro syndrome: A 10-year experience from a single center in China Chun Feng Received Received
  4779-MON Low expressed SRSF1 promotes lck exon 8 skipping to attenuate TCR signaling and treg induction in immune thrombocytopenia Hu Xiang Jr Received Received
  4780-MON Immunological and transcriptomic analysis of febrile neutropenia in hematological malignancies: SOCS3/IL-6/NETs axis and NOD-like receptor signaling dysregulation Dairong Xie Received Received
  4781-MON Impaired coordination between innate and adaptive immunity in hematologic and solid cancer patients following sars-cov-2 infection or vaccination Piers Patten Received Received
  4782-MON Transcriptomic and pathological insights into PI3K–Akt pathway activation in idiopathic multicentric castleman disease, tafro and NOS subtypes Yoshito Nishimura Received Received
  4783-MON RPS6 acts as a translational checkpoint to limit effector skewing and sustain CD8 T cell memory Elena Kostenko Received Received
  4784-MON PRKRA associated with NF-?B activation in pulmonary involvement of idiopathic multicentric castleman disease Yu-han Gao Received Received
  4785-MON Aiming at immune fitness in cancer: Longitudinal functional profiling to predict clinical outcome Maryam Kazerani Received Received
  4786-MON Increased type I interferon signaling is a hallmark of idiopathic multicentric castleman disease Katherine Shona Forsyth Received Received
  4787-MON An open-label Phase II trial of VDJ-001, a high-affinity IL-6R antagonist antibody, for the treatment of patients with idiopathic multicentric castleman disease Lu Zhang Received Received
  4788-MON Siltuximab-mediated suppression of CRP is associated with clinical response in idiopathic multicentric castleman disease Jean-Francois Rossi I Received Received
  4789-MON Somatic mutation discovery in idiopathic multicentric castleman disease (iMCD) lymph node tissue identifies dysregulated intracellular calcium signaling as a potential disease mechanism and therapeutic target Michael Vincent Gonzalez Received Received
  4790-MON Targeted metabolomics identifies a metabolic switch to mitochondrial respiration in antiphospholipid syndrome that drives platelet procoagulant activity Paresh P Kulkarni Received Received
  4791-MON Denatured albumin is a potent ligand mediating platelet activaiton, adhesion and aggregation Xuefeng Wang Received Received
  4792-MON Patients with immune thrombocytopenia and antiplatelet antibodies show increased platelet activation and desialylation Elena Monzon Manzano Received Received
  4793-MON Targeting the CD38-NAD? axis alleviates antibody-driven cytopenia in autoimmune disorders without inducing broad immunosuppression Hui yuan Li Received Received
  4794-MON A platelet-activating, HPA-1a-specific maternal alloantibody identifies a pathogenic subpopulation with the potential to exacerbate fetal/neonatal alloimmune thrombocytopenia Huiying Zhi Received Received
  4795-MON Role of anti-GP antibodies release with platelet-derived extracellular vesicles in regulating ITP platelet apoptosis Ye Jieyu Received Received
  4796-MON Potential paradoxical hemostatic function of ADAMTS13 by enhancing collagen-induced platelet aggregation and activation Huang Dong Received Received
  4797-MON Megakaryocytes engage in emperipolesis with neutrophils and emperipolesis by the immune MK subset leads to efferocytosis and is exacerbated by CXCR1/2 activation in myelofibrosis Anna Rita Migliaccio Sr Received Received
  4798-MON Role of IL-10 in regulating macrophage pyroptosis in immune thrombocytopenia Ziyang Liang Received Received
  4799-MON Platelets modulate the CD4 T cell immune response during immune thrombocytopenia. Sylvain Audia Received Received
  4800-MON Modulation of the lipid metabolism in macrophages through chaperone-mediated autophagy in primary immune thrombocytopenia Yajing Zhao Received Received
  4801-MON Platelet dysfunction in Ehlers–Danlos syndrome is associated with low GPVI and PAR1 expression on platelets Mariia Kumskova Received Received
  4802-MON Integration of Cut&Run, atac-seq and RNA-seq analyses defines the impact of germline ETV6 mutations on chromatin binding and gene expression in megakaryocytes Hyder Mir Received Received
  4803-MON A flk-independent pathway of megakaryopoiesis is differentially responsive to stress and can produce high proportions of functionally distinct platelets James Palis Received Received
  4804-MON Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: Results from a randomized, multicenter, placebo-controlled phase 3 trial Runhui Wu Received Received
  4805-MON Real-world effectiveness and safety of fostamatinib in difficult-to-treat patients: Results of a three-year registry in France. Guillaume Moulis Received Received
  4806-MON Efficacy and safety of romiplostim N01 in cancer treatment–induced thrombocytopenia: Results from a phase II off-label study in China Yu Zhang Jr Received Received
  4807-MON Platelet transfusion is associated with reduced thrombosis yet elevated mortality in consumptive thrombocytopenias: A retrospective cohort study Manas Pustake Received Received
  4808-MON Closing analysis of the patient and disease characteristics of the UK primary paediatric ITP registry Mia Giles Received Received
  4809-MON Decoding acquired platelet dysfunction with eosinophilia: Clinical triad and flow cytometric signatures Sukesh Nair VI Received Received
  4810-MON Effectiveness of sirolimus for pediatric autoimmune cytopenias and factors associated with clinical response Maggie McNeill Received Received
  4811-MON Retrospective analysis of efficacy and safety of romiplostim N01 in the treatment of chemotherapy-induced thrombocytopenia (CIT) in solid tumors Yusheng WANG Received Received
  4812-MON Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase ? Trial Heng Mei Received Received
  4813-MON Real-world clinical trial of hetrombopag (TPO-RA) in the treatment of primary immune thrombocytopenia (ITP) Chen Yunfei Received Received
  4814-MON Effectiveness and safety of splenectomy or thrombopoietin receptor agonists as second-line treatments for patients with immune thrombocytopenia in a real-world setting Ka-Won Kang Received Received
  4815-MON Adverse events reported with eltrombopag and romiplostim: Faers database Shivani Modi Received Received
  4816-MON Neonatal fc receptor antagonists in adult patients with primary immune thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials Sinrraim dos Santos Chaves Ruiz Received Received
  4817-MON Short-term hetrombopag for the management of preoperative thrombocytopenia: A multicenter clinical trial Jing Tan Received Received
  4818-MON Daratumumab can lead to long-lasting remissions in patients with refractory immune thrombocytopenia but with a high incidence of severe infections Elodie Han Received Received
  4819-MON Response to Hetrombopag Among patients with acute and persistent primary immune thrombocytopenia: A real-world study in China Yimei Feng Received Received
  4820-MON The JAK1/2 inhibitor baricitinib revealed unique immune biomarkers in multirefractory immune thrombocytopenia patients Xiaohui Zhang Received Received
  4821-MON Blocking Fc?RIII with anti-CD16 mab (3G8 and GMA161) increases platelets in immune thrombocytopenia: Two pilot studies Miao Xu Received Received
  4822-MON Management and outcomes of acute coronary syndromes in patients with immune thrombocytopenia: A single-center real-world study Xiaohui Zhang Received Received
  4823-MON Dysregulation of the complement system in immune thrombocytopenia Justin Pieter Oosterlee Received Received
  4824-MON First report: A novel deep intronic mutation and treatment using hetrombopag olamine of a patient with MYH9 syndrome and immune thrombocytopenia Yanqing Tan Received Received
  4825-MON Immature platelet fraction as a pre-test probability marker for anti-platelet IgG positivity in thrombocytopenia Afonso Celso Almeida Cardoso Received Received
  4826-MON Impact of helicobacter pylori infection on clinical outcomes in patients with immune thrombocytopenia: A propensity-matched analysis from a national cohort Jamil Nazzal Received Received
  4827-MON Early multi-immune modulation with rilzabrutinib in patients with primary ITP after first-line treatment failure: A phase 3b study (LUNA 4) David Kuter Received Received
  4828-MON Vmx-C001 has no effect on the anticoagulant function of heparin in healthy subjects Gerard Short Received Received
  4829-MON Evaluating ribosomal readthrough as a precision medicine strategy for restoring factor VIII expression in hemophilia a Vishal Srivastava Received Received
  4830-MON Mim8 improves the In Vivo hemostasis of select hemophilia B causing factor IX variants Sebastian E. Leyes Porello Received Received
  4831-MON Comparison of hemostatic dosing of factor IX wild-type and padua (R338L) in multiple hemophilia B mouse models Julia Q. Chau Received Received
  4832-MON ADAMTS13 variant (R1206K) exhibits increased VWF-cleaving activity and inhibition of thrombus formation under flow Szumam Liu Received Received
  4833-MON Tyro3 is a key regulator of clot retraction mediated by platelet-derived protein S Narender Kumar Received Received
  4834-MON Evaluation of the combined effects of emicizumab and marstacimab in plasma from Hemophilia A patients using thrombin generation assay Michela Ronconi Received Received
  4835-MON Evaluating reversal strategies for long-acting factor XI antibodies: RFVIIa®, FEIBA®, Kcentra®, novel FXI mutants, and an anti-idiotypic antibody Christina U. Lorentz Received Received
  4836-MON Phosphatidylserine-rich platelet blebs enhance hemostasis after mucous membrane injury but not after skin or vascular injury: Studies with ANO6-deficient mice Valerie Novakovic Received Received
  4837-MON Platelets stabilize factor VIIIa against loss of activity through subunit dissociation Valerie Novakovic Received Received
  4838-MON Characterization of participants with elevated bleeding rates responding to prophylactic marstacimab treatment in the phase 3 BASIS trial Pascal Klaus Received Received
  4839-MON Exploratory analysis from HAVEN 1–4 to further contextualize injection-site reactions among people with hemophilia A receiving emicizumab Shannon Carpenter Received Received
  4840-MON Real-world outcomes of PK/PD-guided individualized emicizumab dose reduction in Chinese pediatric patients with hemophilia A: A prospective observational study Qianqian Mao Received Received
  4841-MON Pharmacodynamic biomarkers in people with hemophilia A receiving multiple ascending doses of NXT007 Anna Kiialainen Received Received
  4842-MON Self-reported prophylaxis treatment experience among persons living with hemophilia A in the US: A cross-sectional analysis of survey results combined with medical records Eleni Demas Received Received
  4843-MON Cardiovascular disease risk assessment in Japanese adults with hemophilia: Interim results of a multicenter study Yushi Chikasawa Received Received
  4844-MON Long term effect of marstacimab prophylaxis in hemophilia ? and ? on target joints: Results from BASIS and OLE studies Johnny Mahlangu Received Received
  4845-MON Outcomes of marstacimab treatment in adolescent participants with Hemophilia A or B without inhibitors compared with prior routine prophylaxis: Results from the phase 3 BASIS trial Anthony KC Chan Received Received
  4846-MON Quality of life and functional improvements with efanesoctocog alfa in patients with moderate-to-severe Hemophilia A: A real-world survey Maissaa Janbain Received Received
  4847-MON Assessment of coagulation potential of concomitant factor VIII administration in patients with haemophilia a receiving emicizumab prophylaxis (CAGUYAMA Study): A multicenter, open-label, non-randomized clinical trial Masahiro Takeyama Received Received
  4848-MON Immunogenicity assessment of concizumab in patients with Hemophilia A and b: Assays developed to measure anti-drug antibodies and integrated results from clinical trials Thomas Porstmann Received Received
  4849-MON Comparison of hemosil and innovance antithrombin assays using Hemophilia A plasma and antithrombin lowering (to mimic fitusiran) Sibgha Zaheer Received Received
  4850-MON Experience with minor surgeries in people with hemophilia A or B with and without inhibitors receiving fitusiran Steven Pipe Received Received
  4851-MON Rates of inhibitor development and immune tolerance in children with severe Hemophilia A on emicizumab prophylaxis Anna Schwartz Received Received
  4852-MON AAV gene therapy in hemophilia B shows robust bleeding reduction and variable factor IX expression: A bayesian meta-analysis of randomized controlled trials Gowarishankar Palaniswamy Received Received
  4853-MON Retrospective cohort analysis of treatment patterns and bleeding outcomes in the Korean bleeding disorder registry (KBDR) Jung Woo Han Received Received
  4854-MON Use of emicizumab in patients with acquired hemophilia A: An interim safety analysis of a large-scale post-marketing surveillance study Tadashi Matsushita Received Received
  4855-MON Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: First results from wil-33 Akshat Jain Received Received
  4856-MON Real-world study of population pharmacokinetic-guided pdVWF/FVIII (1:1) prophylaxis in people with severe von Willebrand disease: The PopPK-WILPROPHY study Robert F. Sidonio, Jr. Received Received
  4857-MON Comparative analysis of prophylaxis with 1:1 ratio pdVWF/FVIII concentrate vs. recombinant VWF in type 3 von willebrand disease adults in the United States: Clinical and economic perspective Fernando Corrales-Medina Received Received
  4858-MON Systematic literature review and meta-analysis on the safety of fibrinogen concentrate versus cryoprecipitate in bleeding surgical patients David Gomez-Ulloa Received Received
  4859-MON Response to TFPI-inhibition in severe factor v deficiency with a novel compound heterozygous mutation Francis Ayombil Received Received
  4860-MON Fibrinogen concentrate versus cryoprecipitate for bleeding in cardiac surgery patients stratified by surgery risk in the phase 3 fibres Study Jeannie Callum Received Received
  4861-MON A novel VWF mutation associated with macrothrombocytopenia, cytoskeletal defects, and distinct functional abnormalities: A case report Ekaterina Balaian Received Received
  4862-MON Red-lilly app: A digital tool for the evaluation of menstrual bleeding patterns to support the early detection of bleeding disorders in women Susan Halimeh Received Received
  4863-MON The Mayo Clinic enterprise experience and outcomes of perioperative utilization of recombinant factor VIIa (rFVIIa, NovoSeven®) Isabela Chang Received Received
  4864-MON National trends and demographic disparities in mortality due to bleeding disorders in the u.S., 1999–2020 Fnu Bhuvan Received Received
  4865-MON Burden of vitamin d deficiency and bone health risk factors in persons with von Willebrand disease in Arkansas Kimberly O´Brien Received Received
  4866-MON Susoctocog alfa for major surgery in acquired Hemophilia A Inga M. Schimansky Received Received
  4867-MON Double burden: Bleeding disorders and their impact on cardiovascular mortality across demographics and geography in the United States, 1999–2020 Hardik Jain Received Received
  4868-MON Prothrombin complex concentrate in managing direct oral anticoagulant (DOAC)-associated bleeding and real-world use in vitamin k antagonist (VKA)-associated bleeding: The ongoing lex-210 and lex-212 studies Ravindra Sarode Received Received
  4869-MON An interactive database containing all known variants in ADAMTS13 yields new insight into the genetic variation and protein changes underlying congenital TTP Matthew Adam Carter Received Received
  4870-MON Platelet-activating antibodies to the chemokine, platelet factor 4, in cerebral malaria differ from those in heparin-induced thrombocytopenia and vaccine-induced thrombotic thrombocytopenia. Lubica Rauova Received Received
  4871-MON Tropomyosin 1 promotes platelet adhesion and clot contraction to inhibit thrombosis Po-Lun Kung Received Received
  4872-MON Interrelationship between endothelial dysfunction and inflammation and outcomes in pulmonary embolism Martin Lundy Received Received
  4873-MON Proteomic study of extracellular vesicles reveals novel biomarkers for pathogenesis of immune thrombotic thrombocytopenic purpura Li Zhou Received Received
  4874-MON Lipoprotein(a) plasma levels and coagulation biomarkers: Results from a comprehensive laboratory assessment in an angiographically-controlled cardiovascular cohort. Patrick Van Dreden Received Received
  4875-MON Sepsis induces platelet-activating anti-PF4 antibodies with potential protective role against secondary bacterial infection Tao Liu Received Received
  4876-MON Both platelet factor 4 (PF4) and b2-glycoprotein I (b2GPI) bind to von Willebrand factor (VWF) and inhibit ADAMTS13 cleavage: Mechanistic and clinical implications in thrombotic thrombocytopenic purpura (TTP) Amrita Sarkar Received Received
  4877-MON Use of angiopoietin-2 as a biomarker in vascular anomalies beyond complex lymphatic anomalies Svatava Merkle Received Received
  4878-MON Pregnancy-associated atypical hemolytic uremic syndrome: A systematic review and meta-analysis of clinical features, treatment strategies, and Maternal–Fetal outcomes Aminah Tayyab Received Received
  4879-MON High morbidity and early readmissions in thrombotic thrombocytopenic purpura requiring intensive care: Insights from a national database Dhara Popat Received Received
  4880-MON Real-world outcomes of platelet transfusion in heparin-induced thrombocytopenia: A five-year national study Areeba Nayyer Received Received
  4881-MON Procedure-triggered late-onset congenital thrombotic thrombocytopenic purpura: Unmasking functional impact of a heterozygous synonymous ADAMTS13 variant (c.1716GA) associated with reduced enzyme expression Sravya Gundapaneni Received Received
  4882-MON Ophthalmic manifestations of antiphospholipid syndrome Katie Huynh Received Received
  4883-MON Daratumumab for immune-mediated thrombotic thrombocytopenic purpura (iTTP): Results from the international, multicenter darttp study Juri Alessandro Giannotta Received Received
  4884-MON High rates of hypertension, improved renal outcomes in complement-mediated thrombotic microangiopathy Charlotte M Story Received Received
  4885-MON Trends in acute TTP mortality amidst a shifting therapeutic landscape Senthil Sukumar Received Received
  4886-MON Pegcetacoplan for patients with transplant-associated thrombotic microangiopathy treatment: A real-world report of six cases Sondas Al-Sharidah Received Received
  4887-MON Review of the management of patients with immune thrombotic thrombocytopenic purpura with persistently low adamts-13 activity - a challenge beyond rarity. Maria Eva Mingot Sr Received Received
  4888-MON Effect of plasmapheresis on mortality and length of stay in hospitalized patients with thrombotic thrombocytopenic purpura Aman Ullah Received Received
  4889-MON Medical and perioperative management of acute and subacute heparin-induced thrombocytopenia in adults requiring urgent cardiopulmonary bypass surgery. Jimmy Lee Received Received
  4890-MON Clinical manifestations, management, and outcomes in patients with triple positive antiphospholipid antibodies Madeline Young Received Received
  4891-MON Maternal and fetal outcomes in immune-mediated thrombotic thrombocytopenic purpura: A scoping review Meera Sridharan Received Received
  4892-MON Real-world one-month mortality and bleeding outcomes with caplacizumab in thrombotic thrombocytopenic purpura: A propensity-matched cohort study Kanishka Uttam Chandani Received Received
  4893-MON Epik-L1: A Phase 2/3 study of alpelisib in pediatric and adult patients with PIK3CA-driven lymphatic malformations Nydia Caro Received Received
  4894-MON Superficial vein thrombosis of the upper extremities: A retrospective analysis of clot progression and role of thrombophilia testing Terrence Sun Received Received
  4895-MON Pharmacometric analyses supporting apixaban doses in neonates with venous thromboembolism Puneet Gaitonde Received Received
  4896-MON Development and validation of a new model for predicting occult cancer after unprovoked VTE and its comparative performance against riete and some scores Abdulrahman Al Raizah Received Received
  4897-MON Comparative effectiveness and safety of apixaban vs. rivaroxaban in patients with cirrhosis and portal vein thrombosis: An analysis of real-world data Lucy S. Wang Received Received
  4898-MON Efficacy and safety of low-dose vs. standard-dose direct oral anticoagulants for secondary prevention of venous thromboembolism: A systematic review and meta-analysis Ursula Medeiros Araujo de Matos Received Received
  4899-MON primary thromboprophylaxis using direct oral anti-coagulants (DOAC) in malignant pediatric tumors with vascular compression Max Cohen Received Received
  4900-MON Risk factors for thrombo-embolism in neonates: A systematic review of the literature and call to action Marie-Claude Pelland-Marcotte Received Received
  4901-MON Elevated prevalence of hereditary thrombophilia variants in an endogamous jewish-Mexican cohort Ariela Aline Souroujon Received Received
  4902-MON Extended duration anticoagulation in cancer associated thrombosis Imogen Welding Received Received
  4903-MON Reduced versus standard dose apixaban for secondary prevention of cancer-associated venous thromboembolism: A systematic review and meta-analysis Vasu Malhotra Received Received
  4904-MON Arterial thrombotic events in lymphoma patients: Systematic review and meta-analysis Darko Antic Sr Received Received
  4905-MON Elucidating the chronological relationship between central venous line dysfunction, infection and thrombosis in children with cancer: A preliminary analysis Arielle Locke Received Received
  4906-MON Anticoagulation management and outcomes in cancer-associated ovarian and renal vein thrombosis: A multicenter retrospective cohort study Elena Butera Received Received
  4907-MON Abbreviated anticoagulation regimen with direct oral anticoagulants is safe and efficacious in the management of infection-associated cerebral sinovenous thrombosis in children Sriveda Boyalakuntla Received Received
  4908-MON Diagnostic accuracy of PET/CT scan in differentiating malignant and bland thrombi in cancer patients: A systematic review Amir Mahmoud Received Received
  4909-MON Risk of venous thromboembolism associated with CDK 4/6 inhibitors and adjuvant hormonal therapy in non-metastatic breast cancer: A systematic review and meta-analysis Elysa Monique Cortez Received Received
  4910-MON Machine Learning–Based risk stratification in patients with direct anti-xa Inhibitors–Related bleeding treated with four-factor prothrombinex complex concentrate (4F-PCC) Yuen Ting Sin Received Received
  4911-MON Rivaroxaban in pediatric venous malformations complicated by thrombosis: Updated experience from a retrospective single-center cohort Matteo Luciani Received Received
  4912-MON Impact of venous thromboembolism on clinical outcomes in patients with brain cancer: A national inpatient sample analysis from 2018-2020 Jawad Ahmed Received Received
  4913-MON Prevalence and outcomes of inherited and acquired thrombophilia in pediatric patients with venous thromboembolism: Findings from an institutional prospective inception cohort study Evelyn Wooley Received Received
  4914-MON Role of therapeutic anticoagulation in kidney transplant recipients with thrombophilia: A systematic review Zain Al-Momani Received Received
  4915-MON Cardioembolic stroke in children and young adults: Comprehensive management and risk of hemorrhagic transformation-a single institutional experience Robert Burks Received Received
  4916-MON Defining clinical risks of venous thromboembolism in children with intestinal failure Alayna D Koch Received Received
  4917-MON Incidence of asymptomatic deep vein thrombosis in patients with tunneled dialysis catheters undergoing routine venous mapping. Bibi Maryam Received Received
  4918-MON Is there an optimal time to transition to low dose direct oral anticoagulants? Danielle Vlazny Received Received
  4919-MON Efficacy of erythropoietin and intravenous iron for treatment of critical anemia in patients who decline blood transfusions for religious reasons Danielle Olonoff Received Received
  4920-MON A case series on cutaneous reactions to ivig Michel Lu Received Received
  4921-MON Perioperative anemia and transfusion thresholds in vascular surgery procedures – a systematic review David Gou Received Received
  4922-MON Stability of ADAMTS13 activity in liquid plasma and its clinical application in therapeutic plasma exchange for thrombotic thrombocytopenic purpura Wenjing Cao Received Received
  4923-MON Design and characterization of novel albumin-based oxygen carriers as an alternative to whole blood Alejandra Lorenzen Received Received
  4924-MON Critical platelet shortages and a single Institution´s experience with split platelet transfusions: Can you get by with just half a unit? Anup Kumar Trikannad Received Received
  4925-MON Risk of transfusion associated circulatory overload after blood products transfusion in patients with hfref vs. hfpef: A real-world propensity-matched analysis Jamil Nazzal Received Received
  4926-MON Dysregulated lung microbiota impaired hematopoietic stem cell function in mice with pulmonary diseases. Xiangjun Zeng Received Received
  4927-MON Dynamic roles of hematopoietic notch signaling in extramedullary hematopoiesis Kostandin Pajcini Received Received
  4928-MON Critical role for MLL3-phd domains in HSC self-renewal and AML suppression Rohini Muthukumar Received Received
  4929-MON Restraint of TGF-ß signaling by SMAD7 is necessary for the maturation of hematopoietic stem cells in the mouse embryo Laura Bennett Received Received
  4930-MON Development of NOG-W41-based humanized mouse model for studying In Vivo human hematopoiesis Ryoji Ito Received Received
  4931-MON FLT3 ligand facilitates long-term ex vivo expansion of human hematopoietic stem cells by maintaining lymphoid reconstitution potential Masashi Miyauchi Received Received
  4932-MON High expression of GFP on hematopoietic stem cells acts as a neoantigen triggering increased T cell-mediated clearance and reduced self-renewal Aishwarya Krishnan Received Received
  4933-MON Beyond hemostasis: Factor VIII deficiency impacts hematopoietic stem cells development in zebrafish Sara Deola Received Received
  4934-MON Loss of transcription factor myb drives an immune differentiated megakaryocyte phenotype Michael W. Malloy Received Received
  4935-MON CD27, CD62L and ESAM define a multipotent progenitor population with megakaryocytic potential Ryan Mack Received Received
  4936-MON Identification of a development-restricted, megakaryocyte-primed population of hematopoietic progenitor cells during fetal and early postnatal development Ryan Mack Received Received
  4937-MON Synergistic cooperation between progranulin and Jak2/Stat3 signaling determines definitive myeloid cell fate Raquel Espin Palazon Received Received
  4938-MON DNMT1-mediated epigenetic regulation of heterochromatin in cellular aging Maryn Cavalier Received Received
  4939-MON Clonal hematopoiesis is associated with the risk of Alzheimer´s disease in the UK biobank apoe e3/e3 genotype cohort Burcu Cevik Received Received
  4940-MON Clonal hematopoiesis and lung adenocarcinoma pathogenesis Peter Grant Miller Received Received
  4941-MON Clonal hematopoiesis and risk of mortality after incident ischemic stroke: The reasons for geographic and racial differences in stroke Study Radhika Gangaraju Received Received
  4942-MON Association of infection frequency and incident clonal hematopoiesis Ajibike Dorothy Lapite Received Received
  4943-MON Identification of two distinct human hematopoietic stem cell subsets and their age-dependent dynamics by single-cell multi-omics Xinjian Mao Received Received
  4944-MON UBA1a dependency leads to synthetic lethality in vacuoles, E1-ligase, x-linked, auto-inflammatory, somatic (VEXAS) syndrome Bryan T Ciccarelli Received Received
  4945-MON A comparative analysis of epigenetic age acceleration across distinct hematopoietic clones in hematologic diseases Atsushi Marumo Received Received
  4946-MON Tet2 clonal hematopoiesis enhances thrombotic pathologies, increases platelet reactivity, and alters megakaryote function in the context of aging Virginia Camacho Received Received
  4947-MON Development of methods for enriching microglia nuclei from frozen brain samples to study the effect of CHIP on Alzheimer´s disease Dipabarna Bhattacharya Received Received
  4948-MON Smoking and chronic kidney disease are associated with expansion of TET2 clonal hematopoiesis of indeterminate potential (CHIP) Jasmine Singh Received Received
  4949-MON Lineage-specific distribution of clonal hematopoiesis of indeterminate potential across mature hematopoietic subpopulations in cancer patients Ana Perez Gonzalez Received Received
  4950-MON Erythroid PIM1 deficiency promotes hematopoietic aging via jun/jund activation and igkc-mediated proteostasis collapse Yuanlin Xu Received Received
  4951-MON Clonal hematopoiesis of indeterminate potential in coronary disease patients: A 24-year follow-up Sophie Susen Received Received
  4952-MON The role of Tet2-mutant clonal hematopoiesis in solid tumor immunology Shelley Herbrich Received Received
  4953-MON Tet2-associated inflammatory signaling alters healthy hematopoiesis with clonal expansion Alana M Franceski Received Received
  4954-MON Error-corrected sequencing to quantify clonal hematopoiesis in breast cancer survivors treated with metformin in a randomized, placebo controlled, prospective clinical trial Zhan Rong Received Received
  4955-MON Cellular senescence associated with aging and chemotherapy exposure primes bone marrow for immune dysfunction and myeloma persistence Roman Smirnov Received Received
  4956-MON Omic evaluation of G-CSF-induced changes in bone marrow: A focus on lipid metabolism Tekin Aksu Received Received
  4957-MON iPSC-derived mesenchymal stromal cells (iMSC) provide superior support for hematopoietic reconstitution compared to BM-MSCs Olayinka Okeleji Received Received
  4958-MON Altered osteoblast populations dynamics underlie myeloma progression from precursors diseases in bone microenvironment Mattia Dessena Received Received
  4959-MON Monoclonal antibodies against pathogenic S100A8/9 alarmins can restore hematopoiesis and result in immunomodulation in myelodysplasia and leukemia models Rahul Sanawar Received Received
  4960-MON Human iPSC-derived bone marrow organoids for AML engraftment and immunotherapy testing Isabel Huelya Goek Received Received
  4961-MON Cytoskeletal rearrangements and SRC signalling defects controlled by PP1ß drive impaired megakaryocyte maturation and platelet production Gabriel H. M. Araujo Received Received
  4962-MON Piezo1-mediated mechanosensation in bone marrow macrophages promotes hematopoietic support function of BM-MSCs in a CD105-dependent manner Huihui Fu Received Received
  4963-MON Sipa1 loss in host niche boosts anti-AML immune response Runqing Zhang Received Received
  4964-MON Oxygen dependency as a critical regulatory axis affecting hematopoietic stem and progenitor cell function James Ropa Received Received
  4965-MON Preliminary clinical experience with mesenchymal stromal cells in autoimmune hemolytic anemia: A Case series in two dogs and one cat Anezka Klubalova Received Received
  4966-MON Endothelial SRSF1 regulates hematopoietic stem cell function in the bone marrow microenvironment Kruti Bosmia Received Received
  4967-MON Prognostic significance of PNH clones in aplastic anemia treated with immunosuppression or allogeneic HSCT Alfadil Haroon Received Received
  4968-MON Vexas syndrome in Germany: Insights from a prospective registry on clinical presentation, management and outcomes Julia-Annabell Georgi Received Received
  4969-MON Efficacy and safety of HSK39297 monotherapy in patients with paroxysmal nocturnal hemoglobinuria (PNH) Yuemin Gong Received Received
  4970-MON Real-world clinical characteristics and treatment outcomes in PNH patients prescribed pegcetacoplan across europe, the United States and Canada Jens Panse Received Received
  4971-MON The role of red blood cell lifespan in evaluating the condition of patients with paroxysmal nocturnal hemoglobinuria treated with complement inhibitors Lei Ye Received Received
  4972-MON Immune subset clonality profiling in aplastic anemia: A highly sensitive flow cytometry approach to differentiate acquired and inherited syndromes. Sudhanshi Raina Received Received
  4973-MON Factor bb as a biomarker during breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria Matthew Holt Received Received
  4974-MON Serum ferritin changes in iptacopan-treated patients with paroxysmal nocturnal hemoglobinuria Antonio M. Risitano Received Received
  4975-MON The role and mechanism of exosomal aminopeptidase n (APN/CD13)-mediated CTL cell dysfunction in aplastic anemia Li Yan Received Received
  4976-MON Luspatercept combined with immunosuppressive therapy reduces inflammation in aplastic anemia by inhibiting monocyte pyroptosis Zining Wang Received Received
  4977-MON Autoimmunity against POLR3A and cytopenias in aplastic anemia and other bone marrow failure syndromes Serhan Unlu Received Received
  4978-MON The 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension program Antonio M. Risitano Received Received
  4979-MON Apply-PNH: Analysis of complement pathway biomarkers provides evidence for pharmacodynamic response in PNH patients who receive oral iptacopan monotherapy versus continuing anti-C5 therapy Regis Peffault De Latour Received Received
  4980-MON Imputing causality from single-cell transcriptomics in paroxysmal nocturnal hemoglobinuria Hiroki Mizumaki Received Received
  4981-MON Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to Austin G. Kulasekararaj Received Received
  4982-MON The CSMD1 gene is involved in hematopoietic stem cell HSC pruning in patients with acquired immune-mediated aplastic anemia Antonio M. Risitano Received Received
  4983-MON Real-world outcomes of eltrombopag-containing regimens as frontline treatment for aplastic anemia: A multi-center retrospective study Stephen Sze Yuen Lam Received Received
  4984-MON Real-world data on cardiovascular disease incidence in adults with acquired immune aplastic anemia. Manasa Kotamraju Received Received
  4985-MON Invariant patterns of global mutational signatures allow new fundamental insights in etiopathogenesis of bone marrow failure including aplastic anemia and myelodysplasia Felipe de Almeida Sartori Received Received
  4986-MON Real-world data on breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with proximal and terminal complement inhibitors. Kara Kushwaha Received Received
  4987-MON Correlation between efficacy, clonal dynamics evolution, and development of bone marrow failure in PNH/AA syndrome treated with complement inhibitors: A single-center cohort study Chen Yang Received Received
  4988-MON Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis Jun Ho Jang Received Received
  4989-MON SLF2 and SMC5 are novel causative genes for inherited bone marrow failure syndromes, driving HSC aging and predisposing to MDS Sho Shibata Received Received
  4990-MON A unified nanopore-based approach for direct telomere sequencing and genetic diagnosis in inherited bone marrow failure syndromes Shota Kato Received Received
  4991-MON Telomere attrition is common in patients with germline RUNX1 pathogenic variants Rialnat A Lawal Received Received
  4992-MON Results from the first clinical trial of the selective GlyT1 inhibitor bitopertin for steroid-refractory Diamond-Blackfan Anemia (NCT05828108) David J Young Received Received
  4993-MON Characterization of the germline and somatic mutation profile of diamond-blackfan anemia Luiz Fernando Catto Received Received
  4994-MON Toward risk-adjusted hematologic surveillance for telomere biology disorders Aaron N. Cheng Received Received
  4995-MON Phenotypic landscape and clinical outcomes associated with promotor TERT mutations in patients with telomere biology disorders Madeline Ashleigh Franke Received Received
  4996-MON The international diamond blackfan anemia syndrome cancer consortium: Preliminary results Adrianna Vlachos Received Received
  4997-MON Bone marrow alterations and clonal hematopoiesis in germline ETV6 mutation carriers without hematologic malignancy Sara Torres-Esquius Received Received
  4998-MON Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults Sara Torres-Esquius Received Received
  4999-MON SEPTIN6 mutations in pediatric myelodysplastic syndrome disrupt nuclear actin organization Xin Jiang Sr Received Received
  5000-MON Epigenetic reactivation of a tumor suppressor program in AML. Eric Wang Received Received
  5001-MON Regulation of ribosomal RNA synthesis in Acute Myeloid Leukemia Putzer Joseph Hung Received Received
  5002-MON NUP98-rearranged pediatric AML is sustained by a conserved leukemia stem cell program with SPNS2/3 as a targetable vulnerability Jihye Yoon Received Received
  5003-MON FLT3-ITD drives poor prognosis in NPM1 mutated AML via BCAT1-dependent epigenetic regulation Kainan Zhang Received Received
  5004-MON Human HSPCs CRISPR-engineered to endogenously express oncogenic NRAS generate a transplantable lethal myeloid malignancy targetable with novel RAS therapeutics Shirley Liu Received Received
  5005-MON Single-cell multi-omics uncovers differentiation-dependent transcriptional programs shaping epigenetic subgroups in AML Yotaro Ochi Received Received
  5006-MON DARS mediated M2 polarization of tumor associated macrophages drives MPN progression Liansheng Zhang Received Received
  5007-MON Boosting anti-tumor immunity in NRAS;ASXL1-driven Acute Myeloid Leukemia through combined inhibition of MEK and HDACs. Meher Gayatri Bolisetti Received Received
  5008-MON SMARCC1 loss impairs differentiation and enhances self-renewal in ASXL1-mutant hematopoietic cells Taiki Ishida Received Received
  5009-MON Lactylation-related LGALS1 promotes immunosuppressive tumor microenvironment and venetoclax resistance in Acute Myeloid Leukemia Bobin Su Received Received
  5010-MON PI3Kd inhibition enhances trametinib efficacy by suppressing feedback-activated PI3K/AKT signaling in PTPN11-mutant JMML Zhizhuang Zhao Received Received
  5011-MON Targeting DCAF5 restores p53 tumor suppressor function and exerts anti-leukemic effects in AML Jishi Wang Received Received
  5012-MON Single-cell chromatin profiling reveals early epigenetic reprogramming, subtype-specific regulatory networks, and JAK/STAT–IRF vulnerabilities in high-risk chronic myeloid leukemia Sin Tiong Ong Received Received
  5013-MON TOE1 influences canonical wnt signalling in myeloid leukaemia cells through LEF-1 and regulates the proliferation of haematopoietic cells through PAK2 Hyun Park Received Received
  5014-MON Integrating single-cell whole genome and transcriptome sequencing to track the clonal evolution of TP53-mutated myeloid neoplasms Sarun Sereewattanawoot Received Received
  5015-MON Endothelial cell-derived mitochondrial transfer to Acute Myeloid Leukemia alters global gene expression to confer chemoresistance Niraj Dhakal Received Received
  5016-MON Replication fork remodeling is a therapeutic vulnerability in acute myeloid leukemia Cyril Dördelmann Received Received
  5017-MON Persistent binding of DNMT1 to chromatin causes replication dysfunction in TP53-mutated myeloid neoplasms Jeremy T Baeten Received Received
  5018-MON Transcriptional and splicing dysregulation by U2AF1 mutations contribute to inflammatory and migratory alterations in MDS Yuki Hodo Received Received
  5019-MON Characterisation of the wnt signalling responsive surfaceome of myeloid cells reveals PLP2 as a regulator of haematopoietic cell proliferation and monocytic differentiation Aaron Goff Received Received
  5020-MON Low expression of TMSB10 in bone marrow in MDS patients with T cell large granular lymphocytic proliferation is associated with improved immune tolerance status of T cells and disease prognosis: Clinical data and single-cell sequencing analysis Chenxiao Du Received Received
  5021-MON Identification of SHMT2 and ADAM28 as potential mediators of NFIC pro-growth effects in AML Owen Hughes Received Received
  5022-MON The long non-coding RNA WT1-as controls differentiation programs and leukemic cell fate in AML Pascal Fichtel Received Received
  5023-MON P2rx7 in AML blasts orchestrates myeloid differentiation through T cell-mediated visfatin and lymphotoxin signaling Yunqing Liu Received Received
  5024-MON Context-dependent recruitment of co-factors directs RUNX1 activity in normal and leukemic cells Dimitra Dimou Received Received
  5025-MON CD43 functions as a CD47 independent "don´t eat me" signal and novel immune checkpoint in AML Yun Li Received Received
  5026-MON Chronic myeloid leukemia (CML) evolution is not encoded in single-cell microstates, but emerges from population-level macrostates David E. Frankhouser Received Received
  5027-MON HMGA1 chromatin regulators drive transcriptional networks governing cell cycle progression, immune escape, and menin-inhibitor resistance in KMT2A-r Acute Myeloid Leukemia Bailey E. West Received Received
  5028-MON Hnrnpk haploinsufficiency in del(9q) Acute Myeloid Leukemia reveals targetable vulnerabilities Sean M Post Received Received
  5029-MON Inflammatory transcriptome dominates Indian AML: High iscore predicts poor outcomes even in genomically favorable subtypes and reveals regional immune-molecular divergence Rahul Bhargava Received Received
  5030-MON Myc super-enhancer dynamics in T-ALL Georgios Tousinas Received Received
  5031-MON Cutaneous diffuse large B-cell lymphoma induce a macrophage immunosuppressive phenotype through IL-10 secretion Jean Galtier Received Received
  5032-MON Chromatin remodeler SATB2 thorough Bmi1/PRC1 activity controls transformation and reprogramming of ph+ B-cell progenitors Ramesh Chandra Nayak Received Received
  5033-MON Single-cell analysis and functional profiling reveal galectin-3–driven reprogramming of the tumor immune microenvironment in transformed follicular lymphoma Xiaohui Wang I Received Received
  5034-MON PARP1 facilitates transcriptional activity and stability of the BCL6 protein and is a therapeutic target in BCL6 expressing lymphomas Izidore S. S. Lossos Received Received
  5035-MON Functional analysis of STAT3 activating mutations in LGL leukemia reveals epigenetic reprograming and therapeutic vulnerabilities. Zachary Hutchins Received Received
  5036-MON IL-17–Induced CD70 expression promotes T-cell suppression in DLBCL: Implications for immune escape and T-cell exhaustion Ditipriya Mukherjee Received Received
  5037-MON TP53 mutation promotes diffuse large B-cell lymphoma progression via mediating lactylation of ATP5E at Lys44 Linquan Zhan Received Received
  5038-MON CELF2-deficient mutations promote B-cell lymphoma development by inducing a germinal center B-cell fate Tao Pan Received Received
  5039-MON RNA-binding protein FXR1 stabilizes receptor tyrosine kinase FGFR1 and enhances PI3K-Akt signaling to promote T-cell leukemogenesis Boxiao Chen Received Received
  5040-MON The NLP protein is a novel regulator of G2-m Phase of the cell cycle critical for proliferation of human peripheral T-cell lymphomas Julian Tobon Received Received
  5041-MON Dissecting the whole trajectory of aid-induced genomic instability from mutational activity to chromosomal translocation formation Jianli Tao Received Received
  5042-MON Identification of NAE1-dependent ß-catenin neddylation as selective vulnerability in B-cell malignancies Kadriye Nehir Cosgun Received Received
  5043-MON The impact of NR1I2 gene polymorphism and body weight on asciminib pharmacokinetics in patients with chronic myeloid leukemia Naoto Takahashi Received Received
  5044-MON First-in-human randomized placebo-controlled Phase 1 study of RPT1G, a novel hyperbolic NAMPT inhibitor for use in acute leukemias: Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers Gregory Crimmins Received Received
  5045-MON Bioequivalence of ruxolitinib once-daily extended-release vs twice-daily immediate-release tablets in healthy adults Xiaohua Gong Received Received
  5046-MON Dietary serine restriction increases venetoclax efficacy in Acute Myeloid Leukemia Mallikarjun Reddy Received Received
  5047-MON CBX–663, a novel TCR-mimetic T-cell engager targeting a telomerase reverse transcriptase (TERT) peptide-HLA complex, that exhibits potent efficacy against AML cells Ricard Masia Received Received
  5048-MON Engineering dual-specificity PPM1D inhibitors to enhance therapeutic response and overcome chemoresistance in TP53-mutant malignancies Peter Grant Miller Received Received
  5049-MON FLT3-F691L confers kinase-independent resistance via Grb2-dependent MAPK signaling in AML LaQuita M Jones Received Received
  5050-MON Unidirectional synergy between ferroptosis and apoptosis reveals a novel therapeutic strategy for refractory AML Kazuharu Kamachi Received Received
  5051-MON ORM-1153: A CD123-targeting degrader antibody conjugate with GSPT1-degrading payload exhibits potent preclinical antitumor activity in Acute Myeloid Leukemia Dong-Ki Choi Received Received
  5052-MON CD123-targeted radiotheranostics of Acute Myeloid Leukemia with 89Zr/177Lu-labeled pivekimab Yijing Zhao Received Received
  5053-MON Preclinical efficacy of dual BET/HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells Warren Fiskus Received Received
  5054-MON A novel BCL-2 inhibitor, bda-366, targets the TLR4 pathway to induce leukemic cell differentiation in venetoclax-resistant RAS-mutated monocytic leukemia Lixin Wu Received Received
  5055-MON Inhibition of Drp1, a mitochondrial fission GTPase disrupts mitochondrial quality control and impairs stem-like properties in Acute Myeloid Leukemia Priyanka Sharma Received Received
  5056-MON Synergistic correction of polycythemia vera phenotype via dual targeting of JAK2 and Gas6 in Jak2 exon 12 mutant mice Tanja Knopp Jr Received Received
  5057-MON A genome-wide CRISPR screen identifies conventional and novel ferroptosis regulators in Acute Myeloid Leukemia Liang Zhang Received Received
  5058-MON TGM2 as a novel therapeutic target in venetoclax-resistant AML: Disrupting histone serotonylation-driven mitophagy with nanoparticle-delivered inhibitors Yuanbin Song Received Received
  5059-MON Anti-leukemic efficacy of a novel inhibitor for KMT2A-r/FLT3-driven AML via multi-kinase targeting and synergy with menin inhibition Nikola Niederlova Received Received
  5060-MON Co-targeting menin and RAS in KMT2A-r/NPM1c AML with activated RTK//RAS/MAPK signaling Bing Z Carter Received Received
  5061-MON METTL3 inhibition disrupts R-loop homeostasis and activates the cgas-sting pathway in Acute Myeloid Leukemia Hee Doo Yang Received Received
  5062-MON Pre-clinical efficacy of FLT3/BRAF targeting with novel dual inhibitor PHI3 in FLT3/RAS co-mutated AML Shikhar Sharma Received Received
  5063-MON Synergistic enhancement of APR-246 anti-leukemic activity through ENO1 inhibition in TP53- and FLT3-mutated Acute Myeloid Leukemia Hongwei Peng Received Received
  5064-MON Optimal dosing of vobramitamab duocarmazine, a CD276 (B7-H3) antibody-drug conjugate, leads to durable eradication of Acute Myeloid Leukemia in preclinical xenograft models Danielle Kirkey Received Received
  5065-MON Mechanistic study of the Cullin3-CRL3^KEAP1-NRF2 neddylation axis in chemotherapy resistance of Acute Myeloid Leukemia stem cells Li Wang Received Received
  5066-MON BPI-2358 reprograms immunosuppressive macrophages and impairs leukemic progression in MN1-overexpressing AML In Vivo Lucio Pinheiro Received Received
  5067-MON A randomized placebo-controlled Phase 1 trial in healthy volunteers investigating safety, pharmacokinetics and pharmacodynamics of a novel menin inhibitor, balomenib (ZE63-0302): Interim analysis. Amy Burd Received Received
  5068-MON Distinct mTOR- and CDK1-regulated translation circuits sustain FLT3-mutated AML survival under therapy Daniela Ortiz Chavez Received Received
  5069-MON Single-cell analysis of BAX responses reveals venetoclax sensitivity and enables development of BAX-targeting combinations in AML Jiaxin Dong Received Received
  5070-MON Adaptive rebalancing of ROS composition averts LSD1 inhibitor–induced oxidative stress in AML Dharmendra Kashyap Received Received
  5071-MON BTK regulates EZH2 stability in myeloid leukemia associated with down syndrome Kader Cicek Received Received
  5072-MON DYRK1A interacts with EZH2 to regulate transcriptionally active chromatin in myeloid leukemia associated with down syndrome Kader Cicek Received Received
  5073-MON Novel EIF4A1 inhibitors with anti-tumor activity Forum Kayastha Received Received
  5074-MON Cell-free application of Deltex1 to suppress hyperactive notch signaling in t-cell acute lymphoblastic leukemia Jacob Neethling Received Received
  5075-MON NSUN2/YBX1-mediated m5C modification enhances phgdh expression to drive immune evasion via PD-L1 and CCL2 axis in high-grade b-cell lymphoma Guojun Zhang Received Received
  5076-MON Inhibition of PRMT5 with JNJ-64619178 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptosis Fen Zhu Received Received
  5077-MON Docirbrutinib (AS-1763), a novel non-COVALENT BTK inhibitor, demonstrates efficacy in BTK inhibitor-resistant mutant cells Tokiko Asami Received Received
  5078-MON Overcoming leukemia stem cells via targeting AKT-wnt/ß-catenin by AI-powered mRNA-delivery of peptides Zhe Yang Received Received
  5079-MON JAM(A), a chromosome 1q adhesion protein, is overexpressed in 1q amplified myeloma and may represent a novel therapeutic target for high-risk disease. Niamh McAuley Received Received
  5080-MON RPT1G, a novel hyperbolic NAMPT inhibitor, is highly effective against B-cell non-Hodgkin´s lymphoma with germinal center origin Michael Schelle Received Received
  5081-MON Molecular subtypes and BH3 mimetic synergy with anti-leukemia agents in T-cell acute lymphoblastic leukemia Satoshi Yoshimura Received Received
  5082-MON Chick embryo xenograft model of multiple myeloma recapitulates immune response, systemic dissemination, and sensitivity to anti-myeloma therapeutics Izabela Cymer Received Received
  5083-MON Golcadomide demonstrates potent antiproliferative activity in T-cell lymphoma via degradation of IKZF1 and IKZF3 Zhongying Mo Received Received
  5084-MON Serine/glycine starvation induces metabolic rewiring to uncover ATF4-driven therapeutic vulnerabilities in infant ALL Victoria Desiree Assmann Received Received
  5085-MON Heme oxygenase-1 facilitates immune evasion in diffuse large B-cell lymphoma by reprogramming tumor-associated macrophage polarization Wenbin Lei Received Received
  5086-MON Pre-treatment ZNF683? effector CD8? T cells predict response to BiTE therapy in acute lymphoblastic leukemia: Insights from single-cell and TCR sequencing Linghui Zhou Received Received
  5087-MON Selective targeting of sumoylation disrupts mitochondrial homeostasis via TRAP1 to suppress growth of non-Hodgkin lymphoma (NHL) B-cells Vi Lam Received Received
  5088-MON BRM/BRG1 is a novel therapeutic target in ZNF384-rearranged mixed phenotype acute leukemia Clara Libbrecht Received Received
  5089-MON SLM124: A first-in-class anti-CD84 antibody-drug conjugate demonstrates potent anti-tumor activity and favorable tolerability in hematologic malignancy models Chan Chung Whiting Received Received
  5090-MON BMS-986458, a first-in-class, highly selective, and potent ligand-directed degrader (LDD) of B-cell lymphoma 6 (BCL6) combined with T-cell engagers (TCEs) demonstrates preclinical synergistic antitumor efficacy for the treatment of B-cell non-Hodgkin lymp Gauri Deb Received Received
  5091-MON The dual-target molecular glue degrader INNO-235 effectively mediates the degradation of GSPT1 and CK1a, and exhibits potent anti-tumor activity in TP53 mutant burkitt lymphoma Minghao Sun Received Received
  5092-MON Targeting immunoproteasome-dependent ß-catenin degradation as a therapeutic strategy in Relapsed/Refractory acute lymphoblastic leukemia Jodi Forward Received Received
  5093-MON USP28 inhibition upregulates CD20 via c-myc suppression and synergizes with anti-CD20 immunotherapy in B-cell lymphomas Jieyu Xu Received Received
  5094-MON Polyunsaturated fatty acids control lipid membrane dynamics and ferroptosis sensitivity in B-cell lymphoma Etienne Leveille Received Received
  5095-MON Increased incidence of delayed methotrexate elimination in pediatric patients with Philadelphia-chromosome positive (Ph+) or ABL-class fusion positive (ABL-Class) acute lymphoblastic leukemia treated with imatinib: Results of a retrospective cohort study Nicolò Peccatori Received Received
  5096-MON Emergency presentation worsens survival, complications, and reveals profound disparities in acute lymphoblastic leukemia: A national propensity-matched study Nehemias Guevara Received Received
  5097-MON Real-world treatment patterns, outcomes, and unmet needs in patients with ph+ ALL receiving tyrosine kinase inhibitors in the United States: Emerging trends and the role of asciminib-based combinations Marlise Rachael Luskin Received Received
  5098-MON Predictors of long-term survival in adolescents and young adults with acute lymphoblastic leukemia: 20 years of insight from a nationally representative database Sarah S. Makhani Received Received
  5099-MON CRLF2-rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: A possible link? Flavia Mesquita Gava Received Received
  5100-MON Balancing risk and benefit: Fluoroquinolone prophylaxis in hyper-CVAD for acute lymphoblastic leukemia in a high fluoroquinolone-resistance setting Rafael Valdez Jr Received Received
  5101-MON Transplant outcomes of b acute lymphoblastic leukemia treated with inotuzumab ozogamicin with mini–Hyper-CVD based chemo-immunotherapy Rohan Halder Received Received
  5102-MON First report of the GIMEMA INO-first multicenter observational study analyzing infective and non-infective complications in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Livio Pagano Received Received
  5103-MON Clinical features and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia: A 15-year retrospective study Yiyan Zhu Received Received
  5104-MON Associations between serum asparaginase activity and asparaginase-associated toxicities in pediatric ALL patients receiving calaspargase: A report from the DFCI ALL consortium Sara Mohamed Received Received
  5105-MON Sociodemographic determinants of survival in acute lymphoblastic leukemia: A 20-year SEER-based analysis Jahnavi Chaudhari Received Received
  5106-MON Improved survival with intermediate-intensity pediatric-inspired regimen and allo-HSCT in adults with ALL in a resource-limited setting Pedro dos Santos Perez Received Received
  5107-MON A prospective non-randomized controlled study of vaseline-medicated gauze for topical management of chemotherapy-induced oral mucositis in pediatric hematology patients XiaoYuan Wu Received Received
  5108-MON Novel risk stratification of ph-like ALL cohort receiving CD19-directed CAR-T therapy Cai Zihong Received Received
  5109-MON Early identification of thrombosis risk in adult acute lymphoblastic leukemia Fausto Rios-Olais Received Received
  5110-MON An analysis of the cerebral spinal fluid metabolome during intensive chemotherapy and its association with depressive symptoms in children with acute lymphoblastic leukemia Emily Mason Received Received
  5111-MON From 1968 to 2050: Trends and forecasts of acute lymphoblastic leukemia mortality among older adults in United States Haseeb Tareen Received Received
  5112-MON Predictors of outcome in adult patients with Relapsed/Refractory T-cell acute lymphoblastic leukemia Vanthana Bharathi Received Received
  5113-MON Hemorrhage and thrombosis in adult patients with acute lymphoblastic leukemia: A comparative analysis between conventional vs pediatric-inspired induction regimens Raquel Martinez Received Received
  5114-MON CRLF2 expression and MRD kinetics outcomes across the age spectrum in Mexican patients with acute lymphoblastic leukemia: Prevalence and association with post-induction measurable residual disease Marisa Frausto Received Received
  5115-MON Identifying and overcoming mechanisms of resistance to a VpreB1-directed antibody-drug conjugate in the treatment of B-cell acute lymphoblastic leukemia Robin L Williams Received Received
  5116-MON Efficacy of upfront blinatumomab combined with reduced-intensity chemotherapy for newly diagnosed adult Philadelphia chromosome–negative B-lineage acute lymphoblastic leukemia: Interim analysis of two prospective studies of JSCT ALL/MRD2023 and ALL/MRD201 Takahiro Shima Received Received
  5117-MON Efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase 1/2 dose expansion study with extended follow-up Elias Jabbour Received Received
  5118-MON Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel) Claire Roddie Received Received
  5119-MON Impact of asparaginase discontinuation on outcomes in pediatric B-cell precursor acute lymphoblastic leukemia: Post hoc analysis of the JCCG ALL-B12 Study Hisashi Ishida Received Received
  5120-MON Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia Anjali Sunder Advani Received Received
  5121-MON Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative ACUTE lymphoblastic leukemia. FINAL results of pethema LAL19 trial Anna Torrent Received Received
  5122-MON Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data JIN WANG Received Received
  5123-MON Integrating next-generation sequencing disease evaluation and PCR based CAR-T cell tracking to guide decision making in a real-world cohort of pediatric B-cell ALL patients. Thomas Pfeiffer Received Received
  5124-MON Outcome of adult B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab in addition to chemotherapy independent of MRD: First results from the national GMALL registry Nicola Gökbuget Received Received
  5125-MON A phase I study of venetoclax in combination with multiagent cytotoxic chemotherapy for children and adolescents with relapsed or refractory acute lymphoblastic leukemia or mixed phenotype acute leukemia: Results of the dose determination cohort Melissa A. Burns Received Received
  5126-MON Relapsed acute lymphoblastic leukemia treated with venetoclax and navitoclax: Results of the raven study in children and young adults with relapsed/ refractory ALL Seth E Karol Received Received
  5127-MON Efficacy and safety of a retreatment with inotuzumab ozogamicin in adult patients with relapsed/refractory acute lymphoblastic leukemia: A Campus ALL study Gianluca Cavallaro Received Received
  5128-MON Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) yields durable remissions and survival in adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL): Long-term follow-up of a prospective trial Mitin Nachu Received Received
  5129-MON High-dose methotrexate consolidation prior to autologous HSCT in b-ALL: A decade-long retrospective analysis of survival and toxicity outcomes Ni Lu Received Received
  5130-MON Blinatumomab combined with low-dose chemotherapy and TKI as first-line induction for newly diagnosed ph+ b-ALL: Improved efficacy and reduced toxicity Zhenshu Xu Received Received
  5131-MON Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia Hannah Goulart Received Received
  5132-MON Pediatric-inspired USC ALL regimen vs hyper-CVAD in adults with ph-negative ALL: Real-world outcomes including blinatumomab in a predominantly hispanic cohort. Anush Ginosyan Received Received
  5133-MON Blinatumomab following reduced-intensity induction chemotherapy in Chinese children with intermediate- or high-risk B-cell precursor acute lymphoblastic leukemia Ruidong Zhang Received Received
  5134-MON Tyrosine kinase inhibitors, low intensity chemotherapy and allohct for adults with Philadelphia-positive acute lymphoblastic leukemia. Results of the polish adult leukemia group (PALG) ALL7 protocol Sebastian Giebel Received Received
  5135-MON Short-duration blinatumomab for residual disease eradication as a bridge to transplant in B-ALL: Pediatric and adult outcomes in a resource-limited context Paulo Ugarte-Peláez I Received Received
  5136-MON Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl Caner Saygin Received Received
  5137-MON Ph-like B-cell acute lymphoblastic leukemia in a Mexican pediatric cohort: Molecular features and prognostic implications Joaquin Garcia-Solorio I Received Received
  5138-MON Tumor-induced dendritic cell dysfunction impairs T-cell proliferation and confers poor prognosis in high-risk acute lymphoblastic leukemia Anil Kumar Received Received
  5139-MON ALL-pharmacotyping data portal: An open-source platform for exploring genomics of leukemia drug susceptibility and resistance Satoshi Yoshimura Received Received
  5140-MON Development of an individualized prognostic model based on gut microbiota–related genes in pediatric ALL: A study from the target cohort Di Yao Received Received
  5141-MON Development and validation of a weighted cytokine scoring system for immune status Assessment Following CD19 CAR-T Therapy Hui Wang IV Received Received
  5142-MON Crosstalk between CEP72 germline polymorphism and NOTCH1 somatic mutations alters the sensitivity of leukemia cells and normal T cells to vincristine, influencing the prognosis of pediatric T-ALL Ting Guo Received Received
  5143-MON Integrated machine learning analysis for automatic recognition of b-ALL MRD level in flow cytometry list mode data Yu-Fen Wang Received Received
  5144-MON A proteomic signature derived by ensemble machine learning for predicting relapse in pediatric B cell acute lymphoblastic leukemia Veronica Yeung Received Received
  5145-MON Unravelling the biological and clinical features of childhood B-cell precursor acute lymphoblastic leukemia with monosomy 7 Agata Pastorczak Received Received
  5146-MON Comparison of paired bone marrow and peripheral blood measurable residual disease in pediatric acute lymphoblastic leukemia by next-generation sequencing: A report from the dana farber ALL consortium protocol 16-001. Jennifer J.G. Welch Received Received
  5147-MON Unannotated open reading frames expand the antigen repertoire in T cell acute lymphoblastic leukemia Gbolahan G Bamgbose Received Received
  5148-MON Unveiling FLT3 in B-ALL: Molecular drivers and targeted treatment opportunities Anna Ferrari Received Received
  5149-MON Prognostic significance of IKZF1 deletion subtypes in ph-negative BCP-ALL: Biallelic-null deletion predicts the worst survival in TP53-wild type patients Seung-Hwan Lee Received Received
  5150-MON Longitudinal clonotype tracking by next-generation sequencing (NGS) based T-cell receptor (TCR) rearrangement measurable residual disease (MRD) assay in frontline adult T-acute lymphoblastic leukemia (ALL) Niranjan Khaire Received Received
  5151-MON A myeloid transcriptional signature stratifies outcomes in newly diagnosed ETP-ALL Eitan Kugler Received Received
  5152-MON FLAG-IDA as frontline induction improves outcomes in pediatric patients with core-binding factor or KMT2A-rearranged acute myeloid leukemia: A multicenter cohort study in southern China Yongzhi Zheng Received Received
  5153-MON A dynamic comprehensive geriatric assessment demonstrates improvement in patient fitness after induction and predicts survival and treatment tolerability among older adults with newly diagnosed acute myeloid leukemia Samuel Yates Received Received
  5154-MON Menin inhibitors for NPM1-mutated and KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML): A systematic review and meta-analysis Konan Beke Received Received
  5155-MON A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study Lionel Ades Received Received
  5156-MON Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML Reeja Raj Received Received
  5157-MON A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium Nilesh Kapoor Received Received
  5158-MON SRSF2 mutation induces BH3 mimetics sensitivity via BCL2L2 mis-splicing Takumi Matsushima Received Received
  5159-MON First interim analysis of venetoclax real-world observational study on newly-diagnosed AML patients in Italy (VERO): Focus on patient and diseases characteristics and quality of life at baseline Ivana Lotesoriere Jr Received Received
  5160-MON Clinical, cytogenetic and molecular predictors of early mortality in acute promyelocytic leukemia (APL): Real-world analysis Aram Bidikian Received Received
  5161-MON Older age and complex karyotype are the main predictors of mortality irrespective of allogeneic transplant in therapy-related myeloid neoplasms: A single-center retrospective cohort Maria Chiara Di Chio Received Received
  5162-MON Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction? Zongru Li Received Received
  5163-MON Bzip in-frame mutations might abrogate the adverse prognosis of therapy-related CEBPA-mutated AML Guanghui Chang Received Received
  5164-MON Trends in sepsis-related mortality among patients with Acute Myeloid Leukemia: A 24-year nationwide analysis Cher Ying Foo Received Received
  5165-MON Enhancing somatic variant oncogenicity assessment – a prospective quality assurance study for rapid and scalable molecular profiling of hematological malignancies Wenjie Jack Chen Received Received
  5166-MON Predictors of 90-day mortality in elderly and unfit AML patients treated with single-agent hypomethylating agents or in combination with venetoclax Melissa F. F Neumann Received Received
  5167-MON Characteristics and outcomes of CEBPA bZIP in-frame mutations in de novo and treated secondary acute myeloid leukemia Sankalp Arora Received Received
  5168-MON TP53 and PPM1D mutations in AML: Distinct frequencies, shared pathway, and adverse prognostic trends Hasan Abuamsha Received Received
  5169-MON Early cardiotoxicity and survival in pediatric Acute Myeloid Leukemia: The mediating roles of relapse and salvage chemotherapy intensity Quynh Long Khuong Received Received
  5170-MON Gut colonization with MDR gram negative organisms and its impact on bacteremia and sepsis development among children with hematological malignancies Reham Khedr Received Received
  5171-MON Comparative efficacy of azacitidine plus venetoclax in patients with de novo and secondary Acute Myeloid Leukemia Maksim Granatkin Received Received
  5172-MON Transfusion burden during the initial induction Phase in Acute Myeloid Leukemia is tightly associated with treatment intensity Jonathan Canaani Received Received
  5173-MON Demographic trends in Acute Myeloid Leukemia related mortality in the United States: A 25-year national analysis (1999 - 2023) Muhammad Zahid Anwar Received Received
  5174-MON Characterization of children and adolescents with Acute Myeloid Leukemia potentially treatable with menin inhibitors Dirk Prof. Dr. Reinhardt Received Received
  5175-MON Venetoclax plus azacitidine vs. traditional chemotherapy in younger patients with Acute Myeloid Leukemia: A single-center real-world study Xiao-Ling Guo Received Received
  5176-MON Artificial intelligence-driven virtual tumor board enhances precision care in Acute Myeloid Leukemia (AML) David M Swoboda Received Received
  5177-MON FLAG-mitoxantrone combined with low-dose venetoclax (7 Days): A highly efficient regimen and excellent bridge for allogeneic hematopoietic transplant for newly diagnosed and relapsed/refractory AML. Ahmad Ibrahim Received Received
  5178-MON Performance of the ELN 2022 risk stratification in a real-world Canadian AML patient population Eric J. Jiahua Zhao Received Received
  5179-MON Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease William D. D. Marrero Received Received
  5180-MON Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy Archana Sasi Received Received
  5181-MON Therapy-related AML (t-AML) on the rise: A national perspective on evolving trends, treatment outcomes, and prognostic implications in hospitalized patients Prakhyath Srikaram Received Received
  5182-MON Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study Ying Lu Received Received
  5183-MON Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group Gail J Roboz Received Received
  5184-MON Clinical analysis of central nervous system leukemia in patients with Acute Myeloid Leukemia Hui Li Received Received
  5185-MON Clinical significance of RAS-MAPK pathway mutations in Acute Myeloid Leukemia: Insights from a retrospective cohort Moath Albliwi Received Received
  5186-MON Real-world experience with front-line metronomic low-dose weekly decitabine and venetoclax in elderly and/or frail patients with MDS or AML Adit Singhal Received Received
  5187-MON Risk factors associated with intraparenchymal hemorrhage in patients with acute leukemia John Cook Received Received
  5188-MON Leukapheresis for acute leukemia with hyperleukocytosis: Line complications, resource utilization, and early mortality outcomes Elizabeth Pollard Received Received
  5189-MON Adjudicated clinical outcomes of plasma microbial cell-free DNA surveillance in neutropenic patients with Acute Myeloid Leukemia undergoing outpatient chemotherapy Michael Mansour Received Received
  5190-MON Real-world analysis of treatment patterns and outcomes in older patients with Acute Myeloid Leukemia (AML) in the US community oncology setting Ira Zackon Received Received
  5191-MON Comparative outcomes of posaconazole vs. voriconazole/isavuconazole for antifungal prophylaxis in neutropenic adults with Acute Myeloid Leukemia: A propensity-matched retrospective cohort study Mohammad Medical Salameh Received Received
  5192-MON Phase 3 Study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy (EVOLVE-1) Hartmut Döhner Received Received
  5193-MON First-in-human trial of siltuximab in combination with standard induction chemotherapy in patients with acute myeloid leukemia: The Phase 1 siltuxilam study. Pierre Peterlin Received Received
  5194-MON A phase 1/2, first-in-human, multicenter, open-label trial evaluating the safety, tolerability, and antileukemic activity of Debio 1562M in patients with recurrent refractory acute myeloid leukemia (AML) Naval Daver Received Received
  5195-MON Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy: Results from the cadenza study Naveen Pemmaraju Received Received
  5196-MON Efficacy and safety results of TQB3909,a novel BCL-2 inhibitor, in combination with azacitidine for patients with myeloid malignancies Jianxiang Wang Sr Received Received
  5197-MON Preliminary safety and efficacy of the frida study: Iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia Amir T. Fathi Received Received
  5198-MON A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy Justin Watts Received Received
  5199-MON Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations Hartmut Döhner Received Received
  5200-MON Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations Jenny O´Nions Received Received
  5201-MON Preliminary pharmacokinetic and MRD results from AML patients treated with 7- and 14-day dosing schedule of emavusertib added to combination therapy with azacitidine and venetoclax Cristina Papayannidis Received Received
  5202-MON Venetoclax, cladribine plus low-dose cytarabine for relapsed/refractory Acute Myeloid Leukemia: A multicenter, randomized phase II Study Shengli Xue Received Received
  5203-MON Final results of a first-in-human Phase I study of INA03, a novel CD71/TfR1-targeted antibody-drug conjugate, in patients with relapsed or refractory acute leukemia. Sylvain Garciaz Received Received
  5204-MON Multiarm Phase I study of the cyclin dependent kinase (CDK4/6) inhibitor palbociclib in combination for patients with relapsed and refractory acute leukemias Hannah Goulart Received Received
  5205-MON QHRD107 (CDK9 Inhibitor), venetoclax, and azacitidine combination therapy (107VA regimen) in relapsed/refractory Acute Myeloid Leukemia: Data updates and subgroup analysis Yunxiang Zhang Received Received
  5206-MON Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study Alice Scott Mims Received Received
  5207-MON A multicenter phase 1 trial evaluating the safety and preliminary efficacy of revumenib as post-transplant maintenance after allogeneic hematopoietic cell transplant in patients with KMT2A-rearranged or NPM1-mutated acute leukemia Brian John Ball Received Received
  5208-MON Phase 1, open-label, multi-center trial of RPT1G in patients with Relapsed/Refractory Acute Myeloid Leukemia and high-risk Myelodysplastic Syndromes/neoplasms Dennise A De Jesús-Díaz Received Received
  5209-MON Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of zefamenib in patients with relapsed/refractory acute leukemia Depei Wu Sr Received Received
  5210-MON Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia ( Victoria Yee-May Ling Received Received
  5211-MON Trial in progress: A phase II study of ziftomenib monotherapy in unfit patients with newly diagnosed Acute Myeloid Leukemia with NPM1 mutation or KMT2A rearrangement Jayanshu Jain Received Received
  5212-MON VYSION (VYxeoS liposomal® Italian Observational study iN the real practice): Study design and baseline characteristics Livio Pagano Received Received
  5213-MON Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy Jay Yang Received Received
  5214-MON Ruxolitinib combined with dexamethasone is a promising prophylaxis method for differentiation syndrome in acute promyelocytic leukemia (APL2022) Hongming Zhu Received Received
  5215-MON Effectiveness and safety of CPX-351 in younger patients Thomas W LeBlanc Received Received
  5216-MON Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML) Onyee Chan Received Received
  5217-MON Efficacy and Safety of ATRA+ATO/RIF+venetoclax combination therapy in the treatment of adult acute promyelocytic leukemia Yanping Zeng Received Received
  5218-MON A phase 2 clinical study on intensifying idarubicin dosage for inducing remission in acute myeloid leukemia patients aged 65 and younger Mark Lee Received Received
  5219-MON Homoharringtonine added to CLAG regimen improves outcome of pediatric Relapsed/Refractory AML: A multicenter prospective study min ruan Received Received
  5220-MON Improved outcomes with higher cumulative doses of cytarabine consolidation in older patients with acute myeloid leukemia Todd Mudd Received Received
  5221-MON Favorable outcomes including post-transplant survival are seen independent of baseline skin burden in treatment-naïve patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG): Subgroup analysis of a pivotal T Eunice Sue Wang Received Received
  5222-MON Survival outcomes with the use of gemtuzumab-ozogamycin in patients with acute myeloid leukemia receiving intensive chemotherapy stratified by molecular risk category Nicholas Chornenki Received Received
  5223-MON Rapid bone marrow blast reduction-guided selinexor-based regimen therapy in relapsed/refractory and newly diagnosed acute myeloid leukemia Yi Zhu Received Received
  5224-MON Clinical study reveals the high efficacy and well-tolerance of venetoclax combined with homoharringtonine, azacitidine, and cytarabine in newly diagnosed AML Zheng Ge Received Received
  5225-MON Outcomes of older or unfit AML patients admitted to intensive care unit in the venetoclax era Sylvain Garciaz Received Received
  5226-MON A Phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia Sankalp Arora Received Received
  5227-MON Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms Laura Walsh Received Received
  5228-MON A multiarm phase 1b study of personalized oral maintenance therapy with decitabine/cedazuridine (ASTX727) plus physician´s choice of venetoclax, gilteritinib, enasidenib, or ivosidenib in Acute Myeloid Leukemia Alexandre Bazinet Received Received
  5229-MON A comparative analysis of efficacy results in clinical trial publications and US prescribing information demonstrates a high degree of discordance in reported response endpoints for Acute Myeloid Leukemia Mansi Dalal Received Received
  5230-MON Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data Leo Ruhnke Received Received
  5231-MON Efficacy and safety of CPX-351 in high-risk Acute Myeloid Leukemia Manuel Fernández-Villalobos Sr Received Received
  5232-MON Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia Rubén Gómez de Antonio Jr Received Received
  5233-MON Multicenter prospective Phase II study of decitabine priming combined with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed Acute Myeloid Leukemia Liyan Fan Received Received
  5234-MON The venetoclax conundrum: Therapeutic drug monitoring of venetoclax: Correlation with response in Acute Myeloid Leukemia? Yufei Yang Received Received
  5235-MON Mitoxantrone liposome plus cytarabine and azacitidine for newly diagnosed Acute Myeloid Leukemia: A prospective, multicenter, randomized controlled study Fuling Zhou Jr Received Received
  5236-MON Venetoclax-azacitidine-chidamide plus CAG (CACAG-VEN) versus "3+7" induction chemotherapy in Intermediate-adverse Acute Myeloid Leukemia: Efficacy and safety Lei Lv I Received Received
  5237-MON Real-world effectiveness and safety of gilteritinib plus venetoclax and azacitidine in FLT3 mutated acute myeloid leukemia Nianci Chen Sr Received Received
  5238-MON Cladribine based salvage chemotherapy in AML patients with persistent or recurrent disease after venetoclax/HMA Sameem Abedin Received Received
  5239-MON Subclinical cardiac changes following CPX-351 induction in adults with favorable/intermediate-risk AML Chezi Ganzel III Received Received
  5240-MON Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics Elizabeth Herrity Received Received
  5241-MON Daunorubicin and cytarabine liposomal (CPX-351) plus glasdegib for newly diagnosed secondary Acute Myeloid Leukemia: Results of University of California hematologic malignancies consortium trial 1913 Deepa Jeyakumar Received Received
  5242-MON A prospective study reveals feasibility and merits of drug profiling-guided precision therapy for children with high-risk leukemias Yaqun Xu Received Received
  5243-MON Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance Francesco Mannelli Received Received
  5244-MON Trial in progress: A pilot study of venetoclax to AUGMENT epigenetic modification and chemotherapy in pediatric and young adult patients with relapsed and refractory Acute Myeloid Leukemia Zachary Graff Received Received
  5245-MON Interim results of a multi-center clinical trial evaluating copy number aberrations via shallow whole-genome sequencing (LeukoPrint) in Acute Myeloid Leukemia Shichun Tu Received Received
  5246-MON HOXA9/METTL3/BMI1 axis is required for promoting anthracycline resistance in acute myeloid leukemia cells by modulating BMI1 expression through mRNA m6A modification Hao Wang Received Received
  5247-MON Validation of the FL/IL6 score, a new dynamic cytokine-based risk-model in adults with acute myeloid leukemia, a prospective multicentre filo study. Pierre Peterlin Received Received
  5248-MON Additional genetic targets are present in the majority of AML patients with NPM1, KMT2A or NUP98 aberrations potentially impacting combination therapy with menin inhibitors Rainer Ordemann Received Received
  5249-MON Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: Insights from real-world genomic data Yu-Sung Chang Received Received
  5250-MON Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study Thomas Cluzeau Received Received
  5251-MON Developing transcriptomic signature for IDH1 and IDH2 acute leukemia and the demonstration of high prevalence of these signatures in mutation-negative leukemia Maher Albitar Received Received
  5252-MON Association between clonal mutations in Acute Myeloid Leukemia and novel fibrinolytic biomarkers Sahana Shiggaon Received Received
  5253-MON Mitochondrial suppression in Acute Myeloid Leukemia and Myelodysplastic Syndromes: A two-cohort transcriptomic analysis using GEO Eunseuk Lee Received Received
  5254-MON Prognostic impact of mutations in the DNA methylation pathway on clinical outcomes in acute myeloid leukemia: A retrospective cohort study John Hanna Received Received
  5255-MON Allograft inflammatory factor -1 is essential for acute monocytic leukemia infiltration Aili Chen Received Received
  5256-MON FLT3 (CD135) expression in pediatric AML is associated with specific disease characteristics and worse outcome in the setting of sorafenib theraphy: A report from the Children´s Oncology Group AAML1031 protocol. Andrew J. Menssen Sr Received Received
  5257-MON Sensitive detection of novel structural variants and 3D chromosome conformation reveals likely novel drivers including enhancer hijacking in AML Thomas Koehnke Received Received
  5258-MON High protein expression of MDS1 and EVI1 complex locus (MECOM) is prognostically adverse and independent of chromosome 3 rearrangements in acute myelogenous leukemia Steven Kornblau Received Received
  5259-MON Low levels of enhancer of zeste homolog 2 (EZH2) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia. Eduardo de Camargo Magalhaes Received Received
  5260-MON Single-cell multiomics reveals candidate cis-regulatory elements in NPM1-mutant AML Elliot O Eton Received Received
  5261-MON Early peripheral blood blast clearance is a prognostic marker for early treatment response and long-term outcome in pediatric Acute Myeloid Leukemia Noa Wijnen Received Received
  5262-MON DDX41-related myeloid neoplasms: Insights and treatment landscape in 250 patients managed at a large tertiary centre Francesco Versino Jr Received Received
  5263-MON Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics. Yanming Zhang Received Received
  5264-MON Silibinin enhances daunorubicin chemosensitivity in Acute Myeloid Leukemia by suppressing PDIA3-mediated autophagy Ping Weng Received Received
  5265-MON Treatment intensity and transplant independently predict survival in TP53-mutated myeloid neoplasms: A large retrospective cohort study of clinical and genomic factors Sarah Peterson Received Received
  5266-MON TP53-mutated Acute Myeloid Leukemia through a single-cell lens Sun Loo Received Received
  5267-MON Oral–Gut microbiome coalescence and ecosystem fragility promote drug-resistant colonization and infection in relapsed/refractory leukemia xiaomeng feng Jr Received Received
  5268-MON Next generation sequencing profiling of pediatric Acute Myeloid Leukemia reveals distinct genetic landscapes across cytogenetic subgroups Maddalena Benetton Received Received
  5269-MON Prognostic evaluation of ELN-2022 and ELN-2024 risk stratification in newly diagnosed AML patients and development of a novel genetic risk model Xinrui Zhang Received Received
  5270-MON Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia Eduardo de Camargo Magalhaes Received Received
  5271-MON Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia Eduardo de Camargo Magalhaes Received Received
  5272-MON Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax Razan Mohty Received Received
  5273-MON Quantifying treatment-associated monocytic differentiation in AML using a single-cell based myeloid differentiation index (MDX) Li Li Received Received
  5274-MON Prognostic implications of commutational patterns in NPM1-mutated AML receiving intensive treatment. cetlam group study Marcos Rivada Domínguez Jr Received Received
  5275-MON Heterogeneity of immune escape mechanisms in de novo Acute Myeloid Leukemia Tiankai Yin Received Received
  5276-MON Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML/MDS patients with del(5q) complex karyotype - an NCI myelomatch and SWOG report Min Fang Received Received
  5277-MON Proteomics reveals COX7B as a prognostically relevant oxphos-linked protein in pediatric AML Ryanne June Mulligan Received Received
  5278-MON Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations Curtis Lachowiez Received Received
  5279-MON Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients. Eric Stephen Winer Received Received
  5280-MON Mutated and enucleated TIM3 regulates function of Acute Myeloid Leukemia stem cells through c-MYB junwei huang Received Received
  5281-MON Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate Acute Myeloid Leukemia cells Ekaterina N Parfenova Received Received
  5282-MON Pediatric AML blasts drive immunosuppressive reprogramming and metabolic adaptation in macrophages, impairing T cell activation and anti-leukemic immunity Alicia Perzolli Received Received
  5283-MON NUP98 rearrangements (NUP98r) in Acute Myeloid Leukemia (AML): A genomic landscape study Osama Batayneh Received Received
  5284-MON From theory to therapy: Predicting response to chemotherapy with multiomic longitudinal profiling of peripheral blood in AML Jennifer Rangel Ambriz Received Received
  5285-MON Sequential tracking of FLT3-ITD architecture reveals length-dependant impact on clonal clearance and clinical outcome Asmita Shukla Received Received
  5286-MON Single day long read whole genome sequencing for Acute Myeloid Leukemia Parth Shah Received Received
  5287-MON RNA fusion sequencing identifies clinically relevant and novel fusions with therapeutic implications in adults with Acute Myeloid Leukemia (AML) Christine M. McMahon Received Received
  5288-MON CD15 expression on leukemic cells associates with extramedullary infiltration and adverse outcomes in Acute Myeloid Leukemia Fengli Li Received Received
  5289-MON Soluble immune modulators in the bone marrow microenvironment predict long-term survival in pediatric de novo AML: An olink-based proteomic and transcriptomic study Yongping Zhang Jr Received Received
  5290-MON Clinical implications of epigenetic age acceleration as a novel biomarker in Acute Myeloid Leukemia Vikramjit Dhillon Received Received
  5291-MON Molecular risk stratification and MRD-guided consolidation determine outcomes in pediatric non-down syndrome acute megakaryoblastic leukemia: A multicentre Chinese cohort study Yongzhi Zheng Received Received
  5292-MON Measuring minimal residual AML in remission using a novel multi DNA mutation based next generation sequencing assay Darren King Received Received
  5293-MON Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy Bruno Paiva Received Received
  5294-MON Outcomes of NPM1-mutated AMLs in first hematological relapse and prognostic value of MRD Sofiane Fodil Received Received
  5295-MON High prognostic value of NGS-based measurable residual FLT3-ITD in AML patients positive for FLT3-ITD treated with ponatinib in combination with cytarabine in first complete remission. Laurene Fenwarth Received Received
  5296-MON Clinical feasibility of peripheral blood–based MRD monitoring using the miselect R AML MRD assay in Acute Myeloid Leukemia Chun-Kuang Tsai Received Received
  5297-MON Distinct prognosis and transplant timing in core-binding factor Acute Myeloid Leukemia Jingtao Huang Received Received
  5298-MON Single versus double "7+3" induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD? Leo Ruhnke Received Received
  5299-MON Prognostic impact of specific IGHV rearrangements in younger untreated Mantle Cell Lymphoma patients is independent of p53 alterations and may be modified by ibrutinib-based regimens: Insights from the TRIANGLE trial within the MULTIPLY project Simone Ragaini Received Received
  5300-MON Spatially decoding genotype-associated epigenetic landscapes in human lymphoma FFPE tissues via epi-Patho-DBiT Haikuo Li Received Received
  5301-MON Performance of molecular classifiers relative to the international prognostic index (IPI) for overall and event-free survival in diffuse large B-cell lymphoma (DLBCL) George Cholack Received Received
  5302-MON DNMT3B functions as tumor suppressor in mantle cell lymphoma Xiaoyue Gao Received Received
  5303-MON An immune desert phenotype underlies therapy resistance in LBCL through distinct microenvironment-related miRNA profiles Giulia Regazzo Received Received
  5304-MON Integrated genomic and tumor microenvironment subtyping refines risk stratification in primary central nervous system lymphoma Xianggui Yuan Received Received
  5305-MON Deciphering tph cells as prognostic drivers of angioimmunoblastic T-cell lymphoma Haiyan Yang Received Received
  5306-MON Dissecting the biology of hairy cell leukemia variant: Insights from whole exome and RNA sequencing Stamatia Laidou Received Received
  5307-MON Serum mirnas predict response to CAR-T cell therapy in large B-cell lymphoma Ling-Shuang Sheng Received Received
  5308-MON The role of RhoA in diffuse large B-cell lymphoma Ariana Nicole Jacobs Received Received
  5309-MON Phased variant circulating tumor DNA (ctDNA) tracking provides limited additional power in predicting progressive disease compared with duplex variant tracking in patients with Relapsed/Refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) treated with odr Jon Arnason Received Received
  5310-MON Comprehensive genomic profiling of diffuse large B cell lymphoma using targeted NGS: Insights into MYC, BCL2, and BCL6 rearrangements and beyond Mariana Bastos-Oreiro Received Received
  5311-MON Circulating extracellular Vesicle–Derived mirnas identify a high-risk subgroup in extranodal NK/T-cell lymphoma with caebv-like features Kyung Ju Ryu Received Received
  5312-MON Epitranscriptomic signatures define prognosis and therapeutic vulnerabilities in large B-cell lymphoma Caroline Molinaro Received Received
  5313-MON Gene-regulatory axes of diffuse large B-cell lymphoma subtypes Julius C Enssle Received Received
  5314-MON The prevalence of inborn errors of immunity (IEI)-related gene germline variants and its prognostic impact in Chinese pediatric patients with lymphoma Caiyan Zhang Received Received
  5315-MON Morphology guided spatial transcriptomics to study topography of Hodgkin reed sternberg cells interaction with tumor microenvironment and its impact in defining risk of progression in classical Hodgkin lymphoma. Stefano Luminari Sr Received Received
  5316-MON Biomarker analysis to unravel mechanisms of resistance to glofitamab monotherapy in large B cell lymphoma Alessia Bottos Received Received
  5317-MON Genomic characteristics of diffuse large B-cell lymphoma associated with Wiskott-Aldrich syndrome Asami Kodera I Received Received
  5318-MON TP53 mutations in paired bone marrow and cell-free DNA samples of patients with Waldenstroem macroglobulinemia or IgM monoclonal gammopathy of undetermined significance prospectively enrolled in the FIL_biowm study of fondazione italiana linfomi Marzia Varettoni Received Received
  5319-MON Comprehensive analysis of early ctdna kinetics following first cycle of R-CHOP in LBCL patients Sydney Dubois Received Received
  5320-MON Distinct genomic landscape & response dynamics of HIV-associated lymphomas identified by integrated noninvasive host and virome profiling Shuyu Shi Received Received
  5321-MON Targets of BTK and IRAK4 pathways in cns lymphoma: Identification of CXCL10 as a prognostic biomarker in CSF and its receptor, CXCR3, as a mediator of pro-survival signaling James Louis Rubenstein Received Received
  5322-MON Uncovering molecular trajectories in follicular lymphoma using hidden markov models of ctdna dynamics Santiago Barrio Garcia Received Received
  5323-MON Integration of longitudinal ctdna MRD and PET/CT enhances prognostic stratification in newly diagnosed diffuse large B-cell lymphoma: A prospective multicenter study Wei LIU Received Received
  5324-MON Novel mechanistic insights for IRAK1 and IRAK4 signaling provide a framework for the development of dual IRAK1 and IRAK4 protacs for MYD88 mutated lymphomas. Steven Treon Received Received
  5325-MON Differential prognostic impact of chromatin modifier mutations in peripheral T-cell lymphoma: KMT2A emerges as a critical biomarker Youngwoo Jeon Received Received
  5326-MON Spatial transcriptomics uncovers unique tumor microenvironments in folliculotropic versus classic mycosis fungoides Neda Nikbakht Received Received
  5327-MON Spatially resolved profiling reveals the perifollicular border zone as a key immunologic hub in follicular lymphoma undergoing mosunetuzumab therapy Ari R. Pelcovits Received Received
  5328-MON Bioflipi scores define distinct immune profiles in follicular lymphoma Patrizia Mondello Received Received
  5329-MON Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX Anne-Ségolène Cottereau Received Received
  5330-MON Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling Jurik Mutter Received Received
  5331-MON Deep learning-based tumor microenvironment profiling predicts CAR-t efficacy and guides combinatorial immunotherapy in B-cell lymphoma Jiatong Wang Received Received
  5332-MON Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA) Mikael Roussel Received Received
  5333-MON Radiomic features from PET-CT enable diagnostic and prognostic stratification in peripheral T-cell lymphoma Hajime Sakuma Received Received
  5334-MON Plasma proteomic profiles predict future non-Hodgkin lymphoma in healthy adults Qing Qing Luo Received Received
  5335-MON Lipid metabolic reprogramming mediated by YTHDF3 deficiency underlies immunotherapy resistance in extranodal NK/T-cell lymphoma Qingqing Cai Received Received
  5336-MON The immunomodulatory effects of IRF3/7 transcription factors and IL10 in ALK+ anaplastic large cell lymphoma (ALCL) Georgios Rassidakis Received Received
  5337-MON Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas Alice Wang Received Received
  5338-MON An immunometabolic companion biomarker to enhance FDG-PET interpretation and guide frontline therapy in follicular lymphoma Ricky Nelles Received Received
  5339-MON Stepwise engineering of human germinal center B cells to model dark zone high-grade B cell lymphoma driven by sequential BCL2 and MYC deregulation Sabrina Giampaolo Received Received
  5340-MON IQGAP1 is a novel non-degraded substrate of CELMoDs and involved in trafficking of immune cells to the tumor microenvironment Hsiling Chiu Received Received
  5341-MON Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes Paola Ghione Received Received
  5342-MON Intratumoral B cell diversity in follicular lymphoma revealed by single-cell paired transcriptome and BCR sequencing Miranda Sophia Siminski Received Received
  5343-MON Evaluation and validation of automated multiplexed immunofluorescence for clinical lymphoma diagnoses Joseph Lownik Received Received
  5344-MON Immune population changes after glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with follicular lymphoma and marginal zone lymphoma Emily Sumpena Received Received
  5345-MON Adenosine pathway as a therapeutic target in diffuse large B cell lymphoma Maria Montserrat Aguilar-Hernandez Received Received
  5346-MON Longitudinal analysis of T-cell phenotype and function during bispecific antibody therapy Akiva Diamond Received Received
  5347-MON Preclinical evaluation of macrophage reprogramming in treatment of CTCL Neda Nikbakht Received Received
  5348-MON Evaluation of PET/CT during upfront therapy as a prognosticator in follicular lymphoma patients at the University of Debrecen Ádám Jóna Received Received
  5349-MON Promising efficacy of BI-1206, an antibody targeting Fc?RIIB in combination with rituximab and acalabrutinib in R/R NHL patients NHL Laura Fogliatto Received Received
  5350-MON Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO. Ana Muntañola Muntanola Prat Received Received
  5351-MON Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma Paolo Lopedote Received Received
  5352-MON Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after =2 prior therapies: 5-year follow-up of a pivotal Phase II study Elizabeth Elizabeth Budde Received Received
  5353-MON Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after =2 prior therapies: 3-year follow-up from a pivotal Phase II study Sarit Assouline Received Received
  5354-MON FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting Matthew Maurer Received Received
  5355-MON Long term safety and long term disease control of oral ixazomib and short-course rituximab in untreated iNHL Xiancheng Wu Received Received
  5356-MON Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel Aung M Tun Received Received
  5357-MON Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety Umberto Vitolo Received Received
  5358-MON Phase I/? study evaluating the safety and preliminary efficacy of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed/refractory CD20-positive follicular lymphoma Yan Huang Received Received
  5359-MON Bexobrutideg (NX-5948), a novel Bruton´s tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenstroem macroglobulinemia: Updated results from an ongoing Phase 1a/b study Nirav N. Shah Received Received
  5360-MON Safety and efficacy of zanubrutinib in waldenstrom macroglobulinemia patients treated in common clinical practice: A retrospective-prospective study by fondazione italiana linfomi (FIL) Annamaria Frustaci Received Received
  5361-MON Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial Vincent Camus Received Received
  5362-MON A comprehensive geriatric assessment to evaluate individual frailty status and quality of life in patients with Waldenstroem macroglobulinemia: A prospective italian study Annamaria Frustaci Received Received
  5363-MON Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study Qingqing Cai Received Received
  5364-MON Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial Rita Tavarozzi Jr Received Received
  5365-MON Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma Toby A. Eyre Received Received
  5366-MON Final efficacy results of the real-life ambispective urban study on frontline obinutuzumab-based immunochemotherapy for advanced follicular lymphoma Giuseppe Gritti Received Received
  5367-MON Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of high-risk patients Kai Huebel Received Received
  5368-MON Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma Ningjing Lin Received Received
  5369-MON Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial Dai Chihara Received Received
  5370-MON Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial Kim Linton Received Received
  5371-MON Time-stratified risk of second primary solid malignancies among follicular lymphoma survivors in the United States Merry Zhai Received Received
  5372-MON Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory follicular lymphoma Yuqin Song Received Received
  5373-MON Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment naïve follicular lymphoma Swetha Thiruvengadam Received Received
  5374-MON Efficacy and safety of zanubrutinib in patients with non-IgM lymphoplasmacytic lymphoma Mika Geva Received Received
  5375-MON Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon a-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study Huiqiang Huang Received Received
  5376-MON Analysis of the role of baseline PET/CT in a prospective study of unselected patients: The UK MCL biobank Georgina Ursula Naylor Received Received
  5377-MON EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis Jose Villasboas Bisneto Received Received
  5378-MON A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study Aneeqa Zafar Received Received
  5379-MON Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study) Rui Lv Received Received
  5380-MON ZAP trial: MRD-guided chemotherapy and maintenance de-escalation with zanubrutinib-g-CHOP in high-risk FL (Phase II) Zhao Peiqi Received Received
  5381-MON Odronextamab (Odro) plus lenalidomide (+Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): First results from part 1 (safety lead-in) of the Phase 3 OLYMPIA-5 study Umberto Vitolo Received Received
  5382-MON Efficacy and safety of zanubrutinib plus bendamustine-rituximab in newly diagnosed Mantle Cell Lymphoma with TP53 abnormalities or chemotherapy intolerance Yaohui Huang Jr Received Received
  5383-MON Efficacy and safety of orelabrutinib, obinutuzumab, and lenalidomide in previously untreated marginal zone lymphoma: Preliminary results from a prospective, single-arm, multicenter, Phase II study Wei Wang Received Received
  5384-MON Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study Tony Zibo Zhuang Received Received
  5385-MON Evaluating the clinical outcomes of GLP-1 receptor agonists in untreated indolent non-Hodgkin´s lymphomas undergoing active surveillance Patrick Willard Received Received
  5386-MON Is functional cure possible in follicular lymphoma? analysis and development of a predictive model for long-term progression-free (PFS15) patients Andrea Rivero Jr Received Received
  5387-MON Pooled analysis of early-Phase trials highlights robust activity of CD3-CD20 T-cell engagers in follicular lymphoma Suhib Fahmawi Received Received
  5388-MON Risk of lymphoma with antimetabolite and biologic combinations: A pharmacovigilance analysis using the FDA adverse event reporting system database Ronak S Patel Received Received
  5389-MON Determining the origin of TP53 mutations in patients with mature B-cell neoplasms is essential to distinguish lymphoma-related mutations from those due to clonal hematopoiesis, helping to guide treatment decisions Veronika Ecker Received Received
  5390-MON Very low risk for secondary malignancies with btkis in Waldenstroem macroglobulinemia: A retrospective real-world multicenter study. Francesco Autore Received Received
  5391-MON Validation of baseline total metabolic tumor volume (TMTV) as a predictor of early progression (POD24) in follicular lymphoma: A retrospective study of 100 patients in Brazil. Paloma Resende Received Received
  5392-MON Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenstroem macroglobulinemia and shows distinct IgM profiles across IgM-related disorders. Alberto Guijosa Received Received
  5393-MON EPCORE FL-2 Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy (CIT) in previously untreated follicular lymphoma (FL): Trial in progress Paolo Strati Received Received
  5394-MON Promote-FL: Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed/refractory follicular lymphoma Mengyang Di Received Received
  5395-MON Real-world outcomes of immune checkpoint inhibitor rechallenge in patients with classical Hodgkin lymphoma Giuseppe Maiocco Received Received
  5396-MON Curable but not equal: Survival disparities in classic Hodgkin lymphoma by treatment facility type in the United States Aymen Baig Received Received
  5397-MON Comparable survival with transplant-free approach versus autologous stem cell transplantation in adult relapsed/refractory classic Hodgkin lymphoma achieving complete remission Panpan LIU Received Received
  5398-MON Outcomes of immune checkpoint inhibitor therapy in Hodgkin lymphoma with and without pre-existing autoimmune disease: A real-world propensity-matched cohort analysis Madhu Bhargavi Chandra Received Received
  5399-MON A national cancer database study of survival trends in patients with classical Hodgkin lymphoma: Improved survival in the novel agent era Julia Wang Received Received
  5400-MON Nivolumab and pembrolizumab in treatment of relapsed or refractory classical Hodgkin lymphoma: Systematic review and meta-analysis of clinical trials Artem Oganesyan Received Received
  5401-MON Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma Hishan Tharmaseelan Received Received
  5402-MON Brentuximab vedotin (Bv)+AVD efficacy is influenced by interim PET, age, ECOG performance status and CIRS-g in previously untreated patients with stage IV classical Hodgkin lymphoma: An Italian real-life multicentric study Giovanni Manfredi Assanto Received Received
  5403-MON Targeted immunotherapy in children, adolescents, and young adults (CAYA) with newly diagnosed classical Hodgkin lymphoma: A single center experience Jessica Hochberg Received Received
  5404-MON Early-stage nodular lymphocyte predominant Hodgkin lymphoma: Disease characteristics, treatment pattern, and long-term outcomes from a tertiary care cancer institute in India Bhausaheb Bagal Received Received
  5405-MON Reduced pulmonary function and posterior cerebral artery perfusion among Hodgkin lymphoma survivors. Nicholas Phillips Received Received
  5406-MON Disparities in survival outcomes among adolescent and young adults vs adult populations with Hodgkin lymphoma: A population based SEER study Salman Ayub Jajja Received Received
  5407-MON Evaluation of STAT6 and PD-L1 expression in Hodgkin/reed-sternberg (HRS)-like cells in Hodgkin lymphoma-like Richter transformation arising in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Yong Zhang Received Received
  5408-MON Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma Ryan C Lynch Received Received
  5409-MON Outcomes of patients with dual primary T-cell and B-cell lymphoid malignancies Zachary Andrew Hing Received Received
  5410-MON Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P Zachary Epstein-Peterson Received Received
  5411-MON Determinants of survival in primary cutaneous anaplastic large cell lymphoma (pcALCL): Analysis of a real-world pooled database Philip A Haddad Received Received
  5412-MON Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis Zachary Epstein-Peterson Received Received
  5413-MON Clinical disparities in enteropathy-associated T-cell lymphoma: A national cancer database study of 736 patients treated at academic and community cancer centers Oscar Andre Hinojosa Received Received
  5414-MON Molecular determinants of therapeutic response to nivolumab in Relapsed/Refractory PTCL: An integrated multiomic study of A phase II investigator-initiated trial Takeshi Sugio Received Received
  5415-MON High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study Ting Niu Received Received
  5416-MON Comparative outcomes of 14,650 patients with mycosis fungoides/Sezary syndrome from academic and community cancer programs Erin Kaser Received Received
  5417-MON Final results from the embolden trial: pembrolizumab in combination with decitabine and pralatrexate in heavily pretreated patients with peripheral and cutaneous T-cell lymphoma Nathan Lee Roberts Received Received
  5418-MON Chidamide with the methotrexate, ifosfamide, etoposide, doxorubicin liposomes, and dexamethasone (MIEDD) regimen improves efficacy and safety in newly diagnosed primary CNS T-cell lymphoma Jing Liu Received Received
  5419-MON Outcomes of primary cutaneous anaplastic large cell lymphoma across u.S. cancer care settings: A national cancer database analysis. Victor Ramon Mendiola Received Received
  5420-MON Disaggregating aggressive ATLL: A retrospective Study focused on the lymphomatous variant in Latin America Maria Almeida Dias Received Received
  5421-MON Peripheral T-cell lymphomas: Real-world insights into clinical features and prognosis Amaya Llorente-Chávez Received Received
  5422-MON Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib Eduardo Edelman Saul Received Received
  5423-MON Combination of mitoxantrone hydrochloride liposome with gemcitabine, cisplatin and dexamethasone (MGDP) in patients with relapsed or refractory peripheral T cell lymphoma: A prospective, single-arm, multicenter, Phase I/II study Chong Wei Received Received
  5424-MON Racial disparities in mycosis fungoides - from self-reported race to genetic ancestry analysis Shamir Geller Received Received
  5425-MON Brentuximab vedotin plus DHAP as effective salvage therapy in CD30+ peripheral T-cell lymphoma: A retrospective multicenter study Natali Pflug Received Received
  5426-MON Artificial intelligence (AI)–based membrane specific PD-L1 and immune subtypes as predictive biomarkers for danburstotug in relapsed or refractory extranodal NK/T cell lymphoma (R/R ENKTL): Insights from the Phase II trial (DISTINKT) Won Seog Kim Received Received
  5427-MON Persistent racial disparities in Sezary syndrome outcomes despite use of modern therapies: A single-center analysis Lalith Roopesh Received Received
  5428-MON Role of race in severity and survival of those with cutaneous T-cell lymphoma Almeera Lateef Received Received
  5429-MON Selinexor combined with pegaspargase and dexamethasone, followed by radiotherapy, for newly diagnosed stage I–II natural killer/T-cell lymphoma: A multicenter, single-arm, Phase I/II study Siyu Qian Received Received
  5430-MON Cytokine signatures predict response, progression, and immune-related toxicity in Sezary syndrome patients treated with mogamulizumab Erika Morsia Received Received
  5431-MON T-cell clones of uncertain significance are prevalent in cutaneous T-cell lymphomas Safa Najidh Received Received
  5432-MON Single center updated analysis of patients with Relapsed/Refractory peripheral T-cell lymphoma treated with linperlisib. Ranjit Nair Received Received
  5433-MON A multicenter real-world analysis (RWA) of primary cutaneous anaplastic large cell lymphoma (PCALCL) treated in the era of targeted therapies Deepa Jagadeesh Received Received
  5434-MON A Phase II, single-center, single-arm study evaluating the safety and efficacy of golidocitinib in the management of newly diagnosed PTCL (GOLDEN Study) Eduardo Edelman Saul Received Received
  5435-MON Treatment patterns and outcomes for large B-cell lymphoma patients with central nervous system relapse: A multicenter retrospective study (CoNSensus Study) Hirokazu Sasaki Received Received
  5436-MON A novel prognostic scoring system incorporating XPO1 for primary central nervous system lymphoma. Jingjing Ma Received Received
  5437-MON Long-term outcomes, survival predictors and up-front treatment patterns in 568 elderly diffuse large b-cell lymphoma patients from LATAM: Is R-CHOP still the first choice for treating patients older than 60 years? Rita Novello De Vita I Received Received
  5438-MON Construction of a prognostic model for new diffuse large B-cell lymphoma and research on risk factors for secondary central nervous system infiltration juya cui Received Received
  5439-MON Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts Matthew Maurer Received Received
  5440-MON Clinical and pathological features of patients with large B-cell lymphoma relapsing after CAR T-cell therapy Risa Nishiyama Received Received
  5441-MON Estimating and forecasting the incidence, prevalence, and counts of treatment-eligible patients with diffuse large-B cell lymphoma and Mantle Cell Lymphoma in the US Dan Lin Received Received
  5442-MON A US real-world analysis of demographics, transplant patterns, and survival outcomes in posttransplant lymphoproliferative disorder (PTLD) Heidi Raquel Latiolais Received Received
  5443-MON Impact of MYC alterations in de novo large B-cell lymphoma: An italian single center experience Chiara Pagani Received Received
  5444-MON Academic advantage without survival benefit? a national cancer database analysis of primary effusion lymphoma Laura Reyes-Uribe Received Received
  5445-MON Same outcomes, different odds: Socioeconomic disparities in PMBCL care across u.S. cancer centers Laura Reyes-Uribe Received Received
  5446-MON Development and validation of a novel pathologically-based prognostic model for primary central nervous system lymphoma Yupiao Feng II Received Received
  5447-MON Machine learning-based immunoinflammatory phenotypes predict survival in Latin American patients with diffuse large B-cell lymphoma: A multicenter cohort study of grupo de estudio latinoamericano de linfoproliferativos (GELL) Rafael Pichardo-Rodriguez Sr Received Received
  5448-MON Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP Prokop Vodicka Received Received
  5449-MON Mendelian randomization reveals the causative role of genetically predicted viral infection in pan-lymphoma risk Wanying Chen Received Received
  5450-MON Comparative effectiveness of R-minichop versus R-CHOP in older patients with diffuse large B-cell lymphoma: A propensity score-matched analysis from a real-world grupo de estudio latinoamericano de linfoproliferativos (GELL) cohort Brady Beltran Received Received
  5451-MON Real-world outcomes of primary gastric diffuse large B cell lymphoma in Latin America: A multicenter cohort from the grupo de estudio latinoamericano de linfoproliferativos (GELL) Brady Beltran Received Received
  5452-MON Inpatient outcomes of diffuse large B-cell lymphoma: Racial and socioeconomic disparities in a nationally representative sample Hareem Tahir Received Received
  5453-MON Clinicopathological characteristics of high-grade B-cell lymphomas through Bone marrow evaluation Xiaoyan Li Received Received
  5454-MON Efficacy and safety of the TEAM conditioning for autologous stem cell transplantation in lymphoma patients with high-risk of central nervous system relapse Yang Xu Received Received
  5455-MON Clinical outcomes associated with conditioning regimens in patients with primary central nervous system lymphoma undergoing consolidation autologous stem cell transplantation Yuna Lee Received Received
  5456-MON Early mortality and prognostic factors in diffuse large B-cell lymphoma presenting with hemophagocytic lymphohistiocytosis Jianai Sun Received Received
  5457-MON Comparative analysis of consolidation strategies after induction chemotherapy in primary central nervous system lymphoma Yuna Lee Received Received
  5458-MON Ibrutinib in combination with rituximab, methotrexate (MTX), vincristine, and procarbazine (R-MPV/i) for newly diagnosed primary CNS lymphoma (PCNSL) Christian Grommes Received Received
  5459-MON Randomised Phase II study of acalabrutinib in combination with R-CHOP treatment for diffuse large B-cell lymphoma confirms safety and unimpaired treatment delivery Louise Ruth Stanton Received Received
  5460-MON Orelabrutinib combined with R-CDOP regimen for first-line treatment of diffuse large B-cell lymphoma with high-risk CNS-IPI Xibin Xiao Received Received
  5461-MON Orelabrutinib, sintilimab, and temozolomide (OST) in relapsed/refractory primary central nervous system lymphoma Xianggui Yuan Received Received
  5462-MON Low vitamin d is an unmodifiable adverse prognostic factor in older DLBCL patients: Results from the previd randomized trial by fondazione italiana linfomi (FIL). Annalisa Arcari Received Received
  5463-MON NB02 (Poseltinib) combined rituximab and lenalidomide in R/ R PCNSL (POTENTIAL-P): Initial results of safety lead-in cohort. Deok-Hwan Yang Received Received
  5464-MON Zanubrutinib combined with intrathecal chemotherapy for prevention of CNS relapse in high-risk diffuse large B-cell lymphoma Fengping Zhou Received Received
  5465-MON Orelabrutinib plus anti-PD-1 antibody and fotemustine for newly diagnosed primary central nervous system lymphoma: Phase I/II results Wanyue Zhao Received Received
  5466-MON Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China Ou Bai Received Received
  5467-MON Impact of systemic high-dose MTX and BTK inhibitors on outcomes in vitreoretinal lymphoma: A multicenter retrospective analysis Liang Wang Sr Received Received
  5468-MON Dual epigenetic modulation with obinutuzumab/liposomal mitoxantrone in refractory or Relapsed Diffuse large B-cell lymphoma patients post-salvage therapy: A phase II study Changju Qu Received Received
  5469-MON Comparing CHOP, R-CHOP, R-EPOCH, and DA-EPOCH-R in HIV-associated diffuse large B-cell lymphoma: A meta-analysis and systematic review Kai Wang Received Received
  5470-MON Efficacy and safety of polatuzumab vedotin-based regimens for elderly/frail DLBCL patients: A real-world study Xingchen Liu Received Received
  5471-MON Chemotherapy-free induction with pomalidomide, orelabrutinib, and rituximab (POR) followed by high-dose methotrexate,rituximab and orelabrutinin (ROM) in newly diagnosed primary CNS lymphoma: Interim analysis of a phase II study Yan Zhang Received Received
  5472-MON Real-world evidence of improved survival with pola-based regimen in newly diagnosed DLBCL patients with extranodal involvement Xi Chen I Received Received
  5473-MON Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis Evgenii Shumilov Received Received
  5474-MON Intrathecal versus intravenous methotrexate in diffuse large B-cell lymphoma: A real-world comparative outcomes study Muhammad Mujtaba Bhinder Received Received
  5475-MON Efficacy and safety of rituximab, high-dose methotrexate, and thiotepa (R-MT) as first-line induction therapy for primary central nervous system diffuse large B-cell lymphoma Ou Bai Received Received
  5476-MON Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDPM) in Relapsed/Refractory diffuse large B-cell lymphoma: A multicenter, single-arm study Liping Su Received Received
  5477-MON Polatuzumab vedotin combined with orelabrutinib and rituximab (PRO Regimen) as frontline therapy in elderly and frail patients with diffuse large B-cell lymphoma (DLBCL): Results from A phase II study Wenyu Shi Received Received
  5478-MON A chemotherapy-free regimen of sintilimab, rituximab, and lenalidomide ± polatuzumab vedotin in elderly patients with newly diagnosed diffuse large B-cell lymphoma Hanzhen Zhang Received Received
  5479-MON Zilovertamab vedotin plus R-CHP versus R-CHOP for first-line treatment of diffuse large B-cell lymphoma: The phase 3 waveline-010 study Russell Gollard Received Received
  5480-MON Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study Prof. Dr. Max S Topp Received Received
  5481-MON An open-label, Phase 2 study of dapolsertib (MEN1703, SEL24) as monotherapy and in combination with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma Herve Ghesquieres Received Received
  5482-MON Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry Krish Patel Received Received
  5483-MON Outcomes of autologous transplant (ASCT) in patients with chemosensitive late relapse of large B-cell lymphoma (LBCL) Lorenzo Iovino Received Received
  5484-MON Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy Miaomiao Cao Received Received
  5485-MON Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial Mark Hamilton Received Received
  5486-MON Pre-treatment eosinophil levels correlate with superior clinical outcomes in high tumor burden DLBCL patients receiving CD19 CAR-T cell therapy Penelope Lafeuille Received Received
  5487-MON Predicting survival outcomes in CAR-t treated B-cell lymphoma by combining PET/CT imagingand clinical features Blanca Ferrer Lores Received Received
  5488-MON Subgroup analysis in pediatric patients from the Phase 3 study of tabelecleucel for allogeneic or solid organ transplant recipients with Epstein–Barr virus-driven post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chem Sonali Chaudhury Received Received
  5489-MON Genomic heterogeneity and prognostic implications in CAR-t-treated relapsed/refractory primary CNS lymphoma Kai Hu Sr Received Received
  5490-MON Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Transformed Waldenstroem Macroglobulinemia/Lymphoplasmacytic Lymphoma: a DESCAR-T Registry and International Collaborative Study Eric Durot Received Received
  5491-MON Multiple time-point FDG-PET imaging for risk stratification of patients with relapsed/refractory large B-cell lymphoma undergoing CD19-directed CAR-T cell therapy Evgenii Shumilov Received Received
  5492-MON Low serum IgG at apheresis predicts delayed humoral immune reconstitution and increased risk of infections after CD19 CAR T-cell therapy for B-cell lymphoma Daisuke Kaji Received Received
  5493-MON Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma Leon D. Kaulen Received Received
  5494-MON Bridging to CD19 CAR T-cell therapy for LBCL: An analysis of 1,154 patients by the EBMT lymphoma working party and the gocart coalition Philipp Berning Received Received
  5495-MON IL-6 and ferritin levels predict the severity of cytopenia post CAR T-cell treatment with axi-cel for B cell lymphoma Reem Ahmad Awad Received Received
  5496-MON Poor neutrophil recovery following CD19-targeted CAR-T cell therapy predicts inferior outcomes in adult patients with B-cell lymphoma Hiroaki Shimizu Received Received
  5497-MON Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma Gloria Iacoboni Received Received
  5498-MON The cns-IPI score is predictive of severe immune effector cell-associated neurotoxicity after axicabtagene ciloleucel treatment in patients with large B-cell lymphoma Sergi Camarillas Received Received
  5499-MON Pattern of infections and impact on immunocompetence of next generation B-cell depleting immunotherapies in non-Hodgkin´s lymphomas: Results from a multicentre retrospective real- life cohort. Alessia Castellino Received Received
  5500-MON Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphoma Muhammad Bilal Bilal Abid Received Received
  5501-MON Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies Luca Paruzzo Received Received
  5502-MON Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study Anna Guidetti Received Received
  5503-MON Prognostic impact of CAR-T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel Diego Carbonell Received Received
  5504-MON Comparative CRS risk across CAR-T constructs in DLBCL in real-world cohorts Safa S Afridi Received Received
  5505-MON Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy Rintu Sharma VI Received Received
  5506-MON Lymphocyte kinetics as a predictor of clinical outcomes following CAR-T therapy for non-Hodgkin lymphoma Helen Gandler Received Received
  5507-MON Trial-in-progress: A phase 2 randomized trial of remodeling intestinal microbiota using fecal microbiome transplant (FMT) among recipients of chimeric antigen receptor T cells (CAR T) Karamjeet Sandhu Received Received
  5508-MON Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma David Aaron Russler-Germain Received Received
  5509-MON Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell ly Elizabeth Elizabeth Budde Received Received
  5510-MON Glofitamab in combination with polatuzumab vedotin demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) settings: A subgroup analysis Giuseppe Gritti Received Received
  5511-MON Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response Chan Cheah Received Received
  5512-MON Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience Fnu Amisha Received Received
  5513-MON Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma Yasmin Karimi Received Received
  5514-MON Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progresse Tae Min Kim Received Received
  5515-MON CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab Johannes Duell Received Received
  5516-MON Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-007 Marco Ladetto Received Received
  5517-MON A multicenter, single-arm study of camrelizumab combined with rituximab followed by R-CHOP as first-line treatment for young patients with primary extranodal diffuse large B-cell lymphoma: The credit trial Huiqiang Huang Received Received
  5518-MON Prognostic role of FDG-PET in outcomes of relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies Sophie Wollnitza Received Received
  5519-MON Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO Jeremy Abramson Received Received
  5520-MON Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma Karan L. Chohan Received Received
  5521-MON Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma Pierre Stephan Received Received
  5522-MON Risk factors for failure to complete step-up-dosing of bispecific antibody therapy for B-cell lymphomas Michael R Cook Received Received
  5523-MON Odronextamab treatment for patients with rare subtypes of relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL): Updated efficacy and safety analyses from a dedicated cohort of the ELM-2 study Farrukh Awan Received Received
  5524-MON A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress) Krish Patel Received Received
  5525-MON Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma Rahul Shah Received Received
  5526-MON Identification of biomarkers to predict disease progression via molecular analysis of patients (pts) with low-risk myelofibrosis (MF) enrolled in the MOST study Naveen Pemmaraju Received Received
  5527-MON Changes in neutrophil-to-lymphocyte ratio (NLR) in patients with polycythemia vera treated with ruxolitinib reflect changes of JAK2 variant allele frequency (VAF) Chiara Paoli Received Received
  5528-MON Activating STIM1 mutations drive the development of myelofibrosis Molly Brakhane Received Received
  5529-MON The selective PI3Kd inhibitor roginolisib synergizes with ruxolitinib against progenitor cells from naïve and JAK inhibitor-refractory/resistant patients with myelofibrosis Manjola Balliu Received Received
  5530-MON Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study Jian Huang Received Received
  5531-MON Relationship between KIT inhibition by bezuclastinib and effects on disease burden in mouse models of systemic mastocytosis Michelle Crow Received Received
  5532-MON Peripheral blood-based single-cell and genomic profiling of hematopoietic stem and progenitor cells enables accurate diagnosis and risk stratification in myeloproliferative neoplasms Gal Dadi Sr Received Received
  5533-MON Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms Garima Pandey Received Received
  5534-MON PITPß loss disrupts malignant pAKT activation to ameliorate Jak2 V617F-induced myeloproliferative neoplasms (MPN) in mice Nikita Vantsev Received Received
  5535-MON Transcriptomic analysis of CD34? cells in myelofibrosis highlights their role in extracellular matrix dysregulation and marrow fibrosis Simona Bernardi Received Received
  5536-MON Discovery of bispecific T-cell engagers targeting the non-mutated regions of mutant calreticulin for the treatment of myeloproliferative neoplasms Yuya Nishimura Received Received
  5537-MON Selinexor alone and in combination with JAK inhibitors suppresses pro-inflammatory cytokine secretion from primary myelofibrosis cells ex vivo Pietro Taverna Received Received
  5538-MON Interleukin-12 and TNFa signaling drives parallel evolution of independent leukemic clones in JAK2V617F mutant myeloproliferative neoplasms Tyler Parsons Received Received
  5539-MON Characterisation of the megakaryocyte proteome in patients with Philadelphia negative myeloproliferative neoplasms Indu Raman Received Received
  5540-MON Dynamic mutational evolution and transcriptomic remodeling on 3rd-generation TKI therapy in TKI-resistant patients with chronic myeloid leukemia Xiaoshuai Zhang Received Received
  5541-MON Functional characterization of a novel germline JAK2 R989fs mutation Veronika Zimolova Received Received
  5542-MON Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen Ivo Veletic Received Received
  5543-MON Beyond mutations: RNA editing deaminase activation as a dynamic marker to track stem cell fitness and MPN progression Inge Van Der Werf Received Received
  5544-MON The anti-MPL antibody AMM2 prevents cardiovascular dysfunction in a mouse model of myeloproliferative neoplasms Xiaoxi Yang Received Received
  5545-MON Five-year interim analysis of multi-institutional collaborative study for estimating the persistence of treatment free remission in chronic myeloid leukemia after stopping tyrosine kinase inhibitor in Japan: J-SKI Naoto Takahashi Received Received
  5546-MON Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukemia in the chronic phase: Result of JALSG CML RE-STOP219 study. Noriyoshi Iriyama Sr Received Received
  5547-MON XS003, an amorphous re-formulation of nilotinib, demonstrates improved dose linearity and minimal food effect, reducing the risk of QT-prolongation at fed conditions Per Andersson Received Received
  5548-MON Beyond survival in chronic myeloid leukemia: A systematic review of secondary malignancies in the era of tyrosine kinase inhibitors Ghasoub Rola Received Received
  5549-MON Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC Timothy P Hughes Received Received
  5550-MON Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis Fadi G. Haddad Received Received
  5551-MON ASXL1 and NOTCH1 mutations independently predict TKI treatment failure in chronic myeloid leukemia Jian Huang Received Received
  5552-MON High rates of deep molecular response (DMR) in patients (pts) with chronic myeloid leukemia in chronic Phase (CML-CP) who have not achieved dmr after =1 year of prior imatinib (IMA) in the asciminib (ASC) monotherapy arm of the Phase 2 ASC4MORE study Jorge Cortes Received Received
  5553-MON BCR::ABL1/GUSB halving times predict molecular response to asciminib at 18 months Nicholas Cross Received Received
  5554-MON Resistance to imatinib of leukemia growth in non-marrow organs and eradication by dasatinib: Published cases and gene clues Isabel Cunningham Received Received
  5555-MON Genetic evolution in CML patients from diagnosis to TKI failure: An analysis of 121 paired diagnosis and treatment failure samples Ying-Jung Huang Received Received
  5556-MON Long-term outcomes of CML patients undergoing hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors Suravi Raychaudhuri Received Received
  5557-MON SETD2 deficiency in chronic myeloid leukemia (CML) contributes to tyrosine kinase inhibitor (TKI) resistance and disease acceleration by enhancing genetic instability and rewiring cellular metabolism and might be a novel biomarker of high risk disease sin Manuela Mancini Received Received
  5558-MON Intronic DNA variants in EZH2 and GATA2 predict treatment-free remission in chronic myeloid leukemia patients from the destiny trial Shaun David Patterson Received Received
  5559-MON Next generation sequencing from dried blood spots: "Spot on CML" results from low- and middle-income countries Vivian Oehler Received Received
  5560-MON An open label randomized Study of low dose dasatinib (50 mg OD) vs standard dose dasatinib (100 mg OD) vs standard dose imatinib (400 mg OD) as upfront therapy in patients with newly diagnosed chronic myeloid leukemia (CML) - chronic Phase (CP) Neelabh Nayan Sr Received Received
  5561-MON Clinical and molecular features associated with glucolipid metabolic disorders and cardio-/cerebro-vascular adverse events in CML patients receiving olverembatinib therapy Xiaoshuai Zhang Received Received
  5562-MON Early Results of comparison of low-dose generic dasatinib (50 MG/Day) versus imatinib (400 MG/Day) in newly diagnosed chronic Phase chronic myeloid leukemia: Real-world evidence from a single-center, randomized controlled study from India Shivangi Sharma Received Received
  5563-MON ELN milestone-driven TKI switching improves deep molecular response rates in chronic myeloid leukemia Lisi Huang Received Received
  5564-MON Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor Fadi G. Haddad Received Received
  5565-MON Asciminib for newly diagnosed chronic myeloid leukemia: Results from A phase II trial Fadi G. Haddad Received Received
  5566-MON Asciminib and pregnancy in CML: Preliminary human data and clinical implications from 47 reported outcomes Elisabetta Abruzzese Received Received
  5567-MON Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. a randomized national fi-LMC comparative trial of two therapeutic strategies. Emilie Cayssials Received Received
  5568-MON Risk of bleeding in 15,495 patients with myeloproliferative neoplasms by treatment type and thrombotic history Stefanie Antonilli Received Received
  5569-MON MPN (Myeloproliferative Neoplasm) journal: A platform developed by MPN patients for MPN patients to track their disease, aid communication with healthcare team and create a dataset for patient data analytics Ruben A. Mesa Received Received
  5570-MON Thrombocytosis drives alteration of primary hemostasis and acquired von willebrand syndrome occurrence in myeloproliferative neoplasms Mael Heiblig Received Received
  5571-MON Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms Orly Leiva Jr Received Received
  5572-MON Ropeginterferon alfa-2b in 248 patients with polycythemia vera: Results from the italian cohort of a prospective, non-interventional, post-authorization study (ROPEG-PV) Tiziano Barbui Received Received
  5573-MON An analysis of clonal dynamics in patients with indolent systemic mastocytosis treated with avapritinib in the pioneer study Jens Panse Received Received
  5574-MON INCB057643, a bromodomain and extra-terminal protein inhibitor, in combination with ruxolitinib in patients with myelofibrosis: A phase 1 study of safety and efficacy Justin Watts Received Received
  5575-MON Achieving JAK2V617F vaf Franco Castillo Tokumori Received Received
  5576-MON Incidence, prevalence, and clinical outcomes of myelofibrosis with and without cytopenia in the United States Aaron T. Gerds Received Received
  5577-MON Treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib following a switch from ruxolitinib: The my-PAC study Douglas Tremblay Received Received
  5578-MON Diagnostic evolution in systemic mastocytosis: Clinical impact of who 2022 criteria on smoldering systemic mastocytosis identification in pioneer Tracy George Received Received
  5579-MON Survival outcomes in ruxolitinib-treated patients with myelofibrosis following crossover to momelotinib: Application of the response to ruxolitinib at 6 months (RR6) prognostic model to SIMPLIFY-1 Raajit Rampal Received Received
  5580-MON Association between momelotinib exposure and hemoglobin improvement in patients with myelofibrosis and anemia: An exposure-response and time-to-event analysis Vikas Gupta Sr Received Received
  5581-MON Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials Francesca Palandri Received Received
  5582-MON Changes in long-term bone health in patients receiving avapritinib for the treatment of indolent systemic mastocytosis in the pioneer study Mariana Castells Received Received
  5583-MON Pulmonary hypertension on right heart catheterization is associated with worse progression-free survival in patients with myeloproliferative neoplasms Orly Leiva Jr Received Received
  5584-MON Long-term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure Yi Zhang Received Received
  5585-MON Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor (JAKi) treated with imetelstat (IME) in John O. Mascarenhas Received Received
  5586-MON Combined KIT D816V and HaT blood testing: Development and validation of a targeted non-invasive work-up to guide invasive testing for systemic mastocytosis Daniel Koch Received Received
  5587-MON Should dermatologic examinations become routine standard of care in patients with polycythemia vera? Observations from the phase 3 VERIFY study prior to rusfertide exposure Joseph Shatzel Received Received
  5588-MON Comprehensive analyses of patient-reported outcomes from the phase 3 VERIFY study of rusfertide or placebo plus current standard of care for polycythemia vera Aniket Bankar Sr Received Received
  5589-MON A phase II Study of fedratinib and nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment – fraction Study / IKF051 / gsg-MPN-006 Florian H. Heidel Received Received
  5590-MON Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A John O. Mascarenhas Received Received
  5591-MON Competing risk model of relapse versus non-relapse mortality in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation Idoroenyi Amanam Received Received
  5592-MON Exploratory risk score incorporating donor type, MF-HCT high-risk mutations, and day 100 chimerism for outcome stratification in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation Idoroenyi Amanam Received Received
  5593-MON Cytokine profiling identifies an IL-8/IL1RAP-Pathway–Linked inflammatory phenotype in myeloproliferative neoplasms (MPN) associated with high symptom burden and poor outcomes Idoroenyi Amanam Received Received
  5594-MON Real-world temporal evaluation of static risk prediction in polycythemia vera Katie Erdos Received Received
  5595-MON Improved overall survival in patients with advanced systemic mastocytosis treated with avapritinib versus real-world therapy based on mutation-adjusted risk score (MARS) stratification Johannes Luebke Received Received
  5596-MON Aspirin therapy in myelofibrosis: Real-world clinical practice and outcomes in 215 consecutive patients Janick Caron-L´Ecuyer Received Received
  5597-MON Digital PCR-based dynamic monitoring of JAK2V617F burden: A decade-long study unravels its prognostic value in MPN treatment response Hao Cai Received Received
  5598-MON Clinical significance of earlier CHR achievement and long-term CHR maintenance in polycythemia vera patients treated with ropeginterferon alfa-2b Sung-Eun Lee Received Received
  5599-MON Multi-endpoint AI morphology model (MEAM) enhances risk prediction for vascular events and disease progression in MPNs Sharon Ruane Received Received
  5600-MON An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis Andrew T Kuykendall Received Received
  5601-MON Clinical features and outcomes of myelofibrosis patients with MPL mutations Yu-Han Chen Received Received
  5602-MON Dose intensive regimen of CK0804 tregs in myelofibrosis Lucia Masarova Received Received
  5603-MON Triple-negative myeloproliferative neoplasms (TN-MPN): A meta-analysis of clinical and molecular characteristics Sushmitha Nanja Reddy Received Received
  5604-MON Impact of essential thrombocythemia on in-hospital outcomes and thrombotic complications in patients hospitalized with COVID-19: A national inpatient sample analysis (2016–2022) Adnan Humam Hajjar Received Received
  5605-MON A large language model-based framework for automated phenotypic characterization in myeloproliferative neoplasms Muhammad Ali Khan Received Received
  5606-MON A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients. Chi-Joan How Received Received
  5607-MON Phase 1b/2 study of axatilimab in combination with azacitidine in advanced Phase MPN, MDS/ MPN overlap and high-risk CMML Uma Borate Received Received
  5608-MON Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms Anand Ashwin Patel Received Received
  5609-MON Investigating suspected germline STAG2 variants in myeloid neoplasms Eno-obong Blessing Udoh Received Received
  5610-MON Analysis of CD8 cytotoxic t-cells in patients with myelodysplastic syndrome (MDS) and T-cell large granulocyte lymphocytic leukemia (T-LGLL) reveal a distinct phenotype compared to those with t-lgll Makenna May Received Received
  5611-MON Bone marrow microenvironment overlap between vexas and myelodysplastic syndrome demonstrated by targeted transcriptomic and artificial intelligence Maher Albitar Received Received
  5612-MON Genetic landscape of pediatric myelodysplastic syndrome in Japan Masataka Hasegawa Received Received
  5613-MON Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the commands trial Guillermo Garcia-Manero Received Received
  5614-MON Germline alterations of hematopoietic growth factor receptors and maladaptive somatic genetic rescue leads to myeloid neoplasia Serhan Unlu Received Received
  5615-MON Searching for a myelodysplastic syndrome stem cells (MDS-SCs) signature by flow cytometry: Toward a new prognostic tool? Paola Pacelli Received Received
  5616-MON Multi-omics analysis of Del20q reveals PHF20 haploinsufficiency and an HDAC2-centered epigenetic circuit in myeloid neoplasms Mark Orland Received Received
  5617-MON Single-cell transcriptomic analysis reveals ifng/IL-6-mediated inflammatory networks in der(1;7)(q10;p10) Myelodysplastic Syndromes Hongyan Tong Received Received
  5618-MON SF3B1 mutations K700E, K666N, and R625H: Gene expression and aberrant splicing consequences Cyrielle Holuka Received Received
  5619-MON Bone marrow CD57+ LGL cells comprised of NK and CD8 T cells drive bone marrow failure in Myelodysplastic Syndromes Jonathan Ari Feld I Received Received
  5620-MON Impact of different Sf3b1 mutations on hematopoietic function and erythropoiesis Brittnie-lee Duffus Received Received
  5621-MON Insights into clonal and CBC changes at disease evolution among ccus patients Yazan Jabban Received Received
  5622-MON The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) demonstrates robust and sustained hematologic response in subjects with IPSS-R very low, low or intermediate risk myelodysplastic syndrome (MDS) and symptomatic anemia David Bearss Received Received
  5623-MON Not all that glitters is gold: A simple clinical score to unmask adverse SF3B1WT MDS-RS with low blast count Marco Gabriele Gabriele Raddi Received Received
  5624-MON Selinexor in combination with azacitidine or Ruxolitinib for Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Multi-Center Prospective Exploratory Study Xijuan Lin Received Received
  5625-MON Azacitidine and luspatercept metronomic therapy for intermediate- to high-risk myelodysplastic syndrome: A prospective single-center phase II clinical trial Chenlu Yang Received Received
  5626-MON Exposure to agent orange and risk of myelodysplastic syndromes Mikkael Sekeres Received Received
  5627-MON Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: Results of the bexmab Phase 1/2 study Mika Kontro Received Received
  5628-MON RIT1 mutations in myeloid neoplasms Lukas Ronner Received Received
  5629-MON A multi-center study of a machine learning algorithm for identifying undiagnosed patients with myelodysplastic syndrome based on complete blood count data Marek Dudzinski Received Received
  5630-MON Azacitidine (AZA) and venetoclax (VEN) combination for the treatment of immune mediate inflammatory diseases (IMID) associated with myeloid neoplasms (MN) Lin-Pierre Zhao Received Received
  5631-MON Luspatercept for the treatment of transfusion-dependent anemia in patients with myelodysplastic neoplasms with del5q, refractory/resistant/intolerant to prior treatments (QOL-ONE Phoenix) Esther Natalie Oliva Received Received
  5632-MON Non-invasive MDS diagnostic algorithm can also identify pre-MDS and distinguishes normal controls from MDS/pre-MDS patients without bone marrow examination Howard S. Oster Received Received
  5633-MON A prognostic model integrating disease- and patient-oriented factors identifies poor-outcome patients with low-risk MDS: A multicenter real-world cohort study (KOTOSG) Takahisa Nakamura Received Received
  5634-MON MC210807: Phase 1 clinical trial assessing the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in Relapsed/Refractory myeloproliferative chronic myelomonocytic leukemia (CMML). Mrinal M. Patnaik Received Received
  5635-MON Longitudinal genomic and cytogenetic dynamics in myelodysplastic syndromes (MDS): Insights into clonal evolution and disease progression Varsha Singh Received Received
  5636-MON Risk-adjusted comparison of survival in chronic myelomonocytic leukemia with and without allogeneic stem cell transplant: Mayo Clinic experience in 775 consecutive patients Ali Alsugair Received Received
  5637-MON Safety and efficacy of selinexor sequential azacytidine in newly diagnosed patients with myelodysplastic syndromes EB1 or EB2: A single-center, single-arm, phase ib/II trial Liya Ma Received Received
  5638-MON Real-world treatment patterns and outcomes of first-line luspatercept in patients with myelodysplastic syndromes in the United States Mikkael Sekeres Received Received
  5639-MON Identification of novel predictors of cardiovascular disease risk in MDS patients: Results of a prospective observational single-centre cohort study Ioannis Kotsianidis Received Received
  5640-MON A prospective Study of whole genome sequencing for genomic profiling and risk determination in MDS Meagan A. Jacoby Received Received
  5641-MON Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes Alex Bataller Received Received
  5642-MON Artificial intelligence-based diagnosis of myelodysplastic syndromes/neoplasms using bone marrow Palak Dave Received Received
  5643-MON Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression Steven Tessier Received Received
  5644-MON Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling Ziyi N/A Li Received Received
  5645-MON Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure Roberta S. Azevedo Received Received
  5646-MON Efficacy and safety of G-CSF in combination with venetoclax and azacitidine (VAG) in treatment of patients with higher-risk Myelodysplastic Syndromes (MDS) Qingyu Xu Received Received
  5647-MON A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes Ian Bouligny Received Received
  5648-MON Luspatercept response predictors in lower-risk myelodysplastic syndrome Vanthana Bharathi Received Received
  5649-MON Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS) Uwe Platzbecker Received Received
  5650-MON Prevalence, clinical correlates and clonal inferences of concurrent splicing factor mutations in patients with myeloid neoplasms Nickolas Steinauer Received Received
  5651-MON Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset Maximilian Stahl Received Received
  5652-MON Trial in progress: Multi-center clinical trial to replace BM analysis of cytopenia with a peripheral blood assay Gil Gonen-Yaacovi Received Received
  5653-MON Role of the immune microenvironment in the clonal evolution of chronic lymphocytic leukemia Victoria M. Rogness Received Received
  5654-MON Clonal architecture and growth dynamics of ibrutinib-resistant CLL: Oligoclonal BTK/PLCG2 mutations and emerging non-BTK/PLCG2 drivers Chingiz Underbayev Received Received
  5655-MON MGA loss promotes mitochondrial structure changes and redox adaptation in richter´s transformation Prajish Iyer Received Received
  5656-MON Longitudinal immune dynamics associated with chronic lymphocytic leukemia development in mice with 13q14 deletion and modulation by early BTK inhibition Patricia Fernández-Guzmán Received Received
  5657-MON Venetoclax-based therapy remodels T-cell and NK-cell immunity in patients with chronic lymphocytic leukemia Marta Coscia Received Received
  5658-MON Peptide-based antagonists for targeting CXCR4 in ibrutinib resistant chronic lymphocytic leukemia Hannah Lea Wirth Received Received
  5659-MON Harnessing repressive LEF1/ß-catenin complexes to overcome drug resistance in chronic lymphocytic leukemia Kadriye Nehir Cosgun Received Received
  5660-MON Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators Daniel Bihnam Received Received
  5661-MON Multiomic correlates of ex vivo aCD19 chimeric antigen receptor T-cell (CART) cytotoxicity in venetoclax-treated patients with chronic lymphocytic leukemia (CLL) Jacob Wright Received Received
  5662-MON Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study Chieh-Lin Jerry Teng Received Received
  5663-MON Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up Mazyar Shadman Received Received
  5664-MON Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study. Thomas Chatzikonstantinou Received Received
  5665-MON Real-world treatment patterns and outcomes in patients with CLL and cardiovascular comorbidities: Interim analysis of the multicenter study conducted by eric. Thomas Chatzikonstantinou Received Received
  5666-MON Primary analysis of a multicenter, open-label, phase 2 study of sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) Shuhua Yi Received Received
  5667-MON Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL) Paul J. Hampel Received Received
  5668-MON MRD-guided venetoclax-obinutuzumab in CLL: Final analysis of the CLL2-bag trial of the gcllsg Paula Cramer Received Received
  5669-MON Zanubrutinib + venetoclax for treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p) and/or TP53 mutation and unmutated immunoglobulin heavy-chain variable status: 3-year results from SEQUOIA ar Mazyar Shadman Received Received
  5670-MON Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies Toby A. Eyre Received Received
  5671-MON Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12. Luca Laurenti Sr Received Received
  5672-MON First-line ibrutinib + venetoclax shows benefit across genomic subgroups in patients with chronic lymphocytic leukemia (CLL): Results from Phase 2 captivate study and Phase 3 glow study Leo Wang-Kit Cheung Received Received
  5673-MON Pirtobrutinib versus usual care for patients with richter transformation of chronic lymphocytic leukemia: Inverse probability of treatment weighting-based analysis of BRUIN trial and mayo observational cohort Yucai Wang Received Received
  5674-MON Clinical, cytogenetic, and molecular characteristics of patients with both chronic lymphocytic leukemia and myeloproliferative neoplasm Graham Wehmeyer Received Received
  5675-MON Minimal residual disease-guided venetoclax plus rituximab for patients with previously untreated chronic lymphocytic leukemia (VERITA PALG-CLL5): primary endpoint analysis of the prospective, multicenter, Phase 2 trial Krzysztof Jamroziak Received Received
  5676-MON A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia Meghan C. Thompson Received Received
  5677-MON Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Yang Liang Received Received
  5678-MON Chronic obstructive pulmonary disease and prior pneumonia as predictors of infectious risk in chronic lymphocytic leukemia patients receiving acalabrutinib or zanubrutinib: A seifem multicentre Study. Francesco Autore Received Received
  5679-MON Longitudinal analysis of richter syndrome risk and survival in CLL: The role of targeted therapy and molecular markers. experience at the fondazione policlinico gemelli in rome. Luca Laurenti Sr Received Received
  5680-MON Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and/or cardiovascular adverse events Emily B. Tomasulo Received Received
  5681-MON Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE) Inhye E Ahn Received Received
  5682-MON Nodal progression in CLL: Real-world predictors of richter transformation and identification of a distinct high-risk NP-CLL subgroup Nathalie Javidi-Sharifi Received Received
  5683-MON Phase 2 trial of encorafenib plus binimetinib for patients with BRAF V600 mutated relapsed/refractory hairy cell leukemia Robert J Kreitman Received Received
  5684-MON Efficacy of pirtobrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia: A Bayesian network meta-analysis of randomized controlled trials Toby A. Eyre Received Received
  5685-MON Venetoclax initiation monitoring and interventions after acalabrutinib lead-in for chronic lymphocytic leukemia Alexandra Lovell Received Received
  5686-MON Long progression-free survival with venetoclax consolidation in patients with high-risk chronic lymphocytic leukemia treated with ibrutinib. Vishrut Shah Received Received
  5687-MON Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials Mahesh Swaminathan Received Received
  5688-MON Real-world study on the impact of continuous treatment dose interruption or reduction of COVALENT BTK inhibitors on efficacy: A 7-year follow-up in chronic lymphocytic leukemia specialized clinics at tertiary hospitals in shanghai, China Jiaojiao Zhang II Received Received
  5689-MON Characteristics and therapies for pure red cell aplasia in patients with chronic lymphocytic leukemia (CLL) - a real world analysis from trinetx database Jawria Tufail Received Received
  5690-MON The efficacy and safety of pirtobrutinib in patients with CLL/SLL: A phase 2 dose optimization trial in progress Alexey V. Danilov Received Received
  5691-MON CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Meghan C. Thompson Received Received
  5692-MON Benefit VA: Assessing the benefit of venetoclax addition in veterans with CLL/SLL responding to BTK inhibitor therapy Daphne Friedman Received Received
  5693-MON Chromothripsis drives high-risk multiple myeloma by copy number abnormalities and rewiring the epigenome to activate oncogenic programs. Enze Liu Received Received
  5694-MON On the cellular origins of multiple myeloma Dennis D Lee Received Received
  5695-MON LILRB4 drives proinflammatory cytokine secretion in multiple myeloma to promote the immune-cell dysfunction via the generation of myeloid-derived suppressive cells Lanting Liu Received Received
  5696-MON IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma Hatice Satilmis Received Received
  5697-MON Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study Tracy Chow Received Received
  5698-MON Single-cell profiling reveals teclistamab-induced reshaping of nasopharyngeal immunity in multiple myeloma Sofie-Katrin Kadel Received Received
  5699-MON EZH2 inhibition synergizes with aiolos/ikaros degradation via coordinated chromatin remodeling and FoxO activation in multiple myeloma Ting-Hsiang Huang Received Received
  5700-MON The m5C-binding protein YB-1 modulates proteasome inhibitors resistance in multiple myeloma via epigenetic modification Qiqi Shen Received Received
  5701-MON Talquetamab alters T cell transcriptome in presence of GPRC5D on MM cells Umair Munawar Received Received
  5702-MON Bone marrow spatial architecture predicts response duration in smoldering multiple myeloma patients receiving checkpoint inhibitor therapy Yoshinobu Konishi Received Received
  5703-MON Zip-code drug conjugates (ZDCs): Ctdna-guided therapy shows strong efficacy and low toxicity in vitro and In Vivo Leon Bernal-Mizrachi Received Received
  5704-MON N6-methyladenosine (m6A) RNA modification is required to final plasma cell differentiation Morgane Thomas Received Received
  5705-MON BIRC5 inhibition as a novel approach to target RAS mutant and drug-resistant multiple myeloma Jeremiah Pfitzer Received Received
  5706-MON Methionine promotes glycolysis and tumor progression in multiple myeloma by enhancing POU2AF1 expression via m6A modification Chi Ma Received Received
  5707-MON NAMPT in macrophages promotes multiple myeloma drug resistance through mitochondrial metabolic reprogramming and modulates immunosuppression via the SIRT1/STAT3/SPP1 axis. Shunnan Yao Received Received
  5708-MON Novel indirubin-3-monoxime derivative I3MV-8b enhances anti-CD38 monoclonal antibody efficacy in multiple myeloma through dual proteasome and HDAC6 inhibition Xiaoyu Zhang Jr Received Received
  5709-MON MAPK pathway-driven metabolic-inflammatory axis in AL amyloidosis Oshrat Hershkovitz-Rokah Received Received
  5710-MON Multi-omics profiling reveals an immunosuppressive microenvironment and PRL-3 as a therapeutic target in myeloma extramedullary disease Chunxiang Jin Received Received
  5711-MON Bispecific antibody therapy in multiple myeloma is impaired by tumor-associated macrophages through dual immunosuppressive and antigen-dependent mechanisms Heiko Bruns Received Received
  5712-MON Integrated genomic analysis identifies polo-like kinase 4 (PLK4) as a key regulator of chromosomal stability and growth in multiple myeloma Poonam Kalhotra Received Received
  5713-MON Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM Rao H Prabhala Received Received
  5714-MON PRL-3 enhances multiple myeloma cell survival in acidic microenvironments via metabolic adaptation and pH regulation. Henrik Marius Laukli Received Received
  5715-MON A multimodal machine learning framework to predict treatment duration in multiple myeloma patients Fumou Sun Received Received
  5716-MON Immune restoration in long-term myeloma survival revealed by single-cell RNA-sequencing Khanmi Kasomva Received Received
  5717-MON P300/CBP acetyltransferase inhibition and degradation disrupt oncogenic transcriptional programs and reveal epigenetic vulnerabilities in multiple myeloma Olga Motorna Received Received
  5718-MON NQO1 modulates CD38 surface expression in multiple myeloma Seungbin Han Received Received
  5719-MON Targeting CCR7 ubiquitination to disrupt protumoral macrophages: A NEDD4-1-dependent strategy to reverse bortezomib resistance in myeloma Xi Huang Received Received
  5720-MON High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy Ondrej Venglar Received Received
  5721-MON Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8-color flow cytometry panel reveals substantial differences among products kinetics and persistence Ondrej Venglar Received Received
  5722-MON Relationship between myeloma cell genomic alternations and tumor immune microenvironment in bone-related extramedullary disease of newly diagnosed multiple myeloma Xuzhao Zhang Received Received
  5723-MON Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models Junia Vieira Received Received
  5724-MON Transitioning from FISH to NGS for immunoglobulin translocation detection in multiple myeloma Jonathan Keats Received Received
  5725-MON CAR-T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition Kady Anna Dennis Received Received
  5726-MON Tryptophan metabolism plays a significant role in multiple myeloma survival Julia Grace Reinke Received Received
  5727-MON Fingolimod in combination with bortezomib demonstrates synergistic tumor inhibition and bone anabolic effects in myeloma bone disease Smriti Gurung Received Received
  5728-MON Pomalidomide promotes activation induced cell death of pre-activated, memory BCMA CAR-T cells in a model of high, but not low, tumor burden multiple myeloma Kirsten Pfeffer Received Received
  5729-MON Oncogenic ASPP2?: A novel regulator of drug resistance and tumor progression in multiple myeloma Kerstin Maria Kampa-Schittenhelm Received Received
  5730-MON Evolution of t(11;14) biology in multiple myeloma and it´s role on outcomes to venetoclax treatment Praneeth Reddy Sudalagunta Received Received
  5731-MON LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK Maria Luisa Guerrera Received Received
  5732-MON Subclonal genomic heterogeneity shapes immune crosstalk and clinical outcomes in multiple myeloma Parvathi Sudha Received Received
  5733-MON Functional genomic screens identify positive and negative regulators of venetoclax resistance Vikas Gupta Received Received
  5734-MON Hyperuricemia modifies multiple myeloma pathobiology and modulates conventional, novel, and immuno-oncology drug sensitivity Upasana Ray Received Received
  5735-MON Deciphering the role of EP300 in maintaining the enhancer landscape and lineage-specific epigenetic vulnerability in multiple myeloma Rajib Shome Received Received
  5736-MON The use of MYD88 and IGH PCR in the diagnosis and follow up of ?ing-neel syndrome June Hyun Received Received
  5737-MON Nationwide real-world outcomes of POEMS syndrome: Long-term impact of ASCT, maintenance therapy, and relapse strategies in Japan Emiko Sakaida Received Received
  5738-MON Prognostic value of mayo 2012 vs. european-modified mayo 2004 staging in AL amyloidosis patients with discordant stage classifications Miran Han Received Received
  5739-MON Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis Thomas George Received Received
  5740-MON Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy Simon Zhen Received Received
  5741-MON Disease characteristics, treatment patterns, and outcomes of AL amyloidosis patients with high-risk FISH cytogenetics Tamer Hellou Jr Received Received
  5742-MON High neutrophil-to-lymphocyte ratio does not predict MGUS to myeloma progression but is associated with worse survival as a marker of global inflammation Virginia Hsiao Received Received
  5743-MON Modeling discordant cardiac and renal recovery trajectories in AL amyloidosis using interpretable machine learning John Hanna Received Received
  5744-MON Mass spectrometry-based screening for monoclonal gammopathy in individuals undergoing physical examinations: Analyses of consecutive 15,068 cases in China Zi-han Yang Received Received
  5745-MON Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis Xinyi Xiong Received Received
  5746-MON Effectiveness of second-line therapies following upfront daratumumab plus bortezomib, cyclophosphamide and dexamethasone: A new benchmark Eugene Brailovski Received Received
  5747-MON Efficacy and safety of venetoclax in high-risk Relapsed/Refractory AL amyloidosis: A systematic review and meta-analysis Muhammad Atif Khan Received Received
  5748-MON Circulating immune profile in patients with amyloidosis Philip L. McCarthy Received Received
  5749-MON Laboratory characteristics of monoclonal gammopathy of undetermined significance (MGUS) in a diverse sample from three large cancer epidemiology cohorts. Wendy Cozen Received Received
  5750-MON Descriptive analysis of IgM monoclonal gammopathy of undetermined significance progression events in US veterans Lawrence Liu Received Received
  5751-MON Patient-derived amyloidogenic light chain triggers cardiovascular toxicity In Vivo and reveals ICAM-1 as a novel potential biomarker in patients with AL amyloidosis Panagiota-Efstathia Nikolaou Received Received
  5752-MON Adapted physical activity during first line therapy in multiple myeloma : Innovative assessment of physical status during first-line therapy in 22 multiple myeloma patients Cecile Sonntag Mottier Received Received
  5753-MON Baseline cytomegalovirus IgG levels predict reactivation in patients with multiple myeloma receiving elranatamab Ukyo Kondo Received Received
  5754-MON Prophylactic intravenous immunoglobulin in patients receiving BCMA-targeted bispecific antibody therapy for multiple myeloma: A systematic review and meta-analysis Gisele Nogueira Bezerra Received Received
  5755-MON GLP-1 agonist use is associated with reduced risk of multiple myeloma in type II diabetes. Eric Irons Received Received
  5756-MON Machine learning uncovers prognostically distinct myeloma cast nephropathy phenotypes not captured by standard risk stratification systems Michael Sang Hughes Received Received
  5757-MON Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma Daniel Morillo Received Received
  5758-MON Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma. Meera Mohan Received Received
  5759-MON Characteristics of immune genes rearrangements in Chinese multiple myeloma patients Donghua He Received Received
  5760-MON Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients Darren Pan Received Received
  5761-MON Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights Yating Li Received Received
  5762-MON Conditional progression free survival (PFS) in patients with multiple myeloma (MM) after upfront autologous stem cell transplantation (ASCT): A secondary CIBMTR analysis Utkarsh Goel Received Received
  5763-MON Cytogenetic subgroup analysis of the advance trial: A randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM) Michael Durante Received Received
  5764-MON The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma Narsis Cancer Attar Received Received
  5765-MON Novel criteria for evaluating early treatment response with whole body magnetic resonance imaging and prognostic implications in patients with newly diagnosed multiple myeloma Ioannis Ntanasis-Stathopoulos Received Received
  5766-MON A multivariable prediction model for early mortality in multiple myeloma patients with renal impairment Menghan Liu I Received Received
  5767-MON The importance of MRI in diagnostic workup of smoldering multiple myeloma Roshani Patel Received Received
  5768-MON Quality-adjusted survival analysis of neurologic events with ciltacabtagene autoleucel (Cilta-cel) vs standard of care (SOC) in patients (Pts) with lenalidomide-refractory multiple myeloma (MM) who received 1–3 prior lines of therapy (LOT): Cartitude-4 tr Surbhi Sidana Received Received
  5769-MON Extended treatment-free hospitalization-free time and quality of life benefits with CAR T-cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the KarMMa-3 trial Krina Patel Received Received
  5770-MON AI-based decision support (M-BOT) for treatment selection in multiple myeloma Alexander Luchinin Received Received
  5771-MON Journey of relapsed or refractory multiple myeloma (RRMM) after quadruple-class exposure (QCEx): Poor outcomes and high attrition Doris K. Hansen Received Received
  5772-MON Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies Valentina Cardenas Castro Received Received
  5773-MON Do chip mutations predict frailty and toxicity in transplant-eligible patients with multiple myeloma? Steven Chun-Min Shih Received Received
  5774-MON METTL14 overexpression identifies a biologically aggressive subgroup and correlates with adverse clinical outcomes in multiple myeloma Liping Zuo Received Received
  5775-MON A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study) Ola Landgren Received Received
  5776-MON Operational cure in patients with newly diagnosed multiple myeloma after autologous stem cell transplantation: Long-term survivors and impact of induction regimens. Jose Miguel Mateos Perez Received Received
  5777-MON Main biologic and clinic features at presentation and treatment results in very elderly patients ( 75 Years) with Multiple myeloma: A multicentric experience Roberto Latagliata Sr Received Received
  5778-MON Targeted capture sequencing identifies driver mutations and enables prognostic modeling in multiple myeloma Yang Yang Received Received
  5779-MON Baseline characteristics, serological and measurable residual disease responses and outcomes in newly diagnosed multiple myeloma patients not planned for autologous stem cell transplant; Results from a prospective randomised study using MRD guided therapy Aditya Ranjithkumar Nair Received Received
  5780-MON Low skeletal muscle mass and cancer cachexia among patients with multiple myeloma undergoing CAR-T cell therapy Samuel Yates Received Received
  5781-MON Validation of the high-risk consensus genomic staging system in the era of bispecific antibodies: Role of NGS and cytogenetic reclassification Maria Sanchez-Tabernero Jr Received Received
  5782-MON Treatment of high-risk newly diagnosed multiple myeloma with minimal residual disease-guided therapy:daratumumab, carfilzomib, lenalidomide, and dexamethasone (DKRd) Hongying You Received Received
  5783-MON Atypical IGH::CCND1 rearrangements by fluorescent in situ hybridization are associated with higher risk cytogenetic features in multiple myeloma Changqing Xia Received Received
  5784-MON Identification of dynamic markers for multiple myeloma in patients with MGUS and T2DM Su-Hsin Chang Received Received
  5785-MON The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D Leo Rasche Received Received
  5786-MON The T cell immunosenescence profile of patients with newly diagnosed multiple myeloma as an indicator of frailty: Preliminary data from the immuno-NDMM protocol. Stefano Crippa I Received Received
  5787-MON Representativeness of clone size measurement by using NGS-based immunoglobulin gene rearrangement test in comparison to flow cytometry in clonal plasma cell disorders Hyeseong Ryu Received Received
  5788-MON Multiple myeloma in adolescents and young adults (AYA): A comparative analysis of global and u.S.a, epidemiological trends, risk factors, and projections (1990–2040) Rupayan Kundu Received Received
  5789-MON Quantitative morphological parameters of bone marrow plasma cells are predictive of outcomes in plasma cell dyscrasias Guangqi Wang Received Received
  5790-MON Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings Orthi Ayesha Shahzad Received Received
  5791-MON Circulating tumor cells (CTCs) combined with frailty index offer an improved stratification system for transplant-ineligible newly diagnosed multiple myeloma patients Ioannis V Kostopoulos Received Received
  5792-MON Risk score and survival outcomes for multiple myeloma patients with disease refractory to BCMA CAR-T. Joshua Gustine Received Received
  5793-MON Mass spectrometry compared to serum electrophoresis and immunofixation to detect monoclonal proteins and therapeutic antibodies in plasma cell disorders Malin Hultcrantz Received Received
  5794-MON Tumor flare pain reaction during teclistamab step-up dosing with tocilizumab prophylaxis: An underrecognized toxicity in the outpatient setting Gaspard Jadot Received Received
  5795-MON Post-treatment loss of MMR vaccine immunity in multiple myeloma patients following autologous stem cell transplantation: A retrospective cohort analysis Sidharth Mahajan Received Received
  5796-MON Sustained MRD negativity via multimodal NGS/NGF overcomes high-risk cytogenetics and predicts long-term survival in transplant-eligible multiple myeloma: A real-world cohort study Yuhe Peng II Received Received
  5797-MON Geographic, demographic, and risk factor burden of multiple myeloma in the United States: Insights from the global burden of disease study 2021 Akash Arvindbhai Hirpara Received Received
  5798-MON Impact of pre-transplant functional status and comorbidities on outcomes in individuals with multiple myeloma undergoing autologous hematopoietic cell transplantation Sawyer Bawek Received Received
  5799-MON Outcomes of patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant stratified by the 2025 ims/IMWG risk classification Priyanka Venkatesh Received Received
  5800-MON Clinical validation of a high sensitivity method to detect residual disease in blood of treated myeloma patients David L Murray Received Received
  5801-MON An immune proteomic atlas of 300 million bone marrow cells reveals prognostic cell states in multiple myeloma Dimitra Karagkouni Received Received
  5802-MON Incidence of CMV-reactivation in multiple myeloma patients receiving bispecific antibodies Jordan Snyder Received Received
  5803-MON Evaluating the CAR-hematotox score in patients with refractory-relapsed multiple myeloma treated with bispecific T-cell engager therapy Emmanuel Bugarin Estrada Received Received
  5804-MON Spatial biomarkers of CAR-T treatment response in relapsed refractory multiple myeloma Julia Tianjiao Wang Received Received
  5805-MON Impact of pulmonary hypertension on in-hospital outcomes among patients hospitalized with multiple myeloma: A 2015–2022 national inpatient sample analysis Salman Fazal Jr Received Received
  5806-MON Incidence and characteristics of infections in patients with multiple myeloma treated with BCMA bispecific antibodies in British Columbia Andree-Anne Pelland Received Received
  5807-MON Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with rela Susan Bal Received Received
  5808-MON A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results Giada Bianchi Received Received
  5809-MON Kpg-818, a novel cereblon (CRBN) modulator, in patients with hematological malignancies: Results of a Phase 1, open-label, multiple ascending dose study Aaron S Rosenberg Received Received
  5810-MON Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial Anna Sureda Balarí Received Received
  5811-MON Bortezomib-bendamustine-melphalan or high-dose melphalan in autologous hematopoietic stem cell transplantation for previously transplanted relapsed multiple myeloma – a single center retrospective cohort study Thomas Silfverberg Received Received
  5812-MON Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome Jin Lu Received Received
  5813-MON Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma Aarif Ahsan Received Received
  5814-MON Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma Beatrice Razzo Received Received
  5815-MON Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings Tadao Ishida Received Received
  5816-MON Safety and efficacy of triple vs quadruple therapy in transplant ineligible multiplemyeloma patients – a meta-analysis of randomized controlled trials Sai Sushrutha Mudupula Vemula Sr Received Received
  5817-MON All-trans retinoic acid and RARß agonists enhance the efficacy of IMiD-based treatments for t(4;14) multiple myeloma Ling Zhong Received Received
  5818-MON Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study Yuan Jian Received Received
  5819-MON Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 ira Jin Lu Received Received
  5820-MON Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis María-Victoria Mateos Received Received
  5821-MON Utility and sensitivity of wett-SA53 to measure dysgeusia associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in Relapsed/Refractory multiple myeloma: Preliminary data from the talisman study Rakesh Popat Received Received
  5822-MON A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma Wenming Chen Received Received
  5823-MON Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change Suzanne Trudel Received Received
  5824-MON Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma Benjamin Puliafito Received Received
  5825-MON Cancer-selective targeting of the NF-?B pathway via GADD45ß/MKK7 inhibition: Results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma Aristeidis Chaidos Received Received
  5826-MON Isatuximab subcutaneous in relapsed/refractory multiple myeloma: Exposure-response and serum m-protein dynamics analyses from phase 3 iraklia Study and the phase 1b Study Kamilia Abdelraouf Received Received
  5827-MON Talquetamab outcomes from practice outside of clinical trials: The bital study María-Victoria Mateos Received Received
  5828-MON Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results Jian Xu Received Received
  5829-MON Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial Zhongjun Xia Received Received
  5830-MON Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study Wen Gao Received Received
  5831-MON QLS4131, a next-generation GPRC5D×BCMA×CD3 trispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM): Initial results of a first-in-human Phase ?a study Gang An Received Received
  5832-MON Phase II trial of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone in multiple myeloma following BCMA CAR T-cell therapy Benjamin A Derman Received Received
  5833-MON Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis Corbin Wright Received Received
  5834-MON Final results of a multi-center phase 2 trial of isatuximab-lenalidomide in patients with high risk smoldering multiple myeloma (HRSMM) Sheeba Koshy Thomas Received Received
  5835-MON Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1 Ja Min Byun Received Received
  5836-MON First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients. Aurore Perrot Sr Received Received
  5837-MON A novel conditioning regimen combining selinexor with melphalan Improves Survival in Patients with multiple myeloma:a prospective study Liangliang Ma Received Received
  5838-MON Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group Artur Jurczyszyn Received Received
  5839-MON Second autologous transplantation remains a valid consolidation option in patients with relapsed multiple myeloma: A report from the Latin American bone marrow transplantation group Eloisa Riva Received Received
  5840-MON Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocu Saad Z. Usmani Received Received
  5841-MON An immune-therapeutic salvage strategy for ´functional´ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01. Sueh-Li Lim Received Received
  5842-MON Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22) Sueh-Li Lim Received Received
  5843-MON Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study Ajay K Nooka Received Received
  5844-MON Surzetoclax (ABBV-453) in combination with daratumumab and dexamethasone in biomarker-selected patients with Relapsed/Refractory multiple myeloma: A Phase 1/2, multicenter, open-label platform study John McKay Received Received
  5845-MON MagnetisMM-6 part 2: A phase 3, open-label, randomized study of elranatamab in combination with daratumumab and lenalidomide vs daratumumab, lenalidomide, and dexamethasone in transplant-ineligible or -deferred patients with newly diagnosed multiple myelo Ja Min Byun Received Received
  5846-MON Clonoseq MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma. Brandon Kale Received Received
  5847-MON Novel allogeneic BCMA CAR-expressing iNKT cells with PD1 deletion demonstrate superior tumor control in a multiple myeloma preclinical model Hua Zhang Received Received
  5848-MON CD38BiTE-secretion overcomes antigen escape in BCMA-targeted CAR T cell therapy for multiple myeloma Jianlin Liu Received Received
  5849-MON Real-world comparative outcomes of CAR-T cell therapy versus pomalidomide-based regimens in relapsed/refractory multiple myeloma: A propensity-matched cohort study Madhu Bhargavi Chandra Received Received
  5850-MON BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma Hector Jose Garcia Pleitez Received Received
  5851-MON Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma Michael Slade Received Received
  5852-MON Subsequent primary malignancies after CAR-T therapy: A study from the US multiple myeloma immunotherapy consortium Eli Zolotov Received Received
  5853-MON Impact of renal impairment and lymphodepletion regimen on outcomes after CAR T-cell therapy in relapsed/refractory multiple myeloma Nora Grieb Received Received
  5854-MON An update: Safety and efficacy of GPRC5D targeting CAR-T cell therapy in relapsed/refractory multiple myeloma patients Yongwei Zheng Received Received
  5855-MON Baseline PET-CT in predicting CRS and survival outcomes of R/R MM patients following CAR T-cell therapy Pingnan Xiao Received Received
  5856-MON Suppressive dexamethasone (SupDex) to prevent delayed non-icans delayed neurotoxicity (DNT) post ciltacabtagene-autoleucel(cilta-cel) in patients with relapsed myeloma.suppressive dexamethasone (SupDex) to prevent delayed non-icans delayed neurotoxicity ( Karla Feliciano Salva Received Received
  5857-MON Evolving real-world uptake and patient characteristics of bispecific antibodies in Relapsed/Refractory multiple myeloma: Insights from a US community oncology network Ira Zackon Received Received
  5858-MON Non-genotoxic conditioning to increase donor chimerism levels in a mismatched murine transplant model for sickle cell disease Mohamed Ali Received Received
  5859-MON BET inhibition targets pathogenic interstitial macrophages to limit antibody mediated fibrosis in bronchiolitis obliterans chronic gvhd Rathan Kumar Received Received
  5860-MON AML blasts and monocytic myeloid-derived suppressor cells (M-MDSC) inhibit human mucosal-associated invariant t (MAIT) cells activation. Charlotte Calvo Received Received
  5861-MON Liver-targeted delivery of bioengineered induced tregs via nanoparticles prevents and treats acute gvhd Mathew Sebastian Received Received
  5862-MON Post allo-HCT menin-inhibition enhances graft-versus-leukemia effects by endogenous retrovirus induction in AML and T-cell activation Viktor Fetsch Received Received
  5863-MON ZFP36L2 as a promising therapeutic target in acute graft-versus-host disease: Evidence from murine models and clinical validation Li Li Received Received
  5864-MON Spatial communication modules identify prognostic cell-cell signaling hubs in chronic graft-versus-host disease Bruno Fernandes Matuck Received Received
  5865-MON IL-39/IL-39R signaling drives acute graft-versus-host disease Denggang Fu Sr Received Received
  5866-MON At-211-anti-CD45 radioimmunotherapy as conditioning prior to haploidentical hematopoietic cell transplantation in mouse models Francesca Kayaban Gaerlan Received Received
  5867-MON Monocarboxylate transporter 1 deficient donor T cells rewire metabolism and ameliorate aGVHD lethality Eun Ko Received Received
  5868-MON Ornithine decarboxylase deficiency in donor T cells preserves strong GVL activity while attenuating acute and preventing steroid-resistant gut GVHD in a recipient tissue PD-L1-dependent manner Qinjian Li Received Received
  5869-MON Dietary fiber intake improves survival in allogeneic HCT patients and exhibits synergistic effects with taurine supplementation in preclinical models Jenny Paredes Received Received
  5870-MON Single-cell transcriptional profiling identifies ADGRG1+ CD8 T cells as critical mediators of graft-versus-leukemia effect in AML relapse after haploidentical hematopoietic stem cell transplantation Yi Luo Received Received
  5871-MON Refined design of a CD117 antibody-drug conjugate safely and effectively conditions non-human primates for autologous transplant-based gene therapy Lev Gorfinkel Received Received
  5872-MON Role of ferroptosis in aGVHD-induced liver tissue damage: Mediation by Acsl4-regulated PUFA-pls Shufen Wang Received Received
  5873-MON ST-101: Manufacturing GMP-compliant HLA-compatible definitive human hematopoietic stem and progenitors cells from iPSCs using Piezo1 agonists for clinical transplant Michael P Cooke Received Received
  5874-MON Decoding CAR t cell membrane architecture with the proximity network assay William Love Received Received
  5875-MON IMV101, a novel CD19-targeted In Vivo CAR T therapy exhibits potent efficacy and tolerable safety profiles in preclinical models Zhenggang Jiang Received Received
  5876-MON Novel DKK1-A2 CAR-T cell therpy for hematologic malignancies Yufei Zhang Received Received
  5877-MON CAR-T cells targeting CD79b and CD19 exhibit robust antitumour activity against B cell lymphoma Yuyang Gao Received Received
  5878-MON Dex and IL-7 enhance persistence of CAR T cells to promote long-term remission in mouse models of multiple myeloma Ryan Urak Received Received
  5879-MON Triple base-edited dual targeting CD70/33 CAR T cells to avoid cytokine-mediated resistance in Acute Myeloid Leukemia Alexandra Bratt Received Received
  5880-MON IL-2 mutein-mediated improvement of CAR T function in Relapsed/Refractory diffuse B cell lymphoma Allan Pavy Received Received
  5881-MON Dynamic changes in the bone marrow niche following CD19-targeted CAR-T cell infusion in diffuse large B cell lymphoma (DLBCL). Timothy I Shaw Received Received
  5882-MON Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL Jay Y Spiegel Received Received
  5883-MON Targeting CSF1R to overcome myeloid cell suppression in CART therapy Grace Elizabeth DeFranco Received Received
  5884-MON Fludarabine pharmacokinetics and dynamic immune monitoring as predictive biomarkers for CD19 and BCMA CAR-T Elisha Y Pinker Received Received
  5885-MON BRD4 sustains immunosuppressive erythroid precursors to compromise CAR-T cell function Mengmeng Huang Received Received
  5886-MON M6A-driven control of T cell fitness via lrpprc defines a novel regulatory axis to enhance adoptive cell therapy Jeremy A Meier Received Received
  5887-MON Adipose tissue-associated lipid serum signatures modulate efficacy and toxicity of CAR-T cell therapy in lymphoid malignancies David Cordas Dos Santos Received Received
  5888-MON Off-the-shelf CD117 CAR-iNKT cells as a safe and effective allogeneic immunotherapy targeting AML and its immunosuppressive microenvironment Hao Yan Received Received
  5889-MON A functional CAR-T cell atlas to unravel regulatory mechanisms of CAR-T therapies Juan Roberto Rodriguez-Madoz Received Received
  5890-MON Stimulated CAR-T cells from non-Hodgkin lymphomas patients engage and activate monocytes via extracellular vesicles Besjana Xhahysa Received Received
  5891-MON Folate receptor beta targeting of tumor-associated macrophages improves lymphoma cell responses to CD19 CAR T cells Kerttu Kalander Received Received
  5892-MON Signaling role of viral protein motif and its application in CAR T cell therapy Wooram Jung Received Received
  5893-MON Enhancing CAR T cell responses in lymphoma through coadministration of vaccine-educated T cells Giulia Cheloni Received Received
  5894-MON Metabolic pathway signatures unpinning response to CD19 CAR T-cell therapy in aggressive B-cell non-Hodgkin´s lymphoma Melinda Tan Received Received
  5895-MON The development of an off-the-shelf CAR T-cell therapy co-targeting CD19 and CD38 for broad application in autoimmune disease Mark Jelcic Received Received
  5896-MON Intravenously administered LV-169 delivers a functional BCMA-CAR transgene to niche-resident T cells and leads to elimination of disseminated myeloma in MHC-deficient NSG mice Stephen Russell Received Received
  5897-MON Attention-based multiple instance learning predicts CAR T cell therapy outcomes from infusion product single-cell RNA-seq data and identifies engineering targets in large B cell lymphoma Kameron B Rodrigues Received Received
  5898-MON AMPK agonism improves In vivo CAR T cell function across a range of platforms and clinical indications Craig Byersdorfer Received Received
  5899-MON In silico design of degron tags for precise modulation of CAR T-cell activity using clinically utilized drugs Panagiotis Karagiannis Received Received
  5900-MON CD7-negative T cell immune reconstitution after CD7-targted CAR-T cell therapy Haiqiong Zheng Received Received
  5901-MON Reducing Acute Myeloid Leukemia resistance to CAR T cell therapy by epigenetic activation of the tumor inflammasome-pyroptosis signaling Xin Huang Received Received
  5902-MON Lentiviral vectors engineered for direct In Vivo delivery to resting T cells Gopal Naik Nenavath Received Received
  5903-MON ß-hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming Shan Liu Received Received
  5904-MON Pre-treatment with carfilzomib significantly improves response in R/R MM patients undergoing BCMA-directed CAR T cell therapy Judith S. Hecker Received Received
  5905-MON Identification and functional characterization of a novel best-in-class anti-CD79b CAR T cell immunotherapy using a multidimensional screening strategy Jean Lemoine Received Received
  5906-MON Humanin-like 8 regulates metabolic fitness and anti-apoptotic programming in CD19 CAR-T cells Samira Naderinezhad Received Received
  5907-MON Development of a CAR-NK therapy regulated by the KLRC1 locus as a new platform for selective control of acute myeloid leukaemia Asunción Borrero Borrego Received Received
  5908-MON Scalable production and anti-tumor efficacy of iPSC-derived immortalized anti-CD19 CAR macrophages Akihiro Nakajima Received Received
  5909-MON Development of ALK-directed TCR-T cells with potent and specific anti-tumor activity against ALK-positive anaplastic large cell lymphoma Simone Piane Received Received
  5910-MON Long-term outcomes of double-negative T cell therapy in AML patients with relapse post allo-HSCT Dongyao Wang Received Received
  5911-MON Exploiting HLA-e restricted T cell receptors to develop universal cellular therapies for virus-associated malignancies Chelston Ang Received Received
  5912-MON Dual-function engineered bacteria remodel AML tumor microenvironment via IL-12 delivery and adenosine depletion to sustain NK cell immunity Stephanie Sendker Received Received
  5913-MON Engineered iPSC-derived NK cells targeting the SIGLEC7-glyco-immune checkpoint improves anti-tumor activity in solid cancers Jaya Lakshmi Thangaraj Received Received
  5914-MON Machine learning-guided optimization of anti-CD70 natural ligand-based CAR-lymphocytes for Acute Myeloid Leukemia Amrik Kang Received Received
  5915-MON Reactivating mutant p53 in T cells enhances anti-tumor activity in Acute Myeloid Leukemia Li Li Received Received
  5916-MON Integrative single-cell multi-omic and functional profiling of human bone marrow regulatory T cells to enhance GVHD-preventive cell therapies Jessica Diarra Received Received
  5917-MON Phenotypic characterization of chimeric ilt receptor natural killer (CIR-NK) cells targeting HLA-G+ tumors for allogeneic donor identification Henri Bayle Received Received
  5918-MON Lipid nanoparticle-mediated mRNA transfection enables efficient and safe generation of CAR macrophages. Felix Chiu Received Received
  5919-MON Siltuximab versus tocilizumab for the management of CAR T-cell associated cytokine release syndrome Mayur Narkhede Received Received
  5920-MON CTA311, a universal anti-CD19 CAR t-cell therapy with improved persistence for patients with CD19+ relapsed/ refractory (R/R) b-cell acute lymphoblastic leukemia (B-ALL) Xiaoyu Zhu Received Received
  5921-MON Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and Muharrem Muftuoglu Received Received
  5922-MON Allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B) for refractory autoimmune hemolytic anemia Lele Zhang Received Received
  5923-MON Glofitamab for patients with Non–Large B-cell lymphoma refractory or relapsing after anti-CD19 CAR T-cell therapy: Final bicar study (LYSA) results. Guillaume Cartron Received Received
  5924-MON Autologous hematopoietic stem cell transplantation followed by CD19/CD22 dual-target CAR-T therapy for refractory or relapsed burkitt lymphoma Xian Zhang Received Received
  5925-MON Phase 1 clinical trial of point-of-care manufactured, fully human anti-CD19 CAR-T cells for treatment of Relapsed/Refractory lymphoid malignancies Nikki Agarwal Received Received
  5926-MON Unsupervised proteomic and metabolomic longitudinal serum profiling of anti-CD19 CAR-T cell therapy recipients reveals clinically distinct groups Jaromir Tomasik Received Received
  5927-MON Allogeneic induced pluripotent stem cell-derived invariant natural killer T cell therapy: A phase 1 clinical Trial Takahiro Aoki Received Received
  5928-MON Impact and predictors of icans on survival in lymphoma and myeloma patients treated with CAR T cell therapy Abdulaziz Abu Haimed Received Received
  5929-MON Autologous hematopoietic stem cell transplantation combined with inaticabtagene autoleucel in adults with high-risk B-cell acute lymphoblastic leukemia: Interim analysis of a phase II study Rongli Zhang Received Received
  5930-MON Long term remission and survival in patients with relapsed or refractory non-Hodgkin lymphoma after treatment of brl-201, a CRISPR-based non-viral PD-1 locus specifically integrated anti-CD19 CAR-T cells: 4-year follow-up of a first-in-human phase I study Qian Tan Received Received
  5931-MON CARMA-1: The phase I Study of SENL101, a naturally selected nanobody based CD7 CAR-T therapy, in relapsed or refractory T-ALL/lbl Xiangyu Zhao Received Received
  5932-MON Impact of clonal hematopoiesis on hematologic recovery and outcomes following tumor-infiltrating lymphocyte therapy Zhuoer Xie Received Received
  5933-MON Novel bispecific epitope anti-CD5 nanobody CAR-T cells for refractory or relapsed T-cell malignancies Haiyang LU Received Received
  5934-MON A tandem bispecific nanobody CAR (SL1703) T cells targeting CD19/BCMA for refractory or relapsed multiple myeloma as salvage treatment after BCMA CAR-T therapy failure Su Li Received Received
  5935-MON Lipo-MIT-based bridging therapy enables effective CAR-T treatment in high-risk relapsed or refractory B-cell lymphoma Heng Mei Received Received
  5936-MON Safety and efficacy of less differentiated CAR T-cell products in relapsed/refractory B-cell non-Hodgkin lymphomas: A meta-analysis Gabriela Marengone Altizani Received Received
  5937-MON Torque teno virus in pediatric CAR-T recipients Antonio Perez Received Received
  5938-MON Long term follow up autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy Sairah Ahmed Received Received
  5939-MON Donor-derived CAR-T cells co-infused with the allogenic graft on the platform of T cell depletion or post-transplant cyclophosphamide in children with advanced B-cell neoplasms Larisa Shelikhova Received Received
  5940-MON High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Resul Joost S.P. Vermaat Received Received
  5941-MON Donor-derived secondary CAR-T cell therapy for relapsed leukemia following initial CAR-T bridged to allogeneic transplantation: Efficacy and safety analysis Yiqing Ren Received Received
  5942-MON Defining a high-risk population for CAR-T-cell therapy: The impact of clonal hematopoiesis and pre-existing neutropenia on severe outcomes in patients treated for malignant and non-malignant conditions Alisha Weiss-Haug Received Received
  5943-MON Multiomic signatures of durable response in a Phase I/II trial of tandem aCD22-aCD19 CAR-T therapy for relapsed B-lineage acute lymphoblastic leukaemia Michaela Su-Fern Seng Received Received
  5944-MON MT-601 demonstrates favorable safety and durable responses in relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL) Geoffrey Shouse Received Received
  5945-MON CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities. Luca Paruzzo Received Received
  5946-MON Point of care anti-CD19 CAR-T for autoimmune diseases Ronit Marcus Received Received
  5947-MON Feasibility and tolerability of a CD4 re-directed chimeric antigen receptor T cell therapy (CD4CAR) in hematologic malignancies: Initial Results from multi-institutional first-in-human trials Rita Assi Received Received
  5948-MON Unveiling the "second wave": Viral-triggered biphasic CAR-T expansion drives late-onset IEC-HS: Characterization and successful management Yajing Zhang Received Received
  5949-MON First-in-human Phase I study of autologous CD5-knockout anti-CD5 CAR-T cells in CD5? hematologic malignancies Jiali Cheng Received Received
  5950-MON Singe agent off-the-shelf CAR-NK (CD-19 t-haNK) cell therapy in combination with rituxumab Results in complete response in participants with waldenstrom´s macroglobulinemia Jacqueline Thomson Received Received
  5951-MON Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients. Mark A Forsberg Received Received
  5952-MON Increased alemtuzumab exposure correlates with improved responses in heavily pretreated R/R ALL patients: Analysis of the balli-01 trial Xenia Naj Received Received
  5953-MON Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity Kenneth JC Lim Received Received
  5954-MON A single-arm, open-label, multi-center, phase 1b/2 Study to evaluate the safety, efficacy, and cellular pharmacokinetic profile of CTD402 in participants with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LB Lori Muffly Received Received
  5955-MON A phase 1b/2a study of CTO1681 for the prevention of cytokine release syndrome in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy Jordan Gauthier Received Received
  5956-MON Motixafortide (CXCR4 inhibition) alone and in combination with natalizumab (VLA-4 inhibition) to mobilize hematopoietic stem cells for gene therapy in sickle cell disease: A first-in-human, safety and feasibility study Zachary D. Crees Received Received
  5957-MON Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy Zachary D. Crees Received Received
  5958-MON Preclinical development of an optimized manufacturing, CRISPR-edited, fully non-viral 1XX-enhanced anti-BCMA CAR-T therapy for multiple myeloma Alexis R. Talbot Received Received
  5959-MON Expanding access to haploidentical transplantation : Clinical feasibility of a centralized nationwide distribution model for fresh TCRa/ß-depleted grafts in France Jean-Sebastien Diana Received Received
  5960-MON Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial Peipei Ye Sr Received Received
  5961-MON Current practices, organizational structures, technologies and challenges in developing atmps: A survey by dare-NL, nxtgen hightech, T2EVOLVE and ctiwp of EBMT - a gocart-coalition initiative Anil Deshantri Received Received
  5962-MON Individualizing apheresis processing volumes using a predictive algorithm: Analysis of the CAR T-cell collection protocol utilized in ACIT001/EXC002, a phase lb/ll trial of decentralized production of CAR T-cells for treatment of relapsed/refractory aggre Jennifer Croden Received Received
  5963-MON Outcomes of omidubicel-expanded umbilical cord blood transplantation in patients with severe aplastic anemia Georg Aue Received Received
  5964-MON Real-world experience with apheresis for gene therapy in transfusion-dependent ß-thalassemia: The largest single-center report Vismay Deshani Received Received
  5965-MON Eltrombopag plus G-CSF for peripheral blood stem cell mobilization: Final analysis of a single arm, Phase 2 trial Ta-Chuan Yu Received Received
  5966-MON More than IL-2: Optimizing feeder-free NK cell function through cytokine synergy Maxima Warmuzová Received Received
  5967-MON Preclinical feasibility analysis for Phase I study using adoptive iNKT cell transfer to prevent GVHD Kelsey Busken Received Received
  5968-MON Impact of dementia on in-hospital outcomes in hematopoietic stem cell transplant (HSCT) recipients: A nationwide cohort study Laith Sorour Received Received
  5969-MON Ruxolitinib combined with decitabine-intensified modified busulfan/cyclophosphamide conditioning regimen reduces relapse after allogeneic hematopoietic stem cell transplantation in Acute Myeloid Leukemia Daihong Liu Received Received
  5970-MON Clinically significant cytomegalovirus infection (csCMVi) after matched related donor allogeneic HSCT using post-transplant cyclophosphamide: A systematic review and meta-analysis. Rishi Bothara Received Received
  5971-MON Tailoring TBI for vulnerable patients: 8 gy TBI shows comparable outcomes to 12 gy TBI in adult ALL allo-HSCT Tomoyo Kubo Sr Received Received
  5972-MON Romiplostim N01 enhances platelet engraftment in ASCT using non-cryopreserved pbscs for plasma cell neoplasms: A single-center phase II study in China Xianfu Sheng Jr Received Received
  5973-MON Sequential therapy with fitcy preparative regimen for patients above the age of 70 years with active AML – a single center retrospective analysis Ron Ram I Received Received
  5974-MON Thiotepa and busulfan combined with cyclophosphamide conditioning regimen plus maintenance therapy improved the disease-free survival of patients with relapsed/refractory haematologic malignancies after undergoing allogeneic transplantation Shulian Chen Received Received
  5975-MON Cellular features of graft vs host disease prophylaxis impact on CD4 T cell reconstitution post allo-HCT Kingsley Kumashie Received Received
  5976-MON High-dose cryopreserved bone marrow from deceased donors may reduce relapse in HLA-mismatched allogeneic transplantation: Day 180 post-transplant HOPE update Sagar Munjal Received Received
  5977-MON A novel thiotepa-containing conditioning regimen for haploidentical hematopoietic cell transplantation in pediatric aplastic anemia at high risk of cardiotoxicity Feng Zhang Received Received
  5978-MON Optimizing patient selection to decrease non-relapse mortality with reduced intensity conditioning: A validation study using the CIBMTR dataset Yu Akahoshi Received Received
  5979-MON Impact of fludarabine exposure on overall survival in patients receiving fludarabine/cyclophosphamide reduced intensity conditioning hematopoietic cell transplantation for hematologic malignancies Biplov Adhikari Received Received
  5980-MON Impact of thiotepa dose in haploidentical allogeneic stem cell transplantation with thiotepa-busulfan-fludarabine conditioning for Acute Myeloid Leukemia in remission: A retrospective analysis of the EBMT acute leukemia working party Fabio Andreozzi Received Received
  5981-MON Outcomes of HLA-matched unrelated versus haploidentical hematopoietic cell transplantation in acute leukemia: A multicenter observational study in Brazil facilitated by the CIBMTR Mariana Nassif Kerbauy I Received Received
  5982-MON A single-centre comparison of thiotepa-treosulfan versus thiotepa-busulfan based conditioning regimens in adults with haematological malignancies undergoing allogeneic haematopoietic stem cell transplant. Kye Ling Wong Received Received
  5983-MON Treosulfan – based conditioning in allogeneic hematopoietic stem-cell transplantation for lymphoid malignancies: Long term follows up. Avichai Shimoni Received Received
  5984-MON Effect of pre-allogeneic HCT splenic irradiation on post-transplant engraftment and outcomes in patients with myelofibrosis: A single-center experience Yenny Moreno Vanegas Received Received
  5985-MON Outcomes and associated factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation for multiple myeloma in patients over 70 years of age Aqeeb Ur Rehman Received Received
  5986-MON The efficacy and safety of using low-dose cyclophosphamide, fludarabine and thymoglobulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent non-severe aplastic anemia:a retrospective study. Jia Wei Received Received
  5987-MON Optimizing outcomes and accessibility of matched sibling donor transplantation for severe hemoglobinopathies in low-resource settings Mohana Reddy Jr Received Received
  5988-MON Prophylactic rituximab administered on day -1 during conditioning significantly reduces early EBV reactivation in pediatric allogeneic HSCT: Real-world evidence from a propensity-matched cohort of 834 patients Senlin Zhang Jr Received Received
  5989-MON Study on five-year continuous improvement path for perianal infection prevention and control in hematopoietic stem cell transplantation Patients—Achieving zero infection through data-driven and optimized nursing schemes XiaoXia Wang Sr Received Received
  5990-MON Clinical outcomes of adenovirus infection in allogeneic hematopoietic cell transplant recipients: A real-world propensity-matched analysis Abid Nawaz Khan health Adil Received Received
  5991-MON The ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) as a bridge to allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia: A single-center experience Xiaomei Chen Received Received
  5992-MON Enhancing the sequential flamsa-treosulfan conditioning regimen with venetoclax – first results from the multicenter flamsaclax Phase I/II trial Guido Kobbe Received Received
  5993-MON Efficacy and safety of FLAG and CLAG regimens (Replacing Cyclophosphamide) in conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory malignant hematologic diseases Yanzhi Song Received Received
  5994-MON CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide Rima M. Saliba Received Received
  5995-MON Haploidentical hematopoietic stem cell transplantation using low-dose alemtuzumab is effective for standard-risk hematological malignancies Shinichi Kako Received Received
  5996-MON MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis Rima M. Saliba Received Received
  5997-MON Treosulfan-based vs. busulfan-based conditioning for hematopoietic stem cell transplantation: A systematic review and meta-analysis. Faiqa Amin Received Received
  5998-MON Safety of myeloablative total marrow and lymphoid irradiation versus chemotherapy-based conditioning in adults with high-risk acute lymphoblastic leukemia in a limited resources setting Alexia E. Gonzalez-Lozano Received Received
  5999-MON Earlier detection of transplant-associated thrombotic microangiopathy using harmonization criteria: A real-world comparative evaluation with conventional criteria Seonghan Lee Received Received
  6000-MON Safety and feasibility of outpatient myeloablative total marrow and lymphoid Irradiation–based allogeneic transplantation in adults with high-risk acute lymphoblastic leukemia Alexia E. Gonzalez-Lozano Received Received
  6001-MON Trial in progress: Safety and feasibility of a venetoclax-augmented treosulfan-based reduced intensity conditioning before allogeneic stem cell transplantation in AML, MDS/AML and higher risk MDS (VeStAL) Lucas Mix Received Received
  6002-MON Peripheral blood or bone marrow grafts for unrelated donors with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis Leonardo Javier Arcuri Sr Received Received
  6003-MON SOCS1 in graft CD8+ T cells ameliorates intestinal aGVHD by modulating chemokine-driven monocyte-to-M1 macrophage polarization Huidong Guo Received Received
  6004-MON Response dynamics to belumosudil in chronic graft-versus-host disease: Characterizing late responses and organ-specific response expectations from the rockstar study Zachariah Defilipp Received Received
  6005-MON Impact of anti-thymocyte globulin on graft-versus-host disease risk among HLA-matched related donors undergoing allogeneic hematopoietic cell transplantation for aplastic anemia Daniel Olivieri Received Received
  6006-MON Immune and DNA-damage responses in the intestinal stroma of patients presenting with lower gastro-intestinal symptoms after allogeneic stem cell transplantation Adam Kuba Received Received
  6007-MON An mRNA-based cytomegalovirus vaccine induces robust T-cell immune responses in cytomegalovirus-seropositive adults who have undergone allogeneic hematopoietic cell transplantation Jessica Little Received Received
  6008-MON Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program Leyla Shune Received Received
  6009-MON Serum MMP-7 as an early and specific biomarker for hepatic graft-versus-host disease Yuta Hasegawa Received Received
  6010-MON Long-term treatment duration and safety of axatilimab among patients with chronic graft-versus-host disease in AGAVE-201 Carrie Kitko Received Received
  6011-MON Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program. Udo Holtick Received Received
  6012-MON Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: Interim safety analysis of a phase 2, randomized study Robert Zeiser Received Received
  6013-MON Haploidentical donor regulatory T cells and memory T cells are safe and effective in children with refractory graft-versus-host disease with concurrent viral infections Michael Maschan Received Received
  6014-MON Dissecting complement pathway activation after allogeneic hematopoietic cell transplant: Results of a monocentric longitudinal monitoring program. Camille Malbrun Received Received
  6015-MON A novel Janus kinase 1 and 2 inhibitor, baricitinib, for steroid-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation Chen Zhao Received Received
  6016-MON Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis Usman Ilyas Received Received
  6017-MON A preliminary study on the roles and mechanisms of IL-17A monoclonal antibody in chronic graft-versus-host disease Min Xu Received Received
  6018-MON FK506 improves B cell reconstitution after allo-HSCT compared to csa: A real-world study Hao Zhou Received Received
  6019-MON 6-gingerol ameliorates murine gastrointestinal graft-versus-host disease by inhibiting pyroptosis of intestinal epithelial cell Guancui Yang Received Received
  6020-MON Haploidentical hematopoietic cell transplantation (Haplo-HCT) using ex vivo TCR-aß–Depleted grafts and upfront memory T-cell add-back mitigates the negative impact of pre-transplant measurable residual disease (MRD) in adults with Acute Myeloid Leukemia ( Evelyn Su-yin Aun Received Received
  6021-MON Gingerol ameliorates chronic graft-versus-host disease by regulating treg/Th17 transdifferenciation Yuxuan He Received Received
  6022-MON Post-transplant bendamustine (PT-BEN) with or without cyclophosphamide for gvhd prophylaxis after haplo-identical or matched unrelated donor transplants: A phase I/II trial Issa F. Khouri Received Received
  6023-MON TFH subsets in patients after allogenic transplant are dysregulated prior to chronic GVHD development Isabel University Sandner Received Received
  6024-MON Outcomes after bone marrow versus peripheral blood matched unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based gvhd prophylaxis Amna Bint I Munir Received Received
  6025-MON Propensity score matching analysis comparing the efficacy and long-term outcomes of belumosudil to the best available treatment as a historical control, used as second-line therapy or beyond for chronic GVHD after steroid failure. Sergio Rodriguez-Rodriguez Received Received
  6026-MON Real-world effectiveness and safety of belumosudil in pediatric chronic graft-versus-host disease: A retrospective cohort study Min Zhou Received Received
  6027-MON Elevated TIM3 expression on bone marrow T cells drives immune dysfunction in early relapsed blood cancer after allogeneic hematopoietic stem cell transplantation Wonhyoung Seo Received Received
  6028-MON Donor-derived sars-cov-2-specific T cells to prevent COVID-19 early post allogeneic hematopoietic stem cell transplant Zara Hasnani Received Received
  6029-MON Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors Roni Tamari Received Received
  6030-MON Comparative efficacy and safety of ruxolitinib and remestemcel-l in the treatment of steroid-refractory acute graft-versus-host disease: Systematic review and meta-analysis Karthik Sai Makineni Received Received
  6031-MON Propensity score matching analysis comparing the efficacy and treatment outcomes of belumosudil treatment with ruxolitinib therapy as second-line or beyond in chronic GVHD patients after steroid failure Sergio Rodriguez-Rodriguez Received Received
  6032-MON Treatment of steroid-refractory acute graft-versus-host disease by mesenchymal stromal cells: The francophone society of bone marrow transplantation and cellular therapy (SFGM-TC) experience in 43 patients Ludovic Jondreville Received Received
  6033-MON Chronic graft-versus-host disease after haploidentical transplantation in aplastic anemia: Clinical characteristics, risk factors, and survival outcomes Minghao Lin Received Received
  6034-MON VIP pathway inhibition alters microbial metabolism to balance graft-versus-leukemia and gvhd Kayla Robinson Received Received
  6035-MON ACCELERATE: A platform protocol to investigate post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in patients with hematologic malignancies undergoing mismatched unrelated donor peripheral blood stem cell transplantation Stephen R. Spellman Received Received
  6036-MON Physical activity in patients undergoing hematopoietic stem cell transplantation Lauren Paige Waldman Received Received
  6037-MON Secondary malignancies after hematopoietic cell transplantation for sickle cell disease: A single-center experience Mohsen Alzahrani Sr Received Received
  6038-MON Incidence and risk factors for CNS relapse in adult ALL after allogeneic hematopoietic cell transplant Catherine Thuy Khanh Le Received Received
  6039-MON Impact of infectious complications on outcomes after allogeneic hematopoietic stem cell transplantation in elderly patients: A geth-TC study Sara Fernandez-Luis Received Received
  6040-MON Spatial asymmetry of blasts in bone marrow after hematopoietic stem cell transplantation for AML/MDS Ruowen Wei Received Received
  6041-MON Prognostic analysis of salvage allogeneic HCT in acute leukemia patients relapsing after autologous HCT: a study from the acute leukemia working party of the EBMT Mingyang Wang Received Received
  6042-MON Living the recovery: One-year qol outcomes for patients receiving ptcy gvhd prophylaxis on the access clinical trial Rachel Cusatis Received Received
  6043-MON Nelarabine treatment before allogeneic stem cell transplantation was associated with an increased risk of neurological adverse events in patients with T-ALL/lbl: A retrospective study of the kanto study group for cell therapy. Kaori Kondo Received Received
  6044-MON Real-world outcomes with blinatumomab as a bridging therapy for allogeneic hematopoietic stem cell transplantation in relapsed/refractory or measurable residual disease-positive B-cell acute lymphoblastic leukemia: A CIBMTR database analysis Wael Saber Received Received
  6045-MON Thrombotic thrombocytopenic purpura after allogeneic hematopoietic cell transplantation: A rare but fatal complication. Zhixue Li Received Received
  6046-MON Novel insights from the largest cohort to date: Elucidating risk factors, clinical outcomes, and prognostic predictors in autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation Liqian Zhang Received Received
  6047-MON Outcomes and risk factors of second allogeneic hematopoietic stem cell transplantation in patients with relapsed hematological malignancy after first transplantation Xiaolu Zhu Received Received
  6048-MON Factors associated with the development of second primary malignancies after allogeneic stem cell hematopoietic transplantation. no association with In Vivo T-cell depletion Juan Manuel Cerezo-Martin Sr Received Received
  6049-MON Allo-HSCT mitigates the prognostic differences between bZIP and non-bZIP CEBPA mutations in AML: A long-term follow-up study of lu daopei hospital Yanli Zhao Received Received
  6050-MON A longitudinal study on the impact of hematopoietic stem cell transplantation on sickle cardiomyopathy Parul Rai Received Received
  6051-MON The limited impact of preexisting rheumatologic diseases on outcomes after allogeneic hematopoietic stem cell transplantation: A nationwide Propensity–Matched analysis Noirna Tanaka Received Received
  6052-MON Old mismatched donors are associated with inferior outcomes after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome, but not in Acute Myeloid Leukemia Dong Hyun Kim Received Received
  6053-MON Clinical efficacy of allogeneic hematopoietic stem cell transplantation in infant acute leukemia Ruijuan Sun Received Received
  6054-MON Allogeneic hematopoietic stem cell transplantation for myelofibrosis; Patterns, treatment and outcome after relapse and long-term follow up. Avichai Shimoni Received Received
  6055-MON Social determinants of health and late mortality among allogeneic blood or marrow transplant (BMT) survivors: A BMTSS report Aman Wadhwa Received Received
  6056-MON Clinical features and prognostic model for adenovirus infection following allogeneic hematopoietic stem cell transplantation: Insights from a Chinese cohort Jiaxin Zhang Received Received
  6057-MON Post-transplant FLT3 inhibitor maintenance is associated with improved survival in FLT3-ITD positive acute myelogenous leukemia irrespective of pre-transplant MRD status Tamer Othman Received Received
  6058-MON Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD anderson symptom inventory (MDASI-BMT) Portia Smallbone Received Received
  6059-MON Single-center retrospective analysis of maribavir in the treatment of refractory and drug-intolerant cytomegalovirus viremia and cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation Wei Ma Jr Received Received
  6060-MON Multicenter propensity score matched study on allogeneic stem cell transplantation in adult sickle cell disease: Comparison of donor vs. no donor outcomes Can Boga Received Received
  6061-MON Safety and efficacy of blinatumomab for EBV viremia and PTLD following allogeneic hematopoietic stem cell transplantation Yunchao Su Received Received
  6062-MON A novel protocol of dual passing cord blood pre-/post-transplant reduced relapse in TCRaß cell depleted HCT Huaying Liu Received Received
  6063-MON Letermovir prophylaxis for cytomegalovirus and immune reconstitution after allogeneic hematopoietic stem cell transplantation: A single-center real-world study Xueyao Li Received Received
  6064-MON Characterization of patients with restrictive patterns of lung disease following allogeneic hematopoietic stem cell transplantation Gunjan Gaur Received Received
  6065-MON Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT Arnon Nagler Received Received
  6066-MON Outcomes of 544 patients with t(6;9) Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation: An EBMT Study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP) Fabio Andreozzi Received Received
  6067-MON The impact of additional cytogenetic abnormalities and complex karyotype on outcomes of adult patients with Philadelphia-positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in first complete remission: A study from the AL Arnon Nagler Received Received
  6068-MON Pacritinib in transplant-eligible myelofibrosis: Final analysis of the phase 2 HOVON-134 trial Ruben Van Dijck Received Received
  6069-MON Next-generation sequencing-based mutation profile in secondary compared to de novo acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: A study from the ALWP/EBMT Arnon Nagler Received Received
  6070-MON Younger donors, better outcomes: The impact of donor age in haploidentical transplantation for acute myeloid leukemia. study conducted on behalf of geth-TC Daniel Munárriz Lorca Received Received
  6071-MON Mutational patterns and prognosis in younger versus older AML patients with myelodysplasia-related gene mutations undergoing allogeneic hematopoietic stem cell transplantation Yu Wang Received Received
  6072-MON Microbiome and cytokine features are associated with graft-versus-host disease incidence in allogeneic hematopoietic cell transplantation patients Antonio Luiz LC Cruz Gomes Received Received
  6073-MON Molecular stratification of relapse risk post-allogeneic hematopoietic stem cell transplantation in myeloid neoplasms with non-adverse risk cytogenetics Khalid Abu-Zeinah Received Received
  6074-MON Allogeneic hematopoietic stem cell transplantation outcomes in pediatric acute lymphoblastic leukemia: A multicenter analysis from the cccg-ALL-2015 protocol Xiaohang Huang Received Received
  6075-MON Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes Alexandre Bazinet Received Received
  6076-MON Refined elderly comorbidity index is highly predictive of post-transplant survival in older adults with Acute Myeloid Leukemia and myelodysplastic syndrome Fnu Amisha Received Received
  6077-MON Pre-transplant CAR T-cell therapy is associated with inferior survival and increased non-relapse mortality in pediatric B-ALL: A single-center retrospective analysis Rozalyn Chok Received Received
  6078-MON The efficacy of short-course blinatumomab immunotherapy as a bridge-to-HSCT in ph-negative B-cell acute lymphoblastic leukemia xia Shao Received Received
  6079-MON Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party Nour Moukalled Received Received
  6080-MON Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation Yuhua Ru Received Received
  6081-MON Utilisation of machine learning algorithms to predict relapse risk following allogeneic stem cell transplantation (alloSCT) for patients with myeloid malignancies Ray Mun Koo Received Received
  6082-MON IDH2 R172 mutation is associated with improved survival in IDH-mutated AML/MDS patients undergoing allogeneic stem cell transplantation: A geth-TC multicenter study Ana Perez Gonzalez Received Received
  6083-MON Improved outcomes following allogeneic hematopoietic stem cell transplantation in patients with DDX41-mutated myeloid neoplasms: A prospective analysis of survival, GVHD, and transplant-related mortality Shreyas Hanmantgad Received Received
  6084-MON Novel machine learning (ML) and traditional statistical techniques in survival analysis of real-world data for allogeneic hematopoietic cell transplantation (HCT) consolidation in patients with acute lymphoblastic leukemia (ALL) John Behman Received Received
  6085-MON Comparable outcomes in patients aged =70 vs. Howard Chang Received Received
  6086-MON MO-TRANS update: A randomized, double-blind, placebo-controlled, multi-center phase III study of mocravimod (MOC) as maintenance treatment in AML patients undergoing allogeneic hematopoietic cell transplantation Marcos de Lima Received Received
  6087-MON Lentiviral vector transduced autologous CD34+ cells with FVIII transgene for gene therapy of Hemophilia A with history of inhibitors Alok Srivastava V Received Received
  6088-MON Preliminary safety and efficacy of anti-CD19/CD20 bispecific CAR-T cell therapy (JWCAR201) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: Results from an ongoing phase I study Wenhao Zhang Jr Received Received
  6089-MON Correction of ineffective erythropoiesis and durable clinical benefit with exagamglogene autotemcel for transfusion-dependent ß-thalassemia Franco Locatelli Received Received
  6090-MON Rapid, efficient and durable fetal hemoglobin production following CS-101 treatment in transfusion-dependent ß-thalassemia participants: An autologous, ex vivo edited CD34+ stem cell product using the innovative transformer base editor (tBE) Jia Chen Received Received
  6091-MON An engineered AAVrh10 vector containing an optimized factor IX transgene improves therapeutic response during hemophilia b gene therapy Shamshul Huda Received Received
  6092-MON Lentiviral hematopoietic stem and progenitor cell gene therapy with Etuvetidigene autotemcel for the treatment of Wiskott-Aldrich Syndrome Francesca Ferrua Received Received
  6093-MON Elevation of liver health biomarkers before and after etranacogene dezaparvovec gene therapy in hemophilia B: Associations with long-term clinical outcomes Wolfgang Miesbach Received Received
  6094-MON Highly efficient collection and manufacture of autologous HSC gene therapy cell product for patients with sickle cell disease using a lentiviral vector containing a shmir targeting BCL11a John P Manis Received Received
  6095-MON A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model Pamela De Falco Received Received
  6096-MON Apheresis blood processing with heparin improves stem cell collection outcomes for sickle cell gene therapy David Justus Received Received
  6097-MON Targeted lnp delivery of an RNA gene writer In Vivo enables generation of functional CAR-T cells Cecilia Cotta-Ramusino Received Received
  6098-MON Safety and activity of gene therapy with AAV8 GBA1 (LY-M001)on type I adults gaucher disease Weiyan Zheng Received Received
  6099-MON Targeted disruption of BCL11A ZnF4 enhances fetal hemoglobin in ß-thalassemia and sickle cell disease: A druggable approach Safana Farooq Received Received
  6100-MON Developing SEMA4A-directed CAR t cells to overcome low BCMA antigen density in multiple myeloma Francesca Albano Received Received
  6101-MON Inhibition of the aryl hydrocarbon receptor eliminates leukemia stem cells in murine models of Acute Myeloid Leukemia Alyona Oryshchuk Received Received
  6102-MON Upregulation of BCMA expression by selinexor Christina Mathilde Verbruggen Received Received
  6103-MON F1 subunit-specific ATP synthase inhibition disrupts AML mitochondrial metabolism distinctly from other electron transport chain inhibitors Matthew T Villaume Received Received
  6104-MON Synergistic antitumor effects and mechanisms of KPT-330 combined with venetoclax in Acute Myeloid Leukemia Yifan Liu Received Received
  6105-MON New class of dual agonistic T-cell engagers for the in-patient activation and expansion of v delta 1 T cells with broad antigen agnostic antitumour activity Andre Simoes Received Received
  6106-MON GB3226, a novel, orally active, first-in-class small molecule inhibitor of ENL-yeats and FLT3 kinase for the treatment of Relapsed/Refractory Acute Myeloid Leukemia Louis M Renzetti I Received Received
  6107-MON A multifunctional nanoplatform for ferroptosis inducing/chemo/photothermal therapy enhances therapeutic effect and prevents adverse gastrointestinal reaction of methotrexate Mengyao Wang Received Received
  6108-MON Selective degradation of oncogenic signaling nodes by momelotinib-based protacs exerts potent anti-leukemic response in B-ALL, AML, and MF while sparing normal cells Joshua Schwieterman Received Received
  6109-MON High-throughput screening uncloaks actionable compounds for ttmv::rara AML Zhanrui Cheng Received Received
  6110-MON Long-read whole genome sequencing improves clinical management in acute leukemia Anna Lux Received Received
  6111-MON Novel insights in therapeutic antibody therapies using advanced microscopy techniques Christina Mathilde Verbruggen Received Received
  6112-MON Deep learning enables automated quantification of hematopoietic stem and progenitor cells (HSPCs) in zebrafish embryos Xavier Emmett Vesco Received Received
  6113-MON AI-driven platform voyager identifies a novel poison exon and splicing modulator to target specific degradation of STAT1 Craig Michael Forester Received Received
  6114-MON Comparing the accuracy of natural language processing labelling versus manual chart review and ICD-10 codes to identify bleeding events in patients with cancer Thomas Francis Fusillo Received Received
  6115-MON Hematobot: Retrieval-augmented large language model-based assistants for therapy, toxicity and frailty management in multiple myeloma by the spanish society of hematology and hemotherapy (SEHH) Marta Sonia Gonzalez Perez Received Received
  6116-MON Machine learning accurately predicts mortality in adult NPM1-mutant Acute Myeloid Leukemia using baseline clinical and genomic features Rahul Thakur Received Received
  6117-MON Long-read single-cell isoform sequencing for cell type-specific detection of genomic rearrangement-dependent and -independent fusion transcripts Wencke Walter Received Received
  6118-MON ML-driven analysis of iscn karyotypes enables detection of novel prognostic markers in chronic lymphocytic leukemia (CLL) Alessandro Baldi Received Received
  6119-MON Detecting lineage-specific regulatory activity and stemness retention in single-cell multiomics of human hematopoiesis Cailin Jordan Received Received
  6120-MON Development of whole blood viscosity measurements under hypoxia for use in sickle cell disease Mary C Aliche Received Received
  6121-MON Targeted long-read sequencing with adaptive sampling in multiple myeloma: A pilot study toward a unified diagnostic platform Beñat Ariceta Received Received
  6122-MON Automated AI classification in clinical flow cytometry: Transforming B-cell lymphoma diagnostics Chrysanthi Tsamadou Received Received
  6123-MON Machine learning–based detection model for leukemia cells in peripheral blood smears using YOLOv11-large Johan M. Diaz Received Received
  6124-MON Predicting genetic alterations in Acute Myeloid Leukemia through AI-based analysis of bone marrow morphology David Bermejo-Peláez Received Received
  6125-MON Pre-chemotherapy microbiome dysbiosis in hematologic malignancies Chepsy C Philip Received Received
  6126-MON Readability & quality of large language model responses in CAR-T patient education Shiva Balasubramanian Received Received
  6127-MON Varaser : Genetic individual identification free from direct raw data sharing TAEK GYU LEE Received Received
  6128-MON Automated subtype classification of acute leukemia from bone marrow smears using a cross-platform deep learning model Guangqi Wang Received Received
  6129-MON Clinical and technological validation of locally-installed, privacy-compliant, and hematology-tailored ambient AI platform for clinical report transcription assistance and clinical trial patient management Mattia Delleani Received Received
  6130-MON Whole genome sequencing uncovers novel BCR::ABL1 breakpoints and variants in leukemia: Implications for personalized medicine Robert Huether Received Received
  6131-MON AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning Andre De Menezes Silva Corraes Received Received
  6132-MON Marvin: Deep generative model with structured latent space for flow cytometry cell classification and discovery of new population Adrien De Voeght Sr Received Received
  6133-MON From co-occurrence to mutual exclusivity: Long read single-cell rnaseq atlas of healthy human bone marrow unveils RNA isoform landscape Elana Thieme Received Received
  6134-MON A novel random survival forest model for adult NPM1-mutated Acute Myeloid Leukemia patients Yiyi Yao Received Received
  6135-MON Quantitative real-time polymerase chain reaction coupled with high-resolution melting (HRM) for simultaneous detection and quantification of four isoforms of BCR::ABL1 Ayman Mohamed Received Received
  6136-MON Use of red cell deformability measurements to assess the impact of pyruvate kinase activators on combined drug and transfusion therapies Abhinav Pasupuleti Received Received
  6137-MON Quantitative ex vivo synergy profiling uncovers heterogeneous combination responses in AML primary samples Jamin Koo Received Received
  6138-MON Regional hypometabolism on brain FDG-PET one month after receiving chimeric antigen receptor T-cell therapy may be associated with icans Jian Li Received Received
  6139-MON Large language model for abstraction of CAR-T therapy toxicities data Kayla Rose Joseph Received Received
  6140-MON Real-time multimodal AI outperforms conventional scores for early risk prediction in BCMA CAR-T–Treated myeloma Ciara Louise L Freeman Received Received
  6141-MON cfDNA analysis for assessing spatial genomic heterogeneity in multiple myeloma with high metabolic uptake on PET/CT Hee Jeong Cho Received Received
  6142-MON A universally accessible residual Network–Assisted diagnostic and analytic tool (RADIANT) for acute lymphoblastic leukemia Gowrishankar Palaniswamy Received Received
  6143-MON Evaluation of large language models in lymphoma clinical scenarios: A comparative analysis Mengyao Wang Received Received
  6144-MON Polysubstance use and treatment disparities among hospitalized sickle cell disease patients: A nationwide analysis Fiqe Khan Received Received
  6145-MON Newborn screening for sickle cell disease in a hospital setting in luanda, Angola: Local implementing learning from an international consortium Miguel Brito Received Received
  6146-MON Financial and clinical implications of xromi as a new commercial liquid formulation of hydroxyurea Lydia Musula Received Received
  6147-MON Electronic heath record phenotypes to classify sickle cell anemia versus other subtypes of sickle cell disease in the ASH RC data hub John Joseph Strouse Received Received
  6148-MON Evolving annual community health worker time allocation to maximize sickle cell disease medical home efficiency Shirley A Johnson Received Received
  6149-MON Implementation challenges of the learner clinical trial in pregnant women with sickle cell disease in Angola Miguel Brito Received Received
  6150-MON Impact of voxelotor discontinuation on patients with sickle cell disease Jin Han Received Received
  6151-MON Healthcare costs associated with hematopoietic cell transplant for sickle cell disease in the United States and Canada: A comparative analysis Jaspreet Gharial Received Received
  6152-MON Redefining what "on Hydroxyurea" means Neha Bhasin Received Received
  6153-MON Decisions about gene therapy do not occur in isolation: Co-development of a website about treatment options for sickle cell disease Liza-Marie Johnson Received Received
  6154-MON Closing the gap in vaso-occlusive episode triage for sickle cell patients: A quality improvement initiative Saumya Easaw Received Received
  6155-MON Addressing institutional barriers in sickle cell pain management: A resident-led quality improvement study Dhara Popat Received Received
  6156-MON In-hospital outcome of first-time acute chest syndrome in patients with preexisting pulmonary hypertension: A nationwide analysis 2016-2022 Abdi Fite Received Received
  6157-MON Trends in collecting health-related quality-of-life measures among hematology gene therapy clinical trials Hae Lin Cho Received Received
  6158-MON Feasibility and impact of rapid newborn screening for sickle cell disease in Tanzania: Results from the tabora region pilot program (SickleCare) Amon Ryakitimbo Received Received
  6159-MON Building healthcare professional capacity in sickle cell disease through a global case-based discussion program Ombeni Moses Idassi Received Received
  6160-MON Irregulab: Automated interpretation of irregular antibody panels Davide Crucitti Received Received
  6161-MON primary prophylaxis with direct oral anticoagulants (DOACs) for transwomen taking estrogen is not cost-effective Jorge Nicolas Ruiz Lopez Received Received
  6162-MON Current clinical concerns for patients with hereditary hemochromatosis – a Delphi consensus study Jeremy Shearman Received Received
  6163-MON Prospective observational cohort study to collect granular social determinants of health data for hematopoietic cell transplant patients Warren Benjamin Fingrut Received Received
  6164-MON High versus low-cost intravenous iron in Medicare: Utilization patterns of iron infusions in traditional fee-for-service Medicare and Medicare advantage for iron deficiency anemia T. Anders Olsen Received Received
  6165-MON Utility of diagnostic bone marrow examinations for cytopenias and impact on clinical management: A practice audit Nina Castrogiovanni Received Received
  6166-MON Construction and validation of a prediction model for extracorporeal circuit clotting risk during regional citrate anticoagulation in continuous renal replacement therapy for critically ill patients with hematological disorders Jian Zhang Received Received
  6167-MON Toxicity and efficacy profile of cardioprotective vs conventional doxorubicin: A meta-analysis Evani Jain Received Received
  6168-MON Direct oral anticoagulation management to address primary and secondary adherence in atrial fibrillation Surbhi Shah Received Received
  6169-MON Lower dose emicizumab prophylaxis in children with hemophilia A: Real - world outcomes , hemostatic profiles and cost- effectiveness from a resource limited setting Lincy Paul Received Received
  6170-MON Effect of duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors Grace M Ferri Received Received
  6171-MON Impact of iron deficiency anemia on outcomes in postpartum hemorrhage: Insights from a national inpatient sample analysis Kalaivani Babu Received Received
  6172-MON Systematic review on the diagnostic evaluation of pediatric evans syndrome Kirsty Hillier Received Received
  6173-MON An implementation science approach to optimize adoption of hematopoietic cell transplant survivorship care plans Dekozlymn Anderson Received Received
  6174-MON Cost analysis compared with efficacy shows iron dextran surpassing other intravenous iron formulations in children: A tertiary children´s hospital experience Reeja Raj Received Received
  6175-MON Optimizing classical hematology referrals: Development and early evaluation of an enhanced referral intervention Ashley Price Received Received
  6176-MON Improving bone marrow biopsy core length and aspirate adequacy through implementation of a powered device: A single-institution quality improvement initiative Chidambaram Ramasamy Received Received
  6177-MON Increasing guideline-based anti-emetic prophylaxis for chemotherapy-induced nausea/vomiting within a quaternary pediatric hospital Mira Kaur Bhatia Received Received
  6178-MON Cost-effectiveness analysis of mosunetuzumab compared with novel alternative immunotherapies in patients with third-line or later relapsed/refractory follicular lymphoma in Japan Ritsuro Suzuki Received Received
  6179-MON Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) preferred fixed-duration treatments with less frequent administrations in the era of novel bispecific antibodies (BsAbs) Zachary A.K Frosch Received Received
  6180-MON Diverse preferences for treatment options in relapsed/refractory (R/R) follicular lymphoma (FL): Survey results from patients in the United States (US) Krish Patel Received Received
  6181-MON Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: Impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymp Ajay Major Received Received
  6182-MON Understanding secondary immunodeficiency management in patients with hematological malignancies Adil Adatia Received Received
  6183-MON Optimizing processes for adverse event management for bispecific antibodies for diffuse large b-cell lymphoma in community practice: Insights from a quality improvement initiative Krish Patel Received Received
  6184-MON Clinical implications and prevalence of benign ethnic neutropenia (BEN) in lymphoma patients of middle eastern ethnicity Atef Shehata Received Received
  6185-MON The exact system for precision clinical trial matching: Case study of accuracy with follicular lymphoma trials Adam Blum Received Received
  6186-MON Ensuring equitable access to bispecific antibodies in multiple myeloma: Findings from the emmbrace patient and public involvement and engagement (PPIE) sessions. Dunsi Bolarinwa Received Received
  6187-MON Optimizing time to IV methotrexate initiation for planned admissions to the inpatient hematology/oncology service Sean Maximillian Taasan Received Received
  6188-MON Reassessing pre-chemotherapy laboratory testing in R-CHOP: Are we doing too much? Mohamed Warsame Received Received
  6189-MON A pre-admission chemotherapy checklist: Improving timeliness of chemotherapy initiation in a malignant hematology inpatient unit Nina Margaret Dambrosio Received Received
  6190-MON Title: Clinical trial availability and receipt of guideline concordant care among adolescents and young adults (AYAs) with acute lymphoblastic leukemia Julie A. Wolfson Received Received
  6191-MON Mortality trends in patients with co-occurring hematologic malignancies and heart failure in the United States population: A 25-year analysis using the CDC wonder database Vedant Shah Received Received
  6192-MON Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model Beatriz Merchan Muñoz Jr Received Received
  6193-MON Access to diagnostics, therapies, and advanced care for lymphoma in Latin America: A multicenter, survey-based study Perla R. Rocío Colunga-Pedraza I Received Received
  6194-MON US cost consequence and time toxicity model for advanced therapies in the treatment for Relapsed/Refractory third-line or later diffuse large B-cell lymphoma: A comparison of axicabtagene ciloleucel with bispecific antibodies Olalekan Oluwole Received Received
  6195-MON Implementation and utility of measurable residual disease (MRD) testing for multiple myeloma patients at a VA medical center Courtney Eng Received Received
  6196-MON Evaluating the efficacy of montelukast in reducing the incidence and severity of monoclonal antibodies-associated infusion reactions (Phase II Study) Omar Cancer Mahmood Received Received
  6197-MON Cost-effectiveness of frontline blinatumomab in children with standard-risk B-cell acute lymphoblastic leukemia in Ontario, Canada Alexandra Moskalewicz Received Received
  6198-MON Integrating bispecific antibodies into VA oncology care: A multidisciplinary protocol and education model from visn 20 Nicholas Burwick Received Received
  6199-MON Lessons learned from the clinical trial portfolio of ixazomib in multiple myeloma: A systematic review and meta-analysis Darshi Shah Received Received
  6200-MON Artificial intelligence -driven GVHD scoring and response tracking: Advancing FACT compliance, clinical trial readiness, and evidence-based therapy in a transplant program Mayada Abu Shanap Sr Received Received
  6201-MON Barriers to CAR-T cell therapy implementation in community practices: A national survey of hematologists Maria Silvina Odstrcil Bobillo Received Received
  6202-MON Evaluation of CAR-T access barriers in Washington and Alaska: A single-center experience prior to implementing program capacity expansion Melinda Biernacki Received Received
  6203-MON Impact of apheresis-to-infusion interval on outcomes and toxicity of CAR-T therapy in relapsed/refractory DLBCL Ajinkya Buradkar Received Received
  6204-MON Improved outcome of patients with acute myeloid leukemia treated by a dedicated leukemia service in a community hospital Maria Magdalena Sbenghe Received Received
  6205-MON Impact of interhospital transfer on inpatient outcomes in Acute Myeloid Leukemia Abdulmalek Aljafari Received Received
  6206-MON "I feel like I´m being recognized as being a part of his treatment": Caregiver perspectives of the serious illness care program for older patients with hematologic malignancies Jessica Cohen Received Received
  6207-MON Healthcare resource utilization and cost of molecular targeted versus non-targeted therapies in acute myeloid leukemia Pierantonio Russo Received Received
  6208-MON Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy Cameron J Hunter Received Received
  6209-MON AI-powered precision: Unmasking hidden treatment optimizations for lower-risk myelodysplastic syndrome patients based on real-world, multi center EHR data. Marek Dudzinski Received Received
  6210-MON Global, regional, and national trends in the burden of chronic myeloid leukemia from 1990 to 2021: A comprehensive analysis of the 2021 global burden of disease study and projections to 2050 Qinglin Hu I Received Received
  6211-MON Age-related left-digit bias in selection of patients referred for autologous and allogeneic hematopoietic transplantation: An analysis of 877 patients referred to a single center Asad Bashey Received Received
  6212-MON Upfront comprehensive donor search overcomes the impact of poor search prognosis, irrespective of racial background Fei Fang Received Received
  6213-MON Machine learning-based cost prediction in pediatric allogeneic bone marrow transplantation: Development and validation of an interactive clinical decision support tool Mayada Abu Shanap Sr Received Received
  6214-MON Frailty as a prognostic factor in younger adult patients with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation Sergio Rodriguez-Rodriguez Received Received
  6215-MON Chest imaging prior to allogeneic bone marrow transplant: A retrospective study of pre-transplant workup outcomes Zoe Gunthert Received Received
  6216-MON Treatment disparities in sickle cell disease among patients with asymptomatic HIV Fiqe Khan Received Received
  6217-MON Pericapsular nerve block and ablation as a novel pain modifying strategy in sickle cell patients wiht refractory hip pain due to avascular necrosis Benjamin Morales Castelan Received Received
  6218-MON Pregnancy outcomes among women with sickle cell disease: A propensity score-matched analysis approach using the national inpatient sample (2017-2022) Mariana Marrero Castillo Received Received
  6219-MON Association between comorbid depression and antidepressant adherence with adherence to disease-modifying therapies in patients with sickle cell disease in Texas Medicaid Blessing I. Okoye Received Received
  6220-MON Transfer and integration into a young adult clinic for sickle cell disease: Stay with me Elizabeth Prince Received Received
  6221-MON Humanistic and economic burden among caregivers of adults and children with transfusion dependent ß-thalassemia Lauren Lilly Received Received
  6222-MON Stability and evolution of individual-level biomarker patterns across repeated vaso-occlusive crises in sickle cell disease Orlando Agrippa Received Received
  6223-MON Influence of cardiovascular co-morbidities on the in-hospital mortality among patients with sickle cell crisis Adithya Nagendran Received Received
  6224-MON The feasibility of collecting social determinants of health in the national multi-center GRASP sickle cell gene therapy trial Colleen A. Kelly Received Received
  6225-MON Sickle cell disease survival analysis at a large United States southern comprehensive sickle cell disease center: 1995 - 2022 Melinda D. Chance Received Received
  6226-MON Reassessing voxelotor safety and efficacy: Real-world outcomes from the ASH research collaborative data hub Omar Niss Received Received
  6227-MON Burden and trends of sickle cell disease in the United States: Insights from the global burden of disease study 2021 Megha Sasidhar Handral Received Received
  6228-MON Feasibility of impementing pre-marital genetic counseling in kano, northern Nigeria using the cfir-eric model Aisha Galadanci Akilu Received Received
  6229-MON Hydroxyurea use does not worsen age-related decline in blood counts in sickle cell disease Parul Rai Received Received
  6230-MON Nutrition needs assessment for sickle cell disease throughout the lifespan Ariana Patel Received Received
  6231-MON Grndma: Initial reports from an adult sickle cell registry in Malawi Luke Eastburg Received Received
  6232-MON Evaluating the risk of non-melanoma skin cancer in patients with porphyria cutanea tarda: A retrospective cohort study using real-world data Ruhi Kanwar Received Received
  6233-MON Paradoxical venous thromboembolism in immune thrombocytopenia : A national study of mortality,anticoagulation gaps and racial disparities Priyanka Nagdev Received Received
  6234-MON Health state utility values in congenital thrombotic thrombocytopenic purpura (cTTP): A vignette-based valuation Study in the UK general population Harneet Kaur Received Received
  6235-MON Incidence and clinical outcomes of hematologic immune-related toxicities in patients with solid malignancies treated with immune checkpoint inhibitors Andrew Bueno Received Received
  6236-MON Prevalence of iron deficiency in pregnant women with inherited bleeding disorders: A retrospective analysis Gretchen York Received Received
  6237-MON Patient-reported outcomes of avatrombopag for chronic immune thrombocytopenia: Interim analysis of the Phase 4 adopt study Maria Eva Mingot Sr Received Received
  6238-MON Real-world analysis of ravulizumab safety and effectiveness in advanced age patients with paroxysmal nocturnal hemoglobinuria: Insights from the international PNH registry Shreyans Gandhi Received Received
  6239-MON Prevalence and demographics of autoimmune hemolytic anemia in the United States Louis Jackson Received Received
  6240-MON Mortality patterns and geographic variation in acquired hemophilia A among Medicare beneficiaries in the United States Tinatin Muradashvili Received Received
  6241-MON Real world evidence of treatment patterns in hereditary hemorrhagic telangiectasia Kristy Pahl Received Received
  6242-MON Real-world safety of sutimlimab in patients with CAD/CAS: A multinational, multi-center, observational, prospective cohort Study Alexander Röth Received Received
  6243-MON Survival outcomes of patients with secondary hemophagocytic lymphohistiocytosis at two academic medical centers in the United States Catherine Broome Received Received
  6244-MON Mortality trends in patients with co-occurring chronic kidney disease and venous thromboembolism in the United States: A 25-year CDC wonder analysis (1999–2023) Nayanika Tummala Received Received
  6245-MON Sustained improvements in patient-reported outcomes after intravenous efgartigimod in adults with primary immune thrombocytopenia in a Phase 3 clinical trial (ADVANCE IV) and the first 52 weeks in its open-label extension study (ADVANCE IV+) Monica Carpenedo Received Received
  6246-MON Complete blood count monitoring for patients on anticoagulation with direct oral anticoagulants for atrial fibrillation and/or venous thromboembolism. Jordan K Schaefer Received Received
  6247-MON Association of opioid use disorder and thrombotic events in hospitalized patients: A national inpatient database study Kristy Rose Bono Received Received
  6248-MON Clinical outcomes associated with opioid use disorder in hospitalized patients with venous thromboembolism Kristy Rose Bono Received Received
  6249-MON A US retrospective observational Study of rituximab initial and retreatment in patients with warm autoimmune hemolytic anemia (wAIHA) Irina Murakhovskaya Received Received
  6250-MON Transfusion without fear: Real-world outcomes in warm autoimmune hemolytic anemia challenge historical hesitations Emmanuel Nsa Ekpenyong Received Received
  6251-MON Real-world treatment patterns and clinical outcomes of therapies in primary immune thrombocytopenia Sandhya Panch Received Received
  6252-MON Pulmonary Embolism–Attributable mortality among patients with breast cancer in the United States, 1999-2021 Candrika Dini Khairani Received Received
  6253-MON Clinico-pathological profile and treatment patterns of immune mediated aplastic anemia in resource constrained settings – an analysis from the aplastic anemia registry of India Biju George Received Received
  6254-MON Quality of life and symptom burden in PNH: A real-world study on the impact of treatment access Lyam Carlo Chacon Rangel Received Received
  6255-MON Immune checkpoint inhibitor–associated cytopenias: A decade of real-world signal detection from faers (2014–2025) Kashish Magnani Received Received
  6256-MON Real-world outcomes of sutimlimab in cold agglutinin disease: A multicenter trinetx analysis Shanawar Ali Waris Received Received
  6257-MON The impact of immune thrombocytopenia on oral health: Let´s talk Deirdra Terrell Received Received
  6258-MON Increased prevalence of anemia among recently immigrated female South Asian college students: A cross-sectional study from three primary care clinics in a college town Amruth Akhil Alluri Received Received
  6259-MON Real-world overall survival and time to next treatment among elderly United States Medicare beneficiaries with chronic lymphocytic leukemia in the front-line setting Scott Huntington Received Received
  6260-MON Racial and ethnic disparities in the risk of second primary malignancies among diffuse large B-cell lymphoma survivors in the United States Pallawi Torka Received Received
  6261-MON Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma Adam Braun Received Received
  6262-MON Barriers and bridges: Real-world CAR T delivery across US oncology practices Taiga Nishihori Received Received
  6263-MON Beyond the trial: Real-world CRS, icans, and healthcare burden of CAR T-cell therapy across US oncology practices Taiga Nishihori Received Received
  6264-MON Impact of frailty in survival of older patients with classical Hodgkin lymphoma: A retrospective, multicenter study from the spanish registry of lymphoma (RELINF) of the spanish group of lymphoma (GELTAMO) Raul Cordoba Received Received
  6265-MON Patient characteristics and treatment outcomes with Pola-R-CHP: A real-world study of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in the United States (US) Patrick M Reagan Received Received
  6266-MON Geriatric assessment in hematology (GAH) scale for survival prognostication and early treatment discontinuation in older adults: Final results from the spanish hematogeriatric registry Isabel González-gascón-y-Marín Received Received
  6267-MON National health systems characteristics and lymphoma outcomes: A global analysis Héctor Alejandro Vaquera Alfaro Received Received
  6268-MON Patterns of palliative care utilization across health sectors in patients with aggressive non-Hodgkin lymphoma. Joanne M Britto Received Received
  6269-MON Mortality trends of chronic lymphocytic leukemia and pneumonia in the United States (1999–2023): A CDC-wonder analysis Rehan Ishaque Received Received
  6270-MON Real-world evaluation of health care resource utilization, clinical effectiveness, and safety of lisocabtagene maraleucel and axicabtagene ciloleucel administered in the outpatient (OP) setting for R/R large B-cell lymphoma (LBCL) John Baird Received Received
  6271-MON Association between pre-existing mental health history and higher risk of mental health outcomes post-CAR-t therapy in patients with hematologic malignancies Heidi Cho Received Received
  6272-MON CAR T cell therapy referral patterns and characteristics of patients with relapsed or refractory (R/R) large B cell lymphoma (LBCL) in the United States Mazyar Shadman Received Received
  6273-MON Disparities in survival and therapy access in AYA acute lymphoblastic leukemia: A real-world analysis of social determinants in a low- and middle-income country Fausto Rios-Olais Received Received
  6274-MON Advancing strategies to improve chemotherapy adherence in young children with ALL: Understanding the role of behavioral parenting skills and daily barriers to identify novel intervention targets Elizabeth Bouchard Received Received
  6275-MON Progression-free survival in patients with low health-related quality of life treated with zanubrutinib versus ibrutinib monotherapy: Post hoc analysis of the ALPINE trial Loic Ysebaert Received Received
  6276-MON Baseline characterization of nutrition counseling and modifiable cardiovascular risk factors among childhood cancer survivors through EHR-linked data analytics Manuel Gonzales Received Received
  6277-MON R-mini-CHOP preserves efficacy and limits toxicity for patients = 80 years old with DLBCL Paul M. Barr Received Received
  6278-MON The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy Fabio Efficace Received Received
  6279-MON Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: Results from a prospective observational study Fabio Efficace Received Received
  6280-MON Treatment funding source and educational level are important prognostic factors for patients with diffuse large B-cell lymphoma in the state of São paulo, Brazil: Analysis of a large real-world data. Guilherme Duffles Sr Received Received
  6281-MON Socioeconomic disadvantage, as measured by area deprivation index (ADI), impacts survival in patients with relapsed/refractory aggressive lymphoma treated with CART Daniel Antonio Received Received
  6282-MON Axicabtagene ciloleucel versus tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma Jia Yi Tan Received Received
  6283-MON Changes in real-world treatment patterns over time by patient characteristics and time burden of treatment in CLL/SLL Mengyang Di Received Received
  6284-MON Outcomes of inpatient and outpatient chimeric antigen receptor T-cell therapy (CAR T) in newly authorized treatment centers (ATCs) in the United States (US) Olalekan Oluwole Received Received
  6285-MON Initial performance of pirtobrutinib: Real-world outcomes among CLL patients after prior covalent-BTKi and BCL2i use Rushir Choksi Received Received
  6286-MON Evaluation of real-world outcomes among CLL patients based on sequencing of BTKi and BCL2i therapies Taral Patel Received Received
  6287-MON Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study Andrea Visentin Received Received
  6288-MON Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India. Rahul Purwar Received Received
  6289-MON Rehabilitation needs and predictors of functional outcomes following CAR T-cell therapy in lymphoma and multiple myeloma Hanan Alharthy Received Received
  6290-MON Improved survival in Philadelphia Chromosome–Positive acute lymphoblastic leukemia with pre-transplant second- and third-generation TKIs and post-transplant prophylactic maintenance: A study from the EBMT ALWP Iman Abou Dalle Received Received
  6291-MON Association between adolescent and young adult (AYA) age, acuity of illness at diagnosis, and clinical trial enrollment among patients with hematologic malignancies at a pediatric center Joshua Peter Muniz Received Received
  6292-MON Survival after first relapse of pediatric B-ALL differs by insurance type: A real-world analysis from the recall-1 study Katherine T. Lind Received Received
  6293-MON Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study Pengpeng Xu Sr Received Received
  6294-MON Prior bendamustine exposure does not compromise clinical outcomes of bispecific antibody therapy in patients with relapsed/refractory non-Hodgkin lymphoma: A cubic consortium analysis Annie Xiao Received Received
  6295-MON Propensity score matched comparison of outcomes following treatment with pola-R-CHP versus R-CHOP for diffuse large B cell lymphoma patients captured in a real-world database Dillon M Voss Received Received
  6296-MON Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin´s lymphoma Richard J. Lin Received Received
  6297-MON Persistent B-cell aplasia predicts late severe infections after anti-CD19 CAR T-cell treatment in B-cell lymphoma : A methodological approach to long-term safety reporting Remi Tilmont Received Received
  6298-MON Real world epidemiological trends in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), England 2014-2021: Preliminary data from the uncover Study group Indrani Karpha Received Received
  6299-MON PET imaging biomarkers predict survival in peripheral T-cell lymphoma: A systematic review and meta-analysis. Lohitha Dhulipalla Received Received
  6300-MON Ocular-adnexal non-Hodgkin lymphoma among hispanic Latino population: 18 years of experience Camila Amado Rottier Received Received
  6301-MON A post-marketing pharmacovigilance analysis of cardiotoxicities following chimeric antigen receptor T-cell therapy using the FDA adverse event reporting system Malvika Gupta Received Received
  6302-MON Intrathecal chemotherapy for management of immune effector cell-associated neurotoxicity syndrome (ICANS): A multi-center, real-world analysis of clinical outcomes Adam Kidwell Received Received
  6303-MON Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis He Li Sr Received Received
  6304-MON Real-world experience with varnimcabtagene autoleucel (murine CD19 CAR-T) from India: A step towards enhanced patient access with excellent safety and efficacy Anil Kamat Received Received
  6305-MON Golidocitinib combination therapy as first-line treatment in PTCL: Retrospective data from a single centre Wenyu Li Received Received
  6306-MON Prognostic factors and therapeutic outcomes in neurolymphomatosis: A 22-year cohort study from Mayo Clinic Ayo Samuel Falade Received Received
  6307-MON Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival Yanping Sun Received Received
  6308-MON Racial and ethnic disparities in u.S. chronic lymphocytic leukemia clinical trial enrollment: A participation-to-prevalence analysis Anushka Bhaskar Received Received
  6309-MON Risk of hepatitis B virus reactivaton in HBsAg-negative, anti-hbc-positive patients receiving rituximab: A systematic review Rachael Principato Received Received
  6310-MON Incidence and risk factors for immune effector cell-associated neurotoxicity syndrome in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study Aung M Tun Received Received
  6311-MON Patients with burkitt´s lymphoma have a better survival probability if treated in an academic cancer program Carolina Velez-Mejia Received Received
  6312-MON Patterns of care and outcomes in patients with large B-cell lymphoma not treated with full-dose anthracycline regimens: Outcome analysis from the lymphoma epidemiology of outcomes (LEO) prospective cohort study Patrick M Reagan Received Received
  6313-MON Pneumocystis jirovecii pneumonia in patients with hematologic malignancy: Risky business, but for whom? Jared Eckman Received Received
  6314-MON The academic center effect: Better outcomes for patients with DLBCL Carolina Velez-Mejia Received Received
  6315-MON Risk of bleeding in chronic lymphocytic leukemia patients in remission treated with covalent Bruton tyrosine kinase inhibitors and contemporary anticoagulant or antiplatelet drugs: Real-world data analysis Vladimir Otasevic Received Received
  6316-MON Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy Hannah Willis Received Received
  6317-MON Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia Jing-Zhou Hou Received Received
  6318-MON Disparities in access to CAR-T therapy in a Medicaid-predominant population: A Louisiana case study highlighting policy lag Anil Ananthaneni Received Received
  6319-MON Real world experience of anakinra for the treatment of immune effector cell-associated neurotoxicity syndrome in large B-cell lymphoma Rahul Shah Received Received
  6320-MON Comparative safety and efficacy of bendamustine versus fludarabine/cyclophosphamide prior to chimeric antigen receptor- T cell therapy: A systematic review and meta-analysis Muhammad Kashif Amin Received Received
  6321-MON Real-world data of adolescents and young adults with acute lymphoblastic leukemia treated with a modified GMALL protocol in India: Treatment outcomes and challenges Uday Kulkarni Received Received
  6322-MON Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial Chong Wei Received Received
  6323-MON Non-GCB cell of origin leads to inferior outcomes in brazilian diffuse large B-cell lymphoma patients: Bra-DLBCL multicenter registry, retrospective study of over 500 patients Guilherme Fleury Perini Received Received
  6324-MON Survival differences in metropolitan versus nonmetropolitan/rural counties in the US: An analysis according to rural-urban continuum codes (RUCC) in the lymphoma epidemiology of outcomes (LEO) study cohort Mario Ballerini Received Received
  6325-MON Treatment intensity and region of diagnosis affect survival in primary CNS lymphoma in England: A national cohort study from the uncover project. Mark John Bishton Received Received
  6326-MON Early post-infusion cytokine profiling predicts toxicity and outcomes in recipients of NexCAR19 (Actalycabtagene Autoleucel): A pilot study with point-of-care assay integration GOPAL SINHAL Received Received
  6327-MON Race does not impact chimeric antigen receptor T-cell therapy outcomes for multiple myeloma and diffuse large B cell lymphoma Anisha Rajavel Received Received
  6328-MON Impact of holding therapy prior to apheresis on outcomes following CD19 CAR-T cell therapy in large B-cell lymphoma Marina Gomez-Llobell Received Received
  6329-MON Outcomes of outpatient chimeric antigen receptor T-cell therapy administration: A single center experience at an urban hospital Anisha Rajavel Received Received
  6330-MON Incidence and impact of acute coronary syndrome on outcomes in chimeric antigen receptor T-cell therapy: Insights from a six-year nationwide analysis Adamsegd Isac Gebremedhen Received Received
  6331-MON Beyond ECOG: Assessment of physical function enhances risk stratification prior to CAR-T cell therapy Alessandra Holzem Received Received
  6332-MON Time toxicity in ALL: Quantifying home days among adults with acute lymphoblastic leukemia Daniel R Richardson Received Received
  6333-MON Acalabrutinib vs zanubrutinib as first-line therapy in CLL: A propensity score–matched study Angimar Uriepero Received Received
  6334-MON Impact of the CAR-T era on survival in diffuse large B-cell lymphoma: A u.S. population-based cohort study Nishanth Thalambedu Received Received
  6335-MON Comparative neuropsychiatric outcomes of ibrutinib and acalabrutinib in patients with chronic lymphocytic leukemia: A propensity-matched real-world cohort study Kirti Arora Received Received
  6336-MON Survival disparities by race and income among adolescents and young adults with acute lymphoblastic leukemia Salih Akgun Received Received
  6337-MON Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin lymphoma in the United States: A population based cohort study Narendranath Epperla Received Received
  6338-MON Do patients with classic Hodgkin´s lymphoma treated with ABVD in low-middle income countries have a higher risk of neutropenia/febrile neutropenia without G-CSF support? a single-center retrospective study Andre Meireles Received Received
  6339-MON Allogeneic stem cell transplant following CAR T-cell therapy in relapsed/refractory adult acute lymphoblastic leukemia: A real-world analysis Nolan Ryan Holley Received Received
  6340-MON Clinical manifestations, risk factors and prognosis associated with central nervous system relapse after CAR-T therapy for R/R B-cell non-Hodgkin lymphoma: A multi-center analysis Tianning Gu Received Received
  6341-MON Real-world outcomes of transplant-ineligible newly diagnosed multiple myeloma patients treated in the United States with contemporary regimens Salomon Manier Received Received
  6342-MON The burden of myeloma treatment routes and locations on patients and families: Insights from a Pan-European survey Katie Joyner Received Received
  6343-MON Determinants of survival in primary plasma cell leukemia (PPCL): Analysis of a real-world pooled database Philip A Haddad Received Received
  6344-MON Visualizing geographic variation and systemic inequities of disease burden and CAR T-cell therapy access in multiple myeloma in the US Brandon Blue Received Received
  6345-MON Reasons for treatment discontinuation in multiple myeloma: Insights from the PREAMBLE registry Ravi Vij Received Received
  6346-MON Outcomes of elderly patients with newly diagnosed multiple myeloma (NDMM): A retrospective comparison of daratumumab-based induction versus autologous stem cell transplant (autoSCT) Kwan-Keat K Ang Received Received
  6347-MON T-cell redirecting therapies in multiple myeloma: Barriers and knowledge gap among patients, community physicians, and caregivers Abena Prempeh Received Received
  6348-MON Healthcare Providers´ knowledge and attitudes toward venous thromboembolism prophylaxis in multiple myeloma: A cross-sectional survey Ghasoub Rola Received Received
  6349-MON Risk stratification based on machine learning for severe cytokine release syndrome in RRMM patients treated with bispecific antibodies Miguel Luengo-Oroz Received Received
  6350-MON Severe neutropenia after treatment with T-cell engaging bispecific antibodies is associated with higher rates of CRS and disease response Rafaella Ferreira De Araujo Litvin Received Received
  6351-MON Incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections and cardiovascular events between chimeric antigen receptor (CAR) T-cell therapy products in multiple myeloma (MM): A nationwide analy Himil Mahadevia Received Received
  6352-MON Real-world treatment patterns and outcomes in frail and non-frail patients with newly diagnosed multiple myeloma not undergoing frontline transplant: A study using cota oncology database Feng Lin Received Received
  6353-MON Shifting first-line paradigms: Real-world treatment outcomes and healthcare burden in non-transplant newly diagnosed multiple myeloma in France (2015-2022) Feng Lin Received Received
  6354-MON Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey Jay R. Hydren Received Received
  6355-MON Pre-treatment vaccine seroprotection is markedly lower in BCMA-CAR vs CD19-CAR recipients with limited post-therapy modulation Giulia Magno Received Received
  6356-MON Bortezomib-melphalan-prednisone (VMP) +/- daratumumab (DVMP) vs. lenalidomide-dexamethasone (Rd) +/- daratumumab (DRd) in transplant-ineligible real-life multiple myeloma patients: Results from the randomized phase IV real MM trial Mattia D´Agostino Received Received
  6357-MON Long-term outcomes of syngeneic transplantation in multiple myeloma: Valuable legacy or obsolete option? a study from the chronic malignancies working party of the EBMT Iman Abou Dalle Received Received
  6358-MON Real-world characteristics and outcomes of newly diagnosed multiple myeloma patients receiving autologous stem cell transplantation (2018–2024) from the honeur network Blanca Gros Otero Received Received
  6359-MON Characteristics and treatment patterns of nontransplanted patients with newly diagnosed multiple myeloma treated with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) or daratumumab, lenalidomide, and dexamethasone (DRd) in the frontline se Sikander Ailawadhi Received Received
  6360-MON Survival trends in systemic amyloidosis over two decades: A real-world cohort analysis Grace Gorecki Received Received
  6361-MON Myeloma mortality trends in the United States (Excluding Puerto Rico), 1999–2021, and future projections using ARIMA modeling and machine learning Danyal Butt Received Received
  6362-MON Impact of autoimmune disease on outcomes after BCMA-directed CAR-T cell therapy for patients with multiple myeloma Laith Hamed Received Received
  6363-MON The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study Gregorio Barila Received Received
  6364-MON High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study. Swetha Thiruvengadam Received Received
  6365-MON The importance of autologous stem cell transplant (ASCT) in multiple myeloma treatment in the lack of novel therapies Natalia Cristina Rojas Guerrero Received Received
  6366-MON Immune effector cell-associated enterocolitis (IEC-EC) across CAR-T products in myeloma and lymphoma: A real world pharmacovigilance analysis Medha Belwadi Received Received
  6367-MON Talquetamab in Relapsed/Refractory multiple myeloma with renal impairment: A quaternary cancer center experience Hossam M. Ali Received Received
  6368-MON Real-world outcomes in older adults with triple-class exposed multiple myeloma Surbhi Sidana Received Received
  6369-MON One-year outcomes of daratumumab-based vs. non-daratumumab regimens in AL amyloidosis: A propensity-matched real-world study Chidiebube Ugwu Received Received
  6370-MON Impact of pre-existing central nervous system conditions and cognitive impairments on toxicity and outcomes after BCMA-directed CAR-T cell therapy Syed Mohammed Hussain Received Received
  6371-MON Impact of pre-existing psychiatric conditions on toxicity and outcomes of patients after BCMA-directed CAR-T cell therapy Syed Mohammed Hussain Received Received
  6372-MON Real-world outcomes with teclistamab in relapsed/refractory multiple myeloma and severe renal failure: A propensity matched multi-center retrospective study using trinetx database Deevyashali Parekh Received Received
  6373-MON Outcomes for low-income patients with multiple myeloma: A national retrospective trend analysis from 2015 to 2022 Ben Brik Received Received
  6374-MON Recruitment strategies and enrollment for an ongoing virtually supervised prehabilitation exercise intervention in patients diagnosed with multiple myeloma scheduled to receive autologous stem cell transplant: Preliminary findings Amber Normann Received Received
  6375-MON Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged = 75) with relapsed or refractory multiple myeloma (RRMM) Arash Velayati Received Received
  6376-MON Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma Agrima Mian Received Received
  6377-MON Evolution of care and outcomes of kidney transplantation in plasma cell dyscrasias: A single center experience Gaddiel Omar Ahmed-Robles Received Received
  6378-MON Impact of slim-CRAB criteria on treatment initiation in newly diagnosed multiple myeloma in the veteran health administration Mahta Salehi Received Received
  6379-MON Bridging Therapy´s effects on clinical outcomes after commercial BCMA CAR T-cell therapy used in the standard of care treatment of relapsed and refractory multiple myeloma Kimberly Burcher Received Received
  6380-MON Poor survival and temporal trends in blastic plasmacytoid dendritic cell neoplasm: A SEER 2000–2022 analysis Priyanka Nagdev Received Received
  6381-MON Treatment selection and functional outcomes in treatment-related acute myeloid leukemia (tAML) and AML with myelodysplasia-related changes (MRC): A multicenter prospective cohort study Vijaya Raj Bhatt Received Received
  6382-MON Spiritual wellness and quality-of-life in adult patients with newly diagnosed acute leukemia receiving initial therapy: Patient-reported outcomes (PROs) from a prospective observational study Hannah Johnston Received Received
  6383-MON Differences in peripheral neuropathy reports by race informed by electronic patient-reported outcomes (ePROs) deployed in multiple myeloma (MM) clinical practice Emelly Rusli Received Received
  6384-MON Uneven gains: Disparities in pneumonia-associated mortality among myeloid leukemia patients in the United States, 1999–2020 — a CDC wonder and joinpoint analysis Sai Sushrutha Mudupula Vemula Sr Received Received
  6385-MON Socioeconomic inequality in acute myeloid leukaemia treatment in England: What drives this inequality Koki Shimizu Received Received
  6386-MON Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study. Jean-Baptiste Micol Received Received
  6387-MON Examining diet quality and patient-reported outcomes in myeloproliferative neoplasms: Results from a cross-sectional observational study Chi-Joan How Received Received
  6388-MON The humanistic burden of patients with chronic myeloid leukemia (CML) treated with first line (1L) tyrosine kinase inhibitors (TKIs) Kelly Schoenbeck Received Received
  6389-MON Socioeconomic inequalities and health-related quality of life profile of patients with Myelodysplastic Syndromes (MDS): Analysis of 504 patients with higher-risk MDS Fabio Efficace Received Received
  6390-MON Evaluating real-world diagnostic and treatment patterns, risk of thromboembolic events, and mortality for polycythemia vera across an integrated academic-community cancer network Jessica Nino De Rivera Received Received
  6391-MON Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database Prithviraj Bose Received Received
  6392-MON Impact of metformin on the incidence of thrombotic events in ­older patients with polycythemia vera and essential thrombocythemia in the United States Jessica Maria Stempel Received Received
  6393-MON Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA) Jessica Maria Stempel Received Received
  6394-MON High incidence of impaired graft function after allogeneic HSCT for myelofibrosis, and successful utilization of stem cell boost Maria De Los Angeles Leon-Camarena Received Received
  6395-MON Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP Iman Abou Dalle Received Received
  6396-MON Impact of sociodemographic factors on survival outcomes in chronic myeloid leukemia in the United States: A time-trend analysis Qais Bin Abdul Ghaffar Received Received
  6397-MON National analysis of real-world racial and ethnic disparities in mortality, complications, and healthcare costs among adults hospitalized with newly diagnosed Acute Myeloid Leukemia Mevlut Ozmen Received Received
  6398-MON Dosing variability of tyrosine kinase inhibitors in chronic myeloid leukemia Joshua Knapp Received Received
  6399-MON Changing burden of Acute Myeloid Leukemia in the United States: A 23-year national analysis Qais Bin Abdul Ghaffar Received Received
  6400-MON Malnutrition: An underrecognized comorbidity in hematologic malignancies in a single institution review of nutrition referrals Sean Bowden Received Received
  6401-MON Real-world use of venetoclax and hypomethylating agents (HMA) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): A multi-institutional case series Erica N Lamkin Received Received
  6402-MON Respiratory syncytial virus (RSV) infection in adults with blood cancer: An England-wide population study Yeong Jer Lim Received Received
  6403-MON Social determinants of health and outcomes in patients with acute leukemia: Interim results from a prospective, single institution study Maire Okoniewski Received Received
  6404-MON Temporal trends in mortality from hematological cancers with atrial fibrillation and flutter as contributing causes in the United States, 2000–2020: A national vital statistics system analysis Manas Pustake Received Received
  6405-MON Balancing the treatment outcomes: Survival and quality of life among older adults with AML Sara M. Tinsley-Vance Received Received
  6406-MON Social determinants of health shape treatment course and long term outcomes in patients with high-risk myeloproliferative neoplasms Tyler G Bruno Received Received
  6407-MON Area deprivation index does not influence survival in patients with lower-risk myelodysplastic syndromes at a major cancer center Mahesh Swaminathan Received Received
  6408-MON Acute leukemia during pregnancy: A three-decade Mayo Clinic experience Brittany C Kimball Received Received
  6409-MON Outcomes in older adults (=60 Years) with normal karyotype acute myeloid leukemia treated with intensive vs. lower-intensity chemotherapy: Path to a molecularly guided upfront treatment approach Alexander Li Received Received
  6410-MON Comprehensive genomic profiling refines diagnosis and reveals actionable fusions in myeloid malignancies: A real-world analysis John M. Furgason Received Received
  6411-MON High response rates and early treatment patterns with venetoclax and azacitidine from the prospective liven study: Real-world AML care in Canada Michelle Nadine Geddes Received Received
  6412-MON Treatment patterns and clinical outcomes in patients with lower-risk Myelodysplastic Syndromes rreated with first-line luspatercept: Findings from a medical record review in France and Germany Ahmed Hnoosh Received Received
  6413-MON Artificial intelligence (AI) meets real-world disparities: A SEER-based study of Acute Myeloid Leukemia (AML) across race, ethnicity and gender Jahnavi Ethakota Received Received
  6414-MON Two decades of infectious mortality in Myelodysplastic Syndromes: An analysis from the CDC wonder database Diljot Singh Received Received
  6415-MON Clinical impact of atrial fibrillation on hospitalized patients with myeloproliferative neoplasms: A nationwide analysis Samhitha Gundakaram Received Received
  6416-MON Non-cancer related deaths in myeloproliferative neoplasm and Myelodysplastic Syndromes : A populaton based analysis Nikita Tripathi Received Received
  6417-MON Role efficiency in psychosocial care of sickle cell disease: A national survey of social workers Shirley A Johnson Received Received
  6418-MON Enhancing anticoagulation stewardship: A resident-focused quality improvement project Amanda Mun-yi Lee Received Received
  6419-MON National alliance of sickle cell centers consensus recommendations for defining an adult sickle cell disease specialist Francis Coyne Received Received
  6420-MON Blood board: A virtual forum for classical hematology education and care improvement Emma St Martin Received Received
  6421-MON Understanding health literacy among patients with thalassemia: Results from a global patient survey by the Thalassemia Advocacy Advisory Council Sujit Sheth Received Received
  6422-MON Next-generation sequencing for myeloid malignancies: Uncovering clinical gaps in physician knowledge and practice Victoria Harvey-Jones Received Received
  6423-MON Construction of mindfulness based cancer rehabilitation training program for malignant hematology patients based on the Liverpool mindfulness model Jie Liu Received Received
  6424-MON Characterizing Hodgkin lymphoma survivors´ shared decision making across the care continuum Raymond Mailhot Vega Received Received
  6425-MON Digital diagnosis: the development of electronic laboratory simulations to promote active learning in hematology among first-year medical students Raymond David Pastore Received Received
  6426-MON Evaluation of the American society of hematology quality improvement training institute: Impact on learner quality improvement knowledge, confidence, and satisfaction Michael Keng Received Received
  6427-MON Collaborative outreach and education for management of bi-specific antibody treatment side effects in Relapsed/Refractory multiple myeloma (COMBAT-RRMM) Jessica Lewis-Gonzalez Received Received
  6428-MON Integrating patient and clinician perspectives to advance R/R CLL care: Results of a multi-pronged global initiative Carmine Deluca Received Received
  6429-MON Use of an oncology informatics knowledgebase to improve influenza vaccination rate in pediatric oncology patients Renee Gresh Received Received
  6430-MON Real-world changes in CLL treatment patterns following collaborative educational initiatives delivered in community settings Carmine Deluca Received Received
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 06/12/2025 TO 06/12/2026
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert